<SEC-DOCUMENT>0001570562-19-000038.txt : 20190320
<SEC-HEADER>0001570562-19-000038.hdr.sgml : 20190320
<ACCEPTANCE-DATETIME>20190320160713
ACCESSION NUMBER:		0001570562-19-000038
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190320
DATE AS OF CHANGE:		20190320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		19694726

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>evolus12311810-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD0A28703598F55B6901ECA174F470DAE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:15pt;"><font style="font-family:Times New Roman;font-size:15pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:15pt;"><font style="font-family:Times New Roman;font-size:15pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;color:#000000;">_____________________________</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:16pt;"><font style="font-family:Times New Roman;font-size:16pt;color:#000000;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;color:#000000;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font><font style="font-family:Times New Roman;font-size:6pt;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">For the fiscal year ended&#160;December&#160;31, 2018</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">or</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 O</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">R 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to      </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Commission File Number:&#160;001-38381</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:20pt;"><font style="font-family:Times New Roman;font-size:20pt;font-weight:bold;">EVOLUS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">46-1385614</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(State or other jurisdiction of </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Identification Number)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">520 Newport Center Dr., Suite 1200</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Newport Beach, California 92660</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(949) 284-4555</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;text-decoration:underline;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Common Stock, $0.00001 par value per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">The Nasdaq Stock Market LLC</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744; No&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;color:#000000;font-style:normal;font-weight:normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be&#160;submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K (&#167; 229.405) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:7pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:22%;"></td><td style="width:52%;"></td><td style="width:21%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Non-accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9746;</font><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9746;</font></div><div style="font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9746;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial statement accounting standards provide pursuance to Section 13(a) of the Exchange Act. &#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $141.5 million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $27.99&#160;per share for such date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">As of </font><font style="font-family:Times New Roman;font-size:7pt;">March&#160;20, 2019</font><font style="font-family:Times New Roman;font-size:7pt;">, </font><font style="font-family:Times New Roman;font-size:7pt;">27,274,991</font><font style="font-family:Times New Roman;font-size:7pt;">&#32;shares of the registrant&#8217;s sole class of common stock were outstanding.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">None</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sAC1CC8D278AE57FFB2FE31349F7B8293"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:86%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EVOLUS, INC.</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBCC6BA1313F459D1B5EE467A400A46D1"><font style="font-family:Times New Roman;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBCC6BA1313F459D1B5EE467A400A46D1">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s54599D6114485058B6712366AB18222C"><font style="font-family:Times New Roman;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s54599D6114485058B6712366AB18222C">23</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1B</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5858AF4B8D675D9EA37AC0CF0CF175D1"><font style="font-family:Times New Roman;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5858AF4B8D675D9EA37AC0CF0CF175D1">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s373720BC73ED56ADB0F1BF9C98146C16"><font style="font-family:Times New Roman;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s373720BC73ED56ADB0F1BF9C98146C16">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0461E3D0902B5B3297B141D96A185105"><font style="font-family:Times New Roman;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0461E3D0902B5B3297B141D96A185105">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3028EC1D11F1551FBFF6B5263C61F0E5"><font style="font-family:Times New Roman;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3028EC1D11F1551FBFF6B5263C61F0E5">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s66FD303789635B769735D4EDC7F3200E"><font style="font-family:Times New Roman;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s66FD303789635B769735D4EDC7F3200E">63</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 6</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sC3E725C5CB9851AF9348AE2522A10E12"><font style="font-family:Times New Roman;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sC3E725C5CB9851AF9348AE2522A10E12">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 7</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3370F60C8B8C5D29B0A548B9E6DBE00B"><font style="font-family:Times New Roman;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3370F60C8B8C5D29B0A548B9E6DBE00B">65</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 7A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBE440D35FA025C969FF12B72753A5EBA"><font style="font-family:Times New Roman;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBE440D35FA025C969FF12B72753A5EBA">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 8</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s11C811E732DB5EDF8598ECD2ED49C7B8"><font style="font-family:Times New Roman;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s11C811E732DB5EDF8598ECD2ED49C7B8">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 9</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sCAF4C4C18A6058469DF591AECA52C4C8"><font style="font-family:Times New Roman;font-size:10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sCAF4C4C18A6058469DF591AECA52C4C8">108</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 9A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s426038E5411558A78F951D2F42100993"><font style="font-family:Times New Roman;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s426038E5411558A78F951D2F42100993">108</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 9B</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD2F6A30DDDFE53648D36C95A452E8FFA"><font style="font-family:Times New Roman;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD2F6A30DDDFE53648D36C95A452E8FFA">108</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 10</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s49B29CEB50C95AFAA3763CAC5639D68A"><font style="font-family:Times New Roman;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s49B29CEB50C95AFAA3763CAC5639D68A">110</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 11</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s415AE0703C2C5E0FA03BB1735F94905F"><font style="font-family:Times New Roman;font-size:10pt;">Executive Compensation </font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s415AE0703C2C5E0FA03BB1735F94905F">114</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s31F33513FAA153E19E3FB0B1E60D4CEE"><font style="font-family:Times New Roman;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s31F33513FAA153E19E3FB0B1E60D4CEE">123</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 13</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s8F922B1910635E37BD8252C0B642CFAC"><font style="font-family:Times New Roman;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s8F922B1910635E37BD8252C0B642CFAC">125</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 14</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s532C8D66F2765E49A9AFE5A8AE2E1D89"><font style="font-family:Times New Roman;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s532C8D66F2765E49A9AFE5A8AE2E1D89">133</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART IV</font></div><div style="text-align:center;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD6D0E8613C445B6591F9AB32E4BAB2A6"><font style="font-family:Times New Roman;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD6D0E8613C445B6591F9AB32E4BAB2A6">134</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 16</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sABEAFC4350205AE38ECD6456A7828F91"><font style="font-family:Times New Roman;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sABEAFC4350205AE38ECD6456A7828F91">137</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;color:#3216ff;text-decoration:underline;" href="#s26C11A06CA235083A620D7770C7DA184"><font style="font-family:Times New Roman;font-size:10pt;color:#3216ff;text-decoration:underline;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">i</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sD8CB0AB4C75851E78959B5A37F6589E0"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Special Note Regarding Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. Forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to maintain regulatory approval of our sole product, Jeuveau&#8482;, and any related restrictions, limitations and warnings in the label of Jeuveau&#8482; in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the potential market size, opportunity and growth potential for Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the attractiveness of the product characteristics of Jeuveau&#8482; (including the benefits of a 900 kilodalton, or kDa, botulinum toxin type A complex) and the rate and degree of physician and patient acceptance of Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to successfully commercialize Jeuveau&#8482;, including our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the pricing of Jeuveau&#8482;, and the flexibility of our pricing and marketing strategy compared to our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the performance of our third-party licensors, suppliers, manufacturers and distributors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our expectations regarding our future development of Jeuveau&#8482; for other indications and approval in other jurisdictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the accuracy of our estimates regarding the amount and timing of expenses, future revenue, capital requirements and needs for additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory and legislative developments in the United States, European Union, or EU, Canada and other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">developments and projections relating to our competitors and our industry, including competing products and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the loss of key management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our future financial performance and our ability to continue as a going concern; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the ability of ALPHAEON Corporation, or ALPHAEON, our controlling stockholder, to control the direction of our business; </font><font style="font-family:Times New Roman;font-size:10pt;">and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the results of current and any future legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The forward-looking statements included herein are not guarantees of future performance or events and are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control.&#160; As such, our actual results may differ materially from those expressed in any forward-looking statements.&#160; Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1 &#8220;Business&#8221; and Item 1A &#8220;Risk Factors&#8221; of Part&#160;I and Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part&#160;II of this Annual Report on Form&#160;10-K.&#160;Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission, or SEC.&#160;In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements.&#160;Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Annual Report on Form 10-K and the documents we file with the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SEC, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Unless the context indicates otherwise, as used in this Annual Report on Form 10-K, the terms &#8220;Evolus,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc., a Delaware corporation, and our subsidiaries taken as a whole, unless otherwise noted. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">EVOLUS&#8482; and Jeuveau&#8482; are two of our trademarks that are used in this Annual Report on Form 10-K. This Annual Report on Form 10-K also includes trademarks, trade names and service marks that are the property of other organizations, such as BOTOX&#174; and BOTOX&#174; Cosmetic, which we refer to throughout this Annual Report on Form 10-K as BOTOX. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div><a name="s0A256AB19C8156FEA67B792F00A734A1"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sBCC6BA1313F459D1B5EE467A400A46D1"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 1.  &#160;&#160;&#160;&#160;Business.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. On February 1, 2019, the U.S. Food and Drug Administration, or FDA, approved our first product Jeuveau&#8482; (prabotulinumtoxinA-xvfs). We plan to launch Jeuveau&#8482; commercially in the United States in Spring 2019. Jeuveau&#8482; is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. We believe we will offer physicians and consumers a compelling value proposition with Jeuveau&#8482;. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau&#8482;, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have successfully completed a comprehensive global five-study clinical development program which we named TRANSPARENCY. The TRANSPARENCY global clinical program included studies in the United States, EU and Canada to meet the regulatory requirements for a Biologics License Application, or BLA, in the United States, a Marketing Authorization Application, or MAA, in the European Union, or EU, and a New Drug Submission, or NDS, in Canada, for the treatment of moderate to severe glabellar lines between the eyebrows. The program, which was developed in consultation with the FDA, Canadian and European regulatory bodies, included three multicenter, randomized, controlled, single dose Phase III studies and two open label, multiple dose, long-term Phase II studies. Over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in the TRANSPARENCY program. All three Phase III studies in the TRANSPARENCY program successfully met their respective primary endpoints. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We submitted a New Drug Submission, or NDS, to Health Canada and&#160;in August 2018 we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We plan to market the product in Canada in the first half of 2019 through our distribution partner Clarion Medical Technologies, Inc., or Clarion, a Canadian provider of medical and aesthetic equipment and consumables to hospitals, aesthetic clinics and private medical practices. We also submitted an MAA to the European Medicines Agency, or EMA, and it was accepted for review in July 2017. We expect an opinion from the Committee for Medicinal Products for Human Use, or CHMP, in the first quarter of 2019. If the CHMP provides a favorable opinion, we would expect approval of our MAA by end of second quarter 2019.  </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Within the self-pay aesthetic market, the global aesthetic neurotoxin market was estimated to generate approximately $2.5 billion of revenue in 2018 and is estimated to grow to approximately $3.5 billion in 2021.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The United States is the largest portion of this market and was estimated to generate approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 billion</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of revenue in 2018 and is expected to grow to approximately $1.7 billion in 2021. We believe the aesthetic neurotoxin markets is one of the most attractive in healthcare with secular growth trends. We believe the continued growth of the aesthetic neurotoxin market will be driven by an aging population, increased use by individuals between the ages of 19 and 34, whom we refer to as millennials, increasing life expectancy, rising disposable income, improved accessibility to these products and treatments due to an increase in the number of physicians who perform these procedures, continued innovation, and an increasing acceptance and utilization of elective or minimally invasive aesthetic procedures. According to the American Society for Aesthetic Plastic Surgery, aesthetic neurotoxin treatments are the number one cosmetic procedure being considered by millennials, and neurotoxin use among this group has increased by 87% between 2011 and 2016. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau&#8482; is the first known neurotoxin dedicated exclusively to aesthetics. We plan to launch Jeuveau&#8482; in the United States in Spring 2019 by building a commercialization infrastructure, which includes our own specialty sales force of approximately 140 sales representatives. We intend to create a strongly desirable experience for physicians and consumers by leveraging our management team&#8217;s extensive industry experience, our compelling head-to-head clinical data compared with BOTOX, and our unique technology platform designed to transform the aesthetic market by eliminating the friction points existing for customers today. Outside of the United States, we plan to market and sell our neurotoxin through distributors in the territories in which we have the right to sell it.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 30, 2013, we entered into a license and supply agreement, or the Daewoong Agreement,&#160;pursuant to which we have an exclusive distribution license to Jeuveau&#8482; from Daewoong Pharmaceuticals Co., Ltd., or Daewoong, a South </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Korean pharmaceutical manufacturer, for aesthetic indications in the United States, EU, Canada, Australia, Russia, Commonwealth of Independent States, or C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&#8482; will be manufactured by Daewoong in a recently constructed facility in South Korea. We also have the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&#8482;) in a territory covered by the license. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our Compe</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">itive Strengths </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe we will offer physicians and consumers a compelling value proposition beginning with the launch of Jeuveau&#8482; for the following reasons:</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Jeuveau&#8482; will offer the U.S. market the first known 900 kDa neurotoxin alternative to BOTOX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The manufacture of both Jeuveau&#8482; and BOTOX starts with a 900 kDa complex, includes adding the excipients human serum albumin, or HSA, and sodium chloride, and finishes by vacuum drying. We believe Jeuveau&#8482; is the only known neurotoxin product in the United States with a 900 kDa neurotoxin complex other than BOTOX. We also believe an important component of competitiveness in the neurotoxin market relates to the characteristics associated with the 900 kDa complex and the potential of the accessory proteins to increase the effectiveness of the active toxin portion of the complex.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Results from our TRANSPARENCY global clinical program in more than 2,100 patients provides robust data to physicians evaluating the purchase of Jeuveau&#8482;.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the comprehensive TRANSPARENCY clinical data set, including a head-to-head Phase III study comparing Jeuveau&#8482; and BOTOX,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">provides physicians with confidence in recommending Jeuveau&#8482; to their patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Enhanced level of physician-customer interaction through a self-pay, aesthetic-only marketing strategy. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have elected to specifically target the self-pay aesthetic market. With a reduced regulatory burden compared to third-party payor reimbursed therapeutic products, we believe we will achieve a number of benefits that market participants in reimbursed markets are unable to achieve, such as an enhanced level of interaction with our physician-customers. Jeuveau&#8482; is the only U.S. neurotoxin without a therapeutic indication. We believe pursuing an aesthetic-only non-reimbursed product strategy will create meaningful strategic advantages in the United States, including pricing and marketing flexibility. We intend to utilize this flexibility to drive market adoption through programs such as promotional events, experience product programs and pricing strategies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">We are building a unique technology platform</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We intend to create a simple, personal and connected experience for physicians utilizing our proprietary technology platform. We are designing a platform with the goal of limiting friction and enhancing the overall experience for physicians and ultimately consumers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">We have strong relationships with aesthetic key opinion leaders, or KOLs</font><font style="font-family:Times New Roman;font-size:10pt;">. We have established relationships with aesthetic KOLs as a result of our management team&#8217;s industry experience and engagement of our clinical trial investigators. KOLs are important information resources to the general physician-customer market due to their clinical expertise, academic reputations, active clinical practices and their status as medical innovators. The broader physician community often looks to KOLs for their experience with products and procedures as part of their new product and procedure adoption process. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Our management team has significant experience and expertise in medical aesthetics</font><font style="font-family:Times New Roman;font-size:10pt;">. Our management team has extensive experience in self-pay healthcare markets, in the development, market launch and commercialization of major medical products, execution and integration of business development transactions, identification of and partnerships with KOLs, and understanding of the regulatory environment of the healthcare markets. Key members of our leadership team have also served in relevant senior leadership positions with leading aesthetic companies. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our near-term strategy is to enter the U.S. medical aesthetic neurotoxin market with Jeuveau&#8482;. We plan to expand our product offerings over time through in-licensing, partnerships and acquisitions. The key components of our strategy are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Launch Jeuveau&#8482; in the United States with our own specialty sales force of approximately 140 sales representatives. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Partner outside of the United States to reach and serve physicians and consumers in those territories. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Pursue an aesthetic-only strategy to enhance marketing and pricing flexibility along with improving transparency for our customers.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Leverage our strong KOL relationships to assist in scientific presentations, publications, and other methods to drive success of our commercial launch of Jeuveau&#8482;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Establish a leading medical aesthetics company by in-licensing technology, developing partnerships and potentially acquiring products. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Our Market </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our primary market is self-pay aesthetic healthcare, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. By focusing on the self-pay medical aesthetics market, we believe we will not be exposed to reimbursement risk associated with a reliance on payments from such third-party payors, and we will be subject to fewer regulations that place limits on the types of marketing and other interactions we can have with physicians. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Within the self-pay aesthetic market, the global aesthetic neurotoxin market was estimated to generate approximately $2.5 billion of revenue in 2018 and is estimated to grow to approximately $3.5 billion in 2021.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The U.S. aesthetic neurotoxin market was estimated to generate </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 billion</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in sales in 2018. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Within the multiple age groups that receive aesthetic neurotoxin treatments, we will strategically focus our marketing efforts on the Millennial segment which is the largest cohort in the U.S. population. In 2019 there are estimated to be approximately 73 million Millennials, defined as individuals born between 1981 and 1996. Botulinum toxin use among individuals between the age of 19 and 34 increased 87% between 2011 and 2016, and neurotoxin treatments are the number one cosmetic procedure considered by this generation. Approximately 1.7 million females between the age of 30 and 39, which includes many individuals we define as Millennials, are considering neurotoxins in the next twelve months. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the growth in the medical aesthetics market is driven by a number of factors, including:&#160; </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Millennials are increasingly seeking medical aesthetic treatments and utilizing neurotoxins as an entry point for aesthetic procedures due to their minimally invasive nature; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">an aging population together with an increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">rising disposable income, with the U.S. Bureau of Economic Analysis reporting that real disposable income in the United States increased approximately 15% from March 2012 to March 2018;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">growing awareness, utilization and acceptance of elective or minimally invasive aesthetic procedures;&#160;and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">continued innovation and improved accessibility to these treatments due to an increase in the number of physicians who perform these procedu</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">res.</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Currently, BOTOX, Dysport and Xeomin represent a majority of the medical aesthetics botulinum toxin type A market. In 2018, BOTOX U.S. unit market share was approximately 75% and generated approximately $907 million of revenue. In the same year, Dysport and Xeomin U.S. unit market share was approximately 19% and 7%, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Jeuveau&#8482; Overview</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We licensed Jeuveau&#8482; from Daewoong in September 2013 and commenced clinical trials in 2014. Jeuveau&#8482; is an injectable formulation of a 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We completed the TRANSPARENCY global clinical program to meet the regulatory requirements for a BLA in the United States, a MAA in the EU, and a NDS in Canada, for the treatment of moderate to severe glabellar lines. Our program was developed in consultation with the FDA, Canadian and European regulatory bodies. These regulatory bodies provided guidance and feedback on the critical endpoints and statistical methodology required to develop the safety and efficacy endpoints that would support this indication&#8217;s approval.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As demonstrated in the figure below, Jeuveau&#8482; contains a 900 kDa botulinum toxin type A complex produced by the bacterium </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clostridium botulinum.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The active part of the neurotoxin is the 150 kDa component, and the remaining 750 kDA of the complex is made up of accessory proteins that we believe help with the function of the active portion of the toxin. Jeuveau&#8482; has the same mechanism of action as other type A botulinum toxins. When injected intramuscularly at therapeutic doses, botulinum toxin causes a chemical denervation of the muscle resulting in localized reduction of muscle activity. Botulinum toxin type A specifically blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Diagram of Botulinum Toxin Type A</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="a900kda.jpg" alt="a900kda.jpg" style="height:249px;width:205px;"></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table provides a summary of the botulinum toxin type A complex composition for Jeuveau&#8482; and available toxins in the United States. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="products.jpg" alt="products.jpg" style="height:218px;width:362px;"></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">TRANSPARENCY: Evolus Clinical Development for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">In 2014, we initiated a comprehensive five-study clinical development program for Jeuveau&#8482;, which we named TRANSPARENCY, in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU, and a NDS in Canada, for the treatment of moderate to severe glabellar lines. The TRANSPARENCY program, which was developed in consultation with the FDA, Canadian, and European regulatory bodies, included three multicenter, randomized, double-blinded, controlled, single dose Phase III studies titled EV-001, EV-002 and EVB-003. Each Phase III study lasted 150 days. The TRANSPARENCY program also included two open label, multiple dose, long-term Phase II studies titled EV-004 and EV-006, each lasting one year. Between September 2014 and August 2016, over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in this program.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In our clinical trials, subjects received intramuscular injections in five target sites in muscles that contribute to the formation of glabellar lines: the midline of the procerus, the inferomedial aspect of each corrugator, and the superior middle aspect of each corrugator. Each of the five target sites was injected with 0.1 milliliters, or mL, for a total of 0.5mL. Subjects assigned (in the open label studies) or randomized (in the controlled studies) to Jeuveau&#8482; received a total of 20&#160;units per treatment, administered as 4 units per 0.1mL and those subjects who were randomized to the placebo group received 0.5mL saline. In our EVB-003 Phase III trial, the only study of the five with both a placebo and active control arm, subjects randomized to the active control received a total of 20 units of BOTOX administered as 4&#160;units per 0.1mL.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All five studies contributed data to the evaluation of efficacy and safety. The table below summarizes our five-study TRANSPARENCY global clinical program.</font></div><div style="line-height:120%;padding-bottom:22px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Listing of the TRANSPARENCY Clinical Studies - Design Features and Efficacy Assessments</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:12%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:20%;"></td><td style="width:17%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">EV-001</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">EV-002</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">EVB-003</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">EV-004</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">EV-006</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Study</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">U.S. Pivotal Phase III Safety and Efficacy</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">U.S. Pivotal Phase III Safety and Efficacy</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">EU and Canadian Pivotal Phase III Safety and Efficacy</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">U.S. Phase II Long-term Safety</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">U.S. Phase II Long-term Safety</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Population</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (Glabellar Line Scale, or GLS, score &#8805;2) at maximum frown, as independently assessed by both Investigator Assessment (IA) and Subject Assessment(SA)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown, as independently assessed by both IA and SA</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown assessed by IA only and who felt that their glabellar lines had an important psychological impact</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown assessed by IA only</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown, as independently agreed by both IA and SA</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Design, including Duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Randomized (3:1)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Double blind</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Placebo controlled</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Single dose</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">150 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Randomized (3:1)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Double blind</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Placebo controlled</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Single dose</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">150 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Randomized (5:5:1)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Double blind</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Placebo and active controlled</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Single dose</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">150 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Non-randomized</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Open label</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multiple dose (initial treatment plus up to three repeat treatments)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;365 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Non-randomized</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Open label</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Multiple dose (initial treatment plus up to three repeat treatments)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">365 days duration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Treatments</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Single treatment of:<br>20 units of Jeuveau&#8482; or<br>0.5mL saline (Placebo)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Single treatment of:<br>20 units of Jeuveau&#8482; or<br>0.5mL saline (Placebo)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Single treatment of:<br>20 units of Jeuveau&#8482; or<br>20 units of BOTOX or<br>0.5mL saline (Placebo)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">20 units of Jeuveau&#8482;/treatment, up to a maximum of 4 treatments</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">20 units of Jeuveau&#8482;/treatment, up to a maximum of 4 treatments</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Number of Subjects</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">330 randomized (3:1)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">324 randomized (3:1)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">540 randomized (5:5:1)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">352 treated with Jeuveau&#8482;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">570 treated with Jeuveau&#8482;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Location of Sites</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">United States</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">United States</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Canada;&#160;France; Germany; Sweden; United Kingdom</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">United States</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">United States</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Primary Endpoint</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Proportion of subjects classified as responders on Day 30;</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">A composite endpoint</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">A responder was a subject with a &#8805;2 point improvement on the GLS from Day 0 to Day 30 at maximum frown</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Proportion of subjects classified as responders on Day 30</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">A composite endpoint</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">A responder was a subject with a &#8805;2 point improvement on the GLS from Day 0 to Day 30 at maximum frown</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Proportion of subjects classified as responders on Day 30</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Not a composite endpoint</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">A responder was a subject with a GLS score of 0 or 1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">None, all efficacy endpoints were exploratory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">None, all efficacy endpoints were exploratory</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Phase III U.S. Based Clinical Trials. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The two identical U.S. Phase III studies, EV-001 and EV-002, enrolled subjects who were selected from a population of healthy adults, at least 18 years of age, who had moderate to severe glabellar lines at maximum frown, as independently assessed by the investigator and subject using the 4-point photonumeric Glabellar Line Scale, or GLS, where 0=no lines, 1=mild lines, 2=moderate lines and 3=severe lines. On Day 0, eligible subjects were randomly assigned in a 3:1 ratio to receive a single treatment of either Jeuveau&#8482; or placebo. Subjects were followed for 150 days after treatment.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. This was a composite endpoint in which a responder was a subject with a 2 point improvement or greater on the GLS from Day 0 to Day 30 at maximum frown, only if independently agreed by both investigator and subject assessment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Both studies met the primary endpoint of superiority over placebo. The percentages of responders in the intent to treat population for the composite primary endpoint, a two point or greater score composite improvement, in each of the two controlled single dose studies were:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">EV-001: 1.2% placebo, 67.5% Jeuveau&#8482;, with an absolute difference between the groups of 66.3%, 95% CI (59.0, 72.4)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">EV-002: 1.3% placebo, 70.4% Jeuveau&#8482;, with an absolute difference between the groups of 69.1%, 95% CI (61.5, 75.1)</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">U.S. Phase III Primary Endpoint - Composite Score &#8805; 2 Point GLS Improvement at Maximum Frown on Day 30</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="primaryendpoint.jpg" alt="primaryendpoint.jpg" style="height:272px;width:438px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since a two point or greater composite score requires both the investigator and subject to agree simultaneously, studies using this definition generally have a lower responder rate than non-composite studies. Xeomin and Dysport represent two botulinum toxin type A products who also conducted trials using a two point or greater composite responder rate. The Xeomin two point or greater responder rates in their Phase III studies, per FDA labels, were 48% and 60%, and the Dysport rates were 52%, 55% and 60%. Importantly, no comparison across any of the studies can be made. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">U.S. Phase III Primary Endpoint - Components of Composite Score, &#8805; 2 Point GLS Improvement at Maximum Frown on Day 30 by Investigator and Subject Assessment</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="primaryendpointimprovement.jpg" alt="primaryendpointimprovement.jpg" style="height:165px;width:346px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the EV-001 study, analysis of the secondary endpoints investigated the response at maximum frown beyond Day 30 using a two point composite score.  A subject was considered a responder only if a &#8805;2 point improvement had occurred on the GLS at maximum frown from Day 0, by both investigator and subject assessment: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">At Day 90 (post hoc), the percentage of responders was 1.3% in the placebo group and 26.5% in the Jeuveau&#8482; group with an absolute difference of 25.2%, p&lt;0.001.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">At Day 120, the percentage of responders was 1.3% in the placebo group and 8.3% in the Jeuveau&#8482; group with an absolute difference of 7.0%, p=0.023. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">At Day 150 or early termination, the percentage of responders was 0.0% in the placebo group and 4.6% in the Jeuveau&#8482; group.  The absolute difference of 4.6% between the groups remained statistically significant for the composite endpoint, p=0.041.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A p value, as expressed in the data above, is the probability that the difference between two data sets was due to chance. The smaller the p value, the more likely the differences are not due to chance alone. In general, if the p value is less than or equal to 0.05, the outcome is statistically significant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The 2 point composite score results were similar in the EV-002 study to the EV-001 study for the secondary endpoints:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">At Day 90 (post hoc), the percentage of responders was 0.0% in the placebo group and 25.8% in the Jeuveau&#8482; group with an absolute difference of 25.8%, p&lt;0.001. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">At Day 120, the percentage of responders was 0.0% in the placebo group and 12.4% in the Jeuveau&#8482; group, with an absolute difference of 12.4%, p&lt;0.001.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">At Day 150 or early termination, the percentage of responders was 0.0% in the placebo group and 4.6% in the Jeuveau&#8482; group. The absolute difference of 4.6% between the groups remained statistically significant for the composite endpoint, p=0.047.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additional exploratory efficacy analyses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the EV-001 and EV-002 studies </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">were conducted where Jeuveau&#8482; was investigated for a one point or greater improvement as assessed by either the subject or investigator at various days at maximum frown based on the GLS. Jeuveau&#8482; was compared against a placebo at 2 days, 7 days, 14 days, 30 days, 90 days, 120 days and 150 days or early termination.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">U.S. Phase III Exploratory Endpoints - &#8805; 1 Point Improvement GLS at Maximum Frown</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="ev001graph.jpg" alt="ev001graph.jpg" style="height:336px;width:589px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><img src="ev002grapha01.jpg" alt="ev002grapha01.jpg" style="height:326px;width:565px;"></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In each of the EV-001 and EV-002 studies, we also assessed as an exploratory endpoint investigator and patient assessments on the Global Aesthetic Improvement Scale, or GAIS. The GAIS is a five-point scale on which an evaluator, the subject or investigator, can determine the aesthetic outcome for the subject from: much improved, improved, no change, worse or much worse. The rate of positive responders, those who were assessed by either the subject or the investigator as much improved or improved, over the course of the study is provided below.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="globalaestheticimprovement.jpg" alt="globalaestheticimprovement.jpg" style="height:388px;width:633px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">U.S. Phase III studies Exploratory Endpoint - Global Aesthetic Improvement Responders (Much Improved/Improved)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="globalaestheticimprovement2.jpg" alt="globalaestheticimprovement2.jpg" style="height:382px;width:616px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">EV-002 Subject - Glabellar Lines at Maximum Frown</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide13.jpg" alt="slide13.jpg" style="height:288px;width:374px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the EV-001 study, the adverse event, or AE, rate was 32.1% in the placebo group and 38.2% in the Jeuveau&#8482; group. Placebo and Jeuveau&#8482; groups were similar in the overall incidence of subjects who experienced one or more AEs. Three Jeuveau&#8482; subjects (3/246, 1.2%) experienced serious adverse events, or SAEs, but none were assessed as study drug related. Placebo and Jeuveau&#8482; groups were also similar in the percentages of subjects who experienced AEs assessed by the investigator as study drug related: 13.1% of placebo subjects and 15.4% of Jeuveau&#8482; subjects. The drug related eyelid and eyebrow ptosis rates, the drooping of an upper eyelid or eyebrow, respectively, in the Jeuveau&#8482; group was 0.8% and 0.4%, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the EV-002 study, the AE rate was 26.9% in the placebo group and 28.5% in the Jeuveau&#8482; group. Placebo and Jeuveau&#8482; groups were similar in the overall incidence of subjects who experienced one or more AEs. Four Jeuveau&#8482; subjects (4/246, 1.6%) experienced a SAE, but none were assessed as study drug related. Placebo and Jeuveau&#8482; groups were also similar in the percentages of subjects who experienced an AE assessed by the investigator as study drug related: 7.7% of placebo subjects and 9.8% of Jeuveau&#8482; subjects. The drug related eyelid and eyebrow ptosis rates in the Jeuveau&#8482; arm were 1.2% and 0.4% respectively. Overall, AEs with an incidence of 1% or greater were headache at 9.3% in the Jeuveau&#8482; groups and 7.6% in the placebo groups and eyelid ptosis at 1% in the Jeuveau&#8482; groups and 0% in the placebo groups.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">U.S. Phase III Trials - Adverse Event Rate Summary</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="adverseeventtable2a02.jpg" alt="adverseeventtable2a02.jpg" style="height:193px;width:489px;"></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Phase III European and Canadian Clinical Trial for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The EVB-003 study was the third Phase III safety and efficacy study in the Jeuveau&#8482; clinical development program, and was conducted in Europe and Canada. 540 subjects with moderate to severe glabellar lines, or a GLS score of 2 or 3, as assessed by the investigator, were eligible to be enrolled provided that subjects also felt their glabellar lines had an important psychological impact, such as on their mood, anxiety or depressive symptoms. On Day 0, eligible subjects were randomly assigned in a 5:5:1 ratio to receive a single treatment of 20 units of Jeuveau&#8482;, 20 units of BOTOX or placebo. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. A responder was a subject with a GLS score of 0 or 1, as assessed by the investigator at maximum frown. The primary analysis of the primary efficacy endpoint in the EVB-003 study showed the superiority of Jeuveau&#8482; over placebo, and established non-inferiority of Jeuveau&#8482; to BOTOX. The percentages of responders for the primary efficacy endpoint were:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.2% in the placebo group, 95% CI (0.0, 9.8);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">82.8% in the BOTOX group, 95% CI (78.1, 87.5); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">87.2% in the Jeuveau&#8482; group, 95% CI (83.0, 91.5).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence where the result lies. As an example, in the results above for this Phase III study, the results indicate that there is a 95% level of confidence that the responder rate for placebo was between 0.0% and 9.8%, which we express as: 95% CI (0.0, 9.8). </font></div><div style="line-height:120%;padding-bottom:2px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The absolute differences between the treatment groups were:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83.1% between Jeuveau&#8482; and placebo groups, 95% CI (70.3, 89.4), (p&lt;0.001), indicating Jeuveau&#8482; was superior to placebo; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.4% between Jeuveau&#8482; and BOTOX groups, 95% CI (-1.9, 10.8), with non&#8209;inferiority of Jeuveau&#8482; versus BOTOX concluded based on the lower bound of the 95% CI for the absolute difference exceeding -10.0%.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">EU Phase III Primary Endpoint - Responder Rates at Maximum Frown on Day 30 (GLS = 0 or 1) by Investigator Assessment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">EU Phase III Primary Endpoint - Non-Inferiority, at Maximum Frown on Day 30 by Investigator Assessment</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="favors1a01.jpg" alt="favors1a01.jpg" style="height:180px;width:261px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:188px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="favors2.jpg" alt="favors2.jpg" style="height:126px;width:325px;"></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As presented in the table below, within each group, 32.7% of placebo subjects, 41.9% of BOTOX subjects and 37.6% of Jeuveau&#8482; subjects experienced AEs. One placebo subject (1/49, 2.0%), one BOTOX subject (1/246, 0.4%) and three Jeuveau&#8482; subjects (3/245, 1.2%) experienced a total of 11 SAEs and none were assessed as study drug related. The drug related eyelid ptosis rates were 1.6% in the Jeuveau&#8482; arm and 0% in the BOTOX arm and the eyebrow ptosis rates were 0% in the Jeuveau&#8482; arm and 0.4% in the BOTOX arm.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">EU and Canadian Phase III Trial - Adverse Event Rate Summary</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;"><img src="adverseeventtable.jpg" alt="adverseeventtable.jpg" style="height:162px;width:340px;"></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As presented in the table below, in EVB-003, we also assessed as a secondary endpoint &#8805; 1 point improvement GLS at maximum frown for both investigator and patient satisfaction. The investigator assessment at Day 2, the beginning of the study, and at Day 150, at the end of the study, Jeuveau&#8482; is statistically superior to placebo as measured by a one-point improvement on the GLS scale by investigator assessment. We also looked at subject satisfaction on Day 30, and Jeuveau&#8482; was superior to placebo at 91% versus 6%&#160;in the placebo arm.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">EU and Canadian Phase III Trial - Select Secondary Endpoints</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="secondendpointlasttablesa02.jpg" alt="secondendpointlasttablesa02.jpg" style="height:169px;width:522px;"></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*P-Value Placebo vs Jeuveau&#8482; &lt;0.001<br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Phase II Repeat Dose Clinical Trial for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary objective of the Phase II EV-004 study was to demonstrate the safety of Jeuveau&#8482; in adult subjects receiving repeat doses of Jeuveau&#8482; for the treatment of moderate to severe glabellar lines. This multi-dose study lasted one year. Subjects were selected from a population of healthy adults at least 18 years of age who had moderate to severe glabellar lines at maximum frown, as assessed by the investigator. On Day 0, eligible subjects were administered a single treatment, 20 units of Jeuveau&#8482;. On and after Day 90, subjects were eligible for a repeat treatment if their GLS score was 2 or greater at maximum frown, as assessed by the investigator. If a subject did not have a GLS score of 2 or greater, they were followed monthly until eligible for a repeat treatment or until the study ended on Day 365. The test product in this study was different from all the other Evolus sponsored studies because each vial contained lyophilized, instead of vacuum dried, Jeuveau&#8482;. See the section entitled &#8220;Additional Safety Evaluations&#8221; below for additional information. All other studies in the Evolus sponsored program used vials containing vacuum dried Jeuveau&#8482;. Over the course of the one year study, the 352 subjects in the study received a median total dose of 60 units, or 3 treatments. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Total AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">148 subjects (148/352, 42.0%) experienced a total of 265 AEs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7 subjects (7/352, 2.0%) experienced a total of 9 SAEs, none assessed as study drug related.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Study Drug Related AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51 subjects (51/352, 14.5%) experienced a total of 59 AEs (59/265 events, 22.3%) assessed by the investigator as study drug related.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39 subjects (39/352, 11.1%) experienced a study drug related AE following the initial treatment visit, representing 76.5% of all subjects who experienced study drug related AEs (39/51). Progressively lower percentages of subjects experienced study drug related AEs following each repeat treatment: 3.4% (11/319) after the first repeat treatment, 1.5% (4/262) after the second repeat treatment, and none after the third repeat treatment.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Phase II, EV-006 study&#8217;s primary objective was also to demonstrate the safety of Jeuveau&#8482; in adult subjects receiving repeat doses of Jeuveau&#8482; for the treatment of moderate to severe glabellar lines. Like EV-004, the EV-006 was a multi-dose study that lasted one year. Subjects were selected from a population of healthy adults at least 18 years of age who had moderate to severe glabellar lines at maximum frown, agreed by both the investigator and the subject, as opposed to the sole assessment of the investigator in the EV-004 study. On Day 0, eligible subjects were administered a single treatment of 20 units of Jeuveau&#8482;. On and after Day 90, subjects were eligible for repeat treatment if their GLS score was a 2 or greater at maximum frown, as assessed by the investigator. If a subject did not have a GLS score &#8805;2, they were followed monthly until eligible for repeat treatment or until the study ended on Day 365.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Over the course of the one-year study, the 570 subjects in the study received a median total dose of 60 units, or 3 treatments. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Total AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">235 subjects (235/570, 41.2%) experienced a total of 475 AEs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Seven subjects (7/570, 1.2%) experienced eight SAEs, none of the SAEs were assessed as study drug related. One death (1/570, 0.2%) was reported during the study, a SAE, this event was not related to the study drug</font><font style="font-family:Times New Roman;font-size:9pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Study Drug Related AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">61 subjects (61/570, 10.7%) experienced a total of 91 AEs (91/473 events, 19.2%) assessed by the investigator as study drug related.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">37 subjects (37/570, 6.5%) experienced 46 study drug related AEs following the initial treatment visit, representing 60.7% of all subjects who experienced study drug related AEs (37/61). Progressively lower percentages of subjects experienced study drug related AEs following each repeat treatment: 3.6% (19/524) after the first repeat treatment, 3.2% (14/431) after the second repeat treatment, and 1.9% (4/214) after the third repeat treatment</font><font style="font-family:Times New Roman;font-size:9pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The combined Jeuveau&#8482; drug-related eyelid ptosis rate for the EV-004 and EV-006 studies was 0.9%. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Additional Safety Evaluations</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The five Evolus sponsored studies, EV-001, EV-002, EVB-003, EV-004 and EV-006, assessed the vital signs of subjects, and there were no notable differences found between the Jeuveau&#8482; group and placebo. In the U.S.-based studies, EV-001, EV-002, EV-004 and EV-006, additional testing was conducted such as chemistry, hematology, urinalysis, and electrocardiograms, and these additional tests did not reveal any notable differences between the Jeuveau&#8482; and placebo groups.  During the course of the U.S.-based studies, testing was also conducted looking for subjects who developed&#160;antibotulinum toxin antibodies after exposure to the drug, referred to as cases of seroconversion. There were two cases of seroconversion in the EV-004 repeat dose study. The formulation in the EV-004 study was not the same as the formulation used in all the other Evolus studies. Specifically, the formulation for the EV-004 study used a lyophilizing, or freeze drying, method for removing water. The pivotal studies EV-001 and EV-002, and the repeat dose study EV-006, used a Jeuveau&#8482; formulation that was vacuum dried, and there were no cases of seroconversion in any subjects. This vacuum dried formulation was tested for antibotulinum antibody formations in 1,739 treatments in the 570 subjects in the repeat treatment EV-006 trial, and 492 treatments in the two U.S. single treatment Phase III trials, EV-001 and EV-002. We plan to commercialize the vacuum dried formulation of Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong manufactures and supplies Jeuveau&#8482; to us. Daewoong has over 70 years of experience manufacturing pharmaceutical products and is one of the largest pharmaceutical companies in South Korea. Daewoong has recently constructed a facility in which drug product for Jeuveau&#8482; is produced. The facility is located in Gyeonggi-do, South Korea. We believe this facility will be sufficient to meet demand for Jeuveau&#8482; for the foreseeable future. The FDA conducted a </font><font style="font-family:Times New Roman;font-size:10pt;">current Good Manufacturing Practice, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cGMP, and pre-approval inspection of the facility in November 2017 in connection with our BLA for Jeuveau&#8482;. The UK Medicines and Healthcare Products Regulatory Agency, or MHRA, also completed an inspection of the manufacturing facility in February 2018 in connection with our MAA. The U.S. FDA approval of Jeuveau&#8482; in February 2019 included approval to manufacture Jeuveau&#8482; at Daewoong&#8217;s facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong manufactures the Jeuveau&#8482; drug substance in a separate facility on the same campus. The manufacture of Jeuveau&#8482; drug substance is based on the fermentation of Daewoong&#8217;s </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">C.botulinum</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;cell line, followed by isolation and purification of the drug substance. Daewoong has received a U.S. patent for the production process. The drug substance production facility was renovated to comply with FDA and EMA cGMP requirements.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Our History</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We were incorporated in November 2012 and are headquartered in Newport Beach, California. In a series of related transactions in 2013, SCH-AEON, LLC (formerly known as Strathspey Crown Holdings, LLC), or SCH, acquired all of our outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed our equity that it had acquired in 2013 to its subsidiary operating entity, ALPHAEON, in exchange for the payments described in Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Payment Obligations Related to Our Acquisition by ALPHAEON.&#8221; As a result of these transactions, we were a wholly-owned subsidiary of ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 30, 2013, we entered into the Daewoong Agreement with Daewoong, pursuant to which Daewoong agreed to manufacture and supply Jeuveau&#8482; and grant us an exclusive license to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau&#8482; in the United States, EU, Canada, Australia, Russia, C.I.S., and South Africa, each, a covered territory. Daewoong also granted us a non-exclusive license to do the same in Japan. In connection with our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million and agreed to make milestone payments upon certain confidential development and commercial milestones, including payment to Daewoong upon each of FDA and EMA approval of Jeuveau&#8482;. Under the Daewoong Agreement, the maximum aggregate amount of future milestone payments that could be owed to Daewoong upon the satisfaction of all milestones is $13.5 million as of December 31, 2018. In February 2019, we paid $2.0 million to Daewoong upon obtaining FDA approval of Jeuveau&#8482;. Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of Jeuveau&#8482;, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Daewoong Agreement, Daewoong has agreed to supply us with Jeuveau&#8482; at an agreed-upon, transfer price, and we have agreed to make milestone payments upon completion of certain confidential development and commercial milestones. Our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">exclusivity is subject to certain minimum annual purchases upon commercialization, irrespective of aesthetic or therapeutic indications, and if we fail to meet these targets, Daewoong may, at its option, convert the exclusive license to a non-exclusive license. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions.  During the term of the Daewoong Agreement, we cannot purchase, sell or distribute any competing products in a covered territory or Japan or sell Jeuveau&#8482; outside a covered territory or Japan. We also have the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&#8482;) in a covered territory or Japan. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The initial term of the Daewoong Agreement is from September 30, 2013 to the later of (i) the fifth anniversary of approval from the relevant governmental authority necessary to market and sell Jeuveau&#8482; or (ii) September 30, 2023, and automatically renews for unlimited additional three-year terms if we meet certain performance requirements. The Daewoong Agreement will terminate (A) upon written notice by either us or Daewoong upon a continuing default that remains uncured within 90 days (or 30 days for a payment default) by the other party, or (B) without notice upon the bankruptcy or insolvency of our company. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the aesthetic use of Jeuveau&#8482;, we held an option to obtain the therapeutic rights to botulinum toxin products in the licensed territories which was held in trust for ALPHAEON. In September 2018, ALPHAEON exercised the right to obtain the therapeutic rights and remitted the option exercise price directly to Daewoong. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are the sole owner of any marketing authorization and clinical trial results we pursue in a covered territory. However, if we do not renew the Daewoong Agreement or upon termination of the Daewoong Agreement due to a breach by us, we are obligated to transfer our rights to Daewoong.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also provides that Daewoong will indemnify us for any losses arising out of (i) Daewoong&#8217;s willful misconduct or gross negligence in performing its obligations under the agreement, (ii) Daewoong&#8217;s breach of the agreement, or (iii) any allegation that Jeuveau&#8482; or Daewoong&#8217;s trademark infringes or misappropriates the rights of a third party, except, in each case, as a result of our willful misconduct or gross negligence. We have agreed to indemnify Daewoong for any losses arising out of (A) our willful misconduct or gross negligence in performing our obligations under the agreement, or (B) our breach of the agreement, except, in each case, as a result of Daewoong&#8217;s willful misconduct or gross negligence. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our primary competitors in the pharmaceutical market are companies offering injectable dose forms of botulinum toxin. There are only four approved injectable botulinum toxin type A neurotoxins in the United States, including Jeuveau&#8482;. There are also other injectable botulinum toxin type A products being developed for the U.S. market. We believe the primary competing products in this market include BOTOX, Dysport and Xeomin:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">BOTOX, marketed by Allergan plc, or Allergan, received FDA approval in 2002 for glabellar lines. Allergan was the first company to market neurotoxins for aesthetic purposes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Dysport, marketed by Galderma S.A., or Galderma, received FDA approval in 2009 for glabellar lines.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Xeomin, marketed by Merz Pharma GmbH &amp; Co., or Merz, received FDA approval in 2011 for glabellar lines.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the companies commercializing neurotoxins, there are other products and treatments that may indirectly compete with Jeuveau&#8482;, such as dermal fillers, laser treatments, brow lifts, chemical peels, fat injections and cold therapy. We compete with various companies that have products in these medical aesthetic categories. Among these companies are Allergan, Sanofi, Sun Pharma, Valeant Pharmaceuticals International, Inc., or Valeant, Mentor Worldwide LLC, a division of Johnson &amp; Johnson, Merz, Galderma, and Skinceuticals, a division of L&#8217;Oreal SA. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are in various phases of development in North America for the treatment of glabellar lines. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Government Regulation Applicable to Us</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our business has been, and will continue to be, subject to a variety of laws including the Federal Food Drug and Cosmetic Act, or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">FFDCA, and the Public Health Service Act, or the PHS Act, among others. Biologics and medical devices are subject to regulation under the FFDCA and PHS Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the United States, cosmetics, dietary supplements, biopharmaceutical products and medical devices are subject to extensive regulation by the FDA. The FFDCA, PHS Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, regulatory approval, license or clearance, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of these products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending license or marketing applications, warning letters and other enforcement actions, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">U.S. Biological Products Development Process</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">submission to the FDA of an investigative new drug application, or IND, which must become effective before human clinical trials may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed biological product for its intended use, according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements including those for the protection of human research subjects and their health and other personal information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">purity and potency from results of nonclinical testing and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices for the use of human cellular and tissue products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">potential FDA audits of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">FDA review and approval of the BLA</font><font style="font-family:Times New Roman;font-size:9pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Preclinical Studies</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Biological product development in the United States typically involves preclinical laboratory and animal tests. Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs, among other requirements. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not objected to the IND within this 30-day period, the clinical trial proposed in the IND may begin.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Studies</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical trials must be conducted pursuant to an IND and in compliance with federal regulations and GCPs, an international standard meant to protect the rights and health of subjects and to define the roles of clinical trial sponsors, administrators, and monitors, as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">amendments must be submitted to the FDA as part of the IND. The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other requirements or sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. The clinical trial protocol, any protocol amendments, and informed consent information for subjects in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. The IRB also approves the form and content of the informed consent form that must be signed by each clinical trial subject or his or her legal representative, and the IRB must monitor the clinical trial until completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Phase I. The product candidate is initially introduced into a limited population of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for some diseases, or when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the disease or condition for which the product candidate is intended to gain an early indication of its effectiveness.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Phase II. The product candidate is evaluated in a limited patient population, but larger than in Phase I, to identify possible adverse events and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to assess dosage tolerance, optimal dosage and dosing schedule.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Phase III. Clinical trials are undertaken to further evaluate dosage, and provide substantial evidence of clinical efficacy and safety in an expanded patient population, such as several hundred to several thousand subjects, at geographically dispersed clinical trial sites. Phase III clinical trials are typically conducted when Phase II clinical trials demonstrate that a dose range of the product candidate is effective and has an acceptable safety profile. These trials typically have at least 2 groups of patients who, in a blinded fashion, receive either the product or a placebo. Phase III clinical trials are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase III clinical trials are required by the FDA for approval of a BLA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Phase IV. In some cases, the FDA may condition approval of a BLA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the product. Such post-approval studies are typically referred to as Phase IV clinical trials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Marketing Approval</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical trials to support BLAs, which are applications for marketing approval, are typically conducted in three sequential phases, but the phases may overlap. In Phase I, the initial introduction of the investigational biologic candidate into patients, the investigational biologic is tested to assess side effects and, if possible, early evidence on effectiveness. Phase II usually involves trials in a limited subject population to determine the effectiveness of the investigational biologic for a particular indication or indications and identify common adverse effects and safety risks.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If an investigational biologic demonstrates evidence of effectiveness and an acceptable safety profile in Phase II evaluations, Phase III clinical trials are undertaken to obtain additional information about clinical efficacy and safety in a larger number of subjects, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the investigational product and to provide adequate information for its labeling. In most cases, the FDA requires two adequate and well-controlled Phase III clinical trials to demonstrate the efficacy and safety of the biologic for use in a specific indication or population. A single Phase III clinical trial with other confirmatory evidence may be sufficient in rare instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s manufacture and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application fee, and the manufacturer or sponsor under an approved BLA are also subject to annual FDA product and establishment user fees.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such applications for standard review biologics products are reviewed within twelve months of submission; most applications for priority review biologics are reviewed within eight months of submission. Priority review for biologics is limited to those products intended to treat a serious or life-threatening disease with unmet medical need relative to the currently approved products. The review process may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel biologics products or biologics products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the BLA unless it determines that compliance with cGMP is satisfactory. Manufacturers of biologics also must comply with the FDA&#8217;s general biological product standards. After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter outlines the deficiencies in the submission and may require substantial additional testing, including additional large-scale clinical testing or information in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy and may impose other conditions, including labeling restrictions, which can materially affect the product&#8217;s potential market and profitability. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems or safety issues are identified following initial marketing. Changes to some of the conditions established in an approved application, including changes in indications, labeling, ingredients or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Post-Approval Requirements</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase IV testing, Risk Evaluation and Mitigation Strategies, or REMS, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging and labeling procedures must continue to conform to cGMP after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with applicable regulations such as cGMP and the Quality System Regulation. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Biosimilar Approval Process</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, established an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on their similarity to an existing brand product.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a BLA. However, an application may be submitted after four years. The BPCIA is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">complex and is still in the process of being interpreted and implemented by the FDA. As a result, its ultimate impact and implementation are subject to uncertainty.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Government Regulation in Europe</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the European Economic Area, or EEA (which is composed of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are two types of MAs:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when the authorization of a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. Under the accelerated procedure the standard 210 days review period is reduced to 150 days.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in other Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Because we are a biotechnology medicinal products company, we are eligible for a Community MA under the Centralized Procedure.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Product Approval Process Outside the United States and Europe</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to regulations in the United States and EU, we will be subject to a variety of regulations in other jurisdictions governing manufacturing, clinical trials, commercial sales and distribution of our future products.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Whether or not we obtain FDA approval or MA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval or MA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Federal and State Fraud and Abuse</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we do not currently have plans for our neurotoxin product to be covered by insurance or government reimbursement programs, if we were to offer reimbursable products, we could be subject to federal laws and regulations covering reimbursable products, such as the Anti-Kickback Statute, Stark Law and Physician Payment Sunshine Act.  These laws that may affect our ability to operate include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving any remuneration (including any ownership, kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return, for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, service or item for which payment is made, in </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:13px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">whole or in part, under a federal health care program. The Anti-Kickback Statute has been interpreted to apply, among others, to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for a statutory exception or a regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. Violations of the Anti-Kickback Statute may result in substantial civil or criminal penalties, including criminal fines of up to $25,000 for each violation and imprisonment of up to five years for each violation. Violations are also subject to sanctions under the Civil Monetary Penalties Law, including penalties of up to $50,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act of up to $11,000 for each claim submitted, plus up to three times the amounts paid for such claims, and exclusion from participation in the Medicare and Medicaid programs;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal False Claims Act, which prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal healthcare programs that are false or fraudulent. Suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the False Claims Act, the government may impose penalties of not less than $5,500 and not more than $11,000 per claim, plus up to three times the amount of damages which the government sustains because of the submission of a false claim, and may exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. Recently, the civil False Claims Act has been used to assert liability on the basis of kickbacks and improper referrals, improperly reported government pricing metrics such as Medicaid Best Price or Average Manufacturer Price, improper use of supplier or provider Medicare numbers when detailing a provider of services, improper promotion of drugs or off-label uses not expressly approved by the FDA in a drug&#8217;s label, and misrepresentations with respect to the services rendered or items provided, among other issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. Significantly, the HIPAA provisions apply not only to federal programs, but also to private health benefit programs. HIPAA also broadened the authority of the Office of Inspector General to exclude participants from federal healthcare programs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Physician Payments Sunshine Act, and its implementing regulations, which require that certain manufacturers of drugs, medical devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report to the CMS information related to certain payments or other transfers of value made or distributed to physicians, which is defined broadly to include other healthcare providers, teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. Manufacturers are required to submit reports to CMS by the 90th day of each calendar year. Failure to submit the required information may result in civil monetary penalties up to an aggregate of $150,000 per year (and up to an aggregate of $1 million per year for &#8220;knowing failures&#8221;) for all payments, transfers of value or ownership or investment interests not reported in an annual submission, and may </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:13px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">result in liability under other federal laws or regulations. Some state laws require biopharmaceutical companies to adopt or disclose specific compliance policies to regulate a company&#8217;s interactions with healthcare professionals. Moreover, some states, such as Minnesota and Vermont, also impose an outright ban on certain gifts to physicians.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may also be subject to analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers or self-pay patients; state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require pharmaceutical manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Data Privacy and Security Laws and Regulations</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also subject to data privacy and security regulation by the federal government, states and non-U.S. jurisdictions in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state and non-U.S. laws, including the General Data Protection Regulation adopted by the EU, govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Environmental Regulation</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">We are subject to numerous foreign, federal, state, and local environmental, health and safety laws and regulations relating to, among other matters, safe working conditions, manufacturing practices, fire hazard control, product stewardship and end-of-life handling or disposition of products, and environmental protection, including those governing the generation, storage, handling, use, transportation and disposal of hazardous or potentially hazardous substances and biological materials. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">70</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;employees, all of whom constituted full-time employees. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We were incorporated in the State of Delaware in November 2012. Our principal executive offices are located at&#160;520 Newport Center Drive, Suite 1200, Newport Beach, California 92660,&#160;and our telephone number is (949) 284-4555. Our website address is www.evolus.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website a part of this Annual Report on Form 10-K or any other filing we make with the SEC. We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and also a smaller reporting company, and therefore we are subject to reduced public company reporting requirements. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We make available, free of charge, on our website at www.evolus.com our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to such reports, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC.  All such reports are also available free of charge via EDGAR through the SEC website at www.sec.gov.&#160; The contents of these websites are not incorporated into this Annual Report on Form 10-K.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><a name="s54599D6114485058B6712366AB18222C"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">You should carefully consider the risks and uncertainties described below, together with all the other information in this Annual Report on Form 10-K, including Item 7&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and the related notes included in Item 8 &#8220;Financial Statements and Supplementary Data.&#8221; If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations, revenue, and future prospects. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Strategy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We have a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one product and no commercial sales, which, together with our limited operating history, make it difficult to assess our future viability. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a limited operating history. Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have invested substantially all of our efforts and financial resources in the clinical development and regulatory approval of, and commercial planning for, Jeuveau&#8482;, which is currently our only product. We are not profitable and have incurred losses in each year since our inception in 2012. We have a limited operating history upon which you can evaluate our business and prospects. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or experience commercializing a product. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the medical aesthetics field. To date, we have not generated any revenue from product sales relating to Jeuveau&#8482;. We continue to incur significant expenses related to the commercialization of Jeuveau&#8482;. We have recorded net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and had an accumulated deficit as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we begin to commercialize Jeuveau&#8482;. Our ability to achieve revenue and profitability is dependent on our ability to successfully market and commercialize Jeuveau&#8482;. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We currently depend entirely on the successful commercialization of our only product, Jeuveau&#8482;. If we are unable to successfully commercialize Jeuveau&#8482;, we may never generate sufficient revenue to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have only one product, Jeuveau&#8482;, and our business presently depends entirely on our ability to successfully commercialize it in a timely manner. While Jeuveau&#8482; has been approved for sale in the United States and Canada, we have yet to successfully commercialize our product. Our near-term prospects, including our ability to finance our company and generate revenue, as well as our future growth, depend entirely on the successful and timely commercialization of Jeuveau&#8482;. The commercial success of Jeuveau&#8482; will depend on a number of factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our success in educating physicians and consumers about the benefits, administration and use of Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the prevalence, duration and severity of potential side effects experienced with Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">achieving and maintaining compliance with all regulatory requirements applicable to Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability to raise additional capital on acceptable terms, or at all, if needed, to support the commercial launch of Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the acceptance by physicians and consumers of the safety and efficacy of Jeuveau&#8482;;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to successfully commercialize Jeuveau&#8482;, whether alone or in collaboration with others, including our ability to hire, retain and train sales representatives in the United States;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability of our current manufacturer and any third parties with whom we may contract to manufacture Jeuveau&#8482; to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current Good Manufacturing Practice, or cGMP, requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of competing products, the timing of new product introductions by our competitors, and the sales and marketing tactics of our competitors, including bundling of multiple products, in response to our launch of Jeuveau&#8482;.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to commercialize Jeuveau&#8482;. Further, we may never be able to successfully commercialize Jeuveau&#8482; or any future product candidates. In addition, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">are in the process of transitioning</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such transition. Accordingly, we may not be able to generate sufficient revenue through the sale of Jeuveau&#8482; or any future product candidates to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We rely on the Daewoong Agreement to provide us exclusive rights to distribute Jeuveau&#8482; in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of Jeuveau&#8482;. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement, we have secured an exclusive license from Daewoong, a South Korean pharmaceutical manufacturer, to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau&#8482; for aesthetic indications in the United States, EU, Canada, Australia, Russia, C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Daewoong Agreement imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, intellectual property protection and other matters. We are obligated to conduct development activities, obtain regulatory approval of Jeuveau&#8482;, obtain from Daewoong all of our product supply requirements for Jeuveau&#8482; and pay to Daewoong regulatory milestone payments and other cash payments in connection with the net sales of Jeuveau&#8482;. In addition, under the Daewoong Agreement, we are required to submit our commercialization plan to a joint steering committee, or JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, for review and input. Although the Daewoong Agreement provides us with final decision-making power regarding the marketing, promotion, sale and/or distribution of Jeuveau&#8482;, any disagreement among the JSC would be referred to Daewoong&#8217;s and our respective senior management for resolution </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">if the JSC is unable to reach a decision within thirty days, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">which may result in a delay in our ability to implement our commercialization plan or harm our working relationship with Daewoong. After the commercial launch of Jeuveau&#8482;, Daewoong may, at its sole option, elect to convert the exclusive license to a non-exclusive license if we fail to achieve minimum annual purchase targets of Jeuveau&#8482; upon commercialization of the product. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The initial term of the Daewoong Agreement will expire on the later of September 30, 2023 or the fifth anniversary of our receipt of marketing approval in any of the aforementioned territories. The Daewoong Agreement will renew for unlimited additional three year terms after the expiration of the initial term, only if we meet certain performance requirements during the initial term or preceding renewal term, as applicable. We or Daewoong may terminate the Daewoong Agreement if the other party breaches any of its duties or obligations and such breach continues without cure for ninety days, or thirty days in the case of a payment breach, or if we declare bankruptcy or assign our business for the benefit of creditors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Daewoong and Daewoong may have the right to terminate our license. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Daewoong Agreement, we may not have sufficient funds available to meet our obligations, which would allow Daewoong to terminate the Daewoong Agreement. Any termination or loss of rights (including exclusivity) under the Daewoong Agreement would materially and adversely affect our ability to commercialize Jeuveau&#8482;, which in turn would have a material adverse effect on our business, operating results and prospects. If we were to lose our rights under the Daewoong Agreement, we believe it would be difficult for us to find an alternative supplier of a botulinum toxin type A complex. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals that may never be obtained or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. Additionally, if we experience delays as a result of a dispute with Daewoong, the demand for Jeuveau&#8482; could be materially and adversely affected.  Additionally, if the Daewoong Agreement is terminated, breached or has certain other adverse actions, it may constitute an event of default under our loan and security agreement, or credit facility, with Oxford Finance, LLC, or Oxford. Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Oxford, as collateral agent, could exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including cash.  Any such action could materially and adversely affect our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We currently rely solely on Daewoong to manufacture Jeuveau&#8482;, and as such, any production or other problems with Daewoong could adversely affect us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We depend solely upon Daewoong for the manufacturing of Jeuveau&#8482;. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for and qualify alternative suppliers, which could have a material adverse effect on our business. Suppliers of any new product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our reliance on Daewoong entails additional risks, including reliance on Daewoong for regulatory compliance and quality assurance, the possible breach of the Daewoong Agreement by Daewoong, and the possible termination or nonrenewal of the Daewoong Agreement at a time that is costly or inconvenient for us. Our failure, or the failure of Daewoong, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Jeuveau&#8482;. Our dependence on Daewoong also subjects us to all of the risks related to Daewoong&#8217;s business, which are all generally beyond our control. Daewoong&#8217;s ability to perform its obligations under the Daewoong Agreement is dependent on Daewoong&#8217;s operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in South Korea and the broader region in general and the ability of Daewoong to continue to successfully attract customers and compete in its market. Furthermore, Daewoong&#8217;s recently constructed manufacturing facility is Daewoong&#8217;s only facility meeting FDA and EMA cGMP requirements. Daewoong&#8217;s lack of familiarity with, or inability to effectively operate, the facility and produce products of consistent quality, may harm our ability to compete in our market.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on Daewoong for day-to-day compliance with cGMP for production of drug substance and finished products. Facilities used by Daewoong to produce the drug substance and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. If the safety of Jeuveau&#8482; is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging. Any of these factors could adversely impact our ability to effectively commercialize Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any failure or refusal by Daewoong or any other third party to supply Jeuveau&#8482; or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">may prevent or delay our development and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, aesthetic medicine and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau&#8482;. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third parties may assert that we or any of our current or future licensors, including Daewoong, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of Jeuveau&#8482; or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Jeuveau&#8482; or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of Jeuveau&#8482; or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of Jeuveau&#8482; or any of our future product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used by us toward the maintenance of our own intellectual property and the development and commercialization of Jeuveau&#8482; and any of our future product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. Presently, we are a defendant in a lawsuit brought by Medytox, Inc., or Medytox, on June 7, 2017 in the Superior Court of the State of California, alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau&#8482; (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us, or the Medytox Litigation. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong filed a motion to dismiss or stay for forum non conveniens, claiming that the place where the complaint has been filed, in the Superior Court of the State of California, is not the proper place for the trial of the claims in the complaint because, among other reasons, the underlying facts that gave rise to the complaint occurred in South Korea. Daewoong&#8217;s motion to dismiss was granted by the Superior Court of the State of California on October 12, 2017. As a result, the action filed with the Superior Court of the State of California is stayed pending resolution of the proceedings in South Korea. In October 2017, Medytox initiated a civil lawsuit against Daewoong and its parent company, Daewoong Co. Ltd., in the Seoul Central District Court in Seoul, South Korea, related to the same subject matter in the Medytox litigation and is seeking, among other things, money damages, injunctive relief and destruction of related documents and products. None of us, ALPHAEON or SCH are parties to the litigation in the Seoul Central District Court.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 27, 2018, pursuant to a motion to dismiss brought by Daewoong, the Superior Court of the State of California dismissed Medytox&#8217;s suit against Daewoong, without prejudice, on the basis that Medytox had brought a substantially similar proceeding against Daewoong in South Korea. The proceedings against us, ALPHAEON and SCH remain stayed in the Superior Court of the State of California pending resolution of the proceedings between Medytox and Daewoong in South Korea.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code Section 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code Section 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau&#8482;, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing Jeuveau&#8482;, and (v) attorneys&#8217; fees and costs. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us, ALPHAEON, SCH or Daewoong or to quantify any risk of loss. The Medytox Litigation and any other similar claims, suits, government investigations, and proceedings are inherently uncertain and their results may not be favorable for us. For example, if the Medytox Litigation has a negative outcome for us, ALPHAEON or Daewoong, it could result in us losing access to Jeuveau&#8482; and the manufacturing process and require us to negotiate a new license with Medytox for continued access to Jeuveau&#8482;. We may not be able to successfully negotiate such license on terms acceptable to us or at all. If we are unable to license Jeuveau&#8482;, we may not be able to find a replacement product, if at all, without expending significant resources and being required to seek additional regulatory approvals, which would be uncertain, time consuming and costly. Regardless of the outcome, such proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. An adverse ruling against either us or one of the other defendants of any such proceedings could adversely affect our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission, or the ITC, containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau&#8482; is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau&#8482; is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the ITC Complaint.  The ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930.  The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau&#8482; into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau&#8482; within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen BTX Strain, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau&#8482; into the United States and a cease and desist order which would bar sales and marketing of our sole product Jeuveau&#8482; within the United Sates either of which would adversely affect our ability to carry our out our business and which would have an adverse effect on our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, in certain cases if there is preliminary or permanent relief granted under the Medytox Litigation or the ITC matter, it may constitute an event of default under our credit facility.  Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including cash.  Any such action could materially and adversely affect our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties which may not be commercially or more available, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of Jeuveau&#8482; or any future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist that might be enforced against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Borrowings under our credit facility could adversely affect our financial condition and restrict our operating flexibility. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, or the closing date, we entered into the credit facility with Oxford, or the lender, pursuant to which the lender will make term loans available to us of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the credit facility. The credit facility provides that the term loans will be funded in two advances. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was funded on the closing date, and the second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be drawn, at our request, no later than September 30, 2020, upon achieving specified minimum net sales milestones and no event of default is occurring. The credit facility bears an annual interest rate equal to the greater </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. We have agreed to pay interest only on each tranche funded pursuant to the credit facility for the first 36 months until May 2022, which will be followed by a 23-month amortization period. Notwithstanding the foregoing, if we maintain compliance with the specified minimum net sales covenant and meet other conditions during the initial interest-only period, upon our request, the interest only period may be extended by an additional 12 months to a total of 48 months followed by an 11-month amortization period.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of our assets. The credit facility contains customary affirmative and restrictive covenants and representations and warranties. We are bound by certain affirmative covenants setting forth actions that are required during the term of the credit facility including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the credit facility without Oxford&#8217;s prior written consent, including, without limitation, incurring certain additional indebtedness, consummating certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest payments, fees, covenants and restrictions under the credit facility could have important consequences, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limiting our ability to obtain additional financing on satisfactory terms to fund our working capital requirements, capital expenditures, potential acquisitions, debt obligations and other general corporate requirements, and making it more difficult for us to satisfy our obligations with respect to any such additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increasing our vulnerability to general economic downturns, competition and industry conditions, which could place us at a competitive disadvantage compared to our competitors with no debt obligations or with debt obligations on more favorable terms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limiting our ability to pursue acquisition opportunities and to license intellectual property outside specified exceptions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The occurrence of any one of these events could have an adverse effect on our business, financial condition, operating results or cash flows and ability to satisfy our obligations under the credit facility and any other indebtedness. If new debt is incurred in addition to debt incurred under the credit facility, the related risks that we face would be increased. The terms of the credit facility may restrict our current and future operations, particularly our ability to respond to changes in our business or to take certain actions. The credit facility contains, and the terms of any future indebtedness of ours would likely contain, a number of restrictive covenants that impose significant operating restrictions, including restrictions on our ability to engage in acts that may be in our best long-term interests. The credit facility includes covenants that, among other things and subject to certain exceptions and limits, restrict or otherwise limit our ability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">dispose of assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">undergo certain business, management, ownership, business and other fundamental changes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">engage in certain merger, acquisition and consolidation transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">incur additional indebtedness and create liens and other encumbrances;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">make restricted payments, including dividends and other distributions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">engage in certain transactions with affiliates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default including, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against us, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement.  Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against including the ability to declare any outstanding debt immediately due and payable. In addition, the credit facility is secured by certain of our existing and hereafter created or acquired assets, including our intellectual property, cash, accounts receivable, equipment, general intangibles, inventory and all of the proceeds and products of the foregoing. If we are unable to pay any amounts due and payable under the credit facility because we do not have sufficient cash on hand or are unable to obtain alternative financing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">on acceptable terms, the lenders could initiate a bankruptcy proceeding or proceed against any assets that serve as collateral to secure the credit facility. These restrictions could limit our ability to obtain future financings, make needed capital expenditures, withstand future downturns in the economy or otherwise conduct necessary corporate activities. We may also be prevented from taking advantage of business opportunities that arise because of limitations imposed on us by the restrictive covenants under the credit facility.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval of Jeuveau&#8482; initially in the United States, EU and Canada. We expect that we will continue to expend substantial resources for the foreseeable future in order to commercialize Jeuveau&#8482;, for the development of any other indications of Jeuveau&#8482;, and for the clinical development of any additional product candidates we may choose to pursue. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the near term, these expenditures will include costs associated with the development and expansion of our sales force and commercialization infrastructure in connection with commercializing Jeuveau&#8482;. In the long term, these expenditures will include costs associated with the continued commercialization of Jeuveau&#8482; and any of our future product candidates, such as research and development, conducting preclinical studies and clinical trials and manufacturing and supplying as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the regulatory approval process and commercialization expenditures needed to meet our sales objectives is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of Jeuveau&#8482; or any future product candidates. We expect to incur additional costs as we continue to operate as a public company, hire additional personnel and expand our operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We anticipate that our existing cash together with the proceeds from the credit facility will be sufficient to fund our operating plan through the initial launch and commercialization of Jeuveau&#8482;. We have based these estimates, however, on assumptions that may prove to be wrong, and we could spend our available capital resources much faster than we currently expect or require more capital to fund our operations than we currently expect. For example, we may require additional funds earlier than we currently expect in the event that market acceptance of Jeuveau&#8482; is slower than expected. Our currently anticipated expenditures for the commercialization of Jeuveau&#8482; may exceed the net proceeds from our initial public offering and our existing cash and we may need to seek additional debt or equity financing.  Additionally, under our loan facility with Oxford, in order to draw the final $25 million of the facility, we must meet a number of conditions including maintaining compliance with covenants under the loan agreement and the achievement of specified net sales targets based on a trailing six month basis. In the event we are unable to reach this net sales milestone, we will not be able to draw the additional $25 million.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may need to raise additional capital to fund our operations and continue to support both our near and long-term expenditures. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our future capital requirements depend on many factors, including:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of commercialization activities for Jeuveau&#8482; or if any other future product candidates are approved for sale, including marketing, sales and distribution costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the scope, progress, results and costs of researching and developing any future product candidates, and conducting preclinical and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to accurately forecast demand for our products, the ability of our third-party manufacturers to scale production to meet that demand, and our ability to effectively manage our working capital requirements including the purchase of inventory and collection of receivables</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs under our third-party manufacturing and supply arrangements for our current and any future product candidates and any products we commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing of such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of, and the costs involved in, obtaining regulatory approvals for any future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the degree and rate of market acceptance of Jeuveau&#8482; or any future approved products;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products, the timing of new product introductions by competitors and other actions by competitors in the marketplace;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs of operating as a public company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs associated with any acquisition or in-license of products and product candidates, technologies or businesses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to commercialize Jeuveau&#8482; or any future product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event we are unable to raise sufficient capital to fund our commercialization efforts to achieve specified minimum sales targets under the Daewoong Agreement, we will lose exclusivity of the license that we have been granted under the Daewoong Agreement.  In addition, if we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau&#8482; may fail to achieve the broad degree of physician adoption and use necessary for commercial success. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau&#8482; may fail to gain sufficient market acceptance by physicians, consumers and others in the medical aesthetics community. The commercial success of Jeuveau&#8482; and any future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of Jeuveau&#8482;, the treatment of glabellar lines and other aesthetic indications that we may seek to pursue. We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The degree and rate of physician adoption of Jeuveau&#8482; and any future product candidates depend on a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the effectiveness, ease of use, and safety of Jeuveau&#8482; and any future product candidates as compared to existing products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">physician and consumer willingness to adopt Jeuveau&#8482; to treat glabellar lines or other aesthetic indications we may pursue over products and brands with which consumers and physicians may have more familiarity or recognition </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or additional approved uses</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">overcoming any biases physicians or consumers may have toward the use, safety and efficacy of existing products or treatments </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and successful marketing of the benefits of a 900 kDa botulinum toxin type A complex</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the cost of Jeuveau&#8482; and any future product candidates in relation to alternative products or treatments and willingness to pay for the product or treatment on the part of consumers&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">proper training and administration of Jeuveau&#8482; and any future product candidates by physicians and medical staff&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer satisfaction with the results and administration of Jeuveau&#8482; and any future product candidates and overall treatment experience;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in pricing, </font><font style="font-family:Times New Roman;font-size:10pt;">promotional, negative sales tactics, promotion of longer-term purchase agreements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and bundling efforts by competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the filing of various lawsuits by competitors with the intent of preventing or delaying our product launches, to distract management&#8217;s attention from operating our business and to devote significant financial resources to defend such litigation attempts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer demand for the treatment of glabellar lines or other aesthetic indications that may be approved in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the willingness of consumers to pay for Jeuveau&#8482; and any future product candidates relative to other discretionary items, especially during economically challenging times&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the revenue and profitability that Jeuveau&#8482; and any future product candidates may offer a physician as compared to alternative products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the effectiveness of our sales, marketing and distribution efforts and our ability to develop our brand awareness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">any adverse impact on our brand resulting from key opinion leader relationships with ALPHAEON or SCH, whether or not related to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to compete with our competitors&#8217; product bundling offerings as we plan to initially launch Jeuveau&#8482; as a stand-alone product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adverse </font><font style="font-family:Times New Roman;font-size:10pt;">publicity </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">about our product candidates, competitive products, or the industry as a whole, or favorable publicity about competitive products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, in its clinical trials, Jeuveau&#8482; was clinically tested with one Jeuveau&#8482; unit compared to one BOTOX unit. Jeuveau&#8482; is the only known neurotoxin product in the United States with a 900 kDa complex other than BOTOX. We believe that aesthetic physicians&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of Jeuveau&#8482; into their practices. However, the ease of integration of Jeuveau&#8482; into a physician&#8217;s practice may not be as seamless as we anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If Jeuveau&#8482; or any future product candidates fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If there is not sufficient consumer demand for Jeuveau&#8482;, our financial results and future prospects will be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Treatment of glabellar lines with Jeuveau&#8482; is an elective procedure, the cost of which must be borne by the consumer, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a consumer to undergo treatment with Jeuveau&#8482; for the treatment of glabellar lines or other aesthetic indications that we may pursue may be influenced by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience and are still in the process of planning and developing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the extent to which physicians recommend Jeuveau&#8482; to their patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the extent to which Jeuveau&#8482; satisfies consumer expectations </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and overcoming consumer loyalty with existing products and brands</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to properly train physicians in the use of Jeuveau&#8482; such that their consumers do not experience excessive discomfort during treatment or adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the cost, safety and effectiveness of Jeuveau&#8482; versus other aesthetic treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the development </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;availability of alternative products and treatments that seek to address similar goals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer sentiment about the benefits and risks of aesthetic procedures generally and Jeuveau&#8482; in particular;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the success of any direct-to-consumer marketing efforts that we may initiate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability and ease with which physicians are able to incorporate Jeuveau&#8482; into their practices; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in demographic and social trends; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general consumer </font><font style="font-family:Times New Roman;font-size:10pt;">confidence</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which may be impacted by economic and political conditions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau&#8482; is the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy will allow for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, physicians may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to Jeuveau&#8482;, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with Jeuveau&#8482; on price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient consumer demand for Jeuveau&#8482;. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we have not pursued regulatory approval of Jeuveau&#8482; for indications other than for the treatment of glabellar lines, which may limit adoption of Jeuveau&#8482;. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin product and may be able to market such product for use in a way we cannot. For example, we are aware that one of our competitors, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Allergan plc</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or Allergan, has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and therefore is able to market its product across a greater number of indications than Jeuveau&#8482;. If we are unable to obtain approval for indications in addition to glabellar lines, our marketing efforts for Jeuveau&#8482; will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau&#8482; and any future product candidates will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">In the near term, we expect to enter into the highly competitive aesthetic neurotoxin market through the commercial launch of Jeuveau&#8482;. In the long term, we expect to expand our focus to the broader self-pay healthcare market. While numerous companies are engaged in the development, patenting, manufacture and marketing of aesthetic neurotoxin products competitive with Jeuveau&#8482;, Allergan, through its product BOTOX, held approximately 75.0% of the global market share in the aesthetic neurotoxin market by revenue in 2018. Allergan and many of these potential competitors are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, larger sales forces and more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These competitors may also try to compete with Jeuveau&#8482; on price both directly, through rebates and promotional programs to high volume physicians and coupons to consumers, and indirectly, through attractive product bundling with complimentary products, such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger companies may be better capitalized than us and, accordingly, are able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant amount of studies and research papers that they could use to compete with us.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Competitors and other parties may also seek to impact regulatory approval of our future product applications through the filing of citizen petitions or other similar documents, which could require costly and time-consuming responses to the regulatory agencies. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Larger competitors could seek to prevent or delay our market entry via costly litigation which can be lengthy and expensive and serve to distract our management team&#8217;s attention. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We could face competition from other sources as well, including academic institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader self-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our planned strategy to compete in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to self-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event that regulations applicable to reimbursed products are changed to apply to self-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material effect on our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The first use of Jeuveau&#8482; will be in aesthetic medicine. The aesthetic product market, and the facial aesthetic market in particular, is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. We have received regulatory approval of Jeuveau&#8482; for the treatment of glabellar lines. We anticipate that Jeuveau&#8482; will face significant competition from other facial aesthetic products, such as other injectable and topical botulinum toxins and dermal fillers. Jeuveau&#8482; may also compete with unapproved and off-label treatments. In addition, competitors may develop new technologies within the aesthetic market that may be superior in safety and efficacy to Jeuveau&#8482; or offer alternatives to the use of toxins, including surgical and radio frequency techniques. To compete successfully in the aesthetic market, we will have to demonstrate that Jeuveau&#8482; is at least as safe and effective as current products sold by our competitors. Competition in the aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we face more competition in these markets than in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than Jeuveau&#8482; or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing Jeuveau&#8482; and any future product candidates and attracting physician and consumer demand.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau&#8482; or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. For example, one company has filed a Citizen Petition requesting that the FDA not apply the BPCI Act to pre-enactment BLAs. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that Jeuveau&#8482; should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau&#8482; is manufactured exclusively in one facility located in South Korea, and we plan to utilize this facility to support commercial production of Jeuveau&#8482;. If this facility were damaged or destroyed, or if there occurs a significant disruption in operations at this facility for any reason, our ability to continue to operate our business would be materially harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong developed the manufacturing process for Jeuveau&#8482; and manufactures Jeuveau&#8482; in a recently constructed facility located in South Korea. We plan to utilize Daewoong&#8217;s facility for commercial production of Jeuveau&#8482;. If this facility were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other reason, such an event could jeopardize </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong&#8217;s ability to manufacture Jeuveau&#8482; as promptly as we or our customers expect or possibly at all. If we experience delays in achieving our development objectives, or if Daewoong is unable to manufacture Jeuveau&#8482; within a timeframe that meets ours and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If these disruptions exceed coverage provided by Daewoong&#8217;s insurance policies, Daewoong may be unable to satisfy its obligations to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters or political unrest and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or political unrest. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong, the sole manufacturer of Jeuveau&#8482;, manufactures Jeuveau&#8482; in a facility located in South Korea. In addition, the underlying drug substance for Jeuveau&#8482; is also manufactured in a separate facility on the same campus. The risk of extreme weather and earthquakes in the Pacific Rim region is significant due to the proximity of major earthquake fault lines. There is also a level of political unrest or uncertainty in South Korea and the broader region. Natural disasters or political unrest could severely disrupt Daewoong&#8217;s operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a natural disaster, political unrest, power outage or other event occurred that prevented Daewoong from using all or a significant portion of its manufacturing facility, or prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because Daewoong manufactures Jeuveau&#8482; in its facility, in the event of a natural disaster, political unrest, power outage or other event affecting this facility, we would be required to seek additional manufacturing facilities and capabilities that have obtained the necessary approvals required by state, federal or other applicable authorities in order to continue or resume manufacturing activities, which we may not be able to do on commercially reasonable terms if at all. Any disaster recovery and business continuity plans that we and Daewoong have in place or put in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of our or Daewoong&#8217;s lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to market Jeuveau&#8482; is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau&#8482;, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have received regulatory approval for Jeuveau&#8482; in the United States for the treatment of moderate to severe glabellar lines. The terms of that approval restrict our ability to market or advertise Jeuveau&#8482; for other indications, which could limit physician and consumer adoption. Under the U.S. Federal Food Drug and Cosmetic Act, we may generally only market Jeuveau&#8482; for approved indications. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin products and may be able to market such products for use in a way we cannot. For example, we are aware that one of our competitors, Allergan, has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and therefore is able to market its product across a greater number of indications than Jeuveau&#8482;. If we are unable to obtain approval for indications in addition to our anticipated approval for glabellar lines, our marketing efforts for Jeuveau&#8482; will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau&#8482;. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have entered into an agreement with ALPHAEON relating to certain rights to the therapeutic indications of Jeuveau&#8482; under the Daewoong Agreement and, as a result, we will not be able to pursue therapeutic indications for Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 18, 2017, we entered into the therapeutic agreement with ALPHAEON, or the therapeutic agreement, relating to certain rights to the therapeutic indications of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;under the Daewoong Agreement. Pursuant to the Daewoong Agreement, we received an option to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to cover all therapeutic uses in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">United States, EU, Canada, Australia, Russia, C.I.S., and South Africa, or the covered</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;territories, and Japan, or the therapeutic option. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">However, pursuant to the therapeutic agreement, we agreed not to sell, sub-license or otherwise dispose in whole or in part the therapeutic option or the rights underlying the therapeutic option and hold the therapeutic option and the underlying rights </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in trust for ALPHAEON. In September 2018, ALPHAEON exercised the right to obtain the therapeutic option to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and remitted the option exercise price directly to Daewoong.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, under the therapeutic agreement, ALPHAEON has the right to negotiate the entry into an agreement with Daewoong for distribution rights for therapeutic indications of botulinum toxin products that are separate and distinct from the Daewoong Agreement, or the ALPHAEON-Daewoong agreement. We have agreed to ALPHAEON and Daewoong&#8217;s entry into the ALPHAEON-Daewoong agreement, so long as the terms do not diminish, interfere with or adversely affect our ability to distribute Jeuveau&#8482; for aesthetic indications in the covered territories and Japan under the Daewoong Agreement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our entry into the therapeutic agreement eliminates our ability to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for therapeutic indications .</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as Jeuveau&#8482;. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or </font><font style="font-family:Times New Roman;font-size:10pt;">other similar regulatory authorities</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as reflected in the product&#8217;s approved labeling. Physicians could use Jeuveau&#8482; on their patients in a manner that is inconsistent with the approved label of the treatment of moderate to severe glabellar lines, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters from and be subject to other enforcement actions by the FDA, EMA and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Physicians may also misuse Jeuveau&#8482; or any future product candidates or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Jeuveau&#8482; or any future product candidates are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of Jeuveau&#8482; or any future product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau&#8482; or any of our future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling or result in post-approval regulatory action.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unforeseen side effects from Jeuveau&#8482; or our future product candidates could arise either during clinical development or after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, EMA or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau&#8482;, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may withdraw their approval of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require a recall of the product or we may voluntarily recall a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require the addition of warnings or contraindications in the product labeling, narrowing of the indication in the product label or issuance of field alerts to physicians and pharmacies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require us to create a medication guide outlining the risks of such side effects for distribution to patients or institute a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Risk Evaluation and Mitigation Strategies, or </font><font style="font-family:Times New Roman;font-size:10pt;">REMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we may be subject to limitations as to how we market or promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we may be required to change the way the product is administered or modify the product in some other way;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales of the product may decrease significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our brand </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our products. The demand for Jeuveau&#8482; could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although a substantial amount of our effort will focus on the commercialization of Jeuveau&#8482;, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a portfolio of products to serve the self-pay aesthetic market. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize Jeuveau&#8482; or any other future product candidates or generate product revenue. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have limited marketing capabilities and a limited sales organization. To commercialize Jeuveau&#8482; or any other future product candidates in the United States, EU, Canada and other jurisdictions we may seek to enter, we must build our marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. We plan to market Jeuveau&#8482; in the United States through an internal specialized sales force and outside the United States through distributors, and such marketing efforts will be expensive and time consuming. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize Jeuveau&#8482; or any future product candidates. To the extent we commercialize our product candidates by entering into agreements with third-party collaborators, we may have limited or no control over the sales, marketing and distribution activities of these third parties, in which case our future revenues would depend heavily on the success of the efforts of these third parties. If we are not successful in commercializing Jeuveau&#8482; or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We will need to increase the size of our organization, and we may experience difficulties in managing this growth. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">70</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;employees, all of whom constituted full-time employees. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We will need to continue to expand our managerial, operational, finance and other resources to manage our operations, commercialize Jeuveau&#8482; or any other product candidates, and continue our development activities. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">manage any of our future clinical trials effectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">identify, recruit, retain, incentivize and integrate additional employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">continue</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to improve our operational, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates applicable regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory agencies, manufacturing standards, and federal and state healthcare laws and regulations. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">kickbacks, self-dealing and other abusive practices. Although our strategy to focus only on the self-pay market will reduce our risk under the Anti-Kickback Statute, we could face liability under similar state laws that are not limited to products reimbursed by the government or if we obtain regulatory approval for products reimbursed by federal healthcare programs in the future. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, referrals, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment and the curtailment or restructuring of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">In the future, we may rely on third parties and consultants to conduct all of our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the future, we may rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as contract research organizations, or CROs, to conduct clinical trials on our product candidates. The third parties with whom we may contract for execution of any of our future clinical trials may play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, any of these third parties may not be our employees, and except for contractual duties and obligations, we would have limited ability to control the amount or timing of resources that they devote to any of our future programs. Although we may rely on these third parties to conduct our preclinical studies and clinical trials, we would remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable investigational plan and protocol. Moreover, the FDA and other similar regulatory authorities require us to comply with, among other requirements, good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We may also rely on consultants to assist in the execution, including data collection and analysis, of any of our future clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. If the third parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for and will not be able to, or may be delayed in our efforts to, successfully commercialize any future product candidates being tested in such trials. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We plan to rely on third-party distribution partners for the distribution of our products, product candidates and services, which could delay or limit our ability to generate revenue.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With respect to certain markets for our products, product candidates and services, we plan to retain third-party service providers to perform functions related to the marketing, distribution and sale of Jeuveau&#8482; and any future product candidates. Key aspects of those functions may be out of our direct control, including regulatory compliance, warehousing and inventory management, distribution, contract administration, accounts receivable management and call center management. Any future distribution partners may hold significant control over important aspects of the commercialization of our products, including market identification, regulatory compliance, marketing methods, pricing, composition of sales force and promotional activities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to control the amount and timing of resources that any future third-party distribution partners may devote to our products, or prevent any third-party from pursuing the development of alternative technologies or products that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">compete with our products, except to the extent our contractual arrangements protect us against such activities. Also, we may not be able to prevent any other third-party from withdrawing its support of our products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, encounter natural or other disasters at their facilities or otherwise fail to perform their services to us in a satisfactory or predicted manner, or at all, our ability to deliver product to meet commercial demand could be significantly impaired. In addition, we may use third parties to perform various other services for us relating to sample accountability and regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we could be subject to regulatory sanctions, and any indemnity we may receive from such third-party service providers could be limited by such provider&#8217;s ability to pay and otherwise might not be sufficient to cover all losses we may experience.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We will forecast the demand for commercial quantities of our products, and if our forecasts are incorrect, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We purchase Jeuveau&#8482; from Daewoong. Pursuant to the Daewoong Agreement, we submit forecasts of anticipated product orders to Daewoong and may, from time to time, submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a botulinum toxin formulation, from this facility for sale in the South Korean market and other markets in which we do not have exclusive rights. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate our component and material requirements, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We purchase Jeuveau&#8482; from Daewoong. Pursuant to the Daewoong Agreement, we submit forecasts of anticipated product orders to Daewoong and may, from time to time, submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a Jeuveau&#8482; formulation, from this facility. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate our component and material requirements, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If and when we expand internationally, our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to have operations both inside and outside the United States. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">requirements or preferences for domestic products or solutions, which could reduce demand for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">differing existing or future regulatory and certification requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">management communication and integration problems resulting from cultural and geographic dispersion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">greater difficulty in collecting accounts receivable and longer collection periods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">difficulties in enforcing contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">difficulties and costs of staffing and managing non-U.S. operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the uncertainty of protection for intellectual property rights in some countries;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">tariffs and trade barriers, export regulations and other regulatory and contractual limitations on our ability to sell our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">multiple, conflicting and changing laws and regulations such as privacy regulations, including General Data Protection Regulation, or GDPR, tax laws, export and import restrictions, employment laws, immigration laws, labor laws, regulatory requirements and other governmental approvals, permits and licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">more stringent data protection standards in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">greater risk of a failure of foreign employees to comply with both U.S. and foreign laws, including export and antitrust regulations, the U.S. Foreign Corrupt Practices Act, or FCPA, quality assurance and other healthcare regulatory requirements and any trade regulations ensuring fair trade practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">foreign currency exchange rates and the generally lower average sales prices available in most international markets compared to those in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">potentially adverse tax consequences, including multiple and possibly overlapping tax structures and difficulties relating to repatriation of cash; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">political and </font><font style="font-family:Times New Roman;font-size:10pt;">economic</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;instability, political unrest and terrorism.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operations results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">A perception of a conflict of interest of our indirect physician investors by other physicians or consumers could negatively impact our future product sales or product approvals.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering, we were indirectly funded through investments in our controlling stockholder, ALPHAEON, and its majority stockholder, SCH, in part, by leading physicians in the self-pay healthcare market, or the indirect physician investors.  As a result, through ALPHAEON and SCH, these indirect physician investors may have an indirect financial interest in our success (as our successes, if any, will in part be imputed to ALPHAEON and ultimately SCH) and may be more inclined to use, promote or recommend Jeuveau&#8482; to their patients and other physicians.  Other physicians may become aware of the indirect and potential financial interest and investments of these indirect physician investors and who realize  additional incentives by recommending Jeuveau&#8482; and any of our future product candidates. If these other physicians perceive this to be a significant conflict, the other physicians may be unwilling to purchase Jeuveau&#8482; or any of our future product candidates without obtaining additional third-party evidence of their benefits and efficacy. If consumers perceive these indirect physician investors have a conflict of interest in recommending Jeuveau&#8482; or any of our future product candidates, they may be unwilling to purchase Jeuveau&#8482; or any of our future product candidates and may have a negative view of our brand, which could harm our reputation in the market. If physicians do not recommend Jeuveau&#8482; or any of our future product candidates or consumers choose not to purchase any of our products as a result of these conflicts of interest, it could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, ALPHAEON is presently a technology company focused on providing healthcare products and services, including patient financing services, and SCH is presently a holding company with direct and/or indirect interests, as the case may be, in ALPHAEON and various other healthcare related and energy related companies. ALPHAEON and SCH may engage in, acquire or otherwise conduct their business in a manner that partners with or otherwise collaborates with the business of our company, Jeuveau&#8482; and any of our future product candidates. For example, ALPHAEON offers a patient financing service whereby a qualified patient can receive a line of credit for certain approved medical procedures. An aesthetic medical procedure sought by a qualified patient for the treatment of moderate to severe glabellar lines whereby the physician uses Jeuveau&#8482; may be an eligible procedure covered under ALPHAEON&#8217;s patient financing service. As a result, our indirect physician investors may receive an additional incremental benefit through a patient&#8217;s use of ALPHAEON&#8217;s patient financing service and the physician&#8217;s use of Jeuveau&#8482;. If other physicians or consumers perceive this to be a significant conflict, the other physicians or consumers may be unwilling to purchase Jeuveau&#8482; or any of our future product candidates without obtaining additional third-party evidence of their benefits and efficacy, and it may result in a negative view of our brand, which could harm our reputation in the market.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, for our two identical double blind, pivotal U.S. Phase III clinical trials of Jeuveau&#8482; (EV-001 and EV-002), one of the twenty clinical investigators was at the time of the pivotal clinical trial an indirect physician investor in our company. For our pivotal double blind, European Phase III study of Jeuveau&#8482; (EVB-003), one of the nineteen clinical investigators was at the time an indirect physician investor in our company.&#160; Additionally, in our unblinded, non-pivotal U.S. Phase II clinical trials of Jeuveau&#8482; (EV-004 and EV-006), eight of the twenty-nine clinical investigators are or were at the time of the non-pivotal clinical trial indirect physician investors of our company. In the future, clinical investigators for any of our future pivotal or non-pivotal clinical trials may be indirect physician investors in our company. We believe it is likely that they will be required to report some of these relationships to the FDA or EMA to the extent not already disclosed. The FDA or EMA may conclude that a financial relationship, such as an indirect investment, between us and a clinical investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or EMA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or EMA and may ultimately lead to the denial of marketing approval of one or more of our future product candidates. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, should our products become eligible for government reimbursement in the future, such indirect investments or other financial relationships with clinical investigators may become subject to additional regulations and disclosure requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We face an inherent risk of product liability as a result of the commercialization of Jeuveau&#8482; and any of our future product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">decreased demand for Jeuveau&#8482; or any future product candidates or products we develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">termination of clinical trial sites or entire trial programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">withdrawal of clinical trial participants or cancellation of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant costs to defend the related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">a diversion of management&#8217;s time and our resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">loss of revenue; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the inability to commercialize any products we develop; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a decline in our share price.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of Jeuveau&#8482; or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop Jeuveau&#8482; or any future product candidates, conduct our clinical trials and commercialize Jeuveau&#8482; or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management. We believe that our future success is highly dependent upon the contributions of our senior management, particularly David Moatazedi, our President, Chief Executive Officer and member of our board of directors, Lauren Silvernail, our Chief Financial Officer and Executive Vice President, Corporate Development, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of Jeuveau&#8482; or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel, including experienced sales representatives, as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that their former employers own their research output. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the market for aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect Jeuveau&#8482; for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, our product will be wholly-paid for by the consumer. Demand for Jeuveau&#8482; will be tied to discretionary spending levels of our targeted consumer population. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decline in the discretionary spending of our target consumer population, which could lead to a weakened demand for Jeuveau&#8482; or any future product candidates. A severe or prolonged economic down turn may also affect our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our business strategy was developed based on a number of important assumptions about the self-pay healthcare market. For example, we believe that the number of self-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of Jeuveau&#8482; or any of our future product candidates could differ materially from our projections if our assumptions are incorrect.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our near-term strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we cannot offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products and indications for Jeuveau&#8482;. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We incur and expect to incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market, or Nasdaq, and the rules of the SEC require that we satisfy certain corporate governance requirements. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. Any changes we make to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to Section 404 of the Sarbanes-Oxley Act, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. In order to maintain effective internal controls, we will need additional financial personnel, systems and resources. However, for so long as we remain an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b). Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. We will remain an emerging growth company until the earliest of: (i) December 31, 2023; (ii) the first fiscal year after our gross annual revenues are $1.07 billion or more; (iii) the date on which we have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates is $700 million or more as of the end of the second quarter of that fiscal year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we have conducted a review of our internal controls for the purpose of providing the reports required by these rules, during the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other adverse consequences that would materially harm our business and reputation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our research and development and manufacturing activities in the future may, and Daewoong&#8217;s manufacturing and supplying activities presently do, involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of Jeuveau&#8482;, and other hazardous compounds. We and Daewoong are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at Daewoong&#8217;s facilities pending their use and disposal. We and Daewoong cannot eliminate the risk of contamination, which could cause an interruption of Daewoong&#8217;s manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by Daewoong for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of Jeuveau&#8482; and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to consumers, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidates or bring them to market and generate revenue.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire.  In addition, we currently do not have a tax sharing arrangement in place with ALPHAEON. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$99.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of federal NOLs, available to offset our future taxable income, if any. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had federal research and development credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. These federal NOLs and research and development tax credit carryforwards expire at various dates beginning in 2034. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">U.S. federal income&#160;tax reform&#160;could adversely affect us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December&#160;22, 2017, the Tax Cuts and Jobs Act, or TCJA, was signed into law, significantly reforming the Code. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest, allows for the expensing of capital expenditures, puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system and modifies or repeals many business deductions and credits. We have evaluated the effect of the TCJA&#160;based on our management&#8217;s current knowledge and assumptions. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the TCJA is uncertain and subject to potential amendments and technical corrections, as well as Internal Revenue Service interpretations and new Treasury regulations. Because of these uncertainties, our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures or breach by hackers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the internet, attachments to emails, persons inside our organization, or persons </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusions, including by computer hackers, foreign governments, and cyber-terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our current or future product development programs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, government files or penalties and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, or PII, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various international, federal and state privacy and security laws, if applicable, including the GDPR, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. Additionally, the regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and protection of PII. For example, California recently enacted legislation, the California Consumer Privacy Act, that will, among other things, create new individual privacy rights and impose increased obligations on companies handling PII, when it goes into effect on January 1, 2020.  We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">O</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ur liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we or any of our current </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">or</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;future licensors</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau&#8482; or any of our future product candidates, we may not be able to compete effectively in our market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We and our current licensor Daewoong currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clostridium</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">botulinum</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented, for which Daewoong has obtained a U.S. patent. Under the Daewoong Agreement, we license the trademark associated with Jeuveau&#8482;. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to Jeuveau&#8482; to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are reliant on the ability of Daewoong, as the licensor of our only product, and will be reliant on future licensors of any future product candidates, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over our future licensors&#8217; patent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may be issued on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong and our future licensors to defend any third-party claims, including Daewoong&#8217;s defense in connection with the Medytox Litigation, which is defined below. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgment or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong. We may not be able, alone or with any of our current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from using our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We employ individuals who were previously employed at other pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A third-party may hold intellectual property, including patent rights that are important or necessary to the development of our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third-party were able to establish that our trademarks or trade names were infringing their marks, that third-party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third-party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our business and products are subject to extensive government regulation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Daewoong is also subject to extensive regulation by the FDA and the South Korean regulatory authorities as well as other regulatory authorities. Our failure to comply with all applicable regulatory requirements, or Daewoong&#8217;s failure to comply with applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions, including, sanctions, warnings, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event our products receive regulatory approval, we, and our direct and indirect suppliers, including Daewoong, will remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may not obtain regulatory approval for the commercialization of any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">commence criminal investigations and prosecutions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose other civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">suspend any ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">delay or refuse to approve pending applications or supplements to approved applications filed by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">refuse to permit drugs or active ingredients to be imported or exported;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seize or detain products or require us to initiate a product recall.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborators believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Regulatory approval of a BLA or BLA supplement, MAA, or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA, EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">a product candidate may not be deemed safe, effective, pure or potent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the data from preclinical studies and clinical trials may not be deemed sufficient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or in response to citizen petitions or similar documents filed in connection with the product candidate</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">general requirements intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the FDA or other regulatory authorities may change their approval policies or adopt new regulations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau&#8482; and any other approved products will be subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any regulatory approvals that we or our collaborators receive for any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for Jeuveau&#8482; and any other future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and compliance with GCP requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with Jeuveau&#8482; or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">fines, warning letters or holds on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">refusal by the FDA, EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators or suspension or revocation of product license approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">product seizure or detention or refusal to permit the import or export of products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to obtain regulatory approvals in foreign jurisdictions for Jeuveau&#8482; or any future product candidates, we will be unable to market our products outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau&#8482; or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Some participants in our clinical trials have reported adverse events after being treated with Jeuveau&#8482;. If we are successful in commercializing Jeuveau&#8482; or any other product candidate, FDA and other regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authorities could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we do not expect that Jeuveau&#8482; will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future product candidates. Such changes could, among other things, require: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes to manufacturing or marketing methods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes to product labeling or promotional materials;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">recall, replacement, or discontinuance of one or more of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additional recordkeeping.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Our Relationship with ALPHAEON </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">ALPHAEON controls the direction of our business, and the concentrated ownership of our common stock and certain contractual rights of ALPHAEON may prevent you and other stockholders from influencing significant decisions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON, which is majority-owned by SCH, owns&#160;56.0%&#160;of our outstanding shares of common stock. As long as ALPHAEON beneficially owns a majority of the voting power of our outstanding common stock, it will generally be able to determine the outcome of all corporate actions requiring stockholder approval, including the election and removal of directors. Even if ALPHAEON were to beneficially own less than a majority of the voting power of our outstanding common stock, it may have the ability to influence the outcome of such corporate actions if it owns a significant portion of our common stock. In addition, if SCH chooses to sell some or all of its controlling interest in ALPHAEON, it could result in a change-of-control of ALPHAEON that could result in us being indirectly controlled by an unknown third-party.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, we are a &#8220;controlled company&#8221; within the meaning of the NASDAQ corporate governance requirements and  ALPHAEON has the ability to control the direction of our business and the concentrated ownership of our common stock, and the rights described above will prevent you and other stockholders from influencing significant decisions. In addition, we may take actions that stockholders other than ALPHAEON do not view as beneficial. This voting control may also discourage transactions involving a change-of-control of our company, including transactions in which you as a holder of our common stock might otherwise receive a premium for your shares. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If ALPHAEON sells a controlling interest in our company to a third-party in a private transaction, you may not realize any change-of-control premium on shares of our common stock and we may become subject to the control of a presently unknown third-party. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ALPHAEON controls a majority of the voting power of our outstanding common stock. ALPHAEON has the ability, should it choose to do so, to sell some or all of its shares of our common stock in a privately negotiated transaction, which, if sufficient in size, could result in a change-of-control of our company without your approval and without providing for a purchase of your shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, ALPHAEON entered into two substantially similar pledge and security agreements whereby ALPHAEON pledged and granted a continuing first priority lien and security interest in and to all of ALPHAEON&#8217;s right, title and interest in, among other items, securities and all other investment property held by ALPHAEON, including ALPHAEON&#8217;s entire ownership of our capital stock, or the collateral. The collateral secures the payment and performance of the obligations of ALPHAEON under certain convertible notes issued by ALPHAEON and other related agreements.&#160;Upon certain events of default, these secured lenders may take possession, hold, collect, sell, lease, deliver, grant options to purchase or otherwise retain, liquidate or dispose of all or any portion of the collateral, and as such, a change-of-control of our company may result. In addition, upon such events of default, the registration rights granted to ALPHAEON under the stockholder agreement we entered into with ALPHAEON will immediately and automatically be assigned in full to the secured lenders with respect to any registrable securities held by such secured lenders. We have no obligation to maintain ALPHAEON&#8217;s financial viability and ALPHAEON may not remain current on such obligations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The ability of ALPHAEON to privately sell its shares of our common stock, with no requirement for a concurrent offer to be made to acquire your shares of our common stock could prevent you from realizing any change-of-control premium on your shares of our common stock that may otherwise accrue to ALPHAEON on its private sale of our common stock. Additionally, if ALPHAEON privately sells its significant equity interest in our company, we may become subject to the control of a presently unknown third-party. Such third-party may have conflicts of interest with those of other stockholders. In addition, if ALPHAEON sells a controlling interest in our company to a third-party, any future indebtedness we have may be subject to acceleration, and our other commercial agreements and relationships could be impacted, all of which may adversely affect our ability to run our business as described herein and may have a material adverse effect on our operating results and financial condition. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are a &#8220;controlled company&#8221; within the meaning of the listing requirements of the Nasdaq Marketplace Rules, and, as a result, rely on exemptions from certain corporate governance requirements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ALPHAEON controls a majority of the voting power of our outstanding common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Marketplace Rules. Under these rules, a listed company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the requirement that a majority of our board of directors consist of independent directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the requirement that our nominating and corporate governance committee be comprised entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the requirement that our compensation committee be comprised entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement for an annual performance evaluation of our corporate governance and compensation committees.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Presently, we utilize these &#8220;controlled company&#8221; exemptions to the corporate governance requirements of Nasdaq, and as a result, we do not have our nominating and corporate governance and compensation committees consisting entirely of independent directors. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our directors may have actual or potential conflicts of interest because of their ownership of debt and equity securities in ALPHAEON and their positions with ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Vikram Malik, Simone Blank, Bosun Hau, Kristine Romine, M.D., and Robert Hayman serve on our board of directors.  Such directors or entities they are affiliated with currently own and may in the future own shares of common stock or preferred stock of ALPHAEON, debt instruments convertible into equity interests of ALPHAEON, options to purchase shares of common stock or other equity awards of ALPHAEON. These individuals&#8217; or entities&#8217; holdings of ALPHAEON debt or equity securities, options to purchase shares of ALPHAEON or other equity awards may be significant for some of these persons or entities compared to these persons&#8217; or entities&#8217; total assets. Additionally, each of Mr. Malik, Mr. Hau and Ms. Blank serve on the board of directors of ALPHAEON and Mr. Malik serves as ALPHAEON&#8217;s acting President. Their positions at ALPHAEON and the ownership of any ALPHAEON equity or equity awards may create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for ALPHAEON than the decisions have for us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These decisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">corporate opportunities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact that operating decisions for our business may have on ALPHAEON&#8217;s consolidated financial statements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact that operating or capital decisions (including the incurrence of indebtedness) for our business may have on ALPHAEON&#8217;s current or future indebtedness or the covenants under that indebtedness; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing and amount of financing efforts, whether they are debt or equity, and the amount of resulting dilution to existing shareholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">business combinations involving us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our dividend policy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">management stock ownership; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the related party services and agreements between ALPHAEON and us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Potential conflicts of interest could also arise if we decide to enter into any new commercial arrangements with ALPHAEON or SCH in the future or in connection with ALPHAEON&#8217;s desire to enter into new commercial arrangements with third parties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, disputes may arise between ALPHAEON and us relating to our past and ongoing relationship, and these potential conflicts of interest may make it more difficult for us to favorably resolve such disputes, including those related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">indemnification and other matters arising from our initial public offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the nature, quality and pricing of services ALPHAEON agrees to provide to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales or other disposal by ALPHAEON of all or a portion of its ownership interest in us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">business combinations involving us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable to us than if we were dealing with an unaffiliated party. While we are controlled by ALPHAEON, we may not have the leverage to negotiate amendments to these agreements, if required, on terms as favorable to us as those we would negotiate with an unaffiliated third-party.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">ALPHAEON and its directors and officers will have limited liability to us or you for breach of fiduciary duty. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides that, subject to any contractual provision to the contrary, ALPHAEON has no obligation to refrain from: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">engaging in the same or similar business activities or lines of business as we do;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">doing business with any of our clients or consumers; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">employing or otherwise engaging any of our officers or employees.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides for the allocation of certain corporate opportunities between us and ALPHAEON. Under these provisions, neither ALPHAEON nor its other affiliates, nor any of their officers, directors, agents stockholders, members, partners, and subsidiaries (other than us), will have any obligation to present to us certain corporate opportunities.  ALPHAEON is presently a technology company focused on providing healthcare products and services, including patient financing services.  ALPHAEON may engage in other lines of business in the future. For example, a director or officer of our company who also serves as a director, officer or employee of ALPHAEON or any of its other affiliates may present to ALPHAEON certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business, if he or she was not offered such corporate opportunity in his or her capacity as our director or officer, and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to ALPHAEON or its other affiliates instead of to us, we may not be able to benefit from these opportunities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, under our certificate of incorporation, neither ALPHAEON nor any officer or director of ALPHAEON, except as provided in our certificate of incorporation, will be liable to us or to our stockholders for breach of any fiduciary or other duty by reason of any of these activities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH is presently a holding company with direct and/or indirect interests, as the case may be, in ALPHAEON and various other healthcare related and energy related companies. SCH may engage in other lines of business in the future, including engaging, acquiring or otherwise conducting their business in a manner that partners with or otherwise collaborates with the business of our company, Jeuveau&#8482; and any of our future product candidates. While our certificate of incorporation does not provide the same provision with respect to SCH, SCH may be able to exercise voting and investment control over ALPHAEON and effect the allocation of certain corporate opportunities between us and ALPHAEON. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">The trading price of our common stock may be volatile, and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our stock price may be volatile. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, the closing price of our common stock since February 8, 2018, has ranged from a low of $6.85 to a high of $38.49. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The stock market in general and the market for earlier-stage pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements of regulatory approval or disapproval of product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse results from or delays in clinical trials of any of our future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">unanticipated safety concerns related to the use of Jeuveau&#8482; or any of our future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">any termination or loss of rights under the Daewoong Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse developments concerning our manufacturer or any future strategic partnerships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">success or failure of competitive products or medical aesthetic products generally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, new product approvals and introductions, joint ventures or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">overall financial market conditions for the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">quarterly variations in our results of operations or those of our competitors</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">rumors and market speculation involving us or other companies in our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">short selling of our common stock or the publication of opinions regarding our business prospects in a manner that is designed to create negative market momentum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales of substantial amounts of our stock by ALPHAEON or other significant stockholders or our insiders, or the expectation that such sales might occur;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">general economic, industry and market conditions, including the size and growth, if any, of the medical aesthetics market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">additions or departures of key personnel, including our Chief Executive Officer and Chief Financial Officer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements or actions taken by ALPHAEON as our controlling stockholder, including sales of substantial amounts of our common stock by ALPHAEON; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in accounting standards, policies, guidelines, interpretations or principles; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other factors </font><font style="font-family:Times New Roman;font-size:10pt;">described</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market prices of a particular company&#8217;s securities, securities class action litigation has often been instituted against that company. We may become the target of this type of litigation in the future. Securities litigation, if instituted against us, could result in substantial costs and divert our management&#8217;s attention and resources from our business.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">could have an adverse effect on our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The market price of our common stock may be volatile, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could have a material and adverse effect on our business, financial condition, and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. If one or more of the equity research analysts who cover us downgrades our common stock or issues other unfavorable commentary or research the price of our common stock may decline. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our historical financial data is not necessarily representative of the results that we would have achieved as a stand-alone company and may not be a reliable indicator of our future results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our historical financial data included in this Annual Report on Form 10-K does not reflect the financial condition, results of operations or cash flows that we would have achieved as a stand-alone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our historical financial data reflects expense allocations for certain support functions that are provided on a centralized basis within ALPHAEON, such as expenses for business technology, facilities, legal, finance, human resources and business development, that may be higher or lower than the comparable expenses that we would have actually incurred, or will incur in the future, as a stand-alone company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;increases have and will continue to occur in our cost structure as a result of our completed initial public offering, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of common stock by ALPHAEON or others of our common stock, or the perception that such sales may occur, could depress the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON owned&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of our outstanding shares of common stock. Subject to the restrictions described in the paragraph below, future sales of these shares in the public market will be subject to the volume and other restrictions of Rule 144 under the Securities Act for so long as ALPHAEON is deemed to be our affiliate, unless the shares to be sold are registered with the SEC. The sale by ALPHAEON of a substantial number of shares of our common stock, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have filed a registration statement with the SEC covering shares of our common stock available for future issuance under our&#160;2017 Omnibus Incentive Plan, and may file future registration statements covering shares of our common stock for future issuance under any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the lock-up agreements referred to above and subject to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market could have an adverse effect on the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation, bylaws and Delaware law contain provisions that might enable our management to resist a takeover and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and that, f</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rom and after the date on which ALPHAEON no longer beneficially owns </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a majority of the voting power of all of the then-outstanding shares of our capital stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a director may only be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">divide our board of directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">f</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rom and after the date on which ALPHAEON no longer beneficially owns </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a majority of the voting power of all of the then-outstanding shares of our capital stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;our</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, our certificate of incorporation provides that, f</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rom and after the date on which ALPHAEON no longer beneficially owns </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a majority of the voting power of all of the then-outstanding shares of our capital stock, we will be subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change-of-control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our certificate of incorporation specifies that the Court of Chancery of the State of Delaware is the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation and bylaws provide that we can indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Separate indemnity agreements have been issued with each director and executive officer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into with our directors and officers, among other things provide that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have indemnified our directors and officers for serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The rights conferred in our bylaws will not be exclusive. W</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">e may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future, and the payment of dividends is also restricted under our credit facility. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements available to emerging growth companies could make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the extent we take advantage of any of these exemptions, the information that we provide stockholders may be different than what is available with respect to other public companies. Investors may find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our trading price may be more volatile.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><a name="s5858AF4B8D675D9EA37AC0CF0CF175D1"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable. </font></div><div><a name="s373720BC73ED56ADB0F1BF9C98146C16"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 2.&#160;&#160;&#160;&#160;Properties.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our corporate headquarters is located at 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660, in a facility that we sublease, encompassing approximately 17,758 square feet of space. The sublease for this facility expires on January 20, 2020. We also maintain a corporate office located at 1027 Garden Street, Santa Barbara, California 93101, in a facility we lease encompassing approximately 4,450 square feet of space. The lease for this facility expires on May 31, 2020. We believe our facilities are sufficient for our current needs. When our lease expires, we may exercise our renewal option or look for additional or alternate space for our operations, and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</font></div><div><a name="s0461E3D0902B5B3297B141D96A185105"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 3.  &#160;&#160;&#160;&#160;Legal Proceedings.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 7, 2017, Medytox Inc., or Medytox, filed an initial complaint in the Superior Court of the State of California, or the Medytox Litigation, against, us, ALPHAEON, SCH, Daewoong, Byung Kook Lee, Jae Chun Yoon, Jae Seung Yoon and Chang Woo Suh, among others, or collectively, the defendants. On August 14, 2017, Medytox filed an amended complaint against the defendants, or the amended complaint. The amended complaint alleges, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau&#8482; (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong filed a motion to dismiss or stay for forum non conveniens, claiming that the place where the complaint has been filed, in the Superior Court of the State of California, is not the proper place for the trial of the claims in the complaint because, among other reasons, the underlying facts that gave rise to the complaint occurred in South Korea. Daewoong&#8217;s motion to dismiss was granted by the Superior Court of the State of California on October 12, 2017. As a result, the action filed with the Superior Court of the State of California is stayed pending resolution of the proceedings in South Korea. In October 2017, Medytox initiated a civil lawsuit against Daewoong and its parent company, Daewoong Co. Ltd., in the Seoul Central District Court in Seoul, South Korea, related to the same subject matter in the Medytox litigation and is seeking, among other things, money damages, injunctive relief and destruction of related documents and products. We are not a party to the litigation in the Seoul Central District Court.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 27, 2018, pursuant to a motion to dismiss brought by Daewoong, the Superior Court of the State of California dismissed Medytox&#8217;s suit against Daewoong, without prejudice, on the basis that Medytox had brought a substantially similar proceeding against Daewoong in South Korea. The proceedings against us remain stayed in the Superior Court of the State of California pending resolution of the proceedings between Medytox and Daewoong in South Korea.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau&#8482;, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing Jeuveau&#8482;, and (v) attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are vigorously defending Medytox&#8217;s claims against us. Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us or Daewoong or to quantify any risk of loss. The litigation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">could go on for an extended period of time and require us to dedicate significant financial and management resources to those efforts. While we are entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. An adverse ruling against either us or one of the other defendants could materially and adversely affect our business, consolidated financial position, results of operations, or cash flows and could also result in reputational harm. Even if we are successful, the litigation may result in delays in our product development, reputational damage or other collateral consequences.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">ITC Complaint</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission, or the ITC, containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau&#8482; is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau&#8482; is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the ITC Complaint.  On March 6, 2019, the ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145, or the ITC Action. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930.  The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau&#8482; into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau&#8482; within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen BTX Strain, and (vii) exclusion and cease and desist orders. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We intend to defend the claims contained in the ITC complaint and the related </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ITC Action</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;vigorously.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Given the early stage in the ITC Action, we are unable to predict the likelihood of success of Medytox&#8217;s and Allergan&#8217;s claims against us or Daewoong or to quantify the risk of the imposition of an exclusion order or cease and desist order. The ITC Action could require us to dedicate significant financial and management resources to those efforts. While we are entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. An adverse ruling against either us or one of the other defendants could materially and adversely affect our business, consolidated financial position, results of operations, or cash flows and could also result in reputational harm. Even if we are successful, the ITC Action may result in reputational damage or other collateral consequences.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, Medytox initiated a criminal investigation into the foregoing matter in South Korea, which appears to target one or more of the above defendants, but does not appear to target us.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the Medytox Litigation and the ITC Complaint, from time to time, we may be subject to other legal proceedings and claims in the ordinary course of business.</font></div><div><a name="s3028EC1D11F1551FBFF6B5263C61F0E5"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s0CFCE3F52120513AB1F4C053E1EAD654"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">62</font></div></div><hr style="page-break-after:always"><div><a name="s66FD303789635B769735D4EDC7F3200E"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, we consummated the initial public offering of our common stock at a price of $12.00 per share. Our common stock is traded on the Nasdaq under the symbol &#8220;EOLS&#8221;. Prior to the initial public offering, there was no public market for our common stock.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Holders of Record</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of&#160;March</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;12, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had approximately&#160;39&#160;holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, tax considerations, legal or contractual restrictions, business prospects, the requirements of current or then-existing debt instruments, general economic conditions and other factors our board of directors may deem relevant.  The payment of dividends is also restricted under our credit facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Item 12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8212;Securities Authorized for Issuance Under Equity Compensation Plan.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From January 1, 2018 to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the period covered by this Annual Report on Form 10-K, we did not issue any unregistered securities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Purchases of Equity Securities</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We made no purchases of our equity securities during the fourth quarter of the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">63</font></div></div><hr style="page-break-after:always"><div><a name="sC3E725C5CB9851AF9348AE2522A10E12"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 6.&#160;&#160;&#160;&#160;Selected Financial Data.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">64</font></div></div><hr style="page-break-after:always"><div><a name="s3370F60C8B8C5D29B0A548B9E6DBE00B"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 7.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The following discussion contains management&#8217;s discussion and analysis of our financial condition and results of operations and should be read together with the selected financial data in Item 6 and historical financial statements, the notes thereto included in Item 8 &#8220;Financial Statements and Supplementary Data&#8221; and included elsewhere in this Annual Report on Form 10-K.  This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the Item 1A &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors.&#8221;</font></div><div><a name="sB534C8FCE9675B5E952C45D0C4295EF4"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. On February 1, 2019, the U.S. Food and Drug Administration, or FDA, approved our first product Jeuveau&#8482; (prabotulinumtoxinA-xvfs). We plan to launch Jeuveau&#8482; commercially in the United States in Spring 2019. Jeuveau&#8482; is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. We believe we will offer physicians and consumers a compelling value proposition with Jeuveau&#8482;. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau&#8482;, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception in 2012, we have devoted substantially all our efforts to identify and recruit personnel, conduct clinical trials, and seek regulatory approval for Jeuveau&#8482;. Our resources have largely been devoted to the clinical development of Jeuveau&#8482;. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 30, 2013, we entered into a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">License and Supply Agreement, or the Daewoong Agreement, with Daewoong Pharmaceuticals Co., Ltd., or Daewoong, a South Korean pharmaceutical manufacturer, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">pursuant to which Daewoong agreed to manufacture and supply us with Jeuveau&#8482; and granted us an exclusive license to develop, distribute, market and sell the product in the United States, EU, Canada, Australia, Russia, Commonwealth of Independent States, or C.I.S., and South Africa, or the covered territories. Daewoong also granted us a non-exclusive license to do the same in Japan.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We submitted a New Drug Submission, or NDS, to Health Canada and&#160;in August 2018 we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We plan to market the product in Canada in the first half of 2019 through our distribution partner Clarion Medical Technologies, Inc., or Clarion, a Canadian provider of medical and aesthetic equipment and consumables to hospitals, aesthetic clinics and private medical practices. We also submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, and it was accepted for review in July 2017. We expect an opinion from the Committee for Medicinal Products for Human Use, or CHMP, in the first quarter of 2019. If the CHMP provides a favorable opinion, we would expect approval of our MAA by end of second quarter of 2019.  </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never generated revenue from Jeuveau&#8482; and have never been profitable. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We incurred net losses of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to incur significant expenses and increasing net operating losses for the foreseeable future as we seek to commercialize Jeuveau&#8482; and seek regulatory approvals outside of the United States. We utilized contract research organizations, or CROs, to carry out our clinical development. We expect to incur significant expenses related to building our commercialization infrastructure, including marketing, sales and distribution functions, inventory build prior to commercial launch and training and deploying a specialty sales force and implementing a targeted marketing campaign. We also expect to incur additional costs associated with operating as a public company and in building our internal resources. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2018, we completed our initial public offering and sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of our common stock at a public offering price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, inclusive of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds were approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering expenses. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Follow-on Public Offering </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, we completed a follow-on public offering, or the July 2018 public offering, in which we sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock in August 2018, at a public offering price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The net proceeds were approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 30, 2013, we entered into the Daewoong Agreement&#160;pursuant to which we have an exclusive distribution license to Jeuveau&#8482; from Daewoong for aesthetic indications in the United States, EU, Canada, Australia, Russia, C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan.&#160;Under the Daewoong Agreement, we are required to make certain minimum annual purchases upon commercialization in order to maintain the exclusivity of the license. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions. In connection with our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million. We further agreed to make milestone payments upon certain confidential development and commercial milestones, including a confidential payment to Daewoong upon each of the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, approval of Jeuveau&#8482;. Under the Daewoong Agreement, the maximum aggregate amount of future milestone payments that could be owed to Daewoong upon the satisfaction of all milestones is $13.5 million. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the FDA approval in February 2019, the Company paid a $2.0 million milestone payment. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of Jeuveau&#8482;, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of Jeuveau&#8482;.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We had the option, subject to certain payment conditions, to expand the permitted use of the product beyond aesthetic indications and into therapeutic indications. This option was assigned to ALPHAEON who, as of December 31, 2018, exercised the option by remitting payment directly to Daewoong. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For additional information about the Daewoong Agreement, see Item 1 &#8220;Business&#8212;Daewoong License and Supply Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Acquisition by ALPHAEON and Related Payment Obligations</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, SCH-AEON, LLC, or SCH, acquired all of our outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed our equity that it had acquired in 2013 to its operating subsidiary, ALPHAEON. As a result of these transactions, we became a wholly-owned subsidiary of ALPHAEON, which we remained until the completion of our initial public offering in February 2018. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of our acquisition by SCH pursuant to a stock purchase agreement, or the Stock Purchase Agreement, ALPHAEON became obligated to make certain payments to SCH for the benefit of certain of our former stockholders, or the Evolus Founders.  On December 14, 2017, SCH and ALPHAEON entered into an amendment to the Stock Purchase Agreement, or the Amended Purchase Agreement, whereby we also joined as a contractual party. Pursuant to the Amended Purchase Agreement, ALPHAEON&#8217;s existing payment obligations were replaced with revised payment obligations, payable directly to the Evolus Founders.  Effective upon the closing of our initial public offering, ALPHAEON immediately and automatically assigned to us and we immediately and automatically accepted and assumed all of ALPHAEON&#8217;s payment obligations under the Stock Purchase Agreement, as amended by the Amended Purchase Agreement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, the revised payment obligations consist of (i) an approximately $9.2 million payment upon obtaining FDA approval for Jeuveau&#8482; for the treatment of glabellar lines, which was paid in full in February 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&#8482; within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&#8482; outside of the United States, and (iv) a $20.0 million non-interest bearing promissory note that will mature on the 2.5 year anniversary of the first commercial sale of Jeuveau&#8482; in the United States, or the contingent promissory note. The revised payment obligations set forth in (ii) and (iii) above, will terminate for the quarter following the 10 year anniversary of the first commercial sale of Jeuveau&#8482; in the United States. The fair value of the obligations set forth in items (i), (ii) and (iii) are valued quarterly and are referred to in our financial statements as the &#8220;contingent royalty obligation.&#8221; Upon completion of our initial public offering, we assumed and agreed to pay the revised payment obligations under the Amended Purchase Agreement. At the closing of our initial public offering, the outstanding related party borrowings from ALPHAEON were set-off and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations we assumed from ALPHAEON, the fair value of which, immediately prior to our initial public offering date or February 12, 2018, was $55.7 million. In addition, pursuant to the Amended Purchase Agreement, in February 2019 upon FDA approval, we paid one-time bonuses to certain of our current and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">former employees aggregating to approximately $1.6 million, including a one-time bonus of $0.7 million paid to Rui Avelar, M.D., our Chief Medical Officer and Head of Research &amp; Development. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Our</font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;">&#32;Relationship with ALPHAEON Corporation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering and since our acquisition in 2014 by ALPHAEON, we funded our operations primarily through contributions and related party borrowings from ALPHAEON. For periods prior to the completion of our initial public offering on February 12, 2018, we derived our financial statements by allocating expenses associated with our operations from ALPHAEON&#8217;s consolidated financial statements in accordance with applicable accounting standards and SEC regulations. Our management believes that the allocations and results are reasonable for all periods presented in our financial statements. However, allocations may not be indicative of the actual expense we would have incurred had we operated as an independent company for the periods presented and do not include additional expenses we expect to incur in connection with the commercialization of Jeuveau&#8482;, including the creation of a commercialization infrastructure and hiring of our sales force.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, we entered into a services agreement with ALPHAEON, or the services agreement, which became effective in connection with our initial public offering. The services agreement sets forth certain terms between ALPHAEON and us that govern the respective responsibilities and obligations between ALPHAEON and us, as it relates to the services to be performed between us. The fees charged for any services rendered pursuant to the services agreement are the actual cost incurred by ALPHAEON or us, as the case may be, in providing the services for the relevant period.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, pursuant to the services agreement, upon completion of our initial public offering, we paid ALPHAEON $5.0 million towards the repayment of our related party borrowings and the remaining related party borrowings then outstanding were forgiven and the amount was re-characterized as a capital contribution of ALPHAEON. As a result, upon the completion of our initial public offering, we were no longer indebted to ALPHAEON pursuant to our historical related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to February 12, 2018, we incurred obligations to ALPHAEON for the research and development expenses it incurred on our behalf, which included both external and internal expenses as well as general and administrative support services. External research and development expenses included costs for CROs to conduct nonclinical and clinical studies on our product candidate, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. Internal development expenses included costs for the work that ALPHAEON&#8217;s research and development employees perform for us.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sC59FF7592F00530494605902A85C78C3"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Financial Overview</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our historical financial statements for the periods prior to our initial public offering on February 12, 2018 have been prepared on a standalone basis and are derived from ALPHAEON&#8217;s consolidated financial statements and accounting records in conformity with U.S. generally accepted accounting principles, or GAAP.  Our financial statements reflect our financial position, results of operations, stockholders&#8217; equity (deficit), and cash flows as our business was operated as part of ALPHAEON prior to the separation. The financial statements include the allocation of certain assets and liabilities that had historically been held at the ALPHAEON corporate level but which were specifically identifiable or allocable to us.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The financial results reflect amounts attributable to our business, including the costs that ALPHAEON incurred for the development and commercialization of Jeuveau&#8482; and costs and expenses under the Daewoong Agreement. Management believes that the allocations and results are reasonable for all periods presented. However, allocations may not be indicative of the actual expense we would have incurred had the business operated as an independent company for the periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a description of the components of our results of operations:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our general and administrative expenses consist of salaries and personnel-related costs, including stock-based compensation, for our employees in administrative, commercial and other operating functions. Our general and administrative expenses also include professional fees for accounting, auditing and consulting services, legal services, investor relations, travel and facilities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As described above, prior to our initial public offering, ALPHAEON charged us for many of the expenses associated with these functions, including the grant of stock-based compensation of ALPHAEON&#8217;s stock. Pursuant to the services agreement, ALPHAEON provides us and we provide ALPHAEON certain administrative and development support services. For example, we received from ALPHAEON certain general management, communication, intellectual property, human resources, office and information technology services, and we provide general accounting and legal services to ALPHAEON. The amounts to be charged for services rendered pursuant to the services agreement will be the actual cost incurred by ALPHAEON or us, as the case may be, in providing the services for the relevant period. ALPHAEON has historically charged us market rates for the portion of the resources that we use. Since our initial public offering date or February 12, 2018, we have assumed responsibility from ALPHAEON for all of our general and administrative functions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We anticipate our general and administrative expenses to increase in the future to support our continued development and commercialization of Jeuveau&#8482;. Our general and administrative expenses will also increase due to the costs of operating as a public company and may further increase when we are no longer able to rely on certain &#8220;emerging growth company&#8221; exemptions we are afforded under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">Since our inception, we have focused on developing Jeuveau&#8482;. Our research and development expenses primarily consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">personnel costs, which include salaries and related expenses for research and development personnel, including expenses related to stock-based compensation granted to personnel in development functions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">fees paid to clinical study sites and vendors, including CROs, in connection with our clinical studies, costs of acquiring and evaluating clinical study data such as investigator grants, patient screening fees, laboratory work and statistical compilation and analysis, and fees paid to clinical consultants related to the execution of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">expenses to acquire clinical study materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">other consulting fees paid to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">expenses related to compliance with drug development regulatory requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">travel, facilities, which includes cost associated with rent, maintenance and related facilities costs as well as depreciation and amortization, insurance and other expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expense our research and development costs as we incur them. Our expenses related to clinical studies are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with CROs that we may use to conduct and manage our clinical studies on our behalf. We generally accrue expenses related to clinical studies based on contracted amounts applied to the level of patient enrollment and activity. If we modify timelines or contracts based upon changes in the clinical study protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering, ALPHAEON historically charged us for many of the expenses associated with these functions, including, among others, costs for CROs to conduct nonclinical and clinical studies on our product candidate, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON has historically charged us market rates for the portion of the resources that we use. Since our initial public offering date or February 12, 2018, we have assumed responsibility from ALPHAEON for these research and development functions. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our overall research and development expenses to increase if and when we seek to develop future product candidates and pursue regulatory approvals in other jurisdictions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">December 31,</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">2017</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our results of operations for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,689</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">29,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">4,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">24,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revaluation of contingent royalty obligation to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">10,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">10,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">46,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">11,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(46,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(11,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(34,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(863</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(858</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(46,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(11,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(35,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Provision (benefit) for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(7,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">7,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(42,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily attributable to a reduction of $2.3 million in costs related to research and clinical trials which ended in 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and was partially offset by an increase in personnel expenses primarily related to shared-based compensation as we started granting stock-based awards in the first quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">General and administrative expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$29.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily attributable to higher personnel-related expenses as we built out our corporate and commercial infrastructure, higher accounting and legal expenses primarily related to meeting ongoing public company compliance requirements and other legal matters, as well as higher pre-commercialization expenses in the preparation for our product launch</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Personnel-related expenses increased by $12.6 million due to our hiring of additional employees as well as incurring stock-based compensation expenses as we started granting stock-based awards in the first quarter of 2018. The number of general and administrative employees increased to 39 as of December 31, 2018 from 10 as December 31, 2017. We expect that general and administrative expenses will increase due to costs related to the implementation of our commercialization strategy as well as costs related to the ongoing compliance and communication requirements of a public company.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Effective upon the closing of our IPO in February 2018, we assumed all of ALPHAEON&#8217;s payment obligations under the Stock Purchase Agreement, as amended by the Amended Purchase Agreement, including certain royalty obligation payable to Evolus Founders which is recorded at its fair value as of the end of each reporting period. The change of the fair value is primarily driven by assumptions related to revenue forecasts, discount rate, and timing of cash flows. Such change of the fair value is recorded in operating expenses in each period.  We incurred&#160;no&#160;such charge in 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Provision (Benefit) for Income Taxes</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There was no significant income tax provision or benefit for the year ended December 31, 2018, compared to income tax benefit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2017. On December 22, 2017, the U.S. Government enacted the Tax Cuts and Jobs Act, or TCJA.&#160;The TCJA significantly impacted our effective income tax rate by reducing the U.S. federal corporate tax rate from 35% to 21%. For certain of our deferred tax assets and deferred tax liabilities, we have recorded a provisional decrease in net deferred tax assets of $3.2 million, with a corresponding decrease in the valuation allowance of $9.6 million and a benefit to income tax expense of $6.3 million for the year ended December 31, 2017. Our accounting for the elements of the TCJA is complete as of December 31, 2018 and no adjustments were made to the original provisional estimate.</font></div><div><a name="sFB632B4D70D4591B9C55CBA758C70797"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had a cash balance and stockholder&#8217;s equity of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$84.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering and since our acquisition in 2014 by ALPHAEON, we had funded our operations primarily through contributions and related party borrowings from ALPHAEON. We have no revenue, incur operating losses and have an accumulated deficit as a result of ongoing efforts to develop our product Jeuveau&#8482;, including conducting nonclinical testing and clinical trials and providing general and administrative support for these operations. As of December 31, 2018, we had an accumulated deficit of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and working capital of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$89.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We had net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and we used net cash in operating activities of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. We anticipate that operating losses and net cash used in operating activities will increase over the next few years as we commercialize Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2018, we closed our initial public offering and sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock at the price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, inclusive of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds were approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">July 2018 Follow-On Public Offering</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, we closed a follow-on offering and sold&#160;3,600,000&#160;shares of our common stock at the price of $20.00 per share, inclusive of 600,000 shares of common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds were approximately&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, or the closing date, we entered into a loan and security agreement, or the credit facility, with Oxford Finance, LLC, as collateral agent, or Oxford, and the lenders party thereto from time to time, pursuant to which the lender will make term loans available to us of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the credit facility. The credit facility provides that the term loans will be funded in two advances. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was funded on the closing date, and the second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be drawn, at our request, no later than September 30, 2020, upon achieving specified minimum net sales milestones and no event of default is occurring. The credit facility bears an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. We have agreed to pay interest only on each tranche funded pursuant to the credit facility for the first 36 months until May 2022, which will be followed by a 23-month amortization period. Notwithstanding the foregoing, if we maintain compliance with the specified minimum net sales covenant and meet other conditions during the initial interest-only period, upon our request, the interest only period may be extended by an additional 12 months to a total of 48 months followed by an 11-month amortization period.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, we will be required to pay to Oxford a final payment of 5.5% of the full principal amount of the term loans funded, or the final payment. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to 3.0% of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurs thereafter, or the Prepayment Fee.  If the term loans are accelerated following the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">occurrence of an event of default, we will be required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the final payment, the Prepayment Fee, and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of our assets. The credit facility includes affirmative and negative covenants applicable to us, our current subsidiary and any subsidiaries we may create in the future. The affirmative covenants include, among others, covenants requiring us to maintain our legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus 5.0% and Oxford, as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including our cash. These events of default include, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against us, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also provides us with the ability, under certain conditions, to obtain up to a $25.0 million revolving line of credit secured by our inventory, accounts receivable and cash proceeds of both. Oxford has the right of first refusal, but not the obligation, to provide such a revolving line of credit. There is no guarantee that such a line would be available to us on terms favorable to us or at all.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Current and Future Capital Requirements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that our current capital resources together with the proceeds of the credit facility will be sufficient to fund operations through at least the next twelve&#160;months based on our expected cash burn rate from the date of the issuance of this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings, entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to us at all or on attractive terms when needed from these sources. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts.&#160;If we are unable to obtain additional funding from these or other sources when needed, it may be necessary to significantly reduce our scope of operations and current rate of spending through reductions in staff and delaying, scaling back, or stopping our research and development or sales and marketing activities. Insufficient liquidity may also require us to relinquish rights to our product candidate at an earlier stage of development or on less favorable terms than we would otherwise choose.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number and characteristics of any additional product candidates we develop or acquire;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of any cash milestone payments to Daewoong if we successfully achieve certain predetermined milestones; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to forecast demand for our products, scale our supply to meet that demand and manage working capital effectively</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of manufacturing our product or any future product candidates and any products we successfully commercialize, including costs associated with building our supply chain; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of commercialization activities for Jeuveau&#8482;  or any future product candidates are approved or cleared for sale, including marketing, sales and distribution costs;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of building a sales force in anticipation of product commercialization, and the productivity of that sales force and the market acceptance of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any product liability or other lawsuits related to our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the expenses needed to attract and retain skilled personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs associated with being a public company; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including ongoing litigation costs related to Jeuveau&#8482; and the outcome of this and any other future patent litigation we may be involved in; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing, receipt and amount of sales of any future approved or cleared products, if any. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our cash flows for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Operating activities </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(25,667</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(13,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Investing activities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Financing activities </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">118,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">13,035</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Change in cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">93,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cash and restricted cash, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cash, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">93,162</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Operating Activities </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash used in operating activities in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which primarily resulted from the net loss of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and was partially offset by non-cash charges </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">primarily including stock-based compensation&#160;expense of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the revaluation of our contingent royalty obligation. The net operating assets and liabilities changed by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which was primarily driven by timing of vendor invoice payments.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash provided by financing activities during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$118.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which&#160;primarily resulted from the net proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;received in the initial public offering in February 2018 and the follow-on public offering in July 2018, respectively. These were partially offset by a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;related-party borrowing payment to ALPHAEON and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;payment of offering-related costs.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering and since our acquisition by ALPHAEON, ALPHAEON had historically provided us certain services that were not covered under a services agreement, including, without limitation, general and administrative </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">support services and research and development support services. ALPHAEON had allocated a certain percentage of personnel to perform the services that it provided to us based on its good faith estimate of the required services. These allocated costs have historically increased related-party borrowings. The costs reflect ALPHAEON full-time equivalent, or FTE, rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing us these services. We historically have not recorded a mark-up on the external or internal expenses ALPHAEON allocates to us. All ALPHAEON-provided operating expenses shown in our financial statements were treated as related party borrowings from ALPHAEON to us for year ended December 31,&#160;2017&#160;and for the period between January 1, 2018 and February 11, 2018. After the initial public offering, we no longer rely on ALPHAEON for funding and in connection with the closing of our initial public offering the related party borrowings were settled in full. As of the completion of our initial public offering on February 12, 2018, we assumed from ALPHAEON the revised payment obligations under the Amended Purchase Agreement of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon our initial public offering on February 12, 2018, we were released of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;note obligation for all guaranty and security obligations, and the related party receivable from ALPHAEON of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was settled, resulting in a capital contribution of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ALPHAEON&#8217;s security interest in Evolus&#8217; assets was also terminated. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;&#8212;Liquidity and Capital Resources&#8221; for a description of our credit facility with Oxford.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Payment Obligations Related to the Acquisition by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, the revised payment obligations consist of (i) an approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) quarterly royalty payments of a low single digit percentage of net sales of the Product within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of the Product outside of the United States, and (iv) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;promissory note that will mature on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years anniversary of the first commercial sale of the Product in the United States. The revised payment obligations set forth in (ii) and (iii) above will terminate in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year anniversary of the first commercial sale of the Product in the United States. As these revised payment obligations are not perpetual, neither Evolus nor ALPHAEON will have the right to terminate any future payments for a one-time lump sum payment. As of December 31, 2018, we recorded an aggregate balance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on our balance sheet for the revised payment obligations and the promissory note owed to the Evolus Founders (comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the contingent promissory note). </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, in February 2019, Evolus paid one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to certain former and current employees upon FDA approval of the Product, including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to Rui Avelar, M.D., Evolus&#8217; Chief Medical Officer and Head of Research &amp; Development.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">paid the Evolus Founders $9.2 million in February 2019 subsequent to the FDA&#8217;s approval of our BLA of Jeuveau&#8482;.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">License and Supply Agreement with Daewoong</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement,&#160;$13.5 million&#160;in additional cash consideration is due to Daewoong based upon Evolus&#8217; successful completion of certain technical and sales milestones. We </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">paid Daewoong $2.0 million in February 2019 subsequent to the FDA&#8217;s approval of our BLA of Jeuveau&#8482;.</font></div><div><a name="s4AF8FC43D5F45B8589C713A9E1DD6E23"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC. We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose. </font></div><div><a name="s684A5310BBC755F3BC269A3041777F02"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">73</font></div></div><hr style="page-break-after:always"><div><a name="s75DA1067034B5A4B9C4C45D5FB0C10E4"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be most critical for fully understanding and evaluating our financial condition and results of operations, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;">Contingent Royalty Obligation and Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We determine the fair value of the contingent royalty obligation payable to the Evolus Founders under the Amended Purchase Agreement based on significant unobservable inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in operating expenses in the statements of operations and comprehensive loss and in the non-current liabilities in the balance sheets. The significant unobservable input assumptions that can significantly change the fair value includes (i) timing of the FDA approval of the Jeuveau&#8482;, (ii) projected net revenues during the payment period, (iii) the discount rate, and (iv) the timing of payments.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities and is based on an estimated date that we believe the contingent promissory note will mature.  Accretion related to the contingent promissory note is recorded in interest expense of the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities section of the balance sheets. The fair value of the contingent promissory note could be impacted by changes such as: (i) changes in the discount rate, or (ii) a delay in the first commercial sale of Jeuveau&#8482; in the United States.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. We review goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. We perform an annual qualitative assessment of goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, we perform a two-step process. The first step involves comparing the fair value of the our reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, we have determined that there is one reporting unit. There has been no impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The intangible asset in our balance sheets represents in-process research &amp; development, or IPR&amp;D, projects acquired that have not yet been completed. The IPR&amp;D asset had an indefinite useful life and was not amortized, but instead tested for impairment. There has been no impairment of long-lived assets for any periods presented. Upon the FDA approval in February 2019, the IPR&amp;D asset is reclassified to a developed technology asset and amortized over its estimated useful live. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When we establish or reduce the valuation allowance against the deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, we establish reserves for uncertain tax positions. We have not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 22, 2017, the U.S. government enacted TCJA. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning in 2018. We recognized the income tax effects of the TCJA in our 2017 financial statements in accordance with Staff Accounting Bulletin No. 118, which provides SEC staff guidance for the application of ASC Topic 740, Income Taxes, in the reporting period in which the TCJA was signed into law. As such, our 2017 financial results reflected the provisional income tax effects of the TCJA for which the accounting was incomplete but a reasonable estimate was made. Our accounting for the elements of the TCJA was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to our financial statements for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. In addition, we currently don&#8217;t have a tax sharing arrangement in place with ALPHAEON.  Under Section 382 of the  Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating losses, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. These federal NOLs and research and development tax credit carryforwards expire at various dates beginning in 2034. We have not conducted an assessment to determine whether there may have been a Section&#160;382 ownership change. If we have experienced a Section&#160;382 ownership change or if we experience a Section&#160;382 ownership change as a result of future changes in our stock ownership, some of which changes are outside of our control, the tax benefits related to the NOLs or research and development tax credit carryforwards may be limited or lost. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to our financial statements for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s64FA9A2005B25F7FA871D9A0A4BE44D5"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Recently Issued and Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We describe the recently issued accounting pronouncements that apply to us in</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">-Recent Accounting Pronouncements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75</font></div></div><hr style="page-break-after:always"><div><a name="sBE440D35FA025C969FF12B72753A5EBA"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 7A.  &#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosure About Market Risk.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">76</font></div></div><hr style="page-break-after:always"><div><a name="s11C811E732DB5EDF8598ECD2ED49C7B8"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 8.&#160; &#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Index to Financial Statements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s016BEE7B3881592AA4479D5A63C05820"><font style="font-family:Times New Roman;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s016BEE7B3881592AA4479D5A63C05820">78</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s11C811E732DB5EDF8598ECD2ED49C7B8"><font style="font-family:Times New Roman;font-size:10pt;">Financial Statements:</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD1116A99A5275B0AB74BF3DE199BF4DB"><font style="font-family:Times New Roman;font-size:10pt;">Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD1116A99A5275B0AB74BF3DE199BF4DB">79</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2B23F0024AB95FD89928BA15ED287CAA"><font style="font-family:Times New Roman;font-size:10pt;">Statements of Operations and Comprehensive Loss</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2B23F0024AB95FD89928BA15ED287CAA">80</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sDA455E6798555A4DB49181503BCB193C"><font style="font-family:Times New Roman;font-size:10pt;">Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sDA455E6798555A4DB49181503BCB193C">81</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5714A58C6A335E31A40D5EED66447AA6"><font style="font-family:Times New Roman;font-size:10pt;">Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5714A58C6A335E31A40D5EED66447AA6">82</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2385F85B3A5B5C4FAE1934F0E1AD96D9"><font style="font-family:Times New Roman;font-size:10pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2385F85B3A5B5C4FAE1934F0E1AD96D9">83</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">77</font></div></div><hr style="page-break-after:always"><div><a name="s016BEE7B3881592AA4479D5A63C05820"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the Stockholders and the Board of Directors of Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have audited the accompanying balance sheets of Evolus, Inc. (the Company) as of December 31, 2018 and 2017, the related statements of operations and comprehensive loss, stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2018, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Basis for Opinion </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:67%;"></td><td style="width:19%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have served as the Company's auditor since 2017.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Irvine, California</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March&#160;20, 2019</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">78</font></div></div><hr style="page-break-after:always"><div><a name="sD1116A99A5275B0AB74BF3DE199BF4DB"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Balance Sheets</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except par value and share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Related party receivable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">72,639</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">94,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">72,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">2,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">171,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">152,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Current Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,558</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">72,639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Note obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">138,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">5,276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">212,748</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">50,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent promissory note payable to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">15,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">14,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">87,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">227,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Commitments and contingencies (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Stockholders&#8217; equity (deficit)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Convertible Series A Preferred, $0.00001 par value; no shares authorized; 0 and 1,250,000 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 27,274,991 and 16,527,000 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">207,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(123,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(75,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total stockholders&#8217; equity (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">84,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(75,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total liabilities and stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">171,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">152,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">79</font></div></div><hr style="page-break-after:always"><div><a name="s2B23F0024AB95FD89928BA15ED287CAA"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4126984126984%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,689</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">29,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revaluation of contingent royalty obligation to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">10,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">46,142</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11,726</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(11,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(863</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(11,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Provision (benefit) for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(7,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average shares outstanding used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24,402,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">80</font></div></div><hr style="page-break-after:always"><div><a name="sDA455E6798555A4DB49181503BCB193C"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Stockholders&#8217; Equity (Deficit)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:43%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Series A Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Additional Paid In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">59,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(66,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(7,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent - stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent - therapeutic option right, net of tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed distribution to Parent - note obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(61,791</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(4,257</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(66,048</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(75,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(75,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed contribution from Parent, increase of related-party receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed distribution to Parent, increase of convertible note obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,385</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(615</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, convertible note write-off</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, forgiveness of related party borrowings</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Preferred stock conversion upon initial public offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,065,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon initial public offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,047,514</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">53,445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">53,446</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon follow-on offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">3,600,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">34,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,274,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">207,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(123,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">84,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">81</font></div></div><hr style="page-break-after:always"><div><a name="s5714A58C6A335E31A40D5EED66447AA6"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Cash Flows </font></div><div style="line-height:120%;padding-bottom:1px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(4,480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(6,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Tax benefit from therapeutic option right</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Revaluation of contingent royalty obligation to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,432</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(25,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(13,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from initial public offering, net of underwriting fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">56,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from follow-on offering, net of underwriting fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">14,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments on related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(5,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments for offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Tax withholding paid on behalf of employees for stock-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">118,838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Change in cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash and restricted cash, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Noncash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party receivable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(72,639</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(68,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Note obligation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(140,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">138,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">39,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent promissory note payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, convertible note write-off</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital distribution to Parent</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(66,048</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, forgiveness of related party borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent - therapeutic option right, net of tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred offering costs accrued, unpaid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred offering costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,885</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts payable, paid by Parent</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">82</font></div></div><hr style="page-break-after:always"><div><a name="s2385F85B3A5B5C4FAE1934F0E1AD96D9"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;color:#000000;font-weight:bold;">&#160;</font></div><div><a name="s2932D869E6045D0C92F003452D62CBEA"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Organization</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. On February 1, 2019, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved the Company&#8217;s first product Jeuveau&#8482; (the &#8220;Product&#8221;). The Product is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company is headquartered in Newport Beach, California.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company&#8217;s board of directors and its then-sole stockholder approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a split of shares of the Company&#8217;s common stock on a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.6527</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-for-1 basis (the &#8220;Stock Split&#8221;). The Company&#8217;s then-outstanding shares of convertible Series A preferred stock (&#8220;Series A preferred stock&#8221;), the par value of the common stock, and the authorized shares of the common stock were not adjusted as a result of the Stock Split. All issued and outstanding shares of common stock, stock options, restricted stock units and related per share amounts contained in the financial statements have been retroactively adjusted to reflect this Stock Split for all periods presented. The Stock Split was effected on January 26, 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock, which included the exercise by the underwriters of their option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional shares of common stock, at an offering price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;after deducting underwriting discounts and commissions, excluding other offering costs. In connection with the IPO, the Company&#8217;s then-outstanding shares of Series A preferred stock were automatically converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock. In connection with the completion of its IPO, the Company&#8217;s amended and restated certificate of incorporation was further amended and restated to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share.   </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Company completed a follow-on public offering (the &#8220;Follow-On Offering&#8221;) in which the Company sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock in August 2018, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from the Follow-On Offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the completion of its IPO, the Company also entered into a services agreement (the &#8220;Services Agreement&#8221;) with ALPHAEON Corporation (&#8220;ALPHAEON&#8221; or &#8220;Parent&#8221;), its controlling stockholder. The Services Agreement sets forth certain agreements between ALPHAEON and the Company that govern the respective responsibilities and obligations between ALPHAEON and the Company as it relates to the services to be performed between the parties. Pursuant to the Services Agreement, ALPHAEON provides the Company, and the Company provides ALPHAEON, certain administrative and development support services. Prior to the IPO, the Company was dependent upon ALPHAEON for its working capital and financing requirements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON, which is majority-owned by SCH-AEON, LLC (&#8220;SCH&#8221;), owns&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of the Company&#8217;s outstanding shares of common stock.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Financial Condition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he Company incurred operating losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Additionally, the Company used </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash for operations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">has an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. On March 15, 2019, the Company entered into a term loan facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(see Note 11, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain market acceptance of its product and achieve a level of revenues adequate to support its cost structure, and operate its business and sell products without infringing third party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes that its current capital resources will be sufficient to fund operations through at least the next twelve months based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of its equity securities, incurring debt, entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs and other operational goals.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s8D8EE12ED4B3566DB12573870A2FACF0"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The financial statements for the periods prior to the Company&#8217;s IPO have been prepared on a standalone basis and are derived from ALPHAEON&#8217;s consolidated financial statements and accounting records and included an allocation of certain assets and liabilities that have historically been held at the ALPHAEON corporate level but which were specifically identifiable or allocable to the Company. . These results reflect amounts attributable to the Company&#8217;s business, including the costs ALPHAEON incurred for the development and commercialization of the Product and costs and expenses under the License and Supply Agreement (the &#8220;Daewoong Agreement&#8221;) entered into with Daewoong Pharmaceuticals Co., Ltd. (&#8220;Daewoong&#8221;), a South Korean pharmaceutical manufacturer, in September 2013, as further described below in Note 5, C</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">ommitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO, ALPHAEON charged the Company external and internal administrative and research and development expenses that ALPHAEON incurred on the Company&#8217;s behalf. External research and development expenses charged to the Company included costs for contract research organizations (&#8220;CROs&#8221;), costs to conduct nonclinical and clinical studies on the Product, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON charged these costs to the Company at the same amount that ALPHAEON incurred such cost. Internal development expenses included costs for the work that ALPHAEON development employees perform for the Company. ALPHAEON charged the Company a full-time equivalent (&#8220;FTE&#8221;) rate that covers personnel-related expenses, including salaries and benefits, plus an allocation of facility-related expenses, including rent, utilities, depreciation, insurance and property taxes, for those research and development employees who work either directly or indirectly on the development of the Company&#8217;s drugs and certain administrative employees. ALPHAEON calculated the facility-related expenses to the Company based on a percentage of aggregate expenses incurred at ALPHAEON. ALPHAEON calculated depreciation expense of property and equipment using the straight-line method over the estimated useful lives of its assets of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, the Company historically incurred related party borrowings from ALPHAEON for its share of the internal and external expenses for each of these functions based on the Company&#8217;s relative use of each function, plus an allocation of facility-related expenses. The Company&#8217;s management believes that the allocation and results were reasonable. As of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">, the Company did not have any accounts receivable or payable with ALPHAEON pursuant to the Services Agreement or otherwise.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has calculated its income tax amounts using a separate return methodology and has presented these amounts as if it were a separate taxpayer from ALPHAEON in each jurisdiction for each period the Company presented. Subsequent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to the IPO, the Company will prepare a stand-alone tax return. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not have a tax sharing agreement with ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus was formed in November 2012 for the purposes of developing the Product for distribution and sale. In October 2013,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in a Stock Purchase Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH acquired all of the Company&#8217;s outstanding equity in exchange for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Class AA units of SCH and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Class D units of SCH, which resulted in SCH obtaining a controlling financial interest in Evolus.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the transaction with SCH, Evolus had executed a License and Supply Agreement with Daewoong and thereby secured exclusive rights to license and distribute the Product for aesthetic indications in the United States and certain other international markets, as well as non-exclusive rights to distribute in Japan (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 4, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The acquisition of the Company, which represented a business combination by SCH, was to provide SCH and ALPHAEON access to the license held by Evolus to develop, produce and market clinical neurotoxins. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In a series of related transactions in 2013, SCH acquired all of the Company&#8217;s outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed equity that it had acquired in 2013 to ALPHAEON. As a result of these transactions, the Company became a wholly-owned subsidiary of ALPHAEON.  The Company remained a wholly-owned subsidiary of ALPHAEON until the completion of the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH elected to apply push-down accounting pursuant to the guidance in ASC 805, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Business Combinations</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Accordingly, the financial statements reflect the new basis of accounting established by SCH when SCH obtained control of the Company in October 2013. The assets acquired and liabilities assumed in connection with the acquisition were recognized based on their estimated fair values at the acquisition date. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates.&#160;The estimated fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition, SCH and ALPHAEON entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) pursuant to which they were obligated to make certain contingent payments to the Evolus Founders. However, since Evolus did not have an obligation associated with the contingent consideration arrangement prior to the Company&#8217;s IPO, no amounts were recognized in the Company&#8217;s financial statements for the contingent royalty obligation arrangement between SCH and ALPHAEON, and the Evolus Founders. As described in Note 4, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, on December 14, 2017, SCH and ALPHAEON entered into an amendment to the Stock Purchase Agreement (the &#8220;Amended Purchase Agreement&#8221;), and the Company joined as a contractual party. Upon the closing of the IPO on February 12, 2018, ALPHAEON immediately and automatically assigned to the Company its payment obligations under the Amended Purchase Agreement. These payment obligations are referred to as the &#8220;contingent royalty obligation payable to Evolus Founders, a related party&#8221; and the &#8220;contingent promissory note payable to Evolus Founders, a related party&#8221; in the accompanying balance sheets. Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&#8217;s former Chief Operating Officer. Mr. Marmo was retained as a consultant to the Company until December 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">royalty obligations, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although it has received the regulatory approval from the FDA and Health Canada, the Company has not commenced principal operations in the form of commercialized Product sales. The Product also requires regulatory approval from the European Medicines Agency and other similar regulatory authorities prior to commercial sales in the related jurisdictions. The Product and any future product candidates of the Company may not receive necessary approvals in the jurisdictions where approval is sought. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of the Product and any future product candidates, ability to obtain regulatory approval of the Product and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company relies on Daewoong, our exclusive and sole supplier, to manufacture the Product. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of the Product. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:13px;padding-top:0px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;">either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reporting unit. There has been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The intangible asset in the accompanying balance sheets represents IPR&amp;D projects acquired that have not yet been completed. IPR&amp;D assets with indefinite useful lives are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the IPR&amp;D assets are either amortized over their estimated useful lives or written-off immediately. There has been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Offering Costs</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Deferred offering costs, which primarily consisted of direct incremental legal and accounting fees relating to the IPO or Follow-On Offering, are capitalized until such time as the offering closes. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of deferred offering costs were offset against proceeds from the sale of registered equity securities in the Company&#8217;s IPO and Follow-On Offering. As of December&#160;31, 2018, the Company did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t capitalize any deferred offering costs. As of December&#160;31, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of deferred offering costs were capitalized and included in &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; in the accompanying balance sheet.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Joint and Several Liability Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has (i) agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amounts that the Company expects to pay on behalf of its co-obligors. The determination of the &#8220;best estimate&#8221; from within the range of amounts that might be paid involves substantial judgment by the Company&#8217;s management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no reimbursements of research and development expenses during the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At each financial reporting date, the Company accrues and expenses the estimated costs of clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates based upon a review of the agreements, data collected by internal and external personnel regarding the progress or stage of completion of trials or services. This progress or stage of completion of trials or services is monitored pursuant to contracts with clinical research organizations and other service providers. The agreed-upon fee to be paid for such services is based upon facts and circumstances known to the Company at each financial reporting date. If the actual performance of activities varies from the assumptions used in the estimates, the accruals are adjusted accordingly. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Payment Obligation Payable to the Evolus Founders, a Related Party</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in the non-current liabilities in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders, a Related Party</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company assumed the liability concurrent with the IPO and determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees and members of the Board of Directors based on the fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of actual forfeitures, when they occur.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units are based on the fair value of the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Compensation cost related to the grant of awards to the Company&#8217;s employees is recognized as an increase to additional paid-in capital in the balance sheets and in the general and administrative or research and development expenses in the statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the IPO, the ALPHAEON common stock awards were valued at fair value on the date of grant and that fair value was recognized over the requisite service period. Estimates were used to determine the fair value of these awards, as shares of ALPHAEON&#8217;s common stock are not publicly traded. ALPHAEON common stock awards are subject to specified vesting </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">schedules and requirements. The Company estimated the fair value of each ALPHAEON option on the date of grant using the Black-Scholes model. Stock-based compensation expense is allocated to the Company over the required service period over which these ALPHAEON common stock awards and options would vest and is based upon the relative percentage of time utilized by ALPHAEON employees on Company matters. These ALPHAEON awards were recognized as a capital contribution which was recorded in the statement of stockholder&#8217;s equity (deficit) and a corresponding entry was recorded in the accompanying statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the effects of common stock equivalents such as convertible preferred stock and stock options outstanding. Diluted net loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issued common stock were exercised or converted to common stock. Dilutive common share equivalents are comprised of convertible preferred stock and stock options outstanding during the period, but are excluded if their impact is anti-dilutive. Because the impact of these items is anti-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-18,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires transactions in collaborative arrangements to be accounted for under ASC 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company will adopt the guidance on January 1, 2019, and does not expect such adoption will have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2021. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU 2018-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;ASU 2018-13&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the FASB issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">, Compensation - Stock Compensation - Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this ASU clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2019. The Company is in the process of determining the effects the adoption will have on its financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the FASB issued ASU No. 2018-07,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2018-07&#8221;) which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2017-09&#8221;) which amends the scope of modification accounting for stock-based payment arrangements.&#160;The amendment&#160;provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company adopted this guidance effective January 1, 2018 and this guidance did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2017-04,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles&#8212;Goodwill and Other (Topic 350</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">):&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This standard simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for us beginning January&#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU 2017-01,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Business Combinations (Topic 805)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Definition of a Business</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies when transactions should be accounted for as acquisitions (or disposals) of assets or business. ASU 2017-01 is effective for us beginning January&#160;1, 2019. Early adoption is permitted for transactions not previously reported in issued financial statements. The Company is evaluating the effect of this standard on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that supersedes the current lease guidance under </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases, (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard requires lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The new accounting standard will be effective for the Company starting in the first quarter of fiscal 2019. The Company will elect the transition package of three practical expedients permitted under the transition guidance and will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods. Further, the Company will elect a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company will record right-of-use assets and liabilities and the corresponding deferred tax assets and liabilities on its balance sheet as of January 1, 2019, primarily associated with its operating leases. The Company is also finalizing the impact of the standard to its accounting policies, processes, disclosures, and internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2016-13&#8221;), which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. We are in the process of reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s946D23BA527F526085334F4FCCBC821A"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 3.&#160;&#160;&#160;&#160;Goodwill and Intangible Asset</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill and an intangible asset were established as a result of the application of push-down accounting in connection with the acquisition of the Company by SCH in October 2013, as described in Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">, Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The purchase price was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the excess of which over the fair value of net assets acquired was recognized as goodwill of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;Goodwill recognized in connection with the acquisition is not deductible for tax purposes. The net assets acquired as of the acquisition date comprised solely of IPR&amp;D valued at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and a deferred tax liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which represented the difference between the book and tax basis related to the IPR&amp;D asset. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The IPR&amp;D asset related to the development of the Product in clinical trials in the United States as of the acquisition date. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the carrying value of the IPR&amp;D, included in intangible asset in the balance sheets, was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the carrying value of goodwill in the accompanying balance sheets was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The estimated fair value of the IPR&amp;D asset on the acquisition date was determined </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">using a discounted cash flow model using an income approach (the multiple-period excess earnings method). Significant assumptions used in the valuation included projected future cash flows, projected costs, a weighted average cost of capital and appropriate discount rates.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The IPR&amp;D recognized represents the license and associated distribution rights to develop the Product and the ability to pursue new indications and is subject to the success of clinical studies. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of the transaction, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in additional cash consideration is due to Daewoong based upon Evolus&#8217; successful completion of certain technical and sales milestones. The fair value of the milestones was recorded by the Company as an element of the acquired IPR&amp;D at the acquisition date.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Through 2018 the IPR&amp;D asset is classified as an indefinite-lived intangible asset. With the recent FDA approval of Jeuveau, the IPR&amp;D is no longer considered an indefinite-lived asset and amortization of the asset will commence in 2019.</font></div><div><a name="s1F409BBABE785E42AC741B539FB3708D"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Services with ALPHAEON</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO and since the Company&#8217;s acquisition in 2014 by ALPHAEON, the Company had funded its operations primarily through contributions and related party borrowings from ALPHAEON. ALPHAEON has historically provided Evolus certain services, including, without limitation, research and development, general and administrative support services and support services. ALPHAEON had historically allocated a certain percentage of personnel to perform the services that it provides to the Company based on its good faith estimate of the required services. These allocated costs reflect the ALPHAEON FTE rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing Evolus these services. Evolus historically had not paid a mark-up on the external or internal expenses ALPHAEON allocated to it. Prior to February 12, 2018, all research and development, general and administrative, and other support services expenses shown in the Company&#8217;s financial statements for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;excluding stock-based compensation which is treated as a capital contribution, were treated as related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company entered into the Services Agreement with ALPHAEON, which became effective upon the Company&#8217;s IPO. The Services Agreement sets forth certain agreements between ALPHAEON and the Company that governs the respective responsibilities and obligations between ALPHAEON and the Company </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as it relates to the services to be performed between them</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Services Agreement has a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year term and thereafter will renew for successive </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year terms unless sooner terminated by either party. The Company or ALPHAEON may terminate the Services Agreement upon sixty days&#8217; notice to the other party. In accordance with the Services Agreement, the Company paid ALPHAEON </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the first quarter of 2018, subsequent to the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Evolus had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related party accounts receivable or payable with ALPHAEON. As of December&#160;31, 2017, Evolus had related party accounts receivable and related party borrowings of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$72.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;with ALPHAEON, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the amounts that were allocated from ALPHAEON prior to the IPO, and included in Evolus&#8217; general and administrative expenses as disclosed in the accompanying </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">statements of operations and comprehensive loss for the following periods (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Compensation &amp; Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Third party service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Facility related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,906</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">After completion of the Company&#8217;s IPO on February 12, 2018, ALPHAEON did not incur any administrative or research and development expenses on the Company&#8217;s behalf.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Note Obligation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2016, ALPHAEON entered into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;separate debt transactions: (i) a convertible note with one of its stockholders, also a related party (the &#8220;Bridge Note&#8221;) with a principal amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and (ii) a Secured Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which ALPHAEON could issue up to an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(&#8220;Note Facility&#8221; and together with the Bridge Note, the &#8220;Notes&#8221;). The Notes have substantially similar terms and accrue simple interest at a rate of ten percent (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) per annum, subject to adjustment pursuant to terms of the Notes. The Notes may be paid at a redemption price equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;times the face amount of the Note less any prepayment of principal and any principal amount of the Notes that may convert into shares of ALPHAEON on (i) maturity in December 2018, (ii) a required prepayment event, or (iii) prepayment at any time at ALPHAEON&#8217;s election. Upon the occurrence of certain corporate events at ALPHAEON, at the election of the holder, the Notes will convert into a variable number of shares of ALPHAEON with an aggregate fair value equaling the principal value of the Notes or such Notes will continue to maturity as unsecured promissory notes with a reduced interest rate.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ALPHAEON&#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&#8217;s assets, including all of the shares of the Company&#8217;s capital stock held by ALPHAEON, which as of December 31, 2017 represented all of the Company&#8217;s outstanding capital stock, as collateral for the holders of the Notes.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2017, ALPHAEON amended and restated the Purchase Agreement (the &#8220;Amended and Restated Secured Note Purchase Agreement&#8221;) with the Note holders to amend and restate the terms of the Purchase Agreement and the outstanding Notes and form of Notes to be issued. In addition, the Purchase Agreement was amended and restated to, among other things, set forth the terms for the issuance of up to an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in principal amount of Notes. Concurrent with the Amended and Restated Secured Note Purchase Agreement, the Company also executed two substantially similar guaranty and security agreements (the &#8220;Guaranty Agreements&#8221;), with the holders of the Notes. Pursuant to the Guaranty Agreements, the Company absolutely, unconditionally and irrevocably guaranteed, as primary obligor and not merely as surety, the full and punctual payment when due, whether at stated maturity or earlier, by reason of acceleration all the obligations of the Notes. In addition, pursuant to the Guaranty Agreements, the Company agreed to a first priority lien and security interest in and to all its right, title and interest in the assets of the Company. As a result of executing the Guaranty Agreements, there was no requirement that the holders of the Notes first seek payment from ALPHAEON. Instead, they may demand payment from the Company, from ALPHAEON or from both simultaneously. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements stipulate that any payment by the Company under their terms shall result in a dollar-for-dollar offset and reduction in the amount of related party loans owed by the Company to ALPHAEON. The Guaranty Agreements will terminate upon the earlier of (i) the date on which all secured </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">obligations under the Guaranty Agreements have been paid and performed in full and (ii) the date on which the entire outstanding principal amount of the Notes has been either converted into equity or unsecured notes pursuant to the terms of the Notes.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Concurrent with the execution of the Guaranty Agreements with the holders of the Notes in April 2017, the Company jointly and severally agreed to pay the redemption amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;times the principal amount of the Notes upon maturity if not paid by ALPHAEON. As a co-obligor to these Notes, the Company applied the accounting guidance provided in ASC 405-40, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Obligations Resulting from Joint and Several Liability Arrangements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This guidance requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount that the entity has (i) agreed to pay on the basis of its arrangement with its co-obligors and (ii) any additional amount that the entity expects to pay on behalf of its co-obligors. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company initially recorded a liability and corresponding deemed distribution to ALPHAEON as a reduction to additional paid-in-capital in equity in April 2017 to reflect the joint and several liability. These amounts were subsequently adjusted to reflect changes in the balance of the Note obligation.  As the Company and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, the Company developed a range of amounts that it expected to pay under the Guaranty Agreements and selected the amount from within that range that it determined to be the best estimate, which equaled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$138.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, the Company and ALPHAEON entered into amendments with the holder of the convertible bridge note, and with the collateral agent for the holders of the convertible promissory notes. Under the terms of the amendment it was agreed that the Company&#8217;s guaranty of the Notes and the security interest in the Company&#8217;s assets would terminate effective upon the closing of the IPO. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subsequent to December 31, 2017, ALPHAEON issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional convertible promissory notes, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;convertible promissory notes to Murthy Simhambhatla, Ph.D., the Company&#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the Notes increased </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;times the total outstanding principal amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) immediately prior to the IPO. Approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in excess of the then balance of additional paid-in capital was recorded in accumulated deficit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As provided for within the Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements, in conjunction with its recognition of the joint and several liability, the Company also recorded a receivable from ALPHAEON, which equals the current balance of the amounts it owed to ALPHAEON under its related party borrowing arrangements. No amounts were paid under this joint and several liability by the Company in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The difference between the amount of the joint and several liability and the related party receivable of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$66.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was recorded as a deemed distribution to ALPHAEON, in stockholders&#8217; equity (deficit) to additional paid-in capital in the period the transaction with the related party was made. Approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in excess of the then additional paid-in capital balance was recorded in accumulated deficit as of December 31, 2017. In January 2018 immediately prior to its IPO, the Company recorded </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an increase of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the receivable from ALPHAEON with a corresponding increase in additional paid-in capital. The related party receivable balance increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;immediately prior to the IPO</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the Company was released of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;note obligation for all guaranty and security obligations under the Guaranty Agreements, and the related party receivable from ALPHAEON of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was settled, resulting in a capital contribution of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ALPHAEON&#8217;s security interest in Evolus&#8217; assets was also terminated. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 9</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">-Equity Related Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information regarding equity transactions that occurred in connection with the IPO.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evolus Founders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals who were previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&#8217;s former Chief Operating Officer and consultant to the Company through December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Payment Obligations Related to the Acquisition by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition by SCH and ALPHAEON, as described in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Evolus Founders were issued Class D units of SCH which contained certain rights and privileges that provide the Evolus Founders with a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;economic interest in Evolus. The original payment obligations included (i) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">perpetual quarterly royalties of a mid-teen percentage of net sales of the Product within the United States and (iii) a high-single digit percentages of net sales of the Product outside of the United States. As these future royalty streams are perpetual, ALPHAEON had the right under the Stock Purchase Agreement to terminate any future payments for a one-time lump sum payment to SCH of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$145.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, SCH and ALPHAEON entered into the Amended Purchase Agreement, whereby Evolus also joined as a contractual party. Pursuant to the Amended Purchase Agreement, ALPHAEON&#8217;s existing payment obligations were replaced with revised payment obligations, payable directly to the Evolus Founders, to be distributed to them ratably in accordance with their previous respective percentage ownership in Series A preferred stock, and in exchange for the cancellation of the Class D units of SCH. Pursuant to the Amended Purchase Agreement, effective upon the closing of the IPO, ALPHAEON immediately and automatically assigned to Evolus and Evolus immediately and automatically accepted and assumed all of ALPHAEON&#8217;s payment obligations under the Stock Purchase Agreement, as amended by the Amended Purchase Agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, the revised payment obligations consist of (i) an approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) quarterly royalty payments of a low single digit percentage of net sales of the Product within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of the Product outside of the United States, and (iv) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;promissory note that will mature on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years anniversary of the first commercial sale of the Product in the United States. The revised payment obligations set forth in (ii) and (iii) above will terminate in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year anniversary of the first commercial sale of the Product in the United States. As these revised payment obligations are not perpetual, neither Evolus nor ALPHAEON will have the right to terminate any future payments for a one-time lump sum payment. Under the Amended Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders was </font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note) as of February 12, 2018. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for more information about the Company&#8217;s accounting thereof. In addition, the outstanding related party borrowings from ALPHAEON were set-off and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations Evolus assumed from ALPHAEON, the fair value of which, as of February 12, 2018, was </font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, Evolus agreed to make one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to certain of its former and current employees upon FDA approval of the Product, including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;payable to Rui Avelar, M.D., Evolus&#8217; Chief Medical Officer and Head of Research &amp; Development.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus will have the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal will become immediately due and payable at the option of the holder. An event of default will occur under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;days. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of Evolus, all unpaid principal will become immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&#8217; assets, (ii) the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">exclusive license of the Product or the business related to the Product to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company determined the fair value of the contingent royalty obligation payable to the Evolus Founders, a related party, was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and recorded a revaluation charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the accompanying statements of operations and comprehensive loss. The charges were driven by changes in assumptions relating to the timing of cash flows and the discount rate. The Company will revalue the contingent royalty obligation payable to the Evolus Founders, a related party, at each reporting period. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Amended Purchase Agreement, Evolus entered into a tax indemnity agreement with the Evolus Founders (&#8220;Tax Indemnity Agreement&#8221;) pursuant to which, effective upon Evolus&#8217; assumption of the revised payment obligations under the Amended Purchase Agreement, which occurred upon the completion of the IPO, Evolus was obligated to indemnify the Evolus Founders for any tax liability resulting from such assignment of the revised payment obligations from ALPHAEON to Evolus. Under the Stock Purchase Agreement, the payment obligations are contingent and are thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. The entry into the Amended Purchase Agreement would cause the Evolus Founders to be treated for U.S. federal income tax purposes as receiving a distribution from SCH of the right to receive the contingent payments in a transaction in which no gain or loss is recognized such that the Evolus Founders may continue installment sale reporting with respect to the revised payment obligations to the same extent that installment sale reporting was available to SCH with respect to the original payment obligations prior to the execution of the Amended Purchase Agreement. Under the Tax Indemnity Agreement, Evolus was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Evolus&#8217; assumption of the revised payment obligations under the Amended Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (the &#8221;Distribution Agreement&#8221;), with Clarion Medical Technologies Inc. (&#8220;Clarion&#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply the Product to Clarion in Canada.&#160; Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind ALPHAEON&#8217;s acquisition of Clarion. As a result, ALPHAEON owes the equity holders of Clarion an unwinding fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;Unwinding Fee&#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of the Product purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee ALPHAEON owes. In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Distribution Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">if the Company did not receive approval from Health Canada to promote and</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sell the Product in Canada prior to October 31, 2018, the Company was obligated to pay liquidated damages to</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clarion in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;days of December 31, 2018, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">which damages would not reduce the Unwinding Fee. In August 2018, the Company received approval from Health Canada to promote and sell the Product. Accordingly, the Company has concluded that no obligation exists and no liability has been recorded as of December 31, 2018. No amounts have been paid towards the Unwinding Fee as of December 31, 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Therapeutic Optio</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">n Letter Agreement</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 18, 2017, the Company entered into a therapeutic option letter agreement with ALPHAEON whereby certain rights to the therapeutic indications of the Product under the Daewoong Agreement were transferred by the Company to ALPHAEON. The Company recorded this transaction as a reduction of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the related party borrowings and a non-cash capital contribution from ALPHAEON, in additional paid-in capital on the balance sheets as of December 31, 2017. Once exercised, the rights to the therapeutic indications shall be solely in the control of ALPHAEON. As of December 31, 2018, the right to exercise the therapeutic option was exercised by ALPHAEON, which remitted the exercise price directly to Daewoong.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sD37884154BDB5AA391CEA690CD2BA44B"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Operating Lease</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total&#160;rental&#160;expense for the years ended&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong. Certain purchase obligations or milestone payments have been excluded because they are contingent upon the occurrence of future events, including receipt of governmental approvals and our future sales in various jurisdictions, and we do not know the timing of such potential obligations with certainty. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">FDA Milestone Payments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Daewoong Agreement, as described in detail below, the Company is obligated to make future milestone payments for certain confidential development and commercial milestones associated with the Product. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In October 2013, Evolus entered into the Daewoong Agreement with Daewoong. Pursuant to the Daewoong Agreement, the Company has an exclusive distribution license to the Product from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Product will be manufactured by Daewoong in a recently constructed facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than the Product) in a territory covered by the Daewoong Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company held an option to obtain the therapeutic rights to the Product in its licensed territories which was held in trust for ALPHAEON during the fourth quarter of 2017 for a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reduction in related party borrowings. In September&#160;2018, ALPHAEON exercised the right to obtain the therapeutic option to the Product and remitted the option exercise price directly to Daewoong.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions, which have not yet been obtained as of December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. The Company is not subject to any currently pending legal matters or claims that would have a material adverse effect on its accompanying financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;amounts were accrued as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, ALPHAEON, SCH and Daewoong are defendants to a lawsuit brought by Medytox, Inc. (&#8220;Medytox&#8221;) alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain and that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture the Product (the &#8220;Medytox Litigation&#8221;). The Company believes it has meritorious defenses and intends to vigorously defend Medytox&#8217;s claims. Given the early stage in the Medytox Litigation, the Company is unable to determine the likelihood of success of Medytox&#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Citizen Petition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2017, Medytox filed a Citizen Petition (the &#8220;Citizen Petition&#8221;) with the FDA. The Citizen Petition seeks to delay approval of the Biologics License Application submitted by the Company to the FDA in May 2017 for the Product until the FDA determines the identity and source of the botulinum strain for the Product and validates the integrity of the data and information in the Biologics License Application. Medytox further requests that the FDA require the source and identity information in the Biologics License Application to include a single nucleotide polymorphism analysis of the whole genome sequence of the botulinum strain for the Product. In connection with the FDA approval of the Product, on February 1, 2019 the Citizen Petition was dismissed.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">ITC Case</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &#8220;Allergan&#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &#8220;ITC&#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that the Product is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of the Product is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;ITC Complaint&#8221;).  The ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930. The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin bacterial strain</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an exclusion order which would bar imports of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States and a cease and desist order which would bar sales and marketing of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">within the United Sates either of which would adversely affect our ability to carry our out our business and which would have an adverse effect on our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations.</font></div><div><a name="s19044053472c48348422ecf2d3ec8df3"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The carrying amounts of cash, accounts payable, and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments Not Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;contingent promissory note payable under the Amended Purchase Agreement to the Evolus Founders, that will mature </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years after the anniversary date of the first commercial sale of the Product in the United States. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with a corresponding increase to the non-current liabilities in the balance sheets. The Company measures the fair value of this contingent promissory note at present value based on Level 2 inputs, using a discount rate for similar rated debt securities and is based on an estimated date that the Company believes the contingent promissory note will mature. The fair value of the contingent promissory note could be impacted by changes such as: (i) changes in the discount rate assumed, or (ii) a delay in the first commercial sale of the Product in the United States.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company assumed the liability concurrent with its IPO in February 2018 and therefore, did not carry a contingent promissory note payable balance at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The following table (in thousands) presents the difference between the carrying balance and the fair value of the contingent promissory note payable to the Evolus founders, a related party:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.15079365079364%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Carrying Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent promissory note payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">17,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) presents the major security types the Company held at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, that are measured at fair value on a recurring basis. The Company did not hold any major security types that required a fair value measurement on a recurring basis at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Hierarchy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in non-current liabilities in the balance sheets. The significant unobservable input assumptions that can significantly change the fair value includes (i) timing of the FDA approval of the Product, (ii) projected and timing of net revenues during the payment period, which will terminate for the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year anniversary of the first commercial sale of the Product in the United States, (iii) the discount rate, and (iv) the timing of payments. During the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company utilized discount rates ranging from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">18%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, reflecting changes in the Company&#8217;s risk profile. Net revenue projections were also updated to reflect changes in the timing of expected regulatory approval and commercialization.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable to a related party for year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.71428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Assumption of the royalty obligation payable to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">39,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s0ba3ed27cfea46bfb3a1675ca2ce02a0"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accrued Expenses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:6px;text-indent:26px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.17460317460318%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payroll and related benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Professional services and related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">931</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s592AAE49FC5250F8A51D8078AAD81563"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(775</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred (benefit) provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total provision (benefit) for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">72.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which will begin to expire in year 2034. NOL carryforwards generated by the Company have been included in the consolidated and unitary income tax returns of ALPHAEON. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which has an indefinite carryforward period. Deferred tax assets in the accompanying financial statements are presented as if the Company filed separate income tax returns. Accordingly, the NOL and the R&amp;D credit carryforwards allocable to the Company based on ALPHAEON&#8217;s consolidated and unitary income tax returns may ultimately differ from those presented in the financial statements on a separate return methodology.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period (a &#8220;Section 382 ownership change&#8221;), utilization of its pre-change NOL carryforwards and the R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards and R&amp;D credit carryforwards before utilization and may be material. As of December&#160;31, 2018, the Company has not </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">determined to what extent a potential ownership change will impact the annual limitation that may be placed on the Company&#8217;s utilization of its NOL carryovers and R&amp;D credit carryforwards. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The components of deferred tax assets and liabilities were as follows </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">29,782</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(34,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(24,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recorded deferred tax assets of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which have been fully offset by a valuation allowance. The valuation allowance </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increased</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;primarily driven by the current year operating loss. </font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in Federal tax rate due to tax reform</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revaluation of contingent royalty obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax provision (benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.  The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company&#8217;s tax returns for all years since inception are open for audit. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2017, the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) was enacted. The TCJA includes a number of changes to existing U.S. tax laws that impact the company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The TCJA also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017 as well as prospective changes beginning in 2018, including additional limitations on executive compensation, limitations on the deductibility of interest and capitalization of research and development expenditures.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While there were no changes in the net deferred tax assets, the Company has recorded a decrease in the valuation allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and a reduction in the net deferred tax liability and a benefit to income tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The TCJA no longer allows deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance based compensation. It also subjects the principal executive officer, principal financial officer and three other highest paid officers to the limitation and once the individual becomes a covered person, the individual will remain a covered person for all future years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The company recognized the income tax effects of the TCJA in its 2017 financial statements in accordance with Staff Accounting Bulletin No. 118, which provides SEC staff guidance for the application of ASC Topic 740, Income Taxes, in the reporting period in which the TCJA was signed into law. As such, the Company's 2017 financial results reflected the provisional income tax effects of the TCJA for which the accounting was incomplete but a reasonable estimate was made. The Company&#8217;s accounting for the elements of the TCJA was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate.</font></div><div><a name="s512242A770775E80AAE8794B773BED5F"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company completed its IPO of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock, which included the exercise by the underwriters of their option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional shares of common stock, for net proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering costs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Company completed the Follow-On Offering in which the Company sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">102</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">common stock in August 2018, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from the Follow-On Offering, after deducting underwriting discounts and commissions, and excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,500,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized, of which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,250,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were issued or outstanding. ALPHAEON, as the previous sole holder of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock prior to the IPO,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;had certain dividends, conversion, redemption, voting, protective, and liquidation preferences. The number of shares of common stock to which a preferred stockholder was entitled was the product obtained by multiplying the Series A preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the amended and restated certificate of incorporation. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the IPO, all shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock. In addition, the Company also amended and restated its certificate of incorporation. As a result, shares of Series A convertible preferred stock were canceled, with none authorized, issued or outstanding as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the completion of its IPO, the Company also amended and restated its certificate of incorporation to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of preferred stock authorized, of which none were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the completion of its IPO, the Company also amended and restated its certificate of incorporation to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock authorized, of which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27,274,991</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Equity Related Transactions</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the Company assumed from ALPHAEON the revised payment obligations under the Amended Purchase Agreement of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note at that date). See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information. Pursuant to the Amended Purchase Agreement, ALPHAEON agreed to offset and reduce the amount of related party borrowings by the estimated value of the revised payment obligations on a dollar-for-dollar basis and pursuant to the Services Agreement. Additionally, the Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to ALPHAEON in satisfaction of a portion of the outstanding related party borrowings (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The remaining balance of related party borrowings of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was recharacterized as a capital contribution from ALPHAEON pursuant to the Services Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 21, 2017, t</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he board of directors and the then-sole stockholder of the Company approved the Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,361,291</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares, plus an annual increase on each anniversary of November 21, 2017 equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2018, an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,091,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were reserved under the evergreen provision of the Plan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company reserved an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,888,484</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock for future issuance under the Plan.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Award Activity and Balances</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of restricted stock units (&#8220;RSUs&#8221;) is estimated at the Company&#8217;s grant date common share price. Options are granted at exercise prices based on the Company&#8217;s grant date common share price. The RSUs and options generally vest over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">- to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period. There have been no awards with performance conditions and no awards with market conditions. The options generally have a contractual term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ten</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years. The Black&#8209;Scholes option pricing model has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The Company records share&#8209;based compensation expense net of actual forfeitures. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The significant assumptions used in the Black-Scholes option-pricing are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determining Fair Value of the underlying common stock.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;For options awards granted after the completion of the Company&#8217;s IPO, the fair value for its underlying common stock was determined using the fair value of the grant date price as reported on the Nasdaq Global Select Market. Since the Company&#8217;s common stock was not traded in a public stock market exchange prior to the Company&#8217;s IPO, prior to such date the Board of Directors considered numerous factors including new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company&#8217;s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company&#8217;s initial public offering, the Board of Directors determined the Company&#8217;s common stock fair market value on as needed basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Volatility.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company has limited data regarding company&#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Term.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience for exercise and post-vesting employment or contractual termination behavior after its common stock has been publicly traded. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Risk&#8209;Free Rate.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Dividends.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">104</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not grant stock options, restricted stock units, or restricted stock awards during the year ended December 31, 2017. The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.04761904761905%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:63%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.76%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.65%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:43%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,840,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">8,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(582,923)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the Company&#8217;s common stock for those awards that have an exercise price below the estimated fair value at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the year ended December 31, 2018, the Company recorded expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to stock options. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of total unrecognized compensation cost, net of actual forfeitures, related to stock option based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of the status of the Company&#8217;s nonvested options as of and changes during the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted-Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,840,724</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(582,923)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">105</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of restricted stock unit activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:61%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">321,516</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(34,602)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(15,510)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the year ended December 31, 2018, the Company recorded expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to restricted stock units. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of total unrecognized compensation cost, net of actual forfeitures, related to stock option based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.9</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense (in thousands) amounts recorded in the accompanying statements of operations and comprehensive loss pursuant to the Plan in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and allocated to Evolus by ALPHAEON in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">586</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Separation of Service with the Former President and Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2018, the Company entered into a separation agreement (the &#8220;Separation Agreement&#8221;) with its then President and Chief Executive Officer</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Murthy Simhambhatla, Ph.D</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Pursuant to the Separation Agreement, the Company modified previously </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">granted stock options resulting in an incremental vesting of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,424</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;stock options and related stock-based compensation expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As part of the Separation Agreement, the Company issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34,602</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock net of tax withholding for vested restricted stock units. An additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50,112</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock were immediately vested and will be issued in February 2020. Stock-based compensation expense relating to the issuance of common stock and accelerated vesting was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The aforementioned non-cash charges are reflected in general and administrative on the statements of operations and comprehensive loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">106</font></div></div><hr style="page-break-after:always"><div><a name="s52a606bea5764d17bccd11fd8dcbebb4"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 10. Net Loss per Share Attributable to Common Stockholders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average shares outstanding used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24,402,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company incurred a net loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and, accordingly, the Company did not include the following dilutive common equivalent shares:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:61%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">221,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,479,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s09cded5fa74047a0afe511f160220802"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 11. Subsequent Events</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 1, 2019, the FDA granted approval of the Company&#8217;s BLA for the Product. In February 2019, pursuant to the Amended Purchase Agreement, the Company paid a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment to the Evolus Founders and one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to certain former and current employees, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;payable to Rui Avelar, M.D., Evolus&#8217; Chief Medical Officer and Head of Research &amp; Development. In addition, pursuant to the Daewoong Agreement, the Company paid Daewoong a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment in February 2019.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, the Company entered into a credit facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;with Oxford Finance, LLC (&#8220;Oxford&#8221;). Pursuant to the credit facility the lender will make term loans available in two advances. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was funded on the closing date. The second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing six month basis and no event of default is occurring. The credit facility bears an annual interest rate equal to the greater of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the 30-day U.S. Dollar LIBOR rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company has agreed to pay interest only on each tranche funded for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;months until May 2022, which will be followed by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&#8217;s request, the interest only period may be extended by an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;months to a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;months followed by an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company will be required to pay to Oxford a final payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the full principal amount of the term loans funded, or the final payment. The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs thereafter (the &#8220;Prepayment Fee&#8221;). If the term loans are accelerated following the occurrence of an event of default, the Company will be required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the final payment, the Prepayment Fee, and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including its cash.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">107</font></div></div><hr style="page-break-after:always"><div><a name="sCAF4C4C18A6058469DF591AECA52C4C8"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 9. &#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><a name="s426038E5411558A78F951D2F42100993"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 9A. &#160;&#160;&#160;&#160;Controls and Procedures.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective (a)&#160;to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b)&#160;to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our internal control over financial reporting based on the framework in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Internal Control-Integrated Framework</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the evaluation under that framework and applicable SEC rules, our management concluded that our internal control over financial reporting was effective as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm on our internal control over financial reporting due to an exemption established pursuant to the JOBS Act for &#8220;emerging growth companies.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Inherent Limitations of Internal Controls</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well&#160;designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</font></div><div><a name="sD2F6A30DDDFE53648D36C95A452E8FFA"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 9B.  &#160;&#160;&#160;&#160;Other Information.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">108</font></div></div><hr style="page-break-after:always"><div><a name="s9887598835A8570FAF11B59B9DE19444"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">109</font></div></div><hr style="page-break-after:always"><div><a name="s49B29CEB50C95AFAA3763CAC5639D68A"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 10.  &#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Executive Officers and Directors </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth certain information regarding our current executive officers and directors, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including their ages, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40944881889764%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Position(s)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Executive Officers and Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">David Moatazedi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">President, Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Lauren Silvernail</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Rui Avelar, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Chief Medical Officer and Head of Research and Development</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Michael Jafar</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Chief Marketing Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Non-Employee Directors </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Vikram Malik</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Chairman of the Board of Directors</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Simone Blank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Bosun Hau</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Kristine Romine, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Robert Hayman</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">David Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">64</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Executive Officers and Directors</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">David Moatazedi</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as our President, Chief Executive Officer and as a member of our board of directors, since May 2018. Prior to that time, Mr. Moatazedi was the Senior Vice President at Allergan, Inc., or Allergan, and division head of the U.S. Medical Aesthetics division, which includes facial aesthetics, plastic surgery, regenerative medicine, body contouring, and skin care products from March 2016 to May 2018. Since March 2017, Mr. Moatazedi has served as a member of the board of directors of Obalon Therapeutics, Inc., a public medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Mr. Moatazedi has worked in various leadership capacities within Allergan since March 2005, including as Vice President, Sales and Marketing of the U.S. Facial Aesthetics division from August 2014 to March 2016 and Vice President, Sales and Market of the U.S. Plastic Surgery division from February 2013 to August 2014. Prior to Allergan, Mr. Moatazedi was a district manager at Novartis Pharmaceuticals for the Dermatology division. Mr. Moatazedi holds an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Lauren Silvernail</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as our Chief Financial Officer and Executive Vice President, Corporate Development since May 2018. Prior to that time, Mrs. Silvernail served as the Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc., or Revance, a pharmaceutical research and development company, from December 2015 to May 2018 and as Revance's Chief Financial Officer and Executive Vice President, Corporate Development from March 2013 to December 2015. From 2003 to 2012, Mrs.&#160;Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a pharmaceutical research and development company. From 1995 to 2003, Mrs.&#160;Silvernail served in various operating and corporate development positions with Allergan, including Vice President, Business Development. Prior to joining Allergan, Mrs.&#160;Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the board of directors and the audit and compensation committees of Nicox S.A. Mrs.&#160;Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Rui Avelar, M.D.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as our Chief Medical Officer since January 2014 and was appointed our Head of Research and Development in August 2018.  From January 2014 to February 2018, Dr. Avelar also served as the Chief Medical Officer of ALPHAEON. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">110</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Michael Jafar</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as our Chief Marketing Officer since June 2018. &#160;From April 2017 to June 2018, he served as Vice President, Medical Aesthetics at Allergan.&#160;Mr. Jafar has worked in various leadership capacities within Allergan since March 2003, including as Associate Vice President, Strategic Marketing and Communications of the Medical Aesthetics division from May 2015 to April 2017 and roles as Senior Director of Marketing for aesthetic products such as SkinMedica, Latisse and Juvederm from October 2011 to May 2015. Mr. Jafar holds an M.B.A. from the University of Southern California and a B.B.A. from the University of San Diego.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Non-Employee Directors </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Vikram Malik</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as a member and the Chairman of our board of directors since January 2018. Mr. Malik has served as a member of ALPHAEON&#8217;s board of directors since April 2014. Since May 2013, Mr.&#160;Malik has served as the Managing Partner of SCH. From August 2011 to May 2013, Mr.&#160;Malik served as Vice Chairman, Investment Banking for Deutsche Bank Securities, Inc. From November 2010 to August 2011, Mr.&#160;Malik served as a Managing Director in the Healthcare Corporate and Investment Banking Group of Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated. From June 2000 to November 2010, Mr.&#160;Malik served as the Managing Director of Banc of America Securities, LLC. Mr.&#160;Malik received a B.A. in Economics from Delhi University and an M.B.A. from Boston University Graduate School of Management. We believe Mr. Malik&#8217;s extensive experience in the investment banking and financial services industry, as well as his role at SCH, qualifies him to serve on our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Simone Blank</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as a member of our board of directors since January 2018. Ms. Blank has served as the chairman of the board of directors of ALPHAEON since July 2016. Ms. Blank is also the co-owner of Dental Innovations BVBA, the collateral agent for the holders of the convertible promissory notes issued by ALPHAEON.  Since 2013, Ms. Blank has served as a member of the board of directors of several private healthcare companies. From May 2006 to October 2013, Ms. Blank served as a member of the board of directors of Sirona Dental Systems Inc., or Sirona, a dental technology manufacturer previously listed on Nasdaq. From July 1999 to October 2013, Ms. Blank served as Executive Vice President and Chief Financial Officer of Sirona.  Prior to July 1999, Ms. Blank was an engagement manager in the merger and acquisition transaction group of PricewaterhouseCoopers after having gained global financial experience as a certified public accountant and tax advisor. Ms. Blank received a M.Sc. in Economics from the University of Duisburg, Germany. We believe Ms. Blank&#8217;s extensive business and leadership experience qualifies her to serve on our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Bosun Hau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as a member of our board of directors since January 2018. Mr. Hau has served as a member of ALPHAEON&#8217;s board of directors since May&#160;2016. Since February 2018, Mr. Hau has served as a director of Cellular Biomedicine Group, Inc.  Since October 2015, Mr. Hau has served as a Managing Director and Partner of Sailing Capital. From August 2009 to October 2015, Mr. Hau served as a Partner of MVM Life Science Partners LLP. From July 2004 to August 2007, Mr. Hau served as an equity research analyst covering the medical device and pharmaceutical industries for JP Morgan Securities, Inc. and Prudential Securities, Inc. Since 2009, Mr. Hau has served as a member of the board of directors of several private biotechnology, specialty pharmaceutical and medical device companies. Mr. Hau received a B.S. in Molecular and Cellular Biology, a B.S.H.S. in Physiological Sciences and a B.A. in Psychology from the University of Arizona, an M.Sc. in Biotechnology from Johns Hopkins University and an M.B.A in Finance and Health Management from the Wharton School at the University of Pennsylvania. We believe Mr. Hau&#8217;s extensive experience in the venture capital, private equity and financial services industries qualifies him to serve on our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Kristine Romine, M.D.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as a member of our board of directors since January 2018. From April 2017 to February 2018, Dr. Romine served as a member of ALPHAEON&#8217;s board of directors. In July 2003, Dr. Romine founded and has since served as the Chief Executive Officer of Camelback Dermatology &amp; Skin Surgery in Phoenix, Arizona. Dr. Romine holds a B.S. in Biology from the University of Arizona and an M.D. from the Medical College of Wisconsin.&#160;We believe Dr. Romine&#8217;s extensive experience in the dermatology industry qualifies her to serve on our board of directors. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Robert Hayman</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as a member of our board of directors since January 2018. From April 2014 to February 2018, Mr. Hayman served as a member of ALPHAEON&#8217;s board of directors. Since 2011, Mr.&#160;Hayman has served as the owner and Chief Executive Officer of Hayman Properties, a real estate investment and development business. Since 2015, Mr. Hayman has served as Principal and Chief Executive Officer of Perimetrics, LLC, a dental diagnostic service company. Since April 2008, Mr. Hayman served as Principal at Common Sense Concepts, LLC, a dental device development company. From 1993 to February 2008, Mr.&#160;Hayman served as the co-founder, Chief Executive Officer and Chairman of Discus Dental, Inc. Mr.&#160;Hayman attended the masters degree program in Psychology at Pepperdine University, and received a B.S. in Business Administration from Boston University. We believe Mr.&#160;Hayman&#8217;s extensive business and leadership experience qualifies him to serve on our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">David Gill</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, has served as a member of our board of directors since February 2018. Mr. Gill has served as a member of the board of directors and audit committee chairman of Strata Skin Sciences since June 2018 and  Y-mAbs Therapeutics, Inc. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">111</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">since December 2017. Mr. Gill has served as a member of the board of directors and audit committee chairman of Histogenics Corporation since 2015. Since 2012, Mr. Gill has also served as a member of the board of directors and audit committee chairman of Melinta Therapeutics (formerly known as Cempra, Inc.). From May to November 2015, Mr. Gill served as the President and Chief Financial Officer of EndoChoice, Inc., a medical device company focused on gastrointestinal disease. Mr. Gill joined EndoChoice, Inc. as Chief Financial Officer in August 2014 and was subsequently appointed President in 2015.  From February 2011 to August 2013, he served as the Chief Financial Officer of INC Research, now known as Syneos Health, a clinical research organization. Mr. Gill holds a B.S. in Accounting from Wake Forest University and an M.B.A. from Emory University, and is a certified public accountant (inactive). We believe that Mr. Gill&#8217;s extensive experience as an executive in the life sciences industry and his prior service as a senior-level executive in mature life sciences companies qualifies him to serve on our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Family Relationships</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are no family relationships among any of our directors or executive officers.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Board</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Composition</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">Our business and affairs are organized under the direction of our board of directors, which currently consists of seven directors. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation divides our board of directors into three classes, with staggered three-year terms, as follows:  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Class I, which consists of David Gill&#160;and Robert Hayman, whose terms will expire at our annual meeting of stockholders to be held in 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Class II, which consists of Simone Blank&#160;and Bosun Hau, and whose terms will expire at our annual meeting of stockholders to be held in 2020; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Class III, which consists of David Moatazedi, Vikram Malik and Kristine Romine, M.D., whose terms will expire at our annual meeting of stockholders to be held in 20</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">21. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized number of directors may be changed only by resolution of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed between the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in our control or management. From and after the date on which ALPHAEON no longer beneficially owns a majority of the voting power of all of the then-outstanding shares of our capital stock, our directors may only be removed for cause by the affirmative vote of the holders of at least 66&#160;2/3% of our voting stock.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Board Committees</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">Each committee operates under a charter that has been approved by our board of directors. Copies of each committee&#8217;s charter are posted on the Investor Relations section of our website, which is located at www.evolus.com. Each committee has the composition and responsibilities described below. Our board of directors may from time to time establish other committees.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Audit Committee</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">Our audit committee consists of&#160;David Gill, Bosun Hau and&#160;Robert Hayman. Mr. Gill is the chair of the audit committee. Our board of directors has determined that each of the members of our audit committee satisfies the Nasdaq Marketplace Rules and SEC independence requirements. The functions of this committee include, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">evaluating the performance, independence and qualifications of our independent registered public accounting firm and determining whether to retain our existing independent registered public accounting firm or engage a new independent registered public accounting firm;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">112</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reviewing and approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and discussing the statements and reports with our independent registered public accounting firm and management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reviewing with our independent registered public accounting firm and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reviewing and approving related party transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reviewing and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our board of directors has determined that&#160;Mr. Gill qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Marketplace Rules. In making this determination, our board of directors has considered&#160;Mr. Gill&#8217;s&#160;extensive financial experience and business background. Both our independent registered public accounting firm and management periodically meet privately with our audit committee.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Code of Conduct</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our board of directors has adopted a code of conduct that applies to all of our employees, officers and directors, including those officers responsible for financial reporting, which is available on our website, which is located at www.evolus.com. Any amendments to the code, or any waivers of its requirements, will be disclosed on our website.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Section&#160;16(a) Beneficial Ownership Reporting Compliance</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Section 16(a) of the Exchange Act requires our directors, executive officers and beneficial owners of more than 10% of our common stock to file reports of holdings and transactions in our common stock and our other securities with the SEC. To our knowledge, based solely upon the review of copies of such reports furnished to us and written representations that no other reports were required during fiscal year 2018, all of our officers, directors and beneficial owners of more than 10% of our common stock have complied with all applicable Section&#160;16(a) filing requirements, except that one late Form 4 was filed for Kristine Romine, M.D. due to an administrative error.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">113</font></div></div><hr style="page-break-after:always"><div><a name="s415AE0703C2C5E0FA03BB1735F94905F"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 11.  &#160;&#160;&#160;&#160;Executive Compensation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our named executive officers for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi, our President and Chief Executive Officer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Murthy Simhambhatla Ph.D., our former President and Chief Executive Officer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Lauren Silvernail, our Chief Financial Officer and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Executive Vice President, Corporate Development</font><font style="font-family:Times New Roman;font-size:10pt;">; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Michael Jafar, our Chief Marketing Officer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt in the future differ materially from the currently planned programs summarized in this discussion.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As noted above, we are an &#8220;emerging growth company,&#8221; as that term is used in the JOBS Act</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth total compensation paid to our named executive officers for the fiscal years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Name and Principal Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Bonus</font><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Stock Awards</font><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Option Awards</font><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">All Other Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">David Moatazedi</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">361,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">436,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4,995,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5,794,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Murthy Simhambhatla</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">251,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,202,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4,916,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">464,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6,835,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Former President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">500,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">500,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Lauren Silvernail</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">253,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(7)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">673,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2,604,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3,656,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Chief Financial Officer and </font><font style="font-family:Times New Roman;font-size:8pt;">Executive Vice President, Corporate Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Michael Jafar</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">187,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(9)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">324,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(10)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,416,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,976,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3,929,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Chief Marketing Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">_____________</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1)  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Reflects bonuses earned by Messrs. Moatazedi and Jafar and Ms. Silvernail with respect to achievements during the fiscal year ended December 31, 2018, which were paid in February 2019. Each of the bonuses paid is based on 100% achievement of key performance indicators applicable to the respective named executive officers, as determined by our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2)  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Represents the aggregate grant date fair value of stock and option awards granted during 2018, computed in accordance with FASB ASC Topic 718. See Note 9, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to our financial statements included elsewhere in this Annual Report on Form 10-K for a discussion of the assumptions we made in determining the grant date fair value of our stock and option awards.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Pursuant to the Moatazedi employment agreement, which is defined below, Mr. Moatazedi is entitled to an annualized base salary of $550,000. Mr. Moatazedi was appointed our President and Chief Executive Officer in May 2018. As a result, we paid Mr. Moatazedi a base salary of $361,731 for the fiscal year ended December 31, 2018, which represents his prorated base salary from May 2018 to December 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(4) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">As consideration for entering into the Moatazedi employment agreement, Mr. Moatazedi received a $75,000 signing bonus in May 2018. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">114</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5)  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Mr.&#160;Simhambhatla&#8217;s employment ended with us in May 2018. The 2018 salary reported reflects the pro rata portion of Mr.&#160;Simhambhatla&#8217;s annual salary of $500,000 from January 1, 2018 through the end of his employment.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Represents amounts paid pursuant to the Separation Agreement, as defined below, as a result of which Mr. Simhambhatla received (i) continuation of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">base salary through December 31, 2018, and (ii) a lump sum cash payment of $193,151 (representing a prorated portion of Mr. Simhambhalta&#8217;s 2018 annual cash bonus).  The terms of the Separation Agreement are described in more detail below under &#8220;-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">Potential Payments upon Termination or Change in Control.&#8221;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7)  Pursuant to the Silvernail employment agreement, which is defined below, Mrs. Silvernail is entitled to an annualized base salary of $425,000. Mrs. Silvernail was appointed our Chief Financial Officer and Executive Vice President, Corporate Development in May 2018. As a result, we paid Mrs. Silvernail a base salary of $253,365 for the fiscal year ended December 31, 2018, which represents her prorated base salary from May 2018 to December 2018. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(8)  Reflects a one-time payment of $25,000 for relocation expenses.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9)  Pursuant to the Jafar employment agreement, which is defined below, Mr. Jafar is entitled to an annualized base salary of $345,000. Mr. Jafar was appointed our Chief Marketing Officer in June 2018. As a result, we paid Mr. Jafar a base salary of $187,096 for the fiscal year ended December 31, 2018, which represents his prorated base salary from June 2018 to December 2018. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10)  As consideration for entering into the Jafar employment agreement, Mr. Jafar received a $250,000 signing bonus paid in July 2018. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Annual Base Salary</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The annual base salaries of our named executive officers will generally be determined and approved at the beginning of each year, or, if later, in connection with the commencement of employment of the executive, by our board of directors or our compensation committee. The table below sets forth the base salary for each of our executive officers for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018 Base Salary</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Lauren Silvernail</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">425,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Michael Jafar</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Bonus Compensation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Each of our named executive officers serving at the end of 2018 was eligible to receive a discretionary annual bonus equal to a percentage of his or her salary (100% for Mr. Moatazedi, 40% for Ms. Silvernail and 40% for Mr. Jafar) based on the achievement of key performance indicators determined by our board of directors. In May 2018, we paid a signing bonus of $75,000 to Mr. Moatazedi and a signing bonus of $250,000 to Mr. Jafar. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Equity-Based Incentive Awards</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">Our equity-based incentive awards are designed to align our interests and the interests of our current and future stockholders with those of our employees and consultants, including our named executive officers. Our board of directors is responsible for approving equity grants.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">We may grant equity awards at such times as our board of directors determines appropriate. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;We will grant all equity compensation awards pursuant to the 2017 plan. The terms of the 2017 plan are described below under &#8220;&#8212;Equity Compensation Plan.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Agreements with Our Named Executive Officers</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Below is a description of our employment agreements with Mr. Moatazedi, Mrs. Silvernail and Mr. Jafar. As of the date hereof, each of our named executive officers&#8217; employment is &#8220;at will&#8221; and may be terminated at any time, subject to the severance benefits to which our named executive officers may be eligible for as further described below. Prior to his </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">115</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">separation, we were also party to an employment agreement with Mr. Simhambhalta, which we previously filed as an exhibit to the Registration Statement in connection with our initial public offering. Mr. Simhambhalta&#8217;s employment agreement was superseded in its entirety by the terms of the Separation Agreement between Mr. Simhambhalta and us, as described below under &#8220;&#8212;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">Potential Payments upon Termination or Change in Control.&#8221; The terms of the Separation Agreement inform the compensation reflected in the compensation tables set forth in this section.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Employment Agreement with Mr. Moatazedi</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We entered into an employment agreement with Mr.&#160;Moatazedi in May 2018, or the Moatazedi employment agreement, under which Mr.&#160;Moatazedi serves as our President and Chief Executive Officer. The Moatazedi employment agreement provides that Mr.&#160;Moatazedi is an at-will employee, sets forth his initial annual base salary of $550,000, and his eligibility to participate in our employee benefit plans and programs, as in effect from time to time. Mr. Moatazedi also received a signing bonus of $75,000 as consideration for entering into the Moatazedi employment agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Moatazedi employment agreement, Mr.&#160;Moatazedi is entitled to participate in our annual discretionary incentive plan, under which Mr.&#160;Moatazedi may receive an annual incentive bonus of up to 100% of his annual base salary, subject to achievement of key performance indicators, as determined by our board of directors in consultation with Mr. Moatazedi.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Moatazedi employment agreement further grants Mr. Moatazedi an option to purchase 1,182,019 shares of our common stock&#160;in accordance with the terms of the 2017 plan. The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 6, 2018, provided Mr. Moatazedi remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of Mr. Moatazedi or upon certain changes of control of our company. Subject to certain conditions, the option will have an exercise price per share equal to $7.28, the last reported sale price of our common stock on the Nasdaq Global Market on May 4, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, under the Moatazedi employment agreement, if we terminate Mr.&#160;Moatazedi&#8217;s employment without &#8220;cause&#8221; (as defined in the Moatazedi employment agreement), or if Mr. Moatazedi resigns from his employment for &#8220;good reason&#8221; (as defined in the Moatazedi employment agreement), Mr.&#160;Moatazedi will be entitled to a cash severance payment in an amount equal to twelve months of base salary plus his pro-rata share of his annual bonus for the year in which the termination occurred, and accelerated vesting on a portion of his outstanding equity awards (or, if such termination occurs in connection with or following a &#8220;change in control&#8221; (as defined in the 2017 plan), all outstanding equity awards). All severance payments and benefits are conditioned upon the execution by Mr.&#160;Moatazedi of a general release of claims in favor of our company.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Employment Agreement with Mrs. Silvernail</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We entered into an employment agreement with Mrs.&#160;Silvernail in May 2018, or the Silvernail employment agreement, under which Mrs.&#160;Silvernail serves as our Chief Financial Officer and Executive Vice President, Corporate Development. The Silvernail employment agreement provides that Mrs.&#160;Silvernail is an at-will employee, sets forth her initial annual base salary of $425,000, and her eligibility to participate in our employee benefit plans and programs, as in effect from time to time. Mrs. Silvernail also received a one-time payment of $25,000 for relocation expenses.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Silvernail employment agreement, Mrs.&#160;Silvernail is entitled to participate in our annual discretionary incentive plan, under which Mrs.&#160;Silvernail may receive an annual incentive bonus of up to 40% of her annual base salary, subject to achievement of key performance indicators, as determined by our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Silvernail employment agreement further grants Mrs. Silvernail an option to purchase 200,000 shares of our common stock&#160;in accordance with the terms of the 2017 plan. The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 25, 2018, provided Mrs. Silvernail remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of Mrs. Silvernail or upon certain changes of control of our company. Subject to certain conditions, the option will have an exercise price per share equal to $22.44, the last reported sale price of our common stock on the Nasdaq Global Market on May 25, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Mrs. Silvernail was also granted 30,000 restricted stock units in accordance with the 2017 plan. The restricted stock units will vest over a period of four years, with 1/4th of the shares subject to the award vesting annually on the anniversary of May 29, 2018, provided Mrs. Silvernail remains in continuous service on each vesting date, subject to accelerated vesting in certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">116</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">events, including certain terminations of Mrs. Silvernail or upon certain changes of control of our company.  Each restricted stock unit represents a contingent right to receive one share of our common stock.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, subject to certain exceptions, under the Silvernail employment agreement, if we terminate Mrs.&#160;Silvernail&#8217;s employment without &#8220;cause&#8221; (as defined in the Silvernail employment agreement), or if Mrs. Silvernail resigns from her employment for &#8220;good reason&#8221; (as defined in the Silvernail employment agreement), Mrs.&#160;Silvernail will be entitled to a cash severance payment in an amount equal to six months of base salary plus her pro-rata share of her annual bonus for the year in which the termination occurred, and accelerated vesting on a portion of her outstanding equity awards. If such termination or resignation occurs within 12 months after a &#8220;change in control&#8221; (as defined in the 2017 plan) then Mrs. Silvernail will be entitled to a cash severance payment in an amount equal to 12 months of base salary plus her pro-rata share of her annual bonus for the year in which the termination occurs, and accelerated vesting on all outstanding equity awards.  All severance payments and benefits are conditioned upon the execution by Mrs.&#160;Silvernail of a general release of claims in favor of our company.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Employment Agreement with Mr. Jafar</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We entered into an employment agreement with Mr. Jafar in June 2018, or the Jafar employment agreement, under which Mr. Jafar serves as our Chief Marketing Officer. The Jafar employment agreement provides that Mr.&#160;Jafar is an at-will employee, sets forth his initial annual base salary of $345,000, and his eligibility to participate in our employee benefit plans and programs, as in effect from time to time. Mr. Jafar received a signing bonus of $250,000 as consideration for entering into the Jafar employment agreement.  Mr. Jafar also received a one-time payment of $25,000 for relocation expenses.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Jafar employment agreement, Mr. Jafar is entitled to participate in our annual discretionary incentive plan, under which Mr. Jafar may receive an annual incentive bonus of up to 40% of his annual base salary, subject to achievement of key performance indicators, as determined by our board of directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Jafar employment agreement further grants Mr. Jafar an option to purchase 120,000 shares of our common stock&#160;in accordance with the terms of the 2017 plan. The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of June 18, 2018, provided Mr. Jafar remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of Mr. Jafar or upon certain changes of control of our company. Subject to certain conditions, the option will have an exercise price per share equal to $28.32, the last reported sale price of our common stock on the Nasdaq Global Market on June 15, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Mr. Jafar was also granted 50,000 restricted stock units in accordance with the 2017 plan. The restricted stock units will vest over a period of four years, with 1/4th of the shares subject to the award vesting annually on the anniversary of June 18, 2018, provided Mr. Jafar remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of Mr. Jafar or upon certain changes of control of our company.  Each restricted stock unit represents a contingent right to receive one share of our common stock.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, subject to certain exceptions, under the Jafar employment agreement, if we terminate Mr. Jafar&#8217;s employment without &#8220;cause&#8221; (as defined in the Jafar employment agreement), or if Mr. Jafar resigns from his employment for &#8220;good reason&#8221; (as defined in the Jafar employment agreement), Mr. Jafar will be entitled to a cash severance payment in an amount equal to six months of base salary plus his pro-rata share of his annual bonus for the year in which the termination occurred. If such termination or resignation occurs within 12 months after a &#8220;change in control&#8221; (as defined in the 2017 plan) then Mr. Jafar will be entitled to a cash severance payment in an amount equal to 12 months of base salary plus his pro-rata share of his annual bonus for the year in which the termination occurs, and accelerated vesting on all outstanding equity awards.  All severance payments and benefits are conditioned upon the execution by Mr. Jafar of a general release of claims in favor of our company.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Potential Payments upon Termination or Change in Control</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our named executive officers will be entitled to receive certain payments and benefits upon termination of their respective employment with our company, as described above under the section entitled &#8220;&#8212;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">Agreements with Our Named Executive Officers.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On May 5, 2018, Mr. Simhambhalta notified us of his resignation as&#160;President and Chief Executive Officer, and as a member of our board of directors, effective as of May 6, 2018. In connection with Mr. Simhambhalta&#8217;s resignation, we entered into a General Release of Claims Agreement with Mr. Simhambhalta on May 10, 2018, or the Separation Agreement, setting forth </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">117</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the terms of Mr. Simhambhalta&#8217;s separation, which occurred on May 21, 2018, or the Separation Date. Pursuant to the terms of the Separation Agreement, in satisfaction of any and all obligations under his employment agreement, Mr. Simhambhalta will receive the following severance payments: (i)&#160;12 months of base salary, which will be paid periodically pursuant our regularly scheduled pay periods and subject to customary payroll deductions, (ii) a lump sum cash payment of $193,151 (representing a prorated portion of Mr. Simhambhalta&#8217;s 2018 annual cash bonus), which we paid to Mr. Simhambhalta on the Separation Date, subject to customary payroll deductions, (iii) the continuation of health benefits through the end of the 12-month anniversary of the Separation Date, and (iv) reimbursement of any business expenses submitted in accordance with our expense reimbursement policy.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the stock options previously awarded to Mr. Simhambhalta remained outstanding on the Separation Date and will continue to become exercisable as though Mr. Simhambhatla remained in service for 12 months after the Separation Date. All vested stock options held by Mr. Simhambhatla will be exercisable at any time prior to February 6, 2020. Further, the earning and payment of the restricted stock units previously awarded to Mr. Simhambhalta will continue in accordance with the schedule in his award agreement as though he had remained in service.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Outstanding Equity Awards at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;Fiscal Year-End</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes, for each of our named executive officers, the number of outstanding equity awards held on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:10%;"></td><td style="width:9%;"></td><td style="width:13%;"></td><td style="width:10%;"></td><td style="width:14%;"></td><td style="width:8%;"></td><td style="width:10%;"></td><td style="width:7%;"></td><td style="width:9%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Option Awards</font><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font></div><div style="text-align:center;padding-left:181px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Stock Awards</font><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5) </sup></font></div><div style="text-align:center;padding-left:28px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Number of Securities</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Underlying Unexercised</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Options</font></div><div style="text-align:center;padding-left:28px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">shares</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">of stock</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">that</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">have</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">(#)</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">shares</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">of stock</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">that</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">have</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">not</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">(#)</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Market</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">value&#160;of</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">shares</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">of&#160;stock</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">that</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">have</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">not</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">($)</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Name</font></div><div style="padding-top:1px;text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Grant</font></div><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Date</font></div><div style="text-align:center;padding-left:9px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Vesting</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Commencement</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Date</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Exercisable&#160;(#)</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:10px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Unexercisable&#160;(#)</font></div><div style="text-align:center;padding-left:13px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Option</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Price</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">($)</font></div><div style="text-align:center;padding-left:2px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:1px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Option</font></div><div style="text-align:center;padding-left:1px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;padding-left:1px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Date</font></div><div style="text-align:center;padding-left:1px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">David Moatazedi </font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/6/2018</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/6/2018</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,182,019</font><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">7.28</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/6/2028</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Lauren Silvernail</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/29/2018</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/29/2018</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">200,000</font><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">22.44</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/29/2028</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">30,000</font><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$357,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Michael Jafar</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6/18/2018</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6/18/2018</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">120,000</font><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">28.32</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6/18/2028</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,000</font><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$595,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">Chief Marketing Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(1) All of the equity awards set forth above have been granted under the 2017 plan. The terms of the 2017 plan are described below under &#8220;&#8212;Equity Compensation Plan.&#8221; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(2) One-fourth of the shares subject to the option will vest annually on the first four anniversaries of May 6, 2018, subject to continuous service through each vesting date. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(3) One-fourth of the shares subject to the award will vest annually on the first four anniversaries of May 29, 2018, subject to continuous service through each vesting date. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(4) One-fourth of the shares subject to the award will vest annually on the first four anniversaries of June 18, 2018, subject to continuous service through each vesting date.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(5) Reflects restricted stock units, each of which represents a contingent right to receive one share of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">118</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Perquisites and Health and Welfare Benefits</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our named executive officers are eligible to receive employee benefits, including medical, dental, vision, group life, disability and accidental death and dismemberment insurance, in each case on the same basis as all of our other employees.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other than one-time payments of $25,000 to each of Mrs. Silvernail and Mr. Jafar for relocation expenses, we do not provide perquisites or personal benefits to our named executive officers. Our board of directors may elect to adopt qualified or non-qualified benefit plans in the future if it determines that doing so is in our best interests.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Equity Compensation Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our board of directors and our then-sole stockholder approved and adopted the 2017 plan, effective November 21, 2017. Under the 2017 plan, we may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the 2017 plan are summarized below. The plan is scheduled to terminate November 21, 2027, but may be terminated earlier by our board of directors, as described below.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stock Awards</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. ISOs may be granted only to employees. All other awards may be granted to our and our affiliates&#8217; employees, non-employee directors, consultants and other service providers.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Administration, Amendment and Termination</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan is administered by our board of directors or a committee of our board of directors designated by our board of directors to administer the 2017 plan. Our board of directors has retained the right to exercise the authority of any committee that it appoints to administer the 2017 plan to the extent consistent with applicable law and the applicable requirements of any stock exchange.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subject to the terms of the 2017 plan, the plan administrator has the authority (i) to grant and amend awards, which includes determining the type, form, terms and conditions and number of shares subject to any award, (ii) to interpret any provision of the 2017 plan, any award or any award agreement and (iii) to make all determinations and decisions necessary for the administration of the 2017 plan. All determinations and decisions by the plan administrator under the 2017 plan are in its sole discretion and are final and binding.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Securities to be Offered</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for awards based on shares of our common stock. Subject to adjustment as described below, the total number of shares authorized to be awarded under the 2017 plan may not exceed&#160;4,361,291&#160;(all of which will be available for grant as ISOs), plus an annual increase on each anniversary of November 21, 2017 equal to 4% of the total issued and outstanding shares of our common stock as of such anniversary (or such lesser number of shares as may be determined by our board of directors). Shares issued under the 2017 plan may consist in whole or in part of authorized but unissued shares, treasury shares or shares purchased on the open market or otherwise, all as determined by our company from time to time.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any award settled in cash will not be counted as issued shares for any purpose under the 2017 plan. If any award expires, or is terminated, surrendered or forfeited, the unissued shares covered by the award will again be available for the grant of awards. If shares issued pursuant to the 2017 plan are repurchased by, or are surrendered or forfeited to our company, at no more than cost, those shares will again be available for the grant of awards. If shares issuable upon exercise, vesting or settlement of an award or shares owned by a grantee are surrendered or tendered to our company in payment of the purchase price of an award or any taxes required to be withheld for an award, those surrendered or tendered shares will again be available for the grant of awards.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Substitute awards will not be counted against the number of shares available for the grant of awards under the 2017 plan.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Eligibility</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;Eligibility to participate in the 2017 plan is limited to such of our and our affiliates&#8217; employees, officers, non-employee directors, consultants and advisors as determined from time to time by the plan administrator.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stock Options</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for the grant of options to purchase shares of common stock at exercise prices, and subject to terms, conditions and limitations, determined by the plan administrator and set forth in an option agreement delivered to the optionee.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">119</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An option that the 2017 plan administrator intends to be an &#8220;incentive stock option&#8221; as defined in Section 422 of the Code, or an ISO, will be granted only to our employees and will be subject to and be construed consistently with the requirements of Section 422 of the Code. An option that does not qualify as an ISO is referred to as a &#8220;non-qualified stock option.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stock Appreciation Rights</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for the grant of stock appreciation rights, or SARs, which may be awarded either alone or in tandem with, or as a component of, other awards. The applicable award agreement will include information about the terms and conditions under which a SAR will be exercisable, including any performance requirements. A SAR confers on the participant a right to receive, upon exercise, a payment of the excess of (i) the fair market value of one share of our stock on the date of exercise over (ii) the grant price of the SAR as determined by the plan administrator (which will be equal to at least the fair market value on the grant date).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Restricted Stock Awards</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for the grant of restricted stock awards. In general, a restricted stock award is an award of actual shares of common stock issued in the participant&#8217;s name that are subject to certain vesting requirements and that we may hold until the applicable vesting date, at which time the shares are released to the participant. Alternatively, at the discretion of the plan administrator, we may issue a restricted stock certificate bearing the legends required by applicable securities laws.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The plan administrator will determine the terms and conditions of any restricted stock award, which will be set forth in the restricted stock agreement delivered to the participant. A restricted stock award holder will have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in the restricted stock agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Restricted Stock Units</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for the grant of restricted stock units, or RSUs. An RSU represents the right to receive one share of common stock upon the applicable vesting date, but no share is actually issued until vesting. An RSU may be settled in cash rather than stock to the extent provided in the applicable award agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The plan administrator will determine the terms and conditions of any RSUs granted under the 2017 plan. In general, a holder of RSUs will not have any rights of a stockholder but the plan administrator may provide that the holder is entitled to receive dividend equivalent rights.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stock-Based Performance Awards</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The 2017 plan provides for the grant of awards based on various performance conditions as may be specified by the plan administrator. Settlement of performance awards may be in cash, shares, other awards or other property, in the discretion of the plan administrator. The plan administrator may reduce the amount of a settlement otherwise to be made in connection with performance awards.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Stock-Based Awards</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The plan administrator may grant other stock-based awards, either alone or in addition to or in conjunction with other awards under the 2017 plan, based upon the common stock, having terms and conditions as the plan administrator may determine.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Transferability of Awards</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;A participant may not assign or transfer an award under the 2017 plan, except by will or as permitted under the laws of descent and distribution. During a participant&#8217;s lifetime, only the participant personally (or his or her personal representative) may exercise rights under the 2017 plan. However, if authorized by the applicable award agreement, a participant may transfer, not for value, all or part of an award (other than an ISO) to certain family members, in accordance with the terms of the 2017 plan. After a permitted transfer, the award will continue to be subject to the same terms and conditions as it was before the transfer. Subsequent transfers of the award are only permitted if made to another family member as described above.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Rights as Stockholder</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;Unless an applicable award agreement states otherwise, a 2017 plan participant will have no rights as a stockholder with respect to any shares covered by an award until he or she becomes the record holder of the shares.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Withholding for Payment of Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;We may deduct from payments of any kind otherwise due to a 2017 plan participant any federal, state or local taxes of any kind required by law to be withheld in connection with the vesting of or other lapse of restrictions applicable to an award or upon the issuance of any shares of stock upon the exercise of an option or pursuant to an award.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Effect of Certain Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;If (i) the number of outstanding shares of our common stock is increased or decreased or the shares are changed into or exchanged for a different number or kind of shares or other securities of our company on account of any recapitalization, reclassification, stock split, reverse split, combination of shares, exchange of shares, stock dividend or other distribution payable in capital stock, or other increase or decrease in shares effected without receipt of consideration by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">120</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our company or (ii) there occurs any spin-off, split-up, extraordinary cash dividend or other distribution of assets by our company, then (a) the number and kind of shares for which grants of 2017 plan awards may be made, (b) the number and kind of shares for which outstanding awards may be exercised or settled and (c) the performance goals relating to outstanding awards, will all be equitably adjusted by our company. In addition, in the event of any increase or decease in the number of outstanding shares or other transaction described in clause (ii) above, the number and kind of shares for which 2017 plan awards are outstanding and the option price per share of outstanding options will be equitably adjusted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unless otherwise provided in an award agreement, in the event of a corporate transaction (i.e., a reorganization, merger, statutory share exchange, consolidation, sale of all or substantially all of our company&#8217;s assets, acquisition of assets or stock of another entity by our company, or other corporate transaction involving our company or any of our affiliates), the 2017 plan and awards under it will continue in effect in accordance with their terms, except that after a corporate transaction either (i) each outstanding award will be treated as provided for in the corporate transaction agreement or (ii) if not covered in the corporate transaction agreement, each grantee will be entitled to receive for each share of common stock under the grantee&#8217;s awards (upon exercise or payment or transfer in respect of those awards), the same consideration that each of our common stockholders was entitled to receive in the corporate transaction for one share, except that such consideration will remain subject to all of the terms and conditions (including performance criteria) that were applicable to the awards before the corporate transaction. Treatment of 2017 plan awards upon a corporate transaction may include cancellation and liquidation of stock options and SARs (including for $0 if the options or SARs are underwater at the time of the corporate transaction).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Change in Control</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;In the event of a &#8220;change in control&#8221; (as defined in the 2017 plan), either of the following provisions will apply to 2017 plan awards outstanding at the time, depending on whether, and the extent to which, awards are assumed, converted or replaced by the resulting entity in the change in control (and unless otherwise provided in the applicable award agreement):</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:13px;text-align:left;"><font style="padding-bottom:13px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">(1)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If awards are not assumed, converted or replaced by the resulting entity in the change in control, then those awards will become fully exercisable and all restrictions on the awards will lapse, except for performance awards, for which the target payout opportunities attainable will be deemed to have been fully earned as of the change in control based upon the greater of (a) an assumed achievement of all relevant performance goals at the &#8220;target&#8221; level or (b) the actual level of achievement of all relevant performance goals against target as of our fiscal quarter end preceding the change in control.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:13px;text-align:left;"><font style="padding-bottom:13px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">(2)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If awards are assumed, converted or replaced by the resulting entity in the change in control, if, within 24 months after the change in control, the grantee is involuntarily terminated, then the grantee&#8217;s awards will become fully exercisable and all restrictions on the awards will lapse, except for performance awards, for which the target payout opportunities attainable will be deemed to have been fully earned as of the involuntary termination based upon the greater of (a) an assumed achievement of all relevant performance goals at the &#8220;target&#8221; level, or (b) the actual level of achievement of all relevant performance goals against target as of our fiscal quarter end preceding the change in control.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Amendment and Termination</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The plan administrator may amend, suspend or terminate the 2017 plan as to any awards that have not been made. No amendment, suspension or termination of the 2017 plan may, without participant consent, materially impair rights or obligations under any outstanding award. The plan administrator may amend, modify or supplement the terms of any outstanding award, including modification of awards to foreign nationals or individuals who are employed outside the United States to recognize differences in local law, tax policy or custom.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">121</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Director Compensation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below summarizes the compensation paid by us to our directors for the fiscal year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.21428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Name</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fees&#160; Earned&#160;or</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Paid in Cash</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">($)</font><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Option&#160;     Awards($)</font><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">($)</font><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Simone Blank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">44,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">110,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">154,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">David Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">46,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">102,032</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">148,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Bosun Hau</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">44,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">110,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">154,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Robert Hayman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">39,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">110,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">150,068</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Vikram Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">48,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">110,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">158,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">David Moatazedi</font><font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Kristine Romine, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">39,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">110,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">150,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(1)&#160;&#160;&#160;&#160;Represents the aggregate grant date fair value of option awards granted during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, computed in accordance with FASB ASC Topic 718. See footnotes to our financial statements included elsewhere in this Annual Report on Form 10-K for a discussion of the assumptions we made in determining the grant date fair value of our option awards.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(2)&#160;&#160;&#160;&#160;The options reflected in the above table constitute the aggregate number of stock awards and stock options outstanding for each nonemployee director at the end of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(3)&#160;&#160;&#160;&#160;Mr.&#160;Moatazedi does not receive additional compensation for services rendered as a director on our board of directors. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our compensation committee, consisting of Simone Blank, Vikram Malik,&#160;and David Gill, makes decisions relating to compensation of our executive officers, and none of the members of our compensation committee is, or ever has been, an officer or employee of ours nor had any relationship requiring disclosure by us under any paragraph of Item 404 of Regulation S-K of the SEC. None of our executive officers currently serve on the compensation committee or the board of directors of any other entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">122</font></div></div><hr style="page-break-after:always"><div><a name="s31F33513FAA153E19E3FB0B1E60D4CEE"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 12. &#160;&#160;&#160;&#160;Security Ownership of Certain of Beneficial Owners and Management and Related Stockholder Matters.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth information regarding beneficial ownership of our capital stock, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, by:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">each of our directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">each of our named executive officers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">all of our executive officers and directors as a group.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Information with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our outstanding shares of common stock. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options that are either immediately exercisable or exercisable within 60 days of March 23, 2018. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The percentage of beneficial ownership in the table below is based on&#160;</font><font style="font-family:Times New Roman;font-size:10pt;">27,274,991</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock deemed to be outstanding as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Evolus, Inc., 520</font><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Newport Center Drive, Suite 1200, Newport Beach, California 92660.</font></div><div style="line-height:100%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.94488188976378%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Name and address of</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">beneficial owner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares Beneficially Owned</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Percentage of Shares Beneficially Owned</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Officers and Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">David Moatazedi</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Lauren Silvernail</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Murthy Simhambhatla, Ph.D.(1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">206,758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Michael Jafar</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">13,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Vikram Malik(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">29,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Simone Blank(2)(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">308,203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Bosun Hau(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">23,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Kristine Romine, M.D.(2)(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">54,886</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">Robert Hayman(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">13,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">David Gill(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">17,973</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">All executive officers and directors as a group (11&#160;persons)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">716,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;font-weight:bold;">Greater than 5% Holders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">&#160;&#160;&#160;&#160;ALPHAEON Corporation(6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">15,268,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">56.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;">&#160;&#160;&#160;&#160;Wellington Management Group LLP(7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,523,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">_____________</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">* Less than 1%</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:13px;text-align:left;"><font style="padding-bottom:13px;text-align:left;font-family:Times New Roman;font-size:10pt;padding-right:30px;">(1)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Includes options to purchase 172,156 shares of common stock exercisable within 60&#160;days of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:13px;text-align:left;"><font style="padding-bottom:13px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:30px;">(2)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Includes options to purchase 13,179 shares of common stock exercisable within 60&#160;days of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">123</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Includes 295,024 shares of common stock held by Dental Innovations BVBA (&#8220;DI&#8221;). As a shareholder of DI, Ms. Blank may be deemed to share voting and dispositive power over the shares of DI.  Ms. Blank disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Includes 1,360 shares of common stock </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">held by Ms.&#160;Romine&#8217;s&#160;son&#160;who shares the same&#160;household.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Includes options to purchase 14,973 shares of common stock exercisable within 60&#160;days of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;28, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The address of ALPHAEON is 4040 MacArthur Blvd., Suite 210, Newport Beach, California 92660. ALPHAEON&#8217;s voting and investment decisions are made by its board of directors which, as of the date of this Annual Report on Form 10-K, consists of Simone Blank, Jost Fischer, Juliet Tammenoms Bakker, Bosun Hau, Robert Grant, Vikram Malik and Richard Taketa. These members of ALPHAEON&#8217;s board of directors may be deemed to share voting, investment or dispositive power over the shares held by ALPHAEON.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The ownership information disclosed above is based solely on the Schedule&#160;13G report that Wellington Management Group LLP filed with the SEC on February&#160;12, 2019 in its capacity as an investment adviser. According to the Schedule&#160;13G report, Wellington Management Group LLP has shared voting power over 1,416,141 shares covered by the report and shared dispositive power over 1,523,292 shares covered by the report.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Changes in Control</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2016, ALPHAEON entered into two substantially similar pledge and security agreements with DI and Longitude, respectively. Pursuant to the pledge and security agreements, ALPHAEON pledged and granted to DI, as collateral agent for several debt holders, and Longitude a continuing first priority lien and security interest in and to all of ALPHAEON&#8217;s right, title and interest in, among other items, securities and all other investment property held by ALPHAEON, including ALPHAEON&#8217;s entire ownership of our capital stock, or the collateral. The collateral secures the payment and performance of the obligations of ALPHAEON under the convertible promissory notes and convertible bridge note issued by ALPHAEON and other related agreements.&#160;Upon certain events of default, DI and Longitude may take possession, hold, collect, sell, lease, deliver, grant options to purchase or otherwise retain, liquidate or dispose of all or any portion of the collateral. In the event DI or Longitude exercises such rights, upon an event of default, a change-of-control of our company may result.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had one equity compensation plan, our 2017 plan, which was approved by our board of directors and our then-sole stockholder on November 21, 2017.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Plan Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Number of securities to be issued upon exercise of outstanding options, warrants and rights </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-average exercise price of outstanding options, warrants and rights </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">(c)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Equity compensation plans approved by security holders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,452,291</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Equity compensation plans not approved by security holders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">124</font></div></div><hr style="page-break-after:always"><div><a name="s8F922B1910635E37BD8252C0B642CFAC"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 13.  &#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following includes a summary of transactions since January 1, 2017, and each currently proposed transaction to which we have been or are a party, in which the amount involved in the transaction exceeded or will exceed $120,000, and in which any of our directors, director nominees, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than compensation arrangements for our directors and executive officers, which are described in Item 11 &#8220;Executive Compensation.&#8221; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Relationship with ALPHAEON Corporation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the completion of our initial public offering in February 2018, we were a wholly-owned subsidiary of ALPHAEON and an indirectly owned subsidiary, through ALPHAEON, of SCH. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON, owns&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of our outstanding shares of common stock, and as a result, ALPHAEON has significant control of our business, including pursuant to the agreements described below. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with our initial public offering, we and ALPHAEON entered into certain agreements that provide a framework for our ongoing relationship with ALPHAEON following the completion of our initial public offering. Of the agreements summarized below, the material agreements are filed as exhibits to this Annual Report on Form 10-K, and the summaries of these agreements set forth the terms of the agreements that we believe are material. These summaries are qualified in their entirety by reference to the full text of such agreements.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Contribution Agreement and Related Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On October 3, 2013, we entered into a contribution agreement with SCH, the Evolus contributors, and J. Christopher Marmo, Ph.D. as the Evolus contributors&#8217; representative, or the contribution agreement, which was amended in 2014, 2015 and 2016. Pursuant to the contribution agreement, the Evolus contributors contributed to SCH </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16,527,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock, and 1,250,000 shares of our Series A preferred stock (or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock on an as-converted basis), constituting all of our then outstanding capital stock. As consideration, the Evolus contributors received membership interests in SCH. In addition, under the contribution agreement, the Evolus contributors had the option to require SCH to sell to ALPHAEON 1,652,700 shares of our common stock and 125,000 shares of our Series A preferred stock (or 206,587 shares of our common stock on an as-converted basis), which option was exercised in full in 2014. We refer to this option as the Evolus contributors&#8217; put option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the exercise of the Evolus contributors&#8217; put option, SCH and ALPHAEON entered into a contribution agreement on March 28, 2014 whereby SCH contributed 90% of the then outstanding shares of our common stock and 90% of the outstanding shares of our Series A preferred stock to ALPHAEON. In exchange, ALPHAEON issued shares of its equity to SCH. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the exercise of the contributors&#8217; put option, SCH and ALPHAEON entered into a stock purchase agreement. Under the stock purchase agreement, SCH sold and ALPHAEON purchased 10% of the then outstanding shares of our common stock and 10% of the then outstanding shares of our Series A preferred stock. As consideration, ALPHAEON agreed to make certain lump sum and royalty payments to SCH, or the payment obligations, which are ultimately allocable to the Evolus contributors. The payment obligations include (i) a $10.0 million up-front payment upon obtaining FDA approval for Jeuveau&#8482; for the treatment of glabellar lines, (ii) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">perpetual quarterly royalties of a mid-teen percentage of net sales of Jeuveau&#8482; within the United States and (iii) a high-single digit percentages of net sales of Jeuveau&#8482; outside of the United States. As these future royalty streams were perpetual, ALPHAEON had the right under the stock purchase agreement to terminate any future payments for a one-time lump sum payment to SCH of $145.0 million.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the transactions contemplated by the foregoing agreements, ALPHAEON held </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16,527,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock and 1,250,000 shares of our Series A preferred stock (or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock on an as-converted basis), representing all of the outstanding shares of our capital stock. In connection with our initial public offering, all of our issued and outstanding shares of Series A preferred stock converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, SCH and ALPHAEON entered into an amendment to the stock purchase agreement, or the amended purchase agreement, whereby we have also joined as a contractual party. Pursuant to the amended purchase agreement, ALPHAEON&#8217;s existing payment obligations were replaced with revised payment obligations, payable directly to the Evolus contributors, to be distributed to them ratably in accordance with their previous respective percentage ownership in our Series A preferred stock, and in exchange for the cancellation of the Class D units of SCH. Pursuant to the amended purchase </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">125</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">agreement, effective upon the closing of our initial public offering, ALPHAEON immediately and automatically assigned to us and we immediately and automatically accepted and assumed all of ALPHAEON&#8217;s payment obligations under the stock purchase agreement, as amended by the amended purchase agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the amended purchase agreement, the revised payment obligations consist of (i) an approximately $9.2 million up-front payment upon obtaining FDA approval for Jeuveau&#8482; for the treatment of glabellar lines, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&#8482; within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&#8482; outside of the United States, and (iv) a $20.0 million promissory note that will mature on the 2.5 year anniversary of the first commercial sale of Jeuveau&#8482; in the United States. The revised payment obligations set forth in (iii) and (iv) above will terminate for the quarter following the 10 year anniversary of the first commercial sale of Jeuveau&#8482; in the United States. As these revised payment obligations are not perpetual, neither we nor ALPHAEON will have the right to terminate any future payments for a one-time lump sum payment. Under the amended purchase agreement, the estimated value of all revised payment obligations and the promissory note owed to the Evolus contributors was </font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note) as of February 12, 2018.  In addition, under the amended purchase agreement, we agreed to make one-time bonuses to certain of our employees aggregating approximately $1.6 million pursuant to the respective terms of their offer letters, including a one-time bonus of $700,000 payable to Rui Avelar, M.D., our Chief Medical Officer, which was previously payable out of amounts owed to the contributors under the original stock purchase agreement. On February 1, 2019, the FDA granted approval of our BLA for the Product. In February 2019, we paid the $9.2 million milestone payment to the Evolus Founders and one-time bonuses of $1.6 million to certain former and current employees as described above. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the promissory note, ALPHAEON was the borrower prior to the closing of our initial public offering, and we became the borrower after the closing of our initial public offering.  Under the promissory note, we will pay to J. Christopher Marmo, Ph.D. as the representative of the Evolus contributors, or the holder, $20.0 million representing the aggregate principal amount upon maturity of the promissory note. No interest will accrue on the promissory note. We will have the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal will become immediately due and payable at the option of the holder. An event of default will occur under the terms of the promissory note upon any of the following events: (i) we fail to meet the obligations to make the required payments thereunder, (ii) we make an assignment for the benefit of creditors, (iii) we commence any bankruptcy proceeding, (iv) we materially breach the stock purchase agreement or tax indemnity agreement, which is defined below, and such breach is not cured within 30 days, or (v) when ALPHAEON was the borrower, there occurs an event of default under the Notes, which is defined below, that is not cured during the applicable cure period or waived by the noteholders, and such noteholders have exercised their rights to foreclose on the collateral securing the Notes under ALPHAEON&#8217;s pledge of its assets, as discussed further below.  No event of default was triggered or payment by ALPHAEON was made under the promissory note prior to the closing of our initial public offering. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of our company, all unpaid principal will become immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of our assets, (ii) the exclusive license of Jeuveau&#8482; or the business related to Jeuveau&#8482; to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of our company, except a merger, consolidation, or acquisition of our company in which the holders of capital stock of our company immediately prior to such merger, consolidation, or acquisition hold at least 50% of the voting power of the capital stock of our company or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither our initial public offering or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, under the amended purchase agreement, we, ALPHAEON and SCH agreed to terminate the non-competition provision set forth in the contribution agreement, pursuant to which the Evolus contributors were prohibited, subject to limited exceptions, for a period of 5 years, from engaging in any business relating to the development, license, commercialization of, or performing any services or supervisory functions for persons or entities engaged in any business related to, a neurotoxin or neuromodulator.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon completion of our initial public offering, we assumed and agreed to pay the revised payment obligations under the amended purchase agreement. At the closing of our initial public offering, the outstanding related party borrowings from ALPHAEON were set-off and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations we assumed from ALPHAEON, the estimated value of which, as of February 12, 2018, was </font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">126</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the amended purchase agreement, we have entered into a tax indemnity agreement with the Evolus contributors, or the tax indemnity agreement, pursuant to which, effective upon our assumption of the revised payment obligations under the amended purchase agreement, which occurred upon the completion of our initial public offering, we are obligated to indemnify the Evolus contributors for any tax liability resulting from such assignment of the revised payment obligations from ALPHAEON to us. Under the stock purchase agreement, the payment obligations are contingent and are thus eligible for installment sale reporting under Section 453 of the Code. The entry into the amended purchase agreement would cause the Evolus contributors to be treated for U.S. federal income tax purposes as receiving a distribution from SCH of the right to receive the contingent payments in a transaction in which no gain or loss is recognized such that the Evolus contributors may continue installment sale reporting with respect to the revised payment obligations to the same extent that installment sale reporting was available to SCH with respect to the original payment obligations prior to the execution of the amended purchase agreement. Under the tax indemnity agreement, we are obligated to indemnify the Evolus contributors for any taxes or penalties required to be paid by the Evolus contributors in the event the U.S. Internal Revenue Service or other taxing authority were to determine that our assumption of the revised payment obligations under the amended purchase agreement rendered continued installment sale reporting unavailable to the Evolus contributors. Any taxes or penalties paid by us on behalf of the Evolus contributors under the tax indemnity agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus contributors under the amended purchase agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Guaranty</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;of ALPHAEON&#8217;s Convertible Notes and </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Intercreditor Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ALPHAEON was, as of December&#160;31, 2017, the borrower under (i) certain convertible promissory notes issued by ALPHAEON for an aggregate principal amount of approximately $53.0 million, or the convertible promissory notes, and (ii) a certain convertible bridge note issued by ALPHAEON to Longitude for a principal amount of $2.5 million, or the convertible bridge note, collectively, the Notes. Kristine Romine, M.D., a member of our board of directors, DI, and Alpha International Investment Ltd., or Alpha, each hold one or more convertible promissory notes. Simone Blank, a member of our board of directors, is the co-owner of DI. Bosun Hau, a member of our board of directors, is employed by an entity affiliated with Alpha.  In April 2017, we agreed to unconditionally guaranty ALPHAEON&#8217;s obligations under the Notes and we granted to Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes, a first priority lien and security interest in substantially all of our assets pursuant to separate guaranty and security agreements, or the Evolus security agreements. We refer to the ALPHAEON security agreements and the Evolus security agreements collectively as the convertible notes security agreements. In April 2017, we, as guarantor, also entered into an amended and restated intercreditor agreement with ALPHAEON, as borrower, Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes, or the intercreditor agreement. The intercreditor agreement sets forth certain rights of Longitude and DI in connection with the convertible bridge note, the convertible promissory notes and the collateral pledged pursuant to the convertible notes security agreements. ALPHAEON&#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&#8217;s assets, including all of the shares of our capital stock, granted by ALPHAEON to DI, as collateral agent for the holders of the convertible promissory notes, and Longitude, as the holder of the convertible bridge note, pursuant to separate pledge and security agreements, or the ALPHAEON security agreements. On December 14, 2017, ALPHAEON entered into an amendment to the amended and restated secured convertible note purchase agreement, or the amendment, pursuant to which it issued the convertible promissory notes, in order to permit ALPHAEON to issue an additional $3.3 million of convertible promissory notes. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, we and ALPHAEON entered into amendments with each of Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes. Pursuant to these amendments, we obtained a release of our guaranty and a termination of the security interest in our assets and the Evolus security agreements, effective immediately upon the completion of our initial public offering. ALPHAEON's obligations under the ALPHAEON security agreements remained outstanding following the completion of our initial public offering. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We initially recorded a liability and corresponding deemed distribution to ALPHAEON as a reduction to additional paid-in-capital in equity in April 2017 to reflect the joint and several liability. These amounts were subsequently adjusted to reflect changes in the balance of the Notes obligation.  As we and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, we developed a range of amounts that it expected to pay under the Guaranty Agreements and selected the amount from within that range that it determined to be the best estimate, which equaled $138.7 million as of December&#160;31, 2017 (2.5 times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">127</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, we and ALPHAEON entered into amendments with the holder of the convertible bridge note, and with the collateral agent for the holders of the convertible promissory notes. Under the terms of the amendment it was agreed that our guaranty of the Notes and the security interest in our assets would terminate effective upon the closing of the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subsequent to December 31, 2017, ALPHAEON issued $0.8 million additional convertible promissory notes, including $0.1 million convertible promissory notes to Murthy Simhambhatla, Ph.D., the Company&#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the Notes increased $2.0 million to $140.7 million (2.5 times the total outstanding principal amount of $56.3 million) immediately before the IPO. Approximately $0.6 million in excess of the then balance of additional paid-in capital was recorded in accumulated deficit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As provided for within the Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements, in conjunction with its recognition of the joint and several liability, we also recorded a receivable from ALPHAEON, which equals the current balance of the amounts it owed to ALPHAEON under its related party borrowing arrangements. No amounts were paid under this joint and several liability by us in the year ended December 31, 2017. The difference between the amount of the joint and several liability and the related party receivable of $66.1 million in the year ended December 31, 2017, was recorded as a deemed distribution to ALPHAEON, in stockholders&#8217; equity (deficit) to additional paid-in capital in the period the transaction with the related party was made. Approximately $4.3 million in excess of the then additional paid-in capital balance was recorded in accumulated deficit as of December 31, 2017. In January 2018 immediately prior to our IPO, we recorded an increase of $1.1 million in the receivable from ALPHAEON with a corresponding increase in additional paid-in capital. The related party receivable balance increased to $73.7 million immediately prior to the IPO.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the closing date of our initial public offering, we were released of the $140.7 million note obligation for all guaranty and security obligations under the Guaranty Agreements, and the related party receivable from ALPHAEON of $73.7 million was settled, resulting in a capital contribution of $67.0 million. ALPHAEON&#8217;s security interest in Evolus&#8217; assets was also terminated.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Stockholder Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, we entered into a stockholder agreement with ALPHAEON, DI, as collateral agent, and Longitude. The stockholder agreement provides ALPHAEON with certain registration rights, and upon an event of default by ALPHAEON under the Notes, the registration rights granted to ALPHAEON under the stockholder agreement will immediately and automatically be assigned in full to DI and Longitude with respect to any registrable securities held by DI and Longitude.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At any time beginning 180 days after February 7, 2018, ALPHAEON may request that we register for resale all or a portion of its shares of common stock. ALPHAEON may also request that we file an automatic shelf registration statement on Form S-3 that covers the registrable securities requested to be registered, to the extent we are eligible to do so. Depending on certain conditions, and in addition to other exclusions, we may defer a demand registration for up to 90 days in any twelve-month period. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event that we propose to register any of our securities under the Securities Act, either for our account or for the account of our other security holders, ALPHAEON is entitled to certain piggyback registration rights allowing it to include its shares in the registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, ALPHAEON is entitled to notice of the registration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The stockholder agreement provides that we must pay all registration expenses (other than the underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The stockholder agreement contains customary indemnification and contribution provisions by us for the benefit of ALPHAEON and its affiliates and, in limited situations, by ALPHAEON for the benefit of us and any underwriters with respect to written information furnished to us by ALPHAEON and stated by ALPHAEON to be specifically included in any registration statement, prospectus or related document.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The registration rights remain in effect with respect to any shares covered by the stockholder agreement until (i) all such shares have been sold pursuant to an effective registration statement under the Securities Act, or (ii) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the shares without limitation during a three-month period without registration.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">128</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Services Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, we entered into the services agreement with ALPHAEON, which became effective in connection with our initial public offering. The services agreement sets forth certain agreements between ALPHAEON and us that govern the respective responsibilities and obligations between ALPHAEON and us, as it relates to the services to be performed between us</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the services agreement, ALPHAEON provides us, and we provide ALPHAEON, as the case may be, certain administrative and development support services. For example, we receive from ALPHAEON certain general management, communication, intellectual property, human resources, office and information technology services, and we provide general accounting and legal services to ALPHAEON. In addition, pursuant to the services agreement, in 2018 we subleased from ALPHAEON all or part of its lease for its headquarters encompassing approximately 3,639 square feet of space, as certain of our executive, legal and financial personnel were formerly located at ALPHAEON&#8217;s headquarters.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fees charged for any services rendered pursuant to the services agreement are the actual cost incurred by ALPHAEON or us, as the case may be, in providing the services for the relevant period.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, pursuant to the services agreement, upon completion of our initial public offering, we paid ALPHAEON $5.0 million towards the repayment of our related party borrowings and the remaining related party borrowings then outstanding were forgiven and the amount was re-characterized as a capital contribution of ALPHAEON. As a result, upon the completion of our initial public offering, we were no longer indebted to ALPHAEON pursuant to our historical related party borrowings from ALPHAEON.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The services agreement became effective upon the completion of our initial public offering and will have a one year term. Thereafter, the services agreement will renew for successive one year terms unless sooner terminated by either party. We or ALPHAEON may terminate the services agreement upon sixty days&#8217; notice to the other party.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also reimburse ALPHAEON for compensation expenses and amounts due under employment agreements for individuals employed by ALPHAEON who worked full time for us, including J. Christopher Marmo, our former Chief Operating Officer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Therapeutic Option Letter Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 18, 2017, we entered the therapeutic agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">relating to certain rights to the therapeutic indications of botulinum toxin products under the Daewoong Agreement. P</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ursuant to the Daewoong Agreement, we received an option to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to cover all therapeutic uses in the covered territories and Japan, or the therapeutic option. Pursuant to the Daewoong Agreement, we </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">may exercise the therapeutic option for a confidential exercise price</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the therapeutic option fee, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">upon thirty days&#8217; notice to Daewoong. The therapeutic option expired December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">However, pursuant to the t</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">herapeutic agreement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we have agreed not to sell, sub-license or otherwise dispose in whole or in part the therapeutic option or the rights underlying the therapeutic option and we will hold the therapeutic option and the underlying rights in trust for ALPHAEON. We further agreed not to develop or make plans to develop any therapeutic indications for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In exchange for and as of the date of the therapeutic agreement, ALPHAEON reduced the related party borrowings owed by us by the amount of $2.5 million. Once exercised, the rights to the therapeutic indications shall be solely in the control of ALPHAEON. As of December 31, 2018, the right to exercise the therapeutic option was exercised by ALPHAEON, which remitted the exercise price directly to Daewoong. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, under the therapeutic agreement, ALPHAEON has the right to negotiate the entry into an agreement with Daewoong for distribution rights for therapeutic indications of botulinum toxin products that are separate and distinct from the Daewoong Agreement, or the ALPHAEON-Daewoong agreement. We have agreed to ALPHAEON and Daewoong&#8217;s entry into the ALPHAEON-Daewoong agreement, so long as the terms do not diminish, interfere with or adversely affect our ability to distribute Jeuveau&#8482; for aesthetic indications in the covered territories and Japan under the Daewoong Agreement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect these payments to be sufficient to cover all required payments to the Evolus contributors.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Outstanding Payable - Related Party Borrowings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we owed ALPHAEON </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$72.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, representing related party borrowings from ALPHAEON as consideration for certain expenses incurred on our behalf, including research and development expenses, general and administrative support services and development support services. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">129</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To satisfy all outstanding related party borrowings from ALPHAEON through the closing of our initial public offering (inclusive of amounts that have been offset pursuant to the therapeutic agreement), we remunerated ALPHAEON through three methods, each of which was agreed upon by ALPHAEON and our company. First, pursuant to the amended purchase agreement, upon the completion of our initial public offering, we assumed and agreed to pay the revised payment obligations under the amended purchase agreement, and the outstanding related party borrowings from ALPHAEON was offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations we assume from ALPHAEON, the estimated value of which, as of February 12, 2018, was $55.7 million. Second, pursuant to the services agreement, upon the completion of our initial public offering, we paid ALPHAEON $5.0 million from the proceeds of our initial public offering. Third, pursuant to the services agreement, the remaining balance of related party borrowings, after taking into account the offset and reduction of the then-fair value of all payment obligations we assumed from ALPHAEON under the amended purchase agreement, and the payment of $5.0 million, each upon completion of our initial public offering, was re-characterized as a capital contribution of ALPHAEON. As a result of these three methods, we are no longer indebted to ALPHAEON. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, we entered into an exclusive distribution and supply agreement, or the distribution agreement, with Clarion Medical Technologies Inc., or Clarion. The distribution agreement provides terms pursuant to which we will exclusively supply our product to Clarion in Canada.&#160;Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind ALPHAEON&#8217;s acquisition of Clarion. As a result, ALPHAEON and SCH, jointly and severally owe the equity holders of Clarion an unwinding fee of $9.6 million, or the unwinding fee.&#160;We have agreed that the unwinding fee will be reduced, on a dollar-for-dollar basis, pursuant to the terms of the distribution agreement. The distribution agreement sets forth that a portion of the proceeds received from each unit of product purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the unwinding fee ALPHAEON owes. We are not contractually obligated to pay the unwinding fee to the previous equity holders of Clarion. In the event that the distribution agreement is terminated or if we fail to provide product to Clarion in Canada, ALPHAEON and SCH will remain jointly and severally liable to the previous equity holders of Clarion for the balance of the unwinding fee. In addition, if ALPHAEON or SCH repays the unwinding fee in full at any time, the agreement may be terminated by us or if continued, we will no longer utilize a portion of the proceeds received from the sale of each unit of product to reduce the unwinding fee and will thereafter realize the full proceeds of each sale of a unit of product to Clarion. No portion of any amount of the unwinding fee that is paid through the distribution agreement will reduce our related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Distribution Agreement, if the Company did not receive approval from Health Canada to promote and sell the product in Canada prior to October 31, 2018, the Company was obligated to pay liquidated damages to Clarion in the amount of $1.0 million within 30 days of December 31, 2018, which damages would not reduce the Unwinding Fee. In August 2018, the Company received approval from Health Canada to promote and sell the product. As of December 31, 2018, no amounts have been paid towards the Unwinding Fee. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the unwinding fee on December 31, 2022, if demanded by the previous equity holders of Clarion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The distribution agreement will terminate upon the earlier of the fifth anniversary of the approval of our NDS from Health Canada for the product, or at such time the unwinding fee is paid in full. Thereafter, the distribution agreement may be renewed by mutual agreement of the parties. We or Clarion may terminate the distribution agreement if the other party materially breaches without cure for sixty days or becomes insolvent, seeks protection under any bankruptcy proceeding, or such proceeding is instituted against the other party and not dismissed within sixty days. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Employment of David Moatazedi&#8217;s Brother-In-Law</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since September 2018, we&#160;have employed&#160;Mr.&#160;Moatazedi&#8217;s&#160;brother-in-law&#160;as a Marketing Manager and Analyst. He receives compensation commensurate with his level of experience and other employees having similar responsibilities. His offer letter provides for a base salary of $130,000 on an annual basis, a bonus of up to 15% of base salary depending on achievement of certain company and individual performance metrics, an option to purchase up to 5,000 shares of common stock on our standard form of Stock Option Agreement as well as participation in our general employee welfare programs.  The total salary paid to Mr.&#160;Moatazedi&#8217;s&#160;brother-in-law&#160;for 2018 was approximately $39,000.  He also receive an option to purchase </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">130</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,000 shares of common stock and a bonus for 2018 performance, paid in February 2019 of approximately $5,000. He is not considered an officer under Section&#160;16 of the Exchange Act and does not report directly to Mr. Moatazedi.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Consulting and Services Arrangement with David Moatazedi&#8217;s Brother-in-Law</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since 2018, we have engaged in IT consulting firm that is owned by another one of Mr. Moatazedi&#8217;s brothers-in-law to provide consulting services, including direct consulting by the brother-in-law, and certain general IT services.  The total amount paid to the IT consulting firm in 2018 was approximately $119,000, and the firm will continue to provide services in 2019.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have entered into separate indemnification agreements with our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:start;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Policies and Procedures for Transactions with Related Persons</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the charter of our audit committee, our audit committee is responsible for reviewing, approving and ratifying in advance any &#8220;related person transactions.&#8221; For purposes of the charter of our audit committee only, a &#8220;related person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants and had or will have a direct or indirect material interest, involving an amount that exceeds $120,000. A &#8220;related person&#8221; is any executive officer, director or a holder of more than 5% of any class of our equity, including any of their immediate family members and any entity owned or controlled by such persons.</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">In considering related person transactions, our audit committee will take into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">account, among other factors it deems appropriate, whether the related person transaction is on terms no less favorable than terms generally available to an unaffiliated third person under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. In the event a director has an interest in the proposed </font><font style="font-family:Times New Roman;font-size:10pt;">related person transaction</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the director must recuse himself or herself from the deliberations and approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our audit committee will review, on an annual basis, the previously approved related person transactions that are continuous in nature to determine whether such transactions should continue. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Director Independence</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our board of directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our board of directors determined that Messrs. Hau, Hayman and Gill, and Dr. Romine are &#8220;independent directors&#8221; as defined under the Nasdaq Marketplace Rules. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management, including the beneficial ownership of our capital stock by each non-employee director and the transactions involving them described in this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As ALPHAEON continues to control a majority of the voting power of our outstanding common stock, we are a &#8220;controlled company&#8221; for purposes of the&#160;Nasdaq Marketplace Rules. As a controlled company, the&#160;Nasdaq Marketplace Rules provide an exemption&#160;from the obligation to comply with certain corporate governance requirements, including the requirements:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">that a majority of the board of directors consists of independent directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">that we have a nominating and corporate governance committee that is comprised entirely of independent directors&#160;with a written charter addressing the committee&#8217;s purpose and responsibilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">that we have a compensation committee that is comprised entirely of independent directors&#160;with a written charter addressing the committee&#8217;s purpose and responsibilities.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">131</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As set forth below, we intend to rely on the Nasdaq Marketplace Rules independence requirements applicable to &#8220;controlled companies&#8221; for the constitution of our compensation committee and nominating and corporate governance committee. The following is a summary of our aforementioned board of director committees:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Audit Committee</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our audit committee consists of&#160;David Gill, who is the chair of the committee, Bosun Hau and&#160;Robert Hayman. Our board of directors has determined that each of the members of our audit committee satisfies the Nasdaq Marketplace Rules and SEC independence requirements.&#160; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation Committee</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our compensation committee consists of&#160;Simone Blank, who is the chair of the committee,&#160;Vikram Malik and David Gill. Our board of directors has determined that each of the members of our compensation committee is an outside director, as defined pursuant to Section 162(m) of the Code, and satisfies the Nasdaq Marketplace Rules independence requirements applicable to &#8220;controlled companies&#8221; and is a &#8220;non-employee director&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act.&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Nominating and Corporate Governance Committee</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our nominating and corporate governance committee consists of&#160;Bosun Hau, who is the chair of the committee, Simone Blank,&#160;Vikram Malik and Kristine Romine, M.D. Our board of directors has determined that each of the members of the nominating and corporate governance committee satisfies the Nasdaq Marketplace Rules independence requirements applicable to &#8220;controlled companies.&#8221;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:start;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">132</font></div></div><hr style="page-break-after:always"><div><a name="s532C8D66F2765E49A9AFE5A8AE2E1D89"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 14.  &#160;&#160;&#160;&#160;Principal Accounting Fees and Services.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Fees Paid to the Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the aggregate fees for&#160;professional service provided by our independent registered public accounting firm, Ernst &amp; Young LLP, for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:71%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Audit Fees</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">855,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">635,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Audit-related fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">857,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">635,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">_________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:23px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-6px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Audit Fees consist of the fees for professional services rendered for the audit of our annual financial statements, review of our quarterly financial statements, filing of our registration statements, including our Registration Statement on Form S-1 related to our initial public offering and follow-on offering, and accounting consultations for which we have engaged Ernst &amp; Young LLP.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Pre-Approval Policies and Procedures</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with our initial public offering, we adopted a policy under which our audit committee must pre-approve all audit and permissible non-audit services to be provided by our independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services. Pre-approval would generally be requested annually, with any pre-approval detailed as to the particular service, which must be classified in one of the four categories of services listed above. Our audit committee may also, on a case-by-case basis, pre-approve particular services that are not contained in the annual pre-approval request. In connection with this pre-approval policy, our audit committee also considers whether the categories of pre-approved services are consistent with the rules on accountant independence of the SEC and the Public Company Accounting Oversight Board.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, in the event time constraints require pre-approval prior to our audit committee&#8217;s next scheduled meeting, our audit committee has authorized its chairperson to pre-approve services. Engagements so pre-approved are to be reported to our audit committee at its next scheduled meeting.</font></div><div><a name="s48D8F4D585035AD2868CAF7EEC8975DF"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">133</font></div></div><hr style="page-break-after:always"><div><a name="sD6D0E8613C445B6591F9AB32E4BAB2A6"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 15. &#160;&#160;&#160;&#160; Exhibits, Financial Statement Schedules. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(a)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The following documents are filed as part of this Annual Report on Form 10-K:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(1) Financial Statements.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;See Item 8  &#8220;Financial Statements and Supplemental Information&#8221; elsewhere in this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(2) Financial Statement Schedules.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;None. Financial statement schedules have been omitted because they are not applicable.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(3) Exhibits.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form&#160;10-K:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Incorporated by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Filed Herewith</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">(x)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit21s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">2.1&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit21s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Contribution Agreement, dated as of October 3, 2013, by and among Strathspey Crown Holdings, LLC, the Registrant, the Shareholders of the Registrant, and J. Christopher Marmo,  as the Shareholders&#8217; Representative, as amended on September 22, 2014, November 3, 2015, February 15, 2016 and April 14, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">3.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amended and Restated Certificate of Incorporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2/12/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">3.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amended and Restated Bylaws.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2/12/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">4.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Specimen certificate evidencing shares of common stock of the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit42s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">4.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit42s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Agreement, dated as of December 14, 2017, by and among ALPHAEON Corporation, Dental Innovations BVBA, Longitude Venture Partners II, L.P. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit101s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.1&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit101s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit102s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.2&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit102s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amendment to Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit103s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.3&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit103s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">License and Supply Agreement, dated as of September 30, 2013, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit104s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.4&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit104s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">First Amendment to License and Supply Agreement, dated as of February 26, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit105s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.5&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit105s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Second Amendment to License and Supply Agreement, dated as of July 15, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.6+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.7+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Option Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.8+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Dueling Option Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.9+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Restricted Shares Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.10+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">134</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.11+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Indemnification Agreement by and between the Registrant and its directors and officers.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1012s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.12</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1012s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Services Agreement, dated as of January 23, 2018, by and between ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1013s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.13</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1013s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Lease, dated February 5, 2015, by and between J. Carol Duncan and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1014s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.14</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1014s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amended and Restated Intercreditor Agreement, amended and restated as of April 19, 2017, by and among Longitude Venture Partners II, L.P., Dental Innovations BVBA, ALPHAEON Corporation and the Registrant. </font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1015s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.15</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1015s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">First Amendment to Amended and Restated Intercreditor Agreement, dated as of December 14, 2017, by and among Longitude Venture Partners II, L.P., Dental Innovations BVBA, ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1016s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.16</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1016s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Guaranty and Security Agreement, dated as of April 19, 2017, by and between Dental Innovations BVBA and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1017s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.17</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1017s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amendment to Guaranty and Security Agreement, dated as of December 14, 2017, by and between Dental Innovations BVBA and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1018s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.18</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1018s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Guaranty and Security Agreement, dated as of April 19, 2017, by and between Longitude Venture Partners II, L.P. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1019s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.19</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1019s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amendment to Guaranty and Security Agreement, dated as of December 14, 2017, by and between Longitude Venture Partners II, L.P. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1020s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.20&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1020s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Second Amendment to Stock Purchase Agreement, dated as of December 14, 2017, by and among SCH-AEON, LLC (f/k/a Strathspey Crown Holdings, LLC), ALPHAEON Corporation, the Registrant and J. Christopher Marmo, as Contributors&#8217; Representative, and acknowledged by the parties listed as Contributors on the signature pages thereto.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1021s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.21</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1021s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Tax Indemnity Agreement, dated as of December 14, 2017, by and among the Registrant, J. Christopher Marmo, as the Contributors&#8217; Representative and each of the individuals listed on the signature pages thereto.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1022s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.22&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1022s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Exclusive Distribution and Supply Agreement, dated as of November 30, 2017, by and between Clarion Medical Technologies Inc. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1023s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.23&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1023s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Therapeutic Option Letter Agreement, dated December 18, 2017, by and between ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1024s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.24</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1024s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Subordination Agreement, dated as of December 14, 2017, by and among Dental Innovations BVBA, Longitude Venture Partners II, L.P., ALPHAEON Corporation, the Registrant and J. Christopher Marmo, as Contributors&#8217; Representative, and acknowledged by ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1025s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.25</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1025s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Subordination Agreement, dated as of December 14, 2017, by and among Dental Innovations BVBA, Longitude Venture Partners II, L.P., ALPHAEON Corporation and SCH-AEON, LLC (formerly known as Strathspey Crown Holdings, LLC), and acknowledged by ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1026s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.26+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1026s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, by and between Murthy Simhambhatla and the Registrant, effective as of February 12, 2018</font></a><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1028s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.27+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1028s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Separation Agreement and General Release of Claims, dated as of May 10, 2018, by and between Murthy Simhambhatla and the Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.28+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated as of May 6, 2018, by and between David Moatazedi and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1030s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.29+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1030s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated as of May 29, 2018, by and between Lauren Silvernail and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1031s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.30+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1031s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated as of June 18, 2018, by and between Michael Jafar and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1031.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.31+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1031.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated August 15, 2018, by and between Rui Avelar and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1032.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.32+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1032.htm"><font style="font-family:Times New Roman;font-size:10pt;">Separation Agreement and General Release of Claims, dated as of August 28, 2018, by and between J. Christopher Marmo and the Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1033.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.33</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1033.htm"><font style="font-family:Times New Roman;font-size:10pt;">Sublease, dated as of November 7, 2018, by and between Acacia Research Corporation and the Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit211s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">21.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit211s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">List of Subsidiaries.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit23112311810-k.htm"><font style="font-family:Times New Roman;font-size:10pt;">23.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit23112311810-k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s26C11A06CA235083A620D7770C7DA184"><font style="font-family:Times New Roman;font-size:10pt;">24.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s26C11A06CA235083A620D7770C7DA184"><font style="font-family:Times New Roman;font-size:10pt;">Power of Attorney (included on signature page).</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31112311810k.htm"><font style="font-family:Times New Roman;font-size:10pt;">31.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31112311810k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31212311810k.htm"><font style="font-family:Times New Roman;font-size:10pt;">31.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31212311810k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32112311810k.htm"><font style="font-family:Times New Roman;font-size:10pt;">32.1#</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32112311810k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.INS*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Instance Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.SCH*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.CAL*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.DEF*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.LAB*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.PRE*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">136</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">_____________</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Registrant has omitted and filed separately with the Securities and Exchange Commission portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act of 1933, as amended, or the Securities Act.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Annual Report on Form 10-K), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">In accordance with Rule 402 of Regulation S-T, this interactive data file is deemed not filed or part of this Quarterly Report on Form 10-Q for purposes of Sections 11 or 12 of the Securities Act or Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sABEAFC4350205AE38ECD6456A7828F91"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 16. &#160;&#160;&#160;&#160;Form 10-K Summary.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">137</font></div></div><hr style="page-break-after:always"><div><a name="s26C11A06CA235083A620D7770C7DA184"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on </font><font style="font-family:Times New Roman;font-size:10pt;">March&#160;20, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.05555555555556%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">EVOLUS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The undersigned directors and officers of Evolus, Inc. constitute and appoint David Moatazedi and Lauren P. Silvernail, and each of them, as their true and lawful attorneys and agents with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form&#160;10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto; and we do hereby ratify and confirm all that said attorneys and agents shall do or cause to be done by virtue hereof.&#160; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Moatazedi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">President, Chief Executive Officer and</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Member of the Board of Directors</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Lauren P. Silvernail</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Financial Officer and<br>Executive Vice President of Corporate Development<br>(Principal Financial and Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Lauren P. Silvernail</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Vikram Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vikram Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Simone Blank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Simone Blank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Bosun Hau</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Bosun Hau</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Kristine Romine, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Kristine Romine, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAC1CC8D278AE57FFB2FE31349F7B8293"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Robert Hayman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Robert Hayman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 20, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>2
<FILENAME>exhibit1031.htm
<DESCRIPTION>EXHIBIT 10.31
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAEEB0D4B56551AD2CF572A7202B20BF4"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Employment Agreement (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Evolus, Inc.,</font><font style="font-family:inherit;font-size:12pt;">&#32;a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rui Avelar,</font><font style="font-family:inherit;font-size:12pt;">&#32;an individual (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Employee</font><font style="font-family:inherit;font-size:12pt;">.&#8221;) This Agreement is entered into effective as of August 15, 2018 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date&#8221;)</font><font style="font-family:inherit;font-size:12pt;">.   This Agreement amends and restates the terms of the Transfer Letter, dated January 22, 2018, between Employee and the Company (the &#8220;Transfer Letter&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">POSITION AND RESPONSIBILITIES</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Position</font><font style="font-family:inherit;font-size:12pt;">. Employee shall be employed by the Company to render services to the Company in the position of Chief Medical Officer and Head of Research &amp; Development of the Company. Employee shall report directly to the President and Chief Executive Officer (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CEO</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Employee shall use his good faith efforts to perform such duties and responsibilities and shall have such authorities as are normally related to such positions in accordance with the standards of the industry and any additional duties of an executive nature the CEO now or hereafter assigns to Employee consistent with his position as the Company&#8217;s Chief Medical Officer and Head of R&amp;D. </font><font style="font-family:inherit;font-size:12pt;color:#212121;">The principal place of Employee&#8217;s employment under this Agreement shall be Santa Barbara, California, it being understood that periodically Employee shall also be required to work at the Company&#8217;s offices in Orange County, California (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;color:#212121;font-weight:bold;">Company Offices</font><font style="font-family:inherit;font-size:12pt;color:#212121;">&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Activities</font><font style="font-family:inherit;font-size:12pt;">.  During his employment with the Company, Employee shall (i) devote substantially all of Employee&#8217;s business time and energy to the performance of Employee&#8217;s duties for the Company and (ii) hold no other employment. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">COMPENSATION AND BENEFITS</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">. In consideration of the services to be rendered under this Agreement, the Company shall pay Employee a salary at the rate of Four Hundred Thousand ($400,000) per year (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The Base Salary shall be paid in accordance with the Company&#8217;s regularly established payroll practice.  Employee&#8217;s Base Salary shall be reviewed from time to time (not less frequently than annually commencing in 2019) in accordance with the established procedures of the Company for adjusting salaries for similarly situated employees and may be increased, but not decreased in the sole discretion of the Board.</font></div><div style="line-height:125%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Annual Bonus</font><font style="font-family:inherit;font-size:12pt;">. Beginning as of the Effective Date, Employee&#8217;s target opportunity for his annual incentive bonus, as determined by the Board in its reasonable discretion (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) will be equal to 40% of the Base Salary</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">based on 100% achievement of key performance indicators for Employee and the Company as determined by the Board in its sole discretion and communicated to Employee (i) for the year that includes the Effective Date, on or before the 90th day following the Effective Date, and (ii) for each succeeding performance year, on or before the 90th day of each year.  The terms of any written Annual Bonus plan developed by the Board shall govern any Annual Bonus that may be paid.  Any Annual Bonus shall be paid in all events within two and one-half months after the end of the year in which such Annual Bonus becomes earned, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided </font><font style="font-family:inherit;font-size:12pt;">that no Annual Bonus shall be considered earned or payable </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:124%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">unless, subject to Section 5(b), Employee has remained continuously employed through the payment date of the Annual Bonus</font></div><div style="line-height:124%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">FDA Milestone Bonus</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall continue to be eligible for a one-time bonus of $700,000.00 related to the U.S. Food and Drug Administration approval of the Company&#8217;s Botulinum Toxin product candidate as outlined in the Transfer Letter.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">d.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity</font><font style="font-family:inherit;font-size:12pt;">. Employee shall be eligible to participate in the Company&#8217;s 2017 Omnibus Incentive Plan on the same terms and conditions as other similarly situated senior executives of the Company, in accordance with the Plan, as may be amended from time to time.</font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:41px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;padding-left:6px;text-align:left;text-indent:41px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:54px;">e.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:12pt;">. Employee shall be eligible to participate in the benefits made generally available by the Company to its other senior executives, in accordance with the benefit plans established by the Company, and as may be amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:41px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:54px;">f.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">. Employee&#8217;s vacation and other paid time off shall be governed by the Company&#8217;s usual policies applicable to senior management employees.</font></div><div style="line-height:120%;text-align:left;text-indent:41px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:123%;padding-left:6px;text-align:left;text-indent:41px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:54px;">g.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:12pt;">. The Company shall reimburse Employee for reasonable business expenses incurred, and for any other approved expenses incurred, in the performance of Employee&#8217;s duties hereunder in accordance with the Company&#8217;s customary expense reimbursement guidelines.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:123%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:46px;">h.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment Policy</font><font style="font-family:inherit;font-size:12pt;">. As an employee of the Company, Employee shall be subject to and abide by the Company&#8217;s policies, procedures, practices, rules and regulations as adopted or as amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:123%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:46px;">i.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification</font><font style="font-family:inherit;font-size:12pt;">. Employee shall be covered under a directors&#8217; and officers&#8217; liability insurance policy paid for by the Company both during and after (while there remains any potential liability to Employee) the termination of Employee&#8217;s employment to the extent that the Company maintains such a liability insurance policy now or in the future for its active officers and directors. In addition, concurrently herewith the Company and Employee are entering into an Indemnification Agreement. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AT-WILL EMPLOYMENT; TERMINATION BY COMPANY</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination for Cause</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment under this Agreement shall commence on the Effective Date and shall continue indefinitely for no specific term.  The Company may terminate Employee&#8217;s employment with the Company at will at any time upon written notice, with or without Cause or advance notice, for any reason or no reason at all, notwithstanding anything to the contrary contained in or arising from any statements, policies or practices of the Company relating to the employment, discipline or termination of its employees.  For purposes of this Agreement, &#8220;Cause&#8221; shall mean any of the following: (a) the commission of any act of fraud, embezzlement or willful dishonesty by Employee which adversely affects the business of the Company; (b) any unauthorized use or disclosure by Employee of confidential </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">information or trade secrets of the Company; (c) the refusal or omission by Employee to perform any lawful duties properly required of his under this Agreement, provided that any such failure or refusal has been communicated to Employee in writing and Employee has been provided a reasonable opportunity to correct it, if correction is possible; (d) any act or omission by Employee involving malfeasance or gross negligence in the performance of Employee&#8217;s duties to, or material deviation from any of the policies or directives of, the Company, provided, however, that in the case of deviations from policies or directives, (i) the Company must give Employee notice of such deviations within thirty (30) days of the Company becoming aware of such an occurrence, (ii) Employee must be given thirty (30) days to cure or correct the deviation, if curable, and (iii) Employee may only be terminated if the deviation remains uncured after thirty (30) days, if curable, following written notice and upon the approval of the Board of Directors; (e) conduct on the part of Employee which constitutes the breach of any statutory or common law duty of loyalty to the Company; or (f) any illegal act by Employee which the Board determines adversely affects the business of the Company, or any felony committed by Employee, as evidenced by conviction thereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination upon Death</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment under this Agreement shall terminate automatically upon Employee&#8217;s death. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TERMINATION BY EMPLOYEE</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employee may terminate employment with the Company at any time upon written notice for any reason or no reason at all, with or without Good Reason.  For purposes of this Agreement, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Reason&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;shall mean any of the following which is not corrected by the Company within thirty (30) days after the Company has received written notice from Employee referring to this Section 4 and specifying the circumstances purportedly constituting Good Reason and the correction sought (such notice to be given within thirty (30) days after the occurrence of such circumstance): (a) a material diminution in Employee&#8217;s title, duties, authorities, or responsibilities; (b) a material reduction in Employee&#8217;s Base Salary or Annual Bonus opportunity; (c) requiring Employee to relocate his principal place of business more than 30 miles outside of the Santa Barbara County, California (excluding reasonable amounts of time that Employee will work at the Company&#8217;s offices in Orange County, California); or (d) a material breach by the Company of any provision of this Agreement or any other agreement between the Company and Employee.  Notwithstanding the foregoing, a termination of Employee&#8217;s employment with the Company shall not constitute a termination for Good Reason unless such termination occurs not more than ninety (90) days following the initial existence of the condition claimed to constitute good reason. </font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TERMINATION OBLIGATIONS</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination of Employment</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s right to compensation and benefits under this Agreement, if any, upon termination of employment shall be determined in accordance with this </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">All Terminations of Employment</font><font style="font-family:inherit;font-size:12pt;">. Upon any termination of employment, Employee shall be entitled to prompt and full payment of all earned but unpaid Base Salary, accrued but unused vacation, and any Annual Bonus that has become fully earned and payable </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under this Agreement for the year preceding the year in which the date of termination occurs, regardless of whether the payment date of the Annual Bonus for the preceding year is scheduled to occur after Employee&#8217;s termination date (collectively, the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Accrued Benefits&#8221;</font><font style="font-family:inherit;font-size:12pt;">).  Except as provided in Section 5(c), Employee&#8217;s rights following a termination of employment with respect to any benefits, incentives or awards provided to Employee pursuant to the terms of any plan, program or arrangement sponsored or maintained by the Company, whether tax-qualified or not, which are not specifically addressed herein, shall be subject to the terms of such plan, program or arrangement, and this Agreement shall have no effect upon such terms except as specifically provided herein. Employee&#8217;s rights following a termination of employment with respect to the Stock Option and any other stock option or equity-based award that may be hereafter granted to Employee shall be governed by the applicable award agreement. Company acknowledges that any rights Employee may have to indemnification for actions taken as an officer or director under Company&#8217;s charter, other arrangements and its insurance policies shall not be forfeited or terminated with respect to any actions or omissions prior to any termination of employment.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination of Employment by Company without Cause or by Employee for Good Reason</font><font style="font-family:inherit;font-size:12pt;">. If the Company terminates Employee&#8217;s employment under this Agreement for any reason other than Cause, or Employee terminates his employment under this Agreement for Good Reason, and Employee enters into a release as provided in Section 5(e) (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Qualified Termination</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then in addition to the Accrued Benefits,</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Employee shall be entitled to (i) a gross amount, minus appropriate withholding and payroll deductions, equal to (a) in the case of a Qualified Termination that occurs in connection with or within 12 months after Change in Control (as such term is defined in the Plan), 12 months of Employee&#8217;s then current Base Salary, payable in a lump sum within 60 days of Employee&#8217;s execution of a mutually agreeable release, or (b) in the case of any other Qualified Termination, 6 months of Employee&#8217;s then current Base Salary, payable in equal installments through the Company&#8217;s regular payroll over the 6 month period following the Employee&#8217;s date of termination, plus the continuation of health benefits for 6 months; and (ii) a gross amount equal to the Annual Bonus (if any) that Employee would have earned for the calendar year in which the termination of his employment occurs based on the target level of achievement, pro-rated based on the number of full months Employee was employed in that calendar year of his employment, minus appropriate withholding and payroll deductions, payable at the time the Company normally pays Annual Bonuses after the close of the fiscal year in which Employee&#8217;s employment terminates.  </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">d.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Terminations.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Upon termination of Employee&#8217;s employment by Company for </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#32;or by Employee for any reason other than </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">, Employee shall be entitled only to the compensation and benefits provided in Section 5(b) and no severance compensation and benefits.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">e.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:12pt;">. Any and all amounts payable and benefits or additional rights provided pursuant to this Agreement upon a termination of employment beyond the Accrued Benefits (including any post-termination benefits or amounts under this Agreement) shall only be payable if Employee delivers to the Company and does not revoke a general release of claims in favor of the Company in the form acceptable to the Company, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;such release does not purport to: (i) revoke any of the rights provided pursuant to this Agreement or rights to continued indemnification for actions taken as an officer or director prior to the termination of </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:124%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">employment; or (ii) impose upon Employee any new or additional restrictive covenants that do not otherwise survive the termination of Employee&#8217;s employment. Such release must be executed and delivered (and no longer subject to revocation, if applicable) within 45 days following the termination of employment (or such longer period to the extent required by law). Any payments of severance that would otherwise be made during the period before the release becomes effective (i.e., not more than 52 days after the date of termination of employment) shall instead be made on the first regular payroll date after the date the release becomes effective.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;padding-top:4px;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">f.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resignation and Cooperation</font><font style="font-family:inherit;font-size:12pt;">.  Upon any termination of employment, Employee shall be deemed to have resigned from all offices and directorships then held with the Company, including any such positions with its subsidiaries. Following a termination of employment, Employee shall cooperate reasonably in the orderly transfer of his duties to other employees. Employee shall also reasonably (after taking into account Employee&#8217;s post-termination responsibilities and obligations) cooperate with the Company in the defense of any action brought by any third party against the Company that relates to Employee&#8217;s employment by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">g.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Continuing Obligations</font><font style="font-family:inherit;font-size:12pt;">. Employee understands and agrees that Employee&#8217;s obligations under </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sections 5</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6</font><font style="font-family:inherit;font-size:12pt;">, and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7 </font><font style="font-family:inherit;font-size:12pt;">herein (including the exhibits and schedules described therein) shall survive a termination of employment and the termination of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INVENTIONS AND PROPRIETARY INFORMATION; PROHIBITION ON THIRD PARTY INFORMATION</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employee agrees to sign and be bound by the terms of the Company&#8217;s standard employee proprietary information and invention assignment agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARBITRATION</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employee agrees to sign and be bound by the terms of the Company&#8217;s standard employee Arbitration Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ATTORNEYS&#8217; FEES AND COSTS</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:6px;text-indent:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In any dispute arising from or relating to this Agreement or Employee&#8217;s hiring, employment, compensation, benefits, or termination, the prevailing party shall be entitled to recover its attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AMENDMENTS; WAIVERS; REMEDIES</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement may not be amended or waived except by a writing signed by Employee and by a duty authorized representative of the Company other than Employee. Failure to exercise any right under this Agreement shall not constitute a waiver of such right. Any waiver of any breach of this Agreement shall not operate as a waiver of any subsequent breaches. All rights or remedies specified for a party herein shall be cumulative and in addition to all other rights and remedies of the party hereunder or under applicable law.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ASSIGNMENT; BINDING EFFECT</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">. The performance of Employee is personal hereunder, and Employee agrees that Employee shall have no right to assign and shall not assign or purport to assign any rights or obligations under this Agreement. This Agreement may be assigned or transferred by the Company; and nothing in this Agreement shall prevent the consolidation, merger or sale of the Company or a sale of any or all or substantially all of its assets.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:12pt;">. Subject to the foregoing restriction on assignment by Employee, this Agreement shall inure to the benefit of and be binding upon each of the parties; the affiliates, officers, directors, agents, successors and assigns of the Company; and the heirs, devisees, spouses, legal representatives and successors of Employee.</font></div><div style="line-height:124%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOTICES</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All notices or other communications required or permitted hereunder shall be made in writing and shall be deemed to have been duly given if delivered: (a) by hand; (b) by a nationally recognized overnight courier service; or (c) by United States first class registered or certified mail, return receipt requested, to the principal address of the other party, as set forth below. The date of notice shall be deemed to be the earlier of (i) actual receipt of notice by any permitted means, or (ii) five business days following dispatch by overnight delivery service or the United States Mail. Employee shall be obligated to notify the Company in writing of any change in Employee&#8217;s address. Notice of change of address shall be effective only when done in accordance with this paragraph.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Company&#8217;s Notice Address:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17901 Von Karman Ave., Suite 150</font></div><div style="line-height:124%;padding-top:1px;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Irvine, CA 92614 Attention:  Legal</font></div><div style="line-height:247%;padding-top:2px;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employee&#8217;s Notice: to Employee at his address on file in the Company&#8217;s payroll records </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SEVERABILITY</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If any provision of this Agreement shall be held by a court or arbitrator to be invalid, unenforceable or void, such provision shall be enforced to the fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall reduce the time period or scope to the maximum time period or scope permitted by law.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TAX MATTERS</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:12pt;">. Any and all amounts payable under this Agreement or otherwise shall be subject to, and the Company may withhold from such amounts, any federal, state, local or other taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div><div style="line-height:125%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 409A Compliance.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;padding-top:5px;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The intent of the parties hereto is that payments and benefits under this Agreement be exempt from (to the extent possible) Section 409A (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 409A</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the Internal Revenue Code of 1986 and the regulations and guidance promulgated thereunder, as amended (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. To the extent that any provision hereof is modified in order to comply with Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to the parties hereto of the applicable provision without violating the provisions of Section 409A. </font></div><div style="line-height:125%;padding-top:5px;text-align:left;padding-left:102px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;padding-top:4px;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute &#8220;nonqualified deferred compensation&#8221; under Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To the extent that reimbursements or other in-kind benefits under this Agreement constitute &#8220;nonqualified deferred compensation&#8221; for purposes of Section 409A, (A) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Employee, (B) any right to reimbursement or in- kind benefits shall not be subject to liquidation or exchange for another benefit and (C) no such reimbursement, expenses eligible for reimbursement or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For purposes of Section 409A, Employee&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be at the sole discretion of the Board.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#8220;nonqualified deferred compensation&#8221; for purposes of Section 409A be subject to offset by any other amount unless otherwise permitted by Section 409A.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Agreement, to the extent required to avoid the imposition of tax, penalties or interest under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided under this Agreement during the six-month period immediately following a termination of employment shall instead be paid on the first payroll date after the six (6)-month anniversary of the termination of employment (or Employee&#8217;s death, if earlier).</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 280G.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:125%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything contained in this Agreement to the contrary, to the extent that the payments and benefits provided under this Agreement and benefits provided to, or for the benefit of, Employee under any other Company plan or agreement (such payments or benefits are collectively referred to as the &#8220;Benefits&#8221;) would be subject to the excise tax (the &#8220;Excise Tax&#8221;) imposed under Section 4999 of the Code, the Benefits shall be reduced (but not below zero) if and to the extent that a reduction in the Benefits would result in Employee retaining a larger amount, on an after-tax basis (taking into account federal, state and local income taxes and the Excise Tax), than if Employee received all of the Benefits (such reduced amount is referred to hereinafter as the &#8220;Limited Benefit Amount&#8221;).  Unless Employee shall have given prior written notice specifying a different order to the Company to effectuate the Limited Benefit Amount, any such notice consistent with the requirements of Section 409A of the Code to avoid the imputation of any tax, penalty or interest thereunder, the Company shall reduce or eliminate the Benefits by first reducing or eliminating amounts which are payable from any cash severance, then from any payment in respect of an equity award that is not covered by Treas. Reg. Section 1.280G-1 Q/A-24(b) or (c), then from any payment in respect of an equity award that is covered by Treas. Reg. Section 1.280G-1 Q/A-24(c), in each case in reverse order beginning with payments or benefits which are to be paid the farthest in time from the Determination (as defined below).  Any notice given by Employee pursuant to the preceding sentence shall take precedence over the provisions of any other plan, arrangement or agreement governing Employee&#8217;s rights and entitlements to any benefits or compensation.</font></div><div style="line-height:125%;text-align:left;padding-left:102px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10.5pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A determination as to whether the Benefits shall be reduced to the Limited Benefit Amount pursuant to this Agreement and the amount of such Limited Benefit Amount shall be made by the Company&#8217;s independent public accountants or another certified public accounting firm or executive compensation consulting firm of national reputation designated by the Company and acceptable to Employee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Firm</font><font style="font-family:inherit;font-size:12pt;">&#8221;) at the Company&#8217;s expense.  The Firm shall provide its determination (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Determination</font><font style="font-family:inherit;font-size:12pt;">&#8221;), together with detailed supporting calculations and documentation to the Company and Employee within ten (10) business days of the date of termination of Employee&#8217;s employment, if applicable, or such other time as reasonably requested by the Company or Employee.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">GOVERNING LAW</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of the State of California.</font></div><div style="line-height:124%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INTERPRETATION</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Sections and section headings contained in this Agreement are for reference purposes only and shall not affect in any manner the meaning or interpretation of this Agreement. Whenever the context requires, references to the singular shall include the plural and the plural the singular.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OBLIGATIONS SURVIVE TERMINATION OF EMPLOYMENT</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each party agrees that any and all of such party&#8217;s obligations under this Agreement, including any agreement contemplated hereby, shall survive a termination of employment.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">COUNTERPARTS</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;text-align:left;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts, and the signature pages may be transmitted by pdf or electronic means, each of which shall be deemed an original of this Agreement, but all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AUTHORITY</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each party represents and warrants that such party has the right, power and authority to enter into and execute this Agreement and to perform and discharge all of the obligations hereunder; and that this Agreement constitutes the valid and legally binding agreement and obligation of such party and is enforceable in accordance with its terms.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ENTIRE AGREEMENT</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement is intended to be the final, complete and exclusive statement of the terms of Employee&#8217;s employment by the Company and may not be contradicted by evidence of any prior or contemporaneous statements or agreements, except for agreements specifically referenced herein (including the agreements referenced in </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sections 6 </font><font style="font-family:inherit;font-size:12pt;">and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7 </font><font style="font-family:inherit;font-size:12pt;">above). To the extent that the practices, policies or procedures of the Company, now or in the future, apply to Employee and are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Employee&#8217;s duties, position or compensation shall not affect the validity or scope of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EMPLOYEE ACKNOWLEDGEMENT</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL CONCERNING THIS AGREEMENT, THAT EMPLOYEE HAS READ AND UNDERSTANDS THE AGREEMENT, THAT EMPLOYEE IS FULLY AWARE OF ITS LEGAL EFFECT AND THAT EMPLOYEE HAS ENTERED INTO IT FREELY BASED ON EMPLOYEE&#8217;S OWN JUDGMENT AND NOT ON ANY REPRESENTATIONS OR PROMISES OTHER THAN THOSE CONTAINED IN THIS AGREEMENT.</font></div><div style="line-height:126%;text-align:justify;padding-left:8px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:126%;padding-top:4px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[The remainder of this page has intentionally been left blank.  The signature page follows on the next page.]</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;padding-top:4px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By signing below, each of the parties hereto acknowledges and agrees to all of the terms of this Employment Agreement, effective as of the Effective Date.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rui Avelar (&#8220;Employee&#8221;)</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sign name:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;/s/ Rui Avelar&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EVOLUS, INC., a Delaware Corporation (the &#8220;Company&#8221;)</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sign name:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;/s/ David Moatazedi&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Print name:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;David Moatazedi&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>3
<FILENAME>exhibit1032.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0E7AFE1EF42C0F19B3502A713CBAC517"></a></div><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Separation Agreement and General Release of Claims (&#8220;Agreement&#8221;) is made an entered into by and between J. Christopher Marmo (hereafter &#8220;Employee&#8221;) and each of ALPHAEON Corporation (&#8220;ALPHAEON&#8221;) and Evolus, Inc. (&#8220;Evolus&#8221; and collectively with ALPHAEON on behalf of themselves, their parents, their subsidiaries, and other corporate affiliates, collectively referred to as the, the &#8220;Employer Group&#8221;).  By signing this Agreement, the Employee and the Employer Group acknowledge that they have reached a final binding agreement as to the circumstances surrounding Employee&#8217;s separation from employment with the Employer Group under an Employment Agreement originally dated as of October 3, 2013 between Employee and SCH-AEON, LLC (f/k/a Strathspey Crown Holdings, LLC) which agreement was assigned in full to ALPHAEON.  Each of Employee and Employer Group acknowledges that this document contains the entire agreement with respect to the subject matter hereof:</font></div><div style="line-height:130%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:96px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Separation</font><font style="font-family:inherit;font-size:11pt;">.  Employee&#8217;s employment status with the Employer Group will cease effective August 15, 2018 (the &#8220;Separation Date&#8221;).  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Return of Property</font><font style="font-family:inherit;font-size:11pt;">. Employee warrants and represents that on the Separation Date he will return all Employer Group property, including identification cards or badges, access codes or devices, keys, laptops, computers, telephones, mobile phones, hand-held electronic devices, credit cards, electronically stored documents or files, physical files, and any other Employer Group property in the Employee's possession.  After the Separation Date, the Employer Group, may, but is not required to, allow Employee use of certain equipment for purposes of fulfilling certain consulting services; any such use shall be subject to the Company&#8217;s terms and conditions.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:88px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severance</font><font style="font-family:inherit;font-size:11pt;">.  In exchange for my entering into and not revoking this Agreement: </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a) ALPHAEON will pay Employee, after the Separation Date, and Evolus shall reimburse ALPHAEON, a severance amount equal to (i) six (6) months of base salary which will be paid periodically pursuant to ALPHAEON&#8217;s regularly scheduled pay periods and subject to customary payroll deductions (ii) $190,096.96 (representing Employee&#8217;s pro-rata annual bonus for the year ending December 31, 2018 prorated as of Employee&#8217;s Separation Date) which will be paid in a lump sum no later than March 15, 2019 and subject to customary payroll deductions (collectively, the &#8220;Severance Amount&#8221;); </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b) ALPHAEON will provide, and Evolus shall reimburse ALPHAEON for, continuation of Employee&#8217;s health benefits through the end of the six-month anniversary of my Separation Date; </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c) ALPHAEON will provide, and Evolus shall reimburse ALPHAEON for, payment to Employee with respect to all business expenses submitted in accordance with the Employer Group&#8217;s expense reimbursement policies; and </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d) Evolus and Employee will enter into the Consulting Agreement in the form attached as Exhibit A hereto (the &#8220;Consulting Agreement&#8221;).  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">General Releases,</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Release of Employer Group.  In return for the promises in Section 3 above, Employee, on his own behalf, and on behalf of his heirs, grantees, agents, representatives, devisees, trustees, assigns, assignors, attorneys, and any other entities or persons in which Employee has an interest (collectively &#8220;Releasors&#8221;) hereby release and forever discharge the Employer Group and each of their respective past and present agents, employees, representatives, officers, directors, members, managers, attorneys, accountants, insurers, advisors, consultants, assigns, successors, heirs, predecessors in interest, joint ventures, affiliates, subsidiaries, parents, and commonly-controlled entities (collectively &#8220;Releasees&#8221;) from all liabilities, causes of action, charges, complaints, suits, claims, obligations, costs, losses, damages, rights, judgments, attorneys&#8217; fees, expenses, bonds, bills, penalties, fines, and all other legal responsibilities of any form whatsoever, whether known or unknown, whether suspected or unsuspected, whether fixed or contingent, liquidated or unliquidated that Employee had or may claim to have against any of the Releasees, including Employer Group, up through and including the date Employee executed this Agreement, including any and all claims arising under any theory of law, whether common, constitutional, statutory or other of any jurisdiction, foreign or domestic, whether known or unknown, whether in law or in equity, which Employee had or may claim to have against Employer Group or any of the other Releasees.  This general release is intended to have the broadest possible application and releases any tort, contract, common law, constitutional, statutory, and other type of claim Employee had or may claim to have against Employer Group and/or any of the other Releasees.  This general release also includes, but is not limited to, (i) all claims of any kind related to Employee&#8217;s employment with, compensation by and separation from Employer Group, as well as (ii) all claims relating to any acts or omissions occurring prior to or on the date of this Agreement between Employee and Employer Group as well as between Employee and any of the other Releasees.  Releasors specifically release, among other things, claims under all applicable state and federal laws of any kind, including, but not limited to, any claims based on age, sex, pregnancy, race, color, national origin, marital status, religion, veteran status, disability, sexual orientation, medical condition, or other anti-discrimination laws of any type, including, without limitation, Title VII of the Civil Rights Act of 1964 as amended, the Age Discrimination in Employment Act (Title 29, United States Code, Sections 621, et seq.) (&#8220;ADEA&#8221;), the Americans with Disabilities Act, the Fair Labor Standards Act, the Family Medical Leave Act, the California Fair Employment and Housing Act, the California Workers&#8217; Compensation Act, the California Labor Code, including sections 200, et seq., 970 and 132a, the California Civil Code, and the California Constitution, any other federal or state statutory claims of any kind whatsoever, and all common law claims of any kind, whether arising in tort or contract.  If any governmental agency should assume jurisdiction over any claim, charge or complaint arising out of Employee&#8217;s employment with Employer Group, Releasors also waive the right to recover damages or any other remedy as a result of such claim, charge, or complaint.  Employee acknowledges and agrees that, following the payment of the Severance Amount and delivery of any other benefits set forth in Section 2 of this Agreement, Employer Group as well as all of the other Releasees have no other liabilities or obligations to Employee of any kind or nature whatsoever and the Releasors, including, without limitation, owe Employee no liabilities or obligations in connection with or relating to Employee&#8217;s employment with Employer Group.  Employee represents and warrants that Employee is not a plaintiff or party to any suit, arbitration, action, or administrative proceeding in which Employer Group or any of the other Releasees is a party.  Employee also agrees and promises that Employee will not file any suit, arbitration, action, or administrative claim, charge or any other type of action against Employer Group or any of the other Releasees asserting any of the matters released herein.  Employee further agrees not to prosecute, nor allow to be prosecuted on Employee&#8217;s behalf, in any administrative agency, whether state or federal, or in any court, whether state or federal, any claim or demand of any type related to the matters released herein, it being the intention of Employee that with the execution of this release, Employer Group and all of the other Releasees </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">will be absolutely, unconditionally and forever discharged of and from all liabilities and obligations to Employee and the other Releasors, except as set forth in Section 3 of this Agreement.   Notwithstanding any provision hereof to the contrary, neither Employee nor any of the Releasors is releasing, and this Agreement shall not be construed to release, any claims Employee or any of the Releasors have or may have in respect of (a) obligations of the Employer Group to perform this Agreement, (b) obligations of ALPHAEON and Evolus pursuant to the Stock Purchase Agreement, dated as of September 30, 2014 (the &#8220;Stock Purchase Agreement&#8221;), as amended by that certain Amendment to Stock Purchase Agreement (undated) (&#8220;First Amendment&#8221;) and that certain Second Amendment to Stock Purchase Agreement dated as of December 14, 2017 (&#8220;Second Amendment&#8221;), to which Employee is a party, and the Promissory Note (as defined in the Second Amendment), as each maybe amended in accordance with the terms thereof, or (c) obligations of ALPHAEON and Evolus pursuant to the Tax Indemnity Agreement dated as of December 14, 2017 (&#8220;Tax Indemnity Agreement&#8221;), to which Employee is a party, as it may be amended in accordance with the terms thereof.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Representations and Warranties of Employer Group.  Employer Group represents and warrants that </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:168px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.&#160;&#160;&#160;&#160;to its knowledge, each of the (i) Stock Purchase Agreement as amended by the First Amendment and the Second Amendment, (ii) Promissory Note (as defined in the Second Amendment), and (iii) Tax Indemnity Agreement (collectively, &#8220;Employer Group Arrangements&#8221;) remains in full force and effect on the date hereof in accordance with its terms, </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:168px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">b.&#160;&#160;&#160;&#160;Employee&#8217;s separation from Employer Group and entry into this Agreement and the Consulting Agreement will not terminate, impair, or adversely impact (i) any rights of Employee under any of the Employer Group Arrangements, (ii) obligations of Employer Group to Employee under any of the Employer Group Arrangements, and (iii) any of the Employer Group Arrangements.   </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Release of Age Discrimination Claims</font><font style="font-family:inherit;font-size:11pt;">.  Employee understands that the general release in Section 4 above includes a waiver of any and all rights and claims Employee had or may claim to have against Employer Group as well as any of the other Releasees, including any rights and claims which Employee may claim to have arising under the ADEA.  Employee admits that this Agreement satisfies the requirements of 29 U.S.C. &#167; 626(f).  Employee also acknowledges and agrees that Employee has read and understands the terms of this Agreement.  Employee represents that Employee has been advised in writing by this Agreement to consult with an attorney of his choosing regarding the waiver of rights and claims under the ADEA.  Employee also acknowledges that Employee has obtained and considered such legal counsel as Employee deems necessary, such that Employee is entering into this Agreement freely, knowingly, and voluntarily.  Employee further acknowledges that Employee has been given at least twenty-one (21) days in which to consider whether or not to enter into this Agreement.  Employee understands that, at Employee&#8217;s option, Employee may elect not to use the full 21-day period.  Employee also understands that this Agreement shall not become enforceable until eight (8) days after Employee has executed this Agreement.  If Employee does not revoke his acceptance within the seven (7) day period after this Agreement is executed by Employee, Employee understands this Agreement shall become binding and enforceable on the eighth day.  Employee further understands that Employee is not waiving any rights or claims under the ADEA that may arise after the effective date of this Agreement.  </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:11pt;">.  Employee understands and agrees that all of Employee&#8217;s rights under California Civil Code Section 1542 are expressly waived.  Employee understands that Section 1542 provides as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT A CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee understands that waiving Employee&#8217;s rights under Civil Code Section 1542 means that even if Employee should eventually suffer some damage arising out of his employment and/or separation from employment with Employer Group or any of the other Releasees, that Employee will not be able to make any claims for those damages, even as to claims which may now exist, but which Employee does not know exist, and which if known would have affected Employee&#8217;s decision to sign this Agreement.  Employee acknowledges that the discovery of facts or law different from, or in addition to, the facts or law that Employee knows or believes to be true with respect to the claims released in this Agreement and agrees, nonetheless, that this Agreement and the releases contained in it shall be and remain effective in all respects notwithstanding such different or additional facts or the discovery of them.  Employee further declares and represents that Employee intends this Agreement to be complete and not subject to any claim of mistake, and that the releases herein express full and complete releases by Employee and the other Releasors, and that Employee intends that the general release by Employee herein shall be final and complete with respect to Employer Group as well as all other Releasees.  Employee has executed this Agreement with the full knowledge that the general release in Section 4 combined with Employee&#8217;s waiver of any rights under Civil Code Section 1542 cover all possible claims against Employer Group and any of the other Releasees, to the fullest extent permitted by law.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Assignment</font><font style="font-family:inherit;font-size:11pt;">.  Employee warrants and represents that Employee has not assigned or transferred to any person any released matter or any right to the payment or other consideration provided by this Agreement.  Employee agrees to defend, indemnify and hold Employer Group and any of the other Releasees harmless from any and all claims based on or in connection with or arising out of any such assignment or transfer made, purported or claimed.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Wrongdoing</font><font style="font-family:inherit;font-size:11pt;">.  Employee understands that, by signing this Agreement, Employer Group does not admit any wrongdoing and makes no admission that it or any of the other Releasees has engaged, or is now engaging, in any unlawful conduct.  Employee is also admitting no wrongdoing by signing this Agreement.  Employer Group and Employee agree that this Agreement may never be treated as an admission of liability by any party for any purpose.  Employer Group and Employee also agree that no use of this Agreement or any comments made by either party during the discussions or negotiations regarding this Agreement will be used by a party or their representatives in connection with any subsequent legal action except for an action to enforce this Agreement.  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">.  Employee understands that obligations under any confidentiality agreement signed by Employee during his employment with Employer Group remain in effect </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">and survive the termination of Employee&#8217;s employment with Employer Group, provided that, Employer Group agrees as follows:</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The following information shall not be deemed to be confidential or proprietary information of Employer Group under any confidential agreement signed during my employment: (i) information known to Employee prior to its disclosure by Employer Group; (ii) information that is or that thereafter becomes generally known or part of the public domain without breach of or violation by Employee of any such confidentiality agreement; or (iii) information that was received by or disclosed to Employee from a third party that did not owe an obligation of confidentiality to Employer Group.  Accordingly, Employer Group&#8217;s use or disclosure of the foregoing information shall not be deemed a breach or violation of any confidentiality agreement signed by Employee during his employment with Employer Group.  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To the extent any confidentiality agreement entered into by Employee and Employer Group conflicts with or is contrary to the terms and conditions set forth in this Section 9, any such confidentiality agreement is hereby deemed automatically amended, modified, and superseded accordingly.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Confidentiality of Agreement</font><font style="font-family:inherit;font-size:11pt;">.  Employee agrees that the terms and conditions of this Agreement are strictly confidential and shall not be discussed, disclosed or revealed by Employee to any third party, except to Employee&#8217;s attorneys, tax advisors, and spouse, and except insofar as Employee is compelled by law to disclose it.  When releasing this information to any such person, Employee agrees to advise the person receiving the information of its confidential nature.    </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Disparagement</font><font style="font-family:inherit;font-size:11pt;">.  In addition to any other non-disparagement agreement to which Employee may be bound, Employee expressly agrees that Employee will not in any way disparage or otherwise cause to be published or disseminated any negative statements, remarks, comments or information regarding Employer Group or any of the other Releasees.  Notwithstanding the foregoing, Employee shall not be restrained or prohibited, and it shall not be a breach of this Agreement by Employee if Employee makes any statements in any letters, legal filings or other related documents or proceedings in each case in connection with or arising out of the pursuit of a claim that Employee has not released under this Agreement.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:11pt;">.  Employee acknowledges that Employee has carefully read and fully understands the nature of this Agreement, that Employee has been advised to consult with an attorney of his choosing before executing this Agreement, that Employee has had the opportunity to consider this Agreement, and that all of Employee&#8217;s questions concerning this Agreement have been answered to his satisfaction.  Employee also agrees that any rule of construction to the effect that ambiguities are to be resolved against the drafting party will not apply in the interpretation of this Agreement.  The provisions of this Agreement together with the exhibits hereto set forth the entire agreement between Employee and Employer Group concerning Employee&#8217;s severance pay and benefits and Employee&#8217;s termination of employment.  Any other contrary promises, written or oral, are replaced by this Agreement, and are no longer effective unless they are contained in this document or are expressly deemed to survive the cessation of Employee&#8217;s employment with Employer Group in accordance with the terms of the written document in which they are contained.  The validity, interpretation and performance of this Agreement shall be construed and interpreted according to the laws of the State of California.  Any action arising out of or relating to this Agreement shall be conducted before the Judicial Arbitration and Mediation Service (JAMS) before a single arbitrator.  If the parties are unable to agree on an arbitrator, JAMS shall select the arbitrator.  Arbitration shall be located in the County </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">of Orange, State of California. This Agreement may be executed via facsimile and/or email, and in two or more counterparts, each of which taken together shall constitute one and the same instrument. </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Attorneys&#8217; Fees</font><font style="font-family:inherit;font-size:11pt;">.  In the event that any proceeding or action is brought by either party to enforce or interpret the terms of this Agreement, the prevailing party in such proceeding or action shall be entitled to recover its costs of suit, including reasonable attorney&#8217;s fees.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:11pt;">.  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14.1.&#160;&#160;&#160;&#160;This Agreement in all respects has been voluntarily and knowingly entered into by Employee.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14.2.&#160;&#160;&#160;&#160;Employee had an opportunity to seek legal advice from legal counsel of Employee&#8217;s choice with respect to the advisability of executing this Agreement</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14.3&#160;&#160;&#160;&#160;Employee has made such investigation of the facts pertaining to this Agreement as Employee deems necessary.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14.4 &#160;&#160;&#160;&#160;The terms of this Agreement are the result of negotiations between Employee and Employer Group, and are entered into in good faith by Employee and Employer Group in accordance with California law.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14.5&#160;&#160;&#160;&#160;This Agreement has been carefully read by Employee and the contents hereof are known and understood by Employee.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14.6&#160;&#160;&#160;&#160;Employee acknowledges and agrees that upon being paid the final payment of salary on the Separation Date, Employee has been paid all compensation, other than the Annual Bonus referred to in Section 3(a)(ii) of the Agreement which shall be paid on or prior to March 15, 2019, to which Employee is entitled in connection with his employment with the Employer Group, including wages, vacation pay, and bonuses up to and including the Separation Date. All such payments will be less appropriate withholdings.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Limitations</font><font style="font-family:inherit;font-size:11pt;">.&#160;Notwithstanding the foregoing, Employee understands the following:</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15.1&#160;&#160;&#160;&#160;Nothing contained in this Agreement precludes Employee from filing a charge of discrimination with the United States Equal Employment Opportunity Commission (&#8220;EEOC&#8221;) or any state fair employment practices agency (&#8220;FEPA) or participating in an investigation by the EEOC or any FEPA, but Employee will not be entitled to any monetary or other relief from the EEOC or any FEPA on the basis of or in connection with such charge or investigation, or from any Court as a result of litigation brought on the basis of or in connection with such charge or investigation;</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15.2&#160;&#160;&#160;&#160;Nothing in this Agreement prohibits, or is intended in any manner to prohibit, Employee from reporting a possible violation of federal or state law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under whistleblower provisions of federal or state law or regulation. Employee does not need the prior authorization of Employer Group to make any such reports or disclosures, and Employee is not required to notify Employer Group that Employee has made such reports or disclosures.&#160;Nothing in </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">this Agreement limits Employee&#8217;s ability to receive a whistleblower or other award from a governmental agency or entity for information provided to such an agency or entity.</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15.3&#160;&#160;&#160;&#160;Nothing in this Agreement or any other agreement or policy of Employer Group is intended to interfere with or restrain the&#160;immunity provided under 18 U.S.C. &#167; 1833(b) for confidential disclosures of trade secrets to government officials, or lawyers, solely for the purpose of reporting or investigating a suspected violation of law; or in a sealed filing in court or other proceeding.</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">remainder of page intentionally left blank;</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">signature page follows</font><font style="font-family:inherit;font-size:11pt;">.]</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">* * * * IMPORTANT NOTICE * * * *</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS BEEN GIVEN THE OPPORTUNITY TO CONSIDER THIS AGREEMENT FOR 21 DAYS.  SHOULD EMPLOYEE DECIDE NOT TO USE THE FULL 21 DAYS, EMPLOYEE KNOWINGLY AND VOLUNTARILY WAIVES ANY CLAIMS THAT EMPLOYEE WAS NOT IN FACT GIVEN THAT PERIOD OF TIME OR DID NOT USE THE ENTIRE 21 DAYS TO CONSULT AN ATTORNEY AND/OR CONSIDER THIS AGREEMENT. EMPLOYEE ACKNOWLEDGES AND UNDERSTANDS THAT FOR A PERIOD OF SEVEN (7) DAYS FOLLOWING EMPLOYEE&#8217;S EXECUTION OF THIS AGREEMENT, EMPLOYEE MAY REVOKE THIS AGREEMENT AND RELEASE, AND THE RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THIS SEVEN (7) DAY REVOCATION PERIOD HAS EXPIRED.  IF EMPLOYEE DOES NOT REVOKE THIS AGREEMENT AND THE RELEASE IN THE TIME FRAME SPECIFIED, THIS AGREEMENT AND RELEASE SHALL BE DEEMED TO BE EFFECTIVE AT 12:01 A.M. ON THE EIGHTH DAY AFTER EMPLOYEE EXECUTED THE SAME. </font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">CM</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;">(Initials)</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If Employee does not sign this Agreement or if Employee revokes this Agreement within the seven (7) day revocation period noted above or if Employer Group does not execute this Agreement, Employer Group will not, and has no obligation to, provide Employee with any of the benefits listed in Section 3 of the Agreement, including, but not necessarily limited, to any Severance Amount and health insurance coverage. Rather, Employee will receive only those benefits and compensation to which Employee is already entitled under Employer Group policy to which Employee is subject.  If Employee elects not to sign this Agreement, such action will not alter or affect Employee&#8217;s ultimate separation from employment with Employer Group, which will still occur effective as of the Separation Date.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In exchange for the mutual promises contained in this Agreement, the parties execute this Agreement as of the date set forth below.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Employee</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">J. Christopher Marmo</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dated: August 28, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ J. Christopher Marmo</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Employer Group</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ALPHAEON Corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dated: August 28, 2018</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Vikram Malik</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Evolus, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dated: August 28, 2018</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ David Moatazedi</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;"><br>CONSULTING AGREEMENT</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THIS CONSULTING AGREEMENT for independent Consultant consulting services (&#8220;Agreement&#8221;) by and between Evolus, Inc., (&#8220;COMPANY&#8221;) and J. Christopher Marmo (the &#8220;Consultant&#8221;).</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Consulting Services</font><font style="font-family:inherit;font-size:11pt;">. Consultant shall provide COMPANY with the services described on Schedule 1, as well as other services as may be requested from time to time by COMPANY (the &#8220;Services&#8221;). Except as otherwise provided in any specific project assignment, Consultant will have exclusive control over the manner and means of performing the Services, including the choice of place and time.  Consultant will provide, at Consultant&#8217;s own expense, a place of work and all equipment, tools and other materials necessary to complete the Services; however, to the extent necessary to facilitate performance of the Services, Client may, in its discretion, make its equipment or facilities available to Consultant at Consultant&#8217;s request.  While on the COMPANY&#8217;s premises, Consultant agrees to comply with COMPANY&#8217;s then-current access rules and procedures, including those related to safety, security and confidentiality.  Consultant agrees and acknowledges that Consultant has no expectation of privacy with respect to COMPANY&#8217;s telecommunications, networking or information processing systems (including stored computer files, email messages and voice messages) and that Consultant&#8217;s activities, including the sending or receiving of any files or messages, on or using those systems may be monitored, and the contents of such files and messages may be reviewed and disclosed, at any time, without notice.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Independent Consultant Relationship/Conflicts</font><font style="font-family:inherit;font-size:11pt;">.  Consultant shall have the full power, authority, and discretion to select the means, manner, and method of performing the Services hereunder without detail, control or direction from COMPANY or its officers or directors. Consultant shall not be considered an employee of COMPANY for any purposes and they shall not be entitled to participate in any employee benefit plans sponsored or maintained by COMPANY.  During the term of this Agreement, the Consultant shall disclose in writing to COMPANY any actual conflict that Consultant may have in performing the Services hereunder.  For purposes of this Agreement, "actual conflict" shall not include any confidentiality or non-disclosure agreements that Consultant enters into with another person or entity, or discussions with other companies about business or employment opportunities.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11pt;">.  The Consultant shall commence providing Services on August __, 2018 (the &#8220;Effective Date&#8221;), and shall continue to do so until the COMPANY obtains U.S. Food and Drug Administration approval for its botulinum toxin type A product candidate or the Agreement is terminated by either party pursuant to Section 4 of this Agreement.</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;">This Agreement may be extended by mutual written agreement of both parties.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:11pt;">. Either Consultant or the Company may terminate this Agreement prior to its expiration by providing: (a) prior to February 1, 2019, two (2) weeks advanced notice, or (b) After February 1, 2019, one (1) week advanced notice to the other party of its intention to terminate this Agreement. For purposes of this Agreement, email notification shall be deemed to be written notice.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Payment</font><font style="font-family:inherit;font-size:11pt;">.  In consideration of the Services, the Consultant will be paid $500 per hour to be paid on a bi-weekly basis.  The Consultant shall not receive any additional benefits or compensation for consulting services, except for the reimbursement of expenses.  Consultant shall document all hours dedicated to the Services and provide such documentation on a bi-weekly basis. </font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:11pt;">.  Consultant shall not incur any expenses without prior written approval of COMPANY.  Unless otherwise agreed to by the parties, all normal and customary business expenses incurred by Consultant under this Agreement shall be paid by Consultant, and reimbursed, if such expenses are pre-approved in writing by the COMPANY, by COMPANY upon a showing of evidence of such expenses that is reasonably acceptable to the Company.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Consultant Responsible for Taxes</font><font style="font-family:inherit;font-size:11pt;">. The Consultant agrees to accept exclusive liability for the payment of taxes due on any amounts paid under this Agreement.  Because Consultant is an independent contractor, COMPANY will not withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain workers&#8217; compensation insurance on behalf of Consultant. Consultant is solely responsible for, and will file, on a timely basis, all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of Services and receipt of fees under this Agreement.  Consultant is solely responsible for, and must maintain adequate records of, expenses incurred in the course of performing Services under this Agreement.  No part of Consultant&#8217;s compensation will be subject to withholding by COMPANY for the payment of any social security, federal, state or any other employee payroll taxes.  COMPANY will regularly report amounts paid to Consultant by filing Form 1099-MISC with the Internal Revenue Service as required by law.  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Disclosure and Confidentiality Agreement</font><font style="font-family:inherit;font-size:11pt;">. The Consultant agrees to execute and be bound by the Company&#8217;s Non-Disclosure and Confidentiality Agreement attached as Exhibit A.  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Assignment of Work Product; Title</font><font style="font-family:inherit;font-size:11pt;">. The Consultant agrees to assign and hereby assigns to COMPANY the entire right, title and interest for the entire world in and to all work performed, writings, formulas, designs, models, drawings, photographs, design inventions, other inventions and any information ("Work-Product") developed, made, conceived or reduced to practice by the Consultant, either solely or jointly with others, specifically for COMPANY during the performance of the Services relating to COMPANY and pursuant to this Agreement or with use of confidential information, materials or facilities of COMPANY received or used by the Consultant during the period in which the Consultant is retained by COMPANY (or any successor) under this Agreement. The Consultant hereby agrees to: (i) promptly disclose to COMPANY all Work-Product made, conceived, reduced to practice or authored by the Consultant in the course of the performance of this Agreement; and (ii) sign, execute and acknowledge any and all documents, and to perform such acts, as may be necessary, useful or convenient for the purpose of securing to COMPANY or its nominees, patent, trademark, or copyright protection throughout the world upon all Work-Product. All Work-Product, and all products purchased by the Consultant pursuant to this Agreement and paid for by COMPANY shall be the exclusive property of COMPANY and shall be delivered to COMPANY upon termination of this Agreement.   Consultant hereby irrevocably appoints COMPANY as Consultant&#8217;s attorney-in-fact for the purpose of executing such documents on Consultant&#8217;s behalf, which appointment is coupled with an interest.  If Consultant has any rights, including without limitation &#8220;artist&#8217;s rights&#8221; or &#8220;moral rights,&#8221; in the Work Product that cannot </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">be assigned, Consultant hereby unconditionally and irrevocably grants to COMPANY an exclusive (even as to Consultant), worldwide, fully paid and royalty-free, irrevocable, perpetual license, with rights to sublicense through multiple tiers of sublicensees, to use, reproduce, distribute, create derivative works of, publicly perform and publicly display the Work Product in any medium or format, whether now known or later developed.  In the event that Consultant has any rights in the Work Product that cannot be assigned or licensed, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind against COMPANY or COMPANY&#8217;s customers.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:11pt;">.  Consultant represents and warrants that: (a) the Services shall be performed in a professional manner and in material accordance with the industry standards, (b) to his knowledge, Consultant has the right and unrestricted ability to assign the ownership of Work Product to COMPANY as set forth in Section 9 (including without limitation the right to assign the ownership of any Work Product created by Consultant&#8217;s employees or contractors), (c) neither the Work Product nor any element thereof will infringe upon or misappropriate any copyright, patent, trademark, trade secret, right of publicity or privacy, or any other proprietary right of any person, whether contractual, statutory or common law, (d) Consultant will comply with all applicable federal, state, local and foreign laws governing self-employed individuals, including laws requiring the payment of taxes, such as income and employment taxes, and social security, disability, and other contributions.  Consultant agrees to indemnify and hold COMPANY harmless from any and all damages, costs, claims, expenses or other liability (including reasonable attorneys&#8217; fees) arising from or relating to the breach or alleged breach by Consultant of the representations and warranties set forth in this Section 11.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Arbitration, Choice of Law</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement shall be deemed to have been executed and delivered within the State of California, and the rights and obligations of the parties hereunder shall be construed and enforced in accordance with, and governed by, the laws of the State of California without regard to principles of conflict of laws.  In the event of a dispute, the parties agree to binding arbitration in Orange County, California under the Rules of Comprehensive Arbitration before the Judicial Arbitration and Mediation Service ("JAMS"). The prevailing party shall be entitled to recover reasonable attorney fees and costs.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:11pt;">.  If any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of the Agreement which can be given effect without the invalid provisions or applications and, to this end, the provisions of this Agreement are declared to be severable.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Personal Performance</font><font style="font-family:inherit;font-size:11pt;">.  Due to the personal nature of the services to be rendered by the Consultant, the Consultant may not assign this Agreement in whole or in part.  Any attempt to make such an assignment shall be void. The Company may assign all or a portion of its rights and liabilities under this Agreement to a subsidiary, an affiliate or a successor to all or a substantial portion of its business and assets without the necessity of consent from the Consultant.  Subject to the foregoing, this Agreement will inure to the benefit of and be binding upon each of the heirs, assigns and successors of the respective parties.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Advice of Counsel</font><font style="font-family:inherit;font-size:11pt;">.  In entering into this Agreement, the parties recognize that this Agreement is a legally binding contract and acknowledge and agree that each party has had the opportunity to consult with legal counsel of its choice.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This agreement together with the Separation Agreement constitutes and contains the entire Agreement and final understanding between the parties covering the Services provided by the Consultant.  It is intended by the parties as a complete and exclusive statement of the terms of their agreement.  It supersedes all prior negotiations and agreements, proposed or otherwise, whether written or oral, between the parties concerning consulting services provided by the Consultant.  Any representation, promise or agreement not specifically included in this Agreement shall not be binding upon or enforceable against either party.  This is a fully integrated document.  This Agreement may be modified only with a written instrument duly executed by each of the parties.  No person has any authority to make any representation or promise on behalf of any of the parties not set forth herein and this Agreement has not been executed in reliance upon any representations or promises except those contained herein.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Assignment</font><font style="font-family:inherit;font-size:11pt;">.  Consultant shall not assign either in whole or in part any of Consultant's duties or responsibilities hereunder without the written consent of COMPANY, and any attempt of assignment transfer or delegation without such consent shall be void.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Written Reports</font><font style="font-family:inherit;font-size:11pt;">.  The Consultant, when directed, shall provide written reports with respect to the Services rendered hereunder.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Headings</font><font style="font-family:inherit;font-size:11pt;">.  Headings are used only for ease of reference and are not controlling</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">20.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:11pt;">. This Agreement may be executed via facsimile and/or email, and in two or more counterparts, each of which taken together shall constitute one and the same instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">[Signature page follows.]</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In witness whereof, the parties hereto have executed this Agreement as of the date first above written.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Evolus, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;/s/ David Moatazedi&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  David Moatazedi</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Its: CEO and President</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notice Address:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Evolus, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17901 Von Karman Ave., Suite 150</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Irvine, CA 92614</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Consultant: J. Christopher Marmo</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;/s/ J. Christopher Marmo&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  J. Christopher Marmo</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notice and E-mail Address: Address on file with the COMPANY</font></div><div style="line-height:120%;text-align:left;padding-left:88px;text-indent:-88px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 1 to Consulting Agreement</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SERVICES TO BE PROVIDED BY CONSULTANT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Consultant shall provide services relating to the Company&#8217;s business and activities as directed by the Chief Executive Officer of the Company (the &#8220;CEO&#8221;), or his respective designees, which services are limited to the informational responses (IR) to the FDA regarding the Company&#8217;s Biologics License Application for its Botulinum Type A toxin and its resubmission.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This consulting work shall be limited to twenty hours per month or less unless the CEO or his designee provides prior written consent.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Consultant shall provide a report of all hours worked on a bi-weekly basis to the COMPANY.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NON-DISCLOSURE AND CONFIDENTIALITY AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During the term of the Agreement, the COMPANY may share certain proprietary information with the Consultant in connection with the Services. Therefore, in consideration of the mutual promises and covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1. Definition of Confidential Information. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For purposes of this Agreement, &#8220;Confidential Information&#8221; means any data or information that is proprietary to the COMPANY and not generally known to the public, whether in tangible or intangible form, whenever and however disclosed, including, but not limited to: (i) any marketing strategies, plans, financial information, or projections, operations, sales estimates, business plans and performance results relating to the past, present or future business activities of such party, its affiliates, subsidiaries and affiliated companies; (ii) plans for acquisitions, dispositions, products or services, and investor, customer or supplier lists; (iii) any scientific or technical information, regulatory processes, regulatory inquiries, invention, design, process, procedure, formula, improvement, technology or method; (iv) any concepts, business plans, reports, data, know-how, works-in-progress, designs, development tools, specifications, computer software, source code, object code, flow charts, databases, inventions, information and trade secrets; and (v) any other information that should reasonably be recognized as confidential information of the COMPANY. Confidential Information need not be novel, unique, patentable, copyrightable or constitute a trade secret in order to be designated Confidential Information. The Consultant acknowledges that the Confidential Information is proprietary to the COMPANY, has been developed and obtained through great efforts by the COMPANY and that the COMPANY regards all of its Confidential Information as trade secrets.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything in the foregoing to the contrary, Confidential Information shall not include information which: (i) was known by the Consultant prior to receiving the Confidential Information from the COMPANY; (ii) becomes rightfully known to the Consultant from a third-party source not known (after diligent inquiry) by the Consultant to be under an obligation to the COMPANY to maintain confidentiality; (iii) is or becomes publicly available through no fault of or failure to act by the Consultant in breach of this Agreement; (iv) is required to be disclosed in a judicial or administrative proceeding, or is otherwise requested or required to be disclosed by law or regulation, although the requirements of paragraph 4 hereof shall apply prior to any disclosure being made; and (v) is or has been independently </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">developed by employees, consultants or agents of the Consultant without violation of the terms of this Agreement or reference or access to any Confidential Information. </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2. Disclosure of Confidential Information. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">From time to time, the COMPANY may disclose Confidential Information to the Consultant.  The Consultant will: (a) limit disclosure of any Confidential Information to its directors, officers, employees, agents or representatives (collectively &#8220;Representatives&#8221;) who have a need to know such Confidential Information in connection with the current or contemplated business relationship between the parties to which this Agreement relates, and only for that purpose; (b) advise its Representatives of the proprietary nature of the Confidential Information and of the obligations set forth in this Agreement and require such Representatives to keep the Confidential Information confidential; (c) shall keep all Confidential Information strictly confidential by using a reasonable degree of care, but not less than the degree of care used by it in safeguarding its own confidential information; and (d) not disclose any Confidential Information received by it to any third parties (except as otherwise provided for herein).  Each party shall be responsible for any breach of this Agreement by any of their respective Representatives. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3. Use of Confidential Information. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Consultant agrees to use the Confidential Information solely in connection with the current or contemplated business relationship between the parties and not for any purpose other than as authorized by this Agreement without the prior written consent of an authorized representative of the COMPANY.  No other right or license, whether expressed or implied, in the Confidential Information is granted to the Consultant hereunder. Title to the Confidential Information will remain solely in the COMPANY.  All use of Confidential Information by the Consultant shall be for the benefit of the COMPANY and any modifications and improvements thereof by the Consultant shall be the sole property of the COMPANY. Nothing contained herein is intended to modify the parties' existing agreement that their discussions in furtherance of a potential business relationship are governed by Federal Rule of Evidence 408. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4. Compelled Disclosure of Confidential Information. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything in the foregoing to the contrary, the Consultant may disclose Confidential Information pursuant to any governmental, judicial, or administrative order, subpoena, discovery request, regulatory request or similar method, provided that the Consultant promptly notifies, to the extent practicable, the COMPANY in writing of such demand for disclosure so that the COMPANY, at its sole expense, may seek to make such disclosure subject to a protective order or other appropriate remedy to preserve the confidentiality of the Confidential Information; provided in the case of a broad regulatory request with respect to the Consultant&#8217;s business (not targeted at the COMPANY), the Consultant may promptly comply with such request provided the Consultant give (if permitted by such regulator) the COMPANY prompt notice of such disclosure.  The Consultant agrees that it shall not oppose and shall cooperate with efforts by, to the extent practicable, the COMPANY with respect to any such request for a protective order or </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">other relief.  Notwithstanding the foregoing, if the COMPANY is unable to obtain or does not seek a protective order and the Consultant is legally requested or required to disclose such Confidential Information, disclosure of such Confidential Information may be made without liability. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5. Term. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The parties&#8217; duty to hold in confidence Confidential Information that was disclosed during the term of the Agreement shall remain in effect indefinitely. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6. Remedies. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Both parties acknowledge that the Confidential Information to be disclosed hereunder is of a unique and valuable character, and that the unauthorized dissemination of the Confidential Information would destroy or diminish the value of such information. The damages to the COMPANY that would result from the unauthorized dissemination of the Confidential Information would be impossible to calculate. Therefore, both parties hereby agree that the COMPANY shall be entitled to injunctive relief preventing the dissemination of any Confidential Information in violation of the terms hereof. Such injunctive relief shall be in addition to any other remedies available hereunder, whether at law or in equity. The COMPANY shall be entitled to recover its costs and fees, including reasonable attorneys&#8217; fees, incurred in obtaining any such relief. Further, in the event of litigation relating to this Agreement, the prevailing party shall be entitled to recover its reasonable attorney&#8217;s fees and expenses. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7. Return of Confidential Information. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Consultant shall immediately return and redeliver to the other all tangible material embodying the Confidential Information provided hereunder and all notes, summaries, memoranda, drawings, manuals, records, excerpts or derivative information deriving there from and all other documents or materials (&#8220;Notes&#8221;) (and all copies of any of the foregoing, including &#8220;copies&#8221; that have been converted to computerized media in the form of image, data or word processing files either manually or by image capture) based on or including any Confidential Information, in whatever form of storage or retrieval, upon the earlier of (i) the completion or termination of the dealings between the parties contemplated hereunder; (ii) the termination of this Agreement; or (iii) at such time as the COMPANY may so request; provided however that the Consultant may retain such of its documents as is necessary to enable it to comply with its document retention policies. Alternatively, the Consultant, with the written consent of the COMPANY may (or in the case of Notes, at the Consultant&#8217;s option) immediately destroy any of the foregoing embodying Confidential Information (or the reasonably nonrecoverable data erasure of computerized data) and, upon request, certify in writing such destruction by an authorized officer of the Consultant supervising the destruction). </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8. Notice of Breach. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consultant shall notify the COMPANY immediately upon discovery of any unauthorized use or disclosure of Confidential Information by the Consultant or its Representatives, or any other breach of this Agreement by the Consultant or its Representatives, and will cooperate with efforts by the COMPANY to help the COMPANY regain possession of Confidential Information and prevent its further unauthorized use. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>4
<FILENAME>exhibit1033.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9ACDE38E6F94F4605D602A705383B92C"></a></div><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">SUBLEASE</font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">THIS SUBLEASE (this &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Sublease</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) is dated for reference purposes November 7, 2018, and is entered into by and between ACACIA RESEARCH CORPORATION, a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Sublandlord</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), and EVOLUS, INC., a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Subtenant</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Recitals</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;padding-top:16px;text-align:justify;font-family:inherit;font-size:11.5pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:11.5pt;">Sublandlord has leased that certain premises located in the building at 520 Newport Center, Newport Beach, California (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Building</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), consisting of Suite 1200 (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Premises</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), with a total of approximately 17,758 rentable square feet, pursuant to that certain Lease dated January 28, 2002, which lease was amended by a First Amendment to Lease dated August 13, 2004, a Second Amendment to Lease dated February 9, 2005, a Third Amendment to Lease dated March 14, 2006, a Fourth Amendment to Lease dated November 9, 2006, a Fifth Amendment to Lease dated September 10, 2007, a Sixth Amendment to Lease dated January 13, 2011, a Seventh Amendment to Lease dated September 17, 2012, an Eighth Amendment to Lease dated February 28, 2013, and a Ninth Amendment to Lease dated June 26, 2014 (collectively, the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Master Lease</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), by and between Sublandlord, as Tenant, and THE IRVINE COMPANY LLC, a Delaware limited liability company, as Landlord (herein referred to as &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Master Landlord</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).  Sublandlord and Subtenant acknowledge and agree that a true and correct copy of the Master Lease has been provided to Subtenant and where referenced in this Sublease, the applicable provisions of the Master Lease are hereby incorporated by reference into this Sublease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">Sublandlord wishes to sublease to Subtenant, and Subtenant wishes to sublease from Sublandlord, the entirety of the Premises (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Subleased Premises</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), subject to the terms and conditions of this Sublease.  </font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Agreement</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">NOW THEREFORE, in consideration of the mutual promises and covenants contained in this Sublease, and for other valuable consideration which they hereby acknowledge, the parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Defined Terms</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Terms used in this Sublease which are not specifically defined herein shall have the meanings set forth in the Master Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Sublease of Premises</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Subtenant agrees to sublease the Subleased Premises from Sublandlord and Sublandlord agrees to sublease the Subleased Premises to Subtenant.  This Sublease and Subtenant&#8217;s rights to the Subleased Premises shall be subject to the terms and provisions of the Master Lease.  Sublandlord warrants to Subtenant that (a) the Master Lease has not been amended or modified, and (b) Sublandlord has not received any notice of Default under the Master Lease which has not been cured.  So long as Subtenant is not in Default of this Sublease, Subtenant may quietly enjoy the Subleased Premises for the term of this Sublease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:46px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">3.</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(a)&#160;&#160;&#160;&#160;This Sublease is contingent upon Master Landlord consenting to this Sublease in accordance with the terms of the Master Lease.  This Sublease shall commence on the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Commencement </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Date</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;, which shall be the later to occur of (i) the date upon which Master Landlord consents to this Sublease in writing pursuant to that certain Consent to Subletting (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Consent to Subletting</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) to be entered into by Master Landlord, Sublandlord and Subtenant (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Consent Date</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), or (ii) Sunday, December 2, 2018 (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Target Date</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), or (iii) the date on which Sublandlord delivers possession of the Subleased Premises to Subtenant.  The term of this Sublease (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) shall be from the Commencement Date until Monday, January 20, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Expiration Date</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(b)&#160;&#160;&#160;&#160;Notwithstanding the forgoing, in the event Master Landlord has not provided the form of Consent to Subletting to Sublandlord and Subtenant on or before Monday, December 17, 2018 (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Outside Date</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), each of Sublandlord and Subtenant shall have the right to terminate this Sublease by delivering written notice of such termination to the other party, on or after Tuesday, December 18, 2018; provided, however, in the event the Consent to Subletting is ultimately provided by Master Landlord after the Outside Date but before either Sublandlord or Subtenant have delivered a termination notice to the other, such right to terminate shall automatically expire and no longer be available to either of Sublandlord or Subtenant, and this Sublease shall continue as contemplated herein.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(c)&#160;&#160;&#160;&#160;If Sublandlord, for any reason whatsoever, cannot deliver possession of the Subleased Premises to Tenant on or before the Target Date, this Sublease shall not be void or voidable nor shall Sublandlord be liable to Subtenant for any resulting loss or damage.  However, Subtenant shall not be liable for the payment of any rent until the Commencement Date occurs as provided in </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section 3(a)</font><font style="font-family:inherit;font-size:11.5pt;">&#32;above.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(d)&#160;&#160;&#160;&#160;Sublandlord and Subtenant acknowledge and agree that the Expiration Date is intentionally scheduled to be earlier than the date upon which the Master Lease expires, so as to allow Sublandlord time to remove telecommunication cabling and prepare the Subleased Premises for surrender to Master Landlord after Subtenant has vacated, but prior to expiration of the Master Lease.  Notwithstanding the foregoing, so long as Subtenant is not in default hereunder, in the event that Subtenant and Master Landlord enter into a new direct lease for the Subleased Premises that will commence immediately following the expiration of the Master Lease, and Master Landlord affirmatively releases Sublandlord in writing from any obligation to remove the telecommunication cabling and any other improvements from the Subleased Premises, Sublandlord and Subtenant shall enter into an amendment to this Sublease to change the Expiration Date to be commensurate with the expiration of the Master Lease.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, this Sublease shall automatically terminate (without liability of Sublandlord to Subtenant therefor) if and when the term of the Master Lease terminates for any reason.  Any hold over beyond the termination of this Sublease shall only be permitted (i) with the prior written consent of Sublandlord, which consent may be withheld in Sublandlord&#8217;s sole discretion, and (ii) in accordance with the provisions of </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section&#160;15.1</font><font style="font-family:inherit;font-size:11.5pt;">&#32;of the Master Lease, which shall apply to any such hold over.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(f)&#160;&#160;&#160;&#160;In the event the Consent Date occurs prior to the Target Date, Sublandlord shall provide Subtenant with a license for non-exclusive, shared access to the Subleased Premises on Saturday, December 1, 2018 (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Early Access Day</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), subject to the following terms and conditions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(i)&#160;&#160;&#160;&#160;Subtenant and Subteant&#8217;s contractors, subcontractors and employees shall work in harmony and not interfere with Sublandlord and Sublandlord&#8217;s agents shared use of the Subleased Premises during the Early Access Day, and Subtenant hereby acknowledges that Sublandlord </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 2</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">will likely be in the process of removing Sublandlord&#8217;s personal property from the Subleased Premises on the Early Access Day; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(ii)&#160;&#160;&#160;&#160;In the event Subtenant&#8217;s entry causes disharmony or interfere with the work being performed by Sublandlord, Sublandlord may notify Subtenant that the Commencement Date is being extended for the one (1) additional day to allow Sublandlord time to complete its moving activities due to any delay caused by Subtenant&#8217;s entry on the Early Access Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(iii)&#160;&#160;&#160;&#160;Sublandlord shall permit Subtenant and its agents to enter the Subleased Premises on the Early Access Day, subject to compliance by Subtenant with the terms and conditions of this Sublease and the Master Lease, including, but not limited to, all requirements imposed by Master Landlord on third party contractors, including without limitation the maintenance by Subtenant and its contractors and subcontractors of workers&#8217; compensation and public liability and property damage insurance in accordance with the Master Lease, with certificates of such insurance being furnished to Sublandlord and Master Landlord prior to proceeding with any such entry on the Early Access Date;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(iv)&#160;&#160;&#160;&#160;The entry shall be deemed to be under all of the provisions of this Sublease except as to the covenant to pay rent; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(v) &#160;&#160;&#160;&#160;Sublandlord shall not be liable in any way for any injury, loss or damage which may occur to any such work being performed by Subtenant, the same being solely at Subtenant's risk.&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:46px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">4. &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Insurance Certificates</font><font style="font-family:inherit;font-size:11.5pt;">.  Subtenant shall maintain and deliver to Sublandlord certificate(s) of insurance evidencing the insurance required pursuant to </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section 10.1</font><font style="font-family:inherit;font-size:11.5pt;">&#32;and </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Exhibit D</font><font style="font-family:inherit;font-size:11.5pt;">&#32;</font><font style="font-family:inherit;font-size:11.5pt;">of the Master Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:46px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Rent</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">Commencing on the Commencement Date, Subtenant shall pay monthly base full service gross rent (&#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Monthly Base Rent</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) to Sublandlord during the term of this Sublease, without offset, deduction or abatement, which Monthly Base Rent shall be in the amount of Sixty-Five Thousand and No/100 Dollars ($65,000.00).  Monthly Base Rent for any partial month at the beginning or the end of the term of this Sublease shall be prorated on the basis of a 30-day month. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">In addition to Monthly Base Rent, Subtenant is responsible for the payment of the following:  (i) the Parking Charges (as defined in </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section 14</font><font style="font-family:inherit;font-size:11.5pt;">, below), (ii) the actual expenses incurred by Sublandlord for any additional services requested by Subtenant that are to be provided by Master Landlord (i.e., if Subtenant requests the use of after-hours HVAC, such after-hours HVAC charges and assessments which are charged by Master Landlord to Sublandlord shall be payable to Sublandlord by Subtenant); (iii) any charges permitted by and pursuant to the Sublease or the Master Lease as a result of actions or omissions of the Subtenant; and (iv) any actual and direct expenses Sublandlord incurs by reason of Subtenant&#8217;s non-performance of its obligations under this Sublease (collectively, &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Additional Rent</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).  All such amounts shall be payable in full by Subtenant as directed by Sublandlord within ten (10) days after submission of a written invoice therefor by Sublandlord to Subtenant, and such obligations shall survive the expiration or earlier termination of this Sublease. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 3</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">Notwithstanding Subtenant&#8217;s obligation to pay Additional Rent, Sublandlord and Subtenant hereby acknowledge and agree that Subtenant shall not be responsible for separate payment of Operating Expenses under the Master Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">Monthly Base Rent, Additional Rent and all other costs and expenses payable hereunder by Subtenant shall be referred to collectively as &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">rent</font><font style="font-family:inherit;font-size:11.5pt;">.&#8221;  All Monthly Base Rent payments shall be paid to Sublandlord on a monthly basis and are due and payable in advance on the first day of each month.  All other rent (including Additional Rent) shall be paid to Sublandlord within ten (10) days after Sublandlord&#8217;s written demand therefor.  Sublandlord may impose a late charge of five percent (5%) of the amount due or $100, whichever is greater, for any rent payment not received on the date due.  In addition, all amounts not paid by Subtenant when due shall bear interest at the rate of ten percent (10%) per annum until paid.  As a cumulative and non-exclusive remedy, Sublandlord may also treat failure to pay on the first day of a month the Monthly Base Rent payment for such month as a Default by Subtenant, and shall be entitled to any and all remedies for such Default.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">First Month&#8217;s Rent and Security Deposit</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:11.5pt;">Upon execution of this Sublease, Subtenant shall deliver to Sublandlord (a) one (1) full month of Monthly Base Rent for the first month of the term of this Sublease, and (b) a security deposit in the amount of One Hundred Thirty Thousand and No/100 Dollars ($130,000.00) (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Security Deposit</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).  The Security Deposit shall be held by Sublandlord as security for the performance by the Subtenant of its obligations under this Sublease.  The Security Deposit shall be retained by the Sublandlord for the entire Term of this Sublease.  Upon any breach of Subtenant&#8217;s obligations under this Sublease, Sublandlord may apply all or a portion of the Security Deposit as full or partial satisfaction of same.  If any portion of the Security Deposit is so applied, Subtenant shall deposit with Sublandlord an amount sufficient to restore the Security Deposit to its original amount.  So long as Subtenant has satisfied all of its obligations under this Sublease, the Security Deposit shall be returned to the Subtenant within thirty (30) days of the expiration of the Sublease, the return of all keys, fobs and parking transponders to Sublandlord, and the Subleased Premises is vacated in &#8220;broom clean&#8221; condition, with any such restoration of improvements made by Subtenant completed to the satisfaction of Master Landlord, if so required by Master Landlord in connection with the approval of such improvements to be made by Subtenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Condition of the Subleased Premises</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;On the Commencement Date, Sublandlord shall deliver the Subleased Premises in substantially the same condition the Subleased Premises are in on the date hereof.  Subtenant represents and warrants that Subtenant has inspected the Subleased Premises, and has independently determined that the Subleased Premises are suitable for its intended uses.  SUBTENANT ACCEPTS THE SUBLEASED PREMISES &#8220;AS IS, WHERE IS,&#8221; WITHOUT REPRESENTATION OR WARRANTY BY SUBLANDLORD, EXPRESS OR IMPLIED.  Sublandlord shall not be required to make any improvements or repairs to the Subleased Premises, or to provide any tenant improvement or other allowance to Subtenant.  Subtenant shall have no obligation to make any capital repairs or replacements in the Subleased Premises except to the extent necessary to repair or replace any aspect of the Subleased Premises damaged beyond reasonable wear and tear as a result of any act or omission of Subtenant or its employees, agents, contractors, visitors, licensees or invitees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Use of the Subleased Premises; Signage</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Subtenant shall use the Subleased Premises only for general office purposes and in compliance with </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section&#160;5.1</font><font style="font-family:inherit;font-size:11.5pt;">&#32;of the Master Lease.  Subject to approval of Master Landlord, which may or may not be provided pursuant to the Master Lease, and solely at the cost and expense of Subtenant, Subtenant shall have the right to (a) have the name of </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 4</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Subtenant included in the electronic directory of the Building located in the lobby of the Building in place of Sublandlord&#8217;s listing in such directory, and (b) affix Subtenant&#8217;s name on the signage maintained adjacent to the entry door of the Premises and/or in the elevator bay on the floor of the Premises, in accordance with the Master Lease.  In addition to the indemnities set forth in the Master Lease, Subtenant shall indemnify, defend and hold Sublandlord and Master Landlord harmless from and against any and all claims, losses, damages and expenses, including clean-up costs and reasonable attorneys&#8217; fees and expenses, incurred by or asserted against Sublandlord or Master Landlord and arising from or relating to (a) any breach or Default by Subtenant under this Sublease, (b) any act or omission of Subtenant or its employees, agents, contractors, visitors, licensees or invitees, or (c) the introduction or use by Subtenant of hazardous or toxic materials, as such materials may be identified in any federal, state or local law or regulation (&#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Hazardous Substances</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) on or about the Subleased Premises, except to the extent such claims, losses, damages and expenses arise from the negligence or willful misconduct of Sublandlord or Master Landlord, or their respective agents, servants or employees.  Subtenant hereby assumes all risk of damage to the property of Subtenant in, upon or about the Subleased Premises arising from any cause, and Subtenant hereby waives all claims in respect thereof against Sublandlord and Master Landlord, except for any claims resulting from the negligence or willful misconduct of Sublandlord or Master Landlord, as the case may be.  Notwithstanding the foregoing, in no event shall Sublandlord or Master Landlord be liable under any circumstance for a loss of, or injury to Subtenant&#8217;s business, including, without limitation, lost profits.  Subtenant shall not use any Hazardous Substances in, on or about the Subleased Premises in a manner that would constitute a breach or violation of any applicable laws or regulations, or the terms and provisions of the Master Lease.  Subtenant shall obtain and maintain, at Subtenant&#8217;s sole cost, all permits, licenses and approvals required under any applicable laws or regulations for the use, storage or disposal of any Hazardous Substances which are used on or about the Subleased Premises.  Following Subtenant&#8217;s vacation of the Subleased Premises, and prior to the expiration of the term of this Sublease, Subtenant and Sublandlord will conduct an inspection of the Subleased Premises.  Subtenant acknowledges that Subtenant shall not have access to nor use of any portion of the roof of the Building. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Alterations</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;In addition to, and without limitation of the restrictions and limitations on alterations, additions or improvements as set forth in the Master Lease, Subtenant shall not make any improvements, alterations, additions, changes or modifications to the Subleased Premises (collectively, &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Alterations</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) without the prior written consent of Sublandlord and Master Landlord; provided, however, subject to the terms and conditions of this Section 9, Sublandlord will not unreasonably withhold its consent if Master Landlord grants consent pursuant to the terms and conditions of the Master Lease.  In the event Master Landlord approves any Alterations requested by Subtenant, but deems the same to be Alterations that will be Required Removables (as defined below), Sublandlord will not unreasonably withhold its consent to same so long as Subtenant delivers to Sublandlord a supplemental security deposit in an amount reasonably satisfactory to Sublandlord to cover the estimated cost for Subtenant to remove such Required Removables and restore the Subleased Premises to the condition required by Master Landlord upon the expiration of the Master Lease (the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Supplemental Security Deposit</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), which Supplemental Security Deposit shall be returned to Subtenant upon Subtenant&#8217;s removal of such Required Removables and restoration of the Subleased Premises to its previous condition on or prior to the Expiration Date to the satisfaction of Master Landlord.  To the extent any such removal or restoration is not performed by Subtenant on or prior to the Expiration Date, Sublandlord shall have the right to perform such removal and restoration and apply all or a portion of the Supplemental Security Deposit to Sublandlord&#8217;s actual cost and expense incurred in performing such removal and restoration on behalf of Subtenant, and Sublandlord shall return to Subtenant any unapplied portion of the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 5</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Supplemental Security Deposit within thirty (30) days after to the Expiration Date, subject to Subtenant also satisfying any hold over liability for failing to timely perform the restoration prior to the Expiration Date.  Should Master Landlord consent to Subtenant performing any Alterations work that would necessitate any ancillary Building modification or other expenditure by Master Landlord, then Subtenant shall promptly fund the cost thereof to Master Landlord upon request by Master Landlord.  Subtenant shall be responsible for obtaining all required permits for the Alterations and shall perform the work in compliance with all applicable laws, regulations and ordinances with contractors reasonably acceptable to Master Landlord and Sublandlord, and Master Landlord shall be entitled to any supervision fee provided for under the Master Lease.  Any request for consent from Sublandlord and Master Landlord shall be made in writing and shall contain architectural plans describing the work in detail reasonably satisfactory to Sublandlord and Master Landlord.  Sublandlord and/or Master Landlord may elect to cause their own architects to review Subtenant&#8217;s architectural plans, and the reasonable cost of that review shall be reimbursed by Subtenant.  Should the Alterations proposed by Subtenant and consented to by Sublandlord and Master Landlord change the floor plan of the Subleased Premises, then Subtenant shall, at its expense, furnish Sublandlord and Master Landlord with as-built drawings and CAD disks compatible with Master Landlord&#8217;s systems.  Alterations shall be constructed in a good and workmanlike manner using materials of a quality reasonably approved by Sublandlord and Master Landlord.  Unless Sublandlord and Master Landlord otherwise agree in writing, all Alterations affixed to the Subleased Premises, but excluding moveable trade fixtures and furniture, shall become the property of Master Landlord and shall be surrendered with the Subleased Premises at the end of the Term, except that Master Landlord may require Subtenant to remove by the Expiration Date, or sooner termination date of this Sublease, all or any Alterations installed either by Subtenant or by Sublandlord or Master Landlord at Subtenant&#8217;s request (collectively, the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Required Removables</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), and to restore the Subleased Premises to the condition that existed as of the Commencement Date of this Sublease.  At the time Subtenant requests approval for any proposed Alterations, Sublandlord shall submit such request to Master Landlord or reasonably cooperate with the submittal of such request by Subtenant directly to Master Landlord and shall advise Subtenant in writing as to which portions of the subject Alterations are Required Removables as required by Master Landlord.  In connection with its removal of Required Removables, in addition to delivering the supplemental security to Sublandlord as contemplated above, Subtenant shall repair any damage to the Subleased Premises arising from that removal and shall restore the affected area to its pre-existing condition, reasonable wear and tear excepted.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Maintenance</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Except for those obligations of Master Landlord under the Master Lease, Subtenant shall maintain the Subleased Premises and all property contained therein in good and clean order and condition and in every respect as required by the Master Lease.  At the expiration or earlier termination of the term of this Sublease, Subtenant shall surrender the Subleased Premises to Sublandlord in good condition and repair, ordinary wear and tear excepted, and in the condition required for the surrender of same under the provisions of the Master Lease.  In addition, and without limitation of the foregoing, Subtenant shall (a) if Master Landlord so requires, remove any Required Removables made by Subtenant to the Subleased Premises and repair any damage caused by such removal, and (b) if Sublandlord shall so request, leave any Alterations made by Subtenant to the Subleased Premises, except for any trade fixtures or personal property installed or placed by Subtenant in the Subleased Premises.  Subtenant shall have no obligation to remove any improvements that are located in the Subleased Premises as of the date of this Sublease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Utilities; Other Costs</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Sublandlord and Subtenant acknowledge and agree that the Monthly Base Rent includes Subtenant&#8217;s use or consumption of water, electricity, heat and air </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 6</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">conditioning and other utilities supplied to the Subleased Premises.  Sublandlord shall have no liability or responsibility for, and there shall be no abatement of rent with respect to any interruption of any utility, telephone or other services to the Premises.  Additionally, while Subtenant shall have no liability or responsibility for payment or reimbursement of Sublandlord&#8217;s monthly share of Operating Expenses as Tenant under the Master Lease, Subtenant shall be responsible for payment of Additional Rent to Sublandlord to the extent Sublandlord incurs additional expense under the Master Lease pursuant to Subtenant&#8217;s request for after-hour services and/or electric current in excess of that which is furnished to the Premises as part of Tenant&#8217;s Share of Operating Expenses under the Master Lease.  Sublandlord and Subtenant will each use commercially reasonable efforts to coordinate with Master Landlord for the delivery of utilities to be supplied to the Subleased Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Assignment/Subletting</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">Subtenant shall not transfer, assign, encumber or sublet (collectively, &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Transfer</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;) all or any portion of the Subleased Premises or its interest under this Sublease, directly or indirectly, by operation of law or otherwise, or permit the Subleased Premises to be occupied by anyone other than Subtenant, without the prior written consent of both Sublandlord and Master Landlord, which consent may be given or withheld in their respective sole discretion. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;">For purposes of this Sublease, the term &#8220;Transfer&#8221; shall also include any transfer of shares by sale, assignment, bequest, inheritance, operation of law or other disposition (including such a transfer to or by a receiver or trustee in federal or state bankruptcy, insolvency or other proceeding) resulting in a change in the control of Subtenant or any of its parent companies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Casualty or Taking</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;In the event of any casualty or the exercise or threatened exercise of the power of eminent domain, any rights to damages or compensation relating to any improvements installed by Sublandlord, or which Sublandlord may require remain in the Subleased Premises on termination of this Sublease, shall belong to Sublandlord in all cases, and Subtenant may elect to terminate the Sublease.  Any condemnation award for any improvements paid for by Subtenant, to the extent Subtenant has the right to remove same from the Subleased Premises on the termination of the term of this Sublease, may be claimed by Subtenant, subject to any rights of Master Landlord under the Master Lease.  Subtenant shall have no obligation to restore any portion of the Premises in the event of any damage, destruction or eminent domain with respect to any portion of the Premises, except in the event any such damage or destruction is a result of any act or omission of Subtenant or its employees, agents, contractors, visitors, licensees or invitees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">14.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Parking</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:11.5pt;">On the terms and subject to the conditions set forth in the Master Lease, Subtenant may sublease from Sublandlord for the term of this Sublease, up to twenty-three (23) unreserved parking stalls (each, an &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Unreserved Stall</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;, and referred to in the Master Lease as a &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Parking Pass</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), and up to twenty-one (21) reserved parking stalls (each, a &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Reserved Stall</font><font style="font-family:inherit;font-size:11.5pt;">&#8221; and collectively with each Unreserved Stall referred to in this Sublease as a &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Parking Stall</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;), at the rate of $75.00 per Parking Pass per month, and $140.00 per Reserved Stall per month, in addition to the Additional Transponder Costs (as defined below), if any.  For the purpose of this Sublease, the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Additional Transponder Costs</font><font style="font-family:inherit;font-size:11.5pt;">&#8221; shall mean the cost charged by Master Landlord to Sublandlord to issue to Sublandlord, for the use of Subtenant, any additional parking transponders, at the rate charged by Master Landlord for such parking transponders.  Subtenant will only be obligated to pay the Additional Transponder Costs in the event Subtenant requests the use of more than thirty-seven (37) Parking Stalls, which amount corresponds to </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 7</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">the number of parking transponders currently in Sublandlord&#8217;s possession.  For clarity, a parking transponder is needed for each Parking Stall, and while Sublandlord has the right to twenty-three (23) Unreserved Stalls and twenty-one (21) Reserved Stalls, as of the date of this Sublease, Sublandlord is only in possession of thirty-seven (37) parking transponders, since Sublandlord is not currently utilizing all of the Parking Stalls allocated under the Master Lease.  To Sublandlord&#8217;s knowledge, Master Landlord currently charges $35.00 for each new parking transponder issued to a tenant in the Building, but the Additional Transponder Costs will be the amount then charged by Master Landlord at the time such transponders are requested by Subtenant.  The location of the Parking Stalls is subject to Master Landlord and the terms of the Master Lease.  On or before November 15, 2018, Subtenant shall notify Sublandlord in writing as to how many Parking Passes and Reserved Stalls desired by Subtenant for the month during which the Commencement Date occurs, up to the amounts listed above (such requested amount to be referred to collectively as the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Subleased Parking</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).  The aggregate monthly charges for the Subleased Parking is referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Parking Charges</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;; provided, however, the Additional Transponder Costs will be a one-time charge per transponder, not a recurring monthly cost.  The monthly Parking Charges for the Subleased Parking shall be paid by Subtenant to Sublandlord on the first of the month, in addition to the Monthly Base Rent.  To the extent the Commencement Date does not occur on the first of the month, the Parking Charges for the partial initial month of the Term shall be prorated for the number of days in such month, and such prorated Parking Charges shall be paid within five (5) days following the Commencement Date.  The monthly Parking Charges are subject to increase in the event parking costs are increased under the Master Lease.  To the extent Subtenant desires more parking than the Parking Stalls allocated to Sublandlord pursuant to the Sublease, Sublandlord and Subtenant will each use commercially reasonable efforts to coordinate with Master Landlord for the procurement of additional Parking Spaces for Subtenant&#8217;s use, subject to availability and the current terms and conditions imposed by Master Landlord on such additional parking.  To Sublandlord&#8217;s knowledge, Master Landlord currently charges $95.00 for each Unreserved Stall.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">15.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Use of FF&amp;E</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:11.5pt;">Sublandlord hereby agrees to leave in the Subleased Premises, for the benefit and use by Subtenant during the Term at no additional cost to Subtenant, those certain items of furniture, fixtures and equipment expressly listed on </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11.5pt;">&#32;attached hereto and incorporated herein (&#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">FF&amp;E</font><font style="font-family:inherit;font-size:11.5pt;">&#8221;).  Subtenant hereby agrees to maintain such FF&amp;E in good condition and repair, and not remove such FF&amp;E from the Subleased Premises.  Notwithstanding the foregoing, so long as Subtenant is not in default under this Sublease upon the Expiration Date, Subtenant agrees to purchase the FF&amp;E from Sublandlord for One and No/100 Dollar ($1.00) and remove the same from the Subleased Premises on or prior to the Expiration Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">16.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Default</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Article 14</font><font style="font-family:inherit;font-size:11.5pt;">&#32;of the Master Lease is incorporated herein, except that, for the purpose of such incorporation, the term &#8220;Lease&#8221; shall be deemed to refer to this Sublease, the term &#8220;Landlord&#8221; shall refer to Sublandlord, and the term &#8220;Tenant&#8221; shall refer to Subtenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">17.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Compliance with Terms of Master Lease</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;This Sublease is subject to the terms and conditions of the Master Lease and the matters to which the Master Lease are subject and subordinate pursuant to the terms thereof.  Except as provided in this Sublease or with respect to provisions of this Sublease which are expressly inconsistent with or which modify the Master Lease, Subtenant and Sublandlord shall comply with and perform all terms, covenants and conditions of the Master Lease as if Subtenant were the &#8220;Tenant&#8221; thereunder, and as if Sublandlord were the &#8220;Landlord&#8221; thereunder, including, but not limited to, all indemnity obligations, waivers, covenants and agreements in favor of the Master Landlord contained in the Master Lease, as same may be accruing from and after the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 8</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Commencement Date, but Subtenant shall be required to perform such terms, covenants and conditions only to the extent such terms, covenants and conditions relate to the Subleased Premises and to the Sublease Term and to the extent not inconsistent with the terms of this Sublease, and the same shall be incorporated in, and applicable to this Sublease by this reference, and shall inure to the benefit of the Master Landlord as if Sublandlord were &#8220;Landlord&#8221; under the Master Lease.  Sublandlord shall not be required to perform the obligations of the Master Landlord under the Master Lease, and shall have no liability to Subtenant arising from or related to Master Landlord&#8217;s failure to perform any of their respective obligations under the Master Lease.  Notwithstanding anything in this </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section 17</font><font style="font-family:inherit;font-size:11.5pt;">&#32;to the contrary, Sublandlord shall not be deemed or construed to have undertaken any obligation or liability of the &#8220;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:11.5pt;">&#8221; under the Master Lease.  Neither Subtenant nor Sublandlord shall take any action, nor consent to or permit any action to be taken by any of such party&#8217;s employees, agents, contractors, licensees or invitees, that would cause a Default under any provision of the Master Lease.  In the event of any conflict between this Sublease and the Master Lease, as between Sublandlord and Subtenant, the terms of this Sublease shall control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">18.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Time of Essence</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Time is of the essence of this Sublease and each of its provisions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">19.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Partial Invalidity</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;If any term, provision or condition contained in this Sublease shall, to any extent, be invalid or unenforceable, the remainder of this Sublease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Sublease shall be valid and enforceable to the fullest extent possible permitted by law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">20.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;This Sublease shall be construed and enforced in accordance with the laws of the State of California.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">21.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Brokers</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Both parties warrant and represent to each other that no broker has acted as a broker in this transaction except for Allison Schneider Kelly of CBRE as Sublandlord&#8217;s broker, and Michael Lewis of Hughes Marino as Subtenant&#8217;s broker, each of which shall be compensated pursuant to a separate agreement.  Accordingly, both parties further warrant and represent to each other, except for the brokers identified in the preceding sentence, no brokers are entitled to any commission, finder&#8217;s fee, compensation, or remuneration of any type, kind, or nature.  Each party agrees to indemnify and hold harmless the other party from any and all liability, responsibility, claims, damages, costs, and attorney&#8217;s fees of any kind or nature incurred or sustained by the indemnified party as the result of the claim by any broker, or any other party or entity for a commission or finder&#8217;s fee resulting from the activities or actions of the indemnifying party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">22.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Attorneys&#8217; Fees</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Should either Sublandlord or Subtenant bring any action in connection with this Sublease, the prevailing party shall be entitled to recover from the other party such costs and reasonable attorneys&#8217; fees as may have been incurred, including any and all costs incurred in enforcing, perfecting and executing any judgment.   Sublandlord or Subtenant shall each bear their own attorneys&#8217; fees and costs with regard to the negotiation and finalization of this Sublease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">23.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11.5pt;">&#32;&#32;Any notice required or given under this Sublease shall be in writing to each party at the address as set forth below, by hand delivery, electronic mail, overnight courier, or by certified mail, postage prepaid, return receipt requested, effective upon delivery to the address specified below.  The addresses of each party shall be changed by notice given the other party in accordance with the provisions of this </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Section 23</font><font style="font-family:inherit;font-size:11.5pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 9</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">To Sublandlord:&#160;&#160;&#160;&#160;Prior to Commencement Date:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Acacia Research Corporation</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">520 Newport Center Drive, Suite 1200</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Newport Beach, CA  92660</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Attn:  Darren Miller <br>Telephone:  (949) 480-8347</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E-mail:  </font><a style="font-family:inherit;font-size:11.5pt;color:#000000;text-decoration:none;" href="#"><font style="font-family:inherit;font-size:11.5pt;color:#000000;text-decoration:none;">dmiller@acaciares.com</font></a><font style="font-family:inherit;font-size:11.5pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:144px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">After to Commencement Date:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Acacia Research Corporation</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">__________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">__________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Attn:  Darren Miller <br>Telephone:  (949) 480-8347</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E-mail:  </font><a style="font-family:inherit;font-size:11.5pt;color:#000000;text-decoration:none;" href="#"><font style="font-family:inherit;font-size:11.5pt;color:#000000;text-decoration:none;">dmiller@acaciares.com</font></a><font style="font-family:inherit;font-size:11.5pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">With a copy at all times to:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stuart Kane LLP</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">620 Newport Center, Suite 200</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Newport Beach, California  92660</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Attn:  Josh C. Grushkin</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Telephone:  949-791-5151</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E-mail:  </font><a style="font-family:inherit;font-size:11.5pt;color:#000000;text-decoration:none;" href="#"><font style="font-family:inherit;font-size:11.5pt;color:#000000;text-decoration:none;">jgrushkin@stuartkane.com</font></a><font style="font-family:inherit;font-size:11.5pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:11.5pt;">To Subtenant:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Prior to Commencement Date:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:11.5pt;">Evolus, Inc. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">17901 Von Karman Ave., Suite 1500</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Irvine, California 92614</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Attn:  Legal <br>Telephone:  ________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E-mail:  ___________________ </font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">After Commencement Date: </font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">520 Newport Center Drive, Suite 1200</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Newport Beach, CA  92660</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Attn:  _____________________ <br>Telephone:  ________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E-mail:  ___________________ </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 10</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">With a copy at all times to:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">__________________________ <br>__________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">__________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Attn:  _____________________ <br>Telephone:  ________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E-mail:  ___________________ </font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">24.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;text-decoration:underline;">No Agency</font><font style="font-family:inherit;font-size:11.5pt;">.&#160;&#160;&#160;&#160;Neither party shall hold itself out as an agent or affiliate of the other Party and neither Party shall purport to bind the other to any contract or commitment. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">[SIGNATURES APPEAR ON FOLLOWING PAGE]</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 11</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">IN WITNESS WHEREOF, the parties have executed this Sublease as of the date first set forth above.</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:8px;font-size:11.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">SUBLANDLORD:</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">ACACIA RESEARCH CORPORATION, </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:11.5pt;">a Delaware corporation </font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">By:</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">/s/ Marc W. Booth</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Name: </font><font style="font-family:inherit;font-size:11.5pt;">&#160;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Marc W. Booth</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Title: </font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">Chief IP Officer</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">SUBTENANT:</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">EVOLUS, INC., </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:11.5pt;">a Delaware corporation </font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">By:</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">/s/ David Moatazedi</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Name: </font><font style="font-family:inherit;font-size:11.5pt;">&#160;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">David Moatazedi</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Title: </font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">President &amp; CEO</font><font style="font-family:inherit;font-size:11.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:40px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div><a name="s5196CE71C9EAC9BF96F82A7053B84333"></a></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">FF&amp;E to Remain in the Subleased Premises</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">[Attached]</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:306px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">&#32;Page 12</font></div><div style="line-height:120%;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4510092v4 / 101022.0001</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit23112311810-k.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0EC272768F015ACC9CCA8DF1E8B28F03"></a></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;23.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">We consent to the incorporation by reference in the Registration Statement (Forms S-8 No. 333-223068 and 333-229184), pertaining to the 2017 Omnibus Incentive Plan of Evolus, Inc. of our report dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;20, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#333333;">with respect to the financial statements of Evolus, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:67.3076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:31%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Irvine, California&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;20, 2019</font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit31112311810k.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s92E8F6E6E04C5F218F48F45BDB44AC2F"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David Moatazedi, certify that:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a)];</font></div></td></tr></table><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March&#160;20, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit31212311810k.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4A1A2EF2B7F256D38BD307FE1F55BDEF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:138%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Lauren Silvernail, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:66px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a)];</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:33px;text-indent:-34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 20, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit32112311810k.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7C217F6D328052768C14F954205D1A7A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The undersigned hereby certifies, in accordance with 18 U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Evolus, Inc., that the Annual Report on Form&#160;10-K of Evolus, Inc. for the fiscal year ended December&#160;31, 2018 fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Evolus, Inc.</font></div><div style="line-height:138%;text-align:left;padding-left:33px;text-indent:-34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:44%;"></td><td style="width:5%;"></td><td style="width:5%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 20, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 20, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>eols-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:44077D4402115DC19D7DE9210A16237E,x:eb84c6d488d84329978d4e4a53e4c76e-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eols="http://www.evolus.com/20181231" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="eols-20181231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Mar20">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul01-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_srt_OwnershipAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_dei_LegalEntityAxis_eols_OxfordFinanceLLCMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:OxfordFinanceLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-08-01</xbrli:startDate>
			<xbrli:endDate>2018-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassAAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eols:CommonClassAAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eols:CommonClassDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct2013">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_OtherTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:OtherTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_OtherTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:OtherTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_CompensationAndBenefitTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:CompensationAndBenefitTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_StockBasedCompensationTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:StockBasedCompensationTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_FacilityRelatedTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:FacilityRelatedTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_FacilityRelatedTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:FacilityRelatedTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_ThirdPartyServiceFeesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:ThirdPartyServiceFeesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_CompensationAndBenefitTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:CompensationAndBenefitTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_ThirdPartyServiceFeesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:ThirdPartyServiceFeesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_StockBasedCompensationTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eols:StockBasedCompensationTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-Jan31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-14</xbrli:startDate>
			<xbrli:endDate>2017-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-30</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2April_us-gaap_DebtInstrumentAxis_eols_PurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eols_ChiefMedicalOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eols:ChiefMedicalOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_eols_BridgeNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:BridgeNoteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-Jan31_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_eols_PurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec14_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-14</xbrli:startDate>
			<xbrli:endDate>2017-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2April30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eols:CommonClassDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_OtherCommitmentsAxis_eols_DaewoongMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">eols:DaewoongMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-21</xbrli:startDate>
			<xbrli:endDate>2017-11-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheOneMember_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VariableRateAxis_eols_ApplicableRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:ApplicableRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb01_dei_LegalEntityAxis_eols_DaewoongMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:DaewoongMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="transaction">
		<xbrli:measure>eols:transaction</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="unit">
		<xbrli:measure>eols:unit</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>eols:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q4YTD" id="Fact-6E94BF70697B87C8ADB52E344812B677">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q4YTD" id="Fact-1361B2E9A8C4042D705A2E344FF20FC7">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q4YTD" id="Fact-773ECF7810F89EC7C63B2E344B648124">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q4YTD" id="Fact-9B5F7DC96874ACB932B42E344A43FBDD">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q4YTD" id="Fact-EE8373AC59D7963FB04F2E344921BAD2">2018-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q4YTD" id="Fact-4203C2B2B1C0B1B7E9A82E344729BF7B">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q4YTD" id="Fact-53BC5A155D1ED39EAC2E2E344EC606A4">0001570562</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q1Mar20" decimals="INF" id="Fact-AC2D0C998B2E152949A82E3452ADEF0B" unitRef="shares">27274991</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2018Q4YTD" id="Fact-0F7C9FDBE116541CDB114DDBA07A8841">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q4YTD" id="Fact-6538A31EE2575F0AB5702E3486759C09">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2018Q4YTD" id="Fact-A1946ED0E40A5223FB5B2E3487A9A54D">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2018Q4YTD" id="Fact-3362BBC41F77A823B7272E34510EAA69">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2018Q2" decimals="-5" id="Fact-7DA881181F7F6B10B7702E34DD25379A" unitRef="usd">141500000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2018Q4YTD" id="Fact-4A5F4643C83133DAE64F2E344DAA58EB">EVOLUS, INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2018Q4YTD" id="Fact-E04B2B730364E201378E2E3501C452B6">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2018Q4YTD" id="Fact-32B7F14CCF74E066AC112E3486FC358F">true</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2018Q4YTD" id="Fact-0B151BA91B2F53E26D924DDB636070D7">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q4YTD" id="Fact-720FD234E275956168664DDBC1A8A211">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="FD2018Q4YTD" id="Fact-92F266FB6B3BABBCBA692E344C7F0DE7">EOLS</dei:TradingSymbol>
	<eols:AccountsPayablePaidbyParent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-44DDB08C9682C0C8B6F82EAAADFACF0E" unitRef="usd">0</eols:AccountsPayablePaidbyParent>
	<eols:AccountsPayablePaidbyParent contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FE6B2FE56EE8F122F19F2EAAAC9C3F40" unitRef="usd">163000</eols:AccountsPayablePaidbyParent>
	<eols:BusinessAcquisitionUnwindingFee contextRef="D2017Q4Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-EC836DA95CA61E2C62DB2F59D07F856E" unitRef="usd">9600000</eols:BusinessAcquisitionUnwindingFee>
	<eols:BusinessCombinationLiquidatedDamages contextRef="FD2018Q4YTD" decimals="-5" id="Fact-AD7D29CEEAD8CE54267A2F5AACFF08E4" unitRef="usd">1000000</eols:BusinessCombinationLiquidatedDamages>
	<eols:BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval contextRef="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-A947069E9F9BB4807B838288275B0938" unitRef="usd">1600000</eols:BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval>
	<eols:BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded contextRef="FD2018Q4YTD" id="Fact-C9DAE7F595137CFDE7392F5A63B06F72">P30D</eols:BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded>
	<eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassDMember" decimals="-5" id="Fact-4B7A9EF72BF80420DD0C2F460DD1CFD2" unitRef="usd">10000000</eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval>
	<eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval contextRef="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-8568F6F804A45C3610672F53156DBBB1" unitRef="usd">9200000</eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval>
	<eols:BusinessCombinationUpfrontPaymentUponPurchaseAgreement contextRef="D2019Q1Feb01_dei_LegalEntityAxis_eols_DaewoongMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-7FEC45DEEDC13B7BDA018288998C7147" unitRef="usd">2000000</eols:BusinessCombinationUpfrontPaymentUponPurchaseAgreement>
	<eols:CapitalContributionConvertibleNoteWriteOff contextRef="FD2017Q4YTD" decimals="-3" id="Fact-80BB6E1C61BA3FF686A32EA9B30CEBFC" unitRef="usd">0</eols:CapitalContributionConvertibleNoteWriteOff>
	<eols:CapitalContributionConvertibleNoteWriteOff contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F7C18A9AE8C63DD109B02EA9B1AF9E5A" unitRef="usd">66998000</eols:CapitalContributionConvertibleNoteWriteOff>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CF3B748F62346D0B5DB22EA9B961EDD1" unitRef="usd">0</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-42B81F5957F8809BB8362EA9B76A40F1" unitRef="usd">13188000</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-5" id="Fact-2502AD6B165C34C68AAE81E47826C250" unitRef="usd">13200000</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B21853C8E1D7E85E663BA9D687CE2698" unitRef="usd">13188000</eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings>
	<eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-607E1E875FC4DD57421FA9D687C4C407" unitRef="usd">13188000</eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings>
	<eols:CapitalContributionTherapeuticOptionRightNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0FA64F93AC2C0DB32FE62EAA5EE8CABA" unitRef="usd">1505000</eols:CapitalContributionTherapeuticOptionRightNetOfTax>
	<eols:CapitalContributionTherapeuticOptionRightNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9A3D43E14FA3CA3CBD022EAA5EE35D77" unitRef="usd">0</eols:CapitalContributionTherapeuticOptionRightNetOfTax>
	<eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance contextRef="I2018Q4Nov21" decimals="INF" id="Fact-EF7E93AA71CDE5F2692781E6FDAAA3F0" unitRef="shares">1091000</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
	<eols:ContingentPromissoryNote contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D143DE56A5837B0AC5602EA9B0A06EB4" unitRef="usd">0</eols:ContingentPromissoryNote>
	<eols:ContingentPromissoryNote contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CD42D35A0BC4A74466202EA9AF4A893E" unitRef="usd">16042000</eols:ContingentPromissoryNote>
	<eols:ContingentRoyaltyObligation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-09890EF6468F669723912EA9AE329E63" unitRef="usd">0</eols:ContingentRoyaltyObligation>
	<eols:ContingentRoyaltyObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-927A627A89492C0D751E2EA9ACD5E582" unitRef="usd">39700000</eols:ContingentRoyaltyObligation>
	<eols:DebtInstrumentAdditionalAmortizationPeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-23ADEC1C6E399ABA8FC9829391346586">P11M</eols:DebtInstrumentAdditionalAmortizationPeriod>
	<eols:DebtInstrumentAdditionalAmountAuthorizedForIssuance contextRef="I2017Q2April_us-gaap_DebtInstrumentAxis_eols_PurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-DF8481EF23D82C8A3D9F2F3FC729A140" unitRef="usd">30000000</eols:DebtInstrumentAdditionalAmountAuthorizedForIssuance>
	<eols:DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-51A2F28B66176897B1C18292E7E89C25">P12M</eols:DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment>
	<eols:DebtInstrumentAmortizationPeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-134A2B814B401860088B8291CB7B52F4">P23M</eols:DebtInstrumentAmortizationPeriod>
	<eols:DebtInstrumentDefaultInterestRate contextRef="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VariableRateAxis_eols_ApplicableRateMember" decimals="INF" id="Fact-2E6ADF6B90D7C6D18B48829A53B43F41" unitRef="number">0.05</eols:DebtInstrumentDefaultInterestRate>
	<eols:DebtInstrumentNumberOfDebtTransactions contextRef="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-7B456E60E81CA5F5B4832F3D2C10A937" unitRef="transaction">2</eols:DebtInstrumentNumberOfDebtTransactions>
	<eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-369F8AE87F45F119869E82966DDE25C0" unitRef="number">0.055</eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment>
	<eols:DebtInstrumentPeriodOfInterestOnlyPayments contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-09EAAB625F6910AA48658290623741CF">P36M</eols:DebtInstrumentPeriodOfInterestOnlyPayments>
	<eols:DebtInstrumentPrepaymentFeePercentageNextTwelveMonths contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-0B0C4337FCD58DCFBCF88297AEAB82AB" unitRef="number">0.03</eols:DebtInstrumentPrepaymentFeePercentageNextTwelveMonths>
	<eols:DebtInstrumentPrepaymentFeePercentageThereafter contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-B8F3D0FECD1AA4ADD7B6829876825603" unitRef="number">0.01</eols:DebtInstrumentPrepaymentFeePercentageThereafter>
	<eols:DebtInstrumentPrepaymentFeePercentageYearTwo contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-F5EE70682EA6FA698F29829850FABD13" unitRef="number">0.02</eols:DebtInstrumentPrepaymentFeePercentageYearTwo>
	<eols:DebtInstrumentTermAggregatePeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-18B5159DC58B4403F61C8293ED710AC5">P48M</eols:DebtInstrumentTermAggregatePeriod>
	<eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C1C2AC2FC90AFC702C4AA9CEBB2B5C6A" unitRef="usd">1051000</eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable>
	<eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-01CF8C6591B791E05EC7A9CEBB27CD40" unitRef="usd">1051000</eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable>
	<eols:DeferredOfferingCostsAccruedUnpaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8CB616D8D6966CB6B2842EAC36F5E3D4" unitRef="usd">839000</eols:DeferredOfferingCostsAccruedUnpaid>
	<eols:DeferredOfferingCostsAccruedUnpaid contextRef="FD2018Q4YTD" decimals="-3" id="Fact-70DC294F90BD9F5DD2902EAC36EB591B" unitRef="usd">0</eols:DeferredOfferingCostsAccruedUnpaid>
	<eols:DeferredTaxAssetsPromissoryNoteDebtDiscount contextRef="FI2017Q4" decimals="-3" id="Fact-59CB010FD8878409179E7E21138DD772" unitRef="usd">0</eols:DeferredTaxAssetsPromissoryNoteDebtDiscount>
	<eols:DeferredTaxAssetsPromissoryNoteDebtDiscount contextRef="FI2018Q4" decimals="-3" id="Fact-D66425625B1C164C2B1E7E2113915384" unitRef="usd">108000</eols:DeferredTaxAssetsPromissoryNoteDebtDiscount>
	<eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2120D077EDDD5E43ED0B7E23C96AD9B4" unitRef="usd">0</eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount>
	<eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D69E96791EE64EF3D33B7E23C96E62F6" unitRef="usd">105000</eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount>
	<eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-978E929A41332B5458557E24D0642BA3" unitRef="usd">0</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
	<eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BFC871DB1AE7B781256E7E24D072FE96" unitRef="usd">2205000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
	<eols:InterestExpenseOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-954E850C42641224533B2E7D4E5508C1" unitRef="usd">0</eols:InterestExpenseOperatingActivities>
	<eols:InterestExpenseOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-277B42F9A95AEDEB38072E7D4D394542" unitRef="usd">863000</eols:InterestExpenseOperatingActivities>
	<eols:NonCashCapitalDistributionFromParent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CA2E2BE3CE3E760377E32EA9B64DC6D6" unitRef="usd">66048000</eols:NonCashCapitalDistributionFromParent>
	<eols:NonCashCapitalDistributionFromParent contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7D8BC1D17FDBB8A704832EA9B4298B7B" unitRef="usd">0</eols:NonCashCapitalDistributionFromParent>
	<eols:NonCashDeferredOfferingCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CF605E94218224536238A9E6636592AF" unitRef="usd">0</eols:NonCashDeferredOfferingCosts>
	<eols:NonCashDeferredOfferingCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8CD5AD4775DDDC36A193A9E6636A5BD7" unitRef="usd">2885000</eols:NonCashDeferredOfferingCosts>
	<eols:NonCashNoteObligation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2A280082D2CB2B2F61AA2EA9ABB12E60" unitRef="usd">138687000</eols:NonCashNoteObligation>
	<eols:NonCashNoteObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B020219404945384C11F2EA9AA1B3F83" unitRef="usd">-140688000</eols:NonCashNoteObligation>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2017Q4QTD_dei_LegalEntityAxis_eols_ALPHAEONMember" decimals="-5" id="Fact-9F2BD71E5FA1E68466117E11ADDE84BC" unitRef="usd">-2500000</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2017Q4YTD" decimals="-3" id="Fact-705B33E9D0550A0162942EA9A8F4043E" unitRef="usd">0</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F24BA767EB58E677A7062EA9A72741AD" unitRef="usd">68767000</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyReceivable contextRef="D2018Q1Feb12_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-DBBB2578276008CB5DEF7DFF62C316A2" unitRef="usd">73700000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="D2018Q1Jan1-Jan31_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-496C0A10E577D5811F787DFD534716B0" unitRef="usd">1100000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-49BBEF9001E092746BA52EA9A60D45A8" unitRef="usd">-72639000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D5E904BE6B6B777379F9975C1F6DC49B" unitRef="usd">73690000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-140315057871B85BA28D2EA9A4AA3773" unitRef="usd">73690000</eols:NonCashRelatedPartyReceivable>
	<eols:RelatedPartyBorrowingsandNonCashCapitalContribution contextRef="FD2017Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember" decimals="-5" id="Fact-E75D751EA088525BA6F17E04E829AB59" unitRef="usd">2500000</eols:RelatedPartyBorrowingsandNonCashCapitalContribution>
	<eols:RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote contextRef="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-47FED93AA444E42F701DAA00098F8360" unitRef="usd">16000000</eols:RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote>
	<eols:RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation contextRef="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-70C94A4A747F2E60768AA9FE604E30AE" unitRef="usd">39700000</eols:RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation>
	<eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" id="Fact-539A0E2359BAC6B5CE1D3375CC699D6F">P10Y</eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale>
	<eols:RelatedPartyTransactionPeriodofMaturityofPromissoryNote contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" id="Fact-9B1B245A1CE7DEBC0A962F5406D19935">P2Y6M0D</eols:RelatedPartyTransactionPeriodofMaturityofPromissoryNote>
	<eols:RelatedPartyTransactionRenewalPeriodOption contextRef="D2018Q1Jan1-Jan31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-B60A01801CC6D5A2F1A62F31E7333A30">P1Y</eols:RelatedPartyTransactionRenewalPeriodOption>
	<eols:RelatedPartyTransactionTermOfAgreement contextRef="D2018Q1Jan1-Jan31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-625D40FAA31F2AF615252F31B16D3A00">P1Y</eols:RelatedPartyTransactionTermOfAgreement>
	<eols:RelatedPartyTransactionTotalAmountsofTransaction contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-4DA8524C66ADF2E18E8F7DF8D00E9D9E" unitRef="usd">2000000</eols:RelatedPartyTransactionTotalAmountsofTransaction>
	<eols:RelatedPartyTransactionTotalAmountsofTransaction contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-5FF723D0473150E4F282AA0294210F1B" unitRef="usd">140700000</eols:RelatedPartyTransactionTotalAmountsofTransaction>
	<eols:RevaluationofContingentRoyaltyObligationPayabletoRelatedParty contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AF10B0D964E0BA0E365B2E7402DA7C26" unitRef="usd">0</eols:RevaluationofContingentRoyaltyObligationPayabletoRelatedParty>
	<eols:RevaluationofContingentRoyaltyObligationPayabletoRelatedParty contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5579E6D5CF59D56A06B92E7400B2470D" unitRef="usd">10500000</eols:RevaluationofContingentRoyaltyObligationPayabletoRelatedParty>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-7C1E6EECE6A1C907DF7B9868483097E0">P0Y</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-F8156B2BDB73A950A90282151EFF9813">P9Y0M7D</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-92F444A861F60DF00BB4821CD16CAAFF" unitRef="usd">1513000</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-AA7772498A7BF7494B8A82145F644640">P9Y3M29D</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F349B18128430A823EBC821D917910DE" unitRef="usd">8632000</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue>
	<eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C981FB266B0DF947D9D3A9C7A023355E" unitRef="shares">34602</eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q4YTD" decimals="-3" id="Fact-223691720FD6F2C4947DA9C837411013" unitRef="usd">-239000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C002CB8604A423C7FAD6A9C8372C43B3" unitRef="usd">-239000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockPurchaseAgreementPeriodAvailabletoCureBreach contextRef="D2017Q4Dec14_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-A3014E38B7A5A03B14C42F58402005DF">P30D</eols:StockPurchaseAgreementPeriodAvailabletoCureBreach>
	<eols:TaxBenefitFromTherapeuticOptionRight contextRef="FD2017Q4YTD" decimals="-3" id="Fact-ABEEE64DFBCD1EF3FC082E81F78221D4" unitRef="usd">996000</eols:TaxBenefitFromTherapeuticOptionRight>
	<eols:TaxBenefitFromTherapeuticOptionRight contextRef="FD2018Q4YTD" decimals="-3" id="Fact-75F526DC20D7126A4E432E8212571850" unitRef="usd">0</eols:TaxBenefitFromTherapeuticOptionRight>
	<eols:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CF7AC39E6A551F010A8C2F3697BFD2AC" unitRef="usd">-9600000</eols:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance>
	<eols:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-EA477CAB1A4704C583272F3F0CA09E44" unitRef="usd">-6300000</eols:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2C959C9F5F702129963E2E3A5377859C" unitRef="usd">445000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FD50527E72B00F2F5C1C2E3A518125FA" unitRef="usd">1558000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D1725AAA32BAA8AD1C552E3AB1531021" unitRef="usd">977000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-BE593B05591B89D901E52E3AAF76661D" unitRef="usd">3718000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-F010E6386F6EA9809F632F46C9DA54A3" unitRef="usd">868000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-89B7358B75BDB11C833F2F46C9F5E5A6" unitRef="usd">931000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-3" id="Fact-6196B191FD7602AF249A2E41B3CC1181" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-3" id="Fact-C8F34A0E70ECED1E70432E41B28678BD" unitRef="usd">207408000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-ABD4F1C8062C5F140BBBA9D51B464655" unitRef="usd">66998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7B987D988EC6D8E70308A9D51B6472DB" unitRef="usd">66998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B063CE878606E2FEDD272EBE45CC951E" unitRef="usd">1505000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AA9A089730BBEAB9BBCB2EBE45C9023A" unitRef="usd">1505000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-992B3081D907A2AE3B002EBD1162B70F" unitRef="usd">586000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7D37CDED606DDDFC3E5F2EBD11801248" unitRef="usd">586000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C98E0F783AABEE5E29C07DE5F59FAF8D" unitRef="usd">6971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="-5" id="Fact-070A9DB71A0D0AF6337D825D48F41F7C" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F852D874D843324E7B5A825C8A5B1BB0" unitRef="usd">586000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-554B5ACD1A11D6445846825C8509D572" unitRef="usd">551000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F737DC3085BE464F025B825C871AB82F" unitRef="usd">35000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-84969758D84FC4C6F2A4825C88294829" unitRef="usd">6971000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-8DB85AFA5E024EE6DB5482286A232EEB" unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-F552423D6BE609A72AD08257B85D324F" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-F7B570BC9419E8CC613E825C8358FC33" unitRef="usd">5570000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="-5" id="Fact-D7611330249CE503A77A825DEDA011E6" unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-FECCDF1D7220D1482F57825C85DAA35E" unitRef="usd">1401000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="2" id="Fact-6DED24ED1C72DC2F5F947E18C18DF9C3" unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="2" id="Fact-6274B9221521E0E56C4F7E18C172A7B7" unitRef="number">0.18</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="INF" id="Fact-F31818FD589AAD9B19177E1A1CBD14E3" unitRef="year">10</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="0" id="Fact-A9FD096CCAF3CBAD95B9A5958B457432" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-FE40DC3387730C845877A5958B2BBAAB" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-B108E7963EFAA04350A5A5958B5F86C8" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD" decimals="0" id="Fact-0FC153AD29375E8B97C9A5958B3A579B" unitRef="shares">3479093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-3330A78F9641623ACDA2967B42D5936C" unitRef="shares">3257801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-80896E5003E9A67B4B34A5958B502B46" unitRef="shares">221292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-112AEFF004A7E30217482E39C041BBBB" unitRef="usd">152233000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-DD76ACE4AE1B7ABF92DA2E39BE4923A9" unitRef="usd">171844000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-5D3BF9FE68BD8EF4AADF2E394844DA63" unitRef="usd">72824000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-1CAB79411239C1320BB02E39483A7EE8" unitRef="usd">94339000</us-gaap:AssetsCurrent>
	<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassAAMember" decimals="INF" id="Fact-E2C5AA1F222BDBF51B0633A9BA05EECF" unitRef="shares">15000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
	<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassDMember" decimals="INF" id="Fact-4B1CF4209A371481BC7933A9EC972CE4" unitRef="shares">15000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="INF" id="Fact-E70D1BBB7BCB1AA47B9C2F587DC4DD92" unitRef="number">0.5</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassDMember" decimals="-5" id="Fact-96B8AD54D71FC25103022F46C5D195FA" unitRef="usd">145000000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-704946CECAFB18A417F22E7E166B0B41" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-72FA42E81DD6C10CCDB52E7E1550D800" unitRef="usd">10500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-E126415734C36C23D4A72F161412D7A4" unitRef="usd">13500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-DAF7E9C6C954D389C11F2F1199D8FD34" unitRef="usd">20900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-FAAA893005CEADBC87042F1162398EEC" unitRef="usd">56100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-3D51F36D418CD94300132E38081682CB" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-1634CEBDC7A0549CFF0C2E3808165085" unitRef="usd">93162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="-3" id="Fact-B8DC63FD311C4331B5DE2EA8B1DBF815" unitRef="usd">187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-703CE3BB19034253D0E62EA8B09AE0B9" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-494CF751960A99E67DA12EA8B2CA4E4C" unitRef="usd">93162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A35755A2E65F7159E24E2EA8AF95AFC1" unitRef="usd">-187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CA8A67D2C244AC2B64A02EA8ADE12370" unitRef="usd">93162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-E09769469F3A2BD8EADE2E41080F81BA" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-4323E9A57431DC146E6D2E4106C647B2" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4" decimals="INF" id="Fact-AEBB78BCEF09FC0CF3A581E6FDB8FEDC" unitRef="shares">1888484</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-C2EB1B30BA070EB21DCD2E44AC862292" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-062E77F4B10F70AAC92D2E44ABDEBC43" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2018Q1Feb12" decimals="INF" id="Fact-C857871FAE345F316C8333951B26FB89" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-EC42123D4DC05B9499BC2E44ADD16621" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-64B3EA782D4529FBD4D02E44AD2F8245" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2018Q1Feb12" decimals="INF" id="Fact-58425B9B88D7FC566B383394F388F824" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-3FF96642708E7E6956262E44AF76FC9C" unitRef="shares">16527000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-8AB494C5BD5452D926612E44AEA4ACD4" unitRef="shares">27274991</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-DD60123A6D0A585ED8D72E44B0AF10B3" unitRef="shares">16527000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-2F06747A424565D400152E44B01B78BE" unitRef="shares">27274991</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-BA2BA71DBA302957C9872E41B1DB35B1" unitRef="usd">0</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-0D484CB18BC2DF7D5D0C2E41B095331D" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DEB46A4180BC599B55D62E7921889290" unitRef="usd">-4480000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0AE3CA0ACF0B093FDE4E2E791ED8DAA2" unitRef="usd">-46867000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractualObligation contextRef="FI2017Q4" decimals="-3" id="Fact-3D1CE82D1046AA37F2C22E41005FF615" unitRef="usd">0</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="FI2018Q4" decimals="-3" id="Fact-676B1995494CA4020D942E40FF47D4D6" unitRef="usd">50200000</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="I2018Q1Feb12" decimals="-5" id="Fact-575D7F08E30BFBE37E7281E3E1978947" unitRef="usd">39700000</us-gaap:ContractualObligation>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q1Feb12_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E2278A93A7ED5CF2A0583394C659F1AB" unitRef="shares">2065875</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-45918D278D86044985A82F03283267FE" unitRef="usd">-775000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-85D82BD8A569DE8651A82F03284D7B08" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-028BD6C231E293EC18B92F03A42535ED" unitRef="usd">-996000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9002E15A482C05B5A6D22F03A4216089" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FD5E6E232C966874F54E2F0353038C4B" unitRef="usd">-221000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6A6B2190847E5FBFDBB32F035308B09C" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="INF" id="Fact-1DFC4266982EDDCDCE72828E7E761350" unitRef="number">0.07</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_eols_BridgeNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-D22A8E78C545F4774DC22F3D79E0FED6" unitRef="usd">2500000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_eols_PurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-CF9841A6F1644F9050822F3DB5F3E7A5" unitRef="usd">55000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-CBB07973DA3C3B903F302F3E9461CCEB" unitRef="number">0.1</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-CA52E6EC98859F611598828D811E73B6" unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="D2017Q2April30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="3" id="Fact-D2F66DDFEBDE2ED1CBEA2F405279A963" unitRef="number">0.025</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="3" id="Fact-4420709DA52CC11AB3542F3EF8A3D17B" unitRef="number">0.025</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="3" id="Fact-0F8CB29B9690C5A37FB32F412FB65C2C" unitRef="number">0.025</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="3" id="Fact-C9B4DE5E391F876B0E762F4452C9CA8F" unitRef="number">0.025</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentTerm contextRef="FD2018Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" id="Fact-4E0C617E4E7CE1501215A59882C0C83C">P2Y6M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-B0A25677F10E7DAAC59833ACA9CB27C5" unitRef="usd">3200000</us-gaap:DeferredCostsCurrentAndNoncurrent>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-84F6C73DEE462AAA99EC2F0442D12DA7" unitRef="usd">-6276000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E181DD56D980EB8B11972F0442B5D60C" unitRef="usd">44000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8C59ECB411DCB596C68F2E7DBFBB95D8" unitRef="usd">-6255000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3DB6DF8F0F1A0C9A66BC2E7DBE882390" unitRef="usd">65000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-3363BA8712B791A34AA22F1CF401A536" unitRef="usd">14990000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-28BA8F3AB90F41929AA72F1CF4186DE3" unitRef="usd">15055000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-CEA11021EEFEBB514F212E4104263439" unitRef="usd">14990000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-1E3A5742C9A023EFE8E52E4102DBBF14" unitRef="usd">15055000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredOfferingCosts contextRef="FI2017Q4" decimals="-5" id="Fact-9CE843156ED271B76B9633AD8ED74CBF" unitRef="usd">2100000</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredOfferingCosts contextRef="FI2018Q4" decimals="INF" id="Fact-7DBA5644A9885A60E55D33AD5B8DBB5B" unitRef="usd">0</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-EEC1C2C263999CDA45022E40FEA1B6A8" unitRef="usd">38000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-F2B13B43BC860346BA162E40FD534F06" unitRef="usd">25000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3B9558C9AA0986CF21802F046B452B3D" unitRef="usd">21000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-992FB26D55F006B53FA12F046B4DD299" unitRef="usd">21000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2017Q4" decimals="-3" id="Fact-56CC69FF2994830D87292F187A1C9E22" unitRef="usd">3000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-ECC8EBECDD3CD8450BFB2F187A20C6A5" unitRef="usd">3000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-5" id="Fact-D4E6C7BE4142031D95672F337F285100" unitRef="usd">24100000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-5" id="Fact-C5D411AB2716471FD9252F337F189C1B" unitRef="usd">34500000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-25178B8C3325B08A3BDE2F18D8186F14" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-9750AEC6BCDB281243AF2F18D82233E4" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-A7FFDDA5F3758D14F5382F078CA9807A" unitRef="usd">21657000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-03B2AC180CC1731350312F078CBC7DB5" unitRef="usd">29782000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4" decimals="-3" id="Fact-1909EFADB9DF0D868F4F2F17A8F2039E" unitRef="usd">2109000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2018Q4" decimals="-3" id="Fact-737B9EE03347EB2C4EE32F17A8EB3479" unitRef="usd">2436000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="FI2017Q4" decimals="-3" id="Fact-524F7E43A29BA9EF60A77E21EA7C7570" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="FI2018Q4" decimals="-3" id="Fact-B2166AFC651DF963E9757E21EA7393FB" unitRef="usd">648000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-3" id="Fact-D12D5FEFB18F0BF659E02F1726270F95" unitRef="usd">292000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q4" decimals="-3" id="Fact-2946E638E25FC1150D522F1726427BC2" unitRef="usd">1552000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2017Q4" decimals="-3" id="Fact-F65AE45B6D9209F62E422F1821BD96B2" unitRef="usd">11000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2018Q4" decimals="-3" id="Fact-C0E694474A09B247DA8B2F1821CAB1B7" unitRef="usd">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-B98841356E59364EE20D2F18AD7984E1" unitRef="usd">24072000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-6BC9519A48F564E3BE432F18AD6A3AAC" unitRef="usd">34536000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-6BC66F4B9C04848A23482F1D77B50098" unitRef="usd">14990000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-73551AB2F978752CB6A22F1D77A6F9D9" unitRef="usd">15055000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2017Q4" decimals="-3" id="Fact-978CA0D671348523B1282F1CA06280FB" unitRef="usd">14990000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-AE28D42D77EBFD7E81F42F1CA0498DF5" unitRef="usd">15055000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DepreciationAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C4F52FDC27971DBFE4F42E7406A48191" unitRef="usd">218000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5DB7DB0509DC0069AA0E2E74050CB7EA" unitRef="usd">9000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0ED2EB15051C38C00B8D2E7D487ACCA6" unitRef="usd">218000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CFF75FA97AC18D8AF5952E7D475D55D2" unitRef="usd">9000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:Dividends contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D34C991BC3945462A0972EBB3B6122E4" unitRef="usd">66048000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_eols_ALPHAEONMember" decimals="-5" id="Fact-A9C334761A6D0EDC52042EF77F2ADC45" unitRef="usd">66100000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2C3781CC0A54F686E50F2EBB4E8AC6DF" unitRef="usd">61791000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BFD5889D8BF19AC121F52EBB3B58EFD2" unitRef="usd">4257000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q4YTD" decimals="-3" id="Fact-AC69503D24B4693533A6A9BB1CEBAFCC" unitRef="usd">2000000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-513083B0D0C168B779CFA9BB186BAD35" unitRef="usd">1385000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D512B0D768496185701AA9BB1A891CB8" unitRef="usd">615000</us-gaap:Dividends>
	<us-gaap:DueFromRelatedParties contextRef="I2018Q1Feb12_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-E58CDFCA7449AE2AA24A7E00F533BFAD" unitRef="usd">67000000</us-gaap:DueFromRelatedParties>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AE023FE89EBEE4EFB4712E3931A6333B" unitRef="usd">72639000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-2F802CEB2A21D20ACE152F32C0A9856A" unitRef="usd">72600000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-526D7700B6496BA17E222E3931A8725B" unitRef="usd">0</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2018Q4_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="-5" id="Fact-9C6D571EA493BB40171F7DF6904482BF" unitRef="usd">100000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-D5DA4F13957E41ED5C6D7E07D8A1F1CE" unitRef="usd">0</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-19EF74AF2AE82C3FD1842E3AAE9971E0" unitRef="usd">72639000</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-1AF5863F79380AA4DE9D2E3AAD0DF35B" unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-D582B97F5F34EE60E5D67E02E205249C" unitRef="usd">1600000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="I2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eols_ChiefMedicalOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-30DCBEBC84C36A204C777E034A6A8660" unitRef="usd">700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-4D7F27ACBDFC4167B37C2E7426ED2568" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-21E516268FE813760EDF2E742504BE88" unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E94945CD8F7743A097862F45B6F84167" unitRef="usd">109000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4C52079173C6C1A302C82F45B6E86840" unitRef="usd">2577000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-495B346572716722B6EF822C514A01BB">P3Y3M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-CB13EE6BB338D7BA39CA825ACFDC11B1">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-E0374ED342067F6DB88182596720900E" unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-156B935755041F6E522D8229A53C7F32" unitRef="usd">18900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-D1068353CAF20CDE6F267E042549173C" unitRef="usd">10500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-6B0683434570FA5C1D617E1402A71401" unitRef="usd">39700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-FEC7700C541DF99ACBD47E13FEB78B85" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-949881A05143270DB4F6A41F8240826B" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2EC046EE2791842A8F722E73FDF42F7C" unitRef="usd">4819000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_CompensationAndBenefitTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-11F76E8DB9EE6BB1DC902F2F1A225212" unitRef="usd">1174000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_FacilityRelatedTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-4B67AAC6DD58BA8792D12F2F2BFC8799" unitRef="usd">1134000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_OtherTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-7E4D3035F6696ED050D22F2F31D69CC3" unitRef="usd">347000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_StockBasedCompensationTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-C2E248E733C7ADCDB2112F2F269AE6B7" unitRef="usd">551000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_ThirdPartyServiceFeesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-5ADA87F11FCF1E98ED772F2F204AC53C" unitRef="usd">700000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-AAFBE1C861891834A3062F2F3662685B" unitRef="usd">3906000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D31E7CB046E5645FB8C02E73FAFAD857" unitRef="usd">29146000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_CompensationAndBenefitTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-6D369A0A2F638CDA22972F2F13A22900" unitRef="usd">184000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_FacilityRelatedTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-DF1217D5FD952B5D2F372F2F28DF71BD" unitRef="usd">80000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_OtherTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-C44AAF9D10C4FB44040A2F2F2E6C55EC" unitRef="usd">5000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_StockBasedCompensationTransactionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-5C69ADCB7111087B2D582F2F22642809" unitRef="usd">30000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_eols_ThirdPartyServiceFeesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-DF042D9ADB2D7FCB52C92F2F1C9EE745" unitRef="usd">84000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-4EA8FBF55E20663163342F2F34784CD0" unitRef="usd">383000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-5" id="Fact-6420CFF7BE7B42F1DAF32F157FDBE9AF" unitRef="usd">21200000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-3" id="Fact-8503122B2FCBA61753BA2E39BA79E3B5" unitRef="usd">21208000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-3" id="Fact-5B1373CFCDB3A8FC49FA2E39B8DC6A0E" unitRef="usd">21208000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-5" id="Fact-FA1793BF05DDAF513AA22F1520C945E7" unitRef="usd">21200000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2013Q4Oct2013" decimals="-5" id="Fact-C55F4455A2909ACD24CF2F11C5E86ED2" unitRef="usd">21200000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-17D74A2638B218D4D7102F112FC84526" unitRef="usd">56300000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q4YTD" decimals="INF" id="Fact-9FA899E15D61C5D4C9DC33AB4ABEE01B" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2016Q4YTD" decimals="INF" id="Fact-5497B69A3A54D96F2E2F91D28E7BA9C3" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2017Q4YTD" decimals="INF" id="Fact-4FB5394FFFD7BD13A3D591D28DF7E0BB" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2018Q4YTD" decimals="INF" id="Fact-1526931E6E6E5CE0C62F33AC260D747C" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BDBE818025EE128FE84B2E74193D2207" unitRef="usd">-11731000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-19CDB53AA2B23007FA4E2E74179DC01B" unitRef="usd">-46802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-88B65A75DDDE58CD2C682E741D8387DB" unitRef="usd">-7251000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9B145B1B36D4A222F7E02E741BA25DC5" unitRef="usd">65000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8FFF9D8A6516EF9A443A2F220B7B9810" unitRef="usd">-6548000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1E1DC4221EBD1F4DF4432F220B7F21E8" unitRef="usd">7309000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F057F71F2A138A7A16B02F216439B486" unitRef="usd">3221000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4102ED87DF0075FB5FE52F2164422B5B" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FB42E1805AF813E5736A2F20B7C33E6B" unitRef="usd">-3988000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D0E709573701DDA6B7622F20B7D2C301" unitRef="usd">-9828000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1814C6E0566183478A152F21D51DC30D" unitRef="usd">3000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-48DECD410A795418F5282F21D5234A4D" unitRef="usd">17000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D90BE9296BE2663184F22F21A7DDCD4E" unitRef="usd">338000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2018Q4YTD" decimals="-3" id="Fact-959498AB1FFC2D4F5C722F21A7CCF78E" unitRef="usd">416000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9C132AA585A7945FE6CA2F20E7DCB101" unitRef="usd">-132000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8E7CD817824ACE085DC62F20E7E2C7A1" unitRef="usd">16000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4415589666205A75928E2F211D76D965" unitRef="usd">145000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2018Q4YTD" decimals="-3" id="Fact-44EA23D7F93E67AE9B632F211D6EE39D" unitRef="usd">175000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D36A4E5D1F9B023F9EB12E7ED86A3C1E" unitRef="usd">-2432000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6609B46BE869823C6E3A2E7ED74ECFD4" unitRef="usd">1275000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-288C49C6F4F66F42635E2E7F12E35F65" unitRef="usd">303000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7E08424970E07FD8D9B62E7F11330F92" unitRef="usd">2733000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8F4C850FDF3AB07D18E22E7F14BD1DCF" unitRef="usd">-6000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1300DE34D93B8DB146DD2E7F1390ED11" unitRef="usd">-13000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0F17A5A9A3F42532BE6A7DEADC9A90D4" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F82689B2D39F534D00347DEADC9EFAA6" unitRef="usd">211000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2180A790F6157CE667BC2E7E7E52F4A2" unitRef="usd">160000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-AE5815FA0858249EA1112E7E7D2F77E4" unitRef="usd">992000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-44238330DDE3DB0869A22F1484CD469A" unitRef="usd">56100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4" decimals="-5" id="Fact-4296FCD0A0B73DE2BD742F136D3C54E5" unitRef="usd">56100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q4" decimals="-3" id="Fact-E7EF9E8116E9D57306672E39B7D8E8BA" unitRef="usd">56076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-D167327152D5BEEF48702E39B5CF6CDD" unitRef="usd">56076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3AEAB99F6078AD4226312E741509D97F" unitRef="usd">5000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BB5D3799C13232E5BC452E7413447FC1" unitRef="usd">863000</us-gaap:InterestExpense>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-95F858A0872D639893C6A9B378E7498A" unitRef="usd">0</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F3B3CB81C7BDA2392C52A9B378C45B61" unitRef="usd">203000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C6C5C8F39F569EDAA3847E0CEA454BF0" unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-2D1CFB9E87A52D0C26427E0CDCE55951" unitRef="usd">300000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-1E8D11CC828DF58A858E2E41061A8551" unitRef="usd">227776000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-41383BB29A909F9A20DC2E4104CF6B2F" unitRef="usd">87460000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-50C476B9C8D3782124922E41B98E25BF" unitRef="usd">152233000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-812E3F71CF44BFA940BB2E41B864918A" unitRef="usd">171844000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-527958B752966329D2612E3AB9E539B7" unitRef="usd">212748000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D4D4BC133EDE5BC2B60B2E3AB8391F5D" unitRef="usd">5276000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="INF" id="Fact-A0976A9E8EE615D24596A59876608773" unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_dei_LegalEntityAxis_eols_OxfordFinanceLLCMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-F3CD3EBF35AD1F211999A9F75F966831" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheOneMember_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-1D2C9AEDDE8C125F7C70828C10FC7700" unitRef="usd">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-B9BD1D645583AEA8814D828CB52F3390" unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_eols_TermLoanFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-A60F4AEE6D2571484496828B2EE866D0" unitRef="usd">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4" decimals="-3" id="Fact-F30B4424EDCCE2E5D2F82E410232E37E" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4" decimals="-3" id="Fact-16AC50D96254B22CA1832E410107B1F9" unitRef="usd">16904000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="I2018Q1Feb12" decimals="-5" id="Fact-0FD26D76DB5C03148B5281E409856AE9" unitRef="usd">16000000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q4" decimals="INF" id="Fact-75F4C92C28AE2DBC65EC2F2749C3E766" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2018Q4" decimals="INF" id="Fact-00D679D4BCA4277919682F265B9A807F" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_StatementClassOfStockAxis_eols_CommonClassDMember" decimals="2" id="Fact-DADA255F08177B45C9C12F4533CBFF35" unitRef="number">0.10</us-gaap:MinorityInterestOwnershipPercentageByParent>
	<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="I2019Q1_srt_OwnershipAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="3" id="Fact-A5B90287F9822AFBCC46339698420F37" unitRef="number">0.560</us-gaap:MinorityInterestOwnershipPercentageByParent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CD4225B327F455C4B8502EA8AA725AE6" unitRef="usd">13035000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-085A7517B1163BBF22362EA8A93B8D11" unitRef="usd">118838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-756BA08C33879224E3932EA6F4E0D2B5" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-492007835320270DCAFD2EA6F2F15FAF" unitRef="usd">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A6263FE82C0C6BEC49FB2E7F166B1D73" unitRef="usd">-13222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E1560B47E643038B0BA533996398E746" unitRef="usd">-13200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6A5578BEB5CD066392F82E7F153FFF56" unitRef="usd">-25667000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-371CD59519971B0F082D33994DC66119" unitRef="usd">-25700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DB12EEC7D57A10F6FBD92E74225A2212" unitRef="usd">-4480000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A1353C5549DB56584C6B2EBD8D254022" unitRef="usd">-4480000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9ED28151E83D976C1F162E7420DF74FB" unitRef="usd">-46867000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-44C14D7286C3801F3DC097620EE0CBE2" unitRef="usd">-46867000</us-gaap:NetIncomeLoss>
	<us-gaap:NotesPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-00C2BCC819CE9613891B2E3AB3F4EF3E" unitRef="usd">138687000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2017Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-ECDEA673AD4E35AC116F2F40F60AB461" unitRef="usd">138700000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A1C459B74581E4C18AA12E3AB25421D1" unitRef="usd">0</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" decimals="-3" id="Fact-9802FC637AE2B6CAC5D9A41E409C35EA" unitRef="usd">16904000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-1AF1037CD554AA8EAD84A41E40C861B0" unitRef="usd">17181000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesReceivableRelatedParties contextRef="FI2018Q4_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-D5A056BA9620BA8C7CBD2F432D9BBC12" unitRef="usd">56300000</us-gaap:NotesReceivableRelatedParties>
	<us-gaap:NumberOfReportingUnits contextRef="FD2018Q4YTD" decimals="INF" id="Fact-978013C3CF8BF69BAE0233AAC09355F6" unitRef="unit">1</us-gaap:NumberOfReportingUnits>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FAD41BDDC1B0F56095CC2E740AD5FC06" unitRef="usd">11726000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-84E5B44EEEB68A69D80F2E74094BA913" unitRef="usd">46142000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A07AA33BEA5F30F7E3DB2E740E78D5D3" unitRef="usd">-11726000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D0A206F0597C88DA97E22E740CE28AE3" unitRef="usd">-46142000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-25628600C600B3CDE1D72F2173420153" unitRef="usd">1029000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-551A49226F156560CA6B2F211839CCB3" unitRef="usd">890000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-3" id="Fact-50452626A87D2628417E2F2158C088B7" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-966612BE6F5559F6527E2F213286B216" unitRef="usd">139000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-AF902BD71AC094047F192F2B8F00A9A4" unitRef="usd">72600000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4" decimals="-5" id="Fact-3C713625092FCFDC52862F2B8EF1C6A5" unitRef="usd">99800000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7E5F56AD73B9C6A26B062F460D3596E9" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-B9F1A913FF54C4E754CB2F460D29FC00" unitRef="usd">210000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-68C2AF2D4EA9DE9C11622E39BD691511" unitRef="usd">2125000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-2A106CA2F2BEA20DA0E32E39BB78715D" unitRef="usd">221000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-60E4993E82DA6509493D2EA7D022E148" unitRef="usd">1286000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B6653A89E380CF5BE0F62EA7CE2FA165" unitRef="usd">1060000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4E0CAA2209B2247145CF2EA7D3A7FDEB" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6512A7A70F165890648A2EA7D15A6989" unitRef="usd">239000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-17299296D98271EDE5DA2EA6F1E833B9" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EF569741C0FEFB13DC592EA6EFD5453B" unitRef="usd">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-CEFD489F6E0A9D03264D2E44A3ED9C92" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-A0967EA359002BEB4C137DDE2C99C84B" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-2E09A3C3E7014C7E042E2E44A358C3DD" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-93AC3E2C79497FAC09057DDE2B84BD2C" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2018Q1Feb12" decimals="INF" id="Fact-727B139A00096B43DF7133956F7D2EA0" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-9F97A5E524818AE060412E44A5407174" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-301C1885DAAC63F3AB697DDE2E771009" unitRef="shares">2500000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-398CCB69A76102F1A5852E44A49D4488" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-0391669D981D64022FAB7DDE2D6F192C" unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2018Q1Feb12" decimals="INF" id="Fact-C135C63FEC99A8935A59339547136F0E" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-777C7267AAE4A39D7EE32E44A6A61673" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-40F4C28BC8DE601E682E7DDE2FD15260" unitRef="shares">1250000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-2F221F64651B31A8CD4E2E44A5EAA36F" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-130E95ACC4174F3817837DDE2F1B95CB" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-034A9FB7142412E45EC82E44A85306D6" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-18910D3C09276BB82FEC7DDE31824243" unitRef="shares">1250000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-8449DBCBE0BCDBDC55D52E44A79E704B" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-EBEE0AD189ACC631D8B87DDE30837BEF" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-B675199FC68074E181152E41AFEFC43C" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-2ADE6947487EFBB1C14E2E41AD728495" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-69EDC4F47AA65291330A2E41AED0B7AF" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-8F5DCC9F81BF41B9905B2E41AAF07121" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2035ACF997723333603D2E3917C1CF2A" unitRef="usd">185000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-8E16BA532E08B6134B0B2E3917B84B51" unitRef="usd">1177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2018Q1Feb12" decimals="-5" id="Fact-7D5A367F71297B3E5AA233949885E0AE" unitRef="usd">56300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8B4682C61706A38D23AD2EA7C52F31FD" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2018Q4YTD" decimals="-3" id="Fact-03AD9768AEA941087ECC2EA7C3C1D063" unitRef="usd">56330000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2018Q1Feb12" decimals="-5" id="Fact-C56B6592AFAEA7DBE77781E0630BB097" unitRef="usd">56300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E20AC72DFFCECD94F7862EA7C831180D" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q4YTD" decimals="-5" id="Fact-032AFE12205D7F1A98E6339640653753" unitRef="usd">67700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BF2AA32B875CE13881EF2EA7C63F2382" unitRef="usd">67680000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3B44771F9AFA8585E5942EA7CA7A2CD3" unitRef="usd">14321000</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B0569C285842DF5F3DAD2EA7C94DE474" unitRef="usd">1127000</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-B6803FC7DC841BC2325233A8FE4A9460">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-BD0BFA14A1EBCEB9CCCC33A8CFB732BC">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PurchaseObligation contextRef="FI2018Q4" decimals="-5" id="Fact-7F8057E5764FF40660467E0FD3E16B7F" unitRef="usd">6700000</us-gaap:PurchaseObligation>
	<us-gaap:PurchaseObligation contextRef="FI2018Q4_us-gaap_OtherCommitmentsAxis_eols_DaewoongMember" decimals="-5" id="Fact-D31BC244FEBC7896C6D47E1004AF6399" unitRef="usd">3500000</us-gaap:PurchaseObligation>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-3B189E5D628C67C370E12F53D0D1E684" unitRef="usd">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-5" id="Fact-485F09069C93ED04F4682F554C357985" unitRef="usd">55700000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="-5" id="Fact-FC7BDB5B7B1AC6DFD01E2F42892BD0C6" unitRef="usd">800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0BD9B09800CC8C95F6262EA7CD326D06" unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2018Q1QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-EE4FE4527451B0B6543A2F322A03ECDF" unitRef="usd">5000000</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E4773DAB1662580558D12EA7CB93AED7" unitRef="usd">5000000</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CC78EADCBC68BAFEFCD12E72F80D308D" unitRef="usd">6689000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B50D6E1B4F49A9B527C52E72F81537FA" unitRef="usd">6487000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-567F1DD1151A1EF600052E41B5CB5D97" unitRef="usd">-75543000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-2B3B79B892BE881E9FDB7DFCAD1CBEA3" unitRef="usd">-4300000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-6BC3B103F0253494472C2E41B47C310C" unitRef="usd">-123025000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4_srt_CounterpartyNameAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-5" id="Fact-4D74B5DDD94D0889B3987DFB3898DEE4" unitRef="usd">-600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-4776C73937EB64C1AD82339424174D59" unitRef="shares">5047514</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-A4C041661FAFF49D880B33944BF95255" unitRef="shares">47514</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q1Feb12" decimals="INF" id="Fact-9997EEF31A9DEBADD3F5339472BF0E85" unitRef="usdPerShare">12.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3" decimals="2" id="Fact-CA8A3421E9ADEFE051DE33960B71AE5F" unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-27B16DC9550BBD154D2D2E7D4B6A025E" unitRef="usd">586000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-59780D71D6C925AFB82A975B97417859" unitRef="usd">6971000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-A82C565E2D9020D6848B82787E47437E">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-A55908CABCFE5E97D28982787E1F65ED">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-E2725638E145422780B9824F5C90DE5A" unitRef="shares">15510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-D9C910DE1ED4C5B9716A82541B8F08F4" unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-02B3518E168053AB34F2824EFCD84CB5" unitRef="shares">321516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-FFCD31C6E1C92428F35C8253BCFA104E" unitRef="usdPerShare">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-4F69E9DF2DC99FDEE4E4824EC7F9D544" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-0965E771E77E2C964C1F824EC80385CC" unitRef="shares">271404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C61B254BECD4C6DDAD0682538B7FCC43" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-E2B058A8F0E20E51CF4982538B534506" unitRef="usdPerShare">15.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-CFDB48DEC3826E11C298824F2B1F454F" unitRef="shares">34602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C3216C527624D64C350A8253E99B1096" unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-51609A4B2BF41ACDDC0781ED86195E77" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F8BB61CB8588426CBE6F827C5662C9B0" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-540E40C52541649BC69381EC03D6709F" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-A52730469167FE7D905481EC03CC8B71" unitRef="number">0.5776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-C6371C4AAE392EF2748781EC3586B51E" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-5DF2E0DD4E8E95EBB34481EC358C566E" unitRef="number">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q4Nov21" decimals="INF" id="Fact-3204D80F32D9676F415081E4DE60A20A" unitRef="shares">4361291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-7E3A5AB5ED75F7A0BE1D81FD18F67520" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A58118CA6DAF8488FBF78208DAA50415" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-A30FC954A9541A484AF8821BA0BCEBEB" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-DF82B0156A63CB6B946381FAC23EAB6A" unitRef="shares">582923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-01C934C94343E1DC23E0825D78466AD4" unitRef="shares">34602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q4YTD" decimals="INF" id="Fact-83718323F06E3982FC79822FADC0063C" unitRef="shares">3840724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-5BFEF1E5546E2959909281FA2A1158AE" unitRef="shares">3840724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD" decimals="2" id="Fact-DE7EBF9CB762170DC487823171070D7D" unitRef="usdPerShare">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-C6249C8398227665030582196A85810B" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-3A41AD1AD59036FECAF782196A697B57" unitRef="usd">7119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-FD363834ADBFF4E1FAF981F9DDAAF4A3" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-B27BA23F3E778833764681F9DDA38E00" unitRef="shares">3257801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-874432F1476881E0A75282062D795F2C" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-DCA1FD0254D01455FDED82062D83023E" unitRef="usdPerShare">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2017Q4Nov21" decimals="INF" id="Fact-131CAB3C9D28512190B13A3C9E522716" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-6F7B551ED886414D81B68206FF40F099" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-52FF6E63C48B04716271820780004097" unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-16020B818B554A9E7C728206762847F7" unitRef="usdPerShare">11.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-0D6E726ACED49046A7219866AC4091D1">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD" id="Fact-4F10D738B514801F67C681E92D13B8B2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-A44CCE0928BD42BD441281EC8057C3DD">P6Y2M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-595D103744B23EE65493821C2D144F3E" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-01A28E60D50E55C442B7986880937606">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2017Q4" decimals="INF" id="Fact-8A381248D398F8811BCF822F5A0D401A" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2018Q4" decimals="INF" id="Fact-5C8ADF9BFFC20E93F41A822F59EDC29D" unitRef="shares">3257801</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="FD2018Q4YTD" decimals="INF" id="Fact-E9ECA5C3657BD9CC8AFD822FEC96C508" unitRef="shares">582923</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD" decimals="2" id="Fact-DB52CB6081CA4D4A9D4E8247925502B2" unitRef="usdPerShare">9.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4" decimals="2" id="Fact-C11F8A2D5B07A4EBD2A482311DA1726C" unitRef="usdPerShare">0.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4" decimals="2" id="Fact-445776F47340DE11DCDB82311D974436" unitRef="usdPerShare">11.99</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-3F8EC2B77B26DA4BF088827B3B65C623">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-9FA143139A46091A54A8820F82F7151A">P9Y3M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-F1B2251AF575AB111D7F825D1EA45794" unitRef="shares">100424</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="INF" id="Fact-B420FA929FC9E92F5E8D825DA628852B" unitRef="shares">50112</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-373E9A46C2C98A9C1B982EBF6BD2573C" unitRef="shares">1250000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-76CD58B872B05EF5E5DF2EBF6BCCBEBF" unitRef="shares">16527000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-7A1ED4468E12310BBA532EBF6D064697" unitRef="shares">1250000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9592725D09AF4E34D93E2EBF6BC7B3B3" unitRef="shares">16527000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-5D27F2D67DFCEAF5539F2EBF6BC316B0" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9780292C7A8BAEC2E8402EBF6BDBA88A" unitRef="shares">27274991</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-51687B66E3E2F408AAAAA9C44205E795" unitRef="shares">-1250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-85EF411337973A460057A9C441F418B2" unitRef="shares">2065875</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q3Jul01-Jul31" decimals="INF" id="Fact-5B149236CF95DFA0DE4233959D866E7E" unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q3_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-F33A18879C8E25248D893395D387A092" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="INF" id="Fact-081E8C17BA42B6E9A1B5A9C0F29D65A2" unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-FCE133FA503914573D3AA9C0F27F1B03" unitRef="shares">5047514</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-A1B0E9FB6413802D763C81FA6443FF7E" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-92EB0C30622BA164516FA9C15EAA8899" unitRef="usd">67379000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-FE1C9F606094C99383DAA9C15E648340" unitRef="usd">53445000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-CDFC6678EAB011088FB4A9C15E32DEF1" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-2176BA10AF63E2BEC984A9C15E0A49AB" unitRef="usd">67379000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-E3B4071BD6D33972232DA9C15E00FE66" unitRef="usd">53446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-B708F17E915D3EDBBEDD2EC354B6E44E" unitRef="usd">-7106000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B309DF994E6C88BF8A8A2EC350E4A1EE" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FA0EC61052359AA4ADE22EC354D5749E" unitRef="usd">59700000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B8278ABD8E618059F5232EC35132159F" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-375FBA48A531ED1F70502EC3549B954B" unitRef="usd">-66806000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-992BE2CDBACD0BAC0A7C2E41B7BA1774" unitRef="usd">-75543000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-BB874DAD47AFF0C340C02EC351CD5342" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-898C4A4A92FC50653D672EC35A0F3203" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D64D08EBCDAA18D2ABA52EC35D1D7B07" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D4DFBC13FDE1D9540F9B2EC3554A72D7" unitRef="usd">-75543000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-48B2814FED295502D2242E41B673504C" unitRef="usd">84384000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-EADAB1CCB319ABA8EECC2EC350EDC3CF" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8F6C0E7DB58C6431860F2EC35CDD44F9" unitRef="usd">207408000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4CD4DD2C2A3BF2FFFFD12EC352448F0A" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C519C75A012A93DD165A2EC35702A760" unitRef="usd">-123025000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q1Jan1-Jan31" decimals="4" id="Fact-C19C5E04F82720261D76339221C5A9AD" unitRef="number">1.6527</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-C88841CBC12C9C6A2DA62F2C313F11C8" unitRef="usd">1000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-9AFF6DFD89FD4F5092862F2C31A253A0" unitRef="usd">1100000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-F7736018F0F3FBAC99222F2C315F1BD2" unitRef="usd">1200000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-EEC0CA09073328B37CFD2F2C3132745D" unitRef="usd">1200000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-2C86BAE7F66B0AD71CF02F277AFFD324" unitRef="usd">1812000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-3F830306029AD650F8762F277B077C63" unitRef="usd">2109000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-22E33D1ED308E7BE342F2F277AF6FD5E" unitRef="usd">2435000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-541C4CDEB162B9A2FCCC2F2812CF9B1B" unitRef="usd">297000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6F7FC4E23332434202D72F2812DBDEFC" unitRef="usd">326000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B8F23ACDE3C09F33E4D32F348DF40581" unitRef="usd">10500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-5C73DD729683B1D0C7FA2E742B3AA9F0" unitRef="shares">16527000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q4YTD" decimals="0" id="Fact-0AA4FD8D9B796DB7117E2E7429B7ACD4" unitRef="shares">24402368</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2018Q4YTD" id="Fact-9B1DCF7067FFCEE5AF2F2F4307DF4596">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:6px;text-indent:26px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.17460317460318%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Payroll and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Professional services and related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-3621EF23D7F48B3FA82133A09F058E2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). The financial statements for the periods prior to the Company&amp;#8217;s IPO have been prepared on a standalone basis and are derived from ALPHAEON&amp;#8217;s consolidated financial statements and accounting records and included an allocation of certain assets and liabilities that have historically been held at the ALPHAEON corporate level but which were specifically identifiable or allocable to the Company. . These results reflect amounts attributable to the Company&amp;#8217;s business, including the costs ALPHAEON incurred for the development and commercialization of the Product and costs and expenses under the License and Supply Agreement (the &amp;#8220;Daewoong Agreement&amp;#8221;) entered into with Daewoong Pharmaceuticals Co., Ltd. (&amp;#8220;Daewoong&amp;#8221;), a South Korean pharmaceutical manufacturer, in September 2013, as further described below in Note 5, C&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;ommitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2018Q4YTD" id="Fact-7B7D7994C962845F5EC833A19B7A8AC3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;), and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Evolus was formed in November 2012 for the purposes of developing the Product for distribution and sale. In October 2013,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in a Stock Purchase Agreement, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;SCH acquired all of the Company&amp;#8217;s outstanding equity in exchange for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; Class AA units of SCH and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; Class D units of SCH, which resulted in SCH obtaining a controlling financial interest in Evolus.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the transaction with SCH, Evolus had executed a License and Supply Agreement with Daewoong and thereby secured exclusive rights to license and distribute the Product for aesthetic indications in the United States and certain other international markets, as well as non-exclusive rights to distribute in Japan (see &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 4, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;). The acquisition of the Company, which represented a business combination by SCH, was to provide SCH and ALPHAEON access to the license held by Evolus to develop, produce and market clinical neurotoxins. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In a series of related transactions in 2013, SCH acquired all of the Company&amp;#8217;s outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed equity that it had acquired in 2013 to ALPHAEON. As a result of these transactions, the Company became a wholly-owned subsidiary of ALPHAEON.  The Company remained a wholly-owned subsidiary of ALPHAEON until the completion of the IPO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;SCH elected to apply push-down accounting pursuant to the guidance in ASC 805, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Business Combinations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Accordingly, the financial statements reflect the new basis of accounting established by SCH when SCH obtained control of the Company in October 2013. The assets acquired and liabilities assumed in connection with the acquisition were recognized based on their estimated fair values at the acquisition date. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates.&amp;#160;The estimated fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the acquisition, SCH and ALPHAEON entered into a stock purchase agreement (the &amp;#8220;Stock Purchase Agreement&amp;#8221;) pursuant to which they were obligated to make certain contingent payments to the Evolus Founders. However, since Evolus did not have an obligation associated with the contingent consideration arrangement prior to the Company&amp;#8217;s IPO, no amounts were recognized in the Company&amp;#8217;s financial statements for the contingent royalty obligation arrangement between SCH and ALPHAEON, and the Evolus Founders. As described in Note 4, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, on December 14, 2017, SCH and ALPHAEON entered into an amendment to the Stock Purchase Agreement (the &amp;#8220;Amended Purchase Agreement&amp;#8221;), and the Company joined as a contractual party. Upon the closing of the IPO on February 12, 2018, ALPHAEON immediately and automatically assigned to the Company its payment obligations under the Amended Purchase Agreement. These payment obligations are referred to as the &amp;#8220;contingent royalty obligation payable to Evolus Founders, a related party&amp;#8221; and the &amp;#8220;contingent promissory note payable to Evolus Founders, a related party&amp;#8221; in the accompanying balance sheets. Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&amp;#8217;s former Chief Operating Officer. Mr. Marmo was retained as a consultant to the Company until December 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-B6F8231F96FF6EEEA82F2F1FC2ADC45A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Lease&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Total&amp;#160;rental&amp;#160;expense for the years ended&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;was&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;"&gt;Year Ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of December 31, 2018, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, including &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Daewoong. Certain purchase obligations or milestone payments have been excluded because they are contingent upon the occurrence of future events, including receipt of governmental approvals and our future sales in various jurisdictions, and we do not know the timing of such potential obligations with certainty. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;FDA Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Daewoong Agreement, as described in detail below, the Company is obligated to make future milestone payments for certain confidential development and commercial milestones associated with the Product. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License and Supply Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In October 2013, Evolus entered into the Daewoong Agreement with Daewoong. Pursuant to the Daewoong Agreement, the Company has an exclusive distribution license to the Product from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Product will be manufactured by Daewoong in a recently constructed facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than the Product) in a territory covered by the Daewoong Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company held an option to obtain the therapeutic rights to the Product in its licensed territories which was held in trust for ALPHAEON during the fourth quarter of 2017 for a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reduction in related party borrowings. In September&amp;#160;2018, ALPHAEON exercised the right to obtain the therapeutic option to the Product and remitted the option exercise price directly to Daewoong.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&amp;#8217;s future market share in various jurisdictions, which have not yet been obtained as of December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. The Company is not subject to any currently pending legal matters or claims that would have a material adverse effect on its accompanying financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&amp;#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; amounts were accrued as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Medytox Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company, ALPHAEON, SCH and Daewoong are defendants to a lawsuit brought by Medytox, Inc. (&amp;#8220;Medytox&amp;#8221;) alleging, among other things, that Daewoong stole Medytox&amp;#8217;s botulinum toxin bacterial strain and that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture the Product (the &amp;#8220;Medytox Litigation&amp;#8221;). The Company believes it has meritorious defenses and intends to vigorously defend Medytox&amp;#8217;s claims. Given the early stage in the Medytox Litigation, the Company is unable to determine the likelihood of success of Medytox&amp;#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Citizen Petition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In December 2017, Medytox filed a Citizen Petition (the &amp;#8220;Citizen Petition&amp;#8221;) with the FDA. The Citizen Petition seeks to delay approval of the Biologics License Application submitted by the Company to the FDA in May 2017 for the Product until the FDA determines the identity and source of the botulinum strain for the Product and validates the integrity of the data and information in the Biologics License Application. Medytox further requests that the FDA require the source and identity information in the Biologics License Application to include a single nucleotide polymorphism analysis of the whole genome sequence of the botulinum strain for the Product. In connection with the FDA approval of the Product, on February 1, 2019 the Citizen Petition was dismissed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;ITC Case&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &amp;#8220;Allergan&amp;#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &amp;#8220;ITC&amp;#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that the Product is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of the Product is an unfair act. The ITC matter is entitled &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;In the Matter of Certain Botulinum Toxin Products&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;ITC Complaint&amp;#8221;).  The ITC instituted an investigation &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;as ITC Inv. No. 337-TA-1145. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930. The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;the Product&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;the Product&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&amp;#8217;s trade secrets and other confidential information including the alleged stolen &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;botulinum toxin bacterial strain&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;the Product&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; into the United States and a cease and desist order which would bar sales and marketing of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;the Product &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;within the United Sates either of which would adversely affect our ability to carry our out our business and which would have an adverse effect on our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-93DEB612F46CEED3532833A5E99F822D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Payment Obligation Payable to the Evolus Founders, a Related Party&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in the non-current liabilities in the balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Promissory Note Payable to Evolus Founders, a Related Party&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company assumed the liability concurrent with the IPO and determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q4YTD" id="Fact-72FA24A8D5E4776244A133A214AFFB46">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Although it has received the regulatory approval from the FDA and Health Canada, the Company has not commenced principal operations in the form of commercialized Product sales. The Product also requires regulatory approval from the European Medicines Agency and other similar regulatory authorities prior to commercial sales in the related jurisdictions. The Product and any future product candidates of the Company may not receive necessary approvals in the jurisdictions where approval is sought. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company&amp;#8217;s business and its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of the Product and any future product candidates, ability to obtain regulatory approval of the Product and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company relies on Daewoong, our exclusive and sole supplier, to manufacture the Product. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&amp;#8217;s commercialization of the Product. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-A9BEE84ABF89CC2F972933A115D6801F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the Company&amp;#8217;s IPO, ALPHAEON charged the Company external and internal administrative and research and development expenses that ALPHAEON incurred on the Company&amp;#8217;s behalf. External research and development expenses charged to the Company included costs for contract research organizations (&amp;#8220;CROs&amp;#8221;), costs to conduct nonclinical and clinical studies on the Product, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON charged these costs to the Company at the same amount that ALPHAEON incurred such cost. Internal development expenses included costs for the work that ALPHAEON development employees perform for the Company. ALPHAEON charged the Company a full-time equivalent (&amp;#8220;FTE&amp;#8221;) rate that covers personnel-related expenses, including salaries and benefits, plus an allocation of facility-related expenses, including rent, utilities, depreciation, insurance and property taxes, for those research and development employees who work either directly or indirectly on the development of the Company&amp;#8217;s drugs and certain administrative employees. ALPHAEON calculated the facility-related expenses to the Company based on a percentage of aggregate expenses incurred at ALPHAEON. ALPHAEON calculated depreciation expense of property and equipment using the straight-line method over the estimated useful lives of its assets of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As a result, the Company historically incurred related party borrowings from ALPHAEON for its share of the internal and external expenses for each of these functions based on the Company&amp;#8217;s relative use of each function, plus an allocation of facility-related expenses. The Company&amp;#8217;s management believes that the allocation and results were reasonable. As of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt;, the Company did not have any accounts receivable or payable with ALPHAEON pursuant to the Services Agreement or otherwise.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has calculated its income tax amounts using a separate return methodology and has presented these amounts as if it were a separate taxpayer from ALPHAEON in each jurisdiction for each period the Company presented. Subsequent to the IPO, the Company will prepare a stand-alone tax return. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company did not have a tax sharing agreement with ALPHAEON. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-56187FDCE862F05A869833A3C8A651CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Joint and Several Liability Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has (i) agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amounts that the Company expects to pay on behalf of its co-obligors. The determination of the &amp;#8220;best estimate&amp;#8221; from within the range of amounts that might be paid involves substantial judgment by the Company&amp;#8217;s management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
	<us-gaap:DeferredChargesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-E3FA46768158EE65B73533A385D84976">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Deferred offering costs, which primarily consisted of direct incremental legal and accounting fees relating to the IPO or Follow-On Offering, are capitalized until such time as the offering closes. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of deferred offering costs were offset against proceeds from the sale of registered equity securities in the Company&amp;#8217;s IPO and Follow-On Offering. As of December&amp;#160;31, 2018, the Company did &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;t capitalize any deferred offering costs. As of December&amp;#160;31, 2017, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of deferred offering costs were capitalized and included in &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Other assets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8221; in the accompanying balance sheet&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-52B035F3C080A4A92F8B33A6D965C639">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the effects of common stock equivalents such as convertible preferred stock and stock options outstanding. Diluted net loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issued common stock were exercised or converted to common stock. Dilutive common share equivalents are comprised of convertible preferred stock and stock options outstanding during the period, but are excluded if their impact is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the years ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-0F441D14076BFB30E889A5933801AB69">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth the computation of the Company&amp;#8217;s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(46,867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(4,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average shares outstanding used to compute basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;24,402,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;16,527,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company incurred a net loss for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and, accordingly, the Company did not include the following dilutive common equivalent shares:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Common stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Unvested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;221,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,479,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2018Q4YTD" id="Fact-627F90293FB78874F70EA419721E22BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table (in thousands) presents the difference between the carrying balance and the fair value of the contingent promissory note payable to the Evolus founders, a related party:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.15079365079364%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Carrying Balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#333333;"&gt;Contingent promissory note payable to Evolus Founders, a related party&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;16,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;17,181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-7F0E20CA6A8959EE93FCA416A7452DBD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The carrying amounts of cash, accounts payable, and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Instruments Not Recorded at Fair Value on a Recurring Basis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; contingent promissory note payable under the Amended Purchase Agreement to the Evolus Founders, that will mature &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years after the anniversary date of the first commercial sale of the Product in the United States. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;with a corresponding increase to the non-current liabilities in the balance sheets. The Company measures the fair value of this contingent promissory note at present value based on Level 2 inputs, using a discount rate for similar rated debt securities and is based on an estimated date that the Company believes the contingent promissory note will mature. The fair value of the contingent promissory note could be impacted by changes such as: (i) changes in the discount rate assumed, or (ii) a delay in the first commercial sale of the Product in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company assumed the liability concurrent with its IPO in February 2018 and therefore, did not carry a contingent promissory note payable balance at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The following table (in thousands) presents the difference between the carrying balance and the fair value of the contingent promissory note payable to the Evolus founders, a related party:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.15079365079364%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Carrying Balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#333333;"&gt;Contingent promissory note payable to Evolus Founders, a related party&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;16,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;17,181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Instruments Recorded at Fair Value on a Recurring Basis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table (in thousands) presents the major security types the Company held at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, that are measured at fair value on a recurring basis. The Company did not hold any major security types that required a fair value measurement on a recurring basis at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value Hierarchy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#333333;"&gt;Contingent royalty obligation payable to Evolus Founders, a related party&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in non-current liabilities in the balance sheets. The significant unobservable input assumptions that can significantly change the fair value includes (i) timing of the FDA approval of the Product, (ii) projected and timing of net revenues during the payment period, which will terminate for the quarter following the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; year anniversary of the first commercial sale of the Product in the United States, (iii) the discount rate, and (iv) the timing of payments. During the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company utilized discount rates ranging from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, reflecting changes in the Company&amp;#8217;s risk profile. Net revenue projections were also updated to reflect changes in the timing of expected regulatory approval and commercialization.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table (in thousands) shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable to a related party for year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.71428571428571%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Assumption of the royalty obligation payable to Evolus Founders, a related party&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;39,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Change in fair value recorded in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;10,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="FD2018Q4YTD" id="Fact-9E63ADFB1412649E9638A41A186134C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table (in thousands) presents the major security types the Company held at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, that are measured at fair value on a recurring basis. The Company did not hold any major security types that required a fair value measurement on a recurring basis at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value Hierarchy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#333333;"&gt;Contingent royalty obligation payable to Evolus Founders, a related party&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q4YTD" id="Fact-C8B38BCFC73BDD95DDF3A4170FCEFF6A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table (in thousands) shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable to a related party for year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.71428571428571%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Assumption of the royalty obligation payable to Evolus Founders, a related party&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;39,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Change in fair value recorded in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;10,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2018Q4YTD" id="Fact-AD4FC11DC224D33CFDAE33A28EBA2201">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-EF1E6381552F7ECA7E882F10CB2036A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Goodwill and Intangible Asset&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Goodwill and an intangible asset were established as a result of the application of push-down accounting in connection with the acquisition of the Company by SCH in October 2013, as described in Note 2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;, Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The purchase price was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the excess of which over the fair value of net assets acquired was recognized as goodwill of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;Goodwill recognized in connection with the acquisition is not deductible for tax purposes. The net assets acquired as of the acquisition date comprised solely of IPR&amp;amp;D valued at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and a deferred tax liability of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which represented the difference between the book and tax basis related to the IPR&amp;amp;D asset. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The IPR&amp;amp;D asset related to the development of the Product in clinical trials in the United States as of the acquisition date. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the carrying value of the IPR&amp;amp;D, included in intangible asset in the balance sheets, was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the carrying value of goodwill in the accompanying balance sheets was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The estimated fair value of the IPR&amp;amp;D asset on the acquisition date was determined &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;using a discounted cash flow model using an income approach (the multiple-period excess earnings method). Significant assumptions used in the valuation included projected future cash flows, projected costs, a weighted average cost of capital and appropriate discount rates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The IPR&amp;amp;D recognized represents the license and associated distribution rights to develop the Product and the ability to pursue new indications and is subject to the success of clinical studies. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As part of the transaction, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in additional cash consideration is due to Daewoong based upon Evolus&amp;#8217; successful completion of certain technical and sales milestones. The fair value of the milestones was recorded by the Company as an element of the acquired IPR&amp;amp;D at the acquisition date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Through 2018 the IPR&amp;amp;D asset is classified as an indefinite-lived intangible asset. With the recent FDA approval of Jeuveau, the IPR&amp;amp;D is no longer considered an indefinite-lived asset and amortization of the asset will commence in 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2018Q4YTD" id="Fact-161306D0E2E4A91778D433A2CF6D69D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&amp;#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reporting unit. There has been &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of goodwill for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2018Q4YTD" id="Fact-798892DB3CF365729C0F33A3490E095D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Asset&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The intangible asset in the accompanying balance sheets represents IPR&amp;amp;D projects acquired that have not yet been completed. IPR&amp;amp;D assets with indefinite useful lives are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the IPR&amp;amp;D assets are either amortized over their estimated useful lives or written-off immediately. There has been &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of long-lived assets for any periods presented&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-236C91FB9E6BD91297432EFC769E40DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total current benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred (benefit) provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(6,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(6,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total provision (benefit) for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(7,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has federal and state net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;99.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;72.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, which will begin to expire in year 2034. NOL carryforwards generated by the Company have been included in the consolidated and unitary income tax returns of ALPHAEON. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has federal research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) credit carryforwards of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, which will begin to expire in 2034. The Company also has California R&amp;amp;D credit carryforwards of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, which has an indefinite carryforward period. Deferred tax assets in the accompanying financial statements are presented as if the Company filed separate income tax returns. Accordingly, the NOL and the R&amp;amp;D credit carryforwards allocable to the Company based on ALPHAEON&amp;#8217;s consolidated and unitary income tax returns may ultimately differ from those presented in the financial statements on a separate return methodology.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period (a &amp;#8220;Section 382 ownership change&amp;#8221;), utilization of its pre-change NOL carryforwards and the R&amp;amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&amp;#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards and R&amp;amp;D credit carryforwards before utilization and may be material. As of December&amp;#160;31, 2018, the Company has not determined to what extent a potential ownership change will impact the annual limitation that may be placed on the Company&amp;#8217;s utilization of its NOL carryovers and R&amp;amp;D credit carryforwards. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The components of deferred tax assets and liabilities were as follows &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net operating losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;29,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Promissory note - debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(34,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(24,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recorded deferred tax assets of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$34.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$24.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, which have been fully offset by a valuation allowance. The valuation allowance &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;increased&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; during &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; primarily driven by the current year operating loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State income taxes, net of Federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development tax credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in Federal tax rate due to tax reform&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Promissory note - debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Revaluation of contingent royalty obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Meals and entertainment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(6,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(7,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Increases to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.  The Company&amp;#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&amp;#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&amp;#160;months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Company&amp;#8217;s tax returns for all years since inception are open for audit. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In December 2017, the Tax Cuts and Jobs Act (the &amp;#8220;TCJA&amp;#8221;) was enacted. The TCJA includes a number of changes to existing U.S. tax laws that impact the company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The TCJA also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017 as well as prospective changes beginning in 2018, including additional limitations on executive compensation, limitations on the deductibility of interest and capitalization of research and development expenditures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;While there were no changes in the net deferred tax assets, the Company has recorded a decrease in the valuation allowance of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and a reduction in the net deferred tax liability and a benefit to income tax expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the year ended December&amp;#160;31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The TCJA no longer allows deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance based compensation. It also subjects the principal executive officer, principal financial officer and three other highest paid officers to the limitation and once the individual becomes a covered person, the individual will remain a covered person for all future years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The company recognized the income tax effects of the TCJA in its 2017 financial statements in accordance with Staff Accounting Bulletin No. 118, which provides SEC staff guidance for the application of ASC Topic 740, Income Taxes, in the reporting period in which the TCJA was signed into law. As such, the Company's 2017 financial results reflected the provisional income tax effects of the TCJA for which the accounting was incomplete but a reasonable estimate was made. The Company&amp;#8217;s accounting for the elements of the TCJA was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-6291C99D812EB72AD90133A6A8A5694C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&amp;#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&amp;#160;50%&amp;#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-5DFE126833BEDC82864333A7320C7938">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In November 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which requires transactions in collaborative arrangements to be accounted for under ASC 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&amp;#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company will adopt the guidance on January 1, 2019, and does not expect such adoption will have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software: Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2018-15&amp;#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2021. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#8212; Changes to the Disclosure Requirements for Fair Value Measurement.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;ASU 2018-13&amp;#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&amp;#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the FASB issued&amp;#160;ASU No. 2018-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;, Compensation - Stock Compensation - Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The guidance in paragraph 718-740-35-2, as amended by the amendments in&amp;#160;ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&amp;#8217;s tax return. The amendment to paragraph 718-740-35-2 in this ASU clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2019. The Company is in the process of determining the effects the adoption will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2018, the FASB issued ASU No. 2018-07,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(&amp;#8220;ASU 2018-07&amp;#8221;) which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(&amp;#8220;ASU 2017-09&amp;#8221;) which amends the scope of modification accounting for stock-based payment arrangements.&amp;#160;The amendment&amp;#160;provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company adopted this guidance effective January 1, 2018 and this guidance did not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2017-04,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other (Topic 350&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;):&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This standard simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&amp;#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for us beginning January&amp;#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU 2017-01,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Business Combinations (Topic 805)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies when transactions should be accounted for as acquisitions (or disposals) of assets or business. ASU 2017-01 is effective for us beginning January&amp;#160;1, 2019. Early adoption is permitted for transactions not previously reported in issued financial statements. The Company is evaluating the effect of this standard on its financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU 2016-02 and its related amendments which introduced &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a new comprehensive lease accounting model that supersedes the current lease guidance under &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases, (Topic 840)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The new accounting standard requires lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The new accounting standard will be effective for the Company starting in the first quarter of fiscal 2019. The Company will elect the transition package of three practical expedients permitted under the transition guidance and will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods. Further, the Company will elect a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company will record right-of-use assets and liabilities and the corresponding deferred tax assets and liabilities on its balance sheet as of January 1, 2019, primarily associated with its operating leases. The Company is also finalizing the impact of the standard to its accounting policies, processes, disclosures, and internal control over financial reporting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(&amp;#8220;ASU 2016-13&amp;#8221;), which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. We are in the process of reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&amp;#8217;s present or future financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-D5B7460306A19A54C73C33913003133E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Organization&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Evolus, Inc., (&amp;#8220;Evolus&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. On February 1, 2019, the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) approved the Company&amp;#8217;s first product Jeuveau&amp;#8482; (the &amp;#8220;Product&amp;#8221;). The Product is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &amp;#8220;frown lines,&amp;#8221; in adults. The Company is headquartered in Newport Beach, California.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2018, the Company&amp;#8217;s board of directors and its then-sole stockholder approved an amendment to the Company&amp;#8217;s amended and restated certificate of incorporation to effect a split of shares of the Company&amp;#8217;s common stock on a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.6527&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-for-1 basis (the &amp;#8220;Stock Split&amp;#8221;). The Company&amp;#8217;s then-outstanding shares of convertible Series A preferred stock (&amp;#8220;Series A preferred stock&amp;#8221;), the par value of the common stock, and the authorized shares of the common stock were not adjusted as a result of the Stock Split. All issued and outstanding shares of common stock, stock options, restricted stock units and related per share amounts contained in the financial statements have been retroactively adjusted to reflect this Stock Split for all periods presented. The Stock Split was effected on January 26, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) and issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5,047,514&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of common stock, which included the exercise by the underwriters of their option to purchase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;47,514&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; additional shares of common stock, at an offering price to the public of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$12.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. The Company received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; after deducting underwriting discounts and commissions, excluding other offering costs. In connection with the IPO, the Company&amp;#8217;s then-outstanding shares of Series A preferred stock were automatically converted into &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,065,875&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock. In connection with the completion of its IPO, the Company&amp;#8217;s amended and restated certificate of incorporation was further amended and restated to provide for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;authorized shares of common stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of preferred stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Company completed a follow-on public offering (the &amp;#8220;Follow-On Offering&amp;#8221;) in which the Company sold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3,600,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;600,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock in August 2018, at a price to the public of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. The Company received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$67.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from the Follow-On Offering, after deducting underwriting discounts and commissions, excluding other offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the completion of its IPO, the Company also entered into a services agreement (the &amp;#8220;Services Agreement&amp;#8221;) with ALPHAEON Corporation (&amp;#8220;ALPHAEON&amp;#8221; or &amp;#8220;Parent&amp;#8221;), its controlling stockholder. The Services Agreement sets forth certain agreements between ALPHAEON and the Company that govern the respective responsibilities and obligations between ALPHAEON and the Company as it relates to the services to be performed between the parties. Pursuant to the Services Agreement, ALPHAEON provides the Company, and the Company provides ALPHAEON, certain administrative and development support services. Prior to the IPO, the Company was dependent upon ALPHAEON for its working capital and financing requirements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, ALPHAEON, which is majority-owned by SCH-AEON, LLC (&amp;#8220;SCH&amp;#8221;), owns&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;56.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;of the Company&amp;#8217;s outstanding shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity and Financial Condition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying financial statements&amp;#160;have been prepared&amp;#160;on a basis that&amp;#160;assumes that&amp;#160;the Company will continue as a going concern, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&amp;#8217;s assets and the satisfaction of the Company&amp;#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;he Company incurred operating losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$46.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. Additionally, the Company used &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in cash for operations in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$93.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in cash and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;has an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$123.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. On March 15, 2019, the Company entered into a term loan facility of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (see Note 11, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain market acceptance of its product and achieve a level of revenues adequate to support its cost structure, and operate its business and sell products without infringing third party intellectual property rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company believes that its current capital resources will be sufficient to fund operations through at least the next twelve months based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of its equity securities, incurring debt, entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs and other operational goals.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-932501F186B7A251A04F2F2D49E66139">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Services with ALPHAEON&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the Company&amp;#8217;s IPO and since the Company&amp;#8217;s acquisition in 2014 by ALPHAEON, the Company had funded its operations primarily through contributions and related party borrowings from ALPHAEON. ALPHAEON has historically provided Evolus certain services, including, without limitation, research and development, general and administrative support services and support services. ALPHAEON had historically allocated a certain percentage of personnel to perform the services that it provides to the Company based on its good faith estimate of the required services. These allocated costs reflect the ALPHAEON FTE rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing Evolus these services. Evolus historically had not paid a mark-up on the external or internal expenses ALPHAEON allocated to it. Prior to February 12, 2018, all research and development, general and administrative, and other support services expenses shown in the Company&amp;#8217;s financial statements for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; excluding stock-based compensation which is treated as a capital contribution, were treated as related party borrowings from ALPHAEON.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2018, the Company entered into the Services Agreement with ALPHAEON, which became effective upon the Company&amp;#8217;s IPO. The Services Agreement sets forth certain agreements between ALPHAEON and the Company that governs the respective responsibilities and obligations between ALPHAEON and the Company &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;as it relates to the services to be performed between them&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The Services Agreement has a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; year term and thereafter will renew for successive &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; year terms unless sooner terminated by either party. The Company or ALPHAEON may terminate the Services Agreement upon sixty days&amp;#8217; notice to the other party. In accordance with the Services Agreement, the Company paid ALPHAEON &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; during the first quarter of 2018, subsequent to the IPO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, Evolus had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related party accounts receivable or payable with ALPHAEON. As of December&amp;#160;31, 2017, Evolus had related party accounts receivable and related party borrowings of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$72.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; with ALPHAEON, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes the amounts that were allocated from ALPHAEON prior to the IPO, and included in Evolus&amp;#8217; general and administrative expenses as disclosed in the accompanying &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;statements of operations and comprehensive loss for the following periods (in thousands):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Compensation &amp;amp; Benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Third party service fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Facility related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;After completion of the Company&amp;#8217;s IPO on February 12, 2018, ALPHAEON did not incur any administrative or research and development expenses on the Company&amp;#8217;s behalf.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Note Obligation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In 2016, ALPHAEON entered into &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; separate debt transactions: (i) a convertible note with one of its stockholders, also a related party (the &amp;#8220;Bridge Note&amp;#8221;) with a principal amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and (ii) a Secured Convertible Note Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) pursuant to which ALPHAEON could issue up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$55.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;Note Facility&amp;#8221; and together with the Bridge Note, the &amp;#8220;Notes&amp;#8221;). The Notes have substantially similar terms and accrue simple interest at a rate of ten percent (&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;) per annum, subject to adjustment pursuant to terms of the Notes. The Notes may be paid at a redemption price equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; times the face amount of the Note less any prepayment of principal and any principal amount of the Notes that may convert into shares of ALPHAEON on (i) maturity in December 2018, (ii) a required prepayment event, or (iii) prepayment at any time at ALPHAEON&amp;#8217;s election. Upon the occurrence of certain corporate events at ALPHAEON, at the election of the holder, the Notes will convert into a variable number of shares of ALPHAEON with an aggregate fair value equaling the principal value of the Notes or such Notes will continue to maturity as unsecured promissory notes with a reduced interest rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ALPHAEON&amp;#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&amp;#8217;s assets, including all of the shares of the Company&amp;#8217;s capital stock held by ALPHAEON, which as of December 31, 2017 represented all of the Company&amp;#8217;s outstanding capital stock, as collateral for the holders of the Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In April 2017, ALPHAEON amended and restated the Purchase Agreement (the &amp;#8220;Amended and Restated Secured Note Purchase Agreement&amp;#8221;) with the Note holders to amend and restate the terms of the Purchase Agreement and the outstanding Notes and form of Notes to be issued. In addition, the Purchase Agreement was amended and restated to, among other things, set forth the terms for the issuance of up to an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in principal amount of Notes. Concurrent with the Amended and Restated Secured Note Purchase Agreement, the Company also executed two substantially similar guaranty and security agreements (the &amp;#8220;Guaranty Agreements&amp;#8221;), with the holders of the Notes. Pursuant to the Guaranty Agreements, the Company absolutely, unconditionally and irrevocably guaranteed, as primary obligor and not merely as surety, the full and punctual payment when due, whether at stated maturity or earlier, by reason of acceleration all the obligations of the Notes. In addition, pursuant to the Guaranty Agreements, the Company agreed to a first priority lien and security interest in and to all its right, title and interest in the assets of the Company. As a result of executing the Guaranty Agreements, there was no requirement that the holders of the Notes first seek payment from ALPHAEON. Instead, they may demand payment from the Company, from ALPHAEON or from both simultaneously. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements stipulate that any payment by the Company under their terms shall result in a dollar-for-dollar offset and reduction in the amount of related party loans owed by the Company to ALPHAEON. The Guaranty Agreements will terminate upon the earlier of (i) the date on which all secured obligations under the Guaranty Agreements have been paid and performed in full and (ii) the date on which the entire outstanding principal amount of the Notes has been either converted into equity or unsecured notes pursuant to the terms of the Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Concurrent with the execution of the Guaranty Agreements with the holders of the Notes in April 2017, the Company jointly and severally agreed to pay the redemption amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; times the principal amount of the Notes upon maturity if not paid by ALPHAEON. As a co-obligor to these Notes, the Company applied the accounting guidance provided in ASC 405-40, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Obligations Resulting from Joint and Several Liability Arrangements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This guidance requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount that the entity has (i) agreed to pay on the basis of its arrangement with its co-obligors and (ii) any additional amount that the entity expects to pay on behalf of its co-obligors. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company initially recorded a liability and corresponding deemed distribution to ALPHAEON as a reduction to additional paid-in-capital in equity in April 2017 to reflect the joint and several liability. These amounts were subsequently adjusted to reflect changes in the balance of the Note obligation.  As the Company and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, the Company developed a range of amounts that it expected to pay under the Guaranty Agreements and selected the amount from within that range that it determined to be the best estimate, which equaled &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$138.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On December 14, 2017, the Company and ALPHAEON entered into amendments with the holder of the convertible bridge note, and with the collateral agent for the holders of the convertible promissory notes. Under the terms of the amendment it was agreed that the Company&amp;#8217;s guaranty of the Notes and the security interest in the Company&amp;#8217;s assets would terminate effective upon the closing of the IPO. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Subsequent to December 31, 2017, ALPHAEON issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; additional convertible promissory notes, including &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; convertible promissory notes to Murthy Simhambhatla, Ph.D., the Company&amp;#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the Notes increased &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$140.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; times the total outstanding principal amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;) immediately prior to the IPO. Approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in excess of the then balance of additional paid-in capital was recorded in accumulated deficit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As provided for within the Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements, in conjunction with its recognition of the joint and several liability, the Company also recorded a receivable from ALPHAEON, which equals the current balance of the amounts it owed to ALPHAEON under its related party borrowing arrangements. No amounts were paid under this joint and several liability by the Company in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The difference between the amount of the joint and several liability and the related party receivable of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$66.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, was recorded as a deemed distribution to ALPHAEON, in stockholders&amp;#8217; equity (deficit) to additional paid-in capital in the period the transaction with the related party was made. Approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in excess of the then additional paid-in capital balance was recorded in accumulated deficit as of December 31, 2017. In January 2018 immediately prior to its IPO, the Company recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;an increase of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the receivable from ALPHAEON with a corresponding increase in additional paid-in capital. The related party receivable balance increased to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$73.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; immediately prior to the IPO&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of February 12, 2018, the Company was released of the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$140.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; note obligation for all guaranty and security obligations under the Guaranty Agreements, and the related party receivable from ALPHAEON of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$73.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was settled, resulting in a capital contribution of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$67.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. ALPHAEON&amp;#8217;s security interest in Evolus&amp;#8217; assets was also terminated. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Stockholders&amp;#8217; Equity (Deficit)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;-Equity Related Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, for more information regarding equity transactions that occurred in connection with the IPO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals who were previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&amp;#8217;s former Chief Operating Officer and consultant to the Company through December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Payment Obligations Related to the Acquisition by ALPHAEON&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the acquisition by SCH and ALPHAEON, as described in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Evolus Founders were issued Class D units of SCH which contained certain rights and privileges that provide the Evolus Founders with a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; economic interest in Evolus. The original payment obligations included (i) a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;perpetual quarterly royalties of a mid-teen percentage of net sales of the Product within the United States and (iii) a high-single digit percentages of net sales of the Product outside of the United States. As these future royalty streams are perpetual, ALPHAEON had the right under the Stock Purchase Agreement to terminate any future payments for a one-time lump sum payment to SCH of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$145.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On December 14, 2017, SCH and ALPHAEON entered into the Amended Purchase Agreement, whereby Evolus also joined as a contractual party. Pursuant to the Amended Purchase Agreement, ALPHAEON&amp;#8217;s existing payment obligations were replaced with revised payment obligations, payable directly to the Evolus Founders, to be distributed to them ratably in accordance with their previous respective percentage ownership in Series A preferred stock, and in exchange for the cancellation of the Class D units of SCH. Pursuant to the Amended Purchase Agreement, effective upon the closing of the IPO, ALPHAEON immediately and automatically assigned to Evolus and Evolus immediately and automatically accepted and assumed all of ALPHAEON&amp;#8217;s payment obligations under the Stock Purchase Agreement, as amended by the Amended Purchase Agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Amended Purchase Agreement, the revised payment obligations consist of (i) an approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) quarterly royalty payments of a low single digit percentage of net sales of the Product within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of the Product outside of the United States, and (iv) a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; promissory note that will mature on the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years anniversary of the first commercial sale of the Product in the United States. The revised payment obligations set forth in (ii) and (iii) above will terminate in the quarter following the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; year anniversary of the first commercial sale of the Product in the United States. As these revised payment obligations are not perpetual, neither Evolus nor ALPHAEON will have the right to terminate any future payments for a one-time lump sum payment. Under the Amended Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$55.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (comprised of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$39.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent royalty obligation and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent promissory note) as of February 12, 2018. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;for more information about the Company&amp;#8217;s accounting thereof. In addition, the outstanding related party borrowings from ALPHAEON were set-off and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations Evolus assumed from ALPHAEON, the fair value of which, as of February 12, 2018, was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$55.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Amended Purchase Agreement, Evolus agreed to make one-time bonuses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to certain of its former and current employees upon FDA approval of the Product, including a one-time bonus of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; payable to Rui Avelar, M.D., Evolus&amp;#8217; Chief Medical Officer and Head of Research &amp;amp; Development.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Evolus will have the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal will become immediately due and payable at the option of the holder. An event of default will occur under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;30&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; days. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition, upon a change-of-control of Evolus, all unpaid principal will become immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&amp;#8217; assets, (ii) the exclusive license of the Product or the business related to the Product to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company determined the fair value of the contingent royalty obligation payable to the Evolus Founders, a related party, was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$50.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and recorded a revaluation charge of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the accompanying statements of operations and comprehensive loss. The charges were driven by changes in assumptions relating to the timing of cash flows and the discount rate. The Company will revalue the contingent royalty obligation payable to the Evolus Founders, a related party, at each reporting period. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Amended Purchase Agreement, Evolus entered into a tax indemnity agreement with the Evolus Founders (&amp;#8220;Tax Indemnity Agreement&amp;#8221;) pursuant to which, effective upon Evolus&amp;#8217; assumption of the revised payment obligations under the Amended Purchase Agreement, which occurred upon the completion of the IPO, Evolus was obligated to indemnify the Evolus Founders for any tax liability resulting from such assignment of the revised payment obligations from ALPHAEON to Evolus. Under the Stock Purchase Agreement, the payment obligations are contingent and are thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. The entry into the Amended Purchase Agreement would cause the Evolus Founders to be treated for U.S. federal income tax purposes as receiving a distribution from SCH of the right to receive the contingent payments in a transaction in which no gain or loss is recognized such that the Evolus Founders may continue installment sale reporting with respect to the revised payment obligations to the same extent that installment sale reporting was available to SCH with respect to the original payment obligations prior to the execution of the Amended Purchase Agreement. Under the Tax Indemnity Agreement, Evolus was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Evolus&amp;#8217; assumption of the revised payment obligations under the Amended Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Purchase Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (the &amp;#8221;Distribution Agreement&amp;#8221;), with Clarion Medical Technologies Inc. (&amp;#8220;Clarion&amp;#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply the Product to Clarion in Canada.&amp;#160; Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind ALPHAEON&amp;#8217;s acquisition of Clarion. As a result, ALPHAEON owes the equity holders of Clarion an unwinding fee of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;Unwinding Fee&amp;#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of the Product purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee ALPHAEON owes. In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Distribution Agreement, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;if the Company did not receive approval from Health Canada to promote and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;sell the Product in Canada prior to October 31, 2018, the Company was obligated to pay liquidated damages to&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Clarion in the amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; within &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;30&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; days of December 31, 2018, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;which damages would not reduce the Unwinding Fee. In August 2018, the Company received approval from Health Canada to promote and sell the Product. Accordingly, the Company has concluded that no obligation exists and no liability has been recorded as of December 31, 2018. No amounts have been paid towards the Unwinding Fee as of December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Therapeutic Optio&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;n Letter Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On December 18, 2017, the Company entered into a therapeutic option letter agreement with ALPHAEON whereby certain rights to the therapeutic indications of the Product under the Daewoong Agreement were transferred by the Company to ALPHAEON. The Company recorded this transaction as a reduction of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the related party borrowings and a non-cash capital contribution from ALPHAEON, in additional paid-in capital on the balance sheets as of December 31, 2017. Once exercised, the rights to the therapeutic indications shall be solely in the control of ALPHAEON. As of December 31, 2018, the right to exercise the therapeutic option was exercised by ALPHAEON, which remitted the exercise price directly to Daewoong.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q4YTD" id="Fact-6B84EDB342A31CC2DCAF33A522B1D7C3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&amp;#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;There were no reimbursements of research and development expenses during the years ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At each financial reporting date, the Company accrues and expenses the estimated costs of clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates based upon a review of the agreements, data collected by internal and external personnel regarding the progress or stage of completion of trials or services. This progress or stage of completion of trials or services is monitored pursuant to contracts with clinical research organizations and other service providers. The agreed-upon fee to be paid for such services is based upon facts and circumstances known to the Company at each financial reporting date. If the actual performance of activities varies from the assumptions used in the estimates, the accruals are adjusted accordingly. There have been no material adjustments to the Company&amp;#8217;s prior period accrued estimates for clinical trial activities through &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-2B298127F1F67E9FD4E02F439033E432">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:6px;text-indent:26px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.17460317460318%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Payroll and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Professional services and related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-F14B6993A8E336B2DCD2A5938DB2BF68">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company incurred a net loss for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and, accordingly, the Company did not include the following dilutive common equivalent shares:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Common stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Unvested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;221,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,479,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2018Q4YTD" id="Fact-85E9874E9E94B4F2D3852F023785FA50">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The current and deferred expense is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total current benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred (benefit) provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(6,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(6,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total provision (benefit) for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(7,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-D25167609A3937F5C9422F068C052FF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The components of deferred tax assets and liabilities were as follows &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net operating losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;29,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Promissory note - debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(34,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(24,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2018Q4YTD" id="Fact-BD871ED750BF61BEC01BA59372096756">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth the computation of the Company&amp;#8217;s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(46,867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(4,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average shares outstanding used to compute basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;24,402,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;16,527,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-5F8FD37F8A5DD055A7682F1F3B1C3EFD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State income taxes, net of Federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development tax credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in Federal tax rate due to tax reform&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Promissory note - debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Revaluation of contingent royalty obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Meals and entertainment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(6,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(7,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q4YTD" id="Fact-CE19235C90E662EE171E825B98008423">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes stock-based compensation expense (in thousands) amounts recorded in the accompanying statements of operations and comprehensive loss pursuant to the Plan in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and allocated to Evolus by ALPHAEON in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;6,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-A47639ACFAEF4FD6C5C82F200B402912">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;uture minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;"&gt;Year Ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-06A2C1D0145C018680352F2DAF747CE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes the amounts that were allocated from ALPHAEON prior to the IPO, and included in Evolus&amp;#8217; general and administrative expenses as disclosed in the accompanying &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;statements of operations and comprehensive loss for the following periods (in thousands):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Compensation &amp;amp; Benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Third party service fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Facility related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-D24EE9ECA37BA0E687FD8281F2C6B4DC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of restricted stock unit activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;321,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(34,602)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(15,510)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;271,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;15.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-EEDF63505BBEDD2D215F822DEA007AF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of the status of the Company&amp;#8217;s nonvested options as of and changes during the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, are presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.25396825396825%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,840,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(582,923)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Terms (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,840,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;8,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(582,923)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(1,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercisable, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-5288C911AFD3D18AC30681EA90726027">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.04761904761905%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;57.76%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.65%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Dividend yield rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2018Q4YTD" id="Fact-62E1E06EC133A3DD0B022F265FC3F182">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Increases to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-23CE7C26B4234D1F997C33A24A436EC4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has determined that it operates in a single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;operating and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;reportable segment. The Company&amp;#8217;s chief operating decision maker, its Chief Executive Officer, manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q4YTD" id="Fact-7F050640B598FA710DEC33A663EE0731">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes stock-based compensation expense for employees and members of the Board of Directors based on the fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of actual forfeitures, when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&amp;#8217;s common stock, expected risk-free interest rate, and the option&amp;#8217;s expected life. The fair value of the Company&amp;#8217;s restricted stock units are based on the fair value of the grant date of the Company&amp;#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Compensation cost related to the grant of awards to the Company&amp;#8217;s employees is recognized as an increase to additional paid-in capital in the balance sheets and in the general and administrative or research and development expenses in the statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the IPO, the ALPHAEON common stock awards were valued at fair value on the date of grant and that fair value was recognized over the requisite service period. Estimates were used to determine the fair value of these awards, as shares of ALPHAEON&amp;#8217;s common stock are not publicly traded. ALPHAEON common stock awards are subject to specified vesting schedules and requirements. The Company estimated the fair value of each ALPHAEON option on the date of grant using the Black-Scholes model. Stock-based compensation expense is allocated to the Company over the required service period over which these ALPHAEON common stock awards and options would vest and is based upon the relative percentage of time utilized by ALPHAEON employees on Company matters. These ALPHAEON awards were recognized as a capital contribution which was recorded in the statement of stockholder&amp;#8217;s equity (deficit) and a corresponding entry was recorded in the accompanying statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q4YTD" id="Fact-F8733A86F30690CAB766339EDE561C6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). The financial statements for the periods prior to the Company&amp;#8217;s IPO have been prepared on a standalone basis and are derived from ALPHAEON&amp;#8217;s consolidated financial statements and accounting records and included an allocation of certain assets and liabilities that have historically been held at the ALPHAEON corporate level but which were specifically identifiable or allocable to the Company. . These results reflect amounts attributable to the Company&amp;#8217;s business, including the costs ALPHAEON incurred for the development and commercialization of the Product and costs and expenses under the License and Supply Agreement (the &amp;#8220;Daewoong Agreement&amp;#8221;) entered into with Daewoong Pharmaceuticals Co., Ltd. (&amp;#8220;Daewoong&amp;#8221;), a South Korean pharmaceutical manufacturer, in September 2013, as further described below in Note 5, C&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;ommitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the Company&amp;#8217;s IPO, ALPHAEON charged the Company external and internal administrative and research and development expenses that ALPHAEON incurred on the Company&amp;#8217;s behalf. External research and development expenses charged to the Company included costs for contract research organizations (&amp;#8220;CROs&amp;#8221;), costs to conduct nonclinical and clinical studies on the Product, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON charged these costs to the Company at the same amount that ALPHAEON incurred such cost. Internal development expenses included costs for the work that ALPHAEON development employees perform for the Company. ALPHAEON charged the Company a full-time equivalent (&amp;#8220;FTE&amp;#8221;) rate that covers personnel-related expenses, including salaries and benefits, plus an allocation of facility-related expenses, including rent, utilities, depreciation, insurance and property taxes, for those research and development employees who work either directly or indirectly on the development of the Company&amp;#8217;s drugs and certain administrative employees. ALPHAEON calculated the facility-related expenses to the Company based on a percentage of aggregate expenses incurred at ALPHAEON. ALPHAEON calculated depreciation expense of property and equipment using the straight-line method over the estimated useful lives of its assets of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As a result, the Company historically incurred related party borrowings from ALPHAEON for its share of the internal and external expenses for each of these functions based on the Company&amp;#8217;s relative use of each function, plus an allocation of facility-related expenses. The Company&amp;#8217;s management believes that the allocation and results were reasonable. As of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt;, the Company did not have any accounts receivable or payable with ALPHAEON pursuant to the Services Agreement or otherwise.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has calculated its income tax amounts using a separate return methodology and has presented these amounts as if it were a separate taxpayer from ALPHAEON in each jurisdiction for each period the Company presented. Subsequent to the IPO, the Company will prepare a stand-alone tax return. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company did not have a tax sharing agreement with ALPHAEON. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;), and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Evolus was formed in November 2012 for the purposes of developing the Product for distribution and sale. In October 2013,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in a Stock Purchase Agreement, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;SCH acquired all of the Company&amp;#8217;s outstanding equity in exchange for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; Class AA units of SCH and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; Class D units of SCH, which resulted in SCH obtaining a controlling financial interest in Evolus.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the transaction with SCH, Evolus had executed a License and Supply Agreement with Daewoong and thereby secured exclusive rights to license and distribute the Product for aesthetic indications in the United States and certain other international markets, as well as non-exclusive rights to distribute in Japan (see &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 4, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;). The acquisition of the Company, which represented a business combination by SCH, was to provide SCH and ALPHAEON access to the license held by Evolus to develop, produce and market clinical neurotoxins. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In a series of related transactions in 2013, SCH acquired all of the Company&amp;#8217;s outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed equity that it had acquired in 2013 to ALPHAEON. As a result of these transactions, the Company became a wholly-owned subsidiary of ALPHAEON.  The Company remained a wholly-owned subsidiary of ALPHAEON until the completion of the IPO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;SCH elected to apply push-down accounting pursuant to the guidance in ASC 805, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Business Combinations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Accordingly, the financial statements reflect the new basis of accounting established by SCH when SCH obtained control of the Company in October 2013. The assets acquired and liabilities assumed in connection with the acquisition were recognized based on their estimated fair values at the acquisition date. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates.&amp;#160;The estimated fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the acquisition, SCH and ALPHAEON entered into a stock purchase agreement (the &amp;#8220;Stock Purchase Agreement&amp;#8221;) pursuant to which they were obligated to make certain contingent payments to the Evolus Founders. However, since Evolus did not have an obligation associated with the contingent consideration arrangement prior to the Company&amp;#8217;s IPO, no amounts were recognized in the Company&amp;#8217;s financial statements for the contingent royalty obligation arrangement between SCH and ALPHAEON, and the Evolus Founders. As described in Note 4, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, on December 14, 2017, SCH and ALPHAEON entered into an amendment to the Stock Purchase Agreement (the &amp;#8220;Amended Purchase Agreement&amp;#8221;), and the Company joined as a contractual party. Upon the closing of the IPO on February 12, 2018, ALPHAEON immediately and automatically assigned to the Company its payment obligations under the Amended Purchase Agreement. These payment obligations are referred to as the &amp;#8220;contingent royalty obligation payable to Evolus Founders, a related party&amp;#8221; and the &amp;#8220;contingent promissory note payable to Evolus Founders, a related party&amp;#8221; in the accompanying balance sheets. Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&amp;#8217;s former Chief Operating Officer. Mr. Marmo was retained as a consultant to the Company until December 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;royalty obligations, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Although it has received the regulatory approval from the FDA and Health Canada, the Company has not commenced principal operations in the form of commercialized Product sales. The Product also requires regulatory approval from the European Medicines Agency and other similar regulatory authorities prior to commercial sales in the related jurisdictions. The Product and any future product candidates of the Company may not receive necessary approvals in the jurisdictions where approval is sought. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company&amp;#8217;s business and its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of the Product and any future product candidates, ability to obtain regulatory approval of the Product and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company relies on Daewoong, our exclusive and sole supplier, to manufacture the Product. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&amp;#8217;s commercialization of the Product. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has determined that it operates in a single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;operating and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;reportable segment. The Company&amp;#8217;s chief operating decision maker, its Chief Executive Officer, manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&amp;#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reporting unit. There has been &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of goodwill for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Asset&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The intangible asset in the accompanying balance sheets represents IPR&amp;amp;D projects acquired that have not yet been completed. IPR&amp;amp;D assets with indefinite useful lives are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the IPR&amp;amp;D assets are either amortized over their estimated useful lives or written-off immediately. There has been &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of long-lived assets for any periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Deferred offering costs, which primarily consisted of direct incremental legal and accounting fees relating to the IPO or Follow-On Offering, are capitalized until such time as the offering closes. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of deferred offering costs were offset against proceeds from the sale of registered equity securities in the Company&amp;#8217;s IPO and Follow-On Offering. As of December&amp;#160;31, 2018, the Company did &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;t capitalize any deferred offering costs. As of December&amp;#160;31, 2017, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of deferred offering costs were capitalized and included in &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Other assets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8221; in the accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Joint and Several Liability Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has (i) agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amounts that the Company expects to pay on behalf of its co-obligors. The determination of the &amp;#8220;best estimate&amp;#8221; from within the range of amounts that might be paid involves substantial judgment by the Company&amp;#8217;s management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&amp;#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;There were no reimbursements of research and development expenses during the years ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At each financial reporting date, the Company accrues and expenses the estimated costs of clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates based upon a review of the agreements, data collected by internal and external personnel regarding the progress or stage of completion of trials or services. This progress or stage of completion of trials or services is monitored pursuant to contracts with clinical research organizations and other service providers. The agreed-upon fee to be paid for such services is based upon facts and circumstances known to the Company at each financial reporting date. If the actual performance of activities varies from the assumptions used in the estimates, the accruals are adjusted accordingly. There have been no material adjustments to the Company&amp;#8217;s prior period accrued estimates for clinical trial activities through &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Payment Obligation Payable to the Evolus Founders, a Related Party&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in the non-current liabilities in the balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Promissory Note Payable to Evolus Founders, a Related Party&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company assumed the liability concurrent with the IPO and determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes stock-based compensation expense for employees and members of the Board of Directors based on the fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of actual forfeitures, when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&amp;#8217;s common stock, expected risk-free interest rate, and the option&amp;#8217;s expected life. The fair value of the Company&amp;#8217;s restricted stock units are based on the fair value of the grant date of the Company&amp;#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Compensation cost related to the grant of awards to the Company&amp;#8217;s employees is recognized as an increase to additional paid-in capital in the balance sheets and in the general and administrative or research and development expenses in the statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the IPO, the ALPHAEON common stock awards were valued at fair value on the date of grant and that fair value was recognized over the requisite service period. Estimates were used to determine the fair value of these awards, as shares of ALPHAEON&amp;#8217;s common stock are not publicly traded. ALPHAEON common stock awards are subject to specified vesting schedules and requirements. The Company estimated the fair value of each ALPHAEON option on the date of grant using the Black-Scholes model. Stock-based compensation expense is allocated to the Company over the required service period over which these ALPHAEON common stock awards and options would vest and is based upon the relative percentage of time utilized by ALPHAEON employees on Company matters. These ALPHAEON awards were recognized as a capital contribution which was recorded in the statement of stockholder&amp;#8217;s equity (deficit) and a corresponding entry was recorded in the accompanying statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&amp;#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&amp;#160;50%&amp;#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the effects of common stock equivalents such as convertible preferred stock and stock options outstanding. Diluted net loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issued common stock were exercised or converted to common stock. Dilutive common share equivalents are comprised of convertible preferred stock and stock options outstanding during the period, but are excluded if their impact is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the years ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In November 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which requires transactions in collaborative arrangements to be accounted for under ASC 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&amp;#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company will adopt the guidance on January 1, 2019, and does not expect such adoption will have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software: Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2018-15&amp;#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2021. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#8212; Changes to the Disclosure Requirements for Fair Value Measurement.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;ASU 2018-13&amp;#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&amp;#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the FASB issued&amp;#160;ASU No. 2018-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;, Compensation - Stock Compensation - Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The guidance in paragraph 718-740-35-2, as amended by the amendments in&amp;#160;ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&amp;#8217;s tax return. The amendment to paragraph 718-740-35-2 in this ASU clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2019. The Company is in the process of determining the effects the adoption will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2018, the FASB issued ASU No. 2018-07,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(&amp;#8220;ASU 2018-07&amp;#8221;) which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(&amp;#8220;ASU 2017-09&amp;#8221;) which amends the scope of modification accounting for stock-based payment arrangements.&amp;#160;The amendment&amp;#160;provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company adopted this guidance effective January 1, 2018 and this guidance did not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2017-04,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other (Topic 350&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;):&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This standard simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&amp;#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for us beginning January&amp;#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU 2017-01,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Business Combinations (Topic 805)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies when transactions should be accounted for as acquisitions (or disposals) of assets or business. ASU 2017-01 is effective for us beginning January&amp;#160;1, 2019. Early adoption is permitted for transactions not previously reported in issued financial statements. The Company is evaluating the effect of this standard on its financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU 2016-02 and its related amendments which introduced &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a new comprehensive lease accounting model that supersedes the current lease guidance under &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases, (Topic 840)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The new accounting standard requires lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The new accounting standard will be effective for the Company starting in the first quarter of fiscal 2019. The Company will elect the transition package of three practical expedients permitted under the transition guidance and will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods. Further, the Company will elect a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company will record right-of-use assets and liabilities and the corresponding deferred tax assets and liabilities on its balance sheet as of January 1, 2019, primarily associated with its operating leases. The Company is also finalizing the impact of the standard to its accounting policies, processes, disclosures, and internal control over financial reporting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(&amp;#8220;ASU 2016-13&amp;#8221;), which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. We are in the process of reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&amp;#8217;s present or future financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-B51FD96EE2BC04EE96D6343D37665242">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity (Deficit)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company completed its IPO of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5,047,514&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of common stock, which included the exercise by the underwriters of their option to purchase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;47,514&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; additional shares of common stock, for net proceeds of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, after deducting underwriting discounts and commissions, excluding other offering costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Company completed the Follow-On Offering in which the Company sold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3,600,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;600,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock in August 2018, at a price to the public of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. The Company received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$67.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from the Follow-On Offering, after deducting underwriting discounts and commissions, and excluding other offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Convertible Series A Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,500,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Series A preferred stock&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized, of which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,250,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were issued or outstanding. ALPHAEON, as the previous sole holder of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Series A preferred stock prior to the IPO,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; had certain dividends, conversion, redemption, voting, protective, and liquidation preferences. The number of shares of common stock to which a preferred stockholder was entitled was the product obtained by multiplying the Series A preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the amended and restated certificate of incorporation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the IPO, all shares of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Series A preferred stock&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were converted into &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,065,875&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock. In addition, the Company also amended and restated its certificate of incorporation. As a result, shares of Series A convertible preferred stock were canceled, with none authorized, issued or outstanding as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the completion of its IPO, the Company also amended and restated its certificate of incorporation to provide for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of preferred stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. At &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of preferred stock authorized, of which none were issued and outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the completion of its IPO, the Company also amended and restated its certificate of incorporation to provide for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of common stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. At &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock authorized, of which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;27,274,991&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were issued and outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Related Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of February 12, 2018, the Company assumed from ALPHAEON the revised payment obligations under the Amended Purchase Agreement of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$55.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (comprised of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$39.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent royalty obligation and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent promissory note at that date). See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information. Pursuant to the Amended Purchase Agreement, ALPHAEON agreed to offset and reduce the amount of related party borrowings by the estimated value of the revised payment obligations on a dollar-for-dollar basis and pursuant to the Services Agreement. Additionally, the Company paid &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to ALPHAEON in satisfaction of a portion of the outstanding related party borrowings (see &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;). The remaining balance of related party borrowings of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was recharacterized as a capital contribution from ALPHAEON pursuant to the Services Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2017 Omnibus Incentive Plan and Stock-based Compensation Allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On November 21, 2017, t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;he board of directors and the then-sole stockholder of the Company approved the Company&amp;#8217;s 2017 Omnibus Incentive Plan (the &amp;#8220;Plan&amp;#8221;). The Plan provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&amp;#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,361,291&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares, plus an annual increase on each anniversary of November 21, 2017 equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the total issued and outstanding shares of the Company&amp;#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&amp;#8217;s board of directors). On November 21, 2018, an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,091,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were reserved under the evergreen provision of the Plan. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company reserved an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,888,484&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock for future issuance under the Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Award Activity and Balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of restricted stock units (&amp;#8220;RSUs&amp;#8221;) is estimated at the Company&amp;#8217;s grant date common share price. Options are granted at exercise prices based on the Company&amp;#8217;s grant date common share price. The RSUs and options generally vest over a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;- to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year period. There have been no awards with performance conditions and no awards with market conditions. The options generally have a contractual term of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. The Black&amp;#8209;Scholes option pricing model has various inputs, including the grant date common share price, exercise price, risk&amp;#8209;free interest rate, volatility, expected life and dividend yield. The Company records share&amp;#8209;based compensation expense net of actual forfeitures. The change of any of these inputs could significantly impact the determination of the fair value of the Company&amp;#8217;s options as well as significantly impact its results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The significant assumptions used in the Black-Scholes option-pricing are as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Determining Fair Value of the underlying common stock.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;For options awards granted after the completion of the Company&amp;#8217;s IPO, the fair value for its underlying common stock was determined using the fair value of the grant date price as reported on the Nasdaq Global Select Market. Since the Company&amp;#8217;s common stock was not traded in a public stock market exchange prior to the Company&amp;#8217;s IPO, prior to such date the Board of Directors considered numerous factors including new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company&amp;#8217;s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company&amp;#8217;s initial public offering, the Board of Directors determined the Company&amp;#8217;s common stock fair market value on as needed basis.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Expected Volatility.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The Company has limited data regarding company&amp;#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Expected Term.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience for exercise and post-vesting employment or contractual termination behavior after its common stock has been publicly traded. The expected term of &amp;#8220;plain vanilla&amp;#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&amp;#8209;average expected term of the Company&amp;#8217;s options is approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Risk&amp;#8209;Free Rate.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The risk&amp;#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&amp;#8209;coupon issues with a term approximately equal to the expected life of the option being valued.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Dividends.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not grant stock options, restricted stock units, or restricted stock awards during the year ended December 31, 2017. The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.04761904761905%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;57.76%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.65%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Dividend yield rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Terms (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,840,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;8,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(582,923)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(1,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercisable, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the Company&amp;#8217;s common stock for those awards that have an exercise price below the estimated fair value at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the year ended December 31, 2018, the Company recorded expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to stock options. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$18.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of total unrecognized compensation cost, net of actual forfeitures, related to stock option based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3.3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of the status of the Company&amp;#8217;s nonvested options as of and changes during the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, are presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.25396825396825%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,840,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(582,923)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of restricted stock unit activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;321,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(34,602)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(15,510)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;271,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;15.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the year ended December 31, 2018, the Company recorded expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to restricted stock units. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of total unrecognized compensation cost, net of actual forfeitures, related to stock option based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes stock-based compensation expense (in thousands) amounts recorded in the accompanying statements of operations and comprehensive loss pursuant to the Plan in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and allocated to Evolus by ALPHAEON in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;6,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Separation of Service with the Former President and Chief Executive Officer&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2018, the Company entered into a separation agreement (the &amp;#8220;Separation Agreement&amp;#8221;) with its then President and Chief Executive Officer&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, Murthy Simhambhatla, Ph.D&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Pursuant to the Separation Agreement, the Company modified previously &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;granted stock options resulting in an incremental vesting of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,424&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; stock options and related stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As part of the Separation Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;34,602&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock net of tax withholding for vested restricted stock units. An additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;50,112&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock were immediately vested and will be issued in February 2020. Stock-based compensation expense relating to the issuance of common stock and accelerated vesting was approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The aforementioned non-cash charges are reflected in general and administrative on the statements of operations and comprehensive loss for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q4YTD" id="Fact-7E84420820C39CC838B4A9EC36F506A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 1, 2019, the FDA granted approval of the Company&amp;#8217;s BLA for the Product. In February 2019, pursuant to the Amended Purchase Agreement, the Company paid a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment to the Evolus Founders and one-time bonuses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to certain former and current employees, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;including a one-time bonus of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; payable to Rui Avelar, M.D., Evolus&amp;#8217; Chief Medical Officer and Head of Research &amp;amp; Development. In addition, pursuant to the Daewoong Agreement, the Company paid Daewoong a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment in February 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On March 15, 2019, the Company entered into a credit facility of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; with Oxford Finance, LLC (&amp;#8220;Oxford&amp;#8221;). Pursuant to the credit facility the lender will make term loans available in two advances. The first tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was funded on the closing date. The second tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing six month basis and no event of default is occurring. The credit facility bears an annual interest rate equal to the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;9.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, or the 30-day U.S. Dollar LIBOR rate plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;7.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Company has agreed to pay interest only on each tranche funded for the first &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; months until May 2022, which will be followed by a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;23&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&amp;#8217;s request, the interest only period may be extended by an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;12&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; months to a total of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;48&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; months followed by an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month amortization period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company will be required to pay to Oxford a final payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the full principal amount of the term loans funded, or the final payment. The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs thereafter (the &amp;#8220;Prepayment Fee&amp;#8221;). If the term loans are accelerated following the occurrence of an event of default, the Company will be required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the final payment, the Prepayment Fee, and all other obligations that are due and payable, including payment of Oxford&amp;#8217;s expenses and interest at the default rate with respect to any past due amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including its cash.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q4YTD" id="Fact-E0F91A30CB58CDBFD57B33A1DFA02C54">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;royalty obligations, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>eols-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolus.com/20181231" xmlns:eols="http://www.evolus.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.evolus.com/role/AccruedExpenses">
        <link:definition>2107100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.evolus.com/role/AccruedExpensesDetails">
        <link:definition>2407402 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.evolus.com/role/AccruedExpensesTables">
        <link:definition>2307301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.evolus.com/role/BalanceSheets">
        <link:definition>1001000 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.evolus.com/role/CommitmentsAndContingencies">
        <link:definition>2105100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2405402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2305301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.evolus.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.evolus.com/role/FairValueMeasurements">
        <link:definition>2106100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPromissoryNoteDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails">
        <link:definition>2406403 - Disclosure - Fair Value Measurements - Contingent Promissory Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2406402 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsRecurringBasisDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails">
        <link:definition>2406404 - Disclosure - Fair Value Measurements - Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.evolus.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAsset" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAsset">
        <link:definition>2103100 - Disclosure - Goodwill and Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails">
        <link:definition>2403401 - Disclosure - Goodwill and Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolus.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfIncomeTaxDetails" roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails">
        <link:definition>2408402 - Disclosure - Income Taxes - Components of Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2408404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2408403 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfEffectiveTaxDetails" roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails">
        <link:definition>2408405 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.evolus.com/role/IncomeTaxesTables">
        <link:definition>2308301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>2408406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholders" roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders">
        <link:definition>2110100 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>2410402 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>2310301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolus.com/role/Organization">
        <link:definition>2101100 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolus.com/role/OrganizationDetails">
        <link:definition>2401401 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.evolus.com/role/RelatedPartyTransactions">
        <link:definition>2104100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2404402 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsRelatedPartyExpensesDetails" roleURI="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails">
        <link:definition>2404403 - Disclosure - Related Party Transactions - Related Party Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.evolus.com/role/RelatedPartyTransactionsTables">
        <link:definition>2304301 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfCashFlows" roleURI="http://www.evolus.com/role/StatementsOfCashFlows">
        <link:definition>1004000 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfStockholdersEquityDeficit" roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.evolus.com/role/StockholdersEquityDeficit">
        <link:definition>2109100 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitNarrativeDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails">
        <link:definition>2409402 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails">
        <link:definition>2409405 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Nonvested Award Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails">
        <link:definition>2409406 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails">
        <link:definition>2409404 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails">
        <link:definition>2409403 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails">
        <link:definition>2409407 - Disclosure - Stockholders' Equity (Deficit) - Stock-based Compensation Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitTables" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables">
        <link:definition>2309301 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.evolus.com/role/SubsequentEvents">
        <link:definition>2111100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.evolus.com/role/SubsequentEventsDetails">
        <link:definition>2411401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2402402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="eols_ALPHAEONMember" name="ALPHAEONMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_AccountsPayablePaidbyParent" name="AccountsPayablePaidbyParent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ApplicableRateMember" name="ApplicableRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_BridgeNoteMember" name="BridgeNoteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessAcquisitionUnwindingFee" name="BusinessAcquisitionUnwindingFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationLiquidatedDamages" name="BusinessCombinationLiquidatedDamages" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval" name="BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded" name="BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" name="BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement" name="BusinessCombinationUpfrontPaymentUponPurchaseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionConvertibleNoteWriteOff" name="CapitalContributionConvertibleNoteWriteOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionForgivenessofRelatedPartyBorrowings" name="CapitalContributionForgivenessofRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" name="CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionTherapeuticOptionRightNetOfTax" name="CapitalContributionTherapeuticOptionRightNetOfTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ChiefMedicalOfficerMember" name="ChiefMedicalOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_CommonClassAAMember" name="CommonClassAAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_CommonClassDMember" name="CommonClassDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="eols_CompensationAndBenefitTransactionsMember" name="CompensationAndBenefitTransactionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_ContingentPromissoryNote" name="ContingentPromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_ContingentRoyaltyObligation" name="ContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ContingentRoyaltyObligationMember" name="ContingentRoyaltyObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_DaewoongMember" name="DaewoongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAdditionalAmortizationPeriod" name="DebtInstrumentAdditionalAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance" name="DebtInstrumentAdditionalAmountAuthorizedForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" name="DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAmortizationPeriod" name="DebtInstrumentAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentDefaultInterestRate" name="DebtInstrumentDefaultInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentNumberOfDebtTransactions" name="DebtInstrumentNumberOfDebtTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" name="DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPeriodOfInterestOnlyPayments" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" name="DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageThereafter" name="DebtInstrumentPrepaymentFeePercentageThereafter" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageYearTwo" name="DebtInstrumentPrepaymentFeePercentageYearTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentTermAggregatePeriod" name="DebtInstrumentTermAggregatePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" name="DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_DeferredOfferingCostsAccruedUnpaid" name="DeferredOfferingCostsAccruedUnpaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" name="DeferredTaxAssetsPromissoryNoteDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="eols_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" name="EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" name="EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_EvolusIncMember" name="EvolusIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_FacilityRelatedTransactionsMember" name="FacilityRelatedTransactionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_FollowOnOfferingMember" name="FollowOnOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_InterestExpenseOperatingActivities" name="InterestExpenseOperatingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashCapitalDistributionFromParent" name="NonCashCapitalDistributionFromParent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashDeferredOfferingCosts" name="NonCashDeferredOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashNoteObligation" name="NonCashNoteObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashRelatedPartyBorrowings" name="NonCashRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashRelatedPartyReceivable" name="NonCashRelatedPartyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_OtherTransactionsMember" name="OtherTransactionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_OxfordFinanceLLCMember" name="OxfordFinanceLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyBorrowingsandNonCashCapitalContribution" name="RelatedPartyBorrowingsandNonCashCapitalContribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote" name="RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation" name="RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" name="RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote" name="RelatedPartyTransactionPeriodofMaturityofPromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionRenewalPeriodOption" name="RelatedPartyTransactionRenewalPeriodOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionTermOfAgreement" name="RelatedPartyTransactionTermOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionTotalAmountsofTransaction" name="RelatedPartyTransactionTotalAmountsofTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty" name="RevaluationofContingentRoyaltyObligationPayabletoRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_SCHAEONLLCMember" name="SCHAEONLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_StockBasedCompensationTransactionsMember" name="StockBasedCompensationTransactionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" name="StockPurchaseAgreementPeriodAvailabletoCureBreach" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_TaxBenefitFromTherapeuticOptionRight" name="TaxBenefitFromTherapeuticOptionRight" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" name="TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityTrancheOneMember" name="TermLoanFacilityTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityTrancheTwoMember" name="TermLoanFacilityTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ThirdPartyServiceFeesMember" name="ThirdPartyServiceFeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>eols-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:href="eols-20181231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:href="eols-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesDetails" xlink:href="eols-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurements" xlink:href="eols-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsContingentPromissoryNoteDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:href="eols-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAsset" xlink:href="eols-20181231.xsd#GoodwillAndIntangibleAsset" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails" xlink:href="eols-20181231.xsd#GoodwillAndIntangibleAssetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:href="eols-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails" xlink:href="eols-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="eols-20181231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:href="eols-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:href="eols-20181231.xsd#IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:href="eols-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="eols-20181231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/Organization" xlink:href="eols-20181231.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OrganizationDetails" xlink:href="eols-20181231.xsd#OrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsTables" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfCashFlows" xlink:href="eols-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20181231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eols-20181231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:href="eols-20181231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEvents" xlink:href="eols-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEventsDetails" xlink:href="eols-20181231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_a9404622-3e0d-75e3-c107-27ef98863b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_a9404622-3e0d-75e3-c107-27ef98863b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_4783dc20-aefc-5bce-a995-042d9fcf4dcc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_4783dc20-aefc-5bce-a995-042d9fcf4dcc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_cd826f20-6b4c-b457-3189-ea81282fdd01" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_NotesPayableCurrent_cd826f20-6b4c-b457-3189-ea81282fdd01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAsset" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42b61cde-44f6-df44-52b0-1b84b1e28a47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42b61cde-44f6-df44-52b0-1b84b1e28a47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8d3f7f58-e2d6-8ff0-86f5-8d249c7b8257" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8d3f7f58-e2d6-8ff0-86f5-8d249c7b8257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_ed0fcf32-bd00-072a-6e92-10a0ac8015fc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_ed0fcf32-bd00-072a-6e92-10a0ac8015fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7f86d0ad-9065-5c14-f7d0-2ff3cc4df692" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7f86d0ad-9065-5c14-f7d0-2ff3cc4df692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" xlink:label="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_3C3D988A28A8E4C3691C7E2106BAC230" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_3C3D988A28A8E4C3691C7E2106BAC230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e8fd0f39-0d07-8442-4833-5ebc3fe9de2e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e8fd0f39-0d07-8442-4833-5ebc3fe9de2e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_46fd3e47-b379-3d5b-dad7-1fdc5e88b67f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_46fd3e47-b379-3d5b-dad7-1fdc5e88b67f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_147896db-b2dd-402f-9f5b-8c57c745a45a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_147896db-b2dd-402f-9f5b-8c57c745a45a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1c8f4a72-9556-38d6-3d32-089e2d1a35fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1c8f4a72-9556-38d6-3d32-089e2d1a35fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b8a6f67f-d570-db88-37fa-3568c826ebc5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b8a6f67f-d570-db88-37fa-3568c826ebc5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2fc8d554-3ed0-9aae-a23b-3842180d9904" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2fc8d554-3ed0-9aae-a23b-3842180d9904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_cd5d6b42-02c0-feb4-e73a-32cda2d1ac2e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_cd5d6b42-02c0-feb4-e73a-32cda2d1ac2e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_403b8245-2a5c-b405-4865-11cfdebd2992" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_403b8245-2a5c-b405-4865-11cfdebd2992" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_43A6D4B5325674B33FC07E23BDD7D95D" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_43A6D4B5325674B33FC07E23BDD7D95D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_3C2420772CC15E9492B97E24C8DEAC3A" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_3C2420772CC15E9492B97E24C8DEAC3A" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/Organization" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OrganizationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_678cc0a1-75a1-b1b0-39a1-094379144ce2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_678cc0a1-75a1-b1b0-39a1-094379144ce2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_c23b0f03-076e-13f1-e1f8-2a075c507718" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_c23b0f03-076e-13f1-e1f8-2a075c507718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_2d849574-a59f-d3ca-36e0-41805746b19e" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_2d849574-a59f-d3ca-36e0-41805746b19e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ea422513-12bd-029b-0166-7c34286633bc" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ea422513-12bd-029b-0166-7c34286633bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_InterestExpenseOperatingActivities" xlink:label="loc_eols_InterestExpenseOperatingActivities_2F803C583F4539078A339677345339A0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_eols_InterestExpenseOperatingActivities_2F803C583F4539078A339677345339A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxBenefitFromTherapeuticOptionRight" xlink:label="loc_eols_TaxBenefitFromTherapeuticOptionRight_044759610A052F22BEFE2E81F09B4536" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_eols_TaxBenefitFromTherapeuticOptionRight_044759610A052F22BEFE2E81F09B4536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_ab9f554b-15e5-4f4c-5e4e-40e86ea4adb3" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_ab9f554b-15e5-4f4c-5e4e-40e86ea4adb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_913647fc-054b-9279-dca3-8040bc4675e7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_913647fc-054b-9279-dca3-8040bc4675e7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>eols-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:href="eols-20181231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:href="eols-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesDetails" xlink:href="eols-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurements" xlink:href="eols-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsContingentPromissoryNoteDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:href="eols-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAsset" xlink:href="eols-20181231.xsd#GoodwillAndIntangibleAsset" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails" xlink:href="eols-20181231.xsd#GoodwillAndIntangibleAssetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:href="eols-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails" xlink:href="eols-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="eols-20181231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:href="eols-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:href="eols-20181231.xsd#IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:href="eols-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="eols-20181231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/Organization" xlink:href="eols-20181231.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OrganizationDetails" xlink:href="eols-20181231.xsd#OrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsTables" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfCashFlows" xlink:href="eols-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20181231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eols-20181231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:href="eols-20181231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEvents" xlink:href="eols-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEventsDetails" xlink:href="eols-20181231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:to="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:to="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:to="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_88867EDD34E3743052F49146218199EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_88867EDD34E3743052F49146218199EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:to="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CF9AC995ECE11B2BE0E891462182872C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CF9AC995ECE11B2BE0E891462182872C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_F88C452ECE719A9C105E914621830974" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_F88C452ECE719A9C105E914621830974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BB928DB63D4B3B3FA07C91462183B021" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_Goodwill_BB928DB63D4B3B3FA07C91462183B021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_32D7BACC021435CDCDA79146218542CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_NotesPayableCurrent_32D7BACC021435CDCDA79146218542CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_0B7793C7A21B2269A75C91462185B874" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_ContractualObligation_0B7793C7A21B2269A75C91462185B874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_8FE20BF0FDB4B56F4FB791462186C2E6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_LongTermNotesPayable_8FE20BF0FDB4B56F4FB791462186C2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5FD4DF47FA5F344E2FBD91462187E178" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5FD4DF47FA5F344E2FBD91462187E178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:to="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:to="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_90B247694B9216C4CD8191462172C93E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_90B247694B9216C4CD8191462172C93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:to="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_C34B85765336DA59677191E3DBACCBC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:to="loc_eols_DaewoongMember_C34B85765336DA59677191E3DBACCBC6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:to="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:to="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:to="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983" xlink:to="loc_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_5DE97788D2375B4BB6BC91E3DBAE01D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_5DE97788D2375B4BB6BC91E3DBAE01D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06B930E8CC46D717F09D82AC88A66C28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06B930E8CC46D717F09D82AC88A66C28" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06B930E8CC46D717F09D82AC88A66C28" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:to="loc_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:to="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:to="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:to="loc_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:to="loc_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_C339A242A21C40DFF75E92090FEC19AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_C339A242A21C40DFF75E92090FEC19AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAsset" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:to="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:to="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:to="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_1B60327F1044E5EC5B252E6B7ED6EBC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E" xlink:to="loc_eols_SCHAEONLLCMember_1B60327F1044E5EC5B252E6B7ED6EBC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_315A6ACE7440DD43AD182E6B7ED680FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD" xlink:to="loc_eols_EvolusIncMember_315A6ACE7440DD43AD182E6B7ED680FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:to="loc_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:to="loc_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:to="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D4ADF0FE5CC9B49E1268966FB5AE3273" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D4ADF0FE5CC9B49E1268966FB5AE3273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/Organization" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:to="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:to="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_OxfordFinanceLLCMember" xlink:label="loc_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F" xlink:to="loc_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:to="loc_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:to="loc_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:to="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:to="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FD331DEA3B94FBECEC0E824D1D385FF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D" xlink:to="loc_us-gaap_CommonStockMember_FD331DEA3B94FBECEC0E824D1D385FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:to="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:to="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_8DAD4F079D4E7CC30AA0824D1D388D1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:to="loc_us-gaap_IPOMember_8DAD4F079D4E7CC30AA0824D1D388D1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:to="loc_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:to="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:to="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_4F8B59AEC02DC3DCDED2824D1D386397" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504" xlink:to="loc_us-gaap_MajorityShareholderMember_4F8B59AEC02DC3DCDED2824D1D386397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:to="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:to="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_9F1E7583B8847D84DC85824D1D389E1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:to="loc_eols_EvolusIncMember_9F1E7583B8847D84DC85824D1D389E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E77055EF47C2965D40A4824D1D38AF1B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E77055EF47C2965D40A4824D1D38AF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4455C7444A6B109F63C8824D1D385FD2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4455C7444A6B109F63C8824D1D385FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BF506839954A15F2F987824D1D388653" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_BF506839954A15F2F987824D1D388653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_039797839DC640B29347824D1D389809" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_039797839DC640B29347824D1D389809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_224D5F8D1697F1307929824D1D386865" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_224D5F8D1697F1307929824D1D386865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3CB7074AA927F89F1C72824D1D38447E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_NetIncomeLoss_3CB7074AA927F89F1C72824D1D38447E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_F075EF50B2187A8B829A92140C34036C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5" xlink:to="loc_us-gaap_SubsequentEventMember_F075EF50B2187A8B829A92140C34036C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_AFE72123715EED88FA52920910803959" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_AFE72123715EED88FA52920910803959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:to="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:to="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassDMember" xlink:label="loc_eols_CommonClassDMember_CC25DD58138D07EB6A5992091087C951" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2" xlink:to="loc_eols_CommonClassDMember_CC25DD58138D07EB6A5992091087C951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_E1A75C861E8B714BF4069209108895FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2" xlink:to="loc_eols_EvolusIncMember_E1A75C861E8B714BF4069209108895FE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:to="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:to="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_519D1B969A1D10B95400920910895768" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:to="loc_eols_ALPHAEONMember_519D1B969A1D10B95400920910895768" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_D9E687A7C132DFCE627A9209108951E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:to="loc_eols_SCHAEONLLCMember_D9E687A7C132DFCE627A9209108951E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_94F3885F5CD3CE67A3029209108A0052" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:to="loc_eols_ALPHAEONMember_94F3885F5CD3CE67A3029209108A0052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9" xlink:to="loc_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BridgeNoteMember" xlink:label="loc_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:to="loc_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_PurchaseAgreementMember" xlink:label="loc_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:to="loc_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:to="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:to="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_39B2E1CE06DF520C7F7992091092978E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:to="loc_us-gaap_MajorityShareholderMember_39B2E1CE06DF520C7F7992091092978E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_3DE6DBC153266B0643D292091092B108" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_3DE6DBC153266B0643D292091092B108" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_AED3B8A837BCD8B3B24B92091093669B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:to="loc_eols_ChiefMedicalOfficerMember_AED3B8A837BCD8B3B24B92091093669B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionTermOfAgreement" xlink:label="loc_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionRenewalPeriodOption" xlink:label="loc_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentNumberOfDebtTransactions" xlink:label="loc_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E9DBAA5CF051AB592A6092091094038A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E9DBAA5CF051AB592A6092091094038A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance" xlink:label="loc_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D97E06B80D8F91854F4492091095ED70" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D97E06B80D8F91854F4492091095ED70" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation" xlink:label="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote" xlink:label="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionTotalAmountsofTransaction" xlink:label="loc_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_81EA419869D6C1FF15659209109B7266" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_81EA419869D6C1FF15659209109B7266" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_3A2AD7BB160E3FA52C6C9209109CC2B9" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_3A2AD7BB160E3FA52C6C9209109CC2B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote" xlink:label="loc_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_636426936F0C2A9806E49209109DD81D" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_636426936F0C2A9806E49209109DD81D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2EC66605D2674545AF59921250B672C4" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2EC66605D2674545AF59921250B672C4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationLiquidatedDamages" xlink:label="loc_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded" xlink:label="loc_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyBorrowingsandNonCashCapitalContribution" xlink:label="loc_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:to="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:to="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_5F8D6836601F7F021A744DB2CDAAC884" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8" xlink:to="loc_us-gaap_MajorityShareholderMember_5F8D6836601F7F021A744DB2CDAAC884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CompensationAndBenefitTransactionsMember" xlink:label="loc_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ThirdPartyServiceFeesMember" xlink:label="loc_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockBasedCompensationTransactionsMember" xlink:label="loc_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_FacilityRelatedTransactionsMember" xlink:label="loc_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_OtherTransactionsMember" xlink:label="loc_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:to="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:to="loc_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:to="loc_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:to="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:to="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:to="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:to="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6718B2C728F5EAD44B0C966FB7826ECB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_NetIncomeLoss_6718B2C728F5EAD44B0C966FB7826ECB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:to="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:to="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2D4476A015EE0EAEF11C91E3DB31BF7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:to="loc_srt_MinimumMember_2D4476A015EE0EAEF11C91E3DB31BF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1A845A86DFCAE1FF9EAD91E3DB31A4C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:to="loc_srt_MaximumMember_1A845A86DFCAE1FF9EAD91E3DB31A4C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_DECC4B8565ED6B416FF391E3DB312186" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:to="loc_us-gaap_IPOMember_DECC4B8565ED6B416FF391E3DB312186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1DAC64C8CFFA5961CFB791E3DB315A36" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1DAC64C8CFFA5961CFB791E3DB315A36" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:to="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:to="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_C40A7AC5661A9623192B91E3DB319A4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A" xlink:to="loc_eols_SCHAEONLLCMember_C40A7AC5661A9623192B91E3DB319A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_DA096C7D6312A6C2905391E3DB3BCD65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A" xlink:to="loc_eols_EvolusIncMember_DA096C7D6312A6C2905391E3DB3BCD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_F4D03B01F93D4940051491E3DB3C7250" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_F4D03B01F93D4940051491E3DB3C7250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:to="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:to="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:to="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:to="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_6D9023805EAED15823CA91E3DB3E1FD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:to="loc_us-gaap_MajorityShareholderMember_6D9023805EAED15823CA91E3DB3E1FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:to="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:to="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_86212E611227BF46475B91E3DB3FF4D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B" xlink:to="loc_us-gaap_CommonStockMember_86212E611227BF46475B91E3DB3FF4D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:to="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:to="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_74E457C3B7A73FF3B51C91E3DB3F428D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_74E457C3B7A73FF3B51C91E3DB3F428D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_859120733A70EA511E4691E3DB40BF82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_859120733A70EA511E4691E3DB40BF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5AB85F212FD9C5CE693891E3DB417FDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5AB85F212FD9C5CE693891E3DB417FDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_EB2B05FBAF3707C80AB291E3DB41D1E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_EB2B05FBAF3707C80AB291E3DB41D1E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7F105B83879A80EC1B6391E3DB418C14" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7F105B83879A80EC1B6391E3DB418C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_D54EFDD10359FF16535691E3DB4187FF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_D54EFDD10359FF16535691E3DB4187FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_376ACA4BDD8E3139429F91E3DB41BAEF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_376ACA4BDD8E3139429F91E3DB41BAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5327D48EE1E6130E3E0C91E3DB42E665" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5327D48EE1E6130E3E0C91E3DB42E665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_85D61891A6A55C5B306291E3DB424B15" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_85D61891A6A55C5B306291E3DB424B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C667D80C27E46989F2591E3DB429382" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C667D80C27E46989F2591E3DB429382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3E66185AA95FA7E8AB5A91E3DB42DD69" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3E66185AA95FA7E8AB5A91E3DB42DD69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_096BB3B5EEB2FD0D9FD691E3DB423433" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_096BB3B5EEB2FD0D9FD691E3DB423433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9940687F0C94185E964F91E3DB426688" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockSharesIssued_9940687F0C94185E964F91E3DB426688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97B6EA7B8E526755B18091E3DB436D04" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97B6EA7B8E526755B18091E3DB436D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F359889A61D073D9088F91E3DB43220B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F359889A61D073D9088F91E3DB43220B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_187510B24CD8F1657A9F91E3DB43052B" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_187510B24CD8F1657A9F91E3DB43052B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_D0E77E210BDD4264A10B91E3DB44268A" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_D0E77E210BDD4264A10B91E3DB44268A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_28804E8F2BB4A3C8CCFA91E3DB45F517" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_28804E8F2BB4A3C8CCFA91E3DB45F517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CBBBE03424FE5DE901791E3DB454E64" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CBBBE03424FE5DE901791E3DB454E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CB28648EC95193B345C91E3DB45EE0E" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CB28648EC95193B345C91E3DB45EE0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:to="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1BAEBA74B97F9A79B46E91E3DB13D462" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1BAEBA74B97F9A79B46E91E3DB13D462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:to="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:to="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5D934C007D96F9E09819986674286BFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5D934C007D96F9E09819986674286BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_964B59A2E2336DCE8D8291E3DAEBBC95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:to="loc_eols_TermLoanFacilityMember_964B59A2E2336DCE8D8291E3DAEBBC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:to="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:to="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9" xlink:to="loc_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:to="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:to="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:to="loc_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:to="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:to="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_547AD13113DC94B6368A91E3DAEBF801" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:to="loc_eols_SCHAEONLLCMember_547AD13113DC94B6368A91E3DAEBF801" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:to="loc_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_9867C0313C33F19519B691E3DAF54BD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC" xlink:to="loc_eols_EvolusIncMember_9867C0313C33F19519B691E3DAF54BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_6402870AB8E930BFDFB191E3DAF5A600" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:to="loc_eols_TermLoanFacilityMember_6402870AB8E930BFDFB191E3DAF5A600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_BA532F6101E5EDE1249F91E3DAF56E0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9" xlink:to="loc_us-gaap_SubsequentEventMember_BA532F6101E5EDE1249F91E3DAF56E0A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_634086C7EABD0AB6872A91E3DAF57C1A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_634086C7EABD0AB6872A91E3DAF57C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:to="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:to="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:to="loc_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:to="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:to="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:to="loc_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:to="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:to="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2DF63C9604FCEFA043B991BD5741F792" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:to="loc_srt_MinimumMember_2DF63C9604FCEFA043B991BD5741F792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_736A83FFE6AA48F3EF7C91BD57413BD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:to="loc_srt_MaximumMember_736A83FFE6AA48F3EF7C91BD57413BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:to="loc_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:to="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:to="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassAAMember" xlink:label="loc_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:to="loc_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassDMember" xlink:label="loc_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:to="loc_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" xlink:label="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>eols-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:to="lab_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_498749583627BC731D379209100FF68F_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_498749583627BC731D379209100FF68F_label_en-US" xlink:label="lab_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:to="lab_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3_terseLabel_en-US" xlink:label="lab_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3_label_en-US" xlink:label="lab_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:to="lab_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907_label_en-US" xlink:label="lab_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:to="lab_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C_label_en-US" xlink:label="lab_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:to="lab_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:to="lab_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity term of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:to="lab_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:to="lab_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340_terseLabel_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Majority Shareholder</link:label>
    <link:label id="lab_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340_label_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Majority Shareholder [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:to="lab_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883_label_en-US" xlink:label="lab_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:to="lab_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F_label_en-US" xlink:label="lab_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:to="lab_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:type="arc" />
    <link:label id="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751_terseLabel_en-US" xlink:label="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SCH</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751_label_en-US" xlink:label="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751_documentation_en-US" xlink:label="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:to="lab_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:type="arc" />
    <link:label id="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157_terseLabel_en-US" xlink:label="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evolus, Inc.</link:label>
    <link:label id="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157_label_en-US" xlink:label="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:label id="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157_documentation_en-US" xlink:label="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:to="lab_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:to="lab_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:to="lab_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:type="arc" />
    <link:label id="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0_terseLabel_en-US" xlink:label="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class AA</link:label>
    <link:label id="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0_label_en-US" xlink:label="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class AA [Member]</link:label>
    <link:label id="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0_documentation_en-US" xlink:label="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Class AA [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassAAMember" xlink:label="loc_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:to="lab_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:type="arc" />
    <link:label id="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9_terseLabel_en-US" xlink:label="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class D</link:label>
    <link:label id="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9_label_en-US" xlink:label="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class D [Member]</link:label>
    <link:label id="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9_documentation_en-US" xlink:label="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Class D [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassDMember" xlink:label="loc_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:to="lab_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued as part of business acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:to="lab_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred costs offset against IPO proceeds</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:to="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:to="lab_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:type="arc" />
    <link:label id="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016_negatedTerseLabel_en-US" xlink:label="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisional decrease in valuation allowance</link:label>
    <link:label id="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016_label_en-US" xlink:label="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Adjustment, Increase (Decrease) In Valuation Allowance</link:label>
    <link:label id="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016_documentation_en-US" xlink:label="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Adjustment, Increase (Decrease) In Valuation Allowance</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" xlink:label="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:to="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:type="arc" />
    <link:label id="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46_negatedLabel_en-US" xlink:label="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reduction in net deferred tax liability</link:label>
    <link:label id="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46_label_en-US" xlink:label="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Provisional Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46_documentation_en-US" xlink:label="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Provisional Income Tax (Expense) Benefit</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:to="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:to="lab_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:to="lab_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:type="arc" />
    <link:label id="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE_terseLabel_en-US" xlink:label="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE_label_en-US" xlink:label="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating Activities</link:label>
    <link:label id="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE_documentation_en-US" xlink:label="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating Activities</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_InterestExpenseOperatingActivities" xlink:label="loc_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:to="lab_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:type="arc" />
    <link:label id="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C_negatedTerseLabel_en-US" xlink:label="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from therapeutic option right</link:label>
    <link:label id="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C_label_en-US" xlink:label="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit From Therapeutic Option Right</link:label>
    <link:label id="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C_documentation_en-US" xlink:label="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefit From Therapeutic Option Right</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxBenefitFromTherapeuticOptionRight" xlink:label="loc_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:to="lab_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders, a related party</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of underwriting fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on related party borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax withholding paid on behalf of employees for stock-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change in cash and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF_terseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF_label_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Related Party Receivable</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF_documentation_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Related Party Receivable</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:to="lab_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3_label_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Related Party Borrowings</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3_documentation_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Related Party Borrowings</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:to="lab_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:type="arc" />
    <link:label id="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC_terseLabel_en-US" xlink:label="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note obligation</link:label>
    <link:label id="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC_label_en-US" xlink:label="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Note Obligation</link:label>
    <link:label id="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC_documentation_en-US" xlink:label="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Note Obligation</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashNoteObligation" xlink:label="loc_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:to="lab_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentRoyaltyObligation" xlink:label="loc_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:to="lab_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:type="arc" />
    <link:label id="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC_terseLabel_en-US" xlink:label="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC_label_en-US" xlink:label="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Promissory Note</link:label>
    <link:label id="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC_documentation_en-US" xlink:label="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Promissory Note</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentPromissoryNote" xlink:label="loc_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:to="lab_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, convertible note write-off</link:label>
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD_label_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Convertible Note Write-Off</link:label>
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD_documentation_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Convertible Note Write-Off</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionConvertibleNoteWriteOff" xlink:label="loc_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:to="lab_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:type="arc" />
    <link:label id="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capital distribution to Parent</link:label>
    <link:label id="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD_label_en-US" xlink:label="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Capital Distribution From Parent</link:label>
    <link:label id="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD_documentation_en-US" xlink:label="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Capital Distribution From Parent</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashCapitalDistributionFromParent" xlink:label="loc_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:to="lab_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, forgiveness of related party borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5_label_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Forgiveness of Related Party Borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5_documentation_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Forgiveness of Related Party Borrowings</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:to="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent - therapeutic option right, net of tax</link:label>
    <link:label id="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C_label_en-US" xlink:label="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Therapeutic Option Right, Net Of Tax</link:label>
    <link:label id="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C_documentation_en-US" xlink:label="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Therapeutic Option Right, Net Of Tax</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionTherapeuticOptionRightNetOfTax" xlink:label="loc_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:to="lab_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:type="arc" />
    <link:label id="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D_negatedTerseLabel_en-US" xlink:label="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs accrued, unpaid</link:label>
    <link:label id="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D_label_en-US" xlink:label="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs Accrued, Unpaid</link:label>
    <link:label id="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D_documentation_en-US" xlink:label="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs Accrued, Unpaid</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DeferredOfferingCostsAccruedUnpaid" xlink:label="loc_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:to="lab_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:type="arc" />
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE_label_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Offering Costs</link:label>
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE_documentation_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Offering Costs</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashDeferredOfferingCosts" xlink:label="loc_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:to="lab_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:type="arc" />
    <link:label id="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826_negatedTerseLabel_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, paid by Parent</link:label>
    <link:label id="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826_label_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Paid by Parent</link:label>
    <link:label id="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826_documentation_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Paid by Parent</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_AccountsPayablePaidbyParent" xlink:label="loc_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:to="lab_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1_label_en-US" xlink:label="lab_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="lab_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F_label_en-US" xlink:label="lab_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:to="lab_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:type="arc" />
    <link:label id="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B_terseLabel_en-US" xlink:label="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow-on Offering</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B_label_en-US" xlink:label="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B_documentation_en-US" xlink:label="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:to="lab_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="lab_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:to="lab_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:to="lab_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:to="lab_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:to="lab_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E_label_en-US" xlink:label="lab_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:to="lab_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:to="lab_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent - therapeutic option right, net of tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:type="arc" />
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C_terseLabel_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed contribution from Parent, increase of related-party receivable</link:label>
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C_label_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Contribution From Parent, Increase Of Related-Party Receivable</link:label>
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C_documentation_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Contribution From Parent, Increase Of Related-Party Receivable</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:to="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Dividends_8E3025C52273B6620745966FB781B249_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed distribution to Parent - note obligation</link:label>
    <link:label id="lab_us-gaap_Dividends_8E3025C52273B6620745966FB781B249_label_en-US" xlink:label="lab_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:to="lab_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, convertible note write-off</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, forgiveness of related party borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C_label_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C_documentation_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:to="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversion upon initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares, new issues (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, value, new issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:type="arc" />
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:to="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:type="arc" />
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:to="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692" xlink:to="lab_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534" xlink:to="lab_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605" xlink:to="lab_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current benefit</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred (benefit) provision:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred provision (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:type="arc" />
    <link:label id="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note - debt discount</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C_label_en-US" xlink:label="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Promissory Note, Debt Discount</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Promissory Note, Debt Discount</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" xlink:label="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:to="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:to="lab_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:to="lab_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:to="lab_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3_negatedTerseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:to="lab_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:to="lab_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional services and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:type="arc" />
    <link:label id="lab_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323_label_en-US" xlink:label="lab_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323_documentation_en-US" xlink:label="lab_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DocumentAndEntityInformationAbstract" xlink:label="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="lab_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218_terseLabel_en-US" xlink:label="lab_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218_label_en-US" xlink:label="lab_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:to="lab_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9_label_en-US" xlink:label="lab_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:to="lab_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:to="lab_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:to="lab_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:to="lab_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6_label_en-US" xlink:label="lab_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:to="lab_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985_label_en-US" xlink:label="lab_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:to="lab_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:to="lab_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:to="lab_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:to="lab_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6_label_en-US" xlink:label="lab_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:to="lab_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:to="lab_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:to="lab_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:to="lab_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E_label_en-US" xlink:label="lab_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:to="lab_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:to="lab_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:to="lab_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of future minimum payments for operating leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of difference between carrying balance and fair value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of financial instruments recorded at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reconciliation of fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:to="lab_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:to="lab_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36_label_en-US" xlink:label="lab_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:to="lab_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Federal tax rate due to tax reform</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:type="arc" />
    <link:label id="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42_negatedLabel_en-US" xlink:label="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provisional decrease to valuation allowance</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" xlink:label="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42" xlink:to="lab_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42" xlink:type="arc" />
    <link:label id="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F_verboseLabel_en-US" xlink:label="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reduction in net deferred tax liability</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F" xlink:to="lab_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481" xlink:to="lab_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired, indefinite-lived intangible assets (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed in acquisition, deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6_label_en-US" xlink:label="lab_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:to="lab_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration upon successful completion of certain technical and sales milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:type="arc" />
    <link:label id="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67_terseLabel_en-US" xlink:label="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Finance, LLC</link:label>
    <link:label id="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67_label_en-US" xlink:label="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Finance, LLC [Member]</link:label>
    <link:label id="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67_documentation_en-US" xlink:label="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford Finance, LLC [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_OxfordFinanceLLCMember" xlink:label="loc_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:to="lab_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:to="lab_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2_label_en-US" xlink:label="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:to="lab_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:to="lab_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:to="lab_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1_label_en-US" xlink:label="lab_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:to="lab_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0_label_en-US" xlink:label="lab_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:to="lab_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of underwriters fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of convertible preferred stock converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares sold upon completion of follow-on public offering (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash used in operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:to="lab_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of basic and diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of securities excluded from computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1_label_en-US" xlink:label="lab_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:to="lab_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7_label_en-US" xlink:label="lab_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:to="lab_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625_terseLabel_en-US" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625_label_en-US" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="lab_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction amount in period</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:to="lab_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:to="lab_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase percentage of maximum shares outstanding (equal to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:type="arc" />
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456_terseLabel_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456_label_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456_documentation_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:to="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock option costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized costs other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period for unrecognized costs to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Balance</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of Federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:type="arc" />
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note - debt discount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:type="arc" />
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumption of the royalty obligation payable to Evolus Founders, a related party</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recorded in operating expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock-based compensation expense allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="lab_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:type="arc" />
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08_terseLabel_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders, a related party</link:label>
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08_label_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation of Contingent Royalty Obligation Payable to Related Party</link:label>
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08_documentation_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revaluation of Contingent Royalty Obligation Payable to Related Party</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:to="lab_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:to="lab_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:to="lab_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:to="lab_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:to="lab_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108_label_en-US" xlink:label="lab_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:to="lab_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4" xlink:to="lab_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="lab_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:type="arc" />
    <link:label id="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92_terseLabel_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Medical Officer</link:label>
    <link:label id="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92_label_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:label id="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92_documentation_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:to="lab_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:to="lab_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:to="lab_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:type="arc" />
    <link:label id="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8_terseLabel_en-US" xlink:label="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable Rate</link:label>
    <link:label id="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8_label_en-US" xlink:label="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:label id="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8_documentation_en-US" xlink:label="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:to="lab_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:type="arc" />
    <link:label id="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7_terseLabel_en-US" xlink:label="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Daewoong</link:label>
    <link:label id="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7_label_en-US" xlink:label="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Daewoong [Member]</link:label>
    <link:label id="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7_documentation_en-US" xlink:label="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Daewoong [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:to="lab_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:to="lab_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:to="lab_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="lab_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front payment upon obtaining FDA approval</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7_label_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Obtaining FDA Approval</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7_documentation_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Obtaining FDA Approval</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:to="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time bonus payment</link:label>
    <link:label id="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306_label_en-US" xlink:label="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, One-Time Bonus Payment Upon Obtaining FDA Approval</link:label>
    <link:label id="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306_documentation_en-US" xlink:label="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, One-Time Bonus Payment Upon Obtaining FDA Approval</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:to="lab_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front payment upon purchase agreement</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59_label_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Purchase Agreement</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59_documentation_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Purchase Agreement</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:to="lab_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of agreement of interest payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:to="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2_label_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:to="lab_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional period of agreement of interest payment</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Period Of Agreement Of Interest Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Period Of Agreement Of Interest Payment</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:to="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total term of debt</link:label>
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485_label_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Aggregate Period</link:label>
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485_documentation_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Aggregate Period</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:to="lab_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amortization Period</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:to="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of final payment of full principal amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D_label_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:to="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of final payment of full principal amount, next twelve months</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of final payment of full principal amount, year two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of final payment of full principal amount, thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Default interest rate</link:label>
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5_label_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5_documentation_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:to="lab_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57" xlink:to="lab_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:to="lab_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:to="lab_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:to="lab_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:type="arc" />
    <link:label id="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97_terseLabel_en-US" xlink:label="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPHAEON</link:label>
    <link:label id="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97_label_en-US" xlink:label="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPHAEON [Member]</link:label>
    <link:label id="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97_documentation_en-US" xlink:label="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPHAEON [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:to="lab_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="lab_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:to="lab_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:to="lab_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating leases, future minimum payments due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:type="arc" />
    <link:label id="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F_terseLabel_en-US" xlink:label="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation &amp; Benefits</link:label>
    <link:label id="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F_label_en-US" xlink:label="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation And Benefit Transactions [Member]</link:label>
    <link:label id="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F_documentation_en-US" xlink:label="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation And Benefit Transactions [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_CompensationAndBenefitTransactionsMember" xlink:label="loc_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:to="lab_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:type="arc" />
    <link:label id="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647_terseLabel_en-US" xlink:label="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third party service fees</link:label>
    <link:label id="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647_label_en-US" xlink:label="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Party Service Fees [Member]</link:label>
    <link:label id="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647_documentation_en-US" xlink:label="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Party Service Fees [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_ThirdPartyServiceFeesMember" xlink:label="loc_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:to="lab_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:type="arc" />
    <link:label id="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357_terseLabel_en-US" xlink:label="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357_label_en-US" xlink:label="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Transactions [Member]</link:label>
    <link:label id="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357_documentation_en-US" xlink:label="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Transactions [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_StockBasedCompensationTransactionsMember" xlink:label="loc_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:to="lab_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:type="arc" />
    <link:label id="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C_terseLabel_en-US" xlink:label="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility related expenses</link:label>
    <link:label id="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C_label_en-US" xlink:label="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Related Transactions [Member]</link:label>
    <link:label id="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C_documentation_en-US" xlink:label="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Related Transactions [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_FacilityRelatedTransactionsMember" xlink:label="loc_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:to="lab_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:type="arc" />
    <link:label id="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8_terseLabel_en-US" xlink:label="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8_label_en-US" xlink:label="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Transactions [Member]</link:label>
    <link:label id="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8_documentation_en-US" xlink:label="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Transactions [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_OtherTransactionsMember" xlink:label="loc_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:to="lab_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:to="lab_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Note</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:to="lab_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:type="arc" />
    <link:label id="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0_terseLabel_en-US" xlink:label="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Note</link:label>
    <link:label id="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0_label_en-US" xlink:label="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Note [Member]</link:label>
    <link:label id="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0_documentation_en-US" xlink:label="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Note [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BridgeNoteMember" xlink:label="loc_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:to="lab_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:type="arc" />
    <link:label id="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92_terseLabel_en-US" xlink:label="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92_label_en-US" xlink:label="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92_documentation_en-US" xlink:label="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_PurchaseAgreementMember" xlink:label="loc_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:to="lab_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of service agreement</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Term Of Agreement</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Term Of Agreement</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionTermOfAgreement" xlink:label="loc_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:to="lab_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of successive renewal of services agreement</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Renewal Period Option</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Renewal Period Option</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionRenewalPeriodOption" xlink:label="loc_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:to="lab_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on related party borrowings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, number of debt transactions</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Debt Transactions</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Debt Transactions</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentNumberOfDebtTransactions" xlink:label="loc_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:to="lab_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional amount authorized for issuance</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amount Authorized For Issuance</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amount Authorized For Issuance</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance" xlink:label="loc_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:to="lab_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note obligation</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:to="lab_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts of transaction related to contingent royalty obligation</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts Of Transaction Related To Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts Of Transaction Related To Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation" xlink:label="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:to="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts of transaction related to contingent promissory note</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts Of Transaction Related To Contingent Promissory Note</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts Of Transaction Related To Contingent Promissory Note</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote" xlink:label="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:to="lab_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes receivable from related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:to="lab_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346_verboseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total amounts of transaction</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Total Amounts of Transaction</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Total Amounts of Transaction</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionTotalAmountsofTransaction" xlink:label="loc_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:to="lab_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:type="arc" />
    <link:label id="lab_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed distribution to parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:to="lab_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85_verboseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash related party receivable</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:to="lab_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:to="lab_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time lump sum payment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of anniversary</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period of Maturity of Promissory Note</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period of Maturity of Promissory Note</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote" xlink:label="loc_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:to="lab_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of termination of first commercial sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:to="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:type="arc" />
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127_terseLabel_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period available to cure breach</link:label>
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127_label_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Period Available to Cure Breach</link:label>
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127_documentation_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Period Available to Cure Breach</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:to="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting interests acquired (at least)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:type="arc" />
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D_terseLabel_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unwinding fee</link:label>
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D_label_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Unwinding Fee</link:label>
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D_documentation_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Unwinding Fee</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:to="lab_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidated damages</link:label>
    <link:label id="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3_label_en-US" xlink:label="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Liquidated Damages</link:label>
    <link:label id="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3_documentation_en-US" xlink:label="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Liquidated Damages</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationLiquidatedDamages" xlink:label="loc_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:to="lab_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period in which liquidated damages will be awarded</link:label>
    <link:label id="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856_label_en-US" xlink:label="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Period in Which Liquidated Damages will be Awarded</link:label>
    <link:label id="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856_documentation_en-US" xlink:label="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Period in Which Liquidated Damages will be Awarded</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded" xlink:label="loc_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:to="lab_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings and non-cash capital contribution</link:label>
    <link:label id="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945_label_en-US" xlink:label="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Borrowings and Non-Cash Capital Contribution</link:label>
    <link:label id="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945_documentation_en-US" xlink:label="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Borrowings and Non-Cash Capital Contribution</link:label>
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyBorrowingsandNonCashCapitalContribution" xlink:label="loc_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:to="lab_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="lab_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="lab_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:to="lab_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_E052219A54901F09466C914621845C0C_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_E052219A54901F09466C914621845C0C_label_en-US" xlink:label="lab_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:to="lab_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:to="lab_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:to="lab_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C_label_en-US" xlink:label="lab_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:to="lab_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:to="lab_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="lab_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:to="lab_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 27,274,991 and 16,527,000 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:to="lab_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:to="lab_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:to="lab_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation activities with ALPHAEON</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:to="lab_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint and Several Liability Assessment</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:to="lab_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Payment Obligation Payable and Contingent Promissory Note Payable to the Evolus Founders, a Related Party</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>eols-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:href="eols-20181231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:href="eols-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesDetails" xlink:href="eols-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurements" xlink:href="eols-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsContingentPromissoryNoteDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails" xlink:href="eols-20181231.xsd#FairValueMeasurementsRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:href="eols-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAsset" xlink:href="eols-20181231.xsd#GoodwillAndIntangibleAsset" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails" xlink:href="eols-20181231.xsd#GoodwillAndIntangibleAssetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:href="eols-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails" xlink:href="eols-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="eols-20181231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:href="eols-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:href="eols-20181231.xsd#IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:href="eols-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="eols-20181231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="eols-20181231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/Organization" xlink:href="eols-20181231.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OrganizationDetails" xlink:href="eols-20181231.xsd#OrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsTables" xlink:href="eols-20181231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfCashFlows" xlink:href="eols-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20181231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eols-20181231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:href="eols-20181231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:href="eols-20181231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEvents" xlink:href="eols-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEventsDetails" xlink:href="eols-20181231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2B8DE286BDBA924CFC35824D1CB66564" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E7CFA9078B35D477F75824D1CB6BE2D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_C273A0BDB9B2EB0033E891461F9634CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C273A0BDB9B2EB0033E891461F9634CF" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7281A01C00C20AA0647091461F967E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C273A0BDB9B2EB0033E891461F9634CF" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_53B1809A7B63CDC4908D91D449F8FE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C273A0BDB9B2EB0033E891461F9634CF" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_682AF8CF8AB912140ACA91461F97BD09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C273A0BDB9B2EB0033E891461F9634CF" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_357E7AD47C2712114FF291461F97025F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8A0C5DB91423B1E25F1A824D1CB6F949" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8A0C5DB91423B1E25F1A824D1CB6F949" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D490B09ACE6BD5B162A6824D1CB6B736" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B6DC8D3C977EF38762A291462180267C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B6DC8D3C977EF38762A291462180267C" xlink:to="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_609A9BF580CD8DCFFFB2914621813C26" xlink:to="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_88867EDD34E3743052F49146218199EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_082C8560A15487B2082891462181E4A5" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_88867EDD34E3743052F49146218199EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3F3EB6A520540CE6BF15914621809AB3" xlink:to="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:to="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CF9AC995ECE11B2BE0E891462182872C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CF9AC995ECE11B2BE0E891462182872C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3E45C714DE04AE6F724491462183E932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_F88C452ECE719A9C105E914621830974" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_F88C452ECE719A9C105E914621830974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E5E037F4B3168B095569914621823C93" xlink:to="loc_us-gaap_AssetsCurrent_05FACC3EC3005D679ABB914621836E6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_DD19B50E5EB4ADDCD95B9146218341DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BB928DB63D4B3B3FA07C91462183B021" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_Goodwill_BB928DB63D4B3B3FA07C91462183B021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_23034449152A308441DD91462183AE6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_07D6E0219B7A9646636B914621828397" xlink:to="loc_us-gaap_Assets_E052219A54901F09466C914621845C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_40E1F19AF6B9F172A86991462182ADE2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_AccountsPayableCurrent_3B34F6ADAC55D6C50CB1914621848484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7288BBFC4675E957BC379146218518B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_EC4DBE44E9C7A6FA7619914621858E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_32D7BACC021435CDCDA79146218542CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_NotesPayableCurrent_32D7BACC021435CDCDA79146218542CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_FE840E3B3D27E3B24E0F91462184C7B8" xlink:to="loc_us-gaap_LiabilitiesCurrent_9195B9F743856CDF16C8914621856724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_63A8FB03E455EAFBD4B791462185B892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_0B7793C7A21B2269A75C91462185B874" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_ContractualObligation_0B7793C7A21B2269A75C91462185B874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_8FE20BF0FDB4B56F4FB791462186C2E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_LongTermNotesPayable_8FE20BF0FDB4B56F4FB791462186C2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_DF3986B7B0C1C303A157914621865C70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_Liabilities_3C82D1683CB01656A85D914621864B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87E83286B62B32D8E3B99146218614DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_PreferredStockValue_63DC9FC4987396B4CDAD91462186F315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_CommonStockValue_E738923D564AC8B44A94914621870307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_AdditionalPaidInCapital_81DF2D19863603253EDF91462187D66C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5FD4DF47FA5F344E2FBD91462187E178" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5FD4DF47FA5F344E2FBD91462187E178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C9A55B9B9D26164AA5791462186CB34" xlink:to="loc_us-gaap_StockholdersEquity_7D35080752D7B1F38A9991462187210B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F46F03334E7C027B89A7914621840210" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_77DB9C54E58732FD263091462187702F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3740EBDB7652DE7F8E4A91462171F3BB" xlink:to="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93F755DB4006C913AF2091462172EF13" xlink:to="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_90B247694B9216C4CD8191462172C93E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DA1569BE329CB123359191462172E0E2" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_90B247694B9216C4CD8191462172C93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_890238C2AE8756CD815F91462171265E" xlink:to="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_321F704DCD5227A0F29291462173F6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3504694A62C4B720475591462173B35F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_E3A9DC872157BE28988C914621732D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_D04038094577E4E2AAA1914621739376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0492192C5E142947351891462173588B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20E949D05A26E0624C2191462173835C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockSharesIssued_B46E78C7D95638AD16779146217452EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633031DADEE77B41FE969146217292D1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_20818A1364EB74D43D0C91462174212E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B972A471A9D3757B6DB92E6B7EAE2A8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B972A471A9D3757B6DB92E6B7EAE2A8E" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89859DF1DDBB6BCA8AD32E6B7EAEA3E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F2AD715BAD829384636B91E3DBAB2BDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F2AD715BAD829384636B91E3DBAB2BDF" xlink:to="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:to="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_DBBA6FCDAF558D4F20E991E3DBACE67C" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_C34B85765336DA59677191E3DBACCBC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4443059ABE8778AFF52791E3DBACDB74" xlink:to="loc_eols_DaewoongMember_C34B85765336DA59677191E3DBACCBC6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:to="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_05BD0B6F4B09DD5D9CA091E3DBAD2D25" xlink:to="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_A2D504DA9B9E5D784F6B91E3DBAD9983" xlink:to="loc_eols_ALPHAEONMember_209F198FFD5FEB6EA21B91E3DBAD1A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8D42B462B50B1D103D8991E3DBABC33A" xlink:to="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_PurchaseObligation_2B317783B4D3BAFBFBDE91E3DBAD4FDB" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_5DE97788D2375B4BB6BC91E3DBAE01D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_5DE97788D2375B4BB6BC91E3DBAE01D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_LeaseAndRentalExpense_5FAE6026E15D183E78C991E3DBAE7FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_D3D48A0943F09BDDF46F91E3DBAE76BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_230E39A50A6E9AA12EC991E3DBAE40FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C3199F5F7B633B25556591E3DBAEDFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_94B8B06A2FE2BC0B5CE591E3DBAF8140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_79DE3E1732BC0395607291E3DBAD0872" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02AF44DF77091A03286991E3DBAFFE3E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89CF1E3D5E68393249282E6B7EA4BFAF" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_BB8E35CE52CC82AC1A8B2E6B7EA41968" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="eols-20181231.xsd#eols_DocumentAndEntityInformationAbstract" xlink:label="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_DocumentType_BE95DC7F80DE58A3CD0E4DB2CF057218" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_AmendmentFlag_3B252E0311E9083008ED4DB2CF0567D9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_DocumentPeriodEndDate_655AD4538F1206506F614DB2CF053788" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_DocumentFiscalYearFocus_D24C582C3E573F0018CA4DB2CF053B0D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_DocumentFiscalPeriodFocus_989EC09C5312B5BBC0474DB2CF067FDC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_TradingSymbol_BFA1105FCF3D10121D044DB2CF06C2D6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityRegistrantName_28C030A6E43320DAF65A4DB2CF061985" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityCentralIndexKey_7D7D810D48EBA85A5D494DB2CF06E77E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_CurrentFiscalYearEndDate_69163C89A84C84BD95724DB2CF067250" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityFilerCategory_D6D19701CB4D74ABED844DB2CF07F281" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_58BF6FE41A4D25ACAE174DB2CF07ACDB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityPublicFloat_D4533B703102016F33604DB2CF071CB6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityEmergingGrowthCompany_7E0E27DB1DB2A13E57E44DB2CF071C3C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntitySmallBusiness_364FE116B772D5CFE5FA4DB2CF071363" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityExTransitionPeriod_997CE53F20D11C596E2D4DB2CF07467D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityShellCompany_C4BF022612A034435BC54DB2CF08E15E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityVoluntaryFilers_178E579782D5069CC6BE4DDB657E3216" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityCurrentReportingStatus_2B302F99CA0B15C59A744DDBA0676A69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_131E90360212A7D17AF64DB2CF05A323" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_B479053411BF7D6BE12F4DDBC1797858" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C3F56AF368E86F19882BA41624D1B42B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C3F56AF368E86F19882BA41624D1B42B" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_C35B9852B510BB91BC58A41624D4493D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A110AEA6D599FAA9612282AC88A4B924" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A110AEA6D599FAA9612282AC88A4B924" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_B493357FE393E61EEE7782AC88A4F6B7" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C10519837B81095CF64482AC88A5F9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3D22DF60D83A0F1BC49A82AC88A5690B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_06ED59E74A9E5FBA2D6C82AC88A5CA50" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6AB1C7F73EE65EF740D382AC88A56938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06B930E8CC46D717F09D82AC88A66C28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C4F767FC0EB6DD26595682AC88A47C1D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06B930E8CC46D717F09D82AC88A66C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06B930E8CC46D717F09D82AC88A66C28" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_8E93A5D8A42067E8DE1D82AC88A66551" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E16107BB7159CFAE31309209100D0667" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0A3FE8803A53E4BA0CFA9209100E1FE4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56DD19BD07CF75E85D829209100EBF52" xlink:to="loc_eols_ContingentRoyaltyObligationMember_25A7C9A92235D0F49C419209100F810E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_498749583627BC731D379209100FF68F" xlink:to="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:to="loc_srt_MinimumMember_E1E85B3577EE48C910E49209100F5907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D200E777B23B22DB1FE09209100F64C3" xlink:to="loc_srt_MaximumMember_BE955B81D0B14C7C33B892091010803C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_EFBCB9CDA6DC2372FC0A92091010C6B5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_59FCB3E800BAD2560F2492091010A1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_46BB40625280086F97DC92091010E61D" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8B7EA21826CB5217C73992091010A8F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0E15942CB84E6A588C9D92091016F942" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AD1BD993788471253E0492091016EE49" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8E035043C223D672F0CE920910164686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FEBB25B14003ABEACCFB92091017340D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19AE78363E164AFFD68D92091017EE59" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_B26C38A31A1B874E9847920910175292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E82C1006C92B51418E049209100E51E6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_58A51C6251E6D4700A819209101885AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DBA5C3AEF44C26F4070392091019B365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715EDDB32ABE6BC388AB920910185BF9" xlink:to="loc_us-gaap_DebtInstrumentTerm_523E8BE80DB79717C0D592091019BD37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5181D9A2C9B96EE4617692090FEBA3D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5181D9A2C9B96EE4617692090FEBA3D9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8D76D1A18B0D34D6B0A492090FEC485B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_C339A242A21C40DFF75E92090FEC19AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7BB2776119DA59AD3DB092090FEC7933" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_C339A242A21C40DFF75E92090FEC19AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D477A8593B1D0FD4FEA92090FEBB129" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_DF925CF44CE2F091A0BD92090FED11AD" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D24EB187636F27394A6E92090FED3F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DCAADEE3A7545F48E7FF92115B705B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7FCDC26160379FD48E2D92124C80B79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_AAFA7068DA760CBCBB1492090FED7EF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98E16AFCA758023528AE92090FEECF4A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9F585E401C0EB05A9F68A41624FBBAA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9F585E401C0EB05A9F68A41624FBBAA0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_83A4E5B385CA280C96D5A419695C452B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9F585E401C0EB05A9F68A41624FBBAA0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_576824CBED2786144AAEA41A0B67E4C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9F585E401C0EB05A9F68A41624FBBAA0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DFAC043F7EFB32CCAA28A41624FBBF43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAsset" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3525457DE40B788AB4D2E6B7ED67FB7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0AE13D8F06460DE52B8C2E6B7ED6FC97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9A34D6318A7710DFCBCA2E6B7ED61ADB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9A34D6318A7710DFCBCA2E6B7ED61ADB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:to="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_638676B0A248FE7B33A12E6B7ED66D34" xlink:to="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_1B60327F1044E5EC5B252E6B7ED6EBC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6DB70F994CC4152066152E6B7ED6994E" xlink:to="loc_eols_SCHAEONLLCMember_1B60327F1044E5EC5B252E6B7ED6EBC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08040052F7654E22004B2E6B7ED698DE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_315A6ACE7440DD43AD182E6B7ED680FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F29AE09B28A65437937B2E6B7ED60BBD" xlink:to="loc_eols_EvolusIncMember_315A6ACE7440DD43AD182E6B7ED680FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCE604144387DCF8FBDD2E6B7ED64357" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2DAB1C5C06AB8E8737242E6B7ED6C706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_29174645627EA07CE4472E6B7ED6AD50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_71E4A21CB6E5AC619F632E6B7ED699C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_Goodwill_857B42D25F5804507B842E6B7ED60EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_23498BE2ACC88E3969572E6B7ED60FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90BFE6AD3D176AF08D1B2E6B7ED6F15F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_45D8612DBBD77545E3072E6B7ED64B28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_679B72DE92A70B40F9812F3B556FC90F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679B72DE92A70B40F9812F3B556FC90F" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4F1210A4DCAAB8B85EAA2F3B556F4357" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_E06A95D196A16D2CB77A7DDA977A78A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_880DE225C2F5984184AB7DDA977A0F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_C908B6446917E427591C7DDA977A0530" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1263E1E7009695979DF27DDA977BCE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D6120B1A3D86C5A8718E7DDA977BE190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30538732716A31968F3F7DDA977B3477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_763E0BDCEC41B73D7E227DDA977B7BAE" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4093BFDF99261331EC807DDA977B901D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32C37A8E089DFCD2E42E7DDA977AE158" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09E7A40A8689514649907DDA977BA1A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_210D2671C3955F3F30A882AC887815F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_210D2671C3955F3F30A882AC887815F7" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_F8A7E91E36B8BA029FE682AC8879788D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" xlink:label="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_378570B05E77446054A882AC8879687C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_63D735D4DA18FF9531A882AC8879B7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39F9809EF396A399817482AC88793F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6E9BEC8845EB17613B2382AC8879D662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_E6E10829B82C3D4485CF82AC887983A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_CDBB97C2582AF43EE46B82AC887AC342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2A2C87A381C983657E1382AC887A7294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_28C4A32C3256D15C631382AC8878E4CB" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_69808376E536BF783EC082AC887A0A0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_210D2671C3955F3F30A882AC887815F7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1F9FE8E5DCCEECE0236E82AC887A44AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_06587E6161459A61FD0682AC887AE7D9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8795CFB6FB6E48E92FFA82AC887B819A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_210D2671C3955F3F30A882AC887815F7" xlink:to="loc_us-gaap_DeferredTaxLiabilities_DD054301A13E08F24A3082AC887B3011" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_us-gaap_OperatingLossCarryforwards_4F9638B1D150B1BC27DD7DDA97851888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7D7D0D1CB9D1E6B24C947DDA97862CE3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:to="loc_us-gaap_DomesticCountryMember_A0F21B1CABAF7E4FC6227DDA978677F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5B19BAAC0A46963051697DDA9786F2E8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_E001C174DFDE209084767DDA97874F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_912F130DE3FE65DA5ADF7DDA9787C714" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_736B15BAC186B0E624807DDA97878064" xlink:to="loc_us-gaap_ResearchMember_C24D0994323F5359A1847DDA9787AB36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1E2DC905AE3AC0B0E4767DDA97862AF5" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5BD5034605FAE9FBAF617DDA97884241" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_EDA0839D46FB595DB03D7DDA978805CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_88389B0E70640FCEE7307DDA9788D627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5488AA074F1DCEF5F1FB7DDA9788520A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_48DD8A7330519E13260D7DDA978860B8" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" xlink:label="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_DF08312D67F79633E0F37DDA97894D42" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E8E97D9B0F7585D3C4FE7DDA97851F78" xlink:to="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_DBD55906A1A9CEA64E377DDA97899E4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5AD0A5BF0E7D031EA4C17DDA976AA99A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2497A832D57F3F976DB07DDA976A7A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_16CF454D8A726DDB94377DDA976AA7C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4E8108FFDDD2A30A66FD7DDA976B212F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4E8108FFDDD2A30A66FD7DDA976B212F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_32E8A25D1B0C02FF04A47DDA976B1B53" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_66FCBE7AD00507B00C4F7E23CB98461D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_97ABE9157A4C97F3DBFB7E24D03FAA3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_22AB128A415ADE1B51037DDA976BE916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_48DA82E4EB67211EAE4B7DDA976BD22D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_DD2E24A1C1D15EB877467DDA976BFFDA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EF9AF9390C4B03EA09C77DDA976A6831" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_DD2E24A1C1D15EB877467DDA976BFFDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ACA91C73FE9D5356C64E91E3DB7E63C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ACA91C73FE9D5356C64E91E3DB7E63C1" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5C1E9A87785F6C1D626F91E3DB7ED3B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ACA91C73FE9D5356C64E91E3DB7E63C1" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F8BBC1E4B721829567FD91E3DB7F9FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ACA91C73FE9D5356C64E91E3DB7E63C1" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3B3027EA675B39DFE27691E3DB7F6408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ACA91C73FE9D5356C64E91E3DB7E63C1" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2CD137B928E6051D321B91E3DB7F6EE4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDD0B5914D5B3B6F6142F26CB7433A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDD0B5914D5B3B6F6142F26CB7433A4" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5001A8E3F075853703E22F277AE59D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19F015279A3B7601307D2F2812A0B2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3E08054174A06E0827942F273C69C4E2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_988EA4594B39438B21EF2F279F1DF035" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ED91FC53D9E3C037C27EA581240EC631" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ED91FC53D9E3C037C27EA581240EC631" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_47C03E557BBDF4AF8768A581240EBEA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FC548150BD918113A087966FB5AE634B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FC548150BD918113A087966FB5AE634B" xlink:to="loc_us-gaap_NetIncomeLoss_EFFC10167617682055C9966FB5AECA57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_BB6D251AE6EB412DCA13966FB5AE210C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FC548150BD918113A087966FB5AE634B" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_BB6D251AE6EB412DCA13966FB5AE210C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_BD0954F0810213D4CA51966FB5AEB037" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FC548150BD918113A087966FB5AE634B" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_BD0954F0810213D4CA51966FB5AEB037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FC548150BD918113A087966FB5AE634B" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:to="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_277CF485A16AAC8BFEA0966FB5AE2375" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D4ADF0FE5CC9B49E1268966FB5AE3273" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D4ADF0FE5CC9B49E1268966FB5AE3273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15BE61FBD112201B6E78966FB5AE8550" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_EEAB88688411BAD56D63966FB5AE5C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7D8A691E8FBD5EB688E6966FB5AEC544" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BBC261D51B73167EAE7A966FB5AEABEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CD53128BF734F3CBCB30966FB5AE3041" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26240410129FE96FE349966FB5AE18BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75A913A97462A1E4CAB3A5812403AA13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CAB90FD12B70372EAA42A58124033315" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7946F75443EE397EDCF6A58124049E65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/Organization" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F696B7EFDE30609120B03384BEA66DEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F696B7EFDE30609120B03384BEA66DEB" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2BAD260DCE98BCE72F023384BEA6A0D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8DA4EE3E3F3C46453EFD824D1D38188B" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_FB8729AB6A368B982BD282A9CEB30526" xlink:to="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_OxfordFinanceLLCMember" xlink:label="loc_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6E8C23829E31676F107C82A9CEB31C5F" xlink:to="loc_eols_OxfordFinanceLLCMember_80BB1A204D4EC591144582A9CFFB8E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A5189098AA6195C9D0CE824D1D38C2C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2960E1878C629A8CBF01824D1D381AF3" xlink:to="loc_eols_TermLoanFacilityMember_44B0301395A24C3DFFE1824D1D38A4D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B37BF5540DE2B38D3215824D1D38694A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58BA919F9D31C97379B5824D1D38AC8B" xlink:to="loc_us-gaap_SubsequentEventMember_9583FDF47753A13D94A5824D1D383FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_924EA73BED623EF7E7C0824D1D386F97" xlink:to="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FD331DEA3B94FBECEC0E824D1D385FF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B840D286AB8378E43BCB824D1D38694D" xlink:to="loc_us-gaap_CommonStockMember_FD331DEA3B94FBECEC0E824D1D385FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7E729A1BF2C98A31B09D824D1D388EE1" xlink:to="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4A91F6B3C8957F6B1437824D1D38C3FF" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_ADACB8F2791D1199C55C824D1D3880BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6D54B09949DFD1B87029824D1D38CE7B" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_8DAD4F079D4E7CC30AA0824D1D388D1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:to="loc_us-gaap_IPOMember_8DAD4F079D4E7CC30AA0824D1D388D1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9AB0CA1F40F09CF9729E824D1D38D3FA" xlink:to="loc_us-gaap_OverAllotmentOptionMember_052CEC44CA2416AA5034824D1D385277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DF7C7FA15662FA882063824D1D38D092" xlink:to="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_4F8B59AEC02DC3DCDED2824D1D386397" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_586CD1E3820E65BFB8B0824D1D38E504" xlink:to="loc_us-gaap_MajorityShareholderMember_4F8B59AEC02DC3DCDED2824D1D386397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_FA0269A77EA1CFECE82F824D1D3845C1" xlink:to="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_9F1E7583B8847D84DC85824D1D389E1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_B166511A9C08EDE9908A824D1D389EB0" xlink:to="loc_eols_EvolusIncMember_9F1E7583B8847D84DC85824D1D389E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_DF4515A31C0D7CE878C5824D1D3895BF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_EC4058359A2E7935989B824D1D384081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_05D9FE0F7C907B4B8B37824D1D383E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_89EBE3ED7A028514C48C824D1D385755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4535A4EDB47BA52F406C824D1D38E812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_DC4E7EA9E549E8EB30CA824D1D383FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E77055EF47C2965D40A4824D1D38AF1B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E77055EF47C2965D40A4824D1D38AF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4455C7444A6B109F63C8824D1D385FD2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4455C7444A6B109F63C8824D1D385FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BF506839954A15F2F987824D1D388653" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_BF506839954A15F2F987824D1D388653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_039797839DC640B29347824D1D389809" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_039797839DC640B29347824D1D389809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B1344F0E2A57862AE9C824D1D38F65D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_224D5F8D1697F1307929824D1D386865" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_224D5F8D1697F1307929824D1D386865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC051FB4F143861D11EE824D1D383FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3CB7074AA927F89F1C72824D1D38447E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_NetIncomeLoss_3CB7074AA927F89F1C72824D1D38447E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98FD4A389D57A0D349FD824D1D38047C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C4E8EE2750F02A1DB8D5824D1D427F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F4810321138962F84C31824D1D42AE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_C7EFE081E184010BCE56824D1D388393" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DFF8EE3661A0D88814C8824D1D4208B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_271DF6A7210820E0C1DB2E6B7ECCBAE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_271DF6A7210820E0C1DB2E6B7ECCBAE2" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_868A77C1C5D0D578EB0C2E6B7ECCB573" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1216C86955F7739CA1059209107F3018" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1216C86955F7739CA1059209107F3018" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1AF5CF09D3961826037992140A89924D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_F075EF50B2187A8B829A92140C34036C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C94B6AC0F9A5DFED1F0B92140A8BD5C5" xlink:to="loc_us-gaap_SubsequentEventMember_F075EF50B2187A8B829A92140C34036C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55C5FD73978DBBD1CEB99209107FA7B6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_AFE72123715EED88FA52920910803959" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6D2EDF128C6456EFB7D7920910803F2C" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_AFE72123715EED88FA52920910803959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DCBBE29B96CE8EE6F0D4920910879E6E" xlink:to="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassDMember" xlink:label="loc_eols_CommonClassDMember_CC25DD58138D07EB6A5992091087C951" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_277F7519AF802974A97692091087C4B2" xlink:to="loc_eols_CommonClassDMember_CC25DD58138D07EB6A5992091087C951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B90B5207DED9097C895692091087529A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_E1A75C861E8B714BF4069209108895FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DE87437012E4369F5A1F920910884DC2" xlink:to="loc_eols_EvolusIncMember_E1A75C861E8B714BF4069209108895FE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3FC6FCE055B9049F43C792091088AFDC" xlink:to="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_519D1B969A1D10B95400920910895768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:to="loc_eols_ALPHAEONMember_519D1B969A1D10B95400920910895768" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_D9E687A7C132DFCE627A9209108951E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5CE15CEE05EA81CAB17C920910882384" xlink:to="loc_eols_SCHAEONLLCMember_D9E687A7C132DFCE627A9209108951E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9A8199B183D0637FB9BF92091089C0D3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C1A34D27E831BD7BD1399209108A7169" xlink:to="loc_eols_ALPHAEONMember_519D1B969A1D10B95400920910895768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_051C0BCC23801278B9769209108A9081" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ED6F4BA2BA88830844BC9209108BD4A9" xlink:to="loc_us-gaap_ConvertibleDebtMember_C6ECED7468B4F2FE1FB99209108B9FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_D4BBAC0304E1DF09BB529209108BAA8A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BridgeNoteMember" xlink:label="loc_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:to="loc_eols_BridgeNoteMember_0F06718707A86CE305889209108C96C0" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_PurchaseAgreementMember" xlink:label="loc_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2B6DB6AD60395275BC69209108C0F1C" xlink:to="loc_eols_PurchaseAgreementMember_ABBBE3952AA6AB4783B992091091BB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C8F4A4AEF901D3354767920910915601" xlink:to="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_39B2E1CE06DF520C7F7992091092978E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:to="loc_us-gaap_MajorityShareholderMember_39B2E1CE06DF520C7F7992091092978E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_3DE6DBC153266B0643D292091092B108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_3DE6DBC153266B0643D292091092B108" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_AED3B8A837BCD8B3B24B92091093669B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_697CA67040F5E806C4A092091092B75B" xlink:to="loc_eols_ChiefMedicalOfficerMember_AED3B8A837BCD8B3B24B92091093669B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6742D684E4647019494F9209107F442B" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionTermOfAgreement" xlink:label="loc_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionTermOfAgreement_079CAAA16B4D29D2ECBB92091093F2B7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionRenewalPeriodOption" xlink:label="loc_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionRenewalPeriodOption_1DF35B638B9D3BA97ACE92091093D713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3B82CC5630A1B34A7014920910931565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_721E6BE4A965C079744092091093695F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentNumberOfDebtTransactions" xlink:label="loc_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_DebtInstrumentNumberOfDebtTransactions_468EE8CD89DD58267EC892091094A0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0476006158F8E70E5842920910947145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E9DBAA5CF051AB592A6092091094038A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E9DBAA5CF051AB592A6092091094038A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3A5174687B40584EFDF6920910940CAE" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance" xlink:label="loc_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance_EE8CBEB6D8A57B2A240092091094B09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_NotesPayableCurrent_C851A55064A808188341920910940FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D97E06B80D8F91854F4492091095ED70" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D97E06B80D8F91854F4492091095ED70" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation" xlink:label="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation_80F693187924799FFF8C92091095C264" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote" xlink:label="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote_2C93D23D138AA3A254FA920910955468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_07BF78128E6F68CCC17992091095A09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA259524373F25B66E0692091095499B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionTotalAmountsofTransaction" xlink:label="loc_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionTotalAmountsofTransaction_CCFA49BE8CBD8AF8B466920910960346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_Dividends_40AE243ED456C718DD00920910969F1E" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_NonCashRelatedPartyReceivable_D989662CB0BB0CC6D6DF92091096AA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DueFromRelatedParties_49FF4A90C7947309C89A9209109B77EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_81EA419869D6C1FF15659209109B7266" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_81EA419869D6C1FF15659209109B7266" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_3A2AD7BB160E3FA52C6C9209109CC2B9" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_3A2AD7BB160E3FA52C6C9209109CC2B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B1CECE2BFA80993FE8AE9209109C68E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote" xlink:label="loc_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote_46A6A6DE005E6C6529789209109CF0B6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_52E889C06872F7AAD7BE9209109C0434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_636426936F0C2A9806E49209109DD81D" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_636426936F0C2A9806E49209109DD81D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_F729B987703D94F987D09209109DE127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7782F96B0FFC4918D1609209109D8B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FFCEFC7AFE70A62F67219209109DE08F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2EC66605D2674545AF59921250B672C4" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2EC66605D2674545AF59921250B672C4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessAcquisitionUnwindingFee_CC5BC8C0C005501197339209109D0A6D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationLiquidatedDamages" xlink:label="loc_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessCombinationLiquidatedDamages_1FF4BF41698C2924C8CD9209109E0AB3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded" xlink:label="loc_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded_F9451124AFAD6291EF269209109E4856" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RelatedPartyBorrowingsandNonCashCapitalContribution" xlink:label="loc_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_749BD67F9A1DDD0A3CC392091093D92E" xlink:to="loc_eols_RelatedPartyBorrowingsandNonCashCapitalContribution_7F3799CD8987F17E72419209109E2945" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_24CD86C9D3E53C76394E4DB2CDAA7DFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_24CD86C9D3E53C76394E4DB2CDAA7DFE" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5E85B54F122C81241BAE4DB2CDAA5BBB" xlink:to="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_5F8D6836601F7F021A744DB2CDAAC884" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9EFBB11D286BC1E3996D4DB2CDAA06D8" xlink:to="loc_us-gaap_MajorityShareholderMember_5F8D6836601F7F021A744DB2CDAAC884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_D4F3456F6519E5D711B34DB2CDB40F35" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CompensationAndBenefitTransactionsMember" xlink:label="loc_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_CompensationAndBenefitTransactionsMember_9932EF0FD6E64E9D75634DB2CDB4459F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ThirdPartyServiceFeesMember" xlink:label="loc_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_ThirdPartyServiceFeesMember_276AD731B62017BE705C4DB2CDB4F647" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockBasedCompensationTransactionsMember" xlink:label="loc_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_StockBasedCompensationTransactionsMember_64207C6851F96514008D4DB2CDB4B357" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_FacilityRelatedTransactionsMember" xlink:label="loc_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_FacilityRelatedTransactionsMember_A767D105C466F7261E244DB2CDB46B7C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_OtherTransactionsMember" xlink:label="loc_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BAAD36E025B4D0F387AF4DB2CDB492DD" xlink:to="loc_eols_OtherTransactionsMember_AA2784ACEE40FE987FC24DB2CDB453E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22A642A060B535673E844DB2CDAADC63" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_EAC15D43AB99C4901BFB4DB2CDB4BED7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_FEA73749347AA262D8CE4DC0A6CD0987" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_D892DA91F30E63E9B11B2E6B7ECC9324" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_91EC09615042BCB50A852E6B7ECC5C80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:to="loc_us-gaap_NetIncomeLoss_101F3C507B2CEEEFF975975B988F895D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4CEF7447749E529DCC1A975B988FDC8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_us-gaap_ShareBasedCompensation_03011F31E9AEDCA9E739975B988F8E4F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_InterestExpenseOperatingActivities" xlink:label="loc_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_eols_InterestExpenseOperatingActivities_78C803D445ABF0985882975B9890AAFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9636E2DD1EC6784FF967975B9890E566" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxBenefitFromTherapeuticOptionRight" xlink:label="loc_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_eols_TaxBenefitFromTherapeuticOptionRight_4D724B483E64754A471A975B9890B73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E0E4B8E79B848C56DA04975B98905767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_711FB87A7DD567CFD7A8975B988F925C" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7660B691E0113FD82304975B9891A143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E6233456FB7C1C62CFA975B9891242A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B8C8D3E8995FEBA1A716975B9891224E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_4D19570DB808D91E5253975B9891A83D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56A565E3C03B42847F70975B989033A4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9F20E36C41FCBE6AF452975B9891FDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76C641A09D46F5832A51975B988EB7A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ABBAED0C89F95049769975B9892AADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4D76E248D76C1593259F975B98928CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_587ADDAC929C7A6B68BD975B98922F41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7467DB1F71021F91D335975B989207AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_B48AAA9E08ED2D371968975B98937559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2FB5EFF3CE3F2BF8B613975B98936605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_CAA6891CAB2E19A94F1B975B9893A58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_CCF154E6FEFD42D87F99975B9893E2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_D2FA20D96FA8576499FB975B989318CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18E1E911CF01036D8AB0975B9893DE35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F460D8A45155373E7EEA975B98922AC2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_809677802B788A9202B3975B9894B5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5355624F500EE485C612975B98946540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5C493D9F8BE0922EEC4E975B989449E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_783209412FFF0CFB35BD975B98947BCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FD46F9F69853758A9107975B988881B5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6B1C1DFFBB93BB98551D975B98944EBB" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_NonCashRelatedPartyReceivable_9370563EBF635F7E4D64975B989595DF" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_B8405A43A0DACF7C09F4975B9895CCE3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashNoteObligation" xlink:label="loc_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_NonCashNoteObligation_46D9FD572A47518C88AD975B98957EFC" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentRoyaltyObligation" xlink:label="loc_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_ContingentRoyaltyObligation_464D3165AF0E0BFDE21E975B989592C8" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ContingentPromissoryNote" xlink:label="loc_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_ContingentPromissoryNote_3B36A26C8F0F07A979C0975B98968FEC" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionConvertibleNoteWriteOff" xlink:label="loc_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_CapitalContributionConvertibleNoteWriteOff_7D46371B887C139FB343975B989609DD" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashCapitalDistributionFromParent" xlink:label="loc_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_NonCashCapitalDistributionFromParent_78850F741A45EC522DFA975B98967BCD" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_5BB947805F38B3D6DEB5975B98967CE5" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionTherapeuticOptionRightNetOfTax" xlink:label="loc_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_CapitalContributionTherapeuticOptionRightNetOfTax_7C51794C4C0F3F696839975B98968C5C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DeferredOfferingCostsAccruedUnpaid" xlink:label="loc_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_DeferredOfferingCostsAccruedUnpaid_CC52DAE835CEA525FBBB975B9896D08D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_NonCashDeferredOfferingCosts" xlink:label="loc_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_NonCashDeferredOfferingCosts_BDDF51A7C8DAA58BB23B975B98976EBE" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_AccountsPayablePaidbyParent" xlink:label="loc_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_89230426EF93D8CCA981975B9895591A" xlink:to="loc_eols_AccountsPayablePaidbyParent_9F5029D5149ACF94AD2F975B9897A826" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_B4F435F093345D6997C491E3DC4843D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_C429DE05935F64975CE191E3DC485230" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty_ADFDDAA9DCFF559053E291E3DC488C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:to="loc_us-gaap_DepreciationAndAmortization_F06BF46989B297AF4DE991E3DC4891DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0379666D57755A962FA291E3DC484095" xlink:to="loc_us-gaap_OperatingExpenses_1E7D8CB8E81D18D048EA91E3DC4868BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_OperatingIncomeLoss_6CE178C7196BD03A1A2991E3DC48B362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4EDA42CC31236E3A0FDA91E679468B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_EAE100838FCDF960E79D91E3DC488A4F" xlink:to="loc_us-gaap_InterestExpense_D985BC172DC44A40B0B391E629786108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5BEEF65D72D8E2CDF05791E3DC48323E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_AF83BBD2F8C913F2FA8791E3DC48DFD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_NetIncomeLoss_9206F4DD9DCA4459321D91E3DC4878A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_D3FBD04095B3D051098F91E3DC485109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_3D88C967B80B163A94EB91E3DC4800B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C73C15C456458A5F59FF91E3DC486FAB" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8522930AFC427D73B81591E3DC480A47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_A1BF87EDA5B941386FD8966FB77B6439" xlink:to="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16CEB0C600BD9AB50236966FB77C1D72" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:to="loc_us-gaap_IPOMember_CBA31E662FC308D87D0E966FB77DA32F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4E9E80C69DB23C49965C966FB77CFFFE" xlink:to="loc_eols_FollowOnOfferingMember_8AE4C51E78F970D14D2B966FB77DB07B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6AFEEC43FBB41C8F3023966FB77D9054" xlink:to="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_PreferredStockMember_D06F134E88FC0F9A063D966FB77EBE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_CommonStockMember_7BA67D29330FDA7C75FD966FB77EFFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_24BDFF9FEBFFC5CDA211966FB77E20CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B25ED3CCA1EFF80FEB5B966FB77D94AC" xlink:to="loc_us-gaap_RetainedEarningsMember_619CB854AB6065BEDFC5966FB77E2BF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FFB495711EB246188AF7966FB77E593E" xlink:to="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5BC3D4E428BEB812FD44966FB77FBF87" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7F1B7D619D228CD4A213966FB77F08DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39757911291EB95EA5A0966FB77C72A1" xlink:to="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77BE8DF10AA76933B6FF966FB77F027E" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_SharesIssued_777E8E7A347E671C3BB8966FB780590E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockholdersEquity_1E087EC3B39065E945C8966FB78092D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8164A98C8B9E271DD548966FB7807374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5882E95363E2E3B5EAD1966FB780C3E4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_9440030A99F0431E8A39966FB780BD4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_Dividends_8E3025C52273B6620745966FB781B249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_67C488246D0E686EB96A966FB7814241" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_97A8E0B367DB1A6D6091966FB781365C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5340CAD96BD54D98EE2A966FB781C17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CFE475CF649C2B44687B966FB7814018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7A2A4D7E6A281DAC8074966FB7817058" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_749ABDA8796EE25F11DA966FB7823C0F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_1368B67515EE082976C5966FB782C728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6718B2C728F5EAD44B0C966FB7826ECB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_NetIncomeLoss_6718B2C728F5EAD44B0C966FB7826ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_SharesIssued_C3B2CF13F04553F91FB3966FB782D692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F0140947F0449804E296966FB77F545A" xlink:to="loc_us-gaap_StockholdersEquity_BA94288BE6193DF0666F966FB782A534" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_746246C361DFB06F9971824D1C8426B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_746246C361DFB06F9971824D1C8426B2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3A3BFE74AC118E3B40F5824D1C8484D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_F047E777A10C29EC2A4D91E3DB31453C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_F047E777A10C29EC2A4D91E3DB31453C" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_AC01291E2B810634D05B91E3DB318579" xlink:to="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2D4476A015EE0EAEF11C91E3DB31BF7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:to="loc_srt_MinimumMember_2D4476A015EE0EAEF11C91E3DB31BF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1A845A86DFCAE1FF9EAD91E3DB31A4C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39698096ECAB433C00A191E3DB31362D" xlink:to="loc_srt_MaximumMember_1A845A86DFCAE1FF9EAD91E3DB31A4C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B00EB12647FACE4725291E3DB31C2BD" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_DECC4B8565ED6B416FF391E3DB312186" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:to="loc_us-gaap_IPOMember_DECC4B8565ED6B416FF391E3DB312186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1DAC64C8CFFA5961CFB791E3DB315A36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14E49149F96AA66BF90D91E3DB313819" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1DAC64C8CFFA5961CFB791E3DB315A36" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_CE98C74429F97752407991E3DB3168E3" xlink:to="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_C40A7AC5661A9623192B91E3DB319A4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_23FAA9DB29F2AF0977B191E3DB31C65A" xlink:to="loc_eols_SCHAEONLLCMember_C40A7AC5661A9623192B91E3DB319A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0FE00A9669412B508A7191E3DB3140A9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_DA096C7D6312A6C2905391E3DB3BCD65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E5E4F6AEFC9D56EEFD691E3DB3B843A" xlink:to="loc_eols_EvolusIncMember_DA096C7D6312A6C2905391E3DB3BCD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_453F9819E7D5FC1D945C91E3DB3B6482" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_F4D03B01F93D4940051491E3DB3C7250" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2CF9037C49D784D1CA0991E3DB3B7C4A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_F4D03B01F93D4940051491E3DB3C7250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_E976CFA8219C866345F291E3DB3C68C1" xlink:to="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73BE0850EA02C12322F791E3DB3D9C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_FF27B02797CA49625A8491E3DB3C79F7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8B512707B29B031F66F991E3DB3DBB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3D644B8A2D83D02E0DFE91E3DB3D3E5E" xlink:to="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_6D9023805EAED15823CA91E3DB3E1FD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:to="loc_us-gaap_MajorityShareholderMember_6D9023805EAED15823CA91E3DB3E1FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2A7A786411BF620B9EA391E3DB3D8D70" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_FC7C6851106917FCF08E91E3DB3E7625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8E12DE081D64B32412D991E3DB3E970A" xlink:to="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_86212E611227BF46475B91E3DB3FF4D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A19441FC8DDDC385ECA091E3DB3E0F6B" xlink:to="loc_us-gaap_CommonStockMember_86212E611227BF46475B91E3DB3FF4D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A497B93A317B3339F16B91E3DB3FA40A" xlink:to="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_74E457C3B7A73FF3B51C91E3DB3F428D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_309D77B89A9F04C845F591E3DB3F907B" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_74E457C3B7A73FF3B51C91E3DB3F428D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E30F60F3E877BF2B195291E3DB40AF93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_859120733A70EA511E4691E3DB40BF82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_859120733A70EA511E4691E3DB40BF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2322F65252366FB1417691E3DB403BA7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0769326DAFFFEB2DF9B091E3DB407B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A04036EF0EFD82E4C7D491E3DB31AD7C" xlink:to="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5AB85F212FD9C5CE693891E3DB417FDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5AB85F212FD9C5CE693891E3DB417FDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_EB2B05FBAF3707C80AB291E3DB41D1E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_EB2B05FBAF3707C80AB291E3DB41D1E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7F105B83879A80EC1B6391E3DB418C14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7F105B83879A80EC1B6391E3DB418C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_D54EFDD10359FF16535691E3DB4187FF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_D54EFDD10359FF16535691E3DB4187FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_376ACA4BDD8E3139429F91E3DB41BAEF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_376ACA4BDD8E3139429F91E3DB41BAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5327D48EE1E6130E3E0C91E3DB42E665" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5327D48EE1E6130E3E0C91E3DB42E665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_85D61891A6A55C5B306291E3DB424B15" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_85D61891A6A55C5B306291E3DB424B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C667D80C27E46989F2591E3DB429382" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C667D80C27E46989F2591E3DB429382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3E66185AA95FA7E8AB5A91E3DB42DD69" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3E66185AA95FA7E8AB5A91E3DB42DD69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_096BB3B5EEB2FD0D9FD691E3DB423433" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_096BB3B5EEB2FD0D9FD691E3DB423433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9940687F0C94185E964F91E3DB426688" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockSharesIssued_9940687F0C94185E964F91E3DB426688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97B6EA7B8E526755B18091E3DB436D04" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97B6EA7B8E526755B18091E3DB436D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F359889A61D073D9088F91E3DB43220B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F359889A61D073D9088F91E3DB43220B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_FA769098D89E2DDA6AD791E3DB43EA8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ContractualObligation_3E941C4D8D83D87782EC91E3DB4373CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_LongTermNotesPayable_11AD2ABDE2FA1EDEE65E91E3DB43384D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_187510B24CD8F1657A9F91E3DB43052B" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_187510B24CD8F1657A9F91E3DB43052B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_D0E77E210BDD4264A10B91E3DB44268A" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_D0E77E210BDD4264A10B91E3DB44268A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_A3C54FBD532785BDFFF091E3DB444625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2AD09991EE347E2662B091E3DB446E2F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3409FA211A4C8118960D91F63FC73456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_64787B26B4BD39CACD1C91E3DB44D2F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A75ADEE4AF1DF7D717B991E3DB44CBA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A4E0D64625F144E1906B91E3DB451536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_28804E8F2BB4A3C8CCFA91E3DB45F517" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_28804E8F2BB4A3C8CCFA91E3DB45F517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CBBBE03424FE5DE901791E3DB454E64" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CBBBE03424FE5DE901791E3DB454E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CB28648EC95193B345C91E3DB45EE0E" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CB28648EC95193B345C91E3DB45EE0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64A5807C0EF79E66E00D91E3DB45754E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2AA6E5519D840CB8ECE891E3DB45A0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89517D61540429370B0491E3DB46C8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8DFAA995ECB8EB6FBBF891E3DB463556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4C8882A9634EF6F5154D91E3DB404E34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F54B6A0332B58B3DBB8791E3DB462B1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_148EEF6523469457706492090F2144A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_148EEF6523469457706492090F2144A5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_74ED95FFDA840BE8D27A92090F224DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_06519B89AB68114213FD92090F22D375" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_06519B89AB68114213FD92090F22D375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AA9629C9164C97B0205492090F279F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_45035DCEDFCA56A91E5492090F21998B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_25BFAFA72C82E5296D3892090F2842EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_148EEF6523469457706492090F2144A5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3C282B2A19BD553A1875920F1F29EE00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7C759DACC61C737A615D92090F2826CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_F69E808820B3DE22F40792090F297C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_1AA047E109F36751CD2D92090F288CE9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6C0A86FE6DB1CE29D2C8920F9C62D57E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DCB7BACD38CCC6336D8C91E3DB1367B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DCB7BACD38CCC6336D8C91E3DB1367B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:to="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_78B46B00884FC7E8870791E3DB13595F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1BAEBA74B97F9A79B46E91E3DB13D462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99497695289DC04F28B391E3DB13F8A8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1BAEBA74B97F9A79B46E91E3DB13D462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_258FEA13410FE63628F991E3DB1377C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E239B1E3E4501F76823F91E3DB134B47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F1D3D067DF289122DE6591E3DB13CB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_084A0B9BDF672F0E777E91E3DB13BE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_480F74FC80C4B0738A6991E3DB133F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC9D54CF7447EB74D88C91E3DB13AFAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71A1E62CB3D948CAB62A91E3DB13E4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C987604C0C260D85BC6C91E3DB138C5A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8F756758F7FD8A58DF6C91E3DB139466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_809FB90DEDD4ABBEE93591E3DB132067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5C2A2C07B7754CF6610091FCF34AC0CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CDD81D48ECB1A6FAA94291E3DB13DEF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_859FBF841AA2517E131291E3DB1326A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F210429EFC01D3028FF391E3DB132A10" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8886E8C3B8F89F0C461798666E51DD83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8886E8C3B8F89F0C461798666E51DD83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:to="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C3707F173FE43D42B0DC98666E52A1C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E9A45364230EFBE32F0798666E53614B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E1D9B8FFCB0A37ADEA6598666E533C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49E5B9BCB1009F78997C98666E52530B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732CA8C46A39D80A882B98666E55854E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_FC403CA773716A929A3A98666E568529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B7E043E6DD940A8DD66F98666E563CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AECA8FA07866C13AF50098666E57BC39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B784E78B51CA03B7F16198666E54F027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D29A2F25276B4BD1FB9B98666E57E059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A64CF6E0973E9898F12198666E571AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3D1F222691F73CBFE2998666E58811E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FA1F4B48D99BAB944F5D98666E588F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_027E082C5C22CBAED11098666E59733A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F686EA4CA13D29B01C7498666E59229F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C872E759D7909874898498666E578C4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80659DA81682DDF2284998666E594BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E8E4BC859124EDC1602898666E59BD27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_F9C33EF9EF4FFCD1149C98666E594565" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_D774878AF8EA598AB0EA98666E5A00B3" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_41C2F8602A1698C14DD898666E5A1223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5C6E925DE829A274FF4C98666E59BCC1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7F3222AFF30729E1543798666E5A9FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8152F0D4EF77027ED25498666E5AA97D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FF9BEFDB5B490538B89E98666E5B4BD5" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_827C3256F15984969FF398666E5B4AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59B5BC41C62650F7CF5698666E5B1560" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_83AFA8C8C520CF4B4A9198666E5B8DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_AB7AF2F68DD71E38677998666E5A0D84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_93718049AE665267A23598666E5BB01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92BE57C83FDCC82557C698666E53A17D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_B729639D27E00E1F487C98666E5C0A21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E5169F8BC5020BE0A1E098667427C3E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E5169F8BC5020BE0A1E098667427C3E0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:to="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_29787BDF173990C4595598667427BBA2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5D934C007D96F9E09819986674286BFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6271EBE547934E28A51298667428EA72" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5D934C007D96F9E09819986674286BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0092E7F386A5EC49AD6098667427DD31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2BD6BBD0168D398390E1986674282E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C32FD10407549F631E3B986674294CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B902B527153D47FE54C7986674290844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2CA1E4BF87E58DD503B29866742878B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07BF38C4AA31893D8BC6986674297F9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E3B4A9838CCAD26B062282AC881C5605" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05617047514835B1A99882AC881D6066" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_E1DC40C8C0667AB8555C82AC881ED602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D47D50125CB8FA5E2BD782AC881D4505" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10F6E9A481F52E791C1B82AC881EC2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0A6328BDB8CDC67205D382AC881D751C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91CA11635389EB54B44D82AC881EDF35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27D06DDA99FE2813A81982AC881ED26A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4D5738210B00D6B8183791E3DB4FBCC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D5738210B00D6B8183791E3DB4FBCC1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3B4E18A263AB8C589C5F91E3DB4F3AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D5738210B00D6B8183791E3DB4FBCC1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8BE0A418C4925960962591F92B141AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D5738210B00D6B8183791E3DB4FBCC1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86A459452DBE622796E691FB21D530C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D5738210B00D6B8183791E3DB4FBCC1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6434267CC75C4548AA791E3DB4F0F55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_545A48244DE7BFFFF34EA9EC0AD98481" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_EB30DAE237CB3591BDC5A9EC36EB149B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_24B7E683BD664BE9AB4591E3DAEB7FAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_24B7E683BD664BE9AB4591E3DAEB7FAC" xlink:to="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CCC073E997403AEE87D091E3DAEB622B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_964B59A2E2336DCE8D8291E3DAEBBC95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E05FEB9CA7DD4B3B6B4291E3DAEBE64C" xlink:to="loc_eols_TermLoanFacilityMember_964B59A2E2336DCE8D8291E3DAEBBC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5064207ABB751F84F4CE91E3DAEB0B8C" xlink:to="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B4CCD71DB5147284633C91E3DAEBB8A9" xlink:to="loc_eols_ChiefMedicalOfficerMember_C928986251E5F07EA4B791E3DAEB7A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8F1324CD20A0512274E791E3DAEBC31E" xlink:to="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_94414A67F2F4B26E886B91E3DAEB8D49" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0CADDB446C0C78CCA31091E3DAEB1914" xlink:to="loc_eols_ApplicableRateMember_D4222C2B38C63E8441D291E3DAEBAAF8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_D873C5AB2E9E8F592BCE91E3DAEBCC29" xlink:to="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_547AD13113DC94B6368A91E3DAEBF801" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:to="loc_eols_SCHAEONLLCMember_547AD13113DC94B6368A91E3DAEBF801" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1B1D458605AFC515F24E91E3DAEB1868" xlink:to="loc_eols_DaewoongMember_2C3D844C760E3231EA8391E3DAEB25D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_130F9BD8A52E2F0CA3AB91E3DAEB3938" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_9867C0313C33F19519B691E3DAF54BD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D975BFBE1659B4FDE96991E3DAEB73CC" xlink:to="loc_eols_EvolusIncMember_9867C0313C33F19519B691E3DAF54BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8A282064FEDF5340EEF391E3DAF51EE9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_DCF3911BE05F7494558F91E3DAF558F7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_6E86F18CCC5FD8F3046591E3DAF5E516" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F3CD5622E4CCA9C374D91E3DAF52DC4" xlink:to="loc_eols_TermLoanFacilityMember_964B59A2E2336DCE8D8291E3DAEBBC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D0A6B9CC647BB9C7357991E3DAF537C2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_BA532F6101E5EDE1249F91E3DAF56E0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_35D084FDAB8D3555957091E3DAF5FAB9" xlink:to="loc_us-gaap_SubsequentEventMember_BA532F6101E5EDE1249F91E3DAF56E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_B58437A1E8C33E000CAC91E3DAEBA19C" xlink:to="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_1ABF0BB0BF2D7C051F4291E3DAF5FBB7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval_3BD816720565B261E05391E3DAF5E306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1FE01927EF096749281991E3DAF5FC9D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement_5E86203A311C5889B0F491E3DAF53A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_634086C7EABD0AB6872A91E3DAF57C1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_634086C7EABD0AB6872A91E3DAF57C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EF1FA09486BA104393A691E3DAF5CE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7D11AFE75F110315F6DC91E3DAF531E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_E06BC04393C6A44A2AFE91E3DAF55718" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_33E009BA9BD3D1284E9591E3DAF52ED2" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_3C86D79903F64E49DD1B91E3DAF504C6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentTermAggregatePeriod_A83AA529CB2BB7780B1291E3DAF53485" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_74955690A2AA26E2BD959202355E98E6" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_E8962DDC2F0F284E000F91E3DAF5F33D" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_AE28846CE6FE9EBABADB91E3DAF52989" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_44F87E9F3F127726E2CD91E3DAF5E7FF" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_0B1D90265EE6BE77C81691E3DAF54332" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2C80C82154A2BBB2141F91E3DAF5F7E7" xlink:to="loc_eols_DebtInstrumentDefaultInterestRate_3F52474081768E62A71391E3DAF519A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7D635005079750A0198D3384BE9218AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7D635005079750A0198D3384BE9218AC" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E10FD0B432AD0DA72FC23384BE9255AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ED775B76D2FECE1022591BD573F7ECC" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8F62F09A91257B88192391BD573FBCE2" xlink:to="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3423E5133D97A74E558391BD573F0288" xlink:to="loc_us-gaap_MajorityShareholderMember_2A831EF0B0F3E277037F91BD57405340" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_FEE162373268CCEFC9EF91BD57401883" xlink:to="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1E836DF8E441FE0E5B1A91BD5740A34F" xlink:to="loc_eols_SCHAEONLLCMember_4FBCBB39BDBB48C3FAF791BD57400751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_B9370A74C6522E2ADEDE91BD5741863E" xlink:to="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2DF63C9604FCEFA043B991BD5741F792" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:to="loc_srt_MinimumMember_2DF63C9604FCEFA043B991BD5741F792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_736A83FFE6AA48F3EF7C91BD57413BD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52D20FBED7C0CCE9291591BD5741B46A" xlink:to="loc_srt_MaximumMember_736A83FFE6AA48F3EF7C91BD57413BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8541B8D918ECC1D9ACF791BD57429659" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3254B990FADB13A9E76391BD5742BF8B" xlink:to="loc_eols_EvolusIncMember_BCCE1F7DD88CBB30175A91BD57423157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E79B842303D3C929B23291BD57421FA2" xlink:to="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassAAMember" xlink:label="loc_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:to="loc_eols_CommonClassAAMember_882F7A698E1EAA5A501191BD5743CAE0" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_CommonClassDMember" xlink:label="loc_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_206D7FD3012C92A2A45391BD574200A4" xlink:to="loc_eols_CommonClassDMember_3FC3EE27D9DDE805004991BD574349F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0523AC64D1A9A0C225D691BD573F6180" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_A10D5489B4C67D9F8A8391BD5743B1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_A20328C9CD541F9F8CBA91BD57447667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_NumberOfReportingUnits_27906EE78530FDEA4C5F91BD57449FB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0DFD78CA33FCF929BB5491BD5744D4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_C91938B48AB3BB0CB80F91BD574415D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_C7554DF3ADC759D979A891BD57440675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_us-gaap_DeferredOfferingCosts_DF66A434D1F811C8DBC191BD57446C9A" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance" xlink:label="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance_05CE48D10EB86DD1109D91BD5745D016" xlink:type="arc" />
    <link:loc xlink:href="eols-20181231.xsd#eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_499F402259F221F5931291BD57435C00" xlink:to="loc_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit_422549F293FCC9563D5591BD57455A46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FCCAFFA0327A2737E629914620C82B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_947482550D7D99EE2DD6914620C90AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_B050960E6A1B0B20C17F914620C99D88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_UseOfEstimates_F9E06E84DCC8E285D1D5914620C90FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_FE6E1F4721E12C8A764C914620C9BC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_C2CC709B8587225BA000914620C9AFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AAFFFFA85A786DDBEC64914620CA3045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4006C2562A7632D1400C914620CAF612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_AA344BDA735F83A054CD914620CAAA25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_501FC78A59CCBC6F982F914620CA0E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_DebtPolicyTextBlock_0ABF6760D7499D18C40B914620CA429C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A7EACE513349A549202C914620CA5A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7B46C18194BC62D85949914620CACE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ADAFCDB59411689F2A6C914620CBA253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_D8BF9C0D7688E5ED2F88914620D0E0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5A0F20D049B4627A36E8914620D06602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DFD5A7217864BC276E9914620C8F6EA" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BE5EFC818C631FE2661D914620D0653A" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>a900kda.jpg
<TEXT>
begin 644 a900kda.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M2!@:HS%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP: '44T-@\XH5L]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?$OB+26=+W2]*UZUO+VS9&*N)(8Y&="K @A@,$$&NH\4^/?V@SX%7XY_"_\
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MBB@#X)\#_P#*>/6_^Q/D_P#0A7WM7P3X'_Y3QZW_ -B?)_Z$*^]J "BBC/-
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MQ(;X8V_AE?%#M93ZBNL?V8\OV[['O$*[9)B?LQ(2,\=2/JROS'U7P[X$\0_
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MR?[QKRLRW1]MPE\-1^:(U^0[@,-2*&1?O?-TR:6BO+Y4?; >M!4%_8=J**3
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MN0LIX8BOSXUW]G>X_:QN[C0?V<_BA\?IM#99(;SXKZE\6-=O?#FGR*=K1:=
MMZK:I<*<C<K+:QL"&ED=&@(!]M?L5?!;6_V?_P!FCP[X:\37EA>^)5>\U36&
ML-_V&&]OKR>^N(;;?AOLT4MP\<0;YA%&F><UZI7'_ #X0#X"?!W0?"/_  DG
MBSQ>VBP&)]9\3:I)J6JZB[.SM)//(=S$LQP.%50JJ J@#L* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#X)\#_\IX];_P"Q/D_]"%?>U?!/@?\ Y3QZ
MW_V)\G_H0K[VH **&Z49XH I>(_^0%=_]<C7S1<_\?\ )_O&OI7Q 6?1;E1R
MS1D"OFJ__<WTR]2LA&:\K,MTS[;A*2Y)ID=%%%>5S'VG-H%%%!SD8&?:B4BC
MT']G3_D9K[_KD*]GKQG]G)6_X234&V_N_)&/8U[)EJ^@P?\ #1^7<1:8Z7R'
M'I0.E Z<T9KJ/$,/XC?\B9?_ /7,U\YK]W\37T=\08FG\)WBKWC-?. ^^RX^
MZVW/O7CYGJT?<\)R2A-=6Q:*3.?ZTN:\\^SEIN%!Z4'I0WW:AR1+/4/V:?\
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M+@>9*\K;KBZDDF?YW;&]SM&%&%  Z2BB@ HHHH **** "BBB@ HHHH ****
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MQ?$'P/X#TWPK(?\ 3)[+4Q)/%_NKGFN)^'3'_A^UXD&[_F4WX_X$*^]NM "
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M/WGP?_@5_5?D#=:*#UHKY4_9PHHHH ^K/^"7QS?>+O\ ME7UY7R'_P $OO\
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M &E/^2*^(/\ KV-?FG_RU;_>-?I9^TI_R17Q!_U[&OS3_P"6K?[QKXWB?^)
M_>?!_P#@5_5?D!ZT4'K17RI^SA1110!]6?\ !+[_ (_?%W_;*OKROD/_ ()?
M?\?OBW_ME7UY7Z-DG^Y0_KJ?RGXA?\C_ !'JOR04445ZQ\6%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P1\
M.?\ E.UXD_[%-_\ T(5][U\$?#G_ )3M>)/^Q3?_ -"%?>] !1110!A_$O\
MY$'5_P#KV?\ E7Y=ZW_R&+K_ *[M_.OU$^)?_(@ZO_U[/_*OR[UO_D,77_7=
MOYU\CQ-O _<O![X:_JOR*]%%%?(G[<%%%% 'TA_P30_Y*AX@_P"O%/YU]L5\
M3_\ !-#_ )*AX@_Z\4_G7VQ7Z)D7^YQ/Y7\1/^1Y5^7Y!0>E%!Z5[!\.<'^T
MI_R17Q!_U[&OS3_Y:M_O&OTL_:4_Y(KX@_Z]C7YI_P#+5O\ >-?&\3_Q('[S
MX/\ \"OZK\@/6B@]:*^5/V<**** /JS_ ()?<7OB[_ME7UY7R'_P2^.;WQ=_
MVRKZ\K]&R/\ W*']=3^4_$+_ )'^(]5^2"BBBO6/BPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^"/AS_P I
MVO$G_8IO_P"A"OO>O@CX<_\ *=KQ)_V*;_\ H0K[WH ***0?>- &)\2_^1!U
M?_KV?^5?EWK7.L7?_7=OYU^HGQ,&? .K?]>S_P J_+O6O^0S>?\ 7=OYU\CQ
M/M!G[EX/?#B/5?D5Z***^1/VX**** /I#_@FAS\4/$'_ %XI_.OMBOB?_@F:
M?^+G>(/^O%?YU]L5^B9%_N<3^5_$7_D>U?E^04'FB@#!KV#X<X/]I0?\64\0
M?]>QK\TQ_K&_WC7Z7?M*'_BR?B#_ *]C7YHGB9O]ZOC>)OXD/0_>O!_^#7]5
M^0'K1117RI^S!1110!]6?\$ON+WQ=_VRKZ\KY#_X)??\?WB[_ME7UY7Z-D?^
MY0_KJ?RGXA?\C_$>J_)!1117K'Q84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?!'PY_Y3M>)/^Q3?_T(5][U
M\$?#G_E.UXD_[%-__0A7WO0 4TG;3J;(: ,7XE_\B!J__7L_\J_+O664ZU><
M\B=OYU^I?C:S.I>$]0MUY:6!E _"ORX\30-9^*M4MV7:\-RZ_7!KY+B?X8'[
M=X.U4I5X^A3(P:*"<FBOD#]R"@#BB@G H#FMJ?2'_!,[_DIOB#'/^@KGVYK[
M8'2OB_\ X)FZ3<'QSK^H>65M7M5B#>K \U]H5^BY%_N<3^5_$25\]K6\OR ]
M*!THH8X%>N?#G!_M+''P3\0?]>YK\U"0LS[N,$FOTY^.6CR>(?A1K5K$NZ26
MW8*/H,U^8MRIBFE1EQ(LC*WX'%?'<4+WX,_>/!V2='$1\U^09R:*!THKY0_:
M%L%%%!Z4 W;4^K/^"7K;K[Q=[^57UX#D5\G?\$Q]$GM;/Q)J#(1;W1C6-O7'
M6OK$#%?H^2_[G _E'Q DI9]7:[K\D%%%%>J?&A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\$?#G_E.UXD_[
M%-__ $(5][U\$?#G_E.UXD_[%-__ $(5][T (QP*1?F/-./2DH ;( PPW\7!
MKXE_;4_9>O/"?B6X\3:':R7&EWA+W$<8SY+=S^-?;<@8D>G<5R_Q7^(/A_X:
M>#[B_P#$EW;P6"J=RRX_>^P'>N',,)3KT7&I]_8^DX6SO%Y9CHU,*N;FT<>_
M_!['Y@@C^'E3USQ@^E*ORKR58YKI/CO^U-\/_$GB:>3P_P"#?,5F/^E>:8]W
M_ *\Z/QVT\)\OAE&/]TS_P!:_,\3/#4I.*J?@S^M,KIYCB<,JT\.XM]&U_F=
M HRIW?*.WK6CX3\'ZEX[UV'3=+M9;FZN&"A54_+[GZ5REG\>-(BNQ)-X7%P@
M'*?:"N?:OK[]BG]KWX9:K<V^C1Z7#X9U:8;4\WY@Q]/,/K79EM'#8FHH.H>+
MQ9C,SRS!RKT\,Y:;III>;2=_N1[W^S3\#H?@?\/(;'B2^G_>7+C^^>H'M7HY
MR$J%'\P@JVY&&01TQ4L?'%?I5&G&$%"&R/Y+QV+JXG$2Q%=WE)W;%#8%!?<*
M N*<.*TZW.1W(;FW6>W>.0;DD4J1Z@\&O@K]KG]F>_\ A3XMNM6TVU-QH=\3
M)\H)\G/4&OO=P<_>KF/BWXU\.^ O!=UJ'B::UCTZ-"668 ^9[ 'J:\_,,'3Q
M%)^TTMU/J^$>(<5E6-4L/'G4M'%=?^"?F$#YBG;U[ ]J P=@I'S=\5T'QO\
MVF?AWK7B&X;PWX-::.1LBY,YCW'_ '>U>?GXZ:=D_P#%-KN'_3>OS/$5*%&5
ME._R9_5^5T\PQ.'59X=P;Z-K_,Z#(#=>?X1_C6Y\/?AUJGQ1\20:7I-M--/,
MPW.%^2(=R3Z5Q>G_ ![T>WN(VN/"JW,/5H_M!4_G7U_^QI^VS\/-5EM]!72[
M?POJ<HVH&P5?V+UZ.5T<+BIKFJ?(\#B[&9OE^$E5HX9R=MTTTOEN?1?P-^%%
MK\&_ %GI-JNYXUW3O_><]:[1'W"HHY/-0-&596&0P.01ZU*HVI7Z/3C&$5"&
MR/Y+Q6)J5ZLJU5WDVV[]QPHIO5:=6B5C$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@CX<_\IVO$G_8IO\
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M[7W_ ! MQ^-.I ,&EKW#\_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFU6[AT-[55AB7<[-)(H"H,L2P R:\U_X)N_#7QC^Q=\7]4\$?$#PKKWBR_\
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M/-\0M%N=.CN9]0&H"W\B<RRJT.WV1(VS_P!-/:@#QSX<_P#*=KQ)_P!BF_\
MZ$*^]Z_+K]@WXO>-/C1_P63\1ZKXX\$CP'JR^%G3[!]I\XL-P^;-?J** "BB
MB@#F?C/_ ,DIU_\ Z\W_ )5^,>M_\AN^_P"OA_YU^SGQG_Y)5K__ %YO_*OQ
MCUO_ )#=]_U\/_.O@>-/CI?,_I/P#_AXGU7Y%6BBBOA3^C0H!8/\JY/2B@]/
M\*F46U9"?F>B_L]_%"\^$UGXLU+3I&CU"2Q$,4@^\A/!KS[4;^76KZ2ZO))+
MF:8EWDE.YLGGO6GX;!?1M8/]VW7IWYK(4Y5?I^==DL56C24$]#R</EN&AB*N
M*44YR:5^MDB,QQ)'AE4KG.<?>IS0JQ VKM8=-OS+]*<!AMU!&5_K7+S5#UY0
MO%1T.T^!7Q8U#X0^+O.L[J:*RN(VAN8<_+*I!XQTKC[Z;SM3NIE^7SIGD8?W
M02338CNE7O[TW&5;_>S]:VK8JI6@H/9''1R_#TL1.M32BYI7:\O^'!1@44'K
M16)V!1110..Y]-?\$JO^3A#_ -<7_E7Z9#I7YF_\$JO^3A#_ -<7_E7Z9#I7
MZIPK_N$?5G\9^,G_ "4<_P#"@HHKS;_AKOX=_P##+O\ PNC_ (2'_BVG]C_V
M]_;'V"Y_X\MN[S?(\OS^G\/E[O:OI#\J/2:*YWXN?%GP[\!_AAKWC+Q;J<6C
M>&?#-E)J.I7LB/(+>"-=S-L0,[G P%12S$@ $D"L_P 2_M ^#?"7P%NOBA>Z
M]:?\(#9Z)_PD;ZS;J]S"^G^3YXN$$:LTBF/# (I+ C )(% '945YU\$?VJ/"
M'[0DFJ+X<'BR'^QT22Y.N>$=6T!0K[L%&O[: 28V'/EEMO&[&1G#^%G[?7PB
M^-/CNU\.>&_&5KJ&I:DTB:7(]E<V]EKYC5GD_L^[EC6WO]B([-]EDEVJI)P.
M: /8:**"<"@ HIJ-G-*A)'(Q0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4'.:** /@GX>-N_X+L>(O[R^%'R3Z;J^]A7P1\.?^4[7B3_ +%-
M_P#T(5][T %%%% ',_&?GX4Z_P#]>;_RK\8];_Y#=]_U\/\ SK]G/C.<?"G7
M_P#KS?\ E7XQZW_R&[[_ *^'_G7P/&GQTOF?TGX!_P /$^J_(JT445\*?T:%
M!.!100&.#THY6](@;'A@9T36O^O<?SK%7[H^E>P_L@?"0_'"_P#%7A]66.XN
MK$>0Q_A8?XUY]\2/A5K_ ,)O$$NEZWIM]:S1.55WC)W@=",>M=U3 U_JRK)7
M/GL-Q!@HX^KE]6:C-6=GV:W_ $,#/%*#Q2;68%EMYSMXV^4W7\J38Q;'E7#G
MN/*;Y?TKECA\1>_*>Q]<PZ=U-7]22$?OUXII&&;C^*O:/V8?V5/$'Q0U*36[
MRQFM=!TV%YVFF3:)<*>!7C=^G_$UO5B9F\NXD ^@8BMJF!JT8*<U\5SS\#GF
M%QF)JX?#24G3M>WG_P ,1YS10.1T8>QHKCCMJ>W*U] HHHJA1W/IK_@E5_R<
M(?\ KB_\J_3(=*_,W_@E5_R<(?\ KB_\J_3(=*_5.%?]PCZL_C/QD_Y*.?\
MA05^._\ PM3XW?\ $/!_9?\ PI_PG_P@?_"L_L__  D'_"?'[=]D\O'VG[!]
M@QNV_-Y7VC..-V>*_8BO-O\ AD3X=_\ #+O_  I?_A'O^+:?V/\ V#_8_P!O
MN?\ CRV[?*\_S//Z?Q>9N]Z^D/RH^6?^"NGQQ\,>)/C9\%?@1X@CUW4O#GB#
M64\;^/+'1_#TWB!VT+36:2W@NK2WAGG-M=:DMM$66+!$3@LHSGQ3X3>.+OXX
M?\$Y?C!^S/X:UK0?#OB'P+XJL/#OA,_$./4-"M-:\-7VJQS:9;SI=6\=R6FM
MDN=/\E4,C&)<-F1&/Z7>'O@AX7\*_%[Q)X\L=-:/Q9XNL[+3]4OY+J:8S6]I
MYOV>)(W<QPJIFE)$2IO9]S;B 1S_ ,6_V.?AC\>?$>HZKXR\&Z1XCN]8T4>'
M;\7H>2"^L5N%N8XIH=WER&*=?,BD92\3,YC9-[[@#YC_ &E?VA_BQX;^&?QZ
M^$'CY_"FJ^,+SX+^(O&?A?7/ ]I=:=^[@M_LDEO+:S7$\T=PMQ<1-%+'*RR*
M6&V-H_GW/VFO[$_X9%_97_X1K^R_(_X3[P!_PC?]F>7L^S^?!YGV/R^/+_L[
M[5N\KC[-YV?W>^OH;X&_LF> /V<CJ<GA70Y8;[6DCBU#4=2U*ZU?4KZ./=Y<
M4MW>2RSO&F]]J,Y5=QP!FL3X6?L"_"+X+>.[7Q'X;\&VNGZEIK2/I<;WMS<V
M6@&1623^S[261K>PWH[JWV6.+<K$'(XH ]AKG_BLWB%/AWJS>%/LO_"1"W/V
M#[2NZ'S>VX>E=!0>E 'P+=ZW^WQ;Q32?\6O"0AW_ ./(_,!DBO4O^"27[7?C
M;]L?]G6^U[Q];Z7;^(-+U>XTR<:?&4A)B8KD#\*^G->.-!OO^N#_ /H)KXC_
M .""6W_AF;QAMS_R.6I9S_UV- 'VQXL\6:7X#\+ZCKFN:C8Z/HVCVTEY?7UY
M.L%O9P1J7DEDD8A415!)8D  $U\]?\/=?@)]G^U?\)/XF_LO;YO]K?\ ""Z_
M_97D]?M'VW[%]G^S[?G\_P SRMGS[]OS5T'_  4KL-/O_P!BOQC_ &IXG\/>
M$;6U?3[Q-0U^Z^RZ1)-#J%M-#:7DF#MM;F5([:7@_N[AQ@]#R6B?MK?&SQ1X
M7M[S2?V7=<U:2\MP]K?6?Q#\.S:)=.1\LD=T+GSFMBW(E%MYFSYO)W?NZ /I
M+PGXLTOQYX7T[7-#U&QUC1M8MH[RQOK.=9[>\@D4/'+'(I*NC*00P)!!!K0K
MRW]BSX*:O^SU^S1X;\*Z]<V5QK5JUW?7R6+,UE937=W-=O:6Q8!OLUN9S!#E
M5/E0Q_*O0>I4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P1\.?^4[7
MB3_L4W_]"%?>]?!'PY_Y3M>)/^Q3?_T(5][T %%%% ',_&?_ ))5K_\ UYO_
M "K\8];_ .0W??\ 7P_\Z_9SXS_\DIU__KS?^5?C'K?_ "&[[_KX?^=? \:?
M'2^9_2?@'_#Q7JOR*M%%%?"G]&A2,,_[W:EHZU,KM6B->MCZ@_X)0 O\>M1'
M_3HO;WK]%/$'@32/%(_XF.FV-X?[TL*LP_$BOSM_X).L%^/>H_\ 7J/YU^E0
M&!7ZIPQ34L!%3U/XV\8*DX<1RE%V?*CCU^!?A-!SH.F^W^CK_A4EO\$?"<$B
MNN@Z7N7I_HR_X5U1;GI3B.*^A]C3['YG_:6*?_+R7WLYGQYH]KI7PXU:&VMX
M;>);63"1($7[I["OQAU;YM:OAN^5;N4\<?Q&OVF^)1_XM_K'_7I)_P"@FOQ7
MU09UG4/^OJ7_ -"-?$<96BJ<8^9_0_@#S2^MN_\ *0CZYY[T4 T5\##X4?T:
M@HHHJAQW/IK_ ()5?\G"'_KB_P#*OTR'2OS-_P""57_)PA_ZXO\ RK],ATK]
M4X5_W"/JS^,_&3_DHY_X4%%%%?2'Y4%%%% !1110 444$\4 5-<(;0[ST\A_
M_037Y&?\$P?^"GWAW]E/X<>-O"^J^"?'NMW47BW4)/M&CZ6UQ;X,IQAAWK]<
M=>'_ !([[@?\>\F!Z_*:^'O^"#&G6US^S/XP\RWAFD_X3+4LN\8+']\>.: /
M;_VH-"U3]K[]B_PW<>%M$NKBX\2:QX.\2+IUZT=O-#9Q:WIFH7 E$C*H:.VB
ME9DSDE"H#,0#2\3_ + MG\,M5O?$GP1\577P6UB9VNKS3K2!;OPGJC]6:ZTI
MV6)"W\4MJUO*>I=NE>K?M"WOCW1?@AX@F^%>F>&=4\?0VO\ Q)+/7[B6VTR2
M7<H_>M$"^T)N(4;=S!5+QABZ_D/^U9\1[GX@^ ]*L_VN/%WQF\+^/I_%?AVQ
M/@O6-&70_AK<PR:MI\U\8;FS,UM>QPV2W6)KR\W*4E(C1@%4 _73]FSXAZK\
M4O@UI>L:Y=>"[[6'ENK2\N/">IMJ.CRRV]U+;L89656ZQ?/&P)BDWQEF*;CW
M59'@'PGH7@7P5I>C^&-.TO2?#NGVR0Z=9Z; D-G;P ?(L2( BICH%&*UZ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#X(^'/_*=KQ)_V*;_ /H0K[WK
MX(^'/_*=KQ)_V*;_ /H0K[WH *1R0.*6C/- '(_'J]DT[X,>)IXK:2\EAT^5
MU@C^_*0O0>YK\$]*_:HF\5_$VXT>3P1KVGL]V\;S3?=B.<<U_0I>P+<6[(R[
MA("I!&1S7Y0_MS?L[7?P)^,M](MMC2=:E:YAN!$/F8\D9]J^3XJH.5!5$KM'
M[5X,YBJ>.GA'4Y>:SM>U[=/4^/O$G[5<GAWQ5/I8\%:[="WN/(:YC_U;#IN'
MM5WXD_M)R?#K4K6V7P=K>K_:H1/OMSQ&#V/O7I:HC+_J8MW4DH/FI7C5CN>-
M,]OE!VU^?1K0DDI1^X_I:678[WFJFCVU/-_$7[1,GA_P%IVN#PCK-TVH9!M$
M/[R+ZT:)^T9)KWP]U#7T\(ZU;O8,J_89/]=+GJ1]*]&*)C;Y:,JG^Z,'Z4XI
MYQV)&C-(=JHB<N?3%/VT5[L(7?H$L%BHOFJ5-$NY[!_P1 ^/4WQ@_:3UNUC\
M(:UI,-I9*[W-S_J^M?K97RO_ ,$ROV;[CX4_#F;7]4M4L]4UQ1M0(%98>HS[
MU]31G*U^K9)A_986.EKG\:^(68K%YW5:GS\ONWWO84'UI2,BFGYC2L>U>L?$
MG/?%1Y(?AQKDD<+7+QV4K")/O/A"<"OP"TK]JJ;Q-\2;C1V\#:_8M<:A-";B
M;[D9#D9-?T-7$*W$$D;8VR*4.>X-?E+^WG^SI=? _P",M]>"S0:)K$IFM)DB
M^6-CU!(Z&OE.*:+]DJRCS6/VCP:S#DQU3"*?+*5FM;7MNCXZ\5?M42>%_%TV
MDCP5KUX(9/+-U'_JS[U=^)7[1\GPXOK6 >$=8U0W5NLX>#[L>?X3[BO29(1(
M?FCA9^QV \^IISJDIYBC9E^ZQ4$,:_/(UH25I1^Y']-O+\9:353?979YOXA_
M:)D\/> -.\0?\(GK%U_:!VFSC_UL)]6H\-_M$2^(/!.J:U_PB>L6[::X7[(_
M^LGSW7Z5Z1M5MNZ./*CGY1M'X4U5YVK$HW' 54Y?\*M5(Q?NQN3+ XR$>:I4
MLK;W/5O^"*7[0MS\6/VHY;$>#-<T:*&U=Y+JY_U:\<#\:_79&XYKY3_X)?\
M[.-Q\)_A]=>(-3M5M]2\0!6$9C"M&@Z?G7U7$N%%?JN1T'3PD4U;K8_C3Q"S
M".+SRK*G+G2TOO>P\G%?$G_#7?Q$_P"'#/\ PNC_ (2'_BY?_"N/[>_MC[!;
M?\?OE;O-\CR_(Z_P^7M]J^V\<U^8'_#CKPK_ ,.@O^$=_P"%(^$_^&AO^$*\
MGS=]K]N_MC;G/VOS?)W;_P"+S-F.,XKUCXD^O?\ @I1^T/XF^ _[/MKIOP]D
MMX_BI\2]:M/!?@HSP--#;ZC>,0;N0"*4"*V@2>X9G1DQ!A@=V#D?!#]I;XD?
MM,?\$]]%\4>$=-T:/XOW C\/:W;7P"V>@ZO!=K9:I,\7F#>MNZ7$R0B3,H2-
M0^'#5SW[0_[(7Q*_:L_;]T#Q2WBSQ%\+_ _P;T4R^$M2TA=.O+C7-:U!9H;V
M=H;D7$:Q6]H$A436P<O<.T;X!KS.[_98_:,_8<A^/EO\&[K4?B;+\6H+?Q-I
M6JWJ:'87&B^));E+74[AK?\ T2WDDDM&CN8\J(GDLF63:S_O@#O+W]IGQI^Q
MC\5_B)X;\7>-M0^,VB^#_A7J/Q,N[VZTRPL=5T:6R=56R?[%%#;F.[3SI(1(
MBR VL_SR+_JWP_$KXU?L\^'?A#X^\;_$'2_&EC\2/$.AZ#XF\-0Z%!:6.A/J
MQ%O"^DS(JW!6&[FMP_VQYC)")&7RW 0Q? _]GB^\4_L[?$;X/WWPA^)W@$?$
MKPUJ-EK_ (^\5Z]H>L:EKM[<VIM3<7,EI?3S23;9"5'EK#&L>Q0BA4J6'X:_
M&K]H;P[\(? /C?X?:7X+L?AOXAT/7O$WB6'78+NQUU])(N(4TF%&:X"S7<-N
M7^V)"8X3(J^8Y#@ ^QZSO%OBO3_ _AR\U;5;E+/3[&,RSS/]V-1U)K1K/\5>
M%[#QKX>N]+U2V2\T^^C,4\+_ '9%/8T >$:O_P %.?@5+I%VO_"P]'+>3(N1
MNST/M7BG_!OUK]IXC_97\575G.+BWN?%NH31R 8#HTI(/XU[X/\ @FA\#06/
M_"O-#RQ+'Y6ZG\:]$^"'P!\'_LY^$/[!\%:%9^'])\UIC;6X(4NW4\^M %[X
MO:]XH\,_#S4+[P7X=TWQ9XFA\O['I5_JYTFWNLRHK[KD0S>7MC+N/W;;BH7C
M=N'R7\7?VM/C=JWQ&\.?"7Q9^R[\,O$$GQ(TO5+J*QO?B:+O3KBULOLRW*W"
MR:05(/VR(!2K;LMG %?6GQ>T'Q1XF^'FH6/@OQ%IOA/Q--Y?V/5;_2#JUO:X
ME1GW6PFA\S=&'0?O%VEPW.W:?E_Q5^PK^T1XP^-O@_Q_=?M&>!5U[P38:EIV
MGB/X4,L#0W_V4SB13JQ+'-I"5((Q@]<T >\?L>?#-?@_^SMH/A]? /A_X7_8
MY+R4^&-#U4ZII^EF6\FF/E3F*'<KF0R[1&H0R% ,*"?3*YOX0Z#XH\,_#S3[
M'QIXBTWQ9XFA\S[9JMAI!TFWNLRNR;;8S3>7MC*(?WC;BA;C=M'24 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'P1\.?^4[7B3_ +%-_P#T(5][U\$?
M#G_E.UXD_P"Q3?\ ]"%?>]  3BD'KTI::?O<T $AY]/>N1^,/PF\/_%[PC/I
MOB*U@N+-E)#O@-#[ANU=5*ZDC.[BO@/_ (*/_MIZA>^)IO!/AF\DMK*#B^N8
M6^:5O[JGMCO7FYIC:6&H\U;[NY]1PAD&.S7,H4,"^66_-_*NYY%^TK^SSX&^
M$>LSKH_C1=0C:0XMX5$GD^Q->/M::>V0MW(R^NWDU2<L969OF=CEF_B8^II,
M_P!U<'UK\BQU:G5G*4(\I_<&39?BL)AHT<57=226[2O^!KZ5IFCWU\D<VI36
M\;<&01[ME?;W[$7[&WPUGN;77!KUKXHU*$"6.W8@& ^I6O@LN2NWY1NZG%;/
MP]^(&K_"?Q'!JVA7UQ8WD#ABT;$)+[$5WY/CJ&&K*56%UW/!XRX>S'-,'*A@
M<2Z;MMIKY-[KY'[5Q1+ JHBJBJ-H4# 45-G::\E_8_\ VC[?]I/X5P:I\L>H
M6I^SWJ?]- .2!Z5ZVOW:_6L/6A4IJI#9G\0X[ UL'B)X;$*TXNS]1N<4*,T^
MC'-;'%881@URGQ>^%V@_%OP9<Z7XALX;BPD0[F?@Q>X/:NKE.T?3]*^"/^"C
MW[:FH2^))O _AF\>UM[,[;^>,X9F] ?2O/S3'4<+0=2M]W<^IX/R#'YKF,,/
M@'RR6O-MRI=;_D>._M+_ +._@7X1ZO-_8OC'[<JMA;>)1)Y?L37COV33V?\
MX_)<=0VS@51;]Y*9-SM(Q)<L<[C2 9SUV^AK\AQF(IUIN48\MS^X,ER_$87#
MPI8JLZDTOB:7Z&OIFDZ3J%[''-J$T$<C8=UCSGWK[:_8D_8X^&MY<V^MR>(+
M7Q1J4)$L=LY"F CU7O7P<6X9<-\QZ@]*V/ /CW5OA9XAAU30[V:SNK=PX*,<
M2?[+#N#7=E&.HX>K&52',CPN,N'\QS/ RP^#Q+IOMI:7D^J^1^U]M%'!$L<:
MK&L8P%48 %2@X6O(/V-OVD[7]I+X76^H[?)U2U'E7D.>58?Q?C7KX(K]9P^(
MA6IJI3V9_$698&O@\3/#8A-3B[-,5C@44WG-.K<X0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^"/AS_ ,IV
MO$G_ &*;_P#H0K[WKX(^'/\ RG:\2?\ 8IO_ .A"OO>@ IDG!I^:.M GJK&'
M\0M6DT#P3JEY']^VMGD7Z@5^,'B_4I-9\;ZQ>&1F>YNY'WO[GD5^U/B71U\0
M:!>6,G^KNHFC;Z$5^-OQQ\"7GPT^+&N:-J$)AFBNWDC3&"8R?E/XBOA^,HSY
M(5'\*/Z%\!<1AX8BO2G\;LUWL<N.11MH)7=@,#1T7M[BOSZ,HRU/Z>4GSV2#
M&*,[#N_N]J#CYF&YE'I2 Y4$NB[L\$T2DD+1MIGUK_P2.\676G?%C7-,\QFM
M;BT5EA[*V?O5^BB/\^*^$_\ @D-\);@7VM>,+B)DMYHQ:0[AU(/6ON[/'2OU
MSAV%2.!@IG\2>+%:C4XDK>PZ63MU=M09<#BA>31_6@C!%>X^Q^<F;XSU/^R?
M"NHW ^]#;2,/KM-?BQXPUVX\2^,-4O[R1I9YKN5I&/4X8@5^UVMVBZMI%U:L
MNX3Q-'CZ@BOQK^.OPZNOA1\6M>T6[C=&M[EW4L,;PQ)&*^*XRIS=*$^BN?T%
MX!XBC]:Q-+3G:BUYI7O8Y3+-RW>@+Q2%MI^;(SCK2D[693VZ>]?G<9QEJ?T_
M'67F'04"0Q@LO)49%-)V*">C=!WIS(V_''(IRETB$92E)J:^9]9?\$D/%EQH
M_P 6-6TM'8PZI$))5/12HXQ7Z+$8Y]J^#O\ @D-\+;B74=;\47,++;J!%:2$
M??\ [U?>0RP%?K?#<)QP,%,_B7Q7J4*G$=;V+O:UWYV%1LI7S?\ \/"?^-7?
M_#2?_"(_\RA_PE?_  CO]J_[&_R/M7D_AO\ *_X#7TANQ^%?CS_PS]\3/^(>
M#_A(_P#A?7BS_A&?^%9_:_\ A$_^$<T7[#]F\O/V3S_LOVK;M^7?YV_/.>U>
M\?G!^FW[:'[3]K^QU^S=XD\?7&CWWB2ZTM(K?2]$LM_VG7-0N)4@M+./8CL&
MEGDC3*HY4,6VG&*XOQC^W@US_P $Z/\ AH;P'X7M_%6GCPF?&+:3?:P--:*U
MBMFN+F)IDBG'GQ*DB;0A#2)M+*/F'C7[;^L^./VE?^"AOPS\"?#WP?X7\<Z5
M^S^\/Q&\5VVNZR=+LQJ=S%=6NC0+.D-PZ7$7^D78!MRI"1_.I(SY-I]]XX^
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MP2 ^)D]Q)X@\*R,S0VRB\C+'^\<5]S'YCS7YU_\ !($8^-'B3_L'I_.OT6.
M>E?L'#LN; P;/XA\5*,*?$=>RWL_FT&?EH+;6VBD9#BDE&!Q][%>SK<_.MBI
MXAU :/H%]=-Q]G@>3/T!-?C!\6/&]U\0OB3KFL7V);B\NW#'.> Q K]D/B2I
M_P"%>ZM_UZ2?^@FOQ7U3C6]0_P"OJ7_T(U\-QI*7[J*>FMS^B_ '"PG5Q.(M
M[R45?LB'&/3\****^!T6B/Z7>X-\Z;L8/I0079?NY[9[44 ?,*4DVK(<;IWC
MN?8O_!(?XBSZ9XQUSP]+*[07RB2&//RQD=<?6OT%C.Y:_,__ ()5#/[0;?\
M7%J_3 ';CTK]9X;DW@(W>Q_%?B]0ITN)*O(K<R3?K8,9.*=03BBOH#\Q"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>adverseeventtable2a02.jpg
<TEXT>
begin 644 adverseeventtable2a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,W
M-0  DI(  @    ,W-0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC_A>WBC_ *$N/_P)/^%'M(=T'U/$_P#/N7W,]SHKPS_A>WBC_H2X_P#P)/\
MA1_PO;Q1_P!"7'_X$G_"CVD.Z#ZGB?\ GW+[F>YT5X9_PO;Q1_T)<?\ X$G_
M  H_X7MXH_Z$N/\ \"3_ (4>TAW0?4\3_P ^Y?<SW.BO#/\ A>WBC_H2X_\
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MC_A>WBC_ *$N/_P)/^%'M(=T'U/$_P#/N7W,]SHKPS_A>WBC_H2X_P#P)/\
MA1_PO;Q1_P!"7'_X$G_"CVD.Z#ZGB?\ GW+[F>YT5X9_PO;Q1_T)<?\ X$G_
M  H_X7MXH_Z$N/\ \"3_ (4>TAW0?4\3_P ^Y?<SW.BO#/\ A>WBC_H2X_\
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MC_A>WBC_ *$N/_P)/^%'M(=T'U/$_P#/N7W,]SHKPS_A>WBC_H2X_P#P)/\
MA1_PO;Q1_P!"7'_X$G_"CVD.Z#ZGB?\ GW+[F>YT5X9_PO;Q1_T)<?\ X$G_
M  H_X7MXH_Z$N/\ \"3_ (4>TAW0?4\3_P ^Y?<SW.BO#/\ A>WBC_H2X_\
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MC_A>WBC_ *$N/_P)/^%'M(=T'U/$_P#/N7W,]SHKPS_A>WBC_H2X_P#P)/\
MA1_PO;Q1_P!"7'_X$G_"CVD.Z#ZGB?\ GW+[F>YT5X9_PO;Q1_T)<?\ X$G_
M  H_X7MXH_Z$N/\ \"3_ (4>TAW0?4\3_P ^Y?<SW.BO#/\ A>WBC_H2X_\
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MC_A>WBC_ *$N/_P)/^%'M(=T'U/$_P#/N7W,]SHKPS_A>WBC_H2X_P#P)/\
MA1_PO;Q1_P!"7'_X$G_"CVD.Z#ZGB?\ GW+[F>YT5X9_PO;Q1_T)<?\ X$G_
M  H_X7MXH_Z$N/\ \"3_ (4>TAW0?4\3_P ^Y?<SW.BO#/\ A>WBC_H2X_\
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MC_A>WBC_ *$N/_P)/^%'M(=T'U/$_P#/N7W,]SHKPS_A>WBC_H2X_P#P)/\
MA1_PO;Q1_P!"7'_X$G_"CVD.Z#ZGB?\ GW+[F>YT5X9_PO;Q1_T)<?\ X$G_
M  J*Z^/OB2UM7FE\(0Q(HY=[AB!^E'M(/J)X7$15W!V]&>\45F>&M5DUWPKI
M>JS1+#)?6D5PT:G(4LH.![<UIU9S!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\^?%;_ )+E;?\ 8+7^;U1J]\5O^2Y6W_8+
M7^;U1KQ\;_%^1^A<-_[D_P#$_P D%%%%<1](%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5S?A;_D*:Y_U]G_T)JZ2N;\+?\A37
M/^OL_P#H35O#^'/Y?F>;B?\ >Z'K+_TEG24445@>D%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !63XI_Y%F\_P!T?^A"M:LGQ3_R+-Y_
MNC_T(5I2_B1]4<F._P!UJ_X7^3/H;X?_ /)-O#?_ &"[;_T6M=#7/?#_ /Y)
MMX;_ .P7;?\ HM:Z&OH3\D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#Y\^*W_)<K;_L%K_-ZHU>^*W_ "7*V_[!:_S>J->/
MC?XOR/T+AO\ W)_XG^2"BBBN(^D"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *YOPM_R%-<_P"OL_\ H35TE<WX6_Y"FN?]?9_]
M":MX?PY_+\SS<3_O=#UE_P"DLZ2BBBL#T@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *R?%/_(LWG^Z/_0A6M63XI_Y%F\_W1_Z$*TI?
MQ(^J.3'?[K5_PO\ )GT-\/\ _DFWAO\ [!=M_P"BUKH:Y[X?_P#)-O#?_8+M
MO_1:UT-?0GY(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'SY\5O^2Y6W_8+7^;U1J]\5O^2Y6W_8+7^;U1KQ\;_%^1^A<-_[
MD_\ $_R04445Q'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7-^%O^0IKG_7V?_0FKI*YOPM_R%-<_P"OL_\ H35O#^'/Y?F>
M;B?][H>LO_26=)1116!Z04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %9/BG_ )%F\_W1_P"A"M:LGQ3_ ,BS>?[H_P#0A6E+^)'U1R8[
M_=:O^%_DSZ&^'_\ R3;PW_V"[;_T6M=#7/?#_P#Y)MX;_P"P7;?^BUKH:^A/
MR0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MGSXK?\ERMO\ L%K_ #>J-7OBM_R7*V_[!:_S>J->/C?XOR/T+AO_ ')_XG^2
M"BBBN(^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *YOPM_P A37/^OL_^A-725S?A;_D*:Y_U]G_T)JWA_#G\OS/-Q/\ O=#U
ME_Z2SI****P/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !1110 45[UK^M_P#"/^'SJ'V?[1LV+Y>_9G)
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M?[H_]"%:U9/BG_D6;S_='_H0K2E_$CZHY,=_NM7_  O\F?0WP_\ ^2;>&_\
ML%VW_HM:Z&N>^'__ "3;PW_V"[;_ -%K70U]"?D@4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\+?\
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M,+X5Z/ON+G5Y5XC'DPY'<\L?RP/Q-8'CS6/[7\4S^6V8+7]Q'SP<'YC^>?P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'SY\5O^2Y6W_8+7^;U1J]\5O\ DN5M_P!@M?YO5&O'QO\ %^1^
MA<-_[D_\3_)!1117$?2!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<WX6_Y"FN?]?9_P#0FKI*YOPM_P A37/^OL_^A-6\/X<_
ME^9YN)_WNAZR_P#26=)1116!Z04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *YOPM_R%-<_Z^S_Z$U=)7-^%O^0IKG_7V?\ T)JWA_#G\OS/-Q/^]T/6
M7_I+.DHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LGQ3_ ,BS>?[H_P#0A6M63XI_Y%F\_P!T?^A"M*7\2/JCDQW^ZU?\+_)G
MT-\/_P#DFWAO_L%VW_HM:Z&N>^'_ /R3;PW_ -@NV_\ 1:UT-?0GY(%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SY\5O^2Y
M6W_8+7^;U1J]\5O^2Y6W_8+7^;U1KQ\;_%^1^A<-_P"Y/_$_R04445Q'T@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-^%O\
MD*:Y_P!?9_\ 0FKI*YOPM_R%-<_Z^S_Z$U;P_AS^7YGFXG_>Z'K+_P!)9TE%
M%%8'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D^*?
M^19O/]T?^A"M:LGQ3_R+-Y_NC_T(5I2_B1]4<F._W6K_ (7^3/H;X?\ _)-O
M#?\ V"[;_P!%K70USWP__P"2;>&_^P7;?^BUKH:^A/R0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GSXK?\ERMO^P6O\WJC
M5[XK?\ERMO\ L%K_ #>J->/C?XOR/T+AO_<G_B?Y(****XCZ0**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_"W_(4US_K[/\
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M44 %%%% !1110 4444 %%%% !1110 4444 ?/GQ6_P"2Y6W_ &"U_F]4:?\
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M?^?J.@HKG_\ A+[?_H&ZC_WY'^-'_"7V_P#T#=1_[\C_ !H^KU?Y0_M; _\
M/U'045S_ /PE]O\ ] W4?^_(_P :/^$OM_\ H&ZC_P!^1_C1]7J_RA_:V!_Y
M^HZ"BN?_ .$OM_\ H&ZC_P!^1_C1_P )?;_] W4?^_(_QH^KU?Y0_M; _P#/
MU'045S__  E]O_T#=1_[\C_&C_A+[?\ Z!NH_P#?D?XT?5ZO\H?VM@?^?J.@
MHKG_ /A+[?\ Z!NH_P#?D?XT?\)?;_\ 0-U'_OR/\:/J]7^4/[6P/_/U'045
MS_\ PE]O_P! W4?^_(_QH_X2^W_Z!NH_]^1_C1]7J_RA_:V!_P"?J.@HKG_^
M$OM_^@;J/_?D?XT?\)?;_P#0-U'_ +\C_&CZO5_E#^UL#_S]1T%%<_\ \)?;
M_P#0-U'_ +\C_&C_ (2^W_Z!NH_]^1_C1]7J_P H?VM@?^?J.@HKG_\ A+[?
M_H&ZC_WY'^-'_"7V_P#T#=1_[\C_ !H^KU?Y0_M; _\ /U'045S_ /PE]O\
M] W4?^_(_P :/^$OM_\ H&ZC_P!^1_C1]7J_RA_:V!_Y^HZ"BN?_ .$OM_\
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M#=1_[\C_ !H^KU?Y0_M; _\ /U'045S_ /PE]O\ ] W4?^_(_P :/^$OM_\
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M1_PE]O\ ] W4?^_(_P :/J]7^4/[6P/_ #]1T%%<_P#\)?;_ /0-U'_OR/\
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M_P :/J]7^4/[6P/_ #]1T%%<_P#\)?;_ /0-U'_OR/\ &C_A+[?_ *!NH_\
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M^?J.@HKG_P#A+[?_ *!NH_\ ?D?XT?\ "7V__0-U'_OR/\:/J]7^4/[6P/\
MS]1T%%<XWC2T214:QO@S=%,0!/T&:?\ \)?;_P#0-U'_ +\C_&CZO5_E#^UL
M#_S]1T%%<_\ \)?;_P#0-U'_ +\C_&C_ (2^W_Z!NH_]^1_C1]7J_P H?VM@
M?^?J.@HKG_\ A+[?_H&ZC_WY'^-'_"7V_P#T#=1_[\C_ !H^KU?Y0_M; _\
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M_H&ZC_WY'^-'_"7V_P#T#=1_[\C_ !H^KU?Y0_M; _\ /U'045S_ /PE]O\
M] W4?^_(_P :/^$OM_\ H&ZC_P!^1_C1]7J_RA_:V!_Y^HZ"BN?_ .$OM_\
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M?;_] W4?^_(_QH^KU?Y0_M; _P#/U'045S__  E]O_T#=1_[\C_&C_A+[?\
MZ!NH_P#?D?XT?5ZO\H?VM@?^?J.@K)\4_P#(LWG^Z/\ T(55_P"$OM_^@;J/
M_?D?XUGZYXEAO=%N;=+&]C,B@!Y(@%'(/)S6E.A54TVNIS8O-,%/#U(QJ*[3
M_(^H/A__ ,DV\-_]@NV_]%K70USOP^.?AKX;[?\ $KM^O_7-:Z*O:/S8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)[S_DZ
M;3_^P,?_ &I7K%>3WG_)TVG_ /8&/_M2O6* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KB?C'_ ,DBU[_KDG_HU*[:N)^,
M?_)(M>_ZY)_Z-2@#5^'_ /R3;PW_ -@NV_\ 1:UT-<]\/_\ DFWAO_L%VW_H
MM:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR
M?X.?\C?\0_\ L,M_Z,EKUBO)_@Y_R-_Q#_[#+?\ HR6@#UBBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R?Q]_P EV\!?]M:]
M8KR?Q]_R7;P%_P!M:]8H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *XGXQ_\DBU[_KDG_HU*[:N)^,?_ "2+7O\ KDG_ *-2@#5^
M'_\ R3;PW_V"[;_T6M=#7/?#_P#Y)MX;_P"P7;?^BUKH: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R>\_Y.FT_P#[ Q_]
MJ5ZQ7D]Y_P G3:?_ -@8_P#M2O6* "BBB@ HHHH **** "BBB@ HHHH *H:]
MJG]B>&]2U7R?/^PVDMSY6[;OV(6VYP<9QC.#5^L#QY_R3CQ)_P!@FZ_]$M0!
MY%_PT[_U*/\ Y4O_ +56IHO[26C7EVL6MZ-<:;&QQYT4PG5?<C:IQ] :=^S5
M_P B9JW_ &$/_::UW/Q&\):5XG\':DM_;0_:(;9Y8+K:-\3JI(.[KCCD=Q0!
MT]G>6VH645W8SQW%O,@>.6-MRNIZ$&O+OA[XTU_7/B[XKT75+_S]/T^2X6VA
M\F-?+"S[%^95!.%XY)JE^S?JUS=^#]2TZ=F>&QN@8"W10XR5'MD$_P# JS_A
M/_R7SQU_UUNO_2J@#W2BH+V^M=-L9;S4+B.VMH5W22RL%5!ZDFO-;[]H3P59
MWA@B_M&\4-@S6]N-GU^9E./PH ]1HKA+CXQ>$H_"<NOVES-?6\,B1RP6Z 31
MEB0,HY7CCKG'I76:'J\&OZ#9:M9I(D%Y"LT:R@!@",C(!(S^- %^BN?\5>.?
M#_@RW237]02!Y!F.!07DD'J%'./<\5QEK^T-X*N+GRI1J5JF<>;+; K]?E8G
M]* /4Z*J:7JUAK>G1W^DW<5Y:RC*2Q-D'V]C['D56\0>)-(\+::U_KU]%9P#
M@%SEG/HJCEC["@#4HKREOVBO!@NO*$&K,F<><+=-GU^_N_2O0?#OB?1_%>FB
M_P!!OH[N#.&VY#(?1E/(/UH X/XY>,==\'Z+I4_AR^^QRW%PZ2MY*2;@%R!\
MZG%>EV4C36%O)(<N\2LQQU)%>,?M+_\ (NZ'_P!?<G_H%=;K7Q=\)^$+>WLK
M^[DNKV.%/,MK-/,9#M'#$D*#[$YH ] HK@O#/QG\'^*+U+*WNYK&ZD.(XKZ,
M1[SZ!@2N?;.3VKO: "BL'Q1XUT#P=:K-X@U!+8N,QQ %I)/HHY_'I[UQ,/[1
M'@J6Z\IX]4A3/^N>V4I_XZQ;]* /5**HZ/K6FZ_IL>H:->17EK)PLL39&>X/
M<'V/-7J "BBB@ HHHH **** "BBB@ HHHH *XGXQ_P#)(M>_ZY)_Z-2NVKB?
MC'_R2+7O^N2?^C4H U?A_P#\DV\-_P#8+MO_ $6M=#7/?#__ ))MX;_[!=M_
MZ+6NAH **** "BBB@ HHHH **** ,WQ#J_\ 86A7&I>1Y_D[?W>_;NRP7K@^
MOI4?AK7/^$AT5-0^S_9]SLOE[]^,''7 JC\0?^1$U#_MG_Z-6H/AM_R)</\
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MRLP'U.* /2:*1'62-7C8.C %64Y!'J*6@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 >3WG_)TVG_]@8_^U*]8KR>\_P"3IM/_ .P,?_:E>L4
M%%%% !1110 4444 %%%% !1110 5@>//^2<>)/\ L$W7_HEJWZP/'G_)./$G
M_8)NO_1+4 ?.GPP^+<'P]T2\L)M(DOC<W'G!TG";?E QC:?2NCUWXL^*?B1I
MTF@>#/#=Q;I>+Y4\R,96*'@C=@*@(X)/;/2NA_9J_P"1,U;_ +"'_M-:]FH
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M_P#(B:A_VS_]&K5?X<,%\$Q,Q 42R$DGIS4?Q)U.VM_"LUBTBFXNF0+&&^8
M,&+8]/EQ^-6? -F8_ ]M'<+Q/O<J>/E8G'YCG\:Y]\3IV_4]2W+D_O:7J:?<
M<#9:GI.N>++G4_%ET4MP<PPE'8,,_*OR@X 'Y_G783>(? $]L8)/LGE$8VBR
M=<?3"<?A7+^%[72M,\2WNC^)[6%FW;8I)QPK GOZ,"#GZ5Z$WA/PZL9=M+M
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M0 4444 %%%% !1110 4444 >3^/O^2[> O\ MK7K%>3^/O\ DNW@+_MK7K%
M!1110 4444 %%%% !117/>,];O\ P_HJ7VG10RXE"2"96(52#SP1WP/QJ924
M8N3-J%&5>HJ4-V=#7E_Q1_Y&+3?^N/\ [/7=>&]=AU_1H+I'C\_8!/&A^X_?
MCJ!Z>U>?^/;J+6?&=A9Z>XG>,+$Q0[AN+=./3BN7$R4J-UUL>WDU&=+'M35N
M5._EH=IXZUB71O"TTMLVR:9A"C@\J3DDCWP#7&^$;KP=IFGK/J]Q'-J$F2XE
MMW<1<\ ?*1GWKJ_B)ILNH^$9# I9[619]HZD $'\@Q/X5E>"K3PSKFBPQRV%
MJU_"NV9&7YFQ_%[Y'?UJ:BDZ]E;;2YMA)4898Y/FUE[W+:^VE[]/U*GB:_\
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M94-NFA5'55]0-P'# G@?I77?$K6Y++P_!;6DFTW[$%U/6, $@?7(_#ZT7O\
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M;'T(KV.B@""RLK;3;&&SL($M[:! D44:X5%'0 5/110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'D]Y_P G3:?_ -@8_P#M2O6*\GO/^3IM/_[ Q_\ :E>L
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7$_&/_DD6O?]<D_]&I7;5Q/QC_Y)%KW_ %R3_P!&I0!J_#__ ))MX;_[!=M_
MZ+6NAKGOA_\ \DV\-_\ 8+MO_1:UT- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7D_P<_Y&_P"(?_89;_T9+7K%>3_!S_D;_B'_
M -AEO_1DM 'K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'D_C[_DNW@+_MK7K%>3^/O^2[> O^VM>L4 %%%% !1110 4444
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MD_\ PI[Q)_T5'Q!_WW)_\=H_X4]XD_Z*CX@_[[D_^.UZQ10!Y/\ \*>\2?\
M14?$'_?<G_QVC_A3WB3_ **CX@_[[D_^.UZQ10!Y/_PI[Q)_T5'Q!_WW)_\
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MW)_\=KUBB@#R?_A3WB3_ **CX@_[[D_^.T?\*>\2?]%1\0?]]R?_ !VO6**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /)[S_DZ;3_^P,?_ &I7K%>3
MWG_)TVG_ /8&/_M2O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KB?C'_ ,DBU[_KDG_HU*[:N)^,?_)(M>_ZY)_Z-2@#
M5^'_ /R3;PW_ -@NV_\ 1:UT-<]\/_\ DFWAO_L%VW_HM:Z&@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH *XGXQ_\ )(M>_P"N2?\ HU*[:N)^,?\
MR2+7O^N2?^C4H U?A_\ \DV\-_\ 8+MO_1:UT-<]\/\ _DFWAO\ [!=M_P"B
MUKH: "O)_@Y_R-_Q#_[#+?\ HR6O6*\G^#G_ "-_Q#_[#+?^C): /6**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \GO/\ DZ;3_P#L
M#'_VI7K%>3WG_)TVG_\ 8&/_ +4KUB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *XGXQ_\DBU[_KDG_HU*[:N)^,?_ "2+
M7O\ KDG_ *-2@#5^'_\ R3;PW_V"[;_T6M=#7/?#_P#Y)MX;_P"P7;?^BUKH
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_@Y
M_P C?\0_^PRW_HR6O6*\G^#G_(W_ !#_ .PRW_HR6@#UBBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R?Q]_R7;P%_P!M:]8K
MR?Q]_P EV\!?]M:]8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;PW_P!@NV_]%K70USWP_P#^2;>&_P#L%VW_ *+6NAH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G^#G_(W_$/_L,M_P"C):]8
MKR?X.?\ (W_$/_L,M_Z,EH ]8HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \G\??\EV\!?]M:]8KR?Q]_R7;P%_VUKUB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?C'_R2+7O
M^N2?^C4KMJXGXQ_\DBU[_KDG_HU* -7X?_\ )-O#?_8+MO\ T6M=#7/?#_\
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M_9J_Y$S5O^PA_P"TUKV:@ KAOBYXUE\$^")+FPE$>I74@@M"5#;6ZLV""#@
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MH **** "BBB@ KB?C'_R2+7O^N2?^C4KMJXGXQ_\DBU[_KDG_HU* -7X?_\
M)-O#?_8+MO\ T6M=#7/?#_\ Y)MX;_[!=M_Z+6NAH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *\G^#G_(W_ !#_ .PRW_HR6O6*
M\G^#G_(W_$/_ +#+?^C): /6**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /)_'W_)=O 7_;6O6*\G\??\EV\!?]M:]8H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#"@#YW^+GQ(\+_ ! TNQ.E6>I6^I6<IV27$,:JT;#YE)5R>H4CCU]:]O\
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M?K0!ZA7#?&+Q)<^&/AK?7-@YCNKEEM8I!U3?]XCWVAL'L<5W-<I\2O";^,_
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M44 %>3_!S_D;_B'_ -AEO_1DM>L5Y/\ !S_D;_B'_P!AEO\ T9+0!ZQ1110
M4444 %%%% !1110 4444 %%%% !1110!X1X^\=:[XX\8OX#\!.8XPS17=VK8
M\PC[_P P^ZB]"1R3QZ9[WX?_  IT3P)"LZ+]NU4KB2]E7E?4(/X1^I]>U>7Z
M7\#?B-HE[+=Z1XCTVRN)5*R2P7<ZLP)R02(O4 UK?\*W^,?_ $/4'_@QN/\
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M$5G/X[^*.L>.]3C)AMY"+97YVNPPH_X!'Q]2#3OVF'N&?PW#G;;,9SN/3?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)^,?_ "2+7O\
MKDG_ *-2NVKB?C'_ ,DBU[_KDG_HU* -7X?_ /)-O#?_ &"[;_T6M=#7/?#_
M /Y)MX;_ .P7;?\ HM:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPS8:E-;RVLT\(,T$J%&C<<,N#SU!QZC!H GUK6+/0-$N]5U.3RK6TC,DC?R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7$_&/_ ))%KW_7)/\ T:E=
MM7$_&/\ Y)%KW_7)/_1J4 :OP_\ ^2;>&_\ L%VW_HM:Z&N>^'__ "3;PW_V
M"[;_ -%K70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>3_  <_Y&_XA_\ 89;_ -&2UZQ7D_P<_P"1O^(?_89;_P!&2T >L444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3^/O^
M2[> O^VM>L5Y/X^_Y+MX"_[:UZQ0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Q/QC_Y)%KW_7)/_1J5VU<3\8_^21:]_P!<D_\
M1J4 :OP__P"2;>&_^P7;?^BUKH:Y[X?_ /)-O#?_ &"[;_T6M=#0 5Y/\'/^
M1O\ B'_V&6_]&2UZQ7D_P<_Y&_XA_P#89;_T9+0!ZQ1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'D]Y_R=-I__ &!C_P"U*]8KR>\_
MY.FT_P#[ Q_]J5ZQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<3\8_P#DD6O?]<D_]&I7;5Q/QC_Y)%KW_7)/_1J4 :OP
M_P#^2;>&_P#L%VW_ *+6NAKGOA__ ,DV\-_]@NV_]%K70T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>3_!S_D;_B'_ -AEO_1D
MM>L5Y/\ !S_D;_B'_P!AEO\ T9+0!ZQ1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y/X^_P"2[> O^VM>L5Y/X^_Y+MX"_P"V
MM>L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3
M\8_^21:]_P!<D_\ 1J5VU<3\8_\ DD6O?]<D_P#1J4 :OP__ .2;>&_^P7;?
M^BUKH:Y[X?\ _)-O#?\ V"[;_P!%K70T %>3_!S_ )&_XA_]AEO_ $9+7K%>
M3_!S_D;_ (A_]AEO_1DM 'K%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >3WG_ "=-I_\ V!C_ .U*]8KR>\_Y.FT__L#'_P!J5ZQ0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M3\8_^21:]_UR3_T:E=M7$_&/_DD6O?\ 7)/_ $:E &K\/_\ DFWAO_L%VW_H
MM:Z&N>^'_P#R3;PW_P!@NV_]%K70T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %>3_!S_D;_ (A_]AEO_1DM>L5Y/\'/^1O^(?\
MV&6_]&2T >L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >3^/O^2[> O^VM>L5Y/X^_Y+MX"_[:UZQ0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Q/QC_P"21:]_UR3_ -&I7;5Q
M/QC_ .21:]_UR3_T:E &K\/_ /DFWAO_ +!=M_Z+6NAKGOA__P DV\-_]@NV
M_P#1:UT- !7D_P '/^1O^(?_ &&6_P#1DM>L5Y/\'/\ D;_B'_V&6_\ 1DM
M'K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3WG_)
MTVG_ /8&/_M2O6*\GO/^3IM/_P"P,?\ VI7K% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5Q/QC_Y)%KW_ %R3_P!&I7;5
MQ/QC_P"21:]_UR3_ -&I0!J_#_\ Y)MX;_[!=M_Z+6NAKGOA_P#\DV\-_P#8
M+MO_ $6M=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y/\'/\ D;_B'_V&6_\ 1DM>L5Y/\'/^1O\ B'_V&6_]&2T >L4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3^/O^2[>
M O\ MK7K%>3^/O\ DNW@+_MK7K% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7$_&/\ Y)%KW_7)/_1J5VU<3\8_^21:]_UR3_T:
ME &K\/\ _DFWAO\ [!=M_P"BUKH:Y[X?_P#)-O#?_8+MO_1:UT- !7D_P<_Y
M&_XA_P#89;_T9+7K%>3_  <_Y&_XA_\ 89;_ -&2T >L4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y/>?\G3:?_V!C_[4KUBO)[S_
M ).FT_\ [ Q_]J5ZQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<3\8_\ DD6O?]<D_P#1J5VU<3\8_P#DD6O?]<D_]&I0
M!J_#_P#Y)MX;_P"P7;?^BUKH:Y[X?_\ )-O#?_8+MO\ T6M=#0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\
MH'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_
M\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X
M$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_Q
MH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_
MPH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#>
M O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]
M!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"
MUC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P
M+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)
M_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/
M^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD
M&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-
M&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#
MKC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'
M_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_
MQKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C
M1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P%_T#KC_P+D_QH [?
M_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\ H'7'_@7)_C1_PH;P
M%_T#KC_P+D_QH [?_A(-&_Z"UC_X$I_C1_PD&C?]!:Q_\"4_QKB/^%#> O\
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M@+_H'7'_ (%R?XT?\*&\!?\ 0.N/_ N3_&@#M_\ A(-&_P"@M8_^!*?XT?\
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M_P"!<G^-'_"AO 7_ $#KC_P+D_QH [?_ (2#1O\ H+6/_@2G^-'_  D&C?\
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MC_A(-&_Z"UC_ .!*?XUQ'_"AO 7_ $#KC_P+D_QH_P"%#> O^@=<?^!<G^-
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M!UQ_X%R?XT =O_PD&C?]!:Q_\"4_QH_X2#1O^@M8_P#@2G^-<1_PH;P%_P!
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MO_PD&C?]!:Q_\"4_QH_X2#1O^@M8_P#@2G^-<1_PH;P%_P! ZX_\"Y/\:/\
MA0W@+_H'7'_@7)_C0!V__"0:-_T%K'_P)3_&C_A(-&_Z"UC_ .!*?XUQ'_"A
MO 7_ $#KC_P+D_QH_P"%#> O^@=<?^!<G^- ';_\)!HW_06L?_ E/\:XSXN:
MSIES\*-<AMM1M)96B3:D<ZLQ_>+T -1_\*&\!?\ 0.N/_ N3_&N8^(WP@\'^
M'?A[JNK:58S1W=M&K1LUR[ $NHZ$X/!- 'IOP_\ ^2;>&_\ L%VW_HM:Z&N=
M^'P ^&OAO'_0+M__ $6M=%0 5Y/\'/\ D;_B'_V&6_\ 1DM>L5Y/\'/^1O\
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M*\GO/^3IM/\ ^P,?_:E>L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAU7PE#X@LE(O-(?<[*<$PL>?^^6VGV&Z@#UNH+R]M=.LY+O4+F&UMHQEYIY
MB(,XY8\#DUSOPW\5#QCX$L-4=@;D+Y-T!VE7AOIGAOHPKSGX_P"O7%_<Z1X'
MTC]Y=7TJ2S(IZY;;$A^K9/X*: /9=/U.PU:T%UI5[;WUN25$UM*LB$CJ,J2*
MM5D^%O#]OX6\+6&C6F/+M(0A8?QMU9OQ8D_C6M0 4444 %%%% !1110!Y/>?
M\G3:?_V!C_[4KUBO)[S_ ).FT_\ [ Q_]J5ZQ0 4444 %%%% !1110 4444
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M)\4>'O"<NB^+-.-H+64M9N9XY-R-DE?D8XPV3S_>]J .-^ 8'_"<>,C@9$@
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MJKC(#L,*/^ 1X'U8&J_[25I82:[H36N6U>:)HWB09+1[AL)]]Q<#UY]*]@\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\G^#G_ "-_Q#_[#+?^C):]8KR?X.?\C?\ $/\ [#+?^C): /6****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)_'W_)=
MO 7_ &UKUBO)_'W_ "7;P%_VUKUB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^N2?^C4KMJXGXQ_\DBU[_KDG_HU* -7X?_\ )-O#?_8+MO\ T6M=#7/?#_\
MY)MX;_[!=M_Z+6NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\G^#G_(W_ !#_ .PRW_HR6O6*\G^#G_(W_$/_ +#+?^C): /6
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)_
M'W_)=O 7_;6O6*\G\??\EV\!?]M:]8H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *XGXQ_\ )(M>_P"N2?\ HU*[:N)^,?\ R2+7
MO^N2?^C4H U?A_\ \DV\-_\ 8+MO_1:UT-<]\/\ _DFWAO\ [!=M_P"BUKH:
M "O)_@Y_R-_Q#_[#+?\ HR6O6*\G^#G_ "-_Q#_[#+?^C): /6**** "N!^)
M_P 3_P#A7']E_P#$H_M+^T/-_P"7GR?+V;/]ALYW^W2N^KP/]IW_ )EC_M[_
M /:- "C]IT9&?"6!WQJ7_P!JKJO#/Q]\*Z[<I:ZBL^C3R'"FYPT1/IO'3ZD
M>]>D:<,Z5:@\CR4_]!%<;XZ^$WA_QCITQBLX-/U3:3#>01A"6]' ^\#[\^E
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M>?\ )TVG_P#8&/\ [4KUB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*XOXA_$BU\!VD&VQDU2_G/R6D3%<)W9FVG ]..?S-=I10!YM\-_BX?B#KMYI
MK:$=-:UMS,7-UYI)W!=N-BXZUZ#?ZA::7I\U]J-Q';6L"EY)9&PJBO$_A/\
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M O\ MK7K%>3^/O\ DNW@+_MK7K% !1110 4444 %%%% !1110 4444 %%%%
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MW4W/FF51P6^XN!G('K@UU-16EK!8V<-I9Q+#;P((XHT& B@8 'X5+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %<3\8_\ DD6O?]<D_P#1J5VU<3\8
M_P#DD6O?]<D_]&I0!J_#_P#Y)MX;_P"P7;?^BUKH:Y[X?_\ )-O#?_8+MO\
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M?_8+MO\ T6M=#0 4444 %%%% !1110 4444 %%%% !1110 5Y5^T3_R3&/\
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M7O5\VZEP#M<CY4^B_P \GO0!R>N_%+53KQ\'_"C0X[R2P7R7F*;HXPG&$&0
MHQC<QP>PZ$U[7XL^,_!VL6]I\4=!6"SN6VB\@0?)[Y4E'QW P<>O0Q?L[7=G
M82:]HM\5@UO[2&>.0X>15!! ]=K;L_[U=!^T#JFEV_PWET^\>-K^ZFB:SB)R
MZE7!9\=AMW+G_:Q0!ZA%+'/"DT#K)'(H9'4Y# C((-/KF_AY:W5E\-] M[\,
ML\=C$&5A@J-O"GZ# _"NDH **** "BBB@ HHHH **** "BBB@ HHHH *\G^#
MG_(W_$/_ +#+?^C):]8KR?X.?\C?\0_^PRW_ *,EH ]8HHHH **** "BBB@
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M<_!_P]XWN6OI?,T_4F #75OC]YCIO4\-]>#[UWU% 'B5G^S99"Z1M7\37=Y
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M#22>V0,!?8?CFNJHH *XOXC^ [SQ_IMMIT>N_P!F64<GF31K:^:9F_AR=ZX
MYXP>3GL*[2B@"CHFCV?A_0[32M-C\NUM(Q'&O?W)]R<D^YJCXM\'Z1XUT5M-
MUN$O'G=%*AVR0MC&Y3_D'O6Y10!XFG[.,)E6&X\67LFFJVY;40 $?\"W$9]]
MM>L^'O#NF>%M%ATK1;<6]K%R!G)9CU9CW)K3HH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKR?X.?\ (W_$/_L,M_Z,EKUBO)_@Y_R-_P 0_P#L,M_Z,EH ]8HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \G\??\EV\!?\
M;6O6*\G\??\ )=O 7_;6O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD7H&ZX/^RB_,?? ZBM"[TK1/@+X%O+^QE:]UZ_'D0W$ZC+OUX7^%%^\1SD@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?#&BG$2,,"09^5?JY&X_[(QZ5TO[16CW=]X#M+RT1GBT^Z#SJO\ "C*5W8]
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MOP__ .2;>&_^P7;?^BUKH:Y[X?\ _)-O#?\ V"[;_P!%K70T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>3_!S_ )&_XA_]AEO_
M $9+7K%>3_!S_D;_ (A_]AEO_1DM 'K%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'D_C[_DNW@+_ +:UZQ7D_C[_ )+MX"_[
M:UZQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q
M/QC_ .21:]_UR3_T:E=M7$_&/_DD6O?]<D_]&I0!J_#_ /Y)MX;_ .P7;?\
MHM:Z&N>^'_\ R3;PW_V"[;_T6M=#0 5Y/\'/^1O^(?\ V&6_]&2UZQ7C'PNU
M[2-&\8^/UU?5;&P,NLN8Q=7*1;P))<XW$9ZB@#V>BL+_ (3CPG_T-&C?^#"+
M_P"*H_X3CPG_ -#1HW_@PB_^*H W:*PO^$X\)_\ 0T:-_P"#"+_XJC_A./"?
M_0T:-_X,(O\ XJ@#=HK"_P"$X\)_]#1HW_@PB_\ BJ/^$X\)_P#0T:-_X,(O
M_BJ -VBL+_A./"?_ $-&C?\ @PB_^*H_X3CPG_T-&C?^#"+_ .*H W:*PO\
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M5K4'GVDV"R[BI!!!!!'(.153_A./"?\ T-&C?^#"+_XJC_A./"?_ $-&C?\
M@PB_^*H TM+TV#1])MM.L_,^SVL8BB$CEV"C@#)Y.!Q5NL+_ (3CPG_T-&C?
M^#"+_P"*H_X3CPG_ -#1HW_@PB_^*H W:*PO^$X\)_\ 0T:-_P"#"+_XJC_A
M./"?_0T:-_X,(O\ XJ@#=HK"_P"$X\)_]#1HW_@PB_\ BJ/^$X\)_P#0T:-_
MX,(O_BJ "S\&Z-9>+KOQ-% [ZK=IY<D\DK-A>.%!X7A0..U;M87_  G'A/\
MZ&C1O_!A%_\ %4?\)QX3_P"AHT;_ ,&$7_Q5 &[16%_PG'A/_H:-&_\ !A%_
M\51_PG'A/_H:-&_\&$7_ ,50!NT5A?\ "<>$_P#H:-&_\&$7_P 51_PG'A/_
M *&C1O\ P81?_%4 ;M%87_"<>$_^AHT;_P &$7_Q5'_"<>$_^AHT;_P81?\
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M *&C1O\ P81?_%4?\)QX3_Z&C1O_  81?_%4 ;M%87_"<>$_^AHT;_P81?\
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M/_H:-&_\&$7_ ,51_P )QX3_ .AHT;_P81?_ !5 &[16%_PG'A/_ *&C1O\
MP81?_%4?\)QX3_Z&C1O_  81?_%4 ;M%87_"<>$_^AHT;_P81?\ Q5'_  G'
MA/\ Z&C1O_!A%_\ %4 ;M%87_"<>$_\ H:-&_P#!A%_\51_PG'A/_H:-&_\
M!A%_\50!NT5A?\)QX3_Z&C1O_!A%_P#%4?\ "<>$_P#H:-&_\&$7_P 50!NT
M5A?\)QX3_P"AHT;_ ,&$7_Q5'_"<>$_^AHT;_P &$7_Q5 &[16%_PG'A/_H:
M-&_\&$7_ ,51_P )QX3_ .AHT;_P81?_ !5 &[16%_PG'A/_ *&C1O\ P81?
M_%4?\)QX3_Z&C1O_  81?_%4 ;M%87_"<>$_^AHT;_P81?\ Q5'_  G'A/\
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MC1O_  81?_%4 ;M%87_"<>$_^AHT;_P81?\ Q5'_  G'A/\ Z&C1O_!A%_\
M%4 ;M%87_"<>$_\ H:-&_P#!A%_\51_PG'A/_H:-&_\ !A%_\50!NT5A?\)Q
MX3_Z&C1O_!A%_P#%4?\ "<>$_P#H:-&_\&$7_P 50!NT5A?\)QX3_P"AHT;_
M ,&$7_Q5'_"<>$_^AHT;_P &$7_Q5 &[16%_PG'A/_H:-&_\&$7_ ,51_P )
MQX3_ .AHT;_P81?_ !5 &[7D_P '/^1O^(?_ &&6_P#1DM=W_P )QX3_ .AH
MT;_P81?_ !5>9?"?Q)H>G^*O'<M_K6GVL=UJS20/-=(@E7?*=RDGYAR.1ZT
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M7_Q5 &[16%_PG'A/_H:-&_\ !A%_\51_PG'A/_H:-&_\&$7_ ,50!NT5A?\
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M^*H_X3CPG_T-&C?^#"+_ .*H W:*PO\ A./"?_0T:-_X,(O_ (JC_A./"?\
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MR?\ @5/_ /%T?\*5^'W_ $+R?^!4_P#\77=T4 <)_P *5^'W_0O)_P"!4_\
M\71_PI7X??\ 0O)_X%3_ /Q==W10!PG_  I7X??]"\G_ (%3_P#Q='_"E?A]
M_P!"\G_@5/\ _%UW=% '"?\ "E?A]_T+R?\ @5/_ /%T?\*5^'W_ $+R?^!4
M_P#\77=T4 <)_P *5^'W_0O)_P"!4_\ \71_PI7X??\ 0O)_X%3_ /Q==W10
M!PG_  I7X??]"\G_ (%3_P#Q='_"E?A]_P!"\G_@5/\ _%UW=% '"?\ "E?A
M]_T+R?\ @5/_ /%T?\*5^'W_ $+R?^!4_P#\77=T4 <)_P *5^'W_0O)_P"!
M4_\ \71_PI7X??\ 0O)_X%3_ /Q==W10!PG_  I7X??]"\G_ (%3_P#Q='_"
ME?A]_P!"\G_@5/\ _%UW=% '"?\ "E?A]_T+R?\ @5/_ /%T?\*5^'W_ $+R
M?^!4_P#\77=T4 <)_P *5^'W_0O)_P"!4_\ \71_PI7X??\ 0O)_X%3_ /Q=
M=W10!PG_  I7X??]"\G_ (%3_P#Q='_"E?A]_P!"\G_@5/\ _%UW=% '"?\
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M\/O^A>3_ ,"I_P#XNN[HH X3_A2OP^_Z%Y/_  *G_P#BZ/\ A2OP^_Z%Y/\
MP*G_ /BZ[NB@#A/^%*_#[_H7D_\  J?_ .+H_P"%*_#[_H7D_P# J?\ ^+KN
MZ* .$_X4K\/O^A>3_P "I_\ XNC_ (4K\/O^A>3_ ,"I_P#XNN[HH X3_A2O
MP^_Z%Y/_  *G_P#BZ/\ A2OP^_Z%Y/\ P*G_ /BZ[NB@#A/^%*_#[_H7D_\
M J?_ .+H_P"%*_#[_H7D_P# J?\ ^+KNZ* .$_X4K\/O^A>3_P "I_\ XNC_
M (4K\/O^A>3_ ,"I_P#XNN[HH X3_A2OP^_Z%Y/_  *G_P#BZ/\ A2OP^_Z%
MY/\ P*G_ /BZ[NB@#A/^%*_#[_H7D_\  J?_ .+H_P"%*_#[_H7D_P# J?\
M^+KNZ* .$_X4K\/O^A>3_P "I_\ XNC_ (4K\/O^A>3_ ,"I_P#XNN[HH X3
M_A2OP^_Z%Y/_  *G_P#BZ/\ A2OP^_Z%Y/\ P*G_ /BZ[NB@#A/^%*_#[_H7
MD_\  J?_ .+H_P"%*_#[_H7D_P# J?\ ^+KNZ* .$_X4K\/O^A>3_P "I_\
MXND'P3^'PSCP\O/K=S__ !==Y10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0
MO)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==
MW10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]
M_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\
M_%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0
MO)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==
MW10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]
M_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\
M_%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0
MO)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==
MW10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]
M_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\
M_%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0
MO)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==
MW10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]
M_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\
M_%T?\*5^'W_0O)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0
MO)_X%3__ !==W10!PG_"E?A]_P!"\G_@5/\ _%T?\*5^'W_0O)_X%3__ !==
MW10!P9^"?P^)!_X1Y>/^GN?_ .+I?^%*_#[_ *%Y/_ J?_XNN[HH X3_ (4K
M\/O^A>3_ ,"I_P#XNC_A2OP^_P"A>3_P*G_^+KNZ* .$_P"%*_#[_H7D_P#
MJ?\ ^+H_X4K\/O\ H7D_\"I__BZ[NB@#A/\ A2OP^_Z%Y/\ P*G_ /BZ/^%*
M_#[_ *%Y/_ J?_XNN[HH X3_ (4K\/O^A>3_ ,"I_P#XNC_A2OP^_P"A>3_P
M*G_^+KNZ* .$_P"%*_#[_H7D_P# J?\ ^+H_X4K\/O\ H7D_\"I__BZ[NB@#
MA/\ A2OP^_Z%Y/\ P*G_ /BZ/^%*_#[_ *%Y/_ J?_XNN[HH X3_ (4K\/O^
MA>3_ ,"I_P#XNC_A2OP^_P"A>3_P*G_^+KNZ* .$_P"%*_#[_H7D_P# J?\
M^+H_X4K\/O\ H7D_\"I__BZ[NB@#A/\ A2OP^_Z%Y/\ P*G_ /BZ/^%*_#[_
M *%Y/_ J?_XNN[HH X3_ (4K\/O^A>3_ ,"I_P#XNC_A2OP^_P"A>3_P*G_^
M+KNZ* .$_P"%*_#[_H7D_P# J?\ ^+H_X4K\/O\ H7D_\"I__BZ[NB@#A/\
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A?86VE:;;:?81>3:VL2PPQ@D[448 R>3P.IYJQ110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>adverseeventtable.jpg
<TEXT>
begin 644 adverseeventtable.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Q
M,@  DI(  @    ,Q,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%?-?V_Q5_P!#GK/_ '^H^W^*O^ASUG_O]1];I=P_L#'_ ,J^]'TI17S7]O\
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M/6?^_P!1]O\ %7_0YZS_ -_J/K=+N']@8_\ E7WH^E**^:_M_BK_ *'/6?\
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M/6?^_P!1]O\ %7_0YZS_ -_J/K=+N']@8_\ E7WH^E**^:_M_BK_ *'/6?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Y#_  R_.!M4445D=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!U7P5_Y
M'CQ7_P!<;7^35[/7C'P5_P"1X\5_]<;7^35[/7T%'^''T1^3YA_OE7_$_P P
MKYLU#_DH'BS_ +";U])U\V:A_P E \6?]A-ZRQ?\)G?D'^_Q]'^0ZBBBO$/T
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Q+S_D<M._ZX25MUB7G_ ".6
MG?\ 7"2MNM:FT?3]6<.%^.K_ (O_ &V(4445D=P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6)XN_Y%V3_ *Z1_P#H0K;K$\7?\B[)_P!=(_\ T(5K1_B1]3AS
M#_=*O^%_D;=%%%9'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AK&\(
M_P#(K6G_  /_ -#:MD]#6-X1_P"16M/^!_\ H;5JOX;]5^IQ3_WR'^&7YP-J
MBBBLCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .J^"O_ "/'BO\ ZXVO
M\FKV>O&/@K_R/'BO_KC:_P FKV>OH*/\./HC\GS#_?*O^)_F%?-FH?\ )0/%
MG_83>OI.OFS4/^2@>+/^PF]98O\ A,[\@_W^/H_R'4445XA^DA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &)>?\CEIW_7"2MNL2\_Y'+3O^N$E;=:U-H^
MGZLX<+\=7_%_[;$****R.X**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\7?\
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MS_D<M._ZX25MUB7G_(Y:=_UPDK;K6IM'T_5G#A?CJ_XO_;8A11161W!1110
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M?3;Z[A:6UL[B>-3AGCB9E!ZXR!32;V)E)15Y.Q6HHHI%!1110 4444 %%%%
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M_P"YAC<J%7/&<=3[U4O9JC!S,J"Q4LPQ$<.TM5=M7Z:6%UOP7K.A0^?=0I+
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M^+[+6-$OX;?4=8EOU_UL)>9F*D=RI)VFN[\16?\ PF_@F"YTHAIE(F1,@98
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MHBLKPN(P[JRKVO)WT"BBBN4]H**** "BBB@ HHHH **** .J^"O_ "/'BO\
MZXVO\FKV>O&/@K_R/'BO_KC:_P FKV>OH*/\./HC\GS#_?*O^)_F%?-FH?\
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M[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T-8WA'_D5K3_@?_H;5LGH
M:QO"/_(K6G_ _P#T-JU7\-^J_4XI_P"^0_PR_.!M4445D=H4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!U7P5_Y'CQ7_UQM?Y-7L]>,?!7_D>/%?\ UQM?
MY-7L]?04?X<?1'Y/F'^^5?\ $_S"OFS4/^2@>+/^PF]?2=?.K>&?%.O>//%T
MOAZTLIHH]5D60SSE"#VQ^&*G$0E.FXQ-\IQ-/"XN-6J[)7_(@HK3_P"%>?$3
M_H&Z5_X%FC_A7GQ$_P"@;I7_ (%FO,^J5>Q]G_;^ _F?W,S**T_^%>?$3_H&
MZ5_X%FC_ (5Y\1/^@;I7_@6:/JE7L']OX#^9_<S,HK3_ .%>?$3_ *!NE?\
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MZ5_X%FC_ (5Y\1/^@;I7_@6:/JE7L']OX#^9_<S,HK3_ .%>?$3_ *!NE?\
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MY\1/^@;I7_@6:CZI5['3_;^ _F?W,S**T_\ A7GQ$_Z!NE?^!9H_X5Y\1/\
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M!NE?^!9H^J5>P?V_@/YG]S,RBM/_ (5Y\1/^@;I7_@6:/^%>?$3_ *!NE?\
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M **** "BBB@ HHHH **** "BBB@ KS[XW?\ )+KO_KYM_P#T:M>@UY]\;O\
MDEUW_P!?-O\ ^C5H ]!HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M1_\ 5M]#7 _ _P#Y(YHGUN/_ $?)7?/_ *MOH:X'X'_\D<T3ZW'_ */DH [^
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_PS_R7#QO_ ->]A_Z*
M->@5Y_X9_P"2X>-_^O>P_P#11KT"@ KS_P"&_P#R-/CO_L-M_P"@BO0*\_\
MAO\ \C3X[_[#;?\ H(H ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \_P!<_P"2\^%_^P;=5Z!7G^N?\EY\+_\ 8-NJ] H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\^^-W_)+KO_ *^;?_T:M>@UY]\;O^277?\ U\V_
M_HU: /0:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_JV^AK@?@?_ ,D<T3ZW'_H^2@#OZ*** "BBB@ HHHH **** "BBB@ HHHH
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M>,OA[_PEOBKP]K/]I_9/[%G$WD_9_,\[#J^-VX;?NXZ'K7:44 %<+XG^&O\
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M7GPO_P!@VZKT"O/]<_Y+SX7_ .P;=5Z!0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Y]\;O^277?_7S;_\ HU:]!KS[XW?\DNN_^OFW_P#1JT >@T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (_^K;Z&N!^!_\ R1S1/K<?
M^CY*[Y_]6WT-<#\#_P#DCFB?6X_]'R4 =_1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y_P"&?^2X>-_^O>P_]%&O0*\_\,_\EP\;_P#7O8?^BC7H
M% !7G_PW_P"1I\=_]AMO_017H%>?_#?_ )&GQW_V&V_]!% 'H%%%% !1110
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MO;I#)*S\X'"*<<^N.A]#7#_";Q?]D^"1U;Q'.PM]):2$2OR6C7&Q1ZG+;!]
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MF:OK+%X=PYBB/<#MG P.R@>M>KT %%%% !1110 4444 %%%% !1110 4444
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MCCKBK]16MM#96D5K:1+#!"@CCC08"J!@ ?A4M !1110 4444 %%%% !1110
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M3LM]$RW$"JVWS&7/R9]P2![XH E\=^$=6\66]G'H_BF\\/&W9S(UJ'/G!@,
M[77I@^O6O*?#NFW?P?\ BE9Q^)XH-3AUUO)AUC+&2-B0#U/'++N]B#GC%;7@
MWXXZ7I>B0Z-XXAO-/U33D%O([0,PDVC ) ^96P.01[YYP,;6]>?XT_$;0K'P
MW9W T?29?/N+N5-O!*EB?3A0 .I)/% 'T"3@9/ KR;QK\7V>^;PW\.8&UC6I
M28S/$NZ* ]"0>C$>OW1ZGI5/]H+QC>Z/IEAX?TV=K;^TP[74RY!$0P-H([$D
MYQS@8[FJ_@CQ]\*_ VCK:Z9=S-<LH^T7;64GF3-[G' ]!TH [/X6_#YO ^C3
MRZC/]IUC46$MY+G(!ZA >^"22>Y)KNJY7PK\2?#7C/4)K+0+N6>>&+SG5X&3
M"Y SDCU(KE/!7QCG\5_$:Y\.2Z.+:W!E$,H8EU\O/^L!&!G'X' YH ]-U"_M
MM*TVXO[^416UM&TLKG^%0,DUXY\)["Y\<>.]5^(NM1'RQ(8=-1^B#&./]U<+
MGU+'K5GXVZ[=:M>Z9\/M 8M>ZI*KW>W^&//R@^V06/L@]:]0\.Z':^&O#MEI
M%@NV"TB" ]V/=C[DY/XT 9/C[P+8>/O#_P#9][(UO/$WF6UR@RT3X].X/<5P
M,OPS^)>K6HT77_'$,FB<*_E!C-(G<,=@)_%S7LU</\5?'/\ PA7A1C9G=JU^
M3!8Q@9(8]7Q_LY'XE10!YUK6FP>*/%&E_"WPENCT#13YNISH?OL#\V3W.3C_
M 'F/]VM-?%?C#Q7K%SH'PFBLM+T;1L6WV^X0$-C@8RK#'!P I..3UQ78_"CP
M-_PAGA4&^&[5]0(GO9&.6#'HF?;/YDUY[X!\3VGP?UG6?"?C-)K.![HW%K?"
M)G65<!<_*"2"%4C /.X'% '2>&/'?BK0_&UMX0^)4-N\]\O^A:C;@!96[ @
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MU!4C/(/6O0?A=X\F\?\ AB74+JQ%G<6\Y@D"$F-S@'*Y^N,<_K7&?$SQ9?\
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M_)'-$^MQ_P"CY* ._HHHH **** "BBB@ HHHH **** "BBB@ KSGQW\-M?\
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M*"#D$:=%Q_X[6]10 52M=&TRROY[ZRTVTM[NY.9[B*!4DEYS\S 9;GGFKM%
M!5+4=&TS6(Q'JVFVE\B]%NH%D _!@:NT4 4]/TC3=)C,>E:?:V2'JMM L8/X
M*!3M0TRPU:T-KJME;WUN2&,-S$LB$CH<,"*M44 ,AABMH(X+>-(HHU")&BA5
M10,  #H .U59-&TN75H]4ETVS?48EVQWC0*9D&",!\9 P3W[FKM% "$!E(8
M@C!![UFV7AO0]-O3>:=HNGVETV<SP6J(YSU^8#-:=% %+4M%TO645-7TVSOU
M7[JW5NLH'_?0-/L-+L-*M_(TNQMK*'KY=M"L:_DH JU10 5POQ=\+7/B;P.[
MZ4KMJFF2K>68C&79EZJ/4D9P.Y KNJ* ,SPWJ5QK'AJPO[VSGL;F:$&>WN(F
MC>.0<,"K '&0<>HP>]2ZCH>DZPT+:MIEG?- 28C<VZ2&,G&2NX''0=/2KU%
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M/OC=_P DNN_^OFW_ /1JUZ#7GWQN_P"277?_ %\V_P#Z-6@#T&BBB@ HHHH
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M .P;=5Z!7G^N?\EY\+_]@VZKT"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KS[XW?\ )+KO_KYM_P#T:M>@UY]\;O\ DEUW_P!?-O\ ^C5H ]!HHHH
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M:X'X'_\ )'-$^MQ_Z/DH [^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&$7_ ,50!NT5A?\ "<>$_P#H9]&_\&$7_P 51_PG'A/_ *&?1O\ P81?_%4
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MY22=;R,QHQZ MG )KN?^$X\)_P#0SZ-_X,(O_BJ -VBL+_A./"?_ $,^C?\
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MBL+_ (3CPG_T,^C?^#"+_P"*H_X3CPG_ -#/HW_@PB_^*H W:*PO^$X\)_\
M0SZ-_P"#"+_XJC_A./"?_0SZ-_X,(O\ XJ@#=HK"_P"$X\)_]#/HW_@PB_\
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M?^#"+_XJC_A./"?_ $,^C?\ @PB_^*H W:*PO^$X\)_]#/HW_@PB_P#BJ/\
MA./"?_0SZ-_X,(O_ (J@#=HK"_X3CPG_ -#/HW_@PB_^*H_X3CPG_P!#/HW_
M (,(O_BJ -Q_]6WT-<#\#_\ DCFB?6X_]'R5T+^./">QO^*GT;I_T$(O_BJX
MGX.>*O#VF_"?2+34==TRTN8S/OAGO(T=<SN1E2<C@@_C0!ZI16%_PG'A/_H9
M]&_\&$7_ ,51_P )QX3_ .AGT;_P81?_ !5 &[16%_PG'A/_ *&?1O\ P81?
M_%4?\)QX3_Z&?1O_  81?_%4 ;M%87_"<>$_^AGT;_P81?\ Q5'_  G'A/\
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M 4?^%=)10!S?_"N_!O\ T*VD?^ 4?^%'_"N_!O\ T*VD?^ 4?^%=)10!S?\
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M6'KG_)>?"_\ V#;JO0* .;_X5WX-_P"A6TC_ , H_P#"C_A7?@W_ *%;2/\
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M2B@#F_\ A7?@W_H5M(_\ H_\*/\ A7?@W_H5M(_\ H_\*Z2B@#F_^%=^#?\
MH5M(_P# */\ PH_X5WX-_P"A6TC_ , H_P#"NDHH YO_ (5WX-_Z%;2/_ */
M_"C_ (5WX-_Z%;2/_ */_"NDHH YO_A7?@W_ *%;2/\ P"C_ ,*/^%=^#?\
MH5M(_P# */\ PKI** .;_P"%=^#?^A6TC_P"C_PH_P"%=^#?^A6TC_P"C_PK
MI** .;_X5WX-_P"A6TC_ , H_P#"C_A7?@W_ *%;2/\ P"C_ ,*Z2B@#F_\
MA7?@W_H5M(_\ H_\*/\ A7?@W_H5M(_\ H_\*Z2B@#F_^%=^#?\ H5M(_P#
M*/\ PH_X5WX-_P"A6TC_ , H_P#"NDHH YO_ (5WX-_Z%;2/_ */_"C_ (5W
MX-_Z%;2/_ */_"NDHH YO_A7?@W_ *%;2/\ P"C_ ,*/^%=^#?\ H5M(_P#
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MWX-_Z%;2/_ */_"NDHH YO\ X5WX-_Z%;2/_  "C_P */^%=^#?^A6TC_P
MH_\ "NDHH YO_A7?@W_H5M(_\ H_\*/^%=^#?^A6TC_P"C_PKI** .;_ .%=
M^#?^A6TC_P  H_\ "C_A7?@W_H5M(_\  */_  KI** .;_X5WX-_Z%;2/_ *
M/_"C_A7?@W_H5M(_\ H_\*Z2B@#F_P#A7?@W_H5M(_\  */_  H_X5WX-_Z%
M;2/_  "C_P *Z2B@#F_^%=^#?^A6TC_P"C_PH_X5WX-_Z%;2/_ */_"NDHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@#S_P ,_P#)</&__7O8?^BC7H%>?^&?^2X>-_\ KWL/_11KT"@ KS_X;_\
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M5$.0"#T8]ZN^#M8N/$/@S2M7O4C2XO+999%B!" D=@23C\: -JBBB@ HHHH
M**** "BBB@ HHHH \_US_DO/A?\ [!MU7H%>?ZY_R7GPO_V#;JO0* "BBB@
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MXT$1V\G!#9[^E='\/?C)X>U-=!\+06>IK??9XK7S'BC$6Y(^3D/G'RGM5O\
M:!_Y)5-_U]P_S-=KX._Y$70?^P;;_P#HI: *.G>/=+U/Q]J'A&""\6_L(C++
M(Z*(F V="&SGYQU [UL:YJ\&@:#>ZM>)(\%G"TTBQ %B ,G ) S^->2^$?\
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M_P#HU:]!KS[XW?\ )+KO_KYM_P#T:M 'H-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "/_JV^AK@?@?\ \D<T3ZW'_H^2N^?_ %;?0UP/P/\ ^2.:
M)];C_P!'R4 =_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)_Y.UUS_ *\5_P#1$->T44 <G\3/"B^,/ 5_IP53=1KY]JS?PRKR.>V1E?\
M@5>/?!NSU'QYXWMM<UUS/;>'+.*WMRW3> 1&/<CYF)]<5Z1\;/%9\-^ 9;6T
M<B_U8FT@52=P4CYV&/0''U85K?"_PF/!_@&QL)$VW<J_:+H]_,;DC\!A?PH
MZ^LSQ)%J\_AR]C\-7$-MJC1'[-+,FY5;_/<Y /8]*TZ* /"M*^,GB/P9;C2_
MB-X<OI)K?Y1>H-K2#MG/RMU^\&].,\UG:W?:Y\=/$&EV5AH=SIN@V<I>:ZG'
M4'&3G&,X! 4$]?R^AJ* .&^+_AR]\1_#2]LM)B::YA9)XX5&6D"'E1ZG&<#O
MC%<Y\.?BY97R:+X1N=(U&#5HHDM928U\I-B8W$D[AG;T([]:]<HH \.\:PZO
M\./C"WCJRTV74-(U"(1W8A!)C^558$]ON*P)X/(XJGXX^)][\0?!M_8>$-$O
MH-.6!IM0O[Q0JK&GS%%VDC)( ZY]NI'OM% 'E7PRT*#Q-^SO;:-=,4CO([F/
M>.J'SW*M^! /X5S7AKQWK/PAM#X9\<Z'>3V%J[?9+ZU 8%"<X!8A6&3QR",X
MQZ>]44 ?._Q+\>:UX\\$WCZ)H=WI_ARU,<EU=W@"M<$R*J(H&1]Y@3@GIV[^
MO?#'_DEWA[_KQC_E7544 >!?&NUOO!/C6T\9^'I!;R:E!):3D?\ /385W8]U
M((]TS7H7P>\)?\(G\/K19X]M]?C[5<YZ@L/E7\%Q^.:X?6_^+H?'RVTA#YNB
M^',M.5Y5G4@N/Q<*GT4U[F!@8' H **** "BBB@ HHHH **** //]<_Y+SX7
M_P"P;=5Z!7G^N?\ )>?"_P#V#;JO0* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O/OC=_R2Z[_Z^;?_ -&K7H->??&[_DEUW_U\V_\ Z-6@#T&BBB@
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M"@ KS_X;_P#(T^._^PVW_H(KT"O/_AO_ ,C3X[_[#;?^@B@#T"BBB@ HHHH
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M@^!O&EGX\T!]6T^VGMHDG: I/C=D!3G@GCYJ .DHHHH **** "BBO&/V=O\
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M1[PK=4()#*?<,"/PH U**\ITCQGK_CGXL7%IX9O_ ++X7TD;;J5(8W^U,">
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M;;A23N;<!\W/3MSR:].HH \F\1?!N]B\22^(?AWKC:%?SDM+ Q(B8DY."H.
M3SM((STQTJE#\'?%/B74K>?XE^*AJ-K;MN6TM68JWXE5"Y'4@9]Z]FHH CM[
M>&TM8K>VC6*&) D:*,!5 P *XWXG>&?$?C#0H=%T"[L[*TGD!OI9Y'#L@Z(H
M52".YR1T Z$UVU% &=X?T.S\-:#::1ID>RWM8PB\<L>['W)R3]:X#Q/\+=77
MQ9-XH^'>N+HNI763=0R@F*9CU;H>IY(*D9YXKU"B@#R[PU\+=8D\60>)OB)K
MJZUJ%KS;0Q#]S$>>>0HX)R % SS7J-%% !1110 4444 %%%% !1110 4444
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M*R?PNI/4$AOT/>NQKR366'A;]I'2+V+Y+?Q%9FVGQQND' /YK%^M 'K=%%%
M!1110 4444 %%%% !1110 4444 >?ZY_R7GPO_V#;JO0*\_US_DO/A?_ +!M
MU7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GWQN_Y)==_P#7S;_^
MC5KT&O/OC=_R2Z[_ .OFW_\ 1JT >@T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&W5>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>??&[_DEUW_U\V__
M *-6O0:\^^-W_)+KO_KYM_\ T:M 'H-%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "/_JV^AK@?@?_ ,D<T3ZW'_H^2N^?_5M]#7 _ _\ Y(YHGUN/
M_1\E '?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/CEANL+<_P!G::Q'#*N-S#\.?^VAKUBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S_ %S_ )+SX7_[!MU7H%>?ZY_R7GPO_P!@VZKT"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS[XW?\DNN_\ KYM__1JUZ#7GWQN_Y)==_P#7
MS;_^C5H ]!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1_P#5M]#7
M _ __DCFB?6X_P#1\E=\_P#JV^AK@?@?_P D<T3ZW'_H^2@#OZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** //_#/_ "7#QO\ ]>]A_P"BC7H%>?\
MAG_DN'C?_KWL/_11KT"@ KS_ .&__(T^._\ L-M_Z"*] KS_ .&__(T^._\
ML-M_Z"* /0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //]<_Y+SX
M7_[!MU7H%>?ZY_R7GPO_ -@VZKT"@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-$^MQ_Z/DH [^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O/OC=_P DNN_^OFW_ /1JUZ#7GWQN_P"2
M77?_ %\V_P#Z-6@#T&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_%W_@O_ /LJ/^%I7?\ T3_Q=_X+_P#[*O0** //_P#A:5W_ -$_\7?^"_\
M^RH_X6E=_P#1/_%W_@O_ /LJ] HH \__ .%I7?\ T3_Q=_X+_P#[*C_A:5W_
M -$_\7?^"_\ ^RKT"B@#S_\ X6E=_P#1/_%W_@O_ /LJ/^%I7?\ T3_Q=_X+
M_P#[*O0** //_P#A:5W_ -$_\7?^"_\ ^RH_X6E=_P#1/_%W_@O_ /LJ] HH
M \__ .%I7?\ T3_Q=_X+_P#[*C_A:5W_ -$_\7?^"_\ ^RKT"B@#S_\ X6E=
M_P#1/_%W_@O_ /LJ/^%I7?\ T3_Q=_X+_P#[*O0** //_P#A:5W_ -$_\7?^
M"_\ ^RH_X6E=_P#1/_%W_@O_ /LJ] HH \__ .%I7?\ T3_Q=_X+_P#[*C_A
M:5W_ -$_\7?^"_\ ^RKT"B@#Q?4?%NJ7GQ*T;Q#'X$\4K;6-I-!)&=/.]B_0
MCG&/J:ZC_A:5W_T3_P 7?^"__P"RKT"B@#S_ /X6E=_]$_\ %W_@O_\ LJ/^
M%I7?_1/_ !=_X+__ +*O0** //\ _A:5W_T3_P 7?^"__P"RH_X6E=_]$_\
M%W_@O_\ LJ] HH \_P#^%I7?_1/_ !=_X+__ +*C_A:5W_T3_P 7?^"__P"R
MKT"B@#S_ /X6E=_]$_\ %W_@O_\ LJ/^%I7?_1/_ !=_X+__ +*O0** //\
M_A:5W_T3_P 7?^"__P"RH_X6E=_]$_\ %W_@O_\ LJ] HH \_P#^%I7?_1/_
M !=_X+__ +*C_A:5W_T3_P 7?^"__P"RKT"B@#S_ /X6E=_]$_\ %W_@O_\
MLJ/^%I7?_1/_ !=_X+__ +*O0** //\ _A:5W_T3_P 7?^"__P"RH_X6E=_]
M$_\ %W_@O_\ LJ] HH \_P#^%I7?_1/_ !=_X+__ +*C_A:5W_T3_P 7?^"_
M_P"RKT"B@#S_ /X6E=_]$_\ %W_@O_\ LJ/^%I7?_1/_ !=_X+__ +*O0**
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M%I7?_1/_ !=_X+__ +*C_A:5W_T3_P 7?^"__P"RKT"B@#S_ /X6E=_]$_\
M%W_@O_\ LJY?XA^+=4\6^#9])L? GBF&:2:)P\VGG: KACT)/:O:** //_\
MA:5W_P!$_P#%W_@O_P#LJ/\ A:5W_P!$_P#%W_@O_P#LJ] HH \__P"%I7?_
M $3_ ,7?^"__ .RH_P"%I7?_ $3_ ,7?^"__ .RKT"B@#S__ (6E=_\ 1/\
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M^"__ .RKT"B@#S__ (6E=_\ 1/\ Q=_X+_\ [*C_ (6E=_\ 1/\ Q=_X+_\
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MI7?_ $3_ ,7?^"__ .RKT"B@#S__ (6E=_\ 1/\ Q=_X+_\ [*C_ (6E=_\
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M?_1/_%W_ (+_ /[*C_A:5W_T3_Q=_P""_P#^RKT"B@#S_P#X6E=_]$_\7?\
M@O\ _LJ/^%I7?_1/_%W_ (+_ /[*O0** //_ /A:5W_T3_Q=_P""_P#^RH_X
M6E=_]$_\7?\ @O\ _LJ] HH \_\ ^%I7?_1/_%W_ (+_ /[*C_A:5W_T3_Q=
M_P""_P#^RKT"B@#S_P#X6E=_]$_\7?\ @O\ _LJ/^%I7?_1/_%W_ (+_ /[*
MO0** //_ /A:5W_T3_Q=_P""_P#^RH_X6E=_]$_\7?\ @O\ _LJ] HH \_\
M^%I7?_1/_%W_ (+_ /[*C_A:5W_T3_Q=_P""_P#^RKT"B@#S_P#X6E=_]$_\
M7?\ @O\ _LJ/^%I7?_1/_%W_ (+_ /[*O0** //_ /A:5W_T3_Q=_P""_P#^
MRH_X6E=_]$_\7?\ @O\ _LJ] HH \_\ ^%I7?_1/_%W_ (+_ /[*C_A:5W_T
M3_Q=_P""_P#^RKT"B@#S_P#X6E=_]$_\7?\ @O\ _LJ/^%I7?_1/_%W_ (+_
M /[*O0** //_ /A:5W_T3_Q=_P""_P#^RH_X6E=_]$_\7?\ @O\ _LJ] HH
M\_\ ^%I7?_1/_%W_ (+_ /[*C_A:5W_T3_Q=_P""_P#^RKT"B@#S_P#X6E=_
M]$_\7?\ @O\ _LJ/^%I7?_1/_%W_ (+_ /[*O0** //_ /A:5W_T3_Q=_P""
M_P#^RH_X6E=_]$_\7?\ @O\ _LJ] HH \U\ 3ZAJOQ+\5:W=:%JFDVU[!:K"
M-0MC$6**5(]#Z\9KTJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ev001graph.jpg
<TEXT>
begin 644 ev001graph.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,P
M-   DI(  @    ,P-   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \N^(:+)X_TM'4,K0PAE(R"/-?BN_P#^$<T/_H#:
M?_X"I_A7GGQ+DDB\;6$D";Y4MHV1<9W$2/@8%7?^$R\;_P#0N?\ DC/_ /%5
MY\9PC4GS+KV/K:N&Q%?!X=T9)63ZV.[M]%TJTG6>TTRS@E7.V2*W56&1C@@>
ME<#\3=,DLM3L]=L\HQ(1V'9UY4_EQ_P&NL\)ZKJ^K6<\FNV'V*5) J+Y+Q[A
MCKAB<U<\1:2NM^'[JQ(&^1,QD]G'*_K6]2"JTO=1Y6%KU,%CDZSO;1ZWT?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCA<1&32;2MYZ]#N:***Z#R HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1I'<P3/;S>7]UF7N/;D5N4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69>
M:#:WNO6.K2R3"XL0PC52-IW#!R,9[^HK3HH Q-:\)Z?K=Y%>2/<VEY$-JW5I
M+Y<F/3/-.T/PMI^@S2SVYGN+J;B2YNI-\C#TS6S10!S%YX#TVXOI[FUNM0TY
MKDYG2RN/+20]\C!K9TC1[+0M/6STV+RXE.3DY+'U)[FKU% &4GA^U7Q*^N22
M3371B\J-9&!2%?\ 9 ''?N>IJKJ?@^QU+4I+]+J^L+B9 DSV4_E^<O3#<'-;
M]% %/2M*M-%TZ.RT^/RX8^@)R23U)/<U<HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS&U
MM]3^('C+Q)'<^(=4TBPT:Y%G;6NEW'D.6 R978<L#V'3\J].KR/Q]IZWGCJ.
MQ\"W=]9>*+^-?[0FLKCRX8H!P))ACEL<+@@^_3(!GZAXQUR/X4^(+"ZU21M4
MT_6AH\&JPOY32#S%.[*XPVW<#CVSWKN?!^CZ/%J#WFC>--3U\Q*8Y(IM9^UQ
M*3W*@G!XXK(\0>']%\%^ ],T^Y\.2^(=)@O%EOI"Y,B.<YN&0 ^9R3D9Z'TK
M-LK_ $7Q)\6/#]_\.[8>19PS#5;VWM6AA:)E 2-LJ QSR/3\. #UF::.W@DF
MG=8XHU+N[G 50,DD^E>./XRUWQ#\3O#%]9S3V7AFZO)K:TA5V0WH1,M*Z]U)
M("@^F:Z&_FC^,W@ZYM- U*\T6VAO3#=_:;+)G"#.S <84DC/.>,$"N<\4Z#X
MDT_QEX&LV\1V;M]HFCLFBTD1I;;8Q_ )#N&.,9&* -+4Y[O7O$7C!K_Q3?:$
M- 519V]K<^2J+Y8<32#^,,3C!XQQZ5'%XGUKQU;^&/#UG<SV-[<6T6H:W=6K
MF)X81]U05QM,AP<#H".QKIO'UAX6LM!E\0^*='L]2NK.()$TD(WSR'A$ [Y8
M].<9-<+=:#=^'M)T>\\47%W;6NMW<ESXDN;'<K1DI^XA)3YEB&2IQP* /;5&
MU0HS@#')S2UY[\-+CS=6UV/1+F\N_"T;1?V?->.[XD*GS%C9_F9!\O7OTZFO
M0J ,#QUKMQX9\"ZMK%F@>XM8"T089 8D*"1W )S^%>?:[8:]X.\!P^-(/&.I
MW^H0+#/=075QNM+E79046/&%^]P1S^?'J^I16<^EW,6J+$UD\3+.LWW"A'S9
M]L5X[X.\'+XLUA;B*^U63P-ILP.FV5[<%UNG4\, 0"(E/0')XZ]10!H^(M4M
MM9^*CV.K>*K[PWI=GI$4C"'4_L>Z=WW $DX)V'IUXKT?P]IT.F:+%!:ZE=ZG
M"272ZO+G[0[@G/W^X]*X35M>\(:)X^U5_&WAV*PN)HT%OJD\+7,=_'MQ@?*0
MC# !7OCKTJEX.\10^!? .K:WJ6GW\&A7&KR-I=G'#F2.!S\ORL1M4G)Y/?OF
M@#8UR74O%?Q-?PM;ZO>Z1ING6"W=R]A)Y<UQ([85=^,JH'I_AC)D\0:]X+N?
M%N@)J%QK)T_2/[3TVXO/WDT:_=97;^/!^;)[ _A:U+5[;PA\57\3:TL\.AZU
MI<<*7H@=E@E5LA)  2N1^OT)%CPC,OBOXH:SXKL(9?[&_L^/3K>>:(H+IMV]
MF4,,[1TZ4 9=I?3^&-5\)7L/BV\UB+6HV.H17EUYL9C$9=IT'_+,(1SCC''K
M70> ;K4O%.K:CXON[FZBTNZ/V?2K$R,L?DJ<&8IG&YB.I&0*Y_Q1X7T.?Q3;
M^#O">E6EA<:BGGZQ=VT85H;0-DH"/NER,8';V-8^J-I5C>^(;;Q+J&L:=J]G
M*T7A^ULI)HU6!5 @\A4^5B<?-GOUQUH ]SHK,\-/J4OA?3'UY0NI-:QFZ&,8
MDVC=D=CGJ/6M.@ HHHH *X;4O%?B/4_&-]X>\$VFFEM+C1KZ]U,N8U=QN6-5
M0@DXZG/KZ<]S7EWC9K_X>>(+OQ7X?N+.8ZV8H)]*N@^ZXG4;4:'9_%CJ#QUY
MY& "W_PLN]A\"^);W4+""TUWP\WDW%N6+PM(<"-AR#M8GIG/O6UX<D\>7%U:
MS^(6\/#3Y(]\B6<4XF!*Y !9BO7&?QKBM0\)PVWP]OW^(6M?V7?^)]1ADO9X
M82Z1,#F.'C("C;]YC@'OTSIWZW?@?QIX8ATWQ#J>J1ZQ<FVNK'4+G[1N3;GS
MDS]S:>3CB@#N_$>MP^&_#5_K%S&TL=E"TIC7@N1T'MDX&:XVS\:^*+"_\/2>
M*;#2UT_Q#(L,/V)W\VUD==R!]Q(<'ID8QSZ<WOB3XGM+3X<Z_)I[6>I20 6E
MS#O$BP&1@A\Q5.1@,3@^E<5J_AC_ (0.'P=K,/B"ZU\6MW#;6]G>2!XG608+
M0 <@@8(^]P!V&* .FO\ QMXIN6\0:AX;T[3)-)\/SR03)=LXGNFB&9=A!VKC
MG&0<U>U+QY<7EYX:T_PE%!/>ZW$E[)]J5F6UM"H)=@I!R<X'/4&J?B[P9IVG
M66N:O+X@U'2=&O ;G5;&V*;+AL -M)!92_ .#SG%<KX8BUVQU?3ELEM=,UKQ
M/ ]QYUW&9%L;*$ 16\:9&6VD$@GMS0![=17*>"_$&IZE>:UH^N_9IK[1KA(7
MN[12L4X=-RG!)VL!PPSP:ZN@#B_$/BO6V\81^%O!UG937Z6PNKNZOR_DVZ$X
M483DL?KZ>^)O"'BO4=3UC5/#_B:SM[36M+V.YM6+0W$3CY9$SR/<'ID>X&-\
M0(;GPAJ[^/M'O;.&46PL[NSO0Y2[&[*!-F2),\#C'K@9JIH^F^,[?0];\8MI
M\-SXMUF...VL0ZI':1#A1EVQD9W$$\D#WH N>.?B@_A_Q'8:)H5O%>7+74,>
MH2R*S1VRR-A5X(^<\D#L!T->C5\^:_9:SX>\&:3:7OA6\BNI-;MKFZOY[ZWD
M:\N,DX.UR1G.!G@ <FO;1KT:6B1W:1VNKR6K7"Z4]PC3' .0 I.X9&,C(H Q
M?&/C"\TS5]-\.^&(;>[U[4'#!)PS1V\(/S2R!2#CKCD?T+=<\1Z_)XMC\,^%
M(=.:]CLOMEW=7X?RD4MM5553DDD'OP/6O/M)T<:A\/M0^);>)[VT\1312W$E
MQ!,%AC*$A;=HR,%?E5<'/48[5V]MH,_C#2=$\6Q:C=^']<FTU(YYK55(>-AN
M*,C@C 8DCN,T 5Y?B=+%\/YM2DL$77TO7TI-/#%E>\5MNT'@E?XNW'&>]=WI
MOV[^S+;^UO(^W>6//^SJ1&'QSM!)./J:\'L0-./_  D6C+]KL+&^_LS19[]R
M4FNII,37TI&,C.0#QT XQ7I6CZUXATOQU!X:\2W=EJ?VVR:Z@N;2 PM$4(#*
MZ9(VG/#<<CWX .WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>9_VKJ'_ #_W7_?YO\:/[5U#_G_NO^_S?XU?UA=C'^QZG\R/3**\S_M74/\
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M9=ZN^IW&@P/<R2>8_P [A';U,8;83]171WEC;W^G36-RC&WGC,4BH[(2I&"
M5((X]#5BBM3A,O\ X1K1O^$:7P^=/A;2EB$0M6!9=HZ=><YYSUSS5?0?!F@>
M&)I9M$TY;>:90KRM(\CE1T7<Y) 'ITK<HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO77ANIX&<?8^?Z!11176> %%%% !1110 4444 %%%% !1110 4444 >(^/\
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MT2#0-*6RMW>7YB\DLA^:1SU8UI4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY)\5?^1JMO\ KR7_ -#>O6Z\D^*O_(U6W_7DO_H;UR8S^$?0</?[\O1G$T44
M5XI^C'I/PC_YB_\ VQ_]J5I>,_\ D,Q?]>X_]":LWX1_\Q?_ +8_^U*TO&?_
M "&8O^O<?^A-7JP_W9?UU/AL1_R.9^B_])1SU%%%8GHG0^#/^0S+_P!>Y_\
M0EKMJXGP9_R&9?\ KW/_ *$M=M7?0^ ^4S3_ 'E^B"BBBMSS HHHH **** "
MBBB@ HHHH **** "N;^(/_(B:A_VS_\ 1JUTE<W\0?\ D1-0_P"V?_HU:RK?
MPY>C.W ?[Y2_Q1_-'B5%%%?/GZR%?0VJ_P#(&O?^O>3_ -!-?/-?0VJ_\@:]
M_P"O>3_T$UZ."VG_ %W/D.)/XE#U?_MIYG1114FX5ZO7E%>KUUX;J>!G'V/G
M^@4445UG@!1110 4444 %%%% !1110 4444 %%%% 'B/C_\ Y'K4?K'_ .BU
MKG*Z/Q__ ,CUJ/UC_P#1:USE?/U?XDO5GZS@/]TI?X8_D@KUSX5_\BK/_P!?
MC_\ H"5Y'7KGPK_Y%6?_ *_'_P#0$K?!_P 4\SB'_<7ZHI>)O^1BNOJO_H(K
M*K5\3?\ (Q77U7_T$5E5M/XF>?AOX$/1?D%=9X(^[>_5/_9JY.NL\$?=O?JG
M_LU71_B(Y\R_W67R_-'5T445Z!\B%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY)\5?^1JMO\ KR7_ -#>O6Z\D^*O_(U6W_7DO_H;UR8S^$?0</?[\O1G$T44
M5XI^C'I/PC_YB_\ VQ_]J5I>,_\ D,Q?]>X_]":LWX1_\Q?_ +8_^U*TO&?_
M "&8O^O<?^A-7JP_W9?UU/AL1_R.9^B_])1SU%%%8GHG0^#/^0S+_P!>Y_\
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M_LU71_B(Y\R_W67R_-'5T445Z!\B%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY)\5?^1JMO\ KR7_ -#>O6Z\D^*O_(U6W_7DO_H;UR8S^$?0</?[\O1G$T44
M5XI^C'I/PC_YB_\ VQ_]J5I>,_\ D,Q?]>X_]":LWX1_\Q?_ +8_^U*TO&?_
M "&8O^O<?^A-7JP_W9?UU/AL1_R.9^B_])1SU%%%8GHG0^#/^0S+_P!>Y_\
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M_LU71_B(Y\R_W67R_-'5T445Z!\B%%%% !1110 4444 %%%% !1110 4444
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M14FX5ZO7E%>KUUX;J>!G'V/G^@4445UG@!1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DGQ5_Y&JV_
MZ\E_]#>O6Z\D^*O_ "-5M_UY+_Z&]<F,_A'T'#W^_+T9Q-%%%>*?HQZ3\(_^
M8O\ ]L?_ &I6EXS_ .0S%_U[C_T)JS?A'_S%_P#MC_[4K2\9_P#(9B_Z]Q_Z
M$U>K#_=E_74^&Q'_ ".9^B_])1SU%%%8GHG0^#/^0S+_ ->Y_P#0EKMJXGP9
M_P AF7_KW/\ Z$M=M7?0^ ^4S3_>7Z(****W/,"BBB@ HHHH **** "BBB@
MHHHH *YOX@_\B)J'_;/_ -&K725S?Q!_Y$34/^V?_HU:RK?PY>C.W ?[Y2_Q
M1_-'B5%%%?/GZR%?0VJ_\@:]_P"O>3_T$U\\U]#:K_R!KW_KWD_]!->C@MI_
MUW/D.)/XE#U?_MIYG1114FX5ZO7E%>KUUX;J>!G'V/G^@4445UG@!1110 44
M44 %%%% !1110 4444 %%%% 'B/C_P#Y'K4?K'_Z+6N<KH_'_P#R/6H_6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"/\ YB__ &Q_]J5I>,_^0S%_U[C_ -":LWX1_P#,7_[8_P#M2M+QG_R&8O\
MKW'_ *$U>K#_ '9?UU/AL1_R.9^B_P#24<]1116)Z)T/@S_D,R_]>Y_]"6NV
MKB?!G_(9E_Z]S_Z$M=M7?0^ ^4S3_>7Z(****W/,"BBB@ HHHH **** "BBB
M@ HHHH *YOX@_P#(B:A_VS_]&K725S?Q!_Y$34/^V?\ Z-6LJW\.7HSMP'^^
M4O\ %'\T>)4445\^?K(5]#:K_P @:]_Z]Y/_ $$U\\U]#:K_ ,@:]_Z]Y/\
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M* "BBB@ HHHH \1\?_\ (]:C]8__ $6M<Y71^/\ _D>M1^L?_HM:YROGZO\
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MBBB@ HHHH **** "BBB@ HHHH **** "O)/BK_R-5M_UY+_Z&]>MUY)\5?\
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MKZ&U7_D#7O\ U[R?^@FOGFOH;5?^0->_]>\G_H)KT<%M/^NY\AQ)_$H>K_\
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M0HHHH **** "BBB@ HHHH **** "BBB@#B/BK_R+%K_U^+_Z ]>2UZU\5?\
MD6+7_K\7_P! >O):\;&?Q3]&X>_W%>K"M/PU_P C5I7_ %^1?^ABLRM/PU_R
M-6E?]?D7_H8KFA\2/9Q'\&?H_P CVCQ1_P B[<_5/_0A7GU>@^*/^1=N?JG_
M *$*\^KU,1\9\/E/\!^OZ(*N:3_R&K+_ *[I_P"A"J=7-)_Y#5E_UW3_ -"%
M8QW1Z=7^'+T9Z71117J'PH4444 %%%% !1110 4444 %%%% !1110 445\_^
M(?\ D9]4_P"OR7_T,USUZWL4G:YZV69;_:$Y1YN6WE?]4?0%%?-U%<OU[^[^
M/_ /=_U7_P"GW_DO_P!L?2-%<YX _P"1%T[Z2?\ HQJZ.O0A+FBI=SY+$4O8
MUITKWY6U]S"BBBJ,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>K+8-I-P-7\O
M[%L_?>8<#'^.>F.<]*X2-O!?[I)];U.[M8FS':S"5H5QTP G3\:Z7QU9RWWA
M>2.WAFGE65'6*)-^X@]"/2H[?Q9,+=!-X9UF-P,%8[8,H^AR/Y4 ='!)'+;Q
MR0_ZMU#)QC@CCCM3Z9%)YL*2;&3>H;8XPRY['WI] !1110 45@>+_%-OX6TD
MS-B2ZERMO#G[Q]3[#O\ EWK)\"+IXTV[UA[Z/4=4F!EO)%/S1\9V '&!^A^@
MH [6BO._#7AJU\9:4^N^)'FNKB[D?RE$S*L"AL *!]#[5FW.K:E8^&]8T9KZ
M9X[#4([8WA)\Q(')ZGVVX_'% 'JU%>>S6NF^%O%FB?\ "/7&R.Z#B\B\\NCQ
M!<^:W/&.3GIQ]:O>&XF\3^))_%%TI^RPDP:;&P_A'63'J?ZGTH [2BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O)/BK_R-5M_UY+_ .AO7K=>2?%7_D:K
M;_KR7_T-ZY,9_"/H.'O]^7HSB:***\4_1CTGX1_\Q?\ [8_^U*TO&?\ R&8O
M^O<?^A-6;\(_^8O_ -L?_:E:7C/_ )#,7_7N/_0FKU8?[LOZZGPV(_Y',_1?
M^DHYZBBBL3T3H?!G_(9E_P"O<_\ H2UVU<3X,_Y#,O\ U[G_ -"6NVKOH? ?
M*9I_O+]$%%%%;GF!1110 4444 %%%% !1110 4444 %<W\0?^1$U#_MG_P"C
M5KI*YOX@_P#(B:A_VS_]&K65;^'+T9VX#_?*7^*/YH\2HHHKY\_60KZ&U7_D
M#7O_ %[R?^@FOGFOH;5?^0->_P#7O)_Z":]'!;3_ *[GR'$G\2AZO_VT\SHH
MHJ3<*]7KRBO5ZZ\-U/ SC['S_0****ZSP HHHH **** "BBB@ HHHH ****
M"BBB@#Q'Q_\ \CUJ/UC_ /1:USE='X__ .1ZU'ZQ_P#HM:YROGZO\27JS]9P
M'^Z4O\,?R05ZY\*_^15G_P"OQ_\ T!*\CKUSX5_\BK/_ -?C_P#H"5O@_P"*
M>9Q#_N+]44O$W_(Q77U7_P!!%95:OB;_ )&*Z^J_^@BLJMI_$SS\-_ AZ+\@
MKK/!'W;WZI_[-7)UUG@C[M[]4_\ 9JNC_$1SYE_NLOE^:.KHHHKT#Y$****
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M]W+).J3NEO-+]Z2('Y2?U_*NFI$18T"1J$51@*HP!2T %%%% !1110 4444
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MBMSS HHHH **** "BBB@ HHHH **** "N;^(/_(B:A_VS_\ 1JUTE<W\0?\
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M/_9JY.NL\$?=O?JG_LU71_B(Y\R_W67R_-'5T445Z!\B%%%% !1110 4444
M%%%% !1110 4444 <1\5?^18M?\ K\7_ - >O):]:^*O_(L6O_7XO_H#UY+7
MC8S^*?HW#W^XKU85I^&O^1JTK_K\B_\ 0Q696GX:_P"1JTK_ *_(O_0Q7-#X
MD>SB/X,_1_D>T>*/^1=N?JG_ *$*\^KT'Q1_R+MS]4_]"%>?5ZF(^,^'RG^
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MX''IFN@\&_\ (%D_Z[M_Z"M=!73&7-&YXU:G[*HX7O8SM?L+S5= O+#3;_\
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M6\,?QJGHOS,ZBBBO*/N3V[P!_P B+IWTD_\ 1C5RNJ?\A>\_Z[O_ .A&NJ\
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M!WN)F&6)!Z#(/X4 >@T5A^$M;GUW13/>1I'<P3/;S>7]UF7N/;D5N4 %%%%
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MB2]6?K. _P!TI?X8_D@KUSX5_P#(JS_]?C_^@)7D=>N?"O\ Y%6?_K\?_P!
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MNCTZO\.7HSTNBBBO4/A0HHHH **** "BBB@ HHHH **** "BBB@ KY_\0_\
M(SZI_P!?DO\ Z&:^@*^?_$/_ ",^J?\ 7Y+_ .AFO/QWPH^MX8_C5/1?F9U%
M%%>4?<GMW@#_ )$73OI)_P"C&KE=4_Y"]Y_UW?\ ]"-=5X _Y$73OI)_Z,:N
M5U3_ )"]Y_UW?_T(UZ\_X4/3]#X'#?[_ %_5_FRK1117.>L=OX-_Y LG_7=O
M_05KH*Y_P;_R!9/^N[?^@K705Z5+X$?&8W_>)^H4445H<@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+J^L+B9 DSV4_E^<O3#<'-;]% %/2M*M-%TZ.RT^/RX8^@)R23U)/<U<HHH
M**** "BBB@ HHHH **** .4\?^#KSQKI=KI]OK(TZVCF$MQ$UKYRW.,%58;U
M^4'G'?CTKAM8T?Q-;_%SPC;2^)+22Y-O=?9YTTH(L*!/F79YGS9' Y&/>O9*
M* /'(-1\/>&?&?BL?$JT4WE_>&2RN+FS:=;BT(PD2$*1QC!''/TJYX.\2+X
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M_0#7@%>;C)RC)<KL?9<.X:A6I3=6"EKU29TG_"P?$_\ T$__ "7B_P#B:/\
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MJ_\ VT\SHHHJ3<*]7KRBO5ZZ\-U/ SC['S_0****ZSP HHHH **** "BBB@
MHHHH **** "BBB@#Q'Q__P CUJ/UC_\ 1:USE='X_P#^1ZU'ZQ_^BUKG*^?J
M_P 27JS]9P'^Z4O\,?R05ZY\*_\ D59_^OQ__0$KR.O7/A7_ ,BK/_U^/_Z
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MI&/*X(4  =\\UY?XGT_7M$^&-\NM^&+M=0O[R&?4-6GO;=_-D\P$*%1B0O8
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M1110 4444 %%%% !1110 4444 <1\5?^18M?^OQ?_0'KR6O6OBK_ ,BQ:_\
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M')"\<ABF@E&'B<=5-:=8OAG0I=%M;EKRX6YO;R=I[B15PI8]@/2MJ@ HHHH
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M$U#_ +9_^C5K*M_#EZ,[<!_OE+_%'\T>)4445\^?K(5]#:K_ ,@:]_Z]Y/\
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M * :\ KW_P 1_P#(JZK_ ->4W_H!KP"O*QWQ(^YX8_@U/5?D%%%%>>?6GO\
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M7^)+U9^LX#_=*7^&/Y(*]<^%?_(JS_\ 7X__ * E>1UZY\*_^15G_P"OQ_\
MT!*WP?\ %/,XA_W%^J*7B;_D8KKZK_Z"*RJU?$W_ ",5U]5_]!%95;3^)GGX
M;^!#T7Y!76>"/NWOU3_V:N3KK/!'W;WZI_[-5T?XB.?,O]UE\OS1U=%%%>@?
M(A1110 4444 %%%% !1110 4444 %%%% '$?%7_D6+7_ *_%_P#0'KR6O6OB
MK_R+%K_U^+_Z ]>2UXV,_BGZ-P]_N*]6%:?AK_D:M*_Z_(O_ $,5F5I^&O\
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M&6_O$ #/Z58J&SN5O+&"ZC!59XUD4'J 1G^M34 %%%% !1110 4444 %%%%
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M!\IFG^\OT04445N>8%%%% !1110 4444 %%%% !1110 5S?Q!_Y$34/^V?\
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M705S_@W_ ) LG_7=O_05KH*]*E\"/C,;_O$_4****T.0**** "BBB@ HHHH
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M9E_Z]S_Z$M=M7?0^ ^4S3_>7Z(****W/,"BBB@ HHHH **** "BBB@ HHHH
M*YOX@_\ (B:A_P!L_P#T:M=)7-_$'_D1-0_[9_\ HU:RK?PY>C.W ?[Y2_Q1
M_-'B5%%%?/GZR%?0VJ_\@:]_Z]Y/_037SS7T-JO_ "!KW_KWD_\ 037HX+:?
M]=SY#B3^)0]7_P"VGF=%%%2;A7J]>45ZO77ANIX&<?8^?Z!11176> %%%% !
M1110 4444 %%%% !1110 4444 >(^/\ _D>M1^L?_HM:YRNC\?\ _(]:C]8_
M_1:USE?/U?XDO5GZS@/]TI?X8_D@KUSX5_\ (JS_ /7X_P#Z E>1UZY\*_\
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MY$FB22)@R.H96'0@]#3J15"*%4!5 P !P!2T %%%% '+ZM:^([#Q%_:NB?\
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MVG_7<^0XD_B4/5_^VGF=%%%2;A7J]>45ZO77ANIX&<?8^?Z!11176> %%%%
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M] >O):]:^*O_ "+%K_U^+_Z ]>2UXV,_BGZ-P]_N*]6%:?AK_D:M*_Z_(O\
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MW8YQGMFGT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!F^(_^15U7_KRF_P#0#7@%>_\ B/\ Y%75?^O*;_T UX!7E8[X
MD?<\,?P:GJOR"BBBO//K3W_PY_R*NE?]>4/_ * *\ZKT7PY_R*NE?]>4/_H
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MS+_U[G_T):[:N^A\!\IFG^\OT04445N>8%%%% !1110 4444 %%%% !1110
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MR N. ?Y?-1X\\2^7K4&@-?MIEI)&)+N[1&9MIS\BA03SC]?K6CX9U3PB]O\
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M:N5U3_D+WG_7=_\ T(UU7@#_ )$73OI)_P"C&KE=4_Y"]Y_UW?\ ]"->O/\
MA0]/T/@<-_O]?U?YLJT445SGK';^#?\ D"R?]=V_]!6N@KG_  ;_ ,@63_KN
MW_H*UT%>E2^!'QF-_P!XGZA1116AR!1110 4444 %%%% !1110 4444 %>:_
M%S[VD_2;_P!DKTJO-?BY][2?I-_[)7-BOX+_ *ZGM9%_R,*?S_\ 26><4445
MX9^F'2_#W_D>K#Z2?^BVKTOQG_R"(?\ KN/_ $%J\T^'O_(]6'TD_P#1;5Z7
MXS_Y!$/_ %W'_H+5Z>'_ ($O7_(^+S?_ )&E+T7YR.)HHHK,["YI/_(:LO\
MKNG_ *$*]+KS32?^0U9?]=T_]"%>EUVX?9GSF<?Q(^@4445TGB!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<0Z?%.K.4#*UN01N!!'YT :-O\7-"GEMY'L-8M]-N91#!JT]D5M9&)P/GSD
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M_P#0!7G5>B^'/^15TK_KRA_] %>=5[%;X8GY]EW\:MZ_JPHHHKF/9/3-*_Y
MUE_U[Q_^@BK=5-*_Y UE_P!>\?\ Z"*MUZL=D?"U?XDO4****9F%%%% !111
M0 4444 %<5X@_P"0[<?\!_\ 017:UQ7B#_D.W'_ ?_010!FT444 =)X2_P"7
MO_@'_LU</\5?^1JMO^O)?_0WKN/"7_+W_P  _P#9JX?XJ_\ (U6W_7DO_H;U
MR8S^$?0</?[\O1G$T445XI^C'I/PC_YB_P#VQ_\ :E:7C/\ Y#,7_7N/_0FK
M-^$?_,7_ .V/_M2M+QG_ ,AF+_KW'_H35ZL/]V7]=3X;$?\ (YGZ+_TE'/44
M45B>B=#X,_Y#,O\ U[G_ -"6NVKB?!G_ "&9?^O<_P#H2UVU=]#X#Y3-/]Y?
MH@HHHK<\P**** "BBB@"O?:?9ZG:FVU*T@O("0QBN(A(I(.0<$8X-6*** *D
M>E:=$EVL5A:HMZS-=!85 G)&"7X^8D<'.:3^Q],_LH:9_9UI]@"[1:>0OE 9
MSC9C&,^U7*S?$'_("N/^ _\ H0H GT[2=.TB P:386MC$3DQVT*QJ3ZX4"G'
M3K(ZD-1-G;F]6/RA<F)?,"9SMW8SC/..E<#10!W%_H6D:K/'-JFEV5[+%_JW
MN+=)&3Z%@<5D_$ !? >H!0  (@ .W[U*QM._Y"EK_P!=D_\ 0A6U\0?^1$U#
M_MG_ .C5K*M_#EZ,[<!_OE+_ !1_-'B5%%%?/GZR%?0VJ_\ (&O?^O>3_P!!
M-?/-?0VJ_P#(&O?^O>3_ -!->C@MI_UW/D.)/XE#U?\ [:>9T445)N%>KUY1
M7J]=>&ZG@9Q]CY_H%%%%=9X 4444 %%%% !7)_\ " VD^O>*[W4;C[3:^)(8
M(9;7R]IA$<>SA\\D]>@Q[UUE% 'G+_##5KS2XM"U?QI>7OAZ,H#9&SC261%(
M*HTP.2.!VKHI?"UW+XQ35?[<N1I2V9M6T7;^X?((W'G'?TSQUQQ7244 ><CX
M7ZK:Z5-H.E^-+RU\/3;D^PFT225(VSNC68G(')'2NVM=)32_#L>E:*ZVBV]N
M(+9W3S!'A<*Q&1N]>HS6A10!Q5M\,]/B\!OX=FNYGN)9OM<NI(NV5KK=N\[O
MSD#C)XXS5G2?!U_%XCM];\2Z^^M7=E"\-F!:);I"'P';:I.6( !/'TKK** /
M$?'_ /R/6H_6/_T6M<Y71^/_ /D>M1^L?_HM:YROGZO\27JS]9P'^Z4O\,?R
M05ZY\*_^15G_ .OQ_P#T!*\CKUSX5_\ (JS_ /7X_P#Z E;X/^*>9Q#_ +B_
M5%+Q-_R,5U]5_P#01656KXF_Y&*Z^J_^@BLJMI_$SS\-_ AZ+\@KK/!'W;WZ
MI_[-7)UUG@C[M[]4_P#9JNC_ !$<^9?[K+Y?FCJZ***] ^1"BBB@ HHHH **
M** "BBB@#$\5?\@R+_KL/Y&N3KK/%7_(,B_Z[#^1KDZ "M/P_P#\AR#_ (%_
MZ":S*T_#_P#R'(/^!?\ H)H 9\5?^18M?^OQ?_0'KR6O6OBK_P BQ:_]?B_^
M@/7DM>-C/XI^C</?[BO5A6GX:_Y&K2O^OR+_ -#%9E:?AK_D:M*_Z_(O_0Q7
M-#XD>SB/X,_1_D>T>*/^1=N?JG_H0KSZO0?%'_(NW/U3_P!"%>?5ZF(^,^'R
MG^ _7]$%7-)_Y#5E_P!=T_\ 0A5.KFD_\AJR_P"NZ?\ H0K&.Z/3J_PY>C/2
MZ***]0^%"BBB@ HHHH **** /-X+./4?C9XJLIRZQ7.APPN8VVL%;(.#V//6
MLWQQ#I#>%X?A=X1MA=ZC)Y2B- &%BBN&,LK=FP#[G/OST\WA;68_&WB'7].N
M+2-K_25M;+>S9CG4'#.-N N<=,GVKGO"7A/X@^#]+-II]OX2EED<R3W<TUR9
MIV)SEVV<T >GQ*T%FBNS2M'& 6ZER!_,UY#X-UOQ/X'\$W%[K?@VY^Q_:YKR
M^G%TBS(&;)<0D98 8YR#WQCFN\ETWQ9=>*(Y)]5M(= DL#%<6MNI683E2"Z2
M8R,'H<_AGFN:G\(?$.X\/S^&)_$.F7&E3*T+ZE.DK7S0MG*D?=)P<9STH GO
M6OM/\>?\)AI>C3^(=,U;2HHHFM"GF0$$LO#D?(X8$D=.>/7@K,+'#%H'B:2.
MRT/1[IM2UB&,^8HGE<M#9(%^_C() !YSZ5[:NG7&D>$ETSPZ(?M%K:""S^TL
M0@*KM4L0"<<9X%<BGPSFM_ ME86E]&-=M;]-6>]F4NEQ=@DDN."5.2/7H>M
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M[F>C9SG% 'T+7%7_ ,5-#L;N\7[+J=S96$_V>\U*VM=]M;OP"&;.>"<' /\
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MGZ,>D_"/_F+_ /;'_P!J5I>,_P#D,Q?]>X_]":LWX1_\Q?\ [8_^U*TO&?\
MR&8O^O<?^A-7JP_W9?UU/AL1_P CF?HO_24<]1116)Z)T/@S_D,R_P#7N?\
MT):[:N)\&?\ (9E_Z]S_ .A+7;5WT/@/E,T_WE^B"BBBMSS HHHH **** "B
MBB@ K-\0?\@*X_X#_P"A"M*LWQ!_R KC_@/_ *$* .*HHHH LZ=_R%+7_KLG
M_H0K:^(/_(B:A_VS_P#1JUBZ=_R%+7_KLG_H0K:^(/\ R(FH?]L__1JUE6_A
MR]&=N _WRE_BC^:/$J***^?/UD*^AM5_Y U[_P!>\G_H)KYYKZ&U7_D#7O\
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M8_R%<E76^%O^05)_UV/\A0!Y7X__ .1ZU'ZQ_P#HM:YRNC\?_P#(]:C]8_\
MT6M<Y7S]7^)+U9^LX#_=*7^&/Y(*]<^%?_(JS_\ 7X__ * E>1UZY\*_^15G
M_P"OQ_\ T!*WP?\ %/,XA_W%^J*7B;_D8KKZK_Z"*RJU?$W_ ",5U]5_]!%9
M5;3^)GGX;^!#T7Y!76>"/NWOU3_V:N3KK/!'W;WZI_[-5T?XB.?,O]UE\OS1
MU=%%%>@?(A1110 45S&M:WXLLM4D@T7PA%JEHH!2Y;5D@+$CD;"A(P>.M0^
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M -!-<#7?:C_R"[K_ *XO_P"@FN!H **** .U\1_\BKJO_7E-_P"@&O *]_\
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M &I6EXS_ .0S%_U[C_T)J]6'^[+^NI\-B/\ D<S]%_Z2CGJ***Q/1.A\&?\
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M_"UM#_Y]=0_[]I_\775:/JL&MZ3#J%JLB139VK( &&&(YP3Z5\]5[?\ #_\
MY$73OI)_Z,:@#$U#_D)W7_79_P"9JM5G4/\ D)W7_79_YFJU !76^%O^05)_
MUV/\A7)5UOA;_D%2?]=C_(4 >5^/_P#D>M1^L?\ Z+6N<KH_'_\ R/6H_6/_
M -%K7.5\_5_B2]6?K. _W2E_AC^2"O7/A7_R*L__ %^/_P"@)7D=>N?"O_D5
M9_\ K\?_ - 2M\'_ !3S.(?]Q?JBEXF_Y&*Z^J_^@BLJM7Q-_P C%=?5?_01
M656T_B9Y^&_@0]%^05UG@C[M[]4_]FKDZZSP1]V]^J?^S5='^(CGS+_=9?+\
MT=71117H'R(4444 <I\1O$<_A_PJZZ9\VK:C(MEIZ#J97XW?\!&6S[#UK1\(
M^'(/"GA6QT>VY^SQ_O'_ .>DAY9C]231?>%[+4O%>G:]>2W$D^FQNEM;EE\E
M&?[TF,9W8P,YQ@=*9XO\(V'C715TO59;J*!9TG#6LNQBRYP#D$$<],>AZ@4
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M.,]J -KQ2<Z7$1R/.'_H)KDZZSQ5_P @R+_KL/Y&N3H *T_#_P#R'(/^!?\
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M<@A<9X[ DXJ_XMZVG_ _Z4 <Y1110!M^%?\ D)R_]<3_ #%8/Q<^]I/TF_\
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M76^%O^05)_UV/\A7)5UOA;_D%2?]=C_(4 >5^/\ _D>M1^L?_HM:YRNC\?\
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M2/9Q'\&?H_R/:/%'_(NW/U3_ -"%>?5Z#XH_Y%VY^J?^A"O/J]3$?&?#Y3_
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M>(/^0[<?\!_]!%-^%/\ R*MS_P!?K?\ H"4[Q!_R';C_ (#_ .@B@#-HHHH
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M>W>(/^0%<?\  ?\ T(4 <51110!9T[_D*6O_ %V3_P!"%;7Q!_Y$34/^V?\
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MM\+?\@J3_KL?Y"N2KK?"W_(*D_Z['^0H \K\?_\ (]:C]8__ $6M<Y71^/\
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M73OI)_Z,:N5U3_D+WG_7=_\ T(UU7@#_ )$73OI)_P"C&KE=4_Y"]Y_UW?\
M]"->O/\ A0]/T/@<-_O]?U?YLJT445SGK';^#?\ D"R?]=V_]!6N@KG_  ;_
M ,@63_KNW_H*UT%>E2^!'QF-_P!XGZA1116AR!1110 5Y'\5/^1K@_Z\T_\
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M'_"I9_\ H+Q_]^#_ /%5Q_5:W;\CZ'^W,O\ ^?GX2_R.[\.?\BKI7_7E#_Z
M*\ZKTG3;6?3]*M+/$<GV>%(M^\C=M4#.,<=*YW_A"I_^?R/_ +X->C4IRE&*
M1\?@L51I5*DINR;TW\SF**Z?_A"I_P#G\C_[X-'_  A4_P#S^1_]\&L?8U.Q
MZ7]HX7^;\'_D=+I7_(&LO^O>/_T$5;JK:13VMG#!MC;RHU3=O(S@8STJ7=/_
M ,\X_P#OX?\ XFN]:(^4J-.;:):*BW3_ //./_OX?_B:-T__ #SC_P"_A_\
MB:9!+146Z?\ YYQ_]_#_ /$T;I_^><?_ '\/_P 30!+7B/Q"_P"1[U#_ +9?
M^BEKVG=/_P \X_\ OX?_ (FN)\0_#N?7M>N-2_M".#SMO[ORRVW"A>N1Z>E
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MN--W1P>=M_>9+;<,&Z8'IZU%1.4&EV.K!U(T\33G/923?R9X+17HG_"I9_\
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M54J<XS3:,<;C:%6A*$)7;MT?<VJ*BW3_ //./_OX?_B:-T__ #SC_P"_A_\
MB:[#YPEHJ+=/_P \X_\ OX?_ (FC=/\ \\X_^_A_^)H EHJ+=/\ \\X_^_A_
M^)HW3_\ /./_ +^'_P")H \Z^+GWM)^DW_LE>;U[1XN\)3^*C:'[3':?9M_\
M)?=NV_3'W:YO_A4D_P#T%X_^_!_^*H \[KIOAY_R/5A])/\ T6U;W_"I)_\
MH+Q_]^#_ /%5I^'OAY/H.NP:C_:$=QY.[]WY97.5*]<GU]* .@\5?\@R+_KL
M/Y&N3KM=5L)]3M5AS'%M?=G<3V(]/>LG_A%)_P#GYC_(T 8%:?A__D.0?\"_
M]!-7/^$4G_Y^8_R-6=/\/SV%]'<>;')LS\O(SD8Z_C0!C_%7_D6+7_K\7_T!
MZ\EKW'Q7X>G\3Z7%9^=':^7,)=_+YPI&,<>M<E_PJ6?_ *"\?_?@_P#Q5>9B
M:%2=2\4?:Y/FF$PV$5.K.SN^C_1'G=:?AK_D:M*_Z_(O_0Q78_\ "I9_^@O'
M_P!^#_\ %5:TSX8SZ=JMI>_VG')]GF279Y)&[:0<9SQTK".%K*2=OR/2K9W@
M)4I1535I])?Y'6^*/^1=N?JG_H0KSZO1]4LY]2TZ2U_=Q>9CYMQ.,$'ICVKG
M_P#A"I_^?R/_ +X->A6IRE*Z1\KEV+HT:3C4E9W\_(YBKFD_\AJR_P"NZ?\
MH0K;_P"$*G_Y_(_^^#4UIX1GM;V&X^U1OY4BOMVD9P<XK)49WV.ZIF&&<&E+
MIV?^1U5%1;I_^><?_?P__$T;I_\ GG'_ -_#_P#$UWGRA+146Z?_ )YQ_P#?
MP_\ Q-&Z?_GG'_W\/_Q- $M%1;I_^><?_?P__$T;I_\ GG'_ -_#_P#$T 2-
M]T_2OFZOHTF<@CRX_P#OX?\ "O-O^%23_P#07C_[\'_XJ@#SNBO1/^%23_\
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M_P"?GX2_R,#X>_\ (]6'TD_]%M7I?C/_ )!$/_7<?^@M6-X>^'D^@Z[!J/\
M:$=QY.[]WY97.5*]<GU]*Z76M,GU>S2#='#MD#[LEL\$8Z#UKNHTIQI.+6I\
MQF6.P]?'TZU.5XI*[L^[\CSVBNG_ .$*G_Y_(_\ O@T?\(5/_P _D?\ WP:C
MV-3L=/\ :.%_F_!_Y&)I/_(:LO\ KNG_ *$*]+KE;3PC/:WL-Q]JC?RI%?;M
M(S@YQ72[I_\ GG'_ -_#_P#$UTT82BG<\7,L13KSBZ;O9$M%1;I_^><?_?P_
M_$T;I_\ GG'_ -_#_P#$UN>62T4BEBOS@ ^@.:6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y>Z\ :9-=SS6MUJ&GK<'=-#9W&R.0]\K@UN:5I-GHN
MGI9:="(H4YQG))[DGN:N44 94'AZUA\1SZV\DTUW+&(U\Q@5B4=D  Q^.:J:
MEX-L-0U&:]CNKZPFN%"W'V.?RQ..GS#!SQ7044 5=,TVUTC3HK&PC\N"(849
MR3ZDGN:M444 %%%% !1110 4444 %%%% !1110 444$X&3P* "BL./QGX?FO
M5M8]3C,C/Y:G:VQF] ^-I/XUN4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !163J/B?2M)N_LU]/(DNT-A;:1Q@^ZJ14FD>(--U
MWS_[+N&F-N0)0T3H5)SC[P'H: -*BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HK,N?$6EVFKQ:7<7)2\F8*D?E.02>@W 8'YU<O;
MVWTZREN[V588(5W.[= * )Z*@L;VWU&QBO+*3S()EW(^TC(^AYJ>@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJEJFLZ?HMNLVIW*P(
M[;4R"2Q] !DG\*;IFN:;K-O)-IUVDR1'$F05*'W# $?C0!?HK#A\9^'[B\2V
MBU.,R.^Q"48(S>@<C:?SK<H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***PT\:>'I+T6J:G$9"_EAMK;"WH'QM/YT ;E%9VJ>(-+T5H
MUU*[6%Y<[(PK.S8]%4$U-INJV.L6GVG3+E+B+.TLO8^A!Y!^M %NBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFR2)#$\DC;412S$]@.M
M9=EXGT?4+6ZN;:]'DVG^O>1&C$?UW 4 :U%9&F^*M%U>[^RZ??+),5W*C(R%
MQZKN W?A2:CXKT32KMK:^OU291ET5&<H/5MH./QH V**BMKF"\M8[BTE2:&1
M=R.AR&%2T %%%% !1110 4444 %%%% !1110 4444 %%%-DD2&)Y)&VHBEF)
M[ =: '45E67B;2-0L[RZM+HO#9*6N&:)U\L $]" 3P#TJ/3O%FCZK=QVUC<R
M22R E ;:500!GJR@=/>@#9HK'U'Q7HFE7;6U]?JDRC+HJ,Y0>K;0<?C6G;7,
M%Y:QW%I*DT,B[D=#D,* ):*I2ZQ8P7TMG)/B>* W$B!&.R,=R0,#Z=:R(_B!
MX:E91'J#,6.%_P!%EY_\=H Z2BBB@ HK.UK6[;0K:&>[25UFG6!1$ 2&;."<
MD<<5HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK2-R<_3I4FK:%_;&IZ=-<7.+2RD,QM?+SYLF/E).>@],>M:] !1110 4444
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MN[V\;,QZDE1DUSI\%7DVGQ:7>Z_//I,97_1O(579%.0ADSD@8':NL1%CC5$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M].36I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)PRHI!"\=>>^*W:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7-!LO$-@+34%;:K;U=#AD/J#^- &E165H7A^#0(I4M[FZN/-()-S('(P, #
M'%:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %5YM/LKBZCN;BS@EGBQY
M<KQ*S)@Y&"1D<U8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***S?$.K_V#H-QJ7D>?Y.W]WOV[LL%ZX/KZ4 :5%>;?\+=
M_P"H)_Y-_P#V%=E=:@]WX)FU&(- \VGM.H5^8R8]PP>.GK0!KT5YD1?:9X#L
M_$L.OZDU[MC;R+FY,D4Q+8*;3[<_@:VM$O(H?&_BJ\NR((EAM))"Y^X/)R<_
M2@#LZ*Y.?XAZ=;6'VZ;3M56T;_57!M@$E_W26_GCI6C?>*K*REMH$@N[NZN8
MA,EM:Q;Y A_B/( 'XT ;=%8<'B_2I=+N[Z9I;463;;B&XC*R1L>@*]R>V*99
M^+[.YOK>UN+*_L&NO^/=[N#8LQZX!!//UQ0!OT5Y]X<\01Z7J'B.W%A?WLO]
MK7$K+9P;]BYQDDD>AXZ\5UB>)=*?P\=:%R/L2C+,5.5.<;2.N<\8H U:*Y^U
M\86<]Y;6]S9:A8&[.VWDNX-B2GL 03S]<4>.KF>T\$ZC/:3203(J[9(G*LOS
MJ.".: .@HKE_$NL3Z=X,@^R.QU"^2.WMR&^8NXY;/J!DY]<4>"-0NY+.\TC5
MIFFU#2YS%)([$M(AR5;)Y.>?P H ZBBBB@ HHHH **** "BBLW5M6_LOR?W/
MF^9N_CVXQCV/K0!I45@6WB?[1=10_9-OF.$SYN<9./2H_']U<67@;4)[.>2W
MF3R]LD3E67,B@X(YZ&@#HZ*X:]BNO"^K:*]IK-_>B^N5@FM+R?SMR'JZYZ8_
MJ*/!^J6FC>&=8O=0E\N&/5)^V2Q.W  [DT =S17,-X[LHKBTAN]-U2UDO)4B
MA$]N%W;CC=G=C R,]^>E6K[Q9:6NHRV-M9WVHW$ !F6R@W^5GG!)(&?89H W
M:*PG\8:0NBPZFLLDD<[^5'"D9,K2=TV^H_+]*?IOBBSO[Z2RF@NM/NDC\WR;
MV,1ED[L""00/K0!M45S/_">:;Y9N%M-1;3U?:;];8F$<XSG.<>^*Z2.1)8UD
MB8.C@,K Y!!Z&@!U%><:?+-K6IZA#JGB>]TG5TNF2"T679&J@_+A#P^?KG^=
M=%XPU*ZTSP]%9V<S/J=^ZVL$B_*Q8\,_'3CTZ$B@#I:*YGP1J5S<Z7<:=JDC
M2:AID[6\[.26<9^5B3UR,_E734 %%%% !1110 4444 %%<WXN\7?\(K]C_T+
M[5]IW_\ +79MV[?]DY^]^E8FF_%'^T-5M+/^R/+^T3)%O^TYV[F SC9SUK&5
M>G&7*WJ>E2RO%UJ/MJ<+QUUNNGS._HHKE8K^:/XFWT$UU(MG%I@E\MI#Y:G<
M,MCH#CO6QYIU5%<P/'NFF-;AK34$L&?8+]K?$/7&<YSCWQ6M;:W;76O7>DQ)
M+Y]I&DCN0-A##(P<Y[^E &C17.MXTT]=%N-4^SW9MK:[-K*0BY4@@;OO?=R1
MSUYZ5?U37K72FL4D62>2^F$4"0 ,6S_%R0,#CGWH TZ*YJ;QSI\;3O#::A<V
MMLY2:\@@W1(1UYSD@>P-6[_Q7I]D+,1">^EO4$EO#:1[W=/[V,C ^M &U7.>
M+-.LITL9I[.WDE:_MHVD>)2Q0R %<D=.3Q4VD>+++6-8FTR&VO(+J"+S94N(
M@FSD#:><YY!]/>FQ^)=,U#PQ-K;VLKVMJY<I)&I<,AZ@9QG/0YH R-<LUL/$
MEO<:9 D(TRQ-RL,*A RB7]XH Z95F_&G0S_VIXRTW5T8M;R336]KQ@&-(FRP
M_P!YB?P45U5H]MJ%O!J,<"YN(%*LZ#>$8!MI/].E/CLK6)81%;0H+?/DA8P/
M+R,';Z<>E $]%<O\0KNYLO"3S6=Q+;R^?&-\3E6P6Y&15[Q;K!T3PU<W,1_T
MEQY-N!U,C<#\NOX4 ;5%<CX&O[^,WN@Z[,\U_8L'$DC%F>-QD')Y."?U [5U
MU !1110 4444 %%%% !163KFN?V-Y'^C^=YV[^/;C&/8^M9]IXP^U7D,'V';
MYLBIN\[.,G&?NUFZD4[-G7#!UZD/:1CIZHZ:BBN5BOYH_B;?0374BV<6F"7R
MVD/EJ=PRV.@..]:'(=517,#Q[IIC6X:TU!+!GV"_:WQ#UQG.<X]\5K6VMVUU
MKUWI,22^?:1I([D#80PR,'.>_I0!HT5SK>--/71;C5/L]V;:VNS:RD(N5((&
M[[WW<D<]>>E7]4UZUTIK%)%DGDOIA% D #%L_P 7) P..?>@#3HKFIO'.GQM
M.\-IJ%S:VSE)KR"#=$A'7G.2![ U;O\ Q7I]D+,1">^EO4$EO#:1[W=/[V,C
M ^M &U7-^*=,L9IM-FFLK>2634(8W=XE+.O/RDXY'M4^D>+++6-8FTR&VO(+
MJ"+S94N(@FSD#:><YY!]/>FQ^)=,U#PS+KC6LKVUH[/LDC4N&0XRHSC/H<T
M9&KQ1Z3XM2^LHEAATVRA=XHD 'DM+(K@ << [O\ @-/L7:^\96&KL3MO!<I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ev002grapha01.jpg
<TEXT>
begin 644 ev002grapha01.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,W
M,P  DI(  @    ,W,P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6A"%/$X=6C-;=F34445U'AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3/\ RSB'4G\R?J<5[/&BQ1K&@PJ@*H] *R/#GABQ\-V9CM1YD[C][.P^9_\
M >U;-.A2<$Y2W8LSQM/$2C2HJU."LO\ ,****Z#R HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y[QW_R(^H_[J?^AK7+_"F>&&WU/SI4CRT>-[ 9X:NU
M\2Z9-K/AR[L+5HTEF50K2$A1A@>< ^E><?\ "JM<_P"?K3_^_C__ !%<-935
M93BKV1]-ET\-/+ZF&K5%!RE?\O\ (]4^W6G_ #]0_P#?P4JWEJS!5N82Q. !
M(.:\J_X55KG_ #]:?_W\?_XBKFD_#76+#6K*[FN;%H[>XCE8+(^2%8$X^7KQ
M5*M6O\!C/+L HMK$IOT_X)Z?3)X8[FWD@F7='*A1U/<$8(I]%=AX";3NCPDR
M7G@WQ5<+ <36Y>-2P^\K#@_D0:W/AEI!OM>DU*<;H[-<@MSF1L@?D,G\JZ7Q
MKX'N/$.H07FFRV\4H39*)B1NQT(P#SR1^5;?A30?^$=T&.S<HTY8O,Z$D,Q]
M,X[8'X5YM/#R56S^%:GV.+S:C4P%X/\ >S23[];_ *V]3:HHHKTCXT**** .
M#^*.C27>FV^I0)N-J2LN.NP]#^!_G4G@3QA97.D0Z;J%PD%W;KY:&5L"11TP
M3W XQ7;NBR1LDBAD8896&01Z5P&M?"V"XF:;1KH6VXY\B4$H/H>H_6N2I3G"
MI[2GKW1]!A<5AJ^%6#Q;Y;.\9=O)_P!?D=Q=7]I96_GW=S##%C(=W !'MZUY
M%XIU=_&?BBWMM+1GB4^3;@\;B3RQ]!_05>B^%&K&3$]]9HF>J%V/Y%1_.NW\
M-^#]/\-J7AW3W3##3R#G'H!V%1)5:_NM61T49X#++U:=3VE2VFEDOZ]38T^S
M33]-MK.+E+>)8P<8S@8S7DOB2"Y\)>/O[0AC_=O-]IBQP&!/S+[=2/I7L59^
MLZ)8Z]8FUU&+>F<JP.&0^H-;5J7/%*.ZV/,R['K#5Y2JJ\9:2^8S1_$.FZY;
M)+87*,S#F$L ZGT*U#KWBG3=!LY'GN(Y)P"$MT8%V;TQV'N:X>]^$]ZLI_L[
M4+>2/MYX9"/R!J33OA1.9@=6U"-8QU2V!);VRP&/R-9>TQ%N7DU[G=]3RI2]
MHZ]X]K:^G](H^ -/N-;\72:O=#<D#-,[GHTC9P/US^%>EZ]JJ:)H=SJ#@-Y*
M?*I/WF)P!^9%3:;IMII-BEG80B*%.@'4GU)[GWK,\8:)=>(-!-C9211R&57S
M*Q"X&?0&M(4Y4J32U?ZG-B,73QV.C*I[M-67R/-?#6BW'C;Q%/<:E,[1(1)<
M2=VST0>G0_0"O8;2SM["U2VLX4AAC&%1!@"O*O\ A56N?\_6G_\ ?Q__ (BC
M_A56N?\ /UI__?Q__B*YJ/M*2^"[[GLYA'"8V2_VE1BMHVT7XH];HKR3_A56
MN?\ /UI__?Q__B*]0TFT>PT6RM)BK26]O'$Q4\$JH!Q[<5V4ZDYOWHV/GL9A
M</0BG1K*=_*UOQ9;HHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH Y_P 8:!:ZWI$KWLD^VUB>5(XWVJ6"
M\$C'-8?@&^72_A?-?.,BW,TF#WQSC\:[#6/^0'?_ /7M)_Z":\^T $_!+4,
MGY9CQ]: )- \(GQEIPUOQ1?7,SW3,888WVK&N<<#G'0\"K>@O>^%?'(\-7%Y
M+=Z?=PF6T:9LM&1DX_\ '6&/H>*W/ 1SX$TO'_/(_P#H1K&USGXR:!CM:L3[
M<24 4UM9_B#XJU.*\O9H='TV3R5@@;'FMDC)_(G/N*CU;2Y/AQ>66J:-=W#Z
M9).(KJTE?(YR<C\ >>Q^N*O?#0%;[Q&IX87W(/;EJE^+7/@Z(#J;Q !Z_*U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!6U*%[C2KN&%=TDD#HHSC)*D"N>\%:#<V'@IM*UJW\IY&
MD62/>&RK<=5)'2NJHH \_P!/TSQEX1233]'M[75M.WEH/-D"-$"<XY(^I'-:
M'AOPUJA\0S>(O$\D1OG3RX88CE8EZ?RX[]3S7844 </?^'M>T/Q+=:SX3\FY
MCOCNN;*9MNYNN020.I)Z\9/45"V@>)/%>K6DWBJ*WL=/M'\Q;6%PQD;W()_G
M^%=]10 5Q<N@:GKWCU;_ %JV\G2M/_X](FD5O-;/WB 3CGGGT ]:[2B@#E/%
M&@ZI)KECX@\/&)KZT0Q/!,<+*ASQG_@1_/VJDNC^(O$OB#3[SQ':P:?9Z>_F
MQP1R!V=^#DD$^@KN** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "D=UCC9Y&"(H)9F. !ZFEKR[XRRO=WWA/0+NX>VT?5M1\
MN_D5MNX*4VH3Z'<?R![4 =_IWB/1-7N'@TG6-/OIHQEX[:Z21E'N%)(K2KQO
MXL>#?#OA'P;'X@\-6T>BZOI]S%]CEM<JTK%@"AY^;Y<MSS\I]37?^(_&=MX4
M\&)K6LQE;B2)!':)]Z69ER(U_'OV H VY=4T^WU*#3Y[ZVBO;@%H;9YE$DH&
M<E5)R<8/3TJU7S[HNF:[#\<O">L>+)RVIZQ'<7#V^,"U01.$C'T'\_7)/T%0
M 52AUG3+C4IM.M]1M);Z 9EM4G5I8_\ >0'(ZCK7%?%CXE0^!M%^S6+H^M7B
MD6Z'D0KT,K#T'8=S[ U5^%$&AVO@F]G\,:I#K6M3*TU]<G(D><@E00P#!<YQ
MGKR: .[N/$.BV>H)87>KV$%XYPMO+<HLC?12<FM$G R>!7A7@W0?!FL?!O4=
M7\2"VN-3D%P^HWMR0;B";+;<,>5. I '7/>B'Q5K>H_"GPOX1L97?Q%K\31-
M,S$M!:!V'FL>O* #Z!CUQ0![5IVJZ?J]N;C2;^VOH0Q4R6TRR*&';*DC-6ZS
M/#F@6?ACP]::/IJ;8+6,*#CESW8^Y.36G0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!S/C/QQ9>#;>U66WGO]0OI/+L["V&9)F[_ $ R
M.??I6'IGQ1N8]>L]*\9^%[OPU)J#;+.>28312/\ W2P P<D#OU&<51^)$%WH
M7Q \.>-Q8S:AING1R6]Y' F]X P($@'_  +K_LCUK"\9>+=+^*]_HGA;P89;
MN07J7=S>F%D6VC0$$C< <_-UQCH.] '<>-_'UWX7UW2-&TC06UO4-465D@6Z
M$)4( >ZG.1N]/NU8\+^)_$^L:J]MKW@N70K81%UN7OEF#." $VA1C().?:N2
M\5Z=XRN/C=9ZIX;TB":.STXP075\66V5FW%F8KR3\^,#_&MOP_XXUV'QLGA+
MQUIMG::A<PM-97=@[&"X"YR &Y!P">?3H.,@'?UYS<_%6\O]4O+3P1X3O/$<
M5C(8I[M)Q!#O'4*Q4[OT]>F#7<:W(T7A_4)(V*NEK(RD=B$-<5\"HDC^$&EL
MBA6DDG9R/XCYSC/Y #\* -GPE\0--\4V%_(T,^F7>F$B_L[Q=LEO@$Y/MP>?
M8\5S9^,%X]A+KEIX-U&X\,Q.0VJ"=%8J#@N(2,E>.N>.^*S;K3!J?Q\\4Z3&
M_DKJGAEHI&']YMB!OJ :KVFK>*]+^'4G@1O!6I3:JMN]A'=QQ@V3QME?,,G0
M'!Z=_;.* /2=9\9:3H_@E_%#S":P^SK-"5.#-N'R*,]R2![=^E6O#.JWNM^'
M+34M2TW^S)KI/,^RF7S"BG[N3M7DC!QCBO$K4V=U+8Z;KMXH\)>!8D^W3<LE
MY>Y^XHQ\P!) 'L?[PKTK1?BMH6JZQ:Z9-9:KI$M[Q9-J5GY*77IL;)S[9QV'
M7B@#N**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L/QAHVA:WX9NH/%21_P!G1*9I)';;Y.T??#=B.:W*S/$'AW3/
M%&EG3=<MWN+1F#-$LSQAB.F2C D>QXH \;^&O@G_ (2WQ#_PDFI7.IW?AS3Y
M2NC6^IW!E:3:<!^< *". !U^G/1^*? _CC5_B/%XALYO#]U9V(QIUIJ3SE83
M@9<JBXWY&<Y/0>@QZ?:VL%C9Q6MG$D,$*!(XT&%10,  5+0!X+XA_P"%@?\
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M><YVD<=:]9KR*V@UCXO^(=-U6^LGTOPCIL_VFUCF'[Z^D'1B.R_T)ZYR/7:
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M?PM8N=IN93D&4\=3AB3C/;^$4 >X^&+?5[7PW9Q^([[[=J9CW7$OEH@W'G:
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MKTW1O'^FZ9'%J[&.SO=+D<HLH&?+</DY.<9'<CKR0 >AT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*[&B@#@_$_@C5?&?C*R;7;BU7PM8$2I8Q2.9+F7UD&T #M@$\?4X[M55%"H
MJJ,  8 %+10!R?Q#\/ZWXI\/IHNB7=M9V]U*%OYI68/Y.1E4 4Y)]R.F.])X
MC^'UAK/@6W\.:?(=.%@8Y+"9!DP21_=;WZG/U-=;10!YJW@GQCXFU#3%\>ZO
MI<NF:;.MP(--B<-=2+]UI"P '7HO'M7I5%% !1110 4444 %%%% !1110 44
M44 %%%% 'D'CG6M5M/&=]!::G>01+Y>V.*X95&8U/ !]:Y__ (2/7/\ H,ZA
M_P"!3_XUI?$'_D>]0_[9_P#HI:YNO!JRE[26O5GZG@:%)X2DW%?#'IY(TO\
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M 9EA;#2MQD?F<<\#%5M>\-R> [:/7?#-W<+'!(HN;:5]R2*3CG&.^!^.1C%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"$ST__ )XW7_?"_P#Q5;%A>QZA91W4(94DS@.,'@D?TKS"O0?#'_(N6O\
MP/\ ]#-;4:DIRLS@S#!TJ%)2AO?_ #-:BBBND\0**** "BBB@ HHHH ****
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M@_\ (]ZA_P!L_P#T4M<W72?$'_D>]0_[9_\ HI:YNOGZW\27JS]9P'^YTO\
M#'\D%%%%9':>V_#[_D1-/_[:?^C6K-\9_P#(9B_Z]Q_Z$U:7P^_Y$33_ /MI
M_P"C6K-\9_\ (9B_Z]Q_Z$U>T_X$?1'YS3_Y&E7UE^9SU%%%<A[P5V_@S_D#
M2_\ 7P?_ $%:XBNW\&?\@:7_ *^#_P"@K6]#XSR\T_W9^J.@HHHKO/E0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$OB#_ ,CWJ'_;
M/_T4M<W72?$'_D>]0_[9_P#HI:YNOGZW\27JS]9P'^YTO\,?R04445D=I[;\
M/O\ D1-/_P"VG_HUJPO$_P#R,=U_P#_T 5N_#[_D1-/_ .VG_HUJPO$__(QW
M7_ /_0!7L2_@1^7Y'Y[0_P"1G7]9?^E&31117,>T%>@^&/\ D7+7_@?_ *&:
M\^KT'PQ_R+EK_P #_P#0S71A_C/(S?\ @+U_1FM1117<?,!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >)?$'_D>]0_[9_^BEKFZZ3X@_\ (]ZA
M_P!L_P#T4M<W7S];^)+U9^LX#_<Z7^&/Y(****R.T]M^'W_(B:?_ -M/_1K5
MF^,_^0S%_P!>X_\ 0FK2^'W_ "(FG_\ ;3_T:U9OC/\ Y#,7_7N/_0FKVG_
MCZ(_.:?_ "-*OK+\SGJ***Y#W@KM_!G_ "!I?^O@_P#H*UQ%=OX,_P"0-+_U
M\'_T%:WH?&>7FG^[/U1T%%%%=Y\J%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJMYJ=AIVW^T+VWM=W
MW?/E5,_3)J:WN8+N$36LT<\3='C<,I_$4 245%<W=O90^=>7$5O$#@O*X5?S
M-1V>HV.H*S6%Y;W2KU,$JOC\C0!9HIDTT5O"TMQ(D4:\L[L% ^I-0VFHV.H!
MC87EO=!?O>3*KX^N#0!9HJ*YN8+.W:>[FC@A3[TDKA57G')/'6E@GBN8$FMI
M4FB<962-@RL/4$=: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#Q+X@_\ (]ZA_P!L_P#T4M<W72?$'_D>]0_[9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444V6010O(P)"*6( Y.* /,] TW3_ !#XVUX^* LUY#,4AMY9" $!/*C/
M(  _//>K7@M(=/\ B)K6FZ)*9-)6(/M#[E23*\ ]\98?A[52\,>&X/'9N_$'
MB&1Y&EF,:0Q-M"@ 8]^,XJWIUI_PA'Q$MM)T^9Y-.U6/<T3X9D8!L'/U'Y$^
ME "6FFQ^-_'NKR:R6ELM*D\B*V#$+G)'_LI)^M-\8Z#:^#Q9^(O#BFSEAG6.
M6)6)613GU^F,>_M5_P !D)XL\71L0'-]N"D\D;Y.?U%2_%=@/!8!/+7484>I
MP: *GBTQZ[XR\/Z3>2LFF7,9G*YV^8W. ??@#_@50>)=*LO"WB;0;WP_$+6X
MGN!#);QL0LJ9 /'XX_$'M74ZAX9L?$.A65MJ:2*\$:F.6)MKQ-@9P?PKE=<T
MFQ\%6O\ :LEW=:IK,H\FQ:[??L;&-P'L/KVH F\1RR>,_&$/ANT9AI]BWFWT
MB]V'\/X=/J3Z5Z!%$D$*10J$CC4*J@< #@"O,K.'5/#4>FZ!H^R/7-7S<7=U
M,H;REYXYSG&&_(^M:3ZAXA\'ZSI\6MZDFJZ=?2B$R&((\3G'/';GWX!Z4 =[
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >)?$'_ )'O4/\ MG_Z*6N;KI/B#_R/>H?]L_\ T4M<W7S];^)+U9^LX#_<
MZ7^&/Y(****R.T]M^'W_ "(FG_\ ;3_T:U87B?\ Y&.Z_P" ?^@"MWX??\B)
MI_\ VT_]&M6%XG_Y&.Z_X!_Z *]B7\"/R_(_/:'_ ",Z_K+_ -*,FBBBN8]H
M*]!\,?\ (N6O_ __ $,UY]7H/AC_ )%RU_X'_P"AFNC#_&>1F_\  7K^C-:B
MBBNX^8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2^(/\ R/>H
M?]L__12US==)\0?^1[U#_MG_ .BEKFZ^?K?Q)>K/UG ?[G2_PQ_)!11161VG
MMOP^_P"1$T__ +:?^C6K-\9_\AF+_KW'_H35I?#[_D1-/_[:?^C6K-\9_P#(
M9B_Z]Q_Z$U>T_P"!'T1^<T_^1I5]9?F<]1117(>\%=OX,_Y TO\ U\'_ -!6
MN(KM_!G_ "!I?^O@_P#H*UO0^,\O-/\ =GZHZ"BBBN\^5"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \2^(/_(]ZA_VS_\ 12US==)\0?\ D>]0
M_P"V?_HI:YNOGZW\27JS]9P'^YTO\,?R04445D=I[;\/O^1$T_\ [:?^C6K-
M\9_\AF+_ *]Q_P"A-6E\/O\ D1-/_P"VG_HUJS?&?_(9B_Z]Q_Z$U>T_X$?1
M'YS3_P"1I5]9?F<]1117(>\%=OX,_P"0-+_U\'_T%:XBNW\&?\@:7_KX/_H*
MUO0^,\O-/]V?JCH****[SY4**** "BBB@ HHHH **** "BBB@ KSZU\+ZOK?
MQ@G\2^(K3[/IVE1>1I$32(_F$YW2D*3CJ2,X/*^E>@T4 1W$CPVTDD4+3NBE
MEB0@,YQT!) R?<@5Y[X.\'ZQ?^++GQIX]@2+5"3%I]B)%D6RBY Y4D%CGJ/4
MGJ<#T:B@#F/B ?%@\+G_ (0(1'5#,F?,V9$?.[;O^7.<=>V>]8OB_P 'Z_K]
MAX>UW3I[6V\5Z,JR;6SY$K,H\Q/89!Q[$C/.1Z#10!Y-K5A\2?'^GC0-8T:Q
M\.:9,Z_;;I;M9WE4'.$"DXR1T/MSUSZE8V<.G:?;V5JNV"WB6*-<]%48'Z"I
MZ* //?#WAC6-6^(]_P"+_%]G]E-L/LVCV32I)Y,?>0[20&.?7N?:J:Z-XQ\$
M>*M<NO"NCVNO:;K=P;PQO=K;R6TS9W$EN&7)S@<_3OZ=10!QWPZ\*ZAX=LM2
MO=>EB?5M9O&O+I8/]7&3T1?7&3S[UV-%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\<UGP^%-;U36K2^\6ZC;3Q63;X;:U4A2WJ<@>@-=G10 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >)?$'_D>]0_[9_^BEKFZZ3X@_\
M(]ZA_P!L_P#T4M<W7S];^)+U9^LX#_<Z7^&/Y(****R.T]M^'W_(B:?_ -M/
M_1K5A>)_^1CNO^ ?^@"MWX??\B)I_P#VT_\ 1K5A>)_^1CNO^ ?^@"O8E_ C
M\OR/SVA_R,Z_K+_THR:***YCV@KT'PQ_R+EK_P #_P#0S7GU>@^&/^1<M?\
M@?\ Z&:Z,/\ &>1F_P# 7K^C-:BBBNX^8"BBB@ HHHH **** "BBB@ HHHH
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M2",21S^[(2.>/7' .,\U8\)?#M?#^NW&O:QK%SKVM3Q^4;NX0((T]%7)Q^=
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M<?,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >)?$'_ )'O4/\
MMG_Z*6N;KI/B#_R/>H?]L_\ T4M<W7S];^)+U9^LX#_<Z7^&/Y(****R.T]M
M^'W_ "(FG_\ ;3_T:U9OC/\ Y#,7_7N/_0FK2^'W_(B:?_VT_P#1K5F^,_\
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MQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!(526.
M.23VK(OO$MAIFM1:=J#&W,T8>.9QB,DDC:3V/ _.L+QFZ76O:+I^HSM!I%P6
M:5U;:)&'12?3I^= '91R)*FZ)U=?53D4ZN#L(+31_B);6/AN7-K<0,UW DA=
M(\ X/4X.<?G[UWE !1110 4444 9TOB+1()GBFUBPCDC8JZ/=("I'!!&>#34
M\2Z%(ZHFM:>S,<*HND))].M5KCP7X=NKF6XN-*ADEF<N[DMEF)R3U]:X:TT+
M3-9^)IM](LXX--TG#3,F<22 ],Y_O<?130!ZA<W=O90^=>7$5O$#@O*X5?S-
M1V>HV.H*S6%Y;W2KU,$JOC\C7 VFFQ^-_'NKR:R6ELM*D\B*V#$+G)'_ +*2
M?K3?&.@VO@\6?B+PXILY89UCEB5B5D4Y]?IC'O[4 >C3316\+2W$B11KRSNP
M4#ZDU#::C8Z@&-A>6]T%^]Y,JOCZX-<1XM,>N^,O#^DWDK)IES&9RN=OF-S@
M'WX _P"!5!XETJR\+>)M!O?#\0M;B>X$,EO&Q"RID \?CC\0>U 'H5S<P6=N
MT]W-'!"GWI)7"JO..2>.M+!/%<P)-;2I-$XRLD;!E8>H(ZUP/B.63QGXPA\-
MVC,-/L6\V^D7NP_A_#I]2?2O0(HD@A2*%0D<:A54#@ < 4 .HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$OB#_ ,CW
MJ'_;/_T4M<W72?$'_D>]0_[9_P#HI:YNOGZW\27JS]9P'^YTO\,?R04445D=
MI[;\/O\ D1-/_P"VG_HUJPO$_P#R,=U_P#_T 5N_#[_D1-/_ .VG_HUJPO$_
M_(QW7_ /_0!7L2_@1^7Y'Y[0_P"1G7]9?^E&31117,>T%>@^&/\ D7+7_@?_
M *&:\^KT'PQ_R+EK_P #_P#0S71A_C/(S?\ @+U_1FM1117<?,!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >)?$'_D>]0_[9_^BEKFZZ3X@_\
M(]ZA_P!L_P#T4M<W7S];^)+U9^LX#_<Z7^&/Y(****R.T]M^'W_(B:?_ -M/
M_1K5F^,_^0S%_P!>X_\ 0FK2^'W_ "(FG_\ ;3_T:U9OC/\ Y#,7_7N/_0FK
MVG_ CZ(_.:?_ "-*OK+\SGJ***Y#W@KM_!G_ "!I?^O@_P#H*UQ%=OX,_P"0
M-+_U\'_T%:WH?&>7FG^[/U1T%%%%=Y\J%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!XE\0?^1[U#_MG_P"BEKFZZ3X@_P#(]ZA_VS_]%+7-U\_6
M_B2]6?K. _W.E_AC^2"BBBLCM/;?A]_R(FG_ /;3_P!&M6;XS_Y#,7_7N/\
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ML_\ V:MJ/\1'GYC_ +K+Y?FCJZ***] ^1"BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI[;\/O\ D1-/_P"VG_HUJS?&?_(9B_Z]Q_Z$U:7P^_Y$33_^VG_HUJS?&?\
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M@ HHHH \D^*O_(U6W_7DO_H;UQ-=M\5?^1JMO^O)?_0WKB:\'$?Q9'ZGE/\
MN-+T"BBBL#TSUOX5?\BK<_\ 7ZW_ * E6_&__+C_ -M/_9:J?"K_ )%6Y_Z_
M6_\ 0$JWXW_Y<?\ MI_[+7LQ_P!V1^>5?^1Q+U?Y')T445RGMA76>"/^7[_M
MG_[-7)UUG@C_ )?O^V?_ +-6U'^(CS\Q_P!UE\OS1U=%%%>@?(A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$OB#_ ,CWJ'_;/_T4
MM<W72?$'_D>]0_[9_P#HI:YNOGZW\27JS]9P'^YTO\,?R04445D=I[;\/O\
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MUO\ T!*M^-_^7'_MI_[+53X5?\BK<_\ 7ZW_ * E6_&__+C_ -M/_9:]F/\
MNR/SRK_R.)>K_(Y.BBBN4]L*ZSP1_P OW_;/_P!FKDZZSP1_R_?]L_\ V:MJ
M/\1'GYC_ +K+Y?FCJZ***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"@K7$5V_@S_D#2_P#7P?\ T%:WH?&>7FG^[/U1T%%%%=Y\J%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y)\5?^1JMO\ KR7_ -#>N)KMOBK_
M ,C5;?\ 7DO_ *&]<37@XC^+(_4\I_W&EZ!1116!Z9ZW\*O^15N?^OUO_0$J
MWXW_ .7'_MI_[+53X5?\BK<_]?K?^@)5OQO_ ,N/_;3_ -EKV8_[LC\\J_\
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M+HN@6EA<7MQ?S0Q@2W5S*TCRMU))8D]>@["M*@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \2^(/_(]ZA_VS_\ 12US==)\0?\
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M_B2]6?K. _W.E_AC^2"BBBLCM/;?A]_R(FG_ /;3_P!&M6;XS_Y#,7_7N/\
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M5;?]>2_^AO7$UX.(_BR/U/*?]QI>@4445@>F>M_"K_D5;G_K];_T!*M^-_\
MEQ_[:?\ LM5/A5_R*MS_ -?K?^@)5OQO_P N/_;3_P!EKV8_[LC\\J_\CB7J
M_P CDZ***Y3VPKK/!'_+]_VS_P#9JY.NL\$?\OW_ &S_ /9JVH_Q$>?F/^ZR
M^7YHZNBBBO0/D0HHHH **** "BBB@ HHHH **** /"-=UGP?+\=M<G\=26SZ
M?86,5I!'/"TH:0[6.%4$\9<9QWKTOP?;>!M0TF[F\&6^G/:7:^5=+:Q[=XP?
ME=< CACP1WK*\*ZWX-O?'.O"+3(M)\16\QCN3=X62< _?0D]#[8X(SVK$\)R
M64G[0FNMX4\HZ5_9RB_:WQY)N-RXVXXSU_'?0!J^./#O@3P;X/OM9G\+Z4SP
MIM@C-NO[R4\*OY\GV!JY\(?")\)^!8?M4834-1/VNZ&W&PL/E3';"XX]2:PM
M?'_"Q/C'9>'T_>:)X:Q=W_\ =EN/X4/KC@?]]BO2=;US3?#FDRZGK5VEI9PX
MWR,">IP  ,DGV H \Y^/E] GA72-+N95BCU#5(EF9C@")02Q_ E:M>%[KX1Z
MOKL,?AF'2/[2A</ !:F%]R\Y3<HW$8SQGI4_C#Q-X*N-2\,GQ)81W^GWY,MC
MJC@&WA;C[Q)XS\O48]>AK$^-EQI,NFZ(NC26\GB1=0A_L[[,5,B@9].0F<?C
MB@":6QTS7_V@]3LO%T<-U':Z?"=)M+O#1N" 9&"GACNW<>Q]*S- \1:3X!\2
M^/9-+D#>&[%89(H(WR@NF&#'']6R#CH%]!7IWB+P7X?\7PPKXDTN*\:(?(Q9
MD=,]0&4@X]LUYII/A[2?%_CY=)T&QBMO!WA>;?(L8RM[>=.22=X &,G/ /9J
M .J^%OAJ\L[*[\4>(ANU[7F\^<D<PQ_P1CT &./H.U=_7A7A;P]H?C[1=9\1
M>.]3G36H+F592;PQG2@I^7:N< #'<8_&N^^$.KZEK?PUL+K6)'GF5I(DN),[
MIXU8A7.>^.,]\9H [>J6LZ3:Z]HMWI6HJ7MKN)HI IP<'N#V(ZU=HH \JLO!
M7Q,T+3/[ T/Q3I;:2@,<%S<PO]J@C/90 1QVR>.V.,=;X7\(GP/X).DZ 8KJ
M]4-)YMTQ1)IC_$Q4$@=.F>!7444 <3X!\"3^');W6/$5U'J/B/4I"US=)DJB
M]D3(! _ =AT J?XA:!XIU^QL(_!^NKH\L-P))V+LOF+VY4'./[IX/>NOHH \
MN\>^ O%WB+QMI.M:3=:-)!I< $4&HM)M,V26<HJD?W>_\(K2T^V^+*ZE:G4[
MSPLUD)D-PL*S[S'D;@N5QG&<9[UW]% &?KZ:K+H-W'X>:WCU)XRMO)<L5C1C
MQN.%)XZ@8Y(KGO"OP]LM#\ 3^'K\BZDU"-_[1G!YFDD&&()YXZ ^V>M=C10!
MY2/ 'CU?#I\(#Q'I9\.[/(^U>0_VSR.GEX^YC;QG.:]*TG3+?1='M-,L5VV]
MI"L,8/7"C'/O5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\]\(IH:W&I1:[]DDU
M7[4Y=[HJV]>Q4MQZGBO0J\^U>#P?9ZH]E;Z%/J=_G=)%:;VV]SGYNOTH ZZS
MBT%;I3IZ:<+CG:8!'OZ<XQSTK3KCO"<?A6ZOC/I&GM9ZA;@[HIBP=,C!X)(/
M6NQH **** "BBB@#AI?!FM:-JUQ=^#=3AM8;H[I+6Y4E ?;@_AP".F:M^'_!
MUW:ZXVN^([];_4B"J;!A(QC''3MD=!7744 <IXA\(7-[K4>N>'[\:?JB+M=F
M7*2C&.?PXZ'.!5!O!NO:]>0-XPU:":T@;>+6T4A7/OD#^M=U10  !5 48 X
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M!6[\/O\ D1-/_P"VG_HUJPO$_P#R,=U_P#_T 5[$OX$?E^1^>T/^1G7]9?\
MI1DT445S'M!7H/AC_D7+7_@?_H9KSZO0?#'_ "+EK_P/_P!#-=&'^,\C-_X"
M]?T9K4445W'S 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B7Q!
M_P"1[U#_ +9_^BEKFZZ3X@_\CWJ'_;/_ -%+7-U\_6_B2]6?K. _W.E_AC^2
M"BBBLCM/;?A]_P B)I__ &T_]&M6;XS_ .0S%_U[C_T)JTOA]_R(FG_]M/\
MT:U9OC/_ )#,7_7N/_0FKVG_  (^B/SFG_R-*OK+\SGJ***Y#W@KM_!G_(&E
M_P"O@_\ H*UQ%=OX,_Y TO\ U\'_ -!6MZ'QGEYI_NS]4=!1117>?*A1110
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MVK'4]5T*WGO&.7D#.F\^K!2 WX@UTMM;PV=M';VL20PQ*$CC1<*H'0 5QO\
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M*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P ,?R04445D=I[;\/O^1$T__MI_Z-:LWQG_ ,AF+_KW'_H35I?#[_D1-/\
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M9C_NR/SRK_R.)>K_ ".3HHHKE/;"NL\$?\OW_;/_ -FKDZZSP1_R_?\ ;/\
M]FK:C_$1Y^8_[K+Y?FCJZ***] ^1"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N-\!"&V?5;6Z*KJPO',X8_.Z]B/4=:[*N'_ .$4\&W#W\RS,39N?M3"
M=AY9ZG^O3T(H FG\FZ^*EE)II5W@MG%Z\?( P0H8COG'Z>E=E7G6D:#X$URZ
M>WTZ29YER=C2.I8#N,]?YUV6B>'[#P_!+%IJ.BRMN;>Y;G&* -.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** / /$?_ "-6J_\ 7[-_Z&:S:TO$?_(U:K_U^S?^AFLVOG9_$S]?
MP_\ !AZ+\@HHHJ#<]_\ #G_(JZ5_UY0_^@"M*LWPY_R*NE?]>4/_ * *TJ^C
MA\*/Q_$?QI^K_,****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#Q+X@_\CWJ'_;/_ -%+7-UTGQ!_Y'O4/^V?_HI:YNOGZW\2
M7JS]9P'^YTO\,?R04445D=I[;\/O^1$T_P#[:?\ HUJPO$__ ",=U_P#_P!
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M_P#05K>A\9Y>:?[L_5'04445WGRH4444 %%%% !1110 4444 %%%% !1110
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M?]UE\OS1U=%%%>@?(A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:M5_Z_9O_0S6;6EXC_Y&K5?^OV;_ -#-9M?.S^)GZ_A_X,/1?D%%%%0;GO\
MX<_Y%72O^O*'_P! %:59OAS_ )%72O\ KRA_] %:5?1P^%'X_B/XT_5_F%%%
M%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XE\
M0?\ D>]0_P"V?_HI:YNND^(/_(]ZA_VS_P#12US=?/UOXDO5GZS@/]SI?X8_
MD@HHHK([3VWX??\ (B:?_P!M/_1K5A>)_P#D8[K_ (!_Z *W?A]_R(FG_P#;
M3_T:U87B?_D8[K_@'_H KV)?P(_+\C\]H?\ (SK^LO\ THR:***YCV@KT'PQ
M_P BY:_\#_\ 0S7GU>@^&/\ D7+7_@?_ *&:Z,/\9Y&;_P !>OZ,UJ***[CY
M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q+X@_P#(]ZA_VS_]
M%+7-UTGQ!_Y'O4/^V?\ Z*6N;KY^M_$EZL_6<!_N=+_#'\D%%%%9':>V_#[_
M )$33_\ MI_Z-:LWQG_R&8O^O<?^A-6E\/O^1$T__MI_Z-:LWQG_ ,AF+_KW
M'_H35[3_ ($?1'YS3_Y&E7UE^9SU%%%<A[P5V_@S_D#2_P#7P?\ T%:XBNW\
M&?\ (&E_Z^#_ .@K6]#XSR\T_P!V?JCH****[SY4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#Q+X@_\CWJ'_;/_P!%+7-UTGQ!_P"1[U#_ +9_
M^BEKFZ^?K?Q)>K/UG ?[G2_PQ_)!11161VGMOP^_Y$33_P#MI_Z-:LWQG_R&
M8O\ KW'_ *$U:7P^_P"1$T__ +:?^C6K-\9_\AF+_KW'_H35[3_@1]$?G-/_
M )&E7UE^9SU%%%<A[P5V_@S_ ) TO_7P?_05KB*[?P9_R!I?^O@_^@K6]#XS
MR\T_W9^J.@HHHKO/E0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/)/BK_R-5M_UY+_Z&]<37;?%7_D:K;_KR7_T-ZXFO!Q'\61^IY3_ +C2] HH
MHK ],];^%7_(JW/_ %^M_P"@)5OQO_RX_P#;3_V6JGPJ_P"15N?^OUO_ $!*
MM^-_^7'_ +:?^RU[,?\ =D?GE7_D<2]7^1R=%%%<I[85UG@C_E^_[9_^S5R=
M=9X(_P"7[_MG_P"S5M1_B(\_,?\ =9?+\T=71117H'R(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'DGQ5_Y&JV_P"O)?\ T-ZXFNV^*O\ R-5M
M_P!>2_\ H;UQ->#B/XLC]3RG_<:7H%%%%8'IGK?PJ_Y%6Y_Z_6_] 2K?C?\
MY<?^VG_LM5/A5_R*MS_U^M_Z E6_&_\ RX_]M/\ V6O9C_NR/SRK_P CB7J_
MR.3HHHKE/;"NL\$?\OW_ &S_ /9JY.NL\$?\OW_;/_V:MJ/\1'GYC_NLOE^:
M.KHHHKT#Y$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\TUSP[KNFV-WI
M>FVGV[3+FY%Q$8S\\)SDJ1W''^>E;OB?4M5G\1V7A[1;A;.2XB,TMP1DA<G@
M?]\FLMO$NI^#=6GTS79WU57@$MHZH [,3@ ^@.#Z].* -+3+/4M3\5P:WK\,
M>GB)&CLK,R!G8D')/OC)_IQ785R/A[1=4O-77Q#XCD9+D*1;VB\+"I&.1]">
M/SKKJ "BBB@ H)PI)[>@S110!R/AK2/"&H7-YJ>BQQWCO(1(9U9O+8\G"N,C
M.>O_ ->L6]M[?0/B[IBZ(BQ?;8\75O%PN#GG Z= V/49K7OOA^O]K2ZAX>U:
MXT6:?F585W(WX9'UQTJWX=\$VVAZA)J-S=S:CJ,F0;F?J >N!D\^^: ,?PN1
M;?%3Q';SD)+* Z*?XAD'C\"*T?B;<10^ [R.1@'G>-(QZD.&_DIJUXC\&VNO
M7<-_#<S:?J,(PEU;G!Q[_P".15"V^'QEU&&\\1:U=:P8#F..1=J ^XR?Z4 :
MD7AZPUCPGIMEK-HLWE6T8&<AD;8 <$<BN3\2:=IOA:VCT?PO:8U?5OW0D+%G
M6,G!Y/3/3CW]*]*KG=.\)_9_%=WKVH7GVVYF&V%?*V+ OH.3GC S]?6@#EI-
M/NK35M-\$:3?/I\(MS<7=S%\KS,<YP?P_P XJV([_P %>+=)LTU6YU#3M3<P
MF"Y?<\;9'S ^F6!X]_K70^(_"D.O7%M>174UA?VO$5U#U ]"._?\S572O!9M
MM:35M9U6?5KR)=L+2KM6/Z#)]: .IHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#P#Q'_R-6J_]?LW_ *&:S:TO$?\ R-6J_P#7[-_Z&:S:
M^=G\3/U_#_P8>B_(****@W/?_#G_ "*NE?\ 7E#_ .@"M*LWPY_R*NE?]>4/
M_H K2KZ.'PH_'\1_&GZO\SF_'/C*T\%>'VO9E\^[F;RK*T7[UQ*>@ ]/4_U(
MKS3X66VMV_QLUT^*IA+JL^E+/.!TC+M&P0?[H(&/:I6T[Q_)\29_$VK^"#K
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M!6&""%R5."3ZURWASX=?#B]\$++IVG6UYI]W$9/MUQ@S =_WAP4*],#&,<T
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MT/\ D9U_67_I1DT445S'M!7H/AC_ )%RU_X'_P"AFO/J]!\,?\BY:_\  _\
MT,UT8?XSR,W_ ("]?T9K4445W'S 4444 %%%% !1110 4444 %%%% !1110
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M[K_@'_H KV)?P(_+\C\]H?\ (SK^LO\ THR:***YCV@KT'PQ_P BY:_\#_\
M0S7GU>@^&/\ D7+7_@?_ *&:Z,/\9Y&;_P !>OZ,UJ***[CY@**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Q+X@_P#(]ZA_VS_]%+7-UTGQ!_Y'
MO4/^V?\ Z*6N;KY^M_$EZL_6<!_N=+_#'\D%%%%9':>V_#[_ )$33_\ MI_Z
M-:LWQG_R&8O^O<?^A-6E\/O^1$T__MI_Z-:LWQG_ ,AF+_KW'_H35[3_ ($?
M1'YS3_Y&E7UE^9SU%%%<A[P5V_@S_D#2_P#7P?\ T%:XBNW\&?\ (&E_Z^#_
M .@K6]#XSR\T_P!V?JCH****[SY4**** "BBB@ HHHH **** "BBB@ HHHH
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M>S'_ '9'YY5_Y'$O5_D<G1117*>V%=9X(_Y?O^V?_LU<G76>"/\ E^_[9_\
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M;\;_ /+C_P!M/_9:J?"K_D5;G_K];_T!*M^-_P#EQ_[:?^RU[,?]V1^>5?\
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M_P"!_P#H9KSZO0?#'_(N6O\ P/\ ]#-=&'^,\C-_X"]?T9K4445W'S 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'B7Q!_Y'O4/^V?_ **6N;KI
M/B#_ ,CWJ'_;/_T4M<W7S];^)+U9^LX#_<Z7^&/Y(****R.T]M^'W_(B:?\
M]M/_ $:U9OC/_D,Q?]>X_P#0FK2^'W_(B:?_ -M/_1K5F^,_^0S%_P!>X_\
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M/_Y_[7_O\O\ C1_:NG_\_P#:_P#?Y?\ &O,Z*YOK#['M?V/3_F9Z9_:NG_\
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MJ*IZ9X*:'6HM4UO5[C5KFW&(?-38L?OC)KJJ* "BBB@ HHHH **** "BBB@
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MS 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B7Q!_Y'O4/^V?\
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M^<T_^1I5]9?F<]1117(>\%=OX,_Y TO_ %\'_P!!6N(KM_!G_(&E_P"O@_\
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MR_?]L_\ V:N3KK/!'_+]_P!L_P#V:MJ/\1'GYC_NLOE^:.KHHHKT#Y$****
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MC\VP'^^U/G^:,FBBBN,^A"O0?#'_ "+EK_P/_P!#->?5Z#X8_P"1<M?^!_\
MH9KHP_QGD9O_  %Z_HS6HHHKN/F HHHH **** "BBB@ HHHH **** "BBB@
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M?!_]!6MZ'QGEYI_NS]4=!1117>?*A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >2?%7_D:K;_KR7_T-ZXFNV^*O_(U6W_7DO_H;UQ->#B/XLC]3
MRG_<:7H%%%%8'IGK?PJ_Y%6Y_P"OUO\ T!*M^-_^7'_MI_[+53X5?\BK<_\
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MM_[3KS:N"MBI4YN*1]7E^14\7AHUY3:;O^#:/?\ _A(]#_Z#.G_^!2?XT?\
M"1Z'_P!!G3__  *3_&O **Q^O2['=_JQ1_Y^/[D?1%GJ5CJ&_P"P7EO=>7C?
MY,JOMSTS@\=#7.^-_P#EQ_[:?^RUA?"/_F+_ /;'_P!J5N^-_P#EQ_[:?^RU
MU>T=2AS/^M3Q%A5A,S]A%W2_6-SDZ***Y#Z *ZSP1_R_?]L__9JY.NL\$?\
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ME.10 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /$?\
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M -#>N)KP<1_%D?J>4_[C2] HHHK ],];^%7_ "*MS_U^M_Z E6_&_P#RX_\
M;3_V6JGPJ_Y%6Y_Z_6_] 2K?C?\ Y<?^VG_LM>S'_=D?GE7_ )'$O5_D<G11
M17*>V%=9X(_Y?O\ MG_[-7)UUG@C_E^_[9_^S5M1_B(\_,?]UE\OS1U=%%%>
M@?(A1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2?%7_ )&JV_Z\
ME_\ 0WKB:[;XJ_\ (U6W_7DO_H;UQ->#B/XLC]3RG_<:7H%%%%8'IGK?PJ_Y
M%6Y_Z_6_] 2K?C?_ )<?^VG_ ++53X5?\BK<_P#7ZW_H"5;\;_\ +C_VT_\
M9:]F/^[(_/*O_(XEZO\ (Y.BBBN4]L*ZSP1_R_?]L_\ V:N3KK/!'_+]_P!L
M_P#V:MJ/\1'GYC_NLOE^:.KHHHKT#Y$**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#S?XN?\PC_MM_[3KS:O2?BY_P PC_MM_P"TZ\VKQ,5_&?\
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M@_\ (]ZA_P!L_P#T4M<W72?$'_D>]0_[9_\ HI:YNOGZW\27JS]9P'^YTO\
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MK>A\9Y>:?[L_5'04445WGRH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'DGQ5_Y&JV_Z\E_]#>N)KMOBK_R-5M_UY+_ .AO7$UX.(_BR/U/*?\
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MT^AZ&@#4HKGO#/C33O%EYJ<6CPW3P:=/Y#WCJHAE<=1&0Q+8]< <CUKH: /
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M:YNND^(/_(]ZA_VS_P#12US=?/UOXDO5GZS@/]SI?X8_D@HHHK([3VWX??\
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M)7'!Y\P\?WL]Z /2/$'B/2O"VE'4M>NOLMHKA#)Y;/\ ,>@PH)_2N4_X7?\
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M)5OQO_RX_P#;3_V6O9C_ +LC\\J_\CB7J_R.3HHHKE/;"NL\$?\ +]_VS_\
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M% !1110!YQ\>?^21ZA_UV@_]&"LGXP^5;>"O"VJ&:%I].O+>>*QE)_TO"C*
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M\?O^2?6G_84@_D]>GUYU\;M,O]6\#6L&E6-S>S+J4+F.VA:1@H#9.%!..>M
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MI^K3BVAN],D?_1Y6^ZL@<G.?48 Y/;% '-?$'_D>]0_[9_\ HI:YNND^(/\
MR/>H?]L__12US=?/UOXDO5GZS@/]SI?X8_D@HHHK([3VWX??\B)I_P#VT_\
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M%6Y_Z_6_] 2K?C?_ )<?^VG_ ++53X5?\BK<_P#7ZW_H"5;\;_\ +C_VT_\
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M:?-80:38QV=P29K9+9!'(3UW*!@_C5NUM;>RM8[:R@CM[>)=L<42!$0>@ X
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M/<\G)^E &;\7/^81_P!MO_:=>;5Z3\7/^81_VV_]IUYM7B8K^,_ZZ'Z9D?\
MR+Z?S_\ 2F%%%%<I[1Z3\(_^8O\ ]L?_ &I6[XW_ .7'_MI_[+6%\(_^8O\
M]L?_ &I6[XW_ .7'_MI_[+7K4_\ =E_74^"Q?_(ZE_7V#DZ***P/5"NL\$?\
MOW_;/_V:N3KK/!'_ "_?]L__ &:MJ/\ $1Y^8_[K+Y?FCJZ***] ^1"BBB@
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MS(W8_I7%>+?"]KHFK6WAOPU>ZAJGBKQ GDRZCJ5SY\MI9_QG.!@$ CUP&]J
M-O1%/Q0^)4GB*8%_#?A^0PZ8I'RW,_\ %+[@<$?1?>O5Z\<TS1;K5?&-]X'T
MK7-0\/:)X:M855-/D$-Q=R2#<9&?KC)/MR/6NA^'&L:LGB+Q'X3UG4'U?^Q)
M8OL^H./G='7.QSW88Z]<[O04 >A4444 %%%% !1110!X!XC_ .1JU7_K]F_]
M#-9M:7B/_D:M5_Z_9O\ T,UFU\[/XF?K^'_@P]%^04445!N>_P#AS_D5=*_Z
M\H?_ $ 5R'B?_D8[K_@'_H KK_#G_(JZ5_UY0_\ H KD/$__ ",=U_P#_P!
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MV?\ [-7)UUG@C_E^_P"V?_LU;4?XB//S'_=9?+\T=71117H'R(4444 %%%%
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M44 %%%% !1110 5@^+_"%AXUT>/3=5FN8H8[A+@-;,JMN7.!\RD8Y]*\+HH
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M"(16UM&L42#^%0, 59IL<B31)+"ZR1NH9'4Y# ]"#W%0M?V:,5>[@5E."#(
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M%TQDJHQR,^OO0!J45B_\)59?\\KC_OE?\:/^$JLO^>5Q_P!\K_C0!M45B_\
M"567_/*X_P"^5_QK4L[I+VT2XB#!'S@,.>#C^E 'C'Q!_P"1[U#_ +9_^BEK
MFZZ3X@_\CWJ'_;/_ -%+7-U\_6_B2]6?K. _W.E_AC^2"BBBLCM/;?A]_P B
M)I__ &T_]&M6;XS_ .0S%_U[C_T)JTOA]_R(FG_]M/\ T:U9OC/_ )#,7_7N
M/_0FKVG_  (^B/SFG_R-*OK+\SGJ***Y#W@KM_!G_(&E_P"O@_\ H*UQ%=OX
M,_Y TO\ U\'_ -!6MZ'QGEYI_NS]4=!1117>?*C7=8XV=SA5!)/H!7&^'OBA
MI7B/Q6WA^WTW5[.[6)I@U];")713C(!;=SVR!7:5Y<W_ "= G_8!_P#9S0!Z
MB3@9/ KEO#'Q"T3Q?KFIZ9HAGE.FX\RX*KY4N21E""21D'D@>U<UXXUR^\7^
M(#\/_"4VW<N=:OTZ6L7>,'^\>GZ>N,WX6:/9Z!\6O&>E:;'Y=K:0VT<:YR<;
M>I]R<G\: /8*\^U#XPZ38Z[?Z5!H7B#49=/F,,\EC9K*@8>^_/Y@=*] )"J2
M>@&37@WPV\1^*--L]>O].\#7NK-?:G+=7$S7"VY7.#L4,"789)P/6@#UO2?&
M-AJ7A>;7KJWO-(LX"WFC4XA$Z!>I*@GCGCUK T_XQ>';Z_M89K75=/MKQQ':
MZA>V9CMIV/0*^3U]P*SO$VICXK?!G5?^$7CN%O%=5EL91ME5XW5FC(SUP,CU
MX[\#G?%WC/3/'_@2V\(^&].NGUJ=H$>T:V9!I^Q@6+,1@  %>#T/:@#U;Q9X
MLTWP;H3:IJYE:/>L<<4"AI)78\*H)&3U/7H#6K9W!N[*&X:"6W,J!S#,!O3(
MSAL$C(]B:\:CUG3_ !5XR/B;Q'J$</A/PLPM[.68_+>W>.9 .K=,@#/ 7WKT
MSPUXY\-^+VE7P[JL5Y)",O'M:-P/7:X!QR.<8H WZ**ADO;6&0I+<PHXZJT@
M!% $U%5O[1LO^?RW_P"_J_XT?VC9?\_EO_W]7_&@"S15;^T;+_G\M_\ OZO^
M-3QR)-&'B=70]&4Y!H \F^*O_(U6W_7DO_H;UQ-=M\5?^1JMO^O)?_0WKB:\
M'$?Q9'ZGE/\ N-+T"BBBL#TSUOX5?\BK<_\ 7ZW_ * E6_&__+C_ -M/_9:J
M?"K_ )%6Y_Z_6_\ 0$JWXW_Y<?\ MI_[+7LQ_P!V1^>5?^1Q+U?Y')T445RG
MMA76>"/^7[_MG_[-7)UUG@C_ )?O^V?_ +-6U'^(CS\Q_P!UE\OS1U=%%%>@
M?(A117C'Q[\,:<NEVWB0B9]2:]@MP[3,56/#':%Z#D9_.@#V>BN&^(.A>)/%
M%]I.D:5/+9:')(S:K<P3!)"H^Z@YS@\]/49Z5P_BCPSIOPQ\2>&[CP)=W,.I
M7E^D$^F?:#(+J$_>9E/8<#/3YLCD9H ]QHHKS+4?A_J?CCQQJ4_C:2=?#UOM
M33;&"YVI+ZNP4Y!R,\\\^U 'IM%>1^ 4'ASXO:OX5\.WTU]X>CLA.T3S>8ME
M-D#:&_$\>XS]VL[P;X0T_P")F@:CXH\6WMV^JRW4R1NMRR?V;LZ!5! ! P>1
MT_.@#VVBO%]*^)6J6GP5L9&D:^\0WT\FG::Q&6N&#;1+[[01SW(&>IKT'X?^
M$(_!GA2&P+>;>RDS7MP3DRS-]XY[@=!]* .GKBO$'_(=N/\ @/\ Z"*[6N*\
M0?\ (=N/^ _^@B@#-HHHH *ZWPK_ ,@N3_KL?_05KDJZWPK_ ,@N3_KL?_05
MH \^^*O_ "-5M_UY+_Z&]<37;?%7_D:K;_KR7_T-ZXFO!Q'\61^IY3_N-+T"
MBBBL#TSUOX5?\BK<_P#7ZW_H"5;\;_\ +C_VT_\ 9:J?"K_D5;G_ *_6_P#0
M$JWXW_Y<?^VG_LM>S'_=D?GE7_D<2]7^1R=%%%<I[85UG@C_ )?O^V?_ +-7
M)UUG@C_E^_[9_P#LU;4?XB//S'_=9?+\T=71117H'R(4444 %%%% !1110 4
M444 %%%% !7)^*O^0I'_ -<1_P"A-765R?BK_D*1_P#7$?\ H34 8E%%% !7
M6^%?^07)_P!=C_Z"M<E76^%?^07)_P!=C_Z"M '(_%S_ )A'_;;_ -IUYM7I
M/Q<_YA'_ &V_]IUYM7B8K^,_ZZ'Z9D?_ "+Z?S_]*84445RGM'I/PC_YB_\
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M/_R,=U_P#_T 5U_AS_D5=*_Z\H?_ $ 5R'B?_D8[K_@'_H KVZO\)'YM@/\
M?:GS_-&31117&?0A7H/AC_D7+7_@?_H9KSZO0?#'_(N6O_ __0S71A_C/(S?
M^ O7]&:U%%%=Q\P%%%% !1110 4444 ?-M%%% !1110!])445@7/B?[/=2P_
M9-WEN4SYN,X./2@#?HKG/^$M_P"G+_R+_P#6H_X2W_IR_P#(O_UJ .CHKG/^
M$M_Z<O\ R+_]:M^VF^T6L4VW;YB!\9SC(S0!XM\0?^1[U#_MG_Z*6N;KI/B#
M_P CWJ'_ &S_ /12US=?/UOXDO5GZS@/]SI?X8_D@HHHK([3VWX??\B)I_\
MVT_]&M6%XG_Y&.Z_X!_Z *W?A]_R(FG_ /;3_P!&M6%XG_Y&.Z_X!_Z *]B7
M\"/R_(_/:'_(SK^LO_2C)HHHKF/:"O0?#'_(N6O_  /_ -#->?5Z#X8_Y%RU
M_P"!_P#H9KHP_P 9Y&;_ ,!>OZ,UJ***[CY@**** "BBB@ HHHH ^?\ Q)_R
M-6K?]?LW_H9K-K2\2?\ (U:M_P!?LW_H9K-H **** /H#PW_ ,BKI/\ UY0_
M^@"N3U'_ )"EU_UV?_T(UUGAO_D5=)_Z\H?_ $ 5R>H_\A2Z_P"NS_\ H1H
MK4444 %=]IW_ ""[7_KBG_H(K@:[[3O^07:_]<4_]!% 'C?Q!_Y'O4/^V?\
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MWXW_ .7'_MI_[+53X5?\BK<_]?K?^@)5OQO_ ,N/_;3_ -EKV8_[LC\\J_\
M(XEZO\CDZ***Y3VPKK/!'_+]_P!L_P#V:N3KK/!'_+]_VS_]FK:C_$1Y^8_[
MK+Y?FCJZ***] ^1"BBB@ HHHH **** "BBB@ HHHH *Y/Q5_R%(_^N(_]":N
MLKD_%7_(4C_ZXC_T)J ,2BBB@ KK?"O_ ""Y/^NQ_P#05KDJZWPK_P @N3_K
ML?\ T%: .1^+G_,(_P"VW_M.O-J])^+G_,(_[;?^TZ\VKQ,5_&?]=#],R/\
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M7Y!1114&Y[_X<_Y%72O^O*'_ - %<AXG_P"1CNO^ ?\ H KK_#G_ "*NE?\
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MKO/E0HHHH **** "BBB@#P_7]?UB'Q)J<4.K7T<:7<JHBW+@* YP ,\"L_\
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M_H*T <C\7/\ F$?]MO\ VG7FU>D_%S_F$?\ ;;_VG7FU>)BOXS_KH?IF1_\
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M9M?.S^)GZ_A_X,/1?D%%%%0;GO\ X<_Y%72O^O*'_P! %<AXG_Y&.Z_X!_Z
M*Z_PY_R*NE?]>4/_ * *Y#Q/_P C'=?\ _\ 0!7MU?X2/S; ?[[4^?YHR:**
M*XSZ$*]!\,?\BY:_\#_]#->?5Z#X8_Y%RU_X'_Z&:Z,/\9Y&;_P%Z_HS6HHH
MKN/F HHHH **** "BBB@#YMHHHH **** /I*N!U'_D*77_79_P#T(UWU<#J/
M_(4NO^NS_P#H1H K4444 %=]IW_(+M?^N*?^@BN!KOM._P"07:_]<4_]!% '
MC?Q!_P"1[U#_ +9_^BEKFZZ3X@_\CWJ'_;/_ -%+7-U\_6_B2]6?K. _W.E_
MAC^2"BBBLCM/;?A]_P B)I__ &T_]&M6%XG_ .1CNO\ @'_H K=^'W_(B:?_
M -M/_1K5A>)_^1CNO^ ?^@"O8E_ C\OR/SVA_P C.OZR_P#2C)HHHKF/:"O0
M?#'_ "+EK_P/_P!#->?5Z#X8_P"1<M?^!_\ H9KHP_QGD9O_  %Z_HS6HHHK
MN/F HHHH **** "BBB@#Y_\ $G_(U:M_U^S?^AFLVM+Q)_R-6K?]?LW_ *&:
MS: "BBB@#Z \-_\ (JZ3_P!>4/\ Z *Y/4?^0I=?]=G_ /0C76>&_P#D5=)_
MZ\H?_0!7)ZC_ ,A2Z_Z[/_Z$: *U%%% !7?:=_R"[7_KBG_H(K@:[[3O^07:
M_P#7%/\ T$4 >-_$'_D>]0_[9_\ HI:YNND^(/\ R/>H?]L__12US=?/UOXD
MO5GZS@/]SI?X8_D@HHHK([3VWX??\B)I_P#VT_\ 1K5F^,_^0S%_U[C_ -":
MM+X??\B)I_\ VT_]&M6;XS_Y#,7_ %[C_P!":O:?\"/HC\YI_P#(TJ^LOS.>
MHHHKD/>"NW\&?\@:7_KX/_H*UQ%=OX,_Y TO_7P?_05K>A\9Y>:?[L_5'044
M45WGRH4444 %%%% !1110 45Q][\2]'L-0N+.:VOFDMY6B<K&F"5.#CYNG%0
M?\+6T/\ Y]=0_P"_:?\ Q= ';T5Q'_"UM#_Y]=0_[]I_\71_PM;0_P#GUU#_
M +]I_P#%T =O7%>(/^0[<?\  ?\ T$5UUE=I?Z?;WD(98[B)94##D!AD9]^:
MY'Q!_P AVX_X#_Z"* ,VBBB@ KM?#_\ R K?_@7_ *$:XJNU\/\ _("M_P#@
M7_H1H \D^(/_ "/>H?\ ;/\ ]%+7-UTGQ!_Y'O4/^V?_ **6N;KY^M_$EZL_
M6<!_N=+_  Q_)!11161VGMOP^_Y$33_^VG_HUJS?&?\ R&8O^O<?^A-6E\/O
M^1$T_P#[:?\ HUJS?&?_ "&8O^O<?^A-7M/^!'T1^<T_^1I5]9?F<]1117(>
M\%=OX,_Y TO_ %\'_P!!6N(KM_!G_(&E_P"O@_\ H*UO0^,\O-/]V?JCH***
M*[SY4**** "BBB@ HHHH ^?_ !)_R-6K?]?LW_H9K-K2\2?\C5JW_7[-_P"A
MFLV@ HHHH ^@/#?_ "*ND_\ 7E#_ .@"N<\0?\AVX_X#_P"@BNC\-_\ (JZ3
M_P!>4/\ Z *YSQ!_R';C_@/_ *"* ,VBBB@ KM?#_P#R K?_ (%_Z$:XJNU\
M/_\ ("M_^!?^A&@#S;XJ_P#(U6W_ %Y+_P"AO7$UVWQ5_P"1JMO^O)?_ $-Z
MXFO!Q'\61^IY3_N-+T"BBBL#TSUOX5?\BK<_]?K?^@)5OQO_ ,N/_;3_ -EJ
MI\*O^15N?^OUO_0$JWXW_P"7'_MI_P"RU[,?]V1^>5?^1Q+U?Y')T445RGMA
M76>"/^7[_MG_ .S5R==9X(_Y?O\ MG_[-6U'^(CS\Q_W67R_-'5T445Z!\B%
M%%% !1110 4444 >(_$+_D>]0_[9?^BEKFZZ3XA?\CWJ'_;+_P!%+7-T %%%
M% 'MWP]_Y$33_P#MK_Z-:L[Q!_R';C_@/_H(K1^'O_(B:?\ ]M?_ $:U9WB#
M_D.W'_ ?_010!FT444 %=;X5_P"07)_UV/\ Z"M<E76^%?\ D%R?]=C_ .@K
M0!Y]\5?^1JMO^O)?_0WKB:[;XJ_\C5;?]>2_^AO7$UX.(_BR/U/*?]QI>@44
M45@>F>M_"K_D5;G_ *_6_P#0$JWXW_Y<?^VG_LM5/A5_R*MS_P!?K?\ H"5;
M\;_\N/\ VT_]EKV8_P"[(_/*O_(XEZO\CDZ***Y3VPKK/!'_ "_?]L__ &:N
M3KK/!'_+]_VS_P#9JVH_Q$>?F/\ NLOE^:.KHHHKT#Y$**** "BN8\>>-K3P
M1X?-Y*GVB]G/E65HOWIY.PQUP,C)_J157X=Z'KVGZ5+J/B[4KN[U;46\Z2WD
MG9HK4'D1HF=JXSS@>W04 =C15?4+Q-/TVYO91E+:%Y6&<<*"3_*O&_A_X-UO
MQCX,M=>U/QWXGM9KQY&$5OJ#A H<J, _2@#VRBO.?'6H:OX7\,^'O#FB:G,V
MH:I>1Z>-3NCOD53U<D]7.1S]>^*S;V'6OAKXK\.LOB;4M;TW6;U;&ZM]3D\U
MD=\8DC/\('I[=\\ 'K%%>9ZSJVH^-/B?!X9\/W]S9Z7HA$^L75I,T;2/V@#*
M0<>OOG^[7I@&!B@ KD_%7_(4C_ZXC_T)JZRN3\5?\A2/_KB/_0FH Q**** "
MNM\*_P#(+D_Z['_T%:Y*NM\*_P#(+D_Z['_T%: .1^+G_,(_[;?^TZ\VKTGX
MN?\ ,(_[;?\ M.O-J\3%?QG_ %T/TS(_^1?3^?\ Z4PHHHKE/:/2?A'_ ,Q?
M_MC_ .U*W?&__+C_ -M/_9:POA'_ ,Q?_MC_ .U*W?&__+C_ -M/_9:]:G_N
MR_KJ?!8O_D=2_K[!R=%%%8'JA76>"/\ E^_[9_\ LU<G76>"/^7[_MG_ .S5
MM1_B(\_,?]UE\OS1U=%%%>@?(A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<)8?\ENU/\ Z\%_E'7=UDP^'+2'Q3/KZR3&ZGA$+(6&P#Y>@QG/
MRCO0!RN@2QZ7\6=<M;QQ')>@/!NX#]&P/?!/Y&KWQ/OX(/!LUDS W%X\:11@
M_,<.&)QZ?+C\16SK_A32O$J1_P!I0MYL?"31-M=1Z9[CZUGZ7\/=$TR_2]/V
MF]GCY1KN0/M/K@ #\Z -:RTN&7PU9:?J=M'.L=M&CQRH&&X*!T-<=XN2VM7@
M\)>%K2"WNM2(^TM"@&V/T8CGG^0]Z]$K%TWPO9:;KEWJXEN+F]N_O23LIV#T
M7 &!T'T H X[4M(A?Q5I'@Z2:2VTB*V\W:K;?M,G.<GUX_G4L^FV_@SQWHT7
MA^618M18QW%DSEAMR!OYY[D_\!^M=?KWAC3?$<<8U&-A)"<QS1-M=/H:JZ+X
M*TO1+XWL37%U=D8$]U)O91[<"@#H:*** "BBB@ HHHH **** /FVBBB@ HHH
MH ^DJ\XKT>O.* "BBB@ KT>O.*]'H \ \1_\C5JO_7[-_P"AFLVM+Q'_ ,C5
MJO\ U^S?^AFLVOG9_$S]?P_\&'HOR"BBBH-SW_PY_P BKI7_ %Y0_P#H KD/
M$_\ R,=U_P  _P#0!77^'/\ D5=*_P"O*'_T 5R'B?\ Y&.Z_P" ?^@"O;J_
MPD?FV _WVI\_S1DT445QGT(5Z#X8_P"1<M?^!_\ H9KSZO0?#'_(N6O_  /_
M -#-=&'^,\C-_P" O7]&:U%%%=Q\P%%%% !1110 4444 ?-M%%% !1110!])
M5P.H_P#(4NO^NS_^A&N^K@=1_P"0I=?]=G_]"- %:BBB@ KOM._Y!=K_ -<4
M_P#017 UWVG?\@NU_P"N*?\ H(H \;^(/_(]ZA_VS_\ 12US==)\0?\ D>]0
M_P"V?_HI:YNOGZW\27JS]9P'^YTO\,?R04445D=I[;\/O^1$T_\ [:?^C6K"
M\3_\C'=?\ _] %;OP^_Y$33_ /MI_P"C6K"\3_\ (QW7_ /_ $ 5[$OX$?E^
M1^>T/^1G7]9?^E&31117,>T%>@^&/^1<M?\ @?\ Z&:\^KT'PQ_R+EK_ ,#_
M /0S71A_C/(S?^ O7]&:U%%%=Q\P%%%% !1110 4444 ?/\ XD_Y&K5O^OV;
M_P!#-9M:7B3_ )&K5O\ K]F_]#-9M !1110!] >&_P#D5=)_Z\H?_0!7)ZC_
M ,A2Z_Z[/_Z$:ZSPW_R*ND_]>4/_ * *Y/4?^0I=?]=G_P#0C0!6HHHH *[[
M3O\ D%VO_7%/_017 UWVG?\ (+M?^N*?^@B@#QOX@_\ (]ZA_P!L_P#T4M<W
M72?$'_D>]0_[9_\ HI:YNOGZW\27JS]9P'^YTO\ #'\D%%%%9':>V_#[_D1-
M/_[:?^C6K-\9_P#(9B_Z]Q_Z$U:7P^_Y$33_ /MI_P"C6K-\9_\ (9B_Z]Q_
MZ$U>T_X$?1'YS3_Y&E7UE^9SU%%%<A[P5V_@S_D#2_\ 7P?_ $%:XBNW\&?\
M@:7_ *^#_P"@K6]#XSR\T_W9^J.@HHHKO/E0HHHH **** "BBB@#Y_\ $G_(
MU:M_U^S?^AFLVM+Q)_R-6K?]?LW_ *&:S: "BBB@#Z \-_\ (JZ3_P!>4/\
MZ *YSQ!_R';C_@/_ *"*Z/PW_P BKI/_ %Y0_P#H KG/$'_(=N/^ _\ H(H
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M_P#7E#_Z *YSQ!_R';C_ (#_ .@BNC\-_P#(JZ3_ ->4/_H KG/$'_(=N/\
M@/\ Z"* ,VBBB@ KM?#_ /R K?\ X%_Z$:XJNU\/_P#("M_^!?\ H1H \V^*
MO_(U6W_7DO\ Z&]<37;?%7_D:K;_ *\E_P#0WKB:\'$?Q9'ZGE/^XTO0****
MP/3/6_A5_P BK<_]?K?^@)5OQO\ \N/_ &T_]EJI\*O^15N?^OUO_0$JWXW_
M .7'_MI_[+7LQ_W9'YY5_P"1Q+U?Y')T445RGMA76>"/^7[_ +9_^S5R==9X
M(_Y?O^V?_LU;4?XB//S'_=9?+\T=71117H'R(4444 %%%% !1110!XC\0O\
MD>]0_P"V7_HI:YNND^(7_(]ZA_VR_P#12US= !1110![=\/?^1$T_P#[:_\
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ML?\ VI6[XW_Y<?\ MI_[+7K4_P#=E_74^"Q?_(ZE_7V#DZ***P/5"NL\$?\
M+]_VS_\ 9JY.NL\$?\OW_;/_ -FK:C_$1Y^8_P"ZR^7YHZNBBBO0/D0HHHH
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M )%RU_X'_P"AFO/J]!\,?\BY:_\  _\ T,UT8?XSR,W_ ("]?T9K4445W'S
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M %%%% 'T!X;_ .15TG_KRA_] %<GJ/\ R%+K_KL__H1KK/#?_(JZ3_UY0_\
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MBBN\^5"BBB@ HHHH **** /G_P 2?\C5JW_7[-_Z&:S:TO$G_(U:M_U^S?\
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M]1117(>\%=OX,_Y TO\ U\'_ -!6N(KM_!G_ "!I?^O@_P#H*UO0^,\O-/\
M=GZHZ"BBBN\^5"BBB@ HHHH **** /G_ ,2?\C5JW_7[-_Z&:S:TO$G_ "-6
MK?\ 7[-_Z&:S: "BBB@#Z \-_P#(JZ3_ ->4/_H KG/$'_(=N/\ @/\ Z"*Z
M/PW_ ,BKI/\ UY0_^@"N<\0?\AVX_P" _P#H(H S:*** "NU\/\ _("M_P#@
M7_H1KBJ[7P__ ,@*W_X%_P"A&@#S;XJ_\C5;?]>2_P#H;UQ-=M\5?^1JMO\
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MQ_\ 05H Y'XN?\PC_MM_[3KS:O2?BY_S"/\ MM_[3KS:O$Q7\9_UT/TS(_\
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M_P"1<M?^!_\ H9KHP_QGD9O_  %Z_HS6HHHKN/F HHHH **** "BBB@#Y_\
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M44 %=KX?_P"0%;_\"_\ 0C7%5VOA_P#Y 5O_ ,"_]"- 'DGQ!_Y'O4/^V?\
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MQ5_Y&JV_Z\E_]#>N)KP<1_%D?J>4_P"XTO0****P/3/6_A5_R*MS_P!?K?\
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M+C2+FX'[CS'WK)[9P.?_ -5 '5T5A^*O$\'A?34G>$W-Q,XC@MU;:9#WYP<
M#V]!WK6LY9IK*&6Z@%O,Z!GB#[MA/;.!G\J )J*** "BBB@ HHHH **** /F
MVBBB@ HHHH ^DJ\XKT>O.* "BBB@ KT>O.*]'H \ \1_\C5JO_7[-_Z&:S:T
MO$?_ "-6J_\ 7[-_Z&:S:^=G\3/U_#_P8>B_(****@W/?_#G_(JZ5_UY0_\
MH KD/$__ ",=U_P#_P! %=?X<_Y%72O^O*'_ - %<AXG_P"1CNO^ ?\ H KV
MZO\ "1^;8#_?:GS_ #1DT445QGT(5Z#X8_Y%RU_X'_Z&:\^KT'PQ_P BY:_\
M#_\ 0S71A_C/(S?^ O7]&:U%%%=Q\P%%%% !1110 4444 ?-M%%% !1110!]
M)5P.H_\ (4NO^NS_ /H1KOJX'4?^0I=?]=G_ /0C0!6HHHH *[[3O^07:_\
M7%/_ $$5P-=]IW_(+M?^N*?^@B@#QOX@_P#(]ZA_VS_]%+7-UTGQ!_Y'O4/^
MV?\ Z*6N;KY^M_$EZL_6<!_N=+_#'\D%%%%9':>V_#[_ )$33_\ MI_Z-:L+
MQ/\ \C'=?\ _] %;OP^_Y$33_P#MI_Z-:L+Q/_R,=U_P#_T 5[$OX$?E^1^>
MT/\ D9U_67_I1DT445S'M!7H/AC_ )%RU_X'_P"AFO/J]!\,?\BY:_\  _\
MT,UT8?XSR,W_ ("]?T9K4445W'S 4444 %%%% !1110!\_\ B3_D:M6_Z_9O
M_0S6;6EXD_Y&K5O^OV;_ -#-9M !1110!] >&_\ D5=)_P"O*'_T 5R>H_\
M(4NO^NS_ /H1KK/#?_(JZ3_UY0_^@"N3U'_D*77_ %V?_P!"- %:BBB@ KOM
M._Y!=K_UQ3_T$5P-=]IW_(+M?^N*?^@B@#QOX@_\CWJ'_;/_ -%+7-UTGQ!_
MY'O4/^V?_HI:YNOGZW\27JS]9P'^YTO\,?R04445D=I[;\/O^1$T_P#[:?\
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MY!<G_78_^@K0!R/Q<_YA'_;;_P!IUYM7I/Q<_P"81_VV_P#:=>;5XF*_C/\
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MY_\ )O\ [4K>'/\ D5=*_P"O*'_T 5R'B?\ Y&.Z_P" ?^@"NX_LZU_YY?\
MCQ_QH_LZU_YY?^/'_&NV=/FBHW/F\/C/8UI5>6][]>[N>8T5Z=_9UK_SR_\
M'C_C1_9UK_SR_P#'C_C6/U;S/0_MC^Y^/_ /,:]!\,?\BY:_\#_]#-7?[.M?
M^>7_ (\?\:/[.M?^>7_CQ_QK2G2Y'>YQXO'_ %FFH<MM;[_\ LT56_LZU_YY
M?^/'_&C^SK7_ )Y?^/'_ !K<\PLT56_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@"
MS15;^SK7_GE_X\?\:/[.M?\ GE_X\?\ &@"S15;^SK7_ )Y?^/'_ !H_LZU_
MYY?^/'_&@#YVHKZ)_LZU_P">7_CQ_P :/[.M?^>7_CQ_QH ^=J*^B?[.M?\
MGE_X\?\ &C^SK7_GE_X\?\: +-<#J/\ R%+K_KL__H1KM?[.M?\ GE_X\?\
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M_LZU_P">7_CQ_P : /"/$G_(U:M_U^S?^AFLVOHG^SK7_GE_X\?\:/[.M?\
MGE_X\?\ &@#YVHKZ)_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !H K>&_^15TG_KR
MA_\ 0!7)ZC_R%+K_ *[/_P"A&NU_LZU_YY?^/'_&C^SK7_GE_P"/'_&@#@:*
M[[^SK7_GE_X\?\:/[.M?^>7_ (\?\: .!KOM._Y!=K_UQ3_T$4?V=:_\\O\
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M_MC^Y^/_  #S&NW\&?\ (&E_Z^#_ .@K6O\ V=:_\\O_ !X_XT?V=:_\\O\
MQX_XUI3H\DKW.7%9C]8I^SY;?/\ X!9HJM_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C6YY19HJM_9UK_ ,\O_'C_ (T?V=:_\\O_ !X_XT 6:*K?V=:_\\O_ !X_
MXT?V=:_\\O\ QX_XT 6:*K?V=:_\\O\ QX_XT?V=:_\ /+_QX_XT >$>)/\
MD:M6_P"OV;_T,UFU]$_V=:_\\O\ QX_XT?V=:_\ /+_QX_XT ?.U%?1/]G6O
M_/+_ ,>/^-']G6O_ #R_\>/^- %;PW_R*ND_]>4/_H KG/$'_(=N/^ _^@BN
ML_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !H X&BN^_LZU_YY?^/'_&C^SK7_ )Y?
M^/'_ !H X&NU\/\ _("M_P#@7_H1JS_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C0
M!XW\0?\ D>]0_P"V?_HI:YNOHC^SK7_GE_X\?\:/[.M?^>7_ (\?\:\^>"YI
M.7-OY'UN'XC]C1A2]E?E27Q=E;L?.]%?1']G6O\ SR_\>/\ C1_9UK_SR_\
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M:_\ /+_QX_XT?V=:_P#/+_QX_P"- %FBJW]G6O\ SR_\>/\ C1_9UK_SR_\
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MQ_QH_LZU_P">7_CQ_P :[%2M3]G<^=ECN;&/%<N[VOY6WM^AYC17IW]G6O\
MSR_\>/\ C1_9UK_SR_\ 'C_C67U;S.[^V/[GX_\  /,:ZSP1_P OW_;/_P!F
MKHO[.M?^>7_CQ_QH_LZU_P">7_CQ_P :N%'EE>YSXG,O;TG3Y+7\_P#@%FBJ
MW]G6O_/+_P >/^-']G6O_/+_ ,>/^-=!Y!9HJM_9UK_SR_\ 'C_C1_9UK_SR
M_P#'C_C0!9HJM_9UK_SR_P#'C_C1_9UK_P \O_'C_C0!9HJM_9UK_P \O_'C
M_C1_9UK_ ,\O_'C_ (T >-?$+_D>]0_[9?\ HI:YNOHG^SK7_GE_X\?\:/[.
MM?\ GE_X\?\ &@#YVHKZ)_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !H Q/A[_P B
M)I__ &U_]&M6=X@_Y#MQ_P !_P#0176?V=:_\\O_ !X_XT?V=:_\\O\ QX_X
MT <#17??V=:_\\O_ !X_XT?V=:_\\O\ QX_XT <#76^%?^07)_UV/_H*UH_V
M=:_\\O\ QX_XT?V=:_\ /+_QX_XT >6_%7_D:K;_ *\E_P#0WKB:^B/[.M?^
M>7_CQ_QH_LZU_P">7_CQ_P :X*F#YYN7-OY'U.$XA^K4(T?97LM[_P# /G>B
MOHC^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&H^H_WOP_X)U?ZT?].?\ R;_[4Y+X
M5?\ (JW/_7ZW_H"5;\;_ /+C_P!M/_9:Z+^SK7_GE_X\?\:/[.M?^>7_ (\?
M\:[%2M3]G<^=ECN;&/%<N[VOY6WM^AYC17IW]G6O_/+_ ,>/^-']G6O_ #R_
M\>/^-9?5O,[O[8_N?C_P#S&NL\$?\OW_ &S_ /9JZ+^SK7_GE_X\?\:/[.M?
M^>7_ (\?\:N%'EE>YSXG,O;TG3Y+7\_^ 6:*K?V=:_\ /+_QX_XT?V=:_P#/
M+_QX_P"-=!Y!9HJM_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (T 6:*K?V=:_P#/
M+_QX_P"-']G6O_/+_P >/^- %FBJW]G6O_/+_P >/^-']G6O_/+_ ,>/^- '
MC7Q"_P"1[U#_ +9?^BEKFZ^B?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QH ^=J*^B
M?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QH Q/A[_R(FG_ /;7_P!&M5?Q5_R%(_\
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M=/DM?S_X!9HJM_9UK_SR_P#'C_C1_9UK_P \O_'C_C70>06:*K?V=:_\\O\
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ML4<1<=-P501^:F@#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5\-;.YN=2O4U"[O$DE<3L&0,&(0<\#&./6MGQ#_Q4?C.P\/I\UI98O+W'K_
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M3S'B"-\J^I;&!U'>K]<=\/;&:6TO/$-^O^EZM*9!_LQ@\ ?YZ 5V- !1110
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MHRWUO->Z=<3?ZUK&?R_,]<C!ZUH:'X=T_P /6[Q:=&VZ5MTDLC;GD/N:U**
M.9O/ 6E7-]-=VT]]I\EQS,+*?RUD]<C!K6T70K#0+'[+ID/EH6W.Q.6<^I/>
MM"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#%N/"]E>>(H]7OI;BYEA&(8)64Q1>X7'7ZD_RK:HHH Y>Z\ :3/>
M37%K/?:>;C_71V<_EI)ZY&#^5;.CZ+8Z#8BTTR'RH\[F).2Q]2>YJ_10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45S
MMU:2V\A(25&1BO4 C'%2T4 <U+X%TV;PK#X?:XNQ:0RF57#KO)R3@G;C'S'M
MZ5&O@540*GB7Q$JJ, "_P /^^:ZFB@#)O_#=AJFBQ:9J8ENXX5 6:5\RY QN
MW?WOYUG6G@+2K>^ANKF>^U!X"#"M[/YBQXZ8&!73T4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9>JZ!:ZQ?Z==W,DRR:=-YT0C8 ,<
M@_-D'CY1TQ6I10!AZSX1TW6KR.]E,]K>QC"W5I)Y<F/K2Z'X2TW0;B2YMO.G
MNI1A[FYDWR$?6MNB@#G=3\$Z9J.I-J$<MW87<@Q)+93>69/KP?\ Z]6]'\.V
M'ARTF&EP,\L@W.\CY>4CH"QK7HH YWPAHEUIEO>7FK;?[2U"=I9]K9"C)VJ#
MZ?XU=\0^'K7Q+IJV5])-'&L@E#0, V0".X/K6K10!R"_#FS5@?[<UPX.>;L?
M_$UJZYX4T[7IXKBY,UO=P\1W-M)LD4>F:VJ* .5A^'NE1:C:W[7-_-=V\PF\
M^:<.TA!! 8D=..V.M:I\.VA\4C7O,F^U"'R=FX;-OTQG/XUJT4 96H>';34M
M<L-5GDF6>PSY2HP"G/J",_D17,_$%5UO5-'\-0JK33S>?*^.8HP""?Q&[\J[
MNB@".W@CM;:."!0D<2A$4=@!@5)110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 451UG58-$TF;4
M+M)'AAV[EB +'+!1C)'<URW_  M;0_\ GUU#_OVG_P 70!V]%8&C^-=$UN80
M6UR8IV.%BG7:6^G8_3-;] !1110 4444 %%%% !1110 45F:_KUKX=TY;R]C
MFDC:01@0J"<D$]R/2N<'Q5T//_'KJ _[9I_\70!VU%96B>)-,\00L^FS[F3[
M\3C:Z_4?U%:M !1110 4444 %%5UO[-KLVJW<!N!UA$@W^OW>M6* "BL;Q%X
MGLO#,,$E_%/()V*KY*@XQZY(K!_X6MH?_/KJ'_?M/_BZ .WHKB/^%K:'_P ^
MNH?]^T_^+KM(9!-"DJY"NH89ZX(H ?1110 4444 %%%% !15>XU"SM)%CNKN
M"!W^ZLD@4M] 35B@ HHHH **** "BBB@ HHHH ***@N;VULE4WES#;ACA3+(
M%S],T 3T4BLKH&1@RL,@@Y!%+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>?>+?#]_I.B7^K6_B;6"T9WK#]I8*-S@8X/09KT&N;^(7_(
M@ZG_ +B?^AK0!2\-^&KSR=-U6;Q'JT^^))FMY;@M&VY0<$9Y'-:NI>-/#^DW
MC6M_J<<<Z\,BHSE3Z':#C\:=I[S1^ [5[4$SKIJ&, 9RWE#'ZUQ?@2UUUO#I
MN-(BT.9;AW$TEVTIE8YY5\#'X>AH ]"BU:QN-+;4H+E);-4,AE3Y@ !D].>/
M3K6=:>-?#U]>6UK::BLL]S_JD$;Y/UXXZ=\5SVC:1>:1X?\ %*SW.GO!+'*R
MV]C*SK;R;&W+@@;?X>/:KOPUTNS@\&V=TL$9GG+.\A4%LAB!S]!0!=?X@^%T
MC#MJJ ;BN/*DSD>VW./?I4]YXV\.V$<#W.J1!9T#Q[%9\KZX4''XUS?POTNS
MET+4;B:".62:Z>%RZ@Y0 <?3YC1\+=*LG\/W\TENDCRW+PL74'Y H^7GM\QH
M Z/Q ^C:OX.FFO[UUTN55=KBW8DXW#'0'//&,&GC6]%T+2]+BGOC';W$2I:R
M3!CO4*,%CCC@CDXK@=-)_P"%+:TF3MCNBJ#T&Z,X_4U<\1VL=]9> [6<;HIO
M+1QZ@K&#0!V.G>,_#^K7PL[#4HY)S]U"C)N^A8 '\*O:KK6G:);K/JMVEM&Q
MPN[)+'V Y-<E\2;6"TT[1[NUB2&>#4(TB>-0I12&; Q[J#1-##??&,PZLJO'
M#9!K*.095CP20.Y^]^7M0!M1>//#4R1M%JB-YD@B51&^[<>G&W(^IXK(\4>/
M8-*\06%E:7JJL=QMU%6A8[$^7H<<\$],U4^)5II\=_HEPBHE^UXB_* "\>>2
M?H<8^IJ[XY_Y&CPC_P!?_P#[,E $]_>^&/$%]H6HOJ5P&6Y*V7E!U660%<@@
MKQSCGCKUK=U?Q%I.A*AU:]CMR_*J068CUV@$US?CG_D:/"/_ %__ /LR5#X>
MA@O?B7X@EU15DO;=E%JD@SMCYY4?3;^?O0!U6D>(M)UY7.DWL=P4Y90"K >N
MT@'%07_B[0M+O9[2_P!02">!0TB,C< XQCCD\C@9-<[XDB@LOB1X>FTQ5COK
MB1EN5CXWQ\<L/H6Y]O:F6UA;WOQIU%[F)9/L]HDB!QD!MJ#/Y$T =7H_B+2=
M?5VTF]2X\O[Z@%67WPP!Q[UIUPTL*6?QIMOLJ^5]JTXO,%XWG+<G_OE?RKN:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ%9P6][)-&D,ZSJ86 )8 @ Y!XY-1Z]X8T[Q$(C>K)'/"<Q7$#[)$^AK8HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M Y'6M&YN8;.VDN+J5(88QN=W. H^M $E%<_:^._#5Y=K;0:K&96.!O1T!/\
MO, /UKH* "BL^QU[3-2U"ZL;&[66YM#B:,*1MYQU(P>?3-:% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7S_P#\))KG_09U#_P*?_&OH"OFV@#LO VMZK=^
M-+&"[U.\GA;S-T<MPS*<1L1D$^M>@>//^1%U3_KD/_0A7F/P]_Y'O3_^VO\
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MK*%!!''<[B:YEKKP(UC^YT:^EU$C']G^;<;]WH3NQCWY/M0!UFJ>-0+;3(]
MMOMU]JB[X(G.U47N6^G(_ ^E9.O^+/%WAG3UFU/3=-?S6 2> NR(>I5@3G/O
MG''>H[^R;PSJFA:_:Z3-'I]O;&"XM48R/;!BQSDDYY<_ECBJ/C_QC8Z[X;^R
MZ,DUQ%YJM-<&)E2/'1>1U)_D: .MU?Q'=V'BK1-,AC@:'4 ?-9U.Y<?W><?F
M#47C&_\ )U7P]8O;0SPWE\N[S-P*%2N"NUAS\QZY'M6?XU233]:\/:^T4DMI
M9,5N/+7)C!Q@_P _R'K67KOB6U\0^,?#/]F)(]I#>K_I#QE0[%ER!GT Y^M
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MJ**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\
MK4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?]
M,O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>
MHJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\
M'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1
M_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,
MO_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ
M/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'
MO_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I
M?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\
M>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/
M]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^
MM0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_T
MR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_
M .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE
M_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U
M%ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR
M_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_Z
MU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_
MTR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %
MZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_
M\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?
MVE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_
M ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*
MH_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_
M *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?V
ME_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\
MQ[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_
M &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\
MZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_
M $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O
M_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?
M],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4
M 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O
M_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\
MK4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?]
M,O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>
MHJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\
M'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1
M_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,
MO_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ
M/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'
MO_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I
M?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\
M>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/
M]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^
MM0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_T
MR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_
M .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE
M_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U
M%ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR
M_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_Z
MU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_
MTR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %
MZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_ ![_ .M1_:7_ $R_
M\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*H_VE_P!,O_'O_K4?
MVE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_ *U %ZBJ/]I?],O_
M ![_ .M1_:7_ $R_\>_^M0!>HJC_ &E_TR_\>_\ K4?VE_TR_P#'O_K4 7J*
MH_VE_P!,O_'O_K4?VE_TR_\ 'O\ ZU %ZBJ/]I?],O\ Q[_ZU']I?],O_'O_
& *U '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>favors1a01.jpg
<TEXT>
begin 644 favors1a01.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,P
M-@  DI(  @    ,P-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:!.K,JGH2F,CKW- ':45CZMXGT_2=!CU5V::*<+]G2,9:8L,@"L>3QQ>Z=)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=\5Z#<P:5>:=#ID,GGO<0F($LH4(N>HR/R-=O0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%0I=VTEU):QW$37$0!DB5P70'H2.HJ:@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_%/B&'POX=N-4GC,OEX5(@<
M;V)P!GMZ_A6Q7.^.QH[>#KQ/$,K16C  -&,OOSE=H[G(Z?7M0!A7WB3QSI&C
M_P!M:EI>D-8JH>6WBDD$\:DCJ2=N>>V:W]2U'7;[1=/O_"$-C)]JC65A?[AA
M&4%<;2.>:\XOW\7KX7M8/%$-T?#BN/M$D**+HP@C:)!DX' ]_4UZYI,UE/H]
MI)I3*UDT*^1LZ!,8 _ <4 <!K_BGQ]X:TS[=J=GH(B,BQJL8E9F8] !O]B?P
MKT.Q>XET^WDO8UCN6B5I47HKD#('XYK@]3/_  EWQ6M--7Y]/T%?M%QW5ICC
M ]\?+^35Z'0!@>(]4URTFMK3PYI"WL\X9FGG;;#"!C[Q[DYZ9K$TOQGKEIXN
MM_#_ (PTZUMY;Q=UO<6C'8QYX()/7&.W/;G-=R[K&C/(P55&69C@ >M>=:<#
MXX^)2:[;J?['T93#!,1Q<2\Y(]@3G\!ZT ;NI^+[N'6;[3M$T5M3?3HEENW-
MR(A'N&X*,@[B0,]JL-XSTY?!"^)CN%L\>Y(F(#,^2NP>^X8_6J%UX<UVP\2Z
MKJ7AJ>P$>K1H)DN]X,3J"H92H.>I.#CDUR.E"PMK:UEU"9Y_#OAV3R;8+&2;
M^\9B2RKW )./_P!= 'HGA3^V9-#2X\12AKRY8R^4$51 A^['P.<#UR>:VJQ-
M&\4VFLZC/I_V6\L+V",2M;7L01RA.-PP2",^];= !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !117F^G+J/C;Q1KL5YK^H:7#IMR;>&TL)1$VT$C>Q&<YQ_\
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M0X 7&.*N44 8&G>$++3[ZWNWN[V]DM4*6PNY@ZP C'R@ =N.<UOT44 %%%%
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M?_&CZ]'L'^K%;_GXON9[_17@'_"1ZY_T&=0_\"G_ ,:/^$CUS_H,ZA_X%/\
MXT?7H]@_U8K?\_%]S/?Z*\ _X2/7/^@SJ'_@4_\ C1_PD>N?]!G4/_ I_P#&
MCZ]'L'^K%;_GXON9[_17@'_"1ZY_T&=0_P# I_\ &O7_  -<SW?@RQGNYI)Y
M6\S=)*Y9CB1AR3[5M1Q*JRY4CSLPR>I@:2JRDG=V_/\ R.@HHHKJ/#"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYNKZ1KYNKS<=]GY_H
M?9\+_P#+[_MW_P!N"BBBO,/LPHHHH **** "BBB@ HHHH **** "O;?A]_R(
MFG_]M/\ T:U>)5[;\/O^1$T__MI_Z-:N[!?Q'Z'S/$O^YQ_Q+\F=)1117KGY
M^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YM\7?^81_VV_\
M:=>;5Z3\7?\ F$?]MO\ VG7FU !1110 4444 %%%% !1110 4444 %%%% ';
M_"G_ )&JY_Z\F_\ 0TKUNO)/A3_R-5S_ ->3?^AI7K= !1110 4444 %%%%
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MK6+',KXPJ\?3/X&L:7PI=Q^ =3M\^=K&H+YUR^?OR9W; ?3' ^OO7:44 <'
MEWK>M^&_)TJ]L$TI&-Q)<PF)1\H&Q<_>Y';M7>444 %%%% !1110 4444 %%
M%% !1110 4444 %?-U?2-?-U>;COL_/]#[/A?_E]_P!N_P#MP4445YA]F%%%
M% !1110 4444 %%%% !1110 5[;\/O\ D1-/_P"VG_HUJ\2KVWX??\B)I_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY-_Z&E>MUY)\*?\ D:KG_KR;_P!#2O6Z "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7S=7TC7S=7FX[[/S_0^SX7_ .7W_;O_ +<%%%%>8?9A1110 4444 %%%% !
M1110 4444 %>V_#[_D1-/_[:?^C6KQ*O;?A]_P B)I__ &T_]&M7=@OXC]#Y
MGB7_ './^)?DSI****]<_/PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#S;XN_\PC_ +;?^TZ\VKTGXN_\PC_MM_[3KS:@ HHHH **** "
MBBB@ HHHH **** "BBB@#M_A3_R-5S_UY-_Z&E>MUY)\*?\ D:KG_KR;_P!#
M2O6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ%+NVDNI+6.XB:XB ,D2N"Z
M]"1U%34 %%%% !1110 4444 %%%% !1110 4444 %?-U?2-?-U>;COL_/]#[
M/A?_ )??]N_^W!1117F'V84444 %%%% !1110 4444 %%%% !7MOP^_Y$33_
M /MI_P"C6KQ*O;?A]_R(FG_]M/\ T:U=V"_B/T/F>)?]SC_B7Y,Z2BBBO7/S
M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \V^+O\ S"/^
MVW_M.O-J])^+O_,(_P"VW_M.O-J "BBB@ HHHH **** "BBB@ HHHH ****
M.W^%/_(U7/\ UY-_Z&E>MUY)\*?^1JN?^O)O_0TKUN@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_;O_MP4445YA]F%%%% !1110 4444 %%%% !1110 5[;\/O^1$T_P#[:?\
MHUJ\2KVWX??\B)I__;3_ -&M7=@OXC]#YGB7_<X_XE^3.DHHHKUS\_"BBB@
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M'_;;_P!IUYM7I/Q=_P"81_VV_P#:=>;4 %%%% !1110 4444 %%%% !1110
M4444 =O\*?\ D:KG_KR;_P!#2O6Z\D^%/_(U7/\ UY-_Z&E>MT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>2];S=2O'\Z\E)SES_"/89Q^=;M !1110 4444 %%%% !1110 4444 %%%%
M!7S=7TC7S=7FX[[/S_0^SX7_ .7W_;O_ +<%%%%>8?9A1110 4444 %%%% !
M1110 4444 %>V_#[_D1-/_[:?^C6KQ*O;?A]_P B)I__ &T_]&M7=@OXC]#Y
MGB7_ './^)?DSI****]<_/PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5U"&(Y2WN[O?&/;&!0!@:]J$EW'X&UO41Y0\\&9L8 +%#GZ?*372_$*XCM_
MNH^:P7S%5$'JQ8<5KZGHMAJ^EMIU];JUL0 J+\NS'0KCIBL2U^'^EPW4$MU=
MZAJ"6YS#!>7&^-,=,+@?E0 ZQ\,:7<^%-)36;8,]I:(?,:1HVC)4%OF4@@=:
MYF'RH-/O/%%E9K'IFEJT>DVS [78L%:8YY))[]>/:NZU_29-;TIK".\:TCE<
M><RIN9X^Z#D8SQSS]*GFTJRFT=M+>!19M%Y/E#@!<8XH Y:#4];TK6-"34M2
M74(-74AT%NJ>2VT$%2O4<]_2NUK T[PA9:??6]V]W>WLEJA2V%W,'6 $8^4
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M%% ';_"G_D:KG_KR;_T-*];KR3X4_P#(U7/_ %Y-_P"AI7K= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-U
M?2-?-U>;COL_/]#[/A?_ )??]N_^W!1117F'V84444 %%%% !1110 4444 %
M%%% !7MOP^_Y$33_ /MI_P"C6KQ*O;?A]_R(FG_]M/\ T:U=V"_B/T/F>)?]
MSC_B7Y,Z2BBBO7/S\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \V^+O\ S"/^VW_M.O-J])^+O_,(_P"VW_M.O-J "BBB@ HHHH ****
M"BBB@ HHHH **** .W^%/_(U7/\ UY-_Z&E>MUY)\*?^1JN?^O)O_0TKUN@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **I:QJD6C:3-?W"22)$!\D2Y9B2%  ]R17*W'Q O=-:*76O
M#-Y8V4CA1<&3<5SZKM&/IF@#MZ*R]:\066B:+_:5PQDB; B6/DRL1D ?6L&;
MQS?Z:(9]?\-W&GV,S!1<>>LA7/3<H *_C0!V5%8^J^);32[BVMA#<7MS<J7B
M@LT#L5'\74#'OFI](UVRUG37O;9FCCC9DE6==C1,O4-Z8H T:*P?#>MW>OO=
MWOD)%I?F;+-BI\R8#AG)SC&>G'\JWJ "BBB@ HHHH **** "BBB@ HHHH **
M** "OFZOI&OFZO-QWV?G^A]GPO\ \OO^W?\ VX****\P^S"BBB@ HHHH ***
M* "BBB@ HHHH *]M^'W_ "(FG_\ ;3_T:U>)5[;\/O\ D1-/_P"VG_HUJ[L%
M_$?H?,\2_P"YQ_Q+\F=)1117KGY^%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >;?%W_F$?]MO_:=>;5Z3\7?^81_VV_\ :=>;4 %%%% !
M1110 4444 %%%% !1110 4444 =O\*?^1JN?^O)O_0TKUNO)/A3_ ,C5<_\
M7DW_ *&E>MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7#_$:Y_M&WM?#.GCSM0O95;8/^6:#G<?3_
M  !KH_$NH7NF:#/<Z59R7EV,+'%&A<Y)QG Y('6N%\-ZG<Z*9KN\\+Z[>ZI=
M'-Q=O:G)_P!E>.!_GT  -'Q=;K;:QX+TX_O(8[D*<CAMGE@9'XFMSQ^BR>!-
M3#@$",,,]B&!%9WBBRU'7]$TK6=+LYH;^QF%PEI.-KXSRI![_*#CN*JZUJFL
M>+=+_L6PT#4+!KEE6XN+R/9'$H.3@_Q=/_K4 -T^SU<-X=\0V-C]NVZ4EK+!
MYPC;&,AP6XYS6<+:\DN+[1+B1+.34+E]0U9D<%;2 X(CW=-Q[GT(]Z[75=0B
M\)^%XA$AF>)$MK6+',KXPJ\?3/X&L:7PI=Q^ =3M\^=K&H+YUR^?OR9W; ?3
M' ^OO0!L:)XB\/W30Z9HUTF8X\10^6Z94?W=P&>G;-;E<' EWK>M^&_)TJ]L
M$TI&-Q)<PF)1\H&Q<_>Y';M7>4 %%%% !1110 4444 %%%% !1110 4444 %
M?-U?2-?-U>;COL_/]#[/A?\ Y??]N_\ MP4445YA]F%%%% !1110 4444 %%
M%% !1110 5[;\/O^1$T__MI_Z-:O$J]M^'W_ "(FG_\ ;3_T:U=V"_B/T/F>
M)?\ <X_XE^3.DHHHKUS\_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /-OB[_S"/\ MM_[3KS:O2?B[_S"/^VW_M.O-J "BBB@ HHHH **
M** "BBB@ HHHH **** .W^%/_(U7/_7DW_H:5ZW7DGPI_P"1JN?^O)O_ $-*
M];H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KYNKZ1KYNKS<=]GY_H?9\+_\ +[_MW_VX****\P^S"BBB@ HH
MHH **** "BBB@ HHHH *]M^'W_(B:?\ ]M/_ $:U>)5[;\/O^1$T_P#[:?\
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M44 >;?%W_F$?]MO_ &G7FU>D_%W_ )A'_;;_ -IUYM0 4444 %%%% !1110
M4444 %%%% !1110!V_PI_P"1JN?^O)O_ $-*];KR3X4_\C5<_P#7DW_H:5ZW
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI4\VE64VCMI;P*+-HO)\H< +C'%7** ,#3O"%EI]];W;W=[>R6J%+87<P=8
M1CY0 .W'.:WZ** "BBB@ HHHH **** "BBB@ HHHH **** "OFZOI&OFZO-Q
MWV?G^A]GPO\ \OO^W?\ VX****\P^S"BBB@ HHHH **** "BBB@ HHHH *]M
M^'W_ "(FG_\ ;3_T:U>)5[;\/O\ D1-/_P"VG_HUJ[L%_$?H?,\2_P"YQ_Q+
M\F=)1117KGY^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "OFZOI&OFZO-QWV?G^A]GPO\ \OO^W?\ VX****\P^S"BBB@
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M:*K?VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6:*K?VC:_\]?\ QT_X4?VC:_\
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M;7_GK_XZ?\* +-%5O[1M?^>O_CI_PH_M&U_YZ_\ CI_PH LT56_M&U_YZ_\
MCI_PH_M&U_YZ_P#CI_PH LT56_M&U_YZ_P#CI_PH_M&U_P">O_CI_P * +-%
M5O[1M?\ GK_XZ?\ "C^T;7_GK_XZ?\* +-%5O[1M?^>O_CI_PH_M&U_YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDD)U!23PL)^8-_O,%_.M?P)_R)=E_O3?^C7H Z&BBB@ HHHH **** "BBB@
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M,0_M348<07$3CRB@_A QD?<[\\=.<U/'9^(M$\::SJ5CH7]HV]\5V-]LCBP
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M>CQ.&4_B*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M%\4^(E\,:7'>R6_GJ\ZQ$;]NT$$[NASC'2MJN*^*?_(K6W_7]'_)J '7'CZY
MLXHKZ[\.W4&D2N MX\J[L'HQCQD9^O-;^JZZNF6T$\>GW^HI/]W[#!YI QG)
MY& :SOB& ? .IY&?E3_T8M3G^W/^$>TO_A'_ .S]_D)YOV[?C&P8QM_K0!5_
MX3?_ *ECQ'_X+_\ [*M'4] T_P 2?8;C5(972 %UMW.U26 ^^!W&/7N:SO\
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>favors2.jpg
<TEXT>
begin 644 favors2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$,17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    2   (5H=I  0    !   (:)R=  $    D   0X.H<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     $=I;&)E<G0@2&5R;F%N9&5Z   %D ,  @   !0  !"VD 0  @   !0
M !#*DI$  @    ,P-P  DI(  @    ,P-P  ZAP !P  " P   BJ     !SJ
M    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            ,C Q.3HP,SHQ-" Q
M,3HS,SHT-0 R,#$Y.C S.C$T(#$Q.C,S.C0U    1P!I &P 8@!E '( =  @
M $@ 90!R &X 80!N &0 90!Z    _^$+)&AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF
M868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$
M871E/C(P,3DM,#,M,314,3$Z,S,Z-#4N,#<Q/"]X;7 Z0W)E871E1&%T93X\
M+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C
M.F-R96%T;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI/D=I;&)E<G0@
M2&5R;F%N9&5Z/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R
M/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $,
M @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*
M#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBCZYB/\ GXP_U3R7_H#I_P#@$#T#_AK3XJ?]%+^(/_A0WO\ \71_PUI\5/\
MHI?Q!_\ "AO?_BZ\_HH^N8C_ )^,/]4\E_Z Z?\ X! ] _X:T^*G_12_B#_X
M4-[_ /%T?\-:?%3_ **7\0?_  H;W_XNO/Z*/KF(_P"?C#_5/)?^@.G_ . 0
M/0/^&M/BI_T4OX@_^%#>_P#Q='_#6GQ4_P"BE_$'_P *&]_^+KS^BCZYB/\
MGXP_U3R7_H#I_P#@$#T#_AK3XJ?]%+^(/_A0WO\ \71_PUI\5/\ HI?Q!_\
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M/_A0WO\ \71_PUI\5/\ HI?Q!_\ "AO?_BZ\_HH^N8C_ )^,/]4\E_Z Z?\
MX! ] _X:T^*G_12_B#_X4-[_ /%T?\-:?%3_ **7\0?_  H;W_XNO/Z*/KF(
M_P"?C#_5/)?^@.G_ . 0/0/^&M/BI_T4OX@_^%#>_P#Q='_#6GQ4_P"BE_$'
M_P *&]_^+KS^BCZYB/\ GXP_U3R7_H#I_P#@$#T#_AK3XJ?]%+^(/_A0WO\
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M_&W_ *+!\5/_  J[[_X_7EM% 'J7_#<OQM_Z+!\5/_"KOO\ X_1_PW+\;?\
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MJ[[_ ./T?\-R_&W_ *+!\5/_  J[[_X_7EM% 'J7_#<OQM_Z+!\5/_"KOO\
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M7EM% 'J7_#<OQM_Z+!\5/_"KOO\ X_1_PW+\;?\ HL'Q4_\ "KOO_C]>6T4
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M\5/_  J[[_X_7EM% 'J7_#<OQM_Z+!\5/_"KOO\ X_1_PW+\;?\ HL'Q4_\
M"KOO_C]>6T4 >I?\-R_&W_HL'Q4_\*N^_P#C]'_#<OQM_P"BP?%3_P *N^_^
M/UY;10!ZE_PW+\;?^BP?%3_PJ[[_ ./T?\-R_&W_ *+!\5/_  J[[_X_7EM%
M 'J7_#<OQM_Z+!\5/_"KOO\ X_7U%_P3K_X+3>)_@=XCC\/_ !6U76/&/@^_
MF_Y"EY.]WJ>D/_?+O^\GC_V/^_?_ #SKX+HHL!_3]X)\<Z3\2/"MCK6A:A::
MKH^I1">UO+=_,CG3U%;5?S__ /!//_@I?XM_86\5QVO^D:_X$U";?J&BN_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Z#?\ ! O_ )'/XE?]>EC_ .AW%?2?_!:3_E&A\3/]S3O_ $Z6
ME?-G_! O_D<_B5_UZ6/_ *'<5])_\%I/^4:'Q,_W-._].EI7Z9P[_N=,_P \
M?';_ )+/%?\ ;G_I$3\#J***^@/QT**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=F_G_GI7RI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4&@#X[_X*7_\%%/^&4=-C\+>'K&2;QEK%M]HAN+F(_9K"'.SSO\ IL_H@/\
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MK8L>'\4*N=9[0RSANG"K3Y%.M-WY81T_\F_7_MX^):***\$_9 HHHH ****
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M^TW[%W[??@7_ (*Q>$-8^&OQ-\(Z/;>(/L7GR6!)DLM4AZ-/:L_[R&2/./\
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M7AJSU3Q9XFT_P;XIL[80"ZO[Z/1=4T_^/R]\_P"XFC_[^??_ (#5#X*_#O\
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MI()[?Q1J,B3(_ER1O]JD^>L;XE_&GQG\9+BUF\8>+?%'BJ?3T>.U?6-4GO\
M[/O^_LWO)LJ]^T9JMMKW[0GCR\LKFWNK&\\0ZC/!-"_F1W"/=2;'1ZXRM1&]
M\/OBAXF^$.MR:KX2\2:YX9U*2#[/)>:5J$]A<2)_SSWH_P#J_D2J/BCQ3J7C
M?Q!=:KK.I:AK&JZ@_F75Y>3O<7%P_P#?=W_>/6?10 5U'Q&^-WC/XR1V*>+_
M !AXH\51Z7O^Q)K&J3W_ -CW^7YFS>\FS[B?]^ZY>B@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IUK:S7]Q'#;I)//</Y:(B>9)(]:O@3P'K?Q/\
M&%CH/A_3;S6-8U2?R+6SMD\R2X>OV?\ ^"8__!(/1?V5;>S\9>.%M=>^(Q4-
M#'_K+70,_P ,?]^8=Y>@_@P,LR;L!X__ ,$P/^"*JZ7+IWQ ^,NG1R70"7&F
M>%ID_=VV/N277^W_ -,?^^_^>8_4".-84VJ,*.U.HK T"BBB@ HHHH ****
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M@7I__@,G^%;&&HPU&@?6Z_\ ._O,?_A!]'_Z!>G_ /@,G^%'_"#Z/_T"]/\
M_ 9/\*V,-1AJ- ^MU_YW]YC_ /"#Z/\ ] O3_P#P&3_"C_A!]'_Z!>G_ /@,
MG^%;&&HPU&@?6Z_\[^\Q_P#A!]'_ .@7I_\ X#)_A1_P@^C_ /0+T_\ \!D_
MPK8PU&&HT#ZW7_G?WF/_ ,(/H_\ T"]/_P# 9/\ "C_A!]'_ .@7I_\ X#)_
MA6QAJ,-1H'UNO_._O,?_ (0?1_\ H%Z?_P" R?X4?\(/H_\ T"]/_P# 9/\
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M . R?X4?\(/H_P#T"]/_ / 9/\*V,-1AJ- ^MU_YW]YC_P#"#Z/_ - O3_\
MP&3_  H_X0?1_P#H%Z?_ . R?X5L8:C#4:!];K_SO[S'_P"$'T?_ *!>G_\
M@,G^%'_"#Z/_ - O3_\ P&3_  K8PU&&HT#ZW7_G?WF/_P (/H__ $"]/_\
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M% &/_P ()HO_ $!],_\  5*/^$$T7_H#Z9_X"I6Q10!C_P#"":+_ - ?3/\
MP%2C_A!-%_Z ^F?^ J5L44 8_P#P@FB_] ?3/_ 5*/\ A!-%_P"@/IG_ ("I
M6Q10!C_\()HO_0'TS_P%2C_A!-%_Z ^F?^ J5L44 8__  @FB_\ 0'TS_P !
M4H_X031?^@/IG_@*E;%% &/_ ,()HO\ T!],_P# 5*/^$$T7_H#Z9_X"I6Q1
M0!C_ /"":+_T!],_\!4H_P"$$T7_ * ^F?\ @*E;%% &/_P@FB_] ?3/_ 5*
M/^$$T7_H#Z9_X"I6Q10!C_\ "":+_P! ?3/_  %2C_A!-%_Z ^F?^ J5L44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1KS4/ _B/3?$EGI\_D7,UG)N$<F-VR@#NJ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ 4Y%?RSU_4NGW:_EHJZ9,@HHHK4D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_7[_ (-PO^3=OB%_V,4?_I+'7Y U^OW_  ;A?\F[?$+_ +&*
M/_TECJ:@X[GZ-4445B6%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%%  IR*_EGK^I=/NU_+15TR9!1116I(4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^OW_!N%
M_P F[?$+_L8H_P#TECK\@:_7[_@W"_Y-V^(7_8Q1_P#I+'4U1QW/T:HHHK$L
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWHGV2Z@CV)@O)&G$><2!_,?YXX^N_P""=W[:'CG4_P!K_P#:<^#_ ,9/$_\
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M^R>+YM1O_LTFCV.4(DC&].O[[]Y\^SRT_=OOQ5O_ ()=?\HV_@#_ -D]T/\
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M:OB>WC;3]-UFX\+^"].U71=-OH$EMY[KR+%#/L?.^2.-^G_ _P""OI;]@?\
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MYGF821_,P$3+CFOK3XO_  M\/?''X;ZYX1\5:;;ZQX=\164ECJ%G-DQW$,F
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M2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M +&G6_Y:97Z+T4 ?G#_P7B_Y+M^Q5_V632__ $?;U-\6_P#E9W^%O_9&)_\
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MP)O/VF/V4_CE\7_'*^1K?[3VM:I'=/#UM]._?P".,G_EFDDUP$_V$CK]/**
M/R%_8"_;]M?^"+?P?F_9]_:6\.^)_"#^#]3OI/#7B6RTA[O2/$EE/.\XV.F?
MG\R20_[GW]CH:]$_8JTOQ1_P49_X*T77[4UYX/\ $'@WX8>!_"X\*^"WUJT^
MRWGB#S/M!>X\O_GG_I,__?<>/XZ_3:B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%%&: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLW7=:L_#&D76H:A<
M06=E8PO/<7,[^7' B N[NYX5 !DY[5\O^ O^"U_[+7Q0^*<'@G1_C%X>N/$%
MU/\ 98$FMKN"SGESMV)=20I _/3$GS=J /HJ\^*WAG1_B#8>$[SQ%HEKXJU:
MVDN['1YM0A74+R!/OR1P[O,=$[N!@<US&A?LG> ?"G[2_B#XO:?H#0_$;Q-I
M4>C:IJ_V^Z;[5:1^7LC\CS/(0_N(_G2,/\O6O'_BY\/_ -F_5/\ @J%\-K[Q
M1"/^&C/[$GN/"RA+[_2K%$N-[OL7[)\@^U?ZSY^?]P5Z%^U;_P %#/@U^Q!8
M6,GQ3\?Z/X3DU)"]M9NLUY>7"CJZ06Z/,4SQOV8XH [_ ,:_&+PE\-M;T'2_
M$?BKP[H.I>*;K[#HUEJ6I0VEQJT_R?N+='8&:3YT^2/)^<>M<[J_[)O@#6_V
MG]-^,EUH"S_$K1]%_P"$?LM7-_<XM[$O))Y'D[_(^_-(=_E[_GZXK\Y?V_\
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M$Z/%OAGP?XY\-_$?7_BAIT>DZ%H&BS"\U"6>=TV230#]Y 8^)-DB(^^/&.N
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MZ&N76./S+B\F<A(X(8\?/([G@?C]WI\5WG_!=SQ_X6\"VGQ'\6_LF_%#P_\
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M\\>?%3P9HOP]^)7[4GCKQU\&]!NH)X/"S^'K2UO+A(,>7!<:AO>2>/Y?XTH
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M'A_2]'T#QAXH\>06VIPV$"6_]IP0W5ILGD1/XX]^S?\ Q^9_L5^KU?G1:_\
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MV^O@S\<K7Q1'I$/PAT^^TU/#ZZ3YB:A'=03P9$PF3R?+$V0/+?[G:N6\!?\
M!*L>"/\ @J9XB_:9C^)OBB\DU^R>T/AF=/\ 1H]\$<&QY]_[RW39OC@\OY'Y
MWT ?8%?G%_P2=_Y2X?MY?]A[1/\ V_K]':^;/V4/V O^&7_VN/CQ\4O^$L&N
M?\+PU"QO_P"SAI?V4Z+]E\\;/.\Y_.W^?U\N/'E^] 'SK_P; 7*V_P#P3@O=
M$F9(]8\->,M4L=3M-^9+.?\ </L?WYI/C]=KXB_X.7?@7;V#+=3>'_AOJ-QJ
M2QO_ ,>J2#4D0N/K(G_?:5UWQD_X(T:E9?M!^*OB7\ _C9XP^ .O>/)?M'B6
MRTW3TU+2-3FP?WPMG= LF7=^2WSR/L\O>^?2OV#/^"8GA[]C+Q=XH\<:EXI\
M3?$OXI>-R!K?B_Q#-NO)(^H@A0?ZF+[GR _\LXQ_ E 'M'[3/Q3O/@=^S=\0
MO&MC9_VC>^$/#6I:U:VF/^/F2UM9)TC_ .!E /QK\QO^";'_  1O^$G_  4
M_91L/CC\;9-;^)7Q$^+DEUJM_JBZO/9II[^>\&V-('2/?&80/W@?'*;..?J[
M]BK_ ().6_['_P"TY\9/B))\1O$'CJT^,$DWVC1=5M_W-NDDWF?OW+O]IDY=
M/,*)\DC\5YI;?\$0/&?P2UG6]+^ 7[3WQ"^#7P\\07,EW/X732X]6CLY'_U@
MM9Y)HY(/]\9DX3+O0!SO_!&KPY]MMOVFOV3_ !?<?\+ ^''PBUW^PM+N+Y4E
M^TZ??>>CV,[QXR\?D'T*/))_<0([]HC_ ()3?LV_L'?!C4OB3XZ\1?%CQ/\
M#OX9[]7T7P#KWBV2[\/6UYG$,%K;;/\ 622;$'F.^?,^?(KZ\_8(_8 \&_\
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MQ^7_ '-]>:_\%!?^"?/AGX0_#'P_\8OA'K4WB7X2^+'V1^:WFW&F.^_8F_\
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M (23?]J\O_42>?OW_N-GF?<\C_@=</\ "']BOQE\;?V??&?Q*T?^R/\ A'?
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MV"HH _./P1_P<4> ]8\!VNCZE\/_ (E6_P =?LX@G^'MOX>GDO)-0^X4C?\
MYX>9_&^'V<[.U9O_  ;(:QJGB3]E_P",^H:];QVNN7WQ;U6YU&!?^7>Y>TL'
MD3_OLU^EU% 'C_[:7[57@7]C#]GSQ%XZ\?W:PZ#I\+1FS"B235YF0[+2./!W
MO)TP>,<M\@-?!?\ P2'_ .":Z?%?XQWW[6/Q2\"^&?"&I^*)Q=>!_!VEZ3!8
MVGA^U/W+N2.-/GN)$_C?#_?=_P#6 )^JE% 'Q=_P4:_;$^,G["7Q;\"^--%\
M$S>/O@#)%):>-;;1M/DN?$&CS?O-EU&=^SR/G0\ILS!L,B>8E?'W_!2#]M33
M?^"W7PV\,_ G]G3PGXL\62:QXAMM0USQ-?Z0]II7AJ&'?G?))_RT^?/NB%$W
M^97[)44 <_)J%C\-/AX]SJFH"#3?#]AOO+^[?;LA@3]Y/(_^XA<U^>'_  3R
M\/:A_P %/?VZ_$7[6?BRUNE^'O@N2?PQ\(].NH]F^-))$GU79_??YQG^_(Z?
M\L$-?I?10!^-_P"QQ^T5\/\ _@E/XD^/7@G]I;P7K\?C[QCXOO=6@U__ (1J
M35H_B'93?ZN"!PCI_P ]G\N3RX_WY_Y:>97TU_P;]? WQ?\ !/\ 9'\4W'B/
M0=1\%Z-XW\8WWB7POX9OD*7&@Z9.D?E1D-]S.P_)[;_^6E?>U% 'P#_P5V_8
MG^(OB7XK?#?]I+X%K%>?%CX.%X7T67C_ (232W9]]JA/4XFG39_''/)L_>".
MN3T/_@YA^#VF:&EKXX\$_%CP;\0;= EUX5FT'S+GS^\<;[T#_-Q\XC/^Q7Z5
M44 ?!?[%O[17[1?[75S\4_'_ (\\'0_#/X*ZAH4T/A'PYJMD1KDKHI_TMY/W
M;HDB9XD3_GGL^X[R>,_\$??VF3^QW_P;XS?$R/PSJ?C!_!]YJEV-(L6*SW?_
M !,MG+['\N./?OD?8^R-)'YK]6J* /$/V _VN&_;H_92\+?$YO">J^#?^$C2
M5_[*OG\R6+9(\>])-D?F1OLRC[$S6_\ 'W]CKX6_M17NFW'Q$^'_ (5\:3:-
M')'9/K&GQW?V19,;]F\=]BUZA10!P'P*_9Q\!_LQ>&+K0_A[X1T/P=H]_=?;
MI[/2K1+>W>?RXX]^Q?X]D:#_ (!7YT_\$+_C0?V=O^"2OQH\=+H>J>)7\*>-
MO$.I_P!E:;'_ *1>>7:VDGEQ_P#Q=?JK10!\C_LE_P#!5CPS\>_^"?VH?M!^
M-=!O/A9X=TF2Z2]AOKK[4CHGE[)()-D?G>9O1$^3[^4ZU\@_\$YOV$=/_P""
MDG[5MU^UCXX^&OAGP+\/$NO,^'WA*TTBUL_[3"/\FI7WEIF9_P"/]Y]^3_IG
M&E?KM10 5^8O[3-Q)_P6"_X*5V'P1TUY)O@7\ +U-:\?WD+9M_$&L#_4:;O]
M(_G1Q_UW[HE?IU10!^5?[2.O:-^P%_P6FUSXU?&GPOJ]Y\*O%'A2QTOPCXNM
M=(?4K7P5<0)&LUNZ1H[P;]DS[T0N1/\ )G]YLWO^"56DM\=?^"H7QN^/O@'P
MCK'@?X*>*-"M=&M/MNG?V7'XGU3?!(]\D'_ )OWG_3?^_))7Z;44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E%'44 0_-YJ
M_+\N*RO%'BW3_!/AZZU35+J'3]/L(FFN+B9]D<2*,EF-,\=>.-)^&_A:\UK6
MKVWTW3-.B,UQ<3N(XX4'<FOQ_P#^"A?_  44U7]K'Q'+HNBR7&F^ [*;$-O]
MR34F_P">LWM_<3O7GYEFE/"0YIGZ%X>^'.8\58[V5!<M&/QSZ)>7>7D7?^"B
MO_!2&_\ VH-7E\-^%Y)]/\!6;D$#Y)]893G>_P#L?W$_X&_^Q\H445^;8K%5
M,54]I4/]"N%N%\OX?R^&79=#EC'=]6^[\SIO@_\ %_Q%\!_B%8^)O"^HR:?J
MFGO\CI_JY$_C1T_C1_[E?LE^PM^W?X?_ &R/!BB-H]+\5::@74=+:3[A_P">
ML7]]#QS_  ]/K^(];GPR^)FN?!_QMI_B+PYJ%QIFKZ:^^&XB[_\ 3/\ VX_]
MBNW*\XGA)V?P'P_B;X78+BO"N4?<Q4/@GW_NR_N_^DG]$1;!_I0 #7S#^P/_
M ,% ]%_;"\,+9WK0Z7XRTN,?;K#S/DF_Z;0_WXS_ ..].?O'Z<^YS7Z-A\1"
MM#GIG^?V=9+C<IQD\#F$.2<'U)**,T9K8\P**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV@=7O?VEYOBHUKI?]O3^*/\ A+'MO+?[']J^U?:_+V;_ #/+\S_II_VTHZW
M^CO^"[__ "D,UC_L$:?_ .B*^K_B)\=X]"_X)4_!7QEHGPK\$_%S0/#^BVNF
MZU;:WI?V_P#L6:"T\B2?9L^0>9"\;OQ]].U?FE^UA^U/X@_;$^,5UXX\46>C
MV.JWEK!:20Z5 \=N41-B??=W_P#(E;W[)7[?/Q)_8MO;P^"]4M_[+U*3S+S2
M+Z'SK"=^/GV?P/Q]^/9FE;0#ZN_9._;O\0?%[XKPQ?"/]E/X/+XJTNWDNTO=
M*TI-/DLH_+<?\?.R,1[\;/O_ #^9LK>_X)3?%36OC5_P5W^)7B3Q)H]OX=U^
M^T&]74--B\S_ $.>.>P@=/G_ .N=>&?%#_@N'\:_B#X,OM%TU/"'@>._7;-<
M^&],D@O)/^>GSR3R;/\ ?C^>O&OV/_VRO%7[%GQ:NO&7A>ST/5-8U#3YM-F3
M6(9YX]CR1R/)\CI)YG[O_GI4@<1\:;J2Z^,?BZ:5Y)))-;OI'=_^6G[^2OO3
M_@HM_P H=?V:?I:?^D,E?GEXCUZ;Q1XDU+4KA(XY]0NGNW1/]7O=_,KUSXS?
MMS^+OCA^S?X*^&&K6'AV'P_X!\O^SI[2":.[F\N#R_WSO,Z?Q_P(E: ?9G_!
M9OPOJ'[37[,WP9^+G@NUGUCP78:3.EY]ECW_ -EB>.W?S)$3[B1^1(C_ //-
MT%?._P#P1O\ @?XH^)G[<7@[6]'L;^/0_"ET]]J>I)')]G@1$D_=[_[\F_9L
M_P"FE<5^R)_P4=^)_P"Q9!=6?A/4K.[T.[?S'T?58?/L]_\ ?3YXY$?_ ')*
M]"^.'_!;'XU?&7X?77AN)_#'@RQOHWCN7\.V4D-Q/&XPZ>9)/)L^J;#S2U ^
MD_V<_B-I7Q5_X."_&FL:+)'/IOV2ZM$E0_NY)(+&""1_^_D#U^??[9$K2_M>
M?%1V_>22>,M8WO\ ]OT]._9/_:G\0?L=_&*U\<>%[/1[[5;.UGM(X=5@>2W"
M.FQ_N.C_ /D2N/\ B7X\O/BA\2/$'B>_2W@OO$FHSZE=);)Y<<;SO)(^S_IG
M\],#[V_;<_Y0=?L\_P#87@_]$7]6?^";T37_ /P2!_:6MH%\^?9=R;$_UG_'
MC'_\17R;\5?VY?%GQ>_98\'_  ?U&P\/P>&? ]TEW97-M!/'J$C[)X_WCN_E
M_P#+=_\ EFE0?L??MQ^/OV(?%&H:EX+O-/\ )U=$34--O[7S[.[V?<WI^[D_
M=^9)_JY*0'E_A+Q1?^"/%&FZWI-S)8ZKH]TE_97*?ZRWG1_,1_\ OY7[):C^
MS#X?_P""F_Q*_9]_:#M%MUTM+;/BJRW]'M?,>.W_ .V=V)(9/[\?M7Y>_M@_
MMH>)_P!M7Q5I.J>)=+\,:.^A6KV=K;:+926D&QWW_P#+1Y*^X/ _C'5/^"=_
M_!$K[9<:E>0^+OBW<R-HUN\W_(,2]3[Z?W,6B&?_ *Z2)0P/D7_@J1^U;_PU
MO^U]XCUJSNOM'AS1W_L71-C^9'):P/\ Z]/^NDF]_P#MI'7SS113 *_7[_@W
M"_Y-V^(7_8Q1_P#I+'7Y U^OW_!N%_R;M\0O^QBC_P#26.IJCCN?HU1116)8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !116?X@UF/0- O[Z16D33X'G=5ZOL3?_2@#0HKB?@G\9;+XW^&[O4M/M[J
MVCM;G[*Z7.S=G8C_ ,)/9Z[:@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **-U&>* (
MR0%YKG/B+\2-%^$W@R^U_P 0:C#IFDZ=&9KB>5BJ)C\?TJ#XM_%W0_@KX&U#
MQ)XCU"'3M)TV/?+*[8]?E7^\QQ]T<U^-O[=_[>FO?MB^-/+5KC3?!>FS?\2S
M3-_^L_Z;3?WW_P#1?_C[^7F>:4\)3N_B/TWPU\,<=Q7C>6/N8>'QS_\ ;8]Y
M,T/V^_\ @H+K7[7WBC^S[$SZ3X*L9L6=EO\ WEVW:6;_ &A_SS_@[U\WT45^
M;8K%5*]3VE0_T#X?X<P.2X&&79;#DA#\?7S"BBBL#W HHHH U?!'CC5OASXM
MT_7-#OIM,U;39O.MKB)\NCU^OO\ P3U_X*-Z3^UAH,>AZTT.E^.M/A'VBU/R
MQZ@G_/:'_P!G3JA/-?C;5[PSXFU'P5XCLM6TJ[N-/U2QF2>VN+=]DD#I_'7K
M95FM3"3L_@/S3Q*\-<!Q9@^6?N8B'P3_ $?]T_HN/'>E)P*^.O\ @G7_ ,%*
MK']IW2[?POXIN+?3?'5G$#G&R/5XQ_'#G^/^^@Z'[N1G9]B YYZC^=?HV'Q$
M,1!3@?Y\<0<.X_),;/+\Q@X3A^/FNZ)**,T9KH/%"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[#__  J7_AHC2O\ A=G]H?\ "!^1/]J^S>?Y?G^7\GG^1^_\O_KG^\\SR_\
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M7?V)_P )]X@_MQ/#D,D&F(FGVMI'9I)Y>_Y($3^Y'_W[KI_^"?/[%^H?MO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'\S]WY"?QTO_  S5X+_X>]_\*O\ [$_XH7_A+O[-_LW[;/\ \>O]SSM_F?\
MD2N\_99_Y3_:I_V/WBC_ -OZ/^<__P#W/]6(]*_:]^ G[''[!WQ9N--\5>$O
M%_BS4]<$=_!X?TW5)TM] M=FS[_GQR.\CH[_ +R1_P#MG'7B_P#P44_8?^'G
M@/X!^#?C=\&+R_N/A[XON$M)K&X=YY-,FV28^?/F??A>.1))/DD'WZXW_@L?
M(TG_  4G^)@;Y_W]CC_P76E>Y^-O^5=?P=_V,\G_ *<;NH _/"BBOL/X,_\
M!:WXG? WX3Z#X/TGPK\,KC3_  [91V-K/?:9=27$B1_WW6Z0;ZT ^/*^^?\
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M=5Y_T-4/_@#_ /9T?\.ZKS_H:H?_  !_^SH ]^_X79X-_P"AN\+_ /@T@_\
MBZ/^%V>#?^AN\+_^#2#_ .+KP'_AW5>?]#5#_P" /_V='_#NJ\_Z&J'_ , ?
M_LZ /?O^%V>#?^AN\+_^#2#_ .+H_P"%V>#?^AN\+_\ @T@_^+KP'_AW5>?]
M#5#_ . /_P!G1_P[JO/^AJA_\ ?_ +.@#W[_ (79X-_Z&[PO_P"#2#_XNC_A
M=G@W_H;O"_\ X-(/_BZ\!_X=U7G_ $-4/_@#_P#9T?\ #NJ\_P"AJA_\ ?\
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M^_X79X-_Z&[PO_X-(/\ XNC_ (79X-_Z&[PO_P"#2#_XNO ?^'=5Y_T-4/\
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M7P^>CO%GZ$>/OV>9[3]GCX6?LQVFJ6.J>-+K5&UK7IK=?,30K+S)I'<?W/\
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M[T=/^6=?IE_P30_X*B'QO'9_#_XC7VW5HXS'INN3. E^J#[D[]%DP.'/W_\
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M_0W>%_\ P:0?_%T?\+L\&_\ 0W>%_P#P:0?_ !=> _\ #NJ\_P"AJA_\ ?\
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M .SH_P"'=5Y_T-4/_@#_ /9T >_?\+L\&_\ 0W>%_P#P:0?_ !='_"[/!O\
MT-WA?_P:0?\ Q=> _P##NJ\_Z&J'_P  ?_LZ/^'=5Y_T-4/_ ( __9T >_?\
M+L\&_P#0W>%__!I!_P#%T?\ "[/!O_0W>%__  :0?_%UX#_P[JO/^AJA_P#
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M_"[/!O\ T-WA?_P:0?\ Q='_  NSP;_T-WA?_P &D'_Q=> _\.ZKS_H:H?\
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M?[]?:OA6'[-X7TV/_GG;1I_XX* -2BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<_\3/\ DFWB3_L&7/\
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M^@O#W_(!L/\ KA'_ .@"@"]1110 4444 %%%% !1110 4444 %%%% !1110
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MOQ_2NLMK1;*WCA3A8UV+0!-1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%%  IR*_EGK^I=/NU_+15TR9!1116I(4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^OW_!N%
M_P F[?$+_L8H_P#TECK\@:_7[_@W"_Y-V^(7_8Q1_P#I+'4U1QW/T:HHHK$L
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&1!*A
M5AE6&#7PY^UU_P $?])^._Q9L_$GA;4(?"YU.Z_XGUOY/[N5.=\T*_\ /;C[
MI_=\[^O#_<[]*:.>^:Y<1A:6(AR5D>_P[Q1F618GZUE=5TY[:?Y'!_ SX%^'
M?V=/A_8^&?#%C'9:?9IC@?/(W\3NW\3'N37> Y9OI003W%!*JE=%.G"$>2!X
MV(Q%;$5I5\1/FE+5MDF** <BBJ,0HHHH **** "BBB@ HHHH **** "BBB@
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MBN)OOCIX<TSXD)X2FNY$UN1TC2'R7YWIO'S].E ';4444 %%%% !117.^/\
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MP_\  Q0!TE&*** "C&:** "BN=\>_$C1?AMI\-SK6H1Z;#</Y<;O&[[W_P"
M"MJPO([^UCF@820S)O1O[U %BBBB@ HHHH **Y[XC?$&P^&/A*ZUG4O/^Q67
ME^9Y*>9)\[A.GU-/^'WCVR^)/A2UUC3O/^QWF_R_-3RY/E<IT_ T ;U%%% !
M1110 445S%K\6O#][XVE\.Q:E&VMVXR]ML?(_I0!T]%%% !1110 445SOCWX
ME:+\-[&&YUS4(]-AG?RT=T=]Y_X * .BHJEI6KPZ[ID%Y:NLUK=QI-$XZ.C\
MBKM !1110 4444 %%<SX9^*V@>,-?OM+TW48[K4-/_X^HD5LQ?/LY_&NFH *
M*** "BBB@ HKF=?^*N@>&/%-CHM]J4=MJFH;!:V[*V9=[[$Q^/%=-0 4444
M%%%% !17->/OBCH?PTMK>37-2CTU+I_+A+H[[S_P 5OV\Z74".GS)(N]: )J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** !3D5_+/7
M]2Z?=K^6BKIDR"BBBM20HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[W_ ."3'_(AVG_8W_\
MLEI7P17WO_P28_Y$.T_[&_\ ]DM*SJ ?M#11169H%%%% !7B?[>G_)#X_P#L
M*0_^@25[97B?[>G_ "0^/_L*0_\ H$E '5_LM?\ )!/#'_7I_P"SO7H->??L
MM?\ )!/#'_7I_P"SO7H- !1110 4444 > _\%!O^24Z1_P!AA/\ T3)7KWPQ
M_P"29^&_^P9:_P#HM*\A_P""@W_)*=(_[#"?^B9*]>^&/_),_#?_ &#+7_T6
ME '04444 %%%% !7S'_P3Y_Y#OC3_MU_]#N*^G*^8_\ @GS_ ,AWQI_VZ_\
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M/^V__HBOINOF3P9_R?\ ZI_VW_\ 1% 'TW1110 4444 %?//_!0[_D1_#_\
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MY -A_P!<(_\ T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^,7@?3K#1IKR2>WO?/?SH/+^3RY*^?Z* /L+PE^VAX'T;PII=G//J'GV=M'
M_P#HO1TC%:7_  W)X"_Y^=5_\ Z^*Z* /M3_ (;D\!?\_.J_^ ='_#<G@+_G
MYU7_ , Z^*Z* /M3_AN3P%_S\ZK_ . ='_#<G@+_ )^=5_\  .OBNB@#VO\
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M^'=7P'_Z)'X _P#!/#_A1_P[J^ __1(_ '_@GA_PKVRB@#Q/_AW5\!_^B1^
M/_!/#_A1_P .ZO@/_P!$C\ ?^">'_"O;** /$_\ AW5\!_\ HD?@#_P3P_X4
M?\.ZO@/_ -$C\ ?^">'_  KVRB@#Q/\ X=U? ?\ Z)'X _\ !/#_ (5Y)\;?
M@GX1^!_Q>\'Z7X.\-Z-X8TV\GCNYK;3;5+>.1_.CCWG9_L(E?8]?,?[9'_)>
MO GUA_\ 1] 'TA_8]G_SZV__ 'YH_L>S_P"?6W_[\U<HH I_V/9_\^MO_P!^
M:/['L_\ GUM_^_-7** *?]CV?_/K;_\ ?FO&?V[;"WM?@G&T<,*/_:D'W4_V
M)*]RKQ/]O3_DA\?_ &%(?_0)* .C_9ATRWF^ OAEVM[=W^R_>9/]MZ[W^Q[/
M_GUM_P#OS7%?LM?\D$\,?]>G_L[UZ#0!3_L>S_Y];?\ [\T?V/9_\^MO_P!^
M:N44 4_['L_^?6W_ ._-']CV?_/K;_\ ?FKE% 'S_P#M^6,-K\*-+:.&%)/[
M73[J?],9*]6^&>CVC_#?P]NMH/\ D&6O\'_3-*\K_P""@W_)*=(_[#"?^B9*
M]>^&/_),_#?_ &#+7_T6E &I_8]G_P ^MO\ ]^:/['L_^?6W_P"_-7** *?]
MCV?_ #ZV_P#WYH_L>S_Y];?_ +\U<HH I_V/9_\ /K;_ /?FOFG]@*PANM;\
M9>9#')_QZ_?3_;GKZBKYC_X)\_\ (=\:?]NO_H=Q0!](?V/9_P#/K;_]^:/[
M'L_^?6W_ ._-7** *?\ 8]G_ ,^MO_WYH_L>S_Y];?\ [\U<HH \)_;RL+>U
M^"]JT<,*/_:\'W8_]B2O1/@QH]K+\'O"3-;P,W]BVG\'_3!*\_\ V_/^2*6O
M_87@_P#0)*])^"'_ "1;PC_V!;+_ -$)0!N_V/9_\^MO_P!^:/['L_\ GUM_
M^_-7** *?]CV?_/K;_\ ?FC^Q[/_ )];?_OS5RB@#S;]I[3+>'X"^)G6WMT?
M[+]Y4_VTK'_8PTNWNO@!I+R6\+R>=/\ ,T?7]^]=!^U+_P D$\3_ /7I_P"S
MI6-^Q5_R;]I?_7:?_P!'O0!Z=_8]G_SZV_\ WYH_L>S_ .?6W_[\U<HH I_V
M/9_\^MO_ -^:/['L_P#GUM_^_-7** *?]CV?_/K;_P#?FOEOQM;0Q_M\V<*Q
M1^7]JM?EV?\ 3".OK"OE+QI_RD"L?^OJU_\ 25* /J'^Q[/_ )];?_OS1_8]
MG_SZV_\ WYJY10!3_L>S_P"?6W_[\T?V/9_\^MO_ -^:N44 4_['L_\ GUM_
M^_->-_MR:9;VOP,=HX88W_M"#E4_WZ]PKQ?]NO\ Y(4__80@_P#9Z .H_9UT
MNWE^!_AAVM[=I/[/3^"NT_L>S_Y];?\ [\URG[-__)"O"O\ V#TKMZ *?]CV
M?_/K;_\ ?FC^Q[/_ )];?_OS5RB@"G_8]G_SZV__ 'YH_L>S_P"?6W_[\U<H
MH ^7?@)80S?MG>-4:*-XX_MWR[/^GJ.OI;^Q[/\ Y];?_OS7SC\ ?^3U?&WT
MOO\ TJCKZ:H I_V/9_\ /K;_ /?FC^Q[/_GUM_\ OS5RB@"G_8]G_P ^MO\
M]^:/['L_^?6W_P"_-7** /F/]L6PAMOC5X#2.&.-))$W[$_Z;QU](?V/9_\
M/K;_ /?FOG/]LO\ Y+=X!_ZZ)_Z/CKZ8H I_V/9_\^MO_P!^:/['L_\ GUM_
M^_-7** *?]CV?_/K;_\ ?FC^Q[/_ )];?_OS5RB@#YG_ ."AEA#:Z'X9\N&-
M/W\_W$_ZYUY3^R%"EW^T7X<CD6-X_P#2OD?_ *]9*]=_X*)?\@7PO_UWG_E'
M7DO[&O\ R<AX;_[>O_222LP/M_\ L>S_ .?6W_[\T?V/9_\ /K;_ /?FKE%:
M 4_['L_^?6W_ ._-']CV?_/K;_\ ?FKE% %/^Q[/_GUM_P#OS7S?^T38PQ_M
MA> $6*-8Y$LMZ;/^GN2OIROF?]H[_D\KX?\ ^Y9?^E<E 'T9_8]G_P ^MO\
M]^:/['L_^?6W_P"_-7** *?]CV?_ #ZV_P#WYH_L>S_Y];?_ +\U<HH I_V/
M9_\ /K;_ /?FO"/V_+&&V^&6C^5#&G_$T_@3_IG)7T'7@'_!0;_DEVC_ /84
M_P#:;T >N?#_ $BUE\!:)NMH/^0?!_!_TS%:_P#8]G_SZV__ 'YK/^'7_(A:
M+_V#X/\ T6*W* *?]CV?_/K;_P#?FC^Q[/\ Y];?_OS5RB@"G_8]G_SZV_\
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M[DKZ0_L>S_Y];?\ [\U\Y_M)_P#)X?P__P!VR_\ 2N2OIB@"G_8]G_SZV_\
MWYH_L>S_ .?6W_[\U<HH I_V/9_\^MO_ -^:/['L_P#GUM_^_-7** /FK_@H
M-8PVWA[PSY4,:?OY_N)_L)7T/X>_Y -A_P!<(_\ T 5\^_\ !1#_ )%WPS_U
M\3_^@)7T%X>_Y -A_P!<(_\ T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<_P!K
M#P5JWB'XV^"[S3])U.^M;;R_M$UM:R/'%^^_C=.E?1E% !1110 4444 %>)_
MMZ?\D/C_ .PI#_Z!)7ME% 'GW[+7_)!/#'_7I_[.]>@T44 %%%% !1110!X#
M_P %!O\ DE.D?]AA/_1,E>O?#'_DF?AO_L&6O_HM*Z"B@ HHHH **** "OF/
M_@GS_P AWQI_VZ_^AW%?3E% !1110 4444 >&_M^?\D4M?\ L+P?^@25Z3\$
M/^2+>$?^P+9?^B$KJ:* "BBB@ HHHH X7]HW3+C7O@EXBL[.WN+JZN+7$<,,
M?F22?,.B=ZQ_V1-#OO#_ ,#--M-0M+O3[J.6??#<0O')'^\?'ROS7J5% !11
M10 4444 %?*7C3_E(%8_]?5K_P"DJ5]6T4 %%%% !1110 5XO^W7_P D*?\
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M[_[0KZ'\+?\ (K:;_P!>L?\ Z!4?B3P/H_B]8?[6T?3=5\C_ %7VNU2?R_\
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M0.CCZH^: -BBO%?V]/VN=+_89_94\9_%'5H#?1^%['?;68DVF_NG=(X(.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ_A;]A#Q+XQU:VDL8?B/XSO=9TZ)UQOM42.#?^,D<P_X!0!^E5%%% !1110
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M4(OGL;SXCW7DS_\ +.?_ $6 _)_WVE 'ZF4444 %%%% !1110 4444 %%%%
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M^"F'[6'@*Z^&VK>"/A1\*=-UZ!]-U;Q79:HDDMQ!)\DGEA+J>2/Y"^2D>_\
MN>77W)_P3Z_8G\/_ /!/O]E[P]\-O#LS7R:7ON-0U&5=LNJ7DGSS3NO;LB)S
ML2-!SBO=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>globalaestheticimprovement2.jpg
<TEXT>
begin 644 globalaestheticimprovement2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M-@  DI(  @    ,S-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /'?A[_ ,CXG^[+_(U[%7AGAC6;
M?0?%'VZ\25XE#J1$ 6YX[D5WO_"U=#_Y]=0_[]I_\77G86K"$+2?4^OSO XG
M$8E3I0;7*OU.VHKBXOBCHLTR1K:WX+L%&8T[_P# Z[2NZ%2,_A=SYG$86OAK
M>VC:YROQ"T?^U/"\DT:YGLSYRXZE?XA^7/X5A?#;Q%%;Z/?6-[)M2S4W*$_W
M/XA^!Y_X%7HS*'4JX#*PP01D$5X-XBTV30/$%Y8QLR1Y.P@_>C;D#\OY5QXB
M]*:JKT/H,H4,=AIX&H]O>7Z_UYFMX9MI?%OCPWEVNZ-9#<S \@ 'Y5_/ ^E>
MR5QWPUT?^S_#IO95Q-?-OY'1!PO]3^(KL:VPT.6G=[O4X,ZQ*K8KDA\,/=7R
MW_KR//O$_P /M1USQ'=:C;75K''-LVK(6W#"!>P]JR?^%4ZM_P _ME^;_P#Q
M->KT4I86E)ML=+/,;2IQIQ:LE;;L4KFW<:!+;+\TGV8QC'<[<5YU\)Y%&K:A
M&3\S0*P'L&Y_F*]2KR/7],O_  1XJ&K::F;1Y"T9P2H!ZQM_3_&IQ'N2C4Z(
MVRJ2KT:V$;M*:37JNAZY6)XSD6/P;J;.< P[?Q) 'ZFL&V^*NDO;@W=I=12]
MU0*X_ Y'\JYGQ#XIOO&MS#I>E6CI 7R(\Y:0^K=@!_DTZF(I\C47=L6#RC%+
M$1E5CRQB[MO;0Z#X3QL-*U"0CY&G50?<+S_,5B^*G%K\5[>XFXC6>VD)]AMS
M_(UZ'X9T1= T&"Q!#2#+RN/XG/7_  _"N>^(WAB;5K6+4K",R7%LI62->KIU
MX]P<\>]9SI26'26ZU.C#8ZC/-:DY.T9WC?[K/YV.WHKS3P_\35M;*.UURWED
M>(;1/%@E@.FX''/OFI-;^*,4EF\.AV\JRN,>=. -GN "<FMOK5+EYKG"\DQW
MM?9\GSZ>O]:F98#[5\8F,)# 7DA)]E#9_E7K+,$4LY"JHR23@ 5P/PX\+SV9
M?6=20I+,FV!'^\%/5C]>WX^M7?B9JDMCX;2V@8JUY)L8C^X!DC\>/UK.BW3I
M.<NNIU9A&.,QU/"TG?E2C?TW^XQ/$_CZYU&Y.E>& ^';89XP2\I]$]![]?I5
MOPO\.%A=+WQ$%EE^\MKG*@^KGN?;I]:P?!/B#0O#L<MQJ$-Q)?.=JND8(1/0
M9/4]ZZW_ (6CH/\ SRO?^_2__%5E3E3F^>K+7MV._%4\5AXO"X"DU'K+J_G_
M %Y'9 !5"J  !@ =J6N6TSX@Z/JNI0V-M'="69MJEXP!GWYKJ:[XSC-7BSY.
MOAZV'ERU8M-]PHHHJS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+$6FF0"*/.YCG+,?4GO0!S7PKGC;PBUL&'G6]PZRQG[RYY&1_GH?2H)Y$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#30:G!]^+U7'\0/'R]2>!U.>UK(\0>%=&\4QV\>O6ANXK:02QQ&9U3<.Y56
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MN)EC\QC_  KDC)]A5NO(=,U*P\:>/)O&>O7EM9^&M$D-KI!NY5CCGF_BFRV
M>V/^ ^AKUBTO+:_M4N;&XBN8)!E)87#JP]01P: )J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT<\$JAHY8G#*X/<$<$5+5#2-4TC4[,?V#?65Y;P@1_Z',DBI@<+\I('':K]
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M?_\ ?M/_ (N@#MJ*XG_A:FA?\^]__P!^T_\ BZ/^%J:%_P ^]_\ ]^T_^+H
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MCKCG!/&:]*\(^.1XDU"]TG4M+N-%UJP"M<6,[A_D/1E<<,.G..XH ZNBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M][__ +]I_P#%UY'10!ZY_P +4T+_ )][_P#[]I_\71_PM30O^?>__P"_:?\
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MX3T+6KG[3JFGQRS  &3<R$@>I4C/XUQ=M##KVL7%[I]K&-"\/QO]D@4?)/,
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M?ZL4O^?C^Y'T!_PD.B_]!>P_\"4_QH_X2'1?^@O8?^!*?XU\_P!%'UZ78/\
M5BE_S\?W(^@/^$AT7_H+V'_@2G^-6;34;*_W_8;RWN=F-WDRJ^W/3.#QTKYV
MKT?X1_>U;Z0_^SUK1Q<JDU%HX<PR*GA,-*M&;=K?BTCTJBBBN\^4"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /FYOO'ZTE*WWC]:2@ HHHH **** "BB
MB@!5^]^!_E10OWOP/\J*\C&_Q%Z'W_#7^Z2_Q/\ )!1117"?3A1110 4444
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MO1_A'][5OI#_ .SUTX7^,OZZ'C9Y_P B^I\O_2D>E4445[A^9!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^NAXV>?\B^I\O_2D>E4445[A^9!1110 4444 ?-S?>/UI*5OO'ZTE !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO?@?Y45Y&-_B+T/O^&O]TE_B?Y(****X3Z<**** "BBB@ KT?X1_>U;Z0_\
ML]><5Z/\(_O:M](?_9ZZ<+_&7]=#QL\_Y%]3Y?\ I2/2J***]P_,@HHHH **
M** /FYOO'ZTE*WWC]:2@ HHHH **** "BBB@!5^]^!_E10OWOP/\J*\C&_Q%
MZ'W_  U_NDO\3_)!1117"?3A1110 4444 %>C_"/[VK?2'_V>O.*]'^$?WM6
M^D/_ +/73A?XR_KH>-GG_(OJ?+_TI'I5%%%>X?F04444 %%%% !1110 4444
M %%%% !1110 444$X&3P* "BJ>G:OINL0O+I&H6M_'&VQWM9UE"MZ$J3@^U0
M?\)+H7]I?V=_;6G?;L[?LOVI/-SZ;,YH TZ**Q[SQ?X:TZ\DM-0\0Z5:W,1Q
M)#/>QHZ'&>5+9% &Q1638>+/#NJ7BVFF:_I=Y<N"5AM[R.1VP,G"@DGCFI8/
M$6B76I'3K;6+":]4D&VCND:08Z_*#F@#1HJO?:A9Z79O=ZG=P6=LF-TUQ*(T
M7)P,L2 .:EBECGA26"19(W 9'1LJP/0@CK0 ^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N%UV,:]\0H-$U29XM/CM_-2)6V^>_U_/_OD^M=U65K?AO3O
M$"1_;XV\R+_5S1MM=?QH Y:WT^WT+X@0Z-II,NGWUNS7-G*WF)'@,0<'Z#KS
MS6D/"%QH^K17GAB\:V@>5?M-G(<HRD_,5ST./_U]JU-#\+Z;H#2262.T\HP\
M\S[G(],^E;% !1110 4444 %%%% !1110 45FOXDT..1DDUG3U=3AE:Z0$'T
MZT^WU[2+RX6"TU6QGF?[L<5RC,W?@ YH OT56N]2L=/"F_O;>U#=/.E5,_F:
ME@GAN85EMI4FC;H\;!@?Q% $E%5;S4[#3MO]H7MM:[ON^?*J9^F34\,T5Q"L
ML$B2QN,JZ,""/8B@!]%5_P"T+/[=]B^UP?:\;O(\P>9CUV]:L4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS_D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH **** "BBB@
MHHHH 5?O?@?Y44+][\#_ "HKR,;_ !%Z'W_#7^Z2_P 3_)!1117"?3A1110
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MIW;VNFZO87EQ&,O#;W*2.OU .17@5K_: ^$_CNV\+R3R^'X-5Q:%&);[-O\
MWH0G^';L/T+$]36IXE_X0@V7A4_#'[)_PD'VV$VGV(?O=G\7GXY],[^>O;-
M'N&H:I8:3;K/JM];64+.$62YF6-2QZ+EB!G@\59!#*"I!!&01WKR)M0LO'GQ
M$?6=5N[>W\(^%Y?+@EN)52*ZN^[9;@A<#'T'J:]6L;^SU.U6ZTV[@N[=_NS6
M\@D1OH1Q0!8JAJ&@Z1JTB2:KI5C>O']QKFV20K]"P.*OT4 ,AABMX5B@C2*-
M!A410H4>@ K/;PSH+ZA]O?1-.:\SG[2;2,R9ZYW8S6G10!5OM*T_4_*_M*QM
MKSR7WQ?:(5D\MO[PR.#[BD.E:>VJKJ;6%J;]4\M;LPKYH3^Z'QG')XS5NB@
MJI-I6GW&HPZA<6%K+>VX*PW+PJTD8/4*Q&1U/2K=% $-W9VU_:O;7UO%<P/P
M\4R!U;Z@\&HM.TK3M(MS!I-A:V,).3';0K&I/KA0!5NB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 *OWOP/\J*%^]^!_E17D8W^(O0^_P"&O]TE_B?Y(****X3Z<**** "BBB@
MKT?X1_>U;Z0_^SUYQ7H_PC^]JWTA_P#9ZZ<+_&7]=#QL\_Y%]3Y?^E(]*HHH
MKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_
M>_ _RHKR,;_$7H??\-?[I+_$_P D%%%%<)].%%%% !1110 5Z/\ "/[VK?2'
M_P!GKSBO1_A'][5OI#_[/73A?XR_KH>-GG_(OJ?+_P!*1Z51117N'YD%%%%
M!1110!\W-]X_6DI6^\?K24 %%%% !1110 4444 *OWOP/\J*%^]^!_E17D8W
M^(O0^_X:_P!TE_B?Y(****X3Z<**** "BBB@ KT?X1_>U;Z0_P#L]><5Z/\
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M_P ^D=Q_PM76O^?2P_[X?_XJC_A:NM?\^EA_WP__ ,57#T4?6*O\P?V3@?\
MGTCN/^%JZU_SZ6'_ 'P__P 51_PM76O^?2P_[X?_ .*KAZ*/K%7^8/[)P/\
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MWOP/\J*\C&_Q%Z'W_#7^Z2_Q/\D%%%%<)].%%%% !1110 5Z/\(_O:M](?\
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MG_Q= ';45Q/_  M30O\ GWO_ /OVG_Q='_"U-"_Y][__ +]I_P#%T :?C_\
MY$74?I'_ .C%KQ&O1O$_C_2M;\-W>GVD-VLTP7:9$4*,,&.<,>PKSFO(QO\
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M;C&>XW9'Y"HM"\3>'K*YCM-)T&_M6N)%CW_9UY).!N;<3B@#N:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SK6?%OC"[^)5
MWX7\&0Z(5LK)+B>75%FX9CT!C/HR\8]>:VK;6M?\.^&=3U?XAMI"I9KYB?V0
M)2"N.A\S^(G ';FN23P+XZ_X6-XDUK3=;M-%@U%D\NY\A;J1T085=K<+P!G\
M,5&)];\;:5XJ^&WBN2V_MNT@26"]@7:ERNY71F4=/F"9Q_>Z<<@%N'QE\2+S
M0_\ A);/PSI/]DE//2QDN)/MCQ<G<"/EZ<XQGGI7<^%/$MGXO\,VFM:;N6&Y
M4Y1_O1L"0RGZ$'Z]>]>8O\5]9\*>&[3P_JWA348O$HA%I:$*IM[AE 4.K9^;
ML2H!^HKN?ACX4F\&^ K+2[M@;K+37&#D*[')4?08'X4 5?&7C75--\3:?X6\
M)Z?;WFMWT+7&Z\<K##$,C<VWD\J>GI4/AOQOK2^,YO"?CBQLK34A:_;+>YL'
M8P31@D'A^1T/7T/3'/.^-[>^\5_&73=*\*3+I6JZ-:&XN-6.6*1MTC"=&'S#
M@]=Q_&#3K'4O!OQILSXRO$\02^(;9[6TU(QB(PE<%D\H?* <J./[WUH TK?Q
M_P".?$&F7?B+PIH6EOH%N[^4EY)(+F[1#AF3&%'0\$>W-;FH?$[3X/A;#XOM
MH]S7<82TM&.6>X)*^7QUPP.<=@:Q(? /C7P]IM[X?\*:]ID7A^Y=S&]Y$YN;
M-'R65,?*W4\GZ\5PEO=V-C]FU.VMWU'P]X7E73M$MR0O]I:@[%FE/MG+?0+C
MO0![WX<EUB?P]:3>)([:+4I8P\T5LC*D9/.WYF)R!UYZUIUYO'XV\7^'=;TJ
M'Q_I6EQ:?J\XMH;K3I'S;2M]U9 YYSZC &">V*](H **** "BBB@ HHHH **
M** "BBB@ HHHH **** /FYOO'ZTE*WWC]:2@ HHHH **** "BBB@!5^]^!_E
M10OWOP/\J*\C&_Q%Z'W_  U_NDO\3_)!1117"?3A1110 4444 %>C_"/[VK?
M2'_V>O.*]'^$?WM6^D/_ +/73A?XR_KH>-GG_(OJ?+_TI'I5%%%>X?F04444
M %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !1110 J_>_ _RHH7[WX'^5%>1C
M?XB]#[_AK_=)?XG^2"BBBN$^G"BBB@ HHHH *]'^$?WM6^D/_L]><5Z/\(_O
M:M](?_9ZZ<+_ !E_70\;//\ D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[Q^
MM)2M]X_6DH **** "BBB@ HHHH 5?O?@?Y44+][\#_*BO(QO\1>A]_PU_NDO
M\3_)!1117"?3A1110 4444 %>C_"/[VK?2'_ -GKSBO1_A'][5OI#_[/73A?
MXR_KH>-GG_(OJ?+_ -*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %%
M%% !1110 4444 *OWOP/\J*%^]^!_E17D8W^(O0^_P"&O]TE_B?Y(****X3Z
M<**** "BBB@ KT?X1_>U;Z0_^SUYQ7H_PC^]JWTA_P#9ZZ<+_&7]=#QL\_Y%
M]3Y?^E(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH ****
M %7[WX'^5%"_>_ _RHKR,;_$7H??\-?[I+_$_P D%%%%<)].%%%% !1110 5
MZ/\ "/[VK?2'_P!GKSBO1_A'][5OI#_[/73A?XR_KH>-GG_(OJ?+_P!*1Z51
M117N'YD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>_ _RHKR,;_$7H??\
M#7^Z2_Q/\D%%%%<)].%%%% !1110 5Z/\(_O:M](?_9Z\XKT?X1_>U;Z0_\
ML]=.%_C+^NAXV>?\B^I\O_2D>E4445[A^9!1110 4444 ?-S?>/UI*5OO'ZT
ME !1110 4444 %%%% "K][\#_*BA?O?@?Y45Y&-_B+T/O^&O]TE_B?Y(****
MX3Z<**** "BBB@ KT?X1_>U;Z0_^SUYQ7H_PC^]JWTA_]GKIPO\ &7]=#QL\
M_P"1?4^7_I2/2J***]P_,@HHHH **** /FYOO'ZTE*WWC]:2@ HHHH ****
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MYEDCDO;:*9MTEM!,%B8_3']:Z>RL[?3[**TLXEB@B7:B+T H GHHHH ****
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M444 %>C_  C^]JWTA_\ 9Z\XKT?X1_>U;Z0_^SUTX7^,OZZ'C9Y_R+ZGR_\
M2D>E4445[A^9!1110 4444 ?-S?>/UI*5OO'ZTE !1110 4444 %%%% "K][
M\#_*BA?O?@?Y45Y&-_B+T/O^&O\ =)?XG^2"BBBN$^G"BBB@ HHHH *]'^$?
MWM6^D/\ [/7G%>C_  C^]JWTA_\ 9ZZ<+_&7]=#QL\_Y%]3Y?^E(]*HHHKW#
M\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>_
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MBB@ HHHH **** "BBB@#YN;[Q^M)2M]X_6DH **** "BBB@ HHHH Z/X?_\
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MO1_A'][5OI#_ .SUTX7^,OZZ'C9Y_P B^I\O_2D>E4445[A^9!1110 4444
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M110 4444 *OWOP/\J*%^]^!_E17D8W^(O0^_X:_W27^)_D@HHHKA/IPHHHH
M**** "O1_A'][5OI#_[/7G%>C_"/[VK?2'_V>NG"_P 9?UT/&SS_ )%]3Y?^
ME(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[W
MX'^5%"_>_ _RHKR,;_$7H??\-?[I+_$_R04445PGTX4444 %%%% !7H_PC^]
MJWTA_P#9Z\XKT?X1_>U;Z0_^SUTX7^,OZZ'C9Y_R+ZGR_P#2D>E4445[A^9!
M1110 4444 %%%% !1110 4444 %%%% !17.>/SCP-J./2/\ ]&+7B6YO4_G7
M)7Q/LI<MKGOY;DWU^BZO/RV=MK]%YKN?2%%?-^YO4_G1N;U/YUA]>_N_C_P#
MT_\ 5?\ Z??^2_\ !/I"BOF_<WJ?SHW-ZG\Z/KW]W\?^ '^J_P#T^_\ )?\
M@GTA17S?N;U/YT;F]3^='U[^[^/_   _U7_Z??\ DO\ P3Z0HKYOW-ZG\Z]'
M^$A);5LG/$/_ +/6E+%^TFHV./'9#]4P\J_M+VMI:V[MW/2:***[CYD****
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MY_R+ZGR_]*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %%%% !1110
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MINI3:23MK?\ R?<]LHKQ/_A87B;_ *"(_P"_$?\ \31_PL+Q-_T$1_WXC_\
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M.%%%% !1110 5Z/\(_O:M](?_9Z\XKT?X1_>U;Z0_P#L]=.%_C+^NAXV>?\
M(OJ?+_TI'I5%%%>X?F04444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !11
M10 J_>_ _P J*%^]^!_E17D8W^(O0^_X:_W27^)_D@HHHKA/IPHHHH ****
M"O1_A'][5OI#_P"SUYQ7H_PC^]JWTA_]GKIPO\9?UT/&SS_D7U/E_P"E(]*H
MHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%
M"_>_ _RHKR,;_$7H??\ #7^Z2_Q/\D%%%%<)].%%%% !1110 5Z/\(_O:M](
M?_9Z\XKT?X1_>U;Z0_\ L]=.%_C+^NAXV>?\B^I\O_2D>E4445[A^9!1110
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M8"P\6:K8^(+E;:"(K]E#1\$'OD#GC'ZUV%5;O3+"_96OK&VN6484S0J^/S%
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M70\;//\ D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH ****
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M^T6S,4)VE61AU5@>0>1^8JQK.LZ?X?TF?4]8NDM;2 9>1^W8  <DD\8%>?\
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M110 J_>_ _RHH7[WX'^5%>1C?XB]#[_AK_=)?XG^2"BBBN$^G"BBB@ HHHH
M*]'^$?WM6^D/_L]><5Z/\(_O:M](?_9ZZ<+_ !E_70\;//\ D7U/E_Z4CTJB
MBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH **** "BBB@ HHHH 5?O?@?Y44
M+][\#_*BO(QO\1>A]_PU_NDO\3_)!1117"?3A1110 4444 %>C_"/[VK?2'_
M -GKSBO1_A'][5OI#_[/73A?XR_KH>-GG_(OJ?+_ -*1Z51117N'YD%%%% !
M1110!\W-]X_6DI6^\?K24 %%%% !1110 4444 *OWOP/\J*%^]^!_E17D8W^
M(O0^_P"&O]TE_B?Y(****X3Z<**** "BBB@ KT?X1_>U;Z0_^SUYQ7H_PC^]
MJWTA_P#9ZZ<+_&7]=#QL\_Y%]3Y?^E(]*HHHKW#\R"BBB@ HHHH ^;F^\?K2
M4K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>_ _RHKR,;_$7H??\-?[I+_$
M_P D%%%%<)].%%%% !1110 5Z/\ "/[VK?2'_P!GKSBO1_A'][5OI#_[/73A
M?XR_KH>-GG_(OJ?+_P!*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %
M%%% !1110 4444 *OWOP/\J*%^]^!_E17D8W^(O0^_X:_P!TE_B?Y(****X3
MZ<**** "BBB@ KT?X1_>U;Z0_P#L]><5Z/\ "/[VK?2'_P!GKIPO\9?UT/&S
MS_D7U/E_Z4CTJBBBO</S(**** &R1K+&T;C*N"K#.,@UP?\ PI#X>?\ 0O\
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M]=#QL\_Y%]3Y?^E(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@
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MF?,8D<QH>B^WT],#M774 %%%% !1110 4444 ?-S?>/UI*5OO'ZTE !1110
M4444 %%%% "K][\#_*BA?O?@?Y45Y&-_B+T/O^&O]TE_B?Y(****X3Z<****
M "BBB@ KT?X1_>U;Z0_^SUYQ7H_PC^]JWTA_]GKIPO\ &7]=#QL\_P"1?4^7
M_I2/2J***]P_,@HHHH **** /FYOO'ZTE*WWC]:2@ HHHH **** "BBB@!5^
M]^!_E10OWOP/\J*\C&_Q%Z'W_#7^Z2_Q/\D%%%%<)].%%%% !1110 5Z/\(_
MO:M](?\ V>O.*]'^$?WM6^D/_L]=.%_C+^NAXV>?\B^I\O\ TI'I5%%%>X?F
M04444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !1110 J_>_ _RHH7[WX'^
M5%>1C?XB]#[_ (:_W27^)_D@HHHKA/IPHHHH **** "O1_A'][5OI#_[/7G%
M>C_"/[VK?2'_ -GKIPO\9?UT/&SS_D7U/E_Z4CTJBBBO</S(**** "BBB@#Y
MN;[Q^M)2M]X_6DH **** "BBB@ HHHH 5?O?@?Y44+][\#_*BO(QO\1>A]_P
MU_NDO\3_ "04445PGTX4444 %%%% !7H_P (_O:M](?_ &>O.*]'^$?WM6^D
M/_L]=.%_C+^NAXV>?\B^I\O_ $I'I5%%%>X?F04444 %%%% 'S<WWC]:2E;[
MQ^M)0 4444 %%%% !1110 J_>_ _RHH7[WX'^5%>1C?XB]#[_AK_ '27^)_D
M@HHHKA/IPHHHH **** "O1_A'][5OI#_ .SUYQ7H_P (_O:M](?_ &>NG"_Q
ME_70\;//^1?4^7_I2/2J***]P_,@HHHH **** /FYOO'ZTE*WWC]:2@ HHHH
M **** "BBB@!5^]^!_E10OWOP/\ *BO(QO\ $7H??\-?[I+_ !/\D%%%%<)]
M.%%%% !1110 5Z/\(_O:M](?_9Z\XKT?X1_>U;Z0_P#L]=.%_C+^NAXV>?\
M(OJ?+_TI'I5%%%>X?F04444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !11
M10 J_>_ _P J*%^]^!_E17D8W^(O0^_X:_W27^)_D@HHHKA/IPHHHH ****
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MT:]OIKE);RS^T',T5K,$CD/N"#70Z;IMKI.GQ65A$(H(AA5'\SZF@"U1110
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M\_Y%]3Y?^E(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH
M**** %7[WX'^5%"_>_ _RHKR,;_$7H??\-?[I+_$_P D%%%%<)].%%%% !11
M10 5Z/\ "/[VK?2'_P!GKSBO1_A'][5OI#_[/73A?XR_KH>-GG_(OJ?+_P!*
M1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %%%% !1110 4444 *OWOP
M/\J*%^]^!_E17D8W^(O0^_X:_P!TE_B?Y(****X3Z<**** "BBB@ KT?X1_>
MU;Z0_P#L]><5Z/\ "/[VK?2'_P!GKIPO\9?UT/&SS_D7U/E_Z4CTJBBBO</S
M(**** "BBB@#YN;[Q^M)2M]X_6DH **** "BBB@ HHHH 5?O?@?Y44+][\#_
M "HKR,;_ !%Z'W_#7^Z2_P 3_)!1117"?3A1110 4444 %>C_"/[VK?2'_V>
MO.*]'^$?WM6^D/\ [/73A?XR_KH>-GG_ "+ZGR_]*1Z51117N'YD%%%% !11
M10!\W-]X_6DI6^\?K24 %%%% !1110 4444 *OWOP/\ *BA?O?@?Y45Y&-_B
M+T/O^&O]TE_B?Y(****X3Z<**** "BBB@ KT?X1_>U;Z0_\ L]><5Z/\(_O:
MM](?_9ZZ<+_&7]=#QL\_Y%]3Y?\ I2/2J***]P_,@HHHH **** "BBB@ HHH
MH **** "LO7=)N]6MXH[+5)]-9'W,\(.6&.AY%:E% 'F?ASPAK<AO]VK7^E8
MN#@A"//_ -OJ*W[7P,YU*VN]8UN[U,6K[XHI1\H;.<\D^@KF]%\1Q^%]<U.!
M-/O+BQGN"P818D0@GCK@C\1736OQ!L+N\AMH]-U16FD6-6>!0 2<9/S=* .K
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F
MYOO'ZTE*WWC]:2@ HHHH **** "BBB@!5^]^!_E10OWOP/\ *BO(QO\ $7H?
M?\-?[I+_ !/\D%%%%<)].%%%% !1110 5Z/\(_O:M](?_9Z\XKT?X1_>U;Z0
M_P#L]=.%_C+^NAXV>?\ (OJ?+_TI'I5%%%>X?F04444 %%%% 'S<WWC]:2E;
M[Q^M)0 4444 %%%% !1110 J_>_ _P J*%^]^!_E17D8W^(O0^_X:_W27^)_
MD@HHHKA/IPHHHH **** "O1_A'][5OI#_P"SUYQ7H_PC^]JWTA_]GKIPO\9?
MUT/&SS_D7U/E_P"E(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@
M HHHH **** %7[WX'^5%"_>_ _RHKR,;_$7H??\ #7^Z2_Q/\D%%%%<)].%%
M%% !1110 5Z/\(_O:M](?_9Z\XKT?X1_>U;Z0_\ L]=.%_C+^NAXV>?\B^I\
MO_2D>E4445[A^9!1110 4444 ?-S?>/UI*5OO'ZTE !1110 4444 %%%% "K
M][\#_*BA?O?@?Y45Y&-_B+T/O^&O]TE_B?Y(****X3Z<**** "BBB@ KT?X1
M_>U;Z0_^SUYQ7H_PC^]JWTA_]GKIPO\ &7]=#QL\_P"1?4^7_I2/2J***]P_
M,@HHHH **** /FYOO'ZTE*WWC]:2@ HHHH **** "BBB@!5^]^!_E10OWOP/
M\J*\C&_Q%Z'W_#7^Z2_Q/\D%%%%<)].%%%% !1110 5Z/\(_O:M](?\ V>O.
M*]'^$?WM6^D/_L]=.%_C+^NAXV>?\B^I\O\ TI'I5%%%>X?F04444 %%%% '
MS<WWC]:2E;[Q^M)0 4444 %%%% !1110 J_>_ _RHH7[WX'^5%>1C?XB]#[_
M (:_W27^)_D@HHHKA/IPHHHH **** "O1_A'][5OI#_[/7G%>C_"/[VK?2'_
M -GKIPO\9?UT/&SS_D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_
M6DH **** "BBB@ HHHH 5?O?@?Y44+][\#_*BO(QO\1>A]_PU_NDO\3_ "04
M445PGTX4444 %%%% !7H_P (_O:M](?_ &>O.*]'^$?WM6^D/_L]=.%_C+^N
MAXV>?\B^I\O_ $I'I5%%%>X?F04444 %%%% !1110 4444 %%%% !1110!QU
M[XBUK5M<N-+\*00A;1MMQ=W'W5;I@?KV)XIVG^(M9TW7+?2?%<$.;H[;:[M_
MNNWH?T[ \CCFJ'AC4K7POK.JZ/K4BVKR7)FAGEX613P/F[>OYTOB'4+;Q3XD
MTC2]%D^TFWN//GGBY6-01T;H>GTZ4 =[1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?-S?>/UI*5OO'ZTE !1110 4444 %%
M%% "K][\#_*BA?O?@?Y45Y&-_B+T/O\ AK_=)?XG^2"BBBN$^G"BBB@ HHHH
M *]'^$?WM6^D/_L]><5Z/\(_O:M](?\ V>NG"_QE_70\;//^1?4^7_I2/2J*
M**]P_,@HHHH **** /FYOO'ZTE*WWC]:2@ HHHH **** "BBB@!5^]^!_E10
MOWOP/\J*\C&_Q%Z'W_#7^Z2_Q/\ )!1117"?3A1110 4444 %>C_  C^]JWT
MA_\ 9Z\XKT?X1_>U;Z0_^SUTX7^,OZZ'C9Y_R+ZGR_\ 2D>E4445[A^9!111
M0 4444 ?-S?>/UI*5OO'ZTE !1110 4444 %%%% "K][\#_*BA?O?@?Y45Y&
M-_B+T/O^&O\ =)?XG^2"BBBN$^G"BBB@ HHHH *]'^$?WM6^D/\ [/7G%>C_
M  C^]JWTA_\ 9ZZ<+_&7]=#QL\_Y%]3Y?^E(]*HHHKW#\R"BBB@ HHHH ^;F
M^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>_ _P J*\C&_P 1>A]_
MPU_NDO\ $_R04445PGTX4444 %%%% !7H_PC^]JWTA_]GKSBO1_A'][5OI#_
M .SUTX7^,OZZ'C9Y_P B^I\O_2D>E4445[A^9!1110 4444 ?-S?>/UI*5OO
M'ZTE !1110 4444 %%%% "K][\#_ "HH7[WX'^5%>1C?XB]#[_AK_=)?XG^2
M"BBBN$^G"BBB@ HHHH *]'^$?WM6^D/_ +/7G%>C_"/[VK?2'_V>NG"_QE_7
M0\;//^1?4^7_ *4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH **** "
MBBB@ HHHH 5?O?@?Y44+][\#_*BO(QO\1>A]_P -?[I+_$_R04445PGTX444
M4 %%%% !7H_PC^]JWTA_]GKSBO1_A'][5OI#_P"SUTX7^,OZZ'C9Y_R+ZGR_
M]*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %%%% !1110 4444 *OW
MOP/\J*%^]^!_E17D8W^(O0^_X:_W27^)_D@HHHKA/IPHHHH **** "O1_A']
M[5OI#_[/7G%>C_"/[VK?2'_V>NG"_P 9?UT/&SS_ )%]3Y?^E(]*HHHKW#\R
M"BBB@ HHHH **** "BBB@ HHHH **** .)\3:W97^I-I%IH(UR[@'SG&%A_X
M$!GOSTYIWA?7+&SU$:/<Z&-#O)1E!CY9O^!8S].OUJ/P/-;Z;JVLZ9>RQK?O
M=EU9F_UR]L>O.3^-)XRN+;4?$.AV5E/&;R"Y\V216'[A 1DD]NF<>WN* .YH
MJ*.Y@F;;#-'(V,X5P3BI: "BBB@ HHHH **** "BJEWJNG6#A+Z_M;9CR!-,
MJ$_F:L12QSQ++!(LD;#*NC9!^A% #Z*K7>I6.GA3?WMO:ANGG2JF?S-2P3PW
M,*RVTJ31MT>-@P/XB@"2BJMYJ=AIVW^T+VVM=WW?/E5,_3)J>&:*XA66"1)8
MW&5=&!!'L10 ^BJ_]H6?V[[%]K@^UXW>1Y@\S'KMZU8H **** "BBB@ HHHH
M ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>_ _P J*\C&_P 1
M>A]_PU_NDO\ $_R04445PGTX4444 %%%% !7H_PC^]JWTA_]GKSBO1_A'][5
MOI#_ .SUTX7^,OZZ'C9Y_P B^I\O_2D>E4445[A^9!1110 4444 ?-S?>/UI
M*5OO'ZTE !1110 4444 %%%% "K][\#_ "HH7[WX'^5%>1C?XB]#[_AK_=)?
MXG^2"BBBN$^G"BBB@ HHHH *]'^$?WM6^D/_ +/7G%>C_"/[VK?2'_V>NG"_
MQE_70\;//^1?4^7_ *4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH **
M** "BBB@ HHHH 5?O?@?Y44+][\#_*BO(QO\1>A]_P -?[I+_$_R04445PGT
MX4444 %%%% !7H_PC^]JWTA_]GKSBO1_A'][5OI#_P"SUTX7^,OZZ'C9Y_R+
MZGR_]*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %%%% !1110 4444
M *OWOP/\J*%^]^!_E17D8W^(O0^_X:_W27^)_D@HHHKA/IPHHHH **** "O1
M_A'][5OI#_[/7G%>C_"/[VK?2'_V>NG"_P 9?UT/&SS_ )%]3Y?^E(]*HHHK
MW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>
M_ _RHKR,;_$7H??\-?[I+_$_R04445PGTX4444 %%%% !7H_PC^]JWTA_P#9
MZ\XKT?X1_>U;Z0_^SUTX7^,OZZ'C9Y_R+ZGR_P#2D>E4445[A^9!1110 444
M4 ?-S?>/UI*5OO'ZTE !1110 4444 %%%% "K][\#_*BA?O?@?Y45Y&-_B+T
M/O\ AK_=)?XG^2"BBBN$^G"BBB@ HHHH *]'^$?WM6^D/_L]><5Z/\(_O:M]
M(?\ V>NG"_QE_70\;//^1?4^7_I2/2J***]P_,@HHHH **** /FYOO'ZTE*W
MWC]:2@ HHHH **** "BBB@!5^]^!_E10OWOP/\J*\C&_Q%Z'W_#7^Z2_Q/\
M)!1117"?3A1110 4444 %>C_  C^]JWTA_\ 9Z\XKT?X1_>U;Z0_^SUTX7^,
MOZZ'C9Y_R+ZGR_\ 2D>E4445[A^9!1110 4444 %%%% !1110 4444 %%%%
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M #&!V_PKH_AUJEWJ?AE_MTS7#VUPT"3MR9% !!SWZT =91110 4444 %%%%
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M4 *OWOP/\J*%^]^!_E17D8W^(O0^_P"&O]TE_B?Y(****X3Z<**** "BBB@
MKT?X1_>U;Z0_^SUYQ7H_PC^]JWTA_P#9ZZ<+_&7]=#QL\_Y%]3Y?^E(]*HHH
MKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_
M>_ _RHKR,;_$7H??\-?[I+_$_P D%%%%<)].%%%% !1110 5Z/\ "/[VK?2'
M_P!GKSBO1_A'][5OI#_[/73A?XR_KH>-GG_(OJ?+_P!*1Z51117N'YD%%%%
M!1110!\W-]X_6DI6^\?K24 %%%% !1110 4444 *OWOP/\J*%^]^!_E17D8W
M^(O0^_X:_P!TE_B?Y(****X3Z<**** "BBB@ KT?X1_>U;Z0_P#L]><5Z/\
M"/[VK?2'_P!GKIPO\9?UT/&SS_D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[
MQ^M)2M]X_6DH **** "BBB@ HHHH 5?O?@?Y44+][\#_ "HKR,;_ !%Z'W_#
M7^Z2_P 3_)!1117"?3A1110 4444 %>C_"/[VK?2'_V>O.*]'^$?WM6^D/\
M[/73A?XR_KH>-GG_ "+ZGR_]*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?
MK24 %%%% !1110 4444 *OWOP/\ *BA?O?@?Y45Y&-_B+T/O^&O]TE_B?Y(*
M***X3Z<**** "BBB@ KT?X1_>U;Z0_\ L]><5Z/\(_O:M](?_9ZZ<+_&7]=#
MQL\_Y%]3Y?\ I2/2J***]P_,@HHHH **** /FYOO'ZTE*WWC]:2@ HHHH **
M** "BBB@!5^]^!_E10OWOP/\J*\C&_Q%Z'W_  U_NDO\3_)!1117"?3A1110
M 4444 %>C_"/[VK?2'_V>O.*]'^$?WM6^D/_ +/73A?XR_KH>-GG_(OJ?+_T
MI'I5%%%>X?F04444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !1110 J_>_
M _RHH7[WX'^5%>1C?XB]#[_AK_=)?XG^2"BBBN$^G"BBB@ HHHH *]'^$?WM
M6^D/_L]><5Z/\(_O:M](?_9ZZ<+_ !E_70\;//\ D7U/E_Z4CTJBBBO</S(*
M*** "BBB@ HHHH **** "BBB@ KA/$ZOX@\<V/AV6:2.Q6+SIE4X\P\G^0'Y
MFN[KD-;\+:O=>*AK.C:C!:2+$(U+IN(X(/!!'>@#(\1:+!X(N=/UG0&D@4SK
M!/"9"RR @GO_ +IS^&,8KT:N"U3PCXKUJV2WU/7;6>))!(J^2%PP! /"CU-:
M5KI?C-+R%[KQ!;2P+(ID06Z@LN>1G9W% '5T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%%
M !1110 J_>_ _P J*%^]^!_E17D8W^(O0^_X:_W27^)_D@HHHKA/IPHHHH *
M*** "O1_A'][5OI#_P"SUYQ7H_PC^]JWTA_]GKIPO\9?UT/&SS_D7U/E_P"E
M(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX
M'^5%"_>_ _RHKR,;_$7H??\ #7^Z2_Q/\D%%%%<)].%%%% !1110 5Z/\(_O
M:M](?_9Z\XKT?X1_>U;Z0_\ L]=.%_C+^NAXV>?\B^I\O_2D>E4445[A^9!1
M110 4444 ?-S?>/UI*5OO'ZTE !1110 4444 %%%% "K][\#_*BA?O?@?Y45
MY&-_B+T/O^&O]TE_B?Y(****X3Z<**** "BBB@ KT?X1_>U;Z0_^SUYQ7H_P
MC^]JWTA_]GKIPO\ &7]=#QL\_P"1?4^7_I2/2J***]P_,@HHHH **** /FYO
MO'ZTE*WWC]:2@ HHHH **** "BBB@!5^]^!_E10OWOP/\J*\C&_Q%Z'W_#7^
MZ2_Q/\D%%%%<)].%%%% !1110 5Z/\(_O:M](?\ V>O.*]'^$?WM6^D/_L]=
M.%_C+^NAXV>?\B^I\O\ TI'I5%%%>X?F04444 %%%% 'S<WWC]:2E;[Q^M)0
M 4444 %%%% !1110 J_>_ _RHH7[WX'^5%>1C?XB]#[_ (:_W27^)_D@HHHK
MA/IPHHHH **** "O1_A'][5OI#_[/7G%>C_"/[VK?2'_ -GKIPO\9?UT/&SS
M_D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH **** "BBB@ H
MHHH 5?O?@?Y44+][\#_*BO(QO\1>A]_PU_NDO\3_ "04445PGTX4444 %%%%
M !7H_P (_O:M](?_ &>O.*]'^$?WM6^D/_L]=.%_C+^NAXV>?\B^I\O_ $I'
MI5%%%>X?F04444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !1110 J_>_ _
MRHH7[WX'^5%>1C?XB]#[_AK_ '27^)_D@HHHKA/IPHHHH **** "O1_A'][5
MOI#_ .SUYQ7H_P (_O:M](?_ &>NG"_QE_70\;//^1?4^7_I2/2J***]P_,@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#YN;[Q^M)2M]X_6DH **** "B
MBB@ HHHH 5?O?@?Y44+][\#_ "HKR,;_ !%Z'W_#7^Z2_P 3_)!1117"?3A1
M110 4444 %>C_"/[VK?2'_V>O.*]'^$?WM6^D/\ [/73A?XR_KH>-GG_ "+Z
MGR_]*1Z51117N'YD%%%% !1110!\W-]X_6DI6^\?K24 %%%% !1110 4444
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MWX'^5%"_>_ _RHKR,;_$7H??\-?[I+_$_P D%%%%<)].%%%% !1110 5Z/\
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M110 J_>_ _RHH7[WX'^5%>1C?XB]#[_AK_=)?XG^2"BBBN$^G"BBB@ HHHH
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MS_D7U/E_Z4CTJBBBO</S(**** "BBB@#YN;[Q^M)2M]X_6DH **** "BBB@
MHHHH 5?O?@?Y44+][\#_ "HKR,;_ !%Z'W_#7^Z2_P 3_)!1117"?3A1110
M4444 %>C_"/[VK?2'_V>O.*]'^$?WM6^D/\ [/73A?XR_KH>-GG_ "+ZGR_]
M*1Z51117N'YD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<:+=WDTZ27EHD[;I8+:8+&Y]Q@_E72V%A;:98Q6=C$(H(EPJC_/6@"Q1110
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M\_Y%]3Y?^E(]*HHHKW#\R"BBB@ HHHH ^;F^\?K24K?>/UI* "BBB@ HHHH
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M?@?Y45Y&-_B+T/O^&O\ =)?XG^2"BBBN$^G"BBB@ HHHH *]'^$?WM6^D/\
M[/7G%>C_  C^]JWTA_\ 9ZZ<+_&7]=#QL\_Y%]3Y?^E(]*HHHKW#\R"BBB@
MHHHH ^;F^\?K24K?>/UI* "BBB@ HHHH **** %7[WX'^5%"_>_ _P J*\C&
M_P 1>A]_PU_NDO\ $_R04445PGTX4444 %%%% !7H_PC^]JWTA_]GKSBO1_A
M'][5OI#_ .SUTX7^,OZZ'C9Y_P B^I\O_2D>E4445[A^9!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S<WWC]:2E;[Q^M)0 4444 %%%% !1110 J_>_
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M10 4444 *OWOP/\ *BA?O?@?Y45Y&-_B+T/O^&O]TE_B?Y(****X3Z<****
M"BBB@ KT?X1_>U;Z0_\ L]><5Z/\(_O:M](?_9ZZ<+_&7]=#QL\_Y%]3Y?\
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M/\J*\C&_Q%Z'W_#7^Z2_Q/\ )!1117"?3A1110 4444 %>C_  C^]JWTA_\
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MTX7^,OZZ'C9Y_P B^I\O_2D>E4445[A^9!1110 4444 %%%% !1110 4444
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MWX'^5%"_>_ _RHKR,;_$7H??\-?[I+_$_P D%%%%<)].%%%% !1110 5Z/\
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M110 J_>_ _RHH7[WX'^5%>1C?XB]#[_AK_=)?XG^2"BBBN$^G"BBB@ HHHH
M*]'^$?WM6^D/_L]><5Z/\(_O:M](?_9ZZ<+_ !E_70\;//\ D7U/E_Z4CTJB
MBBO</S(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;F^\?K24K?>/UI*
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M*** "BBB@!5^]^!_E10OWOP/\J*\C&_Q%Z'W_#7^Z2_Q/\D%%%%<)].%%%%
M!1110 5Z/\(_O:M](?\ V>O.*]'^$?WM6^D/_L]=.%_C+^NAXV>?\B^I\O\
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M.*]'^$?WM6^D/_L]=.%_C+^NAXV>?\B^I\O_ $I'I5%%%>X?F04444 %%%%
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M_KH>-GG_ "+ZGR_]*1Z51117N'YD%%%% !1110 4444 %%%% !1110 4444
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MFC_A#]#_ .@?;_\ ?E/_ (FMNBCDCV#ZQ6_G?WLQ/^$/T/\ Z!]O_P!^4_\
MB:LVF@6.G[_L"?9=^-_DA4W8Z9P.>IK2HH48K9"E6J25I2;7J5OL7_3S<?\
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M]B_Z>;C_ +^59HH K?8O^GFX_P"_E'V+_IYN/^_E6:* ,3_A#]#_ .@?;_\
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MM_\ ORG_ ,36W11R1[!]8K?SO[V8G_"'Z'_T#[?_ +\I_P#$T?\ "'Z'_P!
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M1_PA^A_] ^W_ ._*?_$UMT4<D>P?6*W\[^]F)_PA^A_] ^W_ ._*?_$U9M-
ML=/W_8$^R[\;_)"INQTS@<]36E10HQ6R%*M4DK2DVO4K?8O^GFX_[^4?8O\
MIYN/^_E6:*HR(([7RY WGS/CLSY!J>BB@ HHHH **** "BBB@ HHHH ****
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M#R$_?VG@_D1_.NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **Q_%.E6>JZ!<I?QM*L,3RHHD91N"G!(!&?QKFM$M]5N_A%8VV@R+%=
M2AE\POM*+YC9(/KV_&@#O:*\T\4>'+'P=I5GJ6AS3PZLEPBK(9B6N2>H*DX_
M <=CFM/6(7\4^/!H-Y++%IUG:">:&-]OG.2!R1V&X?D?6@#N**X-]/C\%>,M
M(CT=Y4T_5&>&:T:0LJL,889SW(_(^M=Y0 4444 %%%% !1110 4444 %%%%
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MT&VT:9+M;"1[BXFB.Y$'&!D<'[OZBN[JO9Z?9Z?&4L+2"U1CDK#$$!_ "K%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\*R:S$P:-H0\.?XF8?*/S//XT :]%>=^%[O6+7P;J?B"[NKJ[E*-]FCGE9U
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MS*CQN/XE9AC!Z_Y!K1\.V>J#4;B[U/3+#3H64+!;P*K2)ZDNO!S_ )]^CHH
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M/A/XHC4[Y&-E=$L)0.@88/Y'MZ?6NOU7QGHVGZ2]U#?V]Q(4)ABBD#,[8X!
MY ]<UKW^G6>J6IM]0MX[B(\[7'0^H]*R(? GAJ"82II:%@<C?([#\B2* .;^
M'<)T3PSJ6L:A'(MO+M90$)+(@.2!Z?-^E4[W3O"&L:3<:OI-X=+N8U9_)9PI
MW#.!LSW[;37IPC01^6$79C;MQQCTQ6#-X%\-W$YEDTN,,QR0DCHOY @4 4OA
MSJE]JGAQSJ#O*89C'',YR67 .#ZXSU_PKGOAK?VFG7^LPW]Q%;.Q0@3.%SM+
MYZ^F17I%K:6]C:I;V<*0PQC"H@P!67?^#]!U*[:ZO-.C>9CEF5V3<?4[2,T
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M.@:8==&LFV_T\# F\QO[NW[N<=..E ',_%;_ )%6V_Z_5_\ 0'K-\;:=/=>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114
M%V]VD:FQ@AF?/S":8Q@#ZA6_E0!/17/:=XBOK_2)=3;3K>.VB64D"[9G)3/&
M/+ Y(]?\*L^&O$ \0Z:UR;?[+*C[6A+[B 5#*<X'!!!Z4 ;%%8.C^*%UC7+N
MPBM2D4"EX[CS,B4!RA(&..0>YZ5O4 %%%% !1110!%<6T%W T-W#'/$WWHY4
M#*?P-%M:6]E"(;.WBMX@<A(D"J#]!4M% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUH>$];_M_P -6M\Q'G%=DX':1>#],]?QKCTU#5=7\?76M:5HQU6UT\&SM_\
M24A56_B;+=>I_ BI_"-S>Z-XTO=,U33SIL>K9NK:W,RRA7&=P#+QR ?^^10!
MZ%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>globalaestheticimprovement.jpg
<TEXT>
begin 644 globalaestheticimprovement.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Q
M.0  DI(  @    ,Q.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!YO\7/^81_VV_\ :=6=-^)F
MC6>E6EM+;7Q>&%(V*QI@D* <?/[56^+G_,(_[;?^TZW](\'Z!<:)8S3:9$\D
MEO&[L2>25!)ZUY]JCKRY'V/K%+"1RNA]9BVKRM;U8W2_B)I.K:I!8VUO>K+.
MVU3(B!1QGG#&NKK(M/"FAV-U'<VFG1131G*."<@_G6O7934TO?9\_BY8:4U]
M632\^YY-\0K"31?%D&K6>4%P1*K ?=D4C/\ 0_B:]/TN_CU32K:^A^Y/&'QZ
M'N/P/%8_CG1_[8\+7"HN9[?]_%]5'(_$9_2N<^&6O1QZ7>Z?=N%6U!N4)[)_
M%^1Y_&N:/[JNX])'L54\=ED:BUG2=GZ/;]/Q(?BGJYDGM='@).W]]*!W)X4?
MS/XBNT\+Z0-$\.6MF1B4+OEXZN>3^73\*\X\-0R>+?B$^H7*YBCD-RX/. #A
M%_\ 0?P!KUZGA_?G*J_1$YJUAJ%+ QZ*\O5_U^045YE>>'/'4E].]OJ%R(FD
M8H!?L,+GCC/'%7O#.A^+[/Q%;3ZQ>SRV:;_,1[PN#E"!\N>>2*M5I.5N1G-/
M+:,:;FJ\6TKVZ^@SXL_\@_3?^NK_ ,A78>'/^15TK_KRA_\ 0!7(_%E2=-TY
ML<"9@3^ _P *ZSPQ(LOA/2FC.0+2)<^X4 _J*F'^\2]$:8C_ )%-#_%+]34K
MRO7/^2R6W_7Q;_R6O5*\KU@B7XRP",[MMQ!G';"J31BOACZH>2?Q:O\ @E^A
MK?%C_D#6'_7P?_0372^$/^1/TS_KW6N<^*Z,="LI /E6YP3Z$J<?R-=#X.8/
MX-TPJ<CR /Q'!HC_ +Q+T"O_ ,BBE_B?ZFW7E?B7_DKUA_U\6O\ Z$M>J5Y7
MXB_>?&"R5.2MQ;9'IRI_E1BOA7J@R/\ CU/\$OT/5*\H_P":T?\ ;U_[)7J]
M>4?\UH_[>O\ V2C$_8]4/)?^7_\ @D>KT445UG@!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YO\7/\ F$?]MO\ VG5_3/B-H5II-G;2FY\R&!(VQ%D9"@'O
M73ZOX>TS7O)_M6V\_P G=Y?[QEVYQG[I'H*S?^%?>&/^@9_Y,2__ !5<<J=5
M5'.#6I]!2QF G@Z>'Q*E>-]K=6_,J?\ "S?#_K=?]^?_ *]=+INH0ZKIT-[:
M[O)F7<NX8.,XK%_X5]X8_P"@9_Y,2_\ Q5;ME96^G645I9Q^7!$,(FXG ^IY
MK:FJM_?M\CAQ<L X+ZJI)_WK;?(GKPOQ1ILOAWQ->6UN6CAD!,>.\;]OYC\*
M]TK+U;PUI.N31RZI:"=XUVJWF,N!Z?*148BBZL=-S;*<PC@:K=17BUK;\#$^
M&VD?V?X:^UR#$M\WF'V0<*/YG\:Z^FQ1)#"D42A410JJ.P' %.K:G!0BHHX,
M5B)8FO*M+J_^&"BBBK.8Q?%FA_\ "0>'IK-"!,I$D)/3>.WX@D?C7!^%?&DG
MAA7T?7;>810N0N!\\1[@@]1GG_&O5JH:EH>F:N!_:5E%.1T9EPP_X$.:YZE*
M3ESP=F>M@\=3A1>&Q,>:#=]-T_(Y?4?BAI4-JQTV*:YN"/D#IM4'W/7\JS/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M';3V9NEMY(63[I1F^7:1U'K6[_PL#PQ_T$Q_WXD_^)H_X6!X8_Z"8_[\2?\
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MU-3T %%%% !1110 5\W-]X_6OI&OFYOO'ZT )1110 4444 %%%% !7;?"O\
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MS-EYI&ZNQ]3BJFF^#?LWCS4?%.IW_P!ON[B,06<9AV+9PC^ ?,<D]SQWXYH
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MN?\ "U-"_P"?>_\ ^_:?_%T?\+4T+_GWO_\ OVG_ ,77D=% 'KG_  M30O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N3\>>']=\565OH^F7MO8:7</\ \3.;>WGO%_SSC&W'/<DC\LYZRN>\
M0>---\-WT=I?17+R21B0&%%(P21W8>E &A::3%HWAY=,T"*.U6" QVRD?*K8
MX)]>>37F/A+P5\2O!MK<1Z<?"%Q/=2F6XO+MKIYIF)S\S #/Y5U/_"U-"_Y]
M[_\ []I_\71_PM30O^?>_P#^_:?_ != $>L:5\1M5T'35MM:TC2M5BNB]XUF
MCF&2+^$+O4G([@X!]:Z67POH-Q,\UQH>FRS2,7DD>SC)=CR221R2:Y[_ (6I
MH7_/O?\ _?M/_BZ/^%J:%_S[W_\ W[3_ .+H 9X7^'J:%X\\0ZU-::;]EOGA
M;3TAC^>VVJP;C: F<C[I.:O>/_#NK^*](M]&TV[@M+"XG7^TI'9A(T ()2,
M$$GODCIWR:J?\+4T+_GWO_\ OVG_ ,71_P +4T+_ )][_P#[]I_\70 _Q+X)
MNII="U#P?/:Z?J6@JT=I'<QEH)(F4*8V Y P.HYZ_4'AGPKK47BV[\4^+KRS
MGU.:U%G!!8*PAMX0V[ +<L2><FF?\+4T+_GWO_\ OVG_ ,71_P +4T+_ )][
M_P#[]I_\70!VU% .0#10!5U73X=7T>\TVYSY-Y \$FWKM=2I_0UXX?$_C+X=
M:39>!O[&M=1U&96M])O8+H?.F3AFA^\-H[G XZ\$GVT]..M<GX<\#?V3XEU#
MQ%K.H?VOK%X=J7#0^6MO%VCC7<V![YY_/(!3T2QT?X4_#.T77KB(+8(6DF*Y
M+2N2Q5!U)R< >U96AV&M>/\ QCI_BW7[)M*T?3 [:7I\O^NE9ACS9/3V'L/<
MG9^(/@&Z\;S:/+::W_9;:7,\ZAK,7"R.=NTE68#Y=IZ@_>I-.\,>.;;4[:?4
M/B']NM8Y%::V_L2"/SE!Y7<#E<CC(H Q;CP%XET33]6TKP_XBL++PY?/+-(;
MJ!C-9HXS($8';CKR>GZUQWA^\-A/I_B*RT][] XT3PI8S-Y890#YERY[9Y)[
M\X[ U[!XT\-W/BWPY)H]OJC:;#<.HN72'>TD0.2@.X;<\<\\<8YJ#7_ MAK'
MAVPTNSEDTM]+>.33[FV W6SH, @'J,=1WH H:)XNUV'Q=!X:\9Z;9VMW>6[7
M%G<V$S/%+M^\A##(8#GTKMJX_0? ]Y9^)%\0>)O$$VO:G%"8+=S;+;QP(?O;
M44D9/<UV% !1110 4444 %?-S?>/UKZ1KYN;[Q^M "4444 %%%% !1110 5U
M_P -+RVLO$T\M[<16\9M&4/*X09WIQDUR%*O1OI_6LZD^2#EV.K!T%B,1"BW
M:[/H#_A(=%_Z"]A_X$I_C1_PD.B_]!>P_P# E/\ &OG^BO/^O2['U_\ JQ2_
MY^/[D?0'_"0Z+_T%[#_P)3_&C_A(=%_Z"]A_X$I_C7S_ $4?7I=@_P!6*7_/
MQ_<CZ _X2'1?^@O8?^!*?XT?\)#HO_07L/\ P)3_ !KY_HH^O2[!_JQ2_P"?
MC^Y'T!_PD.B_]!>P_P# E/\ &C_A(=%_Z"]A_P"!*?XU\_T4?7I=@_U8I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#&\4>(HO#6D_:GB,\TCB*"%3@R.?Z5S]QXH\6:)"F
MH>(-&LSIV0)?LKGS(@3@$Y8C_/45H^.=$O-5T^TNM* >^TZX%Q%&3P^.H^O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFI2F?:TXB:*0YSG/49/_ .JM/PAH5WI-O>W6JNAO]1G,\ZQ_=0G/ _,UT5%
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M !71> O^1XT[_>?_ -%M7.UT7@+_ )'C3O\ >?\ ]%M6M+^)'U1QX[_=*O\
MAE^3/;Z***^@/R4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %/;[J?3^IIE/;[J?3^IKBQO\->I]+PU_ODO\+_-#:***\<_00HHHH ****
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M9[HAXWE;K*$<J&/N0!GU.37FUUX.M=?\>77A7P)J&IV6@1.7UQ8[HFT1B?\
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M;7T&=OFVTRR+GTRI(H M45534["34WTY+VV:^C02/:B53*JGHQ3.0.1SBK5
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MV;/WAQV_.MKP=H,V@:,\=Y(LEW<S-<3E/NAFQP/IB@#?HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M)?BM_P C/:_]>:_^AO7K5>2_%;_D9[7_ *\U_P#0WH X>BBB@ HHHH ****
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MYM6;;'-#'E(^<<^N.IQT'-<MKO\ Q7_Q>L] 3]YH_AK%Y?\ ]V2X/W$/T_\
MBA0!QS^$[?PGH/@M_%4"KI-]J,EWK:[,1),Z#R%=1P$7D$=.M:O_  D_AWPO
M\1=;UWPJ8#H<&D*+Y;(@07%WYF(E3;P7(/4<8W'UKVJ>"*YA>&YB26)QADD4
M,K#T(/6O++:QL_'7Q(%KI]I##X6\+3$LD$82.ZO?H!@A/Y^QH U?AUI\.AV\
MNH^)[ZU3Q1XA<75S'+*JR*#]R)5)SA1V'T[5Z#7SXW_"*V6D^)-.\?:5-<^,
M+FYN#&6M7DFN=W^J:!P" O3N.GI7L_@N'4[?P1H\.O%FU&.T19]YRV['1CW.
M,9/KF@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110!XI\1/\ D>;W_=C_ /1:US%=/\1/^1YO?]V/_P!%K7,4 %%%% !1110
M4444 .C_ -:G^\*2EC_UJ?[PI*\O'?$C[CAC^%4]4%%%%><?7!1110 4444
M%>L?"G_D6[O_ *^S_P"@+7D]>L?"G_D6[O\ Z^S_ .@+79@_XIX'$'^XOU1W
M-%%%>R?G 4444 %-DD2*-I)75$0%F9C@*!U)-.K/U_\ Y%O4_P#KTE_] - "
M?\)#HO\ T%[#_P "4_QH_P"$AT7_ *"]A_X$I_C7S]10!] _\)#HO_07L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\CQIW^\__HMJUI?Q(^J./'?[I5_PR_)GM]%%%?0'Y*%%%% !1110!XI\1/\
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MT7@+_D>-._WG_P#1;5K2_B1]4<>._P!TJ_X9?DSV^BBBOH#\E"BBB@ HHHH
M\4^(G_(\WO\ NQ_^BUKF*Z?XB?\ (\WO^['_ .BUKF* "BBB@ HHHH ****
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M /JK3\(:%=Z3;WMUJKH;_49S/.L?W4)SP/S- '14444 %%%% !1110 4444
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M***\$_4PHHHH **** "BBB@#VOX=_P#(CV7^])_Z,:NFKF?AW_R(]E_O2?\
MHQJZ:OH*/\./HC\GS#_?*O\ B?YA1116IPA1110!Q?Q3_P"13A_Z^T_]!>O(
M:]>^*?\ R*</_7VG_H+UY#0 4444 %%%% !1110 4]ONI]/ZFF4]ONI]/ZFN
M+&_PUZGTO#7^^2_PO\T-HHHKQS]!"BBB@ HHHH *Z+P%_P CQIW^\_\ Z+:N
M=KHO 7_(\:=_O/\ ^BVK6E_$CZHX\=_NE7_#+\F>WT445] ?DH4444 %%%%
M'BGQ$_Y'F]_W8_\ T6M<Q73_ !$_Y'F]_P!V/_T6M<Q0 4444 %%%% !1110
M Z/_ %J?[PI*6/\ UJ?[PI*\O'?$C[CAC^%4]4%%%%><?7!1110 4444 %>L
M?"G_ )%N[_Z^S_Z M>3UZQ\*?^1;N_\ K[/_ * M=F#_ (IX'$'^XOU1W-%%
M%>R?G 4444 %9^O_ /(MZG_UZ2_^@&M"L_7_ /D6]3_Z])?_ $ T ?/M%%%
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M>QYXKLZ "BN3\2^.1I'B33O#NCZ>=7UF].YK=9O+6WB[R2-M; ]L=OIEFO\
MCBZL?$:^'O#N@RZYJPMQ<SQ+<K!% A.!ND8'D]ACTH Z^BN9\/>.=/UOPY?:
MK=1R:8VF/)%J%O=$!K9T&6!]1CH>]3>"O$MQXN\.KK$VEMIL$[M]E1YM[2Q
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M* /%/B)_R/-[_NQ_^BUKF*Z?XB?\CS>_[L?_ *+6N8H **** "BBB@ HHHH
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M]9T[3_#WB;5M)?0;&2-FDM(I!<W:QXVJX/RKT&2IH ].HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@#J>E#Q9%<Z9
MX?20/?K:/J3-A?-;KM7H3U.?\:W?#4^G'4M7M[;3WL+U+C=<I(V6D!R58<XQ
MUX' S[UR=U%J'A[[+IUQIMU/:VNK+>Q7,$>\21_-\IQT;GH:Z3PU#=W7B+4=
M:U&W-D]U&J06KD>8(UXW,.HR10!U5%%% !1110 4444 %%%% !1110 4444
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M^M)2M]X_6DKYH_90HHHH&%%%% !1110!VOPK_P"1JG_Z\W_]#2O7*\C^%?\
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M HHHH **** "BBB@!P_U;?4?UI*4?ZMOJ/ZTE>)BOXS_ *Z'Z7D7_(OI_/\
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M10!Q?Q3_ .13A_Z^T_\ 07KR&O7OBG_R*</_ %]I_P"@O7D- !1110 4444
M%%%% !3V^ZGT_J:93V^ZGT_J:XL;_#7J?2\-?[Y+_"_S0VBBBO'/T$**** "
MBBB@ KHO 7_(\:=_O/\ ^BVKG:Z+P%_R/&G?[S_^BVK6E_$CZHX\=_NE7_#+
M\F>WT445] ?DH4444 %%%% 'BGQ$_P"1YO?]V/\ ]%K7,5T_Q$_Y'F]_W8__
M $6M<Q0 4444 %%%% !1110 Z/\ UJ?[PI*6/_6I_O"DKR\=\2/N.&/X53U0
M4445YQ]<%%%% !1110 5ZQ\*?^1;N_\ K[/_ * M>3UZQ\*?^1;N_P#K[/\
MZ M=F#_BG@<0?[B_5'<T445[)^<!1110 5GZ_P#\BWJ?_7I+_P"@&M"L_7_^
M1;U/_KTE_P#0#0!\^T444 %%%% !1110 4444 .'^K;ZC^M)2C_5M]1_6DKQ
M,5_&?]=#]+R+_D7T_G^;"BBBN4]L**** "BBB@ KZ/C_ -4G^Z*^<*^CX_\
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M"4^'M2UO1-;NS?13:7$)I896R75DR#C)Z],#ODXN?\+<7_H"G_P*_P#L*/\
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M\CQIW^\__HMJUI?Q(^J./'?[I5_PR_)GM]%%%?0'Y*%%%% !1110!XI\1/\
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M!1110 5Y+\5O^1GM?^O-?_0WKUJO)?BM_P C/:_]>:_^AO0!P]%%% !1110
M4444 %%%% #F^\?K24K?>/UI*^:/V4****!A1110 4444 =K\*_^1JG_ .O-
M_P#T-*]<KR/X5_\ (U3_ /7F_P#Z&E>N5[.#_A'YSQ#_ +\_1!11178?/A11
M10 5\W-]X_6OI&OFYOO'ZT )1110 4444 %%%% !2KT;Z?UI*5>C?3^M88C^
M%(]/*?\ ?J7J%%%%>"?J84444 %%%% !1110![7\._\ D1[+_>D_]&-735S/
MP[_Y$>R_WI/_ $8U=-7T%'^''T1^3YA_OE7_ !/\PHHHK4X0HHHH XOXI_\
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M444 %%%% !2KT;Z?UI*5>C?3^M88C^%(]/*?]^I>H4445X)^IA1110 4444
M%%%% 'M?P[_Y$>R_WI/_ $8U=-7,_#O_ )$>R_WI/_1C5TU?04?X<?1'Y/F'
M^^5?\3_,****U.$**** .+^*?_(IP_\ 7VG_ *"]>0UZ]\4_^13A_P"OM/\
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M%?.%?1\?^J3_ '17I8'[7R/C>*-J7_;WZ#J***],^+"BBB@ KSCXN?ZK2O\
M>E_]DKT>O./BY_JM*_WI?_9* /-**** "BBB@ HHHH **** 'O\ >'^Z/Y4V
MG/\ >'^Z/Y4VOG9_$S]?PW\"'HOR"BBBH-PHHHH **** .S^%W_(VR?]>K_^
MA+7KU>0_"[_D;9/^O5__ $):]>KV<'_"/SKB+_?OD@HHHKL/G@HHHH ****
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M%AMC>/\ N<=.,CZ$]*S-1LO%_BV%-,U2PM](L&=6N)$F$C2 '.  3W]?;F@
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M444 %9^O_P#(MZG_ ->DO_H!K0K/U_\ Y%O4_P#KTE_] - 'S[1110 4444
M%%%% !1110 X?ZMOJ/ZTE*/]6WU']:2O$Q7\9_UT/TO(O^1?3^?YL****Y3V
MPHHHH **** "OH^/_5)_NBOG"OH^/_5)_NBO2P/VOD?&\4;4O^WOT'4445Z9
M\6%%%% !7G'Q<_U6E?[TO_LE>CUYQ\7/]5I7^]+_ .R4 >:4444 %%%% !11
M10 4444 /?[P_P!T?RIM.?[P_P!T?RIM?.S^)GZ_AOX$/1?D%%%%0;A1110
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M*** "BBB@ I5Z-]/ZTE*O1OI_6L,1_"D>GE/^_4O4****\$_4PHHHH ****
M"BBB@#VOX=_\B/9?[TG_ *,:NFKF?AW_ ,B/9?[TG_HQJZ:OH*/\./HC\GS#
M_?*O^)_F%%%%:G"%%%% '%_%/_D4X?\ K[3_ -!>O(:]>^*?_(IP_P#7VG_H
M+UY#0 4444 %%%% !1110 4]ONI]/ZFF4]ONI]/ZFN+&_P ->I]+PU_ODO\
M"_S0VBBBO'/T$**** "BBB@ KHO 7_(\:=_O/_Z+:N=KHO 7_(\:=_O/_P"B
MVK6E_$CZHX\=_NE7_#+\F>WT445] ?DH4444 %%%% 'BGQ$_Y'F]_P!V/_T6
MM<Q73_$3_D>;W_=C_P#1:US% !1110 4444 %%%% #H_]:G^\*2EC_UJ?[PI
M*\O'?$C[CAC^%4]4%%%%><?7!1110 4444 %>L?"G_D6[O\ Z^S_ .@+7D]>
ML?"G_D6[O_K[/_H"UV8/^*>!Q!_N+]4=S1117LGYP%%%% !6?K__ "+>I_\
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M?&!1110 5Y+\5O\ D9[7_KS7_P!#>O6J\E^*W_(SVO\ UYK_ .AO0!P]%%%
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MU/I_4TRGM]U/I_4UQ8W^&O4^EX:_WR7^%_FAM%%%>.?H(4444 %%%% !71>
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MO 7_ "/&G?[S_P#HMJUI?Q(^J./'?[I5_P ,OR9[?1117T!^2A1110 4444
M>*?$3_D>;W_=C_\ 1:US%=/\1/\ D>;W_=C_ /1:US% !1110 4444 %%%%
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M$#_D1=1^D?\ Z,6NCKG/B!_R(NH_2/\ ]&+0!XA1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% !7.?$#_D1=1^D?\ Z,6NCKG/B!_R(NH_2/\
M]&+0!XA1110 4444 %%%% !1110 [^ ?4TE+_ /J:2O!Q'\61^I93_N-+T"B
MBBL#U HHHH **** "OI!?NCZ5\WU](+]T?2O3P/VOE^I\9Q1_P N?^WOT%HH
MHKTCXP**** "O)?BM_R,]K_UYK_Z&]>M5Y+\5O\ D9[7_KS7_P!#>@#AZ***
M "BBB@ HHHH **** '-]X_6DI6^\?K25\T?LH4444#"BBB@ HHHH [7X5_\
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M* "BBB@ HHHH *5>C?3^M)2KT;Z?UK#$?PI'IY3_ +]2]0HHHKP3]3"BBB@
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M7.?$#_D1=1^D?_HQ:Z.N<^('_(BZC](__1BT >(4444 %%%% !1110 4444
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MC\GS#_?*O^)_F%%%%:G"%%%% '%_%/\ Y%.'_K[3_P!!>O(:]>^*?_(IP_\
M7VG_ *"]>0T %%%% !1110 4444 %/;[J?3^IIE/;[J?3^IKBQO\->I]+PU_
MODO\+_-#:***\<_00HHHH **** "NB\!?\CQIW^\_P#Z+:N=KHO 7_(\:=_O
M/_Z+:M:7\2/JCCQW^Z5?\,OR9[?1117T!^2A1110 4444 >*?$3_ )'F]_W8
M_P#T6M<Q73_$3_D>;W_=C_\ 1:US% !1110 4444 %%%% #H_P#6I_O"DI8_
M]:G^\*2O+QWQ(^XX8_A5/5!1117G'UP4444 %%%% !7K'PI_Y%N[_P"OL_\
MH"UY/7K'PI_Y%N[_ .OL_P#H"UV8/^*>!Q!_N+]4=S1117LGYP%%%% !6?K_
M /R+>I_]>DO_ * :T*S]?_Y%O4_^O27_ - - 'S[1110 4444 %%%% !1110
M X?ZMOJ/ZTE*/]6WU']:2O$Q7\9_UT/TO(O^1?3^?YL****Y3VPHHHH ****
M "OH^/\ U2?[HKYPKZ/C_P!4G^Z*]+ _:^1\;Q1M2_[>_0=1117IGQ84444
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M?[I5_P ,OR9[?1117T!^2A1110 4444 >*?$3_D>;W_=C_\ 1:US%=/\1/\
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M><?%S_5:5_O2_P#LE 'FE%%% !1110 4444 %%%% #W^\/\ ='\J;3G^\/\
M='\J;7SL_B9^OX;^!#T7Y!1114&X4444 %%%% '9_"[_ )&V3_KU?_T):]>K
MR'X7?\C;)_UZO_Z$M>O5[.#_ (1^=<1?[]\D%%%%=A\\%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MSGQ _P"1%U'Z1_\ HQ:Z.N<^('_(BZC](_\ T8M 'B%%%% !1110 4444 %%
M%% #OX!]324O\ ^II*\'$?Q9'ZEE/^XTO0****P/4"BBB@ HHHH *^D%^Z/I
M7S?7T@OW1]*]/ _:^7ZGQG%'_+G_ +>_06BBBO2/C HHHH *\E^*W_(SVO\
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M_P ./HC\GS#_ 'RK_B?YA1116IPA1110!Q?Q3_Y%.'_K[3_T%Z\AKU[XI_\
M(IP_]?:?^@O7D- !1110 4444 %%%% !3V^ZGT_J:93V^ZGT_J:XL;_#7J?2
M\-?[Y+_"_P T-HHHKQS]!"BBB@ HHHH *Z+P%_R/&G?[S_\ HMJYVNB\!?\
M(\:=_O/_ .BVK6E_$CZHX\=_NE7_  R_)GM]%%%?0'Y*%%%% !1110!XI\1/
M^1YO?]V/_P!%K7,5T_Q$_P"1YO?]V/\ ]%K7,4 %%%% !1110 4444 .C_UJ
M?[PI*6/_ %J?[PI*\O'?$C[CAC^%4]4%%%%><?7!1110 4444 %>L?"G_D6[
MO_K[/_H"UY/7K'PI_P"1;N_^OL_^@+79@_XIX'$'^XOU1W-%%%>R?G 4444
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M445V'SP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7.?$#_ )$74?I'_P"C%KHZYSX@?\B+J/TC_P#1
MBT >(4444 %%%% !1110 4444 ._@'U-)2_P#ZFDKP<1_%D?J64_[C2] HHH
MK ]0**** "BBB@ KZ07[H^E?-]?2"_='TKT\#]KY?J?&<4?\N?\ M[]!:***
M](^,"BBB@ KR7XK?\C/:_P#7FO\ Z&]>M5Y+\5O^1GM?^O-?_0WH X>BBB@
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M1\;Q1M2_[>_0=1117IGQ84444 %><?%S_5:5_O2_^R5Z/7G'Q<_U6E?[TO\
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M]QI>@4445@>H%%%% !1110 5](+]T?2OF^OI!?NCZ5Z>!^U\OU/C.*/^7/\
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MHHHH XOXI_\ (IP_]?:?^@O7D->O?%/_ )%.'_K[3_T%Z\AH **** "BBB@
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MHHH **** "BBB@ I5Z-]/ZTE*O1OI_6L,1_"D>GE/^_4O4****\$_4PHHHH
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M+7D]>L?"G_D6[O\ Z^S_ .@+79@_XIX'$'^XOU1W-%%%>R?G 4444 %9^O\
M_(MZG_UZ2_\ H!K0K/U__D6]3_Z])?\ T T ?/M%%% !1110 4444 %%%% #
MA_JV^H_K24H_U;?4?UI*\3%?QG_70_2\B_Y%]/Y_FPHHHKE/;"BBB@ HHHH
M*^CX_P#5)_NBOG"OH^/_ %2?[HKTL#]KY'QO%&U+_M[]!U%%%>F?%A1110 5
MYQ\7/]5I7^]+_P"R5Z/7G'Q<_P!5I7^]+_[)0!YI1110 4444 %%%% !1110
M ]_O#_='\J;3G^\/]T?RIM?.S^)GZ_AOX$/1?D%%%%0;A1110 4444 =G\+O
M^1MD_P"O5_\ T):]>KR'X7?\C;)_UZO_ .A+7KU>S@_X1^=<1?[]\D%%%%=A
M\\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5SGQ _Y$74?I'_Z,6NCKG/B!_R(NH_2/_T8M 'B%%%%
M !1110 4444 %%%% #OX!]324O\  /J:2O!Q'\61^I93_N-+T"BBBL#U HHH
MH **** "OI!?NCZ5\WU](+]T?2O3P/VOE^I\9Q1_RY_[>_06BBBO2/C HHHH
M *\E^*W_ ",]K_UYK_Z&]>M5Y+\5O^1GM?\ KS7_ -#>@#AZ*** "BBB@ HH
MHH **** '-]X_6DI6^\?K25\T?LH4444#"BBB@ HHHH [7X5_P#(U3_]>;_^
MAI7KE>1_"O\ Y&J?_KS?_P!#2O7*]G!_PC\YXA_WY^B"BBBNP^?"BBB@ KYN
M;[Q^M?2-?-S?>/UH 2BBB@ HHHH **** "E7HWT_K24J]&^G]:PQ'\*1Z>4_
M[]2]0HHHKP3]3"BBB@ HHHH **** /:_AW_R(]E_O2?^C&KIJYGX=_\ (CV7
M^])_Z,:NFKZ"C_#CZ(_)\P_WRK_B?YA1116IPA1110!Q?Q3_ .13A_Z^T_\
M07KR&O7OBG_R*</_ %]I_P"@O7D- !1110 4444 %%%% !3V^ZGT_J:93V^Z
MGT_J:XL;_#7J?2\-?[Y+_"_S0VBBBO'/T$**** "BBB@ KHO 7_(\:=_O/\
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M\0/^1%U'Z1_^C%KHZYSX@?\ (BZC](__ $8M 'B%%%% !1110 4444 %%%%
M#OX!]324O\ ^II*\'$?Q9'ZEE/\ N-+T"BBBL#U HHHH **** "OI!?NCZ5\
MWU](+]T?2O3P/VOE^I\9Q1_RY_[>_06BBBO2/C HHHH *\E^*W_(SVO_ %YK
M_P"AO7K5>2_%;_D9[7_KS7_T-Z .'HHHH **** "BBB@ HHHH <WWC]:2E;[
MQ^M)7S1^RA1110,**** "BBB@#M?A7_R-4__ %YO_P"AI7KE>1_"O_D:I_\
MKS?_ -#2O7*]G!_PC\YXA_WY^B"BBBNP^?"BBB@ KYN;[Q^M?2-?-S?>/UH
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M_6I_O"DKR\=\2/N.&/X53U04445YQ]<%%%% !1110 5ZQ\*?^1;N_P#K[/\
MZ M>3UZQ\*?^1;N_^OL_^@+79@_XIX'$'^XOU1W-%%%>R?G 4444 %9^O_\
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M^0/K7J2H(H0D"* BX1>@&!P/:N=\-^&[JQU2_P!8UN6&?4KQ\ Q$E8H^R@D
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M )!'_P 77J5% 'EO_"J;K_G_ /\ R"/_ (NC_A5-U_S_ /\ Y!'_ ,77J5%
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M_G__ /((_P#BZ!\*KH9_T_K_ -,1_P#%UZE14RBI*S-:56=&HJE-V:V/+?\
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MHH\^Z_Y\_P#R**LT4 <WXJT6Z\3:2EEM^S;9A+OR'S@$8QD>M<C_ ,*INO\
MG_\ _((_^+KU*B@#RW_A5-U_S_\ _D$?_%T?\*INO^?_ /\ ((_^+KU*B@#R
MW_A5-U_S_P#_ )!'_P 71_PJFZ_Y_P#_ ,@C_P"+KU*B@#RW_A5-U_S_ /\
MY!'_ ,71_P *INO^?_\ \@C_ .+KU*B@#RW_ (53=?\ /_\ ^01_\72GX5W1
M 'V_H,?ZD?\ Q=>HT5$Z<:BM)'3AL56PL^>B[/;H_P SRW_A55U_S_\ _D$?
M_%T?\*JNO^?_ /\ ((_^+KU*BL?JM'M^9Z']N9A_S\_"/^1Y;_PJJZ_Y_P#_
M ,@C_P"+H_X55=?\_P#_ .01_P#%UZE11]5H]OS#^W,P_P"?GX1_R/+?^%57
M7_/_ /\ D$?_ !='_"JKK_G_ /\ R"/_ (NO4J*/JM'M^8?VYF'_ #\_"/\
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MK_G_ /\ R"/_ (NO4J* /+?^%4W7_/\ _P#D$?\ Q='_  JFZ_Y__P#R"/\
MXNO4J* /+E^%=TK _;^AS_J1_P#%TG_"JKK_ )__ /R"/_BZ]2HK*I1A4=Y(
M[L+F&)PB:H2M?R3_ #1Y;_PJJZ_Y_P#_ ,@C_P"+H_X55=?\_P#_ .01_P#%
MUZE16?U6CV_,Z_[<S#_GY^$?\CRW_A55U_S_ /\ Y!'_ ,71_P *JNO^?_\
M\@C_ .+KU*BCZK1[?F']N9A_S\_"/^1Y;_PJJZ_Y_P#_ ,@C_P"+H_X55=?\
M_P#_ .01_P#%UZE11]5H]OS#^W,P_P"?GX1_R/+?^%577_/_ /\ D$?_ !==
M9X4T*Z\,:;+:8^U>9,9=^0F. ,8R?2NFHJX4*<'S11AB,TQF)I^SJSNO1?HB
MMY]U_P ^?_D44>?=?\^?_D459HK8\TK>?=?\^?\ Y%%'GW7_ #Y_^115FB@"
MMY]U_P ^?_D457U!+J^TVYM/LWE_:(7BW^8#MW C.._6M&B@#RW_ (53=?\
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MJM'M^8?VYF'_ #\_"/\ D>6_\*JNO^?_ /\ ((_^+H_X55=?\_\ _P"01_\
M%UZE11]5H]OS#^W,P_Y^?A'_ "/+?^%577_/_P#^01_\77I"S72J%^R9P,?Z
MT5:HK2G2A3^%''BL=B,7;V\KVVT2W]$5O/NO^?/_ ,BBCS[K_GS_ /(HJS16
MIQ%;S[K_ )\__(HH\^Z_Y\__ "**LT4 5O/NO^?/_P BBN;\7>&;KQ4MH,_9
M?LY<] ^[=CW&.E=;10!Y;_PJFZ_Y_P#_ ,@C_P"+H_X53=?\_P#_ .01_P#%
MUZE10!Y;_P *INO^?_\ \@C_ .+H_P"%4W7_ #__ /D$?_%UZE10!Y;_ ,*I
MNO\ G_\ _((_^+H_X53=?\__ /Y!'_Q=>I44 >6_\*INO^?_ /\ ((_^+H_X
M53=?\_\ _P"01_\ %UZE10!Y<WPKNB?^/_L!_J1_\72?\*JNO^?_ /\ ((_^
M+KU*BN=X6BW=K\SV(YUCXQ454T7DO\CRW_A55U_S_P#_ )!'_P 71_PJJZ_Y
M_P#_ ,@C_P"+KU*BE]5H]OS'_;F8?\_/PC_D>6_\*JNO^?\ _P#((_\ BZ/^
M%577_/\ _P#D$?\ Q=>I44?5:/;\P_MS,/\ GY^$?\CRW_A55U_S_P#_ )!'
M_P 71_PJJZ_Y_P#_ ,@C_P"+KU*BCZK1[?F']N9A_P _/PC_ )'#^%O!5UX:
MU9KWS?M.Z(Q[-H3J0<YW'TKK_/NO^?/_ ,BBK-%;0A&"M$\[$8FKBI^TK.[^
M7Z%;S[K_ )\__(HI5FN2X#6NT$\GS <58HJSG"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBJ&N7UQINB7-W96DEY<1K^[@C4L78D <#G SD^P- %^BN
M#U*]\6^']#CUV_U.WN44H;BP-L$"JQ P&^]D9[UW,4@FA2500KJ&&1S@B@!]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1163JVG
M:O>7"/IFN-IT83#1BUCEW'/7+=/I[4 :U%<1H5[KLWCJXTZ36FU"PL8_])<V
ML<8,A'"C:,\'W[&NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BN6\>76KZ7H,NJ:3J?V06P7=$+=7\PLX7[S9QC/85M-J<-E
MH"ZCJ,H2-(%DE<_0?J3VH OT5PWA/Q3JVN>,;N&]4V]D;3S[>V*#*C<H5B<9
MR0<]<<UW- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M15#7+ZXTW1+F[LK22\N(U_=P1J6+L2 .!S@9R?8&@"_17!:G?>+/#^AQ:[?Z
MI;W"AD,^GFV5  Q VJWWLC/^<5IZYKFI3:UI^AZ"R6US=P_:9)YTW>5'S_#Z
M\&@#JJ*Y*+4]8T#Q-8Z9KEY'J5IJ6Y8+D0B)XY!V*KP0<@?C76T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<OXAUC4V\1V7A_0I(
M[:XN(C/-<R('\N,$CA3P3P: .HHKCK;7=3T'Q&^D^(KE+Z&2V>Y@NTB$;X0$
MLK*..BG_ ">(M,F\6>(]+.L6FJ6^GQS%FMK/[,L@*@D#>YY&<=J .VHK%\*:
M\WB'0DNY8A#<([0SHO0.O7'MR#^-;5 !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !16!XQEU.T\/SWVE:A]C:UC:1AY"R&3VRW _*LQM7
M\0WVE:!;Z2A^TW]LLMUJ$D&Z.+Y0>PVY//'T]: .RHKD++5=7T?Q?%HNMWT>
MHP75NTT5R(1$T>W)(8#C'!_2H-*O/$WBNUEU73]4ATNS9V6U@-LLI<*<99CT
MR?2@#MJ*P?">NS:WITXOXTBOK*=K:Y1.FY>X]C_0UO4 %%%% !1110 4444
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MS,Q'IEB36I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU-*LEDSG>+= ?SQ5^B@ JB^AZ3+,99-+LGD)R7:W0G/UQ5ZB@!% 50J@  8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>,.[S-JO<>9PDC#*KMQSGCOWKIZ "BBB@ HHHH **** "BBB@ HHHH ****
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>primaryendpoint.jpg
<TEXT>
begin 644 primaryendpoint.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M,P  DI(  @    ,Y,P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C Q.3HP,SHQ-" Q,#HS-SHU,0 R,#$Y
M.C S.C$T(#$P.C,W.C4Q    1P!I &P 8@!E '( =  @ $@ 90!R &X 80!N
M &0 90!Z    _^$+)&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D
M+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P,3DM,#,M
M,314,3 Z,S<Z-3$N.3,Q/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP
M=&EO;CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D
M-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D
M9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI/D=I;&)E<G0@2&5R;F%N9&5Z/"]R
M9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R
M:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'
M!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S
M+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( WD%F ,!(@ "
M$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  "
M 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1
M\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ?
M 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$
M!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0T
MX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _
M /I&BBB@ HHHH **** "BBB@ HHHH **** "BL75/%^A:+?"SU*_6*X*AO+$
M;N0#TSM!Q^-:-_J-II=HUUJ%Q';PKP7D.!GT]S[4 6:*Q=,\7Z#K%U]FT_4H
MI9NR,&0M]-P&?PK1O]1M-+M&NM0N([>%>"\AP,^GN?:@"S16+IGB_0=8NOLV
MGZE%+-V1@R%OIN S^%/U?Q3HNA2K%JM^D$C#(0*SMCU(4$B@#7HJMI^HVFJ6
M:76GW"7$#]'0_I['VJ'3M;T_5IKF+3KCSVM7\N4JC!5;T#$8/X$T 7Z*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#AOBG!$OAF"58D$C7L>7"C)X;O1X
MEB35/B9H.F7@\RT6%YS$>59OFZCO]T4_XJ_\BI;_ /7['_)J=XNAN=+\4Z3X
MGAMI+JWM4:&Y2)=S(AS\P'_ C^0H C^)EC;P>&8]1MX4AN[.>,PS1J%9><8R
M.W^%0ZUC7/B!X;LKY0]JUJ;HPGE2^&/([_=%5_$VO0^-K&'0_#D-Q<O-,C33
M-$RI"HZY)[YJ_P"*+2XT3Q#HOB&VMI;NUL8C;7"1+N9$P1NQ_P "/Y"@!/B9
M8V\'AF/4;>%(;NSGC,,T:A67G&,CM_A5"UU.V\/>,=1U'Q- X34H8Y+6\\IG
M51MYC&,XZ@?A[TOB;7H?&UC#H?AR&XN7FF1IIFB94A4=<D]\UWDLUOI&E-+<
M2!+>UBRSMV"B@#S"TU.\T_3]1BT>WDMI=?O-NFVQ&UHTY#28[#! !]O:NH\.
M:[X5T"T@T*VU:!IT.)'PVV20]3OQMZ^]9FEZ7?>)[36/$LN8KJ\MY(--C;_E
ME'@@?0GIGW)[UE/JNE2_#]?#::9-_;>!%]D-N=XESS)G'_U^W2@#UFBJ>D6\
M]IHEE;W;[YXK=$D;U8* :N4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<_CC]?2NXM]&TRSG\ZTTVT@E_P">D4"JWY@5:FABN(6BN(TEC889'4,#]0:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU=<_Y]=/_P"_;_\ Q='URD'^KV.[+[SUNBO)/^%JZY_SZZ?_ -^W_P#BZ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*?\ QH_X2/7/^@SJ'_@4_P#C6;11SR[A]7H_R+[D:7_"1ZY_T&=0_P# I_\
M&C_A(]<_Z#.H?^!3_P"-9M%'/+N'U>C_ "+[D:7_  D>N?\ 09U#_P "G_QH
M_P"$CUS_ *#.H?\ @4_^-9M%'/+N'U>C_(ON1I?\)'KG_09U#_P*?_&O4/AK
M>W5_X;N);ZYFN9!=LH>:0N0-B<9/;DUX[7K?PJ_Y%6Y_Z_6_] 2NK"2DZNK/
M"S^E3A@FXQ2U70[:BBBO8/ST**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#-\1_\BKJO_7E-_P"@&O *]_\ $?\ R*NJ
M_P#7E-_Z :\ KRL=\2/N>&/X-3U7Y!1117GGUH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7I/PC_YB_\ VQ_]J5YM7I/P
MC_YB_P#VQ_\ :E=6%_C+^NAXN>?\B^I\O_2D>D4445[9^9A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6U*_ATO2[J_N3B*V
MB:5_< 9P/>O*='\-:K\4"^M^)=1FMM.:0BVM8#V!YVYX'IG!)KTCQ7ILFL>$
MM3L+?_736[",>K 9 _$@"N7^%?B:QN?#-OHLTJ6^HV1:-H)#M9QN)! /7K@C
ML1[T 8.M>"M2^'D#:]X0U6X>& @W%M/@[DZ9.,!A^ (ZCI7IN@:O%K^@6>J0
M*42YC#;3_">A'X$$5S?Q)\4:?I/A6^L#/')?7D36\=NI!8;A@L1V !/XXK1\
M :9-H_@33+2Z!681F1D/\.]BV/\ QZ@#HZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;^(/_ "(FH?\ ;/\
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M:M>)5Y&-_B+T/T#AK_<Y?XG^2"BBBN$^F"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *];^%7_(JW/_ %^M_P"@)7DE>M_"
MK_D5;G_K];_T!*[,'_%/G^(?]Q?JCMJ***]D_.0HHHH **** "BBB@ HHHH
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MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB/\ Y%75?^O*;_T
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MH **** "BBB@ KUOX5?\BK<_]?K?^@)7DE>M_"K_ )%6Y_Z_6_\ 0$KLP?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_1JUXE7MOQ!_Y$34/^V?_HU:\2KR,;_$7H?H'#7^YR_Q/\D%%%%<)],%%%%
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MH **** "BBB@ HHHH **** .;^(/_(B:A_VS_P#1JUXE7MOQ!_Y$34/^V?\
MZ-6O$J\C&_Q%Z'Z!PU_N<O\ $_R04445PGTP4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7K?PJ_P"15N?^OUO_ $!*\DKU
MOX5?\BK<_P#7ZW_H"5V8/^*?/\0_[B_5';4445[)^<A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB/_D5=5_Z\IO_
M $ UX!7O_B/_ )%75?\ KRF_] -> 5Y6.^)'W/#'\&IZK\@HHHKSSZT****
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MB@ HHHH **** "BBB@ HHHH S?$?_(JZK_UY3?\ H!KP"O?_ !'_ ,BKJO\
MUY3?^@&O *\K'?$C[GAC^#4]5^04445YY]:%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5Z3\(_^8O_ -L?_:E>;5Z3\(_^
M8O\ ]L?_ &I75A?XR_KH>+GG_(OJ?+_TI'I%%%%>V?F84444 %%%% !1110
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M:VD<,4%U?2YVD* #SC '&<<DUZWH>DPZ%H=IIEL2T=M&$#$8W'N?Q.35^B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH YOX@_\ (B:A_P!L_P#T:M>)5[;\0?\ D1-0_P"V?_HU:\2KR,;_
M !%Z'Z!PU_N<O\3_ "04445PGTP4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7K?PJ_Y%6Y_P"OUO\ T!*\DKUOX5?\BK<_
M]?K?^@)79@_XI\_Q#_N+]4=M1117LGYR%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!F^(_^15U7_KRF_P#0#7@%>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *])^$?\ S%_^V/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH R?%.IOHWA34M0A_P!;! QC]FZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB/\
MY%75?^O*;_T UX!7O_B/_D5=5_Z\IO\ T UX!7E8[XD?<\,?P:GJOR"BBBO/
M/K0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O2?A'_ ,Q?_MC_ .U*\VKTGX1_\Q?_ +8_^U*ZL+_&7]=#Q<\_Y%]3Y?\
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M% !1110 4444 %%%% !1110 5ZW\*O\ D5;G_K];_P! 2O)*];^%7_(JW/\
MU^M_Z E=F#_BGS_$/^XOU1VU%%%>R?G(4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &;XC_Y%75?^O*;_P! -> 5[_XC
M_P"15U7_ *\IO_0#7@%>5COB1]SPQ_!J>J_(****\\^M"BBB@ HHHH ****
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M34/^V?\ Z-6O$J\C&_Q%Z'Z!PU_N<O\ $_R04445PGTP4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K?PJ_P"15N?^OUO_
M $!*\DKUOX5?\BK<_P#7ZW_H"5V8/^*?/\0_[B_5';4445[)^<A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%%<)],%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5ZW\*O^15N?^OUO_0$KR2O6_A5_P BK<_]?K?^@)79@_XI\_Q#_N+]
M4=M1117LGYR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!F^(_\ D5=5_P"O*;_T UX!7O\ XC_Y%75?^O*;_P! -> 5
MY6.^)'W/#'\&IZK\@HHHKSSZT**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KTGX1_\ ,7_[8_\ M2O-J])^$?\ S%_^V/\
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M[6Z#++Y9D96ZKO8L!^34 =)1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!S?Q!_P"1$U#_ +9_^C5KQ*O;?B#_
M ,B)J'_;/_T:M>)5Y&-_B+T/T#AK_<Y?XG^2"BBBN$^F"BBB@ HHHH ****
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M*1Z11117MGYF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC5KQ*O(QO\1>A^@<-?[G+_$_R04445PGTP4444 %%%% !1110 4444 %%%%
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M(D-S&8W:,@, ?3((KS^Y^#OA.RB\R\U6_MX^F^6YB4?F4H ]$_M"R_Y^X/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !7I/PC_ .8O_P!L?_:E>;5Z3\(_^8O_ -L?_:E=6%_C+^NAXN>?\B^I\O\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB/\
MY%75?^O*;_T UX!7O_B/_D5=5_Z\IO\ T UX!7E8[XD?<\,?P:GJOR"BBBO/
M/K0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O2?A'_ ,Q?_MC_ .U*\VKTGX1_\Q?_ +8_^U*ZL+_&7]=#Q<\_Y%]3Y?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,WQ'_P BKJO_ %Y3?^@&O *]_P#$?_(JZK_UY3?^@&O *\K'?$C[GAC^#4]5
M^04445YY]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Z3\(_^8O\ ]L?_ &I7FU>D_"/_ )B__;'_ -J5U87^,OZZ'BYY
M_P B^I\O_2D>D4445[9^9A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!S?Q!_Y$34/^V?_HU:\2KV
MWX@_\B)J'_;/_P!&K7B5>1C?XB]#] X:_P!SE_B?Y(****X3Z8**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KUOX5?\BK<_
M]?K?^@)7DE>M_"K_ )%6Y_Z_6_\ 0$KLP?\ %/G^(?\ <7ZH[:BBBO9/SD**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#-\1_P#(JZK_ ->4W_H!KP"O?_$?_(JZK_UY3?\ H!KP"O*QWQ(^YX8_@U/5
M?D%%%%>>?6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>D_"/_ )B__;'_ -J5YM7I/PC_ .8O_P!L?_:E=6%_C+^NAXN>
M?\B^I\O_ $I'I%%%%>V?F84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <W\0?^1$U#_MG_P"C5KQ*
MO;?B#_R(FH?]L_\ T:M>)5Y&-_B+T/T#AK_<Y?XG^2"BBBN$^F"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *];^%7_ "*M
MS_U^M_Z E>25ZW\*O^15N?\ K];_ - 2NS!_Q3Y_B'_<7ZH[:BBBO9/SD***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M-\1_\BKJO_7E-_Z :\ KW_Q'_P BKJO_ %Y3?^@&O *\K'?$C[GAC^#4]5^0
M4445YY]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Z3\(_P#F+_\ ;'_VI7FU>D_"/_F+_P#;'_VI75A?XR_KH>+GG_(O
MJ?+_ -*1Z11117MGYF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '-_$'_D1-0_[9_P#HU:\2KVWX
M@_\ (B:A_P!L_P#T:M>)5Y&-_B+T/T#AK_<Y?XG^2"BBBN$^F"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *];^%7_(JW/_
M %^M_P"@)7DE>M_"K_D5;G_K];_T!*[,'_%/G^(?]Q?JCMJ***]D_.0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQ
M'_R*NJ_]>4W_ * :\ KW_P 1_P#(JZK_ ->4W_H!KP"O*QWQ(^YX8_@U/5?D
M%%%%>>?6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>D_"/_F+_P#;'_VI7FU>D_"/_F+_ /;'_P!J5U87^,OZZ'BYY_R+
MZGR_]*1Z11117MGYF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P F_P#["C_A;O\ U!/_ ";_ /L* /2:*\V_X6[_ -03_P F_P#["C_A;O\
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M_OV__P 70!ZEIMA#I6EVUA:C$-M&L:9ZX QD^]6:\D_X6MKG_/KI_P#W[?\
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MFT,>K'J3^))-7: "H));A9"([;>O9O, S4]% %;S[K_GS_\ (HH\^Z_Y\_\
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M;_PJFZ_Y_P#_ ,@C_P"+H_X53=?\_P#_ .01_P#%UZE10!Y;_P *INO^?_\
M\@C_ .+H_P"%4W7_ #__ /D$?_%UZE10!Y;_ ,*INO\ G_\ _((_^+H_X53=
M?\__ /Y!'_Q=>I44 >6_\*INO^?_ /\ ((_^+H_X53=?\_\ _P"01_\ %UZE
M10!Y;_PJFZ_Y_P#_ ,@C_P"+H_X53=?\_P#_ .01_P#%UZE10!Y;_P *INO^
M?_\ \@C_ .+H_P"%4W7_ #__ /D$?_%UZE10!6\^Z_Y\_P#R**//NO\ GS_\
MBBK-% %;S[K_ )\__(HH\^Z_Y\__ "**LT4 5O/NO^?/_P BBCS[K_GS_P#(
MHJS10!6\^Z_Y\_\ R**//NO^?/\ \BBK-% %;S[K_GS_ /(HH\^Z_P"?/_R*
M*LT4 5O/NO\ GS_\BBCS[K_GS_\ (HJS10!6\^Z_Y\__ "**//NO^?/_ ,BB
MK-% %;S[K_GS_P#(HH\^Z_Y\_P#R**LT4 5O/NO^?/\ \BBCS[K_ )\__(HJ
MS10!6\^Z_P"?/_R**//NO^?/_P BBK-% %;S[K_GS_\ (HH\^Z_Y\_\ R**L
MT4 9NI1W6H:5=V?V;R_M$+Q;]X.W<I&<=^M>?_\ "JKK_G__ /((_P#BZ]2H
MK*I1A4=Y([L+F&)PD7&A*R?DG^:/+?\ A55U_P __P#Y!'_Q='_"JKK_ )__
M /R"/_BZ]2HK/ZK1[?F=?]N9A_S\_"/^1Y;_ ,*JNO\ G_\ _((_^+H_X55=
M?\__ /Y!'_Q=>I44?5:/;\P_MS,/^?GX1_R/+?\ A55U_P __P#Y!'_Q='_"
MJKK_ )__ /R"/_BZ]2HH^JT>WYA_;F8?\_/PC_D>6_\ "JKK_G__ /((_P#B
MZ/\ A55U_P __P#Y!'_Q=>I44?5:/;\P_MS,/^?GX1_R/+?^%577_/\ _P#D
M$?\ Q='_  JJZ_Y__P#R"/\ XNO4J*/JM'M^8?VYF'_/S\(_Y'EO_"JKK_G_
M /\ R"/_ (NC_A55U_S_ /\ Y!'_ ,77J5%'U6CV_,/[<S#_ )^?A'_(\M_X
M55=?\_\ _P"01_\ %T?\*JNO^?\ _P#((_\ BZ]2HH^JT>WYA_;F8?\ /S\(
M_P"1Y;_PJJZ_Y_\ _P @C_XNC_A55U_S_P#_ )!'_P 77J5%'U6CV_,/[<S#
M_GY^$?\ (\M_X55=?\__ /Y!'_Q='_"JKK_G_P#_ ""/_BZ]2HH^JT>WYA_;
MF8?\_/PC_D>6_P#"JKK_ )__ /R"/_BZ/^%577_/_P#^01_\77J5%'U6CV_,
M/[<S#_GY^$?\CRW_ (55=?\ /_\ ^01_\71_PJJZ_P"?_P#\@C_XNO4J*/JM
M'M^8?VYF'_/S\(_Y'EO_  JJZ_Y__P#R"/\ XNC_ (55=?\ /_\ ^01_\77J
M5%'U6CV_,/[<S#_GY^$?\CRW_A55U_S_ /\ Y!'_ ,71_P *JNO^?_\ \@C_
M .+KU*BJAAZ<)<T5J8U\UQF(INE5G>+\EZ]$>6_\*INO^?\ _P#((_\ BZ/^
M%4W7_/\ _P#D$?\ Q=>I45N>8>6_\*INO^?_ /\ ((_^+H_X53=?\_\ _P"0
M1_\ %UZE10!Y;_PJFZ_Y_P#_ ,@C_P"+H_X53=?\_P#_ .01_P#%UZE10!Y;
M_P *INO^?_\ \@C_ .+H_P"%4W7_ #__ /D$?_%UZE10!Y;_ ,*INO\ G_\
M_((_^+H_X53=?\__ /Y!'_Q=>I44 >6_\*INO^?_ /\ ((_^+H_X53=?\_\
M_P"01_\ %UZE10!Y;_PJFZ_Y_P#_ ,@C_P"+H_X53=?\_P#_ .01_P#%UZE1
M0!Y;_P *INO^?_\ \@C_ .+H_P"%4W7_ #__ /D$?_%UZE10!Y;_ ,*INO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA+$@<YXH Z*BHK6X6[LX;B,,$FC610W4 C/-2T %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'GGCN[:P\=>';I+::Z:(.PAA7<[\] *Z;0O$<^LW
MDD$VAZCIP2/>)+N$HK<@8!]>?TK!\;)>P>,-"U*UTR\OHK0.T@MH6?OTX'%:
MFG>+[J_U&&UD\-:O:K*VTS30$(GN3B@#)B_XI;XJ/%G;8ZZFY?02_P".<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !16)>^,="TZZEMKR]:.6(X<>1(0#]0N*=;^+M$
MNH;B6"\9DMH_,E)@D7:OKRO/X4 ;-%5=-U.SU>R6[TZ830L2 P!'(ZC!Y%0W
M.NZ;::M!IEQ=!+RXQY<6UCG/3D# Z=Z -"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>primaryendpointimprovement.jpg
<TEXT>
begin 644 primaryendpointimprovement.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (V!)\# 2(  A$! Q$!_\0
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M^1__  _;_:*_Z)+\*/\ P?7G_P ;H_X?M_M%?]$E^%'_ (/KS_XW1_;N7_\
M/Z/WA_Q"_BS_ *%]7_P%GZX45^1__#]O]HK_ *)+\*/_  ?7G_QNC_A^W^T5
M_P!$E^%'_@^O/_C=']NY?_S^C]X?\0OXL_Z%]7_P%GZX45^1_P#P_;_:*_Z)
M+\*/_!]>?_&Z/^'[?[17_1)?A1_X/KS_ .-T?V[E_P#S^C]X?\0OXL_Z%]7_
M ,!9^N%%?D?_ ,/V_P!HK_HDOPH_\'UY_P#&Z/\ A^W^T5_T27X4?^#Z\_\
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M^1__  _;_:*_Z)+\*/\ P?7G_P ;H_X?M_M%?]$E^%'_ (/KS_XW1_;N7_\
M/Z/WA_Q"_BS_ *%]7_P%GZX45^1__#]O]HK_ *)+\*/_  ?7G_QNC_A^W^T5
M_P!$E^%'_@^O/_C=']NY?_S^C]X?\0OXL_Z%]7_P%GZX45^1_P#P_;_:*_Z)
M+\*/_!]>?_&Z/^'[?[17_1)?A1_X/KS_ .-T?V[E_P#S^C]X?\0OXL_Z%]7_
M ,!9^N%%?D?_ ,/V_P!HK_HDOPH_\'UY_P#&Z/\ A^W^T5_T27X4?^#Z\_\
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M^1__  _;_:*_Z)+\*/\ P?7G_P ;H_X?M_M%?]$E^%'_ (/KS_XW1_;N7_\
M/Z/WA_Q"_BS_ *%]7_P%GZX45^1__#]O]HK_ *)+\*/_  ?7G_QNC_A^W^T5
M_P!$E^%'_@^O/_C=']NY?_S^C]X?\0OXL_Z%]7_P%GZX45^1_P#P_;_:*_Z)
M+\*/_!]>?_&Z/^'[?[17_1)?A1_X/KS_ .-T?V[E_P#S^C]X?\0OXL_Z%]7_
M ,!9^N%%?D?_ ,/V_P!HK_HDOPH_\'UY_P#&Z/\ A^W^T5_T27X4?^#Z\_\
MC=']NY?_ ,_H_>'_ !"_BS_H7U?_  %GZX45^1__  _;_:*_Z)+\*/\ P?7G
M_P ;H_X?M_M%?]$E^%'_ (/KS_XW1_;N7_\ /Z/WA_Q"_BS_ *%]7_P%GZX4
M5^1__#]O]HK_ *)+\*/_  ?7G_QNC_A^W^T5_P!$E^%'_@^O/_C=']NY?_S^
MC]X?\0OXL_Z%]7_P%GZX45^1_P#P_;_:*_Z)+\*/_!]>?_&Z/^'[?[17_1)?
MA1_X/KS_ .-T?V[E_P#S^C]X?\0OXL_Z%]7_ ,!9^N%%?D?_ ,/V_P!HK_HD
MOPH_\'UY_P#&Z/\ A^W^T5_T27X4?^#Z\_\ C=']NY?_ ,_H_>'_ !"_BS_H
M7U?_  %GZX45^1__  _;_:*_Z)+\*/\ P?7G_P ;H_X?M_M%?]$E^%'_ (/K
MS_XW1_;N7_\ /Z/WA_Q"_BS_ *%]7_P%GZX45^1__#]O]HK_ *)+\*/_  ?7
MG_QNC_A^W^T5_P!$E^%'_@^O/_C=']NY?_S^C]X?\0OXL_Z%]7_P%GZX45^1
M_P#P_;_:*_Z)+\*/_!]>?_&Z/^'[?[17_1)?A1_X/KS_ .-T?V[E_P#S^C]X
M?\0OXL_Z%]7_ ,!9^N%%?D?_ ,/V_P!HK_HDOPH_\'UY_P#&Z/\ A^W^T5_T
M27X4?^#Z\_\ C=']NY?_ ,_H_>'_ !"_BS_H7U?_  %GZX45^1__  _;_:*_
MZ)+\*/\ P?7G_P ;H_X?M_M%?]$E^%'_ (/KS_XW1_;N7_\ /Z/WA_Q"_BS_
M *%]7_P%GZX45^1__#]O]HK_ *)+\*/_  ?7G_QNC_A^W^T5_P!$E^%'_@^O
M/_C=']NY?_S^C]X?\0OXL_Z%]7_P%GZX45^1_P#P_;_:*_Z)+\*/_!]>?_&Z
M/^'[?[17_1)?A1_X/KS_ .-T?V[E_P#S^C]X?\0OXL_Z%]7_ ,!9^N%%?D?_
M ,/V_P!HK_HDOPH_\'UY_P#&Z/\ A^W^T5_T27X4?^#Z\_\ C=']NY?_ ,_H
M_>'_ !"_BS_H7U?_  %GZX45^1__  _;_:*_Z)+\*/\ P?7G_P ;H_X?M_M%
M?]$E^%'_ (/KS_XW1_;N7_\ /Z/WA_Q"_BS_ *%]7_P%GZX45^1__#]O]HK_
M *)+\*/_  ?7G_QNC_A^W^T5_P!$E^%'_@^O/_C=']NY?_S^C]X?\0OXL_Z%
M]7_P%GZX45^1_P#P_;_:*_Z)+\*/_!]>?_&Z/^'[?[17_1)?A1_X/KS_ .-T
M?V[E_P#S^C]X?\0OXL_Z%]7_ ,!9^N%%?D?_ ,/V_P!HK_HDOPH_\'UY_P#&
MZ/\ A^W^T5_T27X4?^#Z\_\ C=']NY?_ ,_H_>'_ !"_BS_H7U?_  %GZX45
M^1__  _;_:*_Z)+\*/\ P?7G_P ;H_X?M_M%?]$E^%'_ (/KS_XW1_;N7_\
M/Z/WA_Q"_BS_ *%]7_P%GZX45^1__#]O]HK_ *)+\*/_  ?7G_QNC_A^W^T5
M_P!$E^%'_@^O/_C=']NY?_S^C]X?\0OXL_Z%]7_P%GZX45^1_P#P_;_:*_Z)
M+\*/_!]>?_&Z/^'[?[17_1)?A1_X/KS_ .-T?V[E_P#S^C]X?\0OXL_Z%]7_
M ,!9^N%%?D?_ ,/V_P!HK_HDOPH_\'UY_P#&Z/\ A^W^T5_T27X4?^#Z\_\
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M*M2IQE"+<Z4HZSO9Z]%;5K:Z[GQ]14E[9S:;>2V]Q%)!<0.8Y8I%*O&P."K
M\@@\$&O8?V%OV6T_:Q^.,>@WTE]:Z%9VLM[J=S:,JRQH!M149E90S2,G4'@-
MZ5YF'P\Z]6-&FO>;L?:9MF^%RW U,QQ<K4Z<7)OR7;NWT[L\:HKUW]MWX.^$
M/@%\>;SPEX/O=:U"VTBWB6^FU*:*5_M+#>RH8XT&T(T8Z$[MW->14L11E1JR
MI3W3LRLIS*EF."I8^@FH5(J2NK.SU5UYK4**]@_8Z_8ZUW]L#QS<:?I]Q'I>
MD:6BRZEJ4L9D%N&)"(J9&]VPV!D#"L2> #]#W/[#_P"S)IOC7_A$[GXO:ROB
M;>8647ML+=)0P4QL_P!G,:ONXV&0-G([&N_"Y/B*]-5HV47HG)I7?E?<^6SS
MQ#RC*\9++ZG/4JQ7-*-.G*HX1[SY5[NFNNMM>J/ABBO</VTOV'M<_9 \0VK2
MW:ZSX;U5V6PU)(C&=P )BE7D*^.F"0P!(Q@@._8J_8>UK]K_ ,1W3)=C1O#6
MDNJW^HO&78L1D11+P&?'7) 4$$YX!P_LW$_6?JG)[_;^NGF>E_KGDO\ 8_\
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MX)MJC4E2E=6]^%KV[K5:A1117(>^%%%% !1110 4444 %%%% !1110 4444
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M;)(@#-L9,D 8ZC/DW_!/[]F?0OVK/C==^&O$-WJUG8P:1-?K)ITL<<ID26%
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M" [YP<].:X#]L?\ X)Z-\ O ]MXY\(Z\GBWP'>^41<_*9K59,"-RR?))&Q(
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MBOSW_P"#<+_DT_XK_P#96]<_]$6-?H17[Q@_X$/1?D?Y9\0_\C7$_P#7R?\
MZ4PKX0_X.*?^4>UK_P!COH/_ *5"ON^OA#_@XI_Y1[6O_8[Z#_Z5"KK_ ,*7
MHSFRK_?:/^*/YH_/*BBBOP0_U5"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OT1^*_P#P4T_9^^.=E9V_BWP)XSUR"P=I+=+BRML1,P )&+L=@*_.ZBO1
MP.:5L)&<*=FI6O=7VV_,^/XHX(R_/JM"OC'.,Z'-R.$W!KGMS:K7[*_$^UKO
M]J']DF6TE6/X0^(UD9"%;[%!P<<'_C\KXIHHJ,9CIXFW/&*M_*DOR.KAWA?#
MY,JBH5:M3GM?VE252UK[<VV^MM].Q]:_\$\?^"AVD?LI^"M<\.^*[/7M1TRY
MNEO=.&FQ12M;NR[9E;S)4 4[8R,9YW>M>$_M1?'&?]HSX[>(?%LHGCM]1N"M
ME#*?FM[5!LA0C) .P M@XW%CWK@**JMF6(JX:&$F_<CL99?P7E6"SFOGV'IV
MKUE:3OITO9=+V3?=A1117GGU9[!^QU^V+KO[('CFXU#3[>/5-(U1%BU+397,
M8N I)1U?!V.N6P<$89@1R"/HBZ_;@_9CU+QK_P )9<?"+6F\2[S,S?8;;[.\
MI8,9&3[0(V?=SO,9;//<U\+T5ZN%SC$4*:I1LXK5*23L_*^Q\+GGAYE&:8R6
M85.>G5DN64J<Y4W./:?*_>TTUUMIT1[C^VG^W%K?[8'B&U66T71?#>DLS6&F
MI*9#N(P996P SXR!@ *"0,Y)*_L5?MPZU^R!XCNE2T&L^&M6=6O].>0HP8#
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MU*VEVMN]MS+/,BECZU'$4IQA.ES6DZ<9M<UOA<OAVZ;GO_\ PP-_U6GX ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXR_Z#I?^ P_^1/Q?_P"'1W[7O_0'^"__ (4=W_\ (]'_  Z._:]_Z _P7_\
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MBC_5O+?^?2^]_P"8?\1CXR_Z#I?^ P_^1/Q?_P"'1W[7O_0'^"__ (4=W_\
M(]'_  Z._:]_Z _P7_\ "CN__D>OV@HH_P!6\M_Y]+[W_F'_ !&/C+_H.E_X
M##_Y$_%__AT=^U[_ - ?X+_^%'=__(]'_#H[]KW_ * _P7_\*.[_ /D>OV@H
MH_U;RW_GTOO?^8?\1CXR_P"@Z7_@,/\ Y$_%_P#X='?M>_\ 0'^"_P#X4=W_
M /(]'_#H[]KW_H#_  7_ /"CN_\ Y'K]H**/]6\M_P"?2^]_YA_Q&/C+_H.E
M_P" P_\ D3\7_P#AT=^U[_T!_@O_ .%'=_\ R/1_PZ._:]_Z _P7_P#"CN__
M )'K]H**/]6\M_Y]+[W_ )A_Q&/C+_H.E_X##_Y$_%__ (='?M>_] ?X+_\
MA1W?_P CT?\ #H[]KW_H#_!?_P *.[_^1Z_:"BC_ %;RW_GTOO?^8?\ $8^,
MO^@Z7_@,/_D3\7_^'1W[7O\ T!_@O_X4=W_\CT?\.COVO?\ H#_!?_PH[O\
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MT;X0#1_&&D6NLV(N=>NXIO)N(EE3>@@8*VUAD;C@]S75?\.COVO?^@/\%_\
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MW[7O_0'^"_\ X4=W_P#(]?M!11_JWEO_ #Z7WO\ S#_B,?&7_0=+_P !A_\
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MWEO_ #Z7WO\ S#_B,?&7_0=+_P !A_\ (GXO_P##H[]KW_H#_!?_ ,*.[_\
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M_@O_ .%'=_\ R/7[044?ZMY;_P ^E][_ ,P_XC'QE_T'2_\  8?_ ")^+_\
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M5X/_ ,$M_P#E&O\  /\ [)]H?_I##7O% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\3Z+_P %V_@]IG[:
MWCCX+^/?[0^%EYX4G2ULM9\4LMG8ZQ*,^;\Q^6W3&QHY)6"RHQ.4.%;[8KR/
M]IG]@OX.?MD?96^)GP\\-^+;FR3R[>[NH"EY F<[%GC*RA,\[0V/:@#\O/\
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M  M->_\ DV@#[$HKX[_X<&?LH_\ 1,]1_P#"TU[_ .3:/^'!G[*/_1,]1_\
M"TU[_P"3: /L2BOCO_AP9^RC_P!$SU'_ ,+37O\ Y-H_X<&?LH_]$SU'_P +
M37O_ )-H ^Q**^._^'!G[*/_ $3/4?\ PM->_P#DVC_AP9^RC_T3/4?_  M-
M>_\ DV@#[$HKX[_X<&?LH_\ 1,]1_P#"TU[_ .3:/^'!G[*/_1,]1_\ "TU[
M_P"3: /L2BOCO_AP9^RC_P!$SU'_ ,+37O\ Y-KYZ_X*M_\ !'+]G7]GK_@G
M?\5/&GA#P'?:5XD\/Z0+FPNV\5:Q=""3SHUSY<UV\;<,>&4CF@#]2:YOXF?!
MOPA\:M%&F^,O"OAOQ;IPW8M=9TR&_A&[AODE5EYP,\<XKY-\'?\ !!O]E;5/
M".E7,_PVU%Y[BSAED;_A,M=&YF0$G O<=36E_P .#/V4?^B9ZC_X6FO?_)M
M'TI\*?V>O /P(MY(O _@?P?X-BF&V1-"T:VTY9!G."(47/-=A7QW_P .#/V4
M?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9
MZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X
M6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?
M_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'
M_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S
M]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_
M *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)G
MJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\
MX6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO
M?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M
M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)
M17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW
M_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .
M#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)17QW_P .#/V4
M?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\ X6FO?_)M 'V)7F?[:?\ R9Q\6?\
ML3-8_P#2&:O!_P#AP9^RC_T3/4?_  M->_\ DVN$_:C_ ."''[,'@/\ 9E^(
MNN:5\.K^VU31O#&IW]G,?%^N2B*:*TE=&*/>%6PR@X8$''((H ^A_P#@EO\
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MJ/\ X6FO?_)M 'V)17QW_P .#/V4?^B9ZC_X6FO?_)M'_#@S]E'_ *)GJ/\
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MO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\
MR;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_
MPX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_
M91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z
M)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/
M_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::
M]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\
M)M 'V)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M '
MV)17QW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17
MQW_PX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_P
MX,_91_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_9
M1_Z)GJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)
MGJ/_ (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_
M (6FO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M 'V)17QW_PX,_91_Z)GJ/_ (6F
MO?\ R;1_PX,_91_Z)GJ/_A::]_\ )M !_P $?O\ 5?M0?]G!>+?_ $*UK[$K
MX>_X(8_#71O@[\._VA_"_AVT:QT/0/CKXFTZPMVN)+@PP0I9Q1H9)&9VPB*-
MS,2<9)))-?<- !7QW_P6S_Y-E\!_]E3\*?\ IRCK[$KX[_X+9_\ )LO@/_LJ
M?A3_ -.4= 'V)1110 4444 %%%% !1110!XSJ7_!1O\ 9ZT;4;BSO/CO\&;2
M[M)&AG@F\:Z:DD+J2&1E,V0P(((/((J#_AY;^SE_T7_X)_\ A<Z9_P#'Z\)^
M,O\ P0)_9*U31?%?B.?X3[]9N(+O4I+C_A)]9&ZX97D+[1=[?OG.,8]L5\*_
M\&[W_!*3X!?MT_L5>)_%OQ4\!?\ "4^(=.\;7>D6]W_;>HV/EVJ6%A*L>RVN
M(T.'GE.XJ6^;&<   '[7?#/XK>%_C3X1@\0>#O$F@>+-!N7>.'4M&U"*_M)6
M1BKA98F9"58$$ \$$&M^OD_X3?M$_LJ_\$Z-1U?X >'_ !+IGP^;X?:;)XCO
M](U!]0>#3K:=HY6E-[=!XW+M<1X03,Q:0*JYXKU?]E+]N7X5_MN^#=9\0_"_
MQ7%XGT;P_>G3[^[^PW5DD$P19"O^D1QEAL93N4%>>M 'K-%?)_CO_@N5^RA\
M./'K^&]3^-'ATZI%(87-E:7E_:(PX(-S!"\ P?\ ;KZ3^&OQ/\._&7P1I_B7
MPGKFE>)/#^JQ^;9ZCIMRES;7"YP=KJ2#@@@CJ""#R* -VBO"OVJ?^"F'P)_8
MGU2+3_B;\2=#\-:I-&)5TX)-?7P0_==K>W2255/9BH!P<&N5US_@L[^S#X?^
M"D?Q"F^+FA3^%)-4BT5KFSM+N\G@NY8I9HXY;:&%KB+='!*0SQJIV$9S@4 ?
M3]%?#7_!:K_@J%X(_8X^ GC+P+;_ ! N_"7QJUGPRNJ^%[:VTZ[DE</</$DB
MSI"T"$M!,,.X/R\C!&><_P""27_!9SX4?'GX,_"7X;^)/B?=Z_\ '36; VVH
M6=SH^H&6YO%$DCAKC[.+?/EKG/F8XQG/% 'Z$45\^>)/^"JG[/W@SQIX^\/Z
MS\2])T;5?A@R)XDBU"UNK5+%W.$C222().['HD+.QP<#@U8_9@_X*@_ /]LJ
M]U&V^'/Q+T/7KS2+9[R[M98Y]/N(8$X>;R[F.-S&N1EP"HR,GD4 >]T5\L:=
M_P %M/V5=5^)J^$8?C5X3.L/,+=7=;A+ N6*@?;6C%MC(Z^;CISR*^IDD$J!
ME(96&00<@B@!:*^5_BW_ ,%M?V6/@?X^D\,^(?C'X?36()##-'86MWJ<4#@X
M*R36L,D2,#P0S C!ST-?0/P?^-7A+]H'P%9^*/!'B/1_%7AZ_P ^1?Z9=+<0
MN1]Y25/##H5."#P0* .GHKYWUG_@K%^SQX:\0?$#2]5^)^CZ1>_"Z]33O$B:
MA:W5H+*Y9Y$6&-I(E6XD)BDPL!D.$)Z#-6_V7?\ @J/\ ?VS_%;Z#\-OB9HG
MB+741Y!IK13V-W,B??:.*YCC>0 #)* X'/3F@#WVBOS"_P""^W_!7?P[^S]\
M(_$?PR^&WQ.U+PU\=]!U737N;*QT^[CE@MI8EN&_TEH?LY#0RQ-@2$_-CJ"!
M]'?\$_O^"LWP2_;,3P[X'\)?$&3Q/\0[?P[#?:I:2:-J%LVZ*.);AS+- D3$
M2..CG.<C(H ^KZ*** "BBB@ HHHH *^4O^"X?_*)[XW?]@$?^E$-?5M?*7_!
M</\ Y1/?&[_L C_THAH ^E?A]_R(6B?]@^#_ -%K6Q6/\/O^1"T3_L'P?^BU
MK8H **** "BBB@ HHHH **** ./^+_[0G@']GS3K.\\?>./"'@BTU"0PVD_B
M#6;?38[EP,E$:9U#,!R0,G%<SX*_;N^"'Q*UV+2_#OQD^%6OZE.P2*TTWQ;8
M74\C'H%2.4L2?85^=O\ P==V$6J_"SX#6MP@D@N?&,L4J$_?5H4!'Y&O>_CE
M_P &Y?[+/Q3^&VI:3H?@+_A"-;G@<6&LZ7J=XTME-CY7,<LKQR+G&59>1G!4
M\@ ^TOB7\1M&^#_PX\0>+?$=Y_9WA[PMIMSJ^J7?E/-]EM;>)I9I-D:L[;41
MCM52QQ@ GBL3]G3]HOP;^UE\&]'^('P_UC^W_".O^?\ 8+_[)/:^?Y,\EO)^
M[G1)%Q+%(OS*,[<C(()_*?\ X)N_M0>,_BW_ ,$5?VO?AQX[U6;7M8^#/A?Q
M%HMM?S2-+*]I)I=YLB:1OFDV20S!2>0A1>BBOK7_ (-T_P#E#=\'O^XU_P"G
MS4* /MFBOF;XZ_\ !8[]F;]FWX@S>%?&'Q<\/6.OVLWV:YM+2"YU(V<HX*3-
M;12+$P(P0Y!4]<5O:=_P5 ^ FN>// /AK3?B3H^KZO\ $\NOAE--@N+V'461
MMKJ9HHVBB92,%970CTH ][HKG/BO\7O"WP*\"WOB?QGXAT?POX?TY=USJ&IW
M26T$7H-S$ L3P%'+'  )-?-WP^_X+J?LF_$_QM%X?TKXSZ"NI3RB&,ZA8WVG
M6SN3@ 7%Q!'#R?\ ;H ^M**A6_@>Q%T)HC;&/S1,'&PIC.[=TQCG-?*OCO\
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M#'Q=\/:AXFN+A;2VMW@N;:*\F8X6.&>6)(9F8\ 1NV20!G- 'TU17S9\>/\
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M 7/S$8- 'ZE4444 %%%% !1110 4444 ?'?_  0._P"44OPU_P"OWQ!_Z?\
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MBBB@ HHHH **** ,#XK?\DN\2?\ 8*NO_1+5^;'_  :4?\HX_&O_ &4B^_\
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M^!^OCPQX>&N_\(^DO]I#38?M>\O(-WF[=^<<9STKV/\ X*#?L]ZE^U;^Q/\
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MJIKWK]BKXQ?M?_M4?M;/XU\;>"K+X(_ RPT^2RC\):Q&EWJ^KS\E;C?A)8I
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MO_!7KP-K?Q+_ .":7QBT'PYH^J:_KFIZ \-GIVFVDEU=W;^8AV1Q1@N[8!X
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M@ HHHH ^._\ @@=_RBE^&O\ U^^(/_3_ *C7V)7QW_P0._Y12_#7_K]\0?\
MI_U&OL2@ HHHH **** "BBB@ HHHH ^0?^"]O_*(OXT_]@VT_P#3A:U\1?\
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M90!]B45\=_\ #V3Q!_T:7^U=_P"$K9__ "91_P /9/$'_1I?[5W_ (2MG_\
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MO_"5L_\ Y,H_X>R>(/\ HTO]J[_PE;/_ .3* /L2BOCO_A[)X@_Z-+_:N_\
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M#[$HKX[_ .'LGB#_ *-+_:N_\)6S_P#DRC_A[)X@_P"C2_VKO_"5L_\ Y,H
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M]J[_ ,)6S_\ DR@#[$HKX[_X>R>(/^C2_P!J[_PE;/\ ^3*/^'LGB#_HTO\
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M)6S_ /DR@#[$HKX[_P"'LGB#_HTO]J[_ ,)6S_\ DRC_ (>R>(/^C2_VKO\
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M>R>(/^C2_P!J[_PE;/\ ^3* /L2BOCO_ (>R>(/^C2_VKO\ PE;/_P"3*/\
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MHH *\S_;3_Y,X^+/_8F:Q_Z0S5Z97F?[:?\ R9Q\6?\ L3-8_P#2&:@#D_\
M@EO_ ,HU_@'_ -D^T/\ ](8:]XKP?_@EO_RC7^ ?_9/M#_\ 2&&O>* "BBB@
M HHHH **** "BBB@ HHHH **\/\ V^O&'Q[\$_!W3;K]G;PKX,\7^-9-9BBO
M;/Q-,8K2+3S!.9)5(N(/W@E6W &\\._RGJ/D3_AH#_@J/_T0[]GC_P #Y/\
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MS\@<#)^W?^"?/[='A?\ X*)?LQZ/\2O"T,]A%=R266HZ9<.'FTF]BQYD#L
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M\/\ [*7P!\)_#KPM;BWT/PEI\=A;\8:8CF29_P#;DD+R,>[.QKX9_P"#B?\
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M#D]CU7_!$/1?$?A[_@E+\%+7Q5%-#JHT-I$24,&6S>YF>SR&Y'^BM![>G&*
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M3;JZSYMSI\%P\5N<GJJ*OE*?[L2]>M 'VK1110 4444 %%%% !1110 4444
M%?*7_!</_E$]\;O^P"/_ $HAKZMKY2_X+A_\HGOC=_V 1_Z40T ?2OP^_P"1
M"T3_ +!\'_HM:V*Q_A]_R(6B?]@^#_T6M;% !1110 4444 %%%% !1110 44
M44 %%%% 'Y<_LJ_\K5G[2W_9-[/_ -)_#=?J-7Y<_LJ_\K5G[2W_ &3>S_\
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MT\J*Y<$>8*_0?X>?\%*_V>?B%\2(? WAKXO?#S4?$'F"SM=/M-6AQ.XX$4#
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MXL_]B9K'_I#-0!R?_!+?_E&O\ _^R?:'_P"D,->\5X/_ ,$M_P#E&O\  /\
M[)]H?_I##7O% !1110 4444 %%%% !1110 4444 %?#?_!?7]NN7]D#]BJ[\
M.^&YY6^)'Q:=_#/AZWM@6N420!;JX0#G*1N$4CD23Q$9P:^X9ITMH6DD98XX
MU+,S' 4#J2?2OR,_8^"_\%F?^"T'B?XX7D9O_@W^S^J:5X0CF7-O?WP+>3.
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M+=SZ,K ; EO*"(MQ,N) H(*%%(\K ['_ ((GZ?I7P9_X*=_M6_"SX57\NI_
MO0IK2_L5CN#<6FEZFX19+>*0EB<-]IBSN)9;-,EB,T ?J=1110 4444 %%%%
M !1110 4444 %%%% 'QW_P $#O\ E%+\-?\ K]\0?^G_ %&OL2OCO_@@=_RB
ME^&O_7[X@_\ 3_J-?8E !1110 4444 %%%% !1110 4444 %>'_MO_\ !/?X
M=?\ !0CPSX=T?XD6^KWFG>&=0.IVD%G>FW1YBFS,@P0XVDC!_O'UKW"ODK_@
MK3_P4AUW_@F9\/O!7C"U\!CQAX6UG6QI6O7?VMX&T9& :-P%1@Q8+*!NVC<J
MC/S4 <E_P4!_X+T_!W_@GQX[\1>!-6T_Q1K?C[0;**:#2K*R5+6=YH%EA5KA
MF"HF&7<0K%><*V,5P/\ P;3?LZZK\/?V4O%WQ.UJ^T>6\^-6O'7(K'2[N.YM
M]/@3>%5C&[*DI>67=&3N0*BMA@RK]R:7\1/AQ^T=\"5\21ZEX5\6_#O6K+[6
M]W<F*XTV:WV[F,HD^0!1]Y7 *D$, 017YF?\&Z6MV>G_ +5_[6]CX NV;X"6
M'B(7&@.SM]BA8W-T(V@9N AMD7)^]L2 MVH _6^OP]_X+2_MO^/_ /@IG\<+
MW]G/]G_PSXJ\=^"/!-XDWC2;PY&3_;5S%)_J3/M9([>)U8*S@J\RA@KB-"?T
MV\(?MV?#;]O#X5?%'0O@7\0M*\3^+]"T>[M5%H)H'M;J2&5+>5#(J>9'YH&)
M8RR9 ^;D5\<?\&K'Q&\%:?\ LF>+_ 2O9Z7\4-*\475UK^G7)$>HW,92-(I=
MK?.R)L>,C^!U;(&_+ 'J?_!)?_@I?\-/$&JZ=^S4_P ,?$/[/_COP;8>38^$
M-<._[8D:;Y#%.4C:68C=*Q>-6D#-(I<;B/"/A9^TII?_  10_P""I7[1%O\
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MC1+>P@BVR+;*%&W,89?EZ&>>$$ Q-BC^W?\ !+P/XS_X+*_LU? 7XA6\&A_
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MHH *\S_;3_Y,X^+/_8F:Q_Z0S5Z97F?[:?\ R9Q\6?\ L3-8_P#2&:@#D_\
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M0$C =0ZLNX=1N4C(Y!'%344 ?/'[!O\ P3/^'_\ P3XD\:7OA:^\4^)/$7Q
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MTZSBMX?VP_C-'# @CC0:;I6%4# '^H]*E_X=M_&'_H\;XS_^"S2O_C%?8E%
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M_P 8H_X=M_&'_H\;XS_^"S2O_C%?8E% 'QW_ ,.V_C#_ -'C?&?_ ,%FE?\
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M4?\ #MOXP_\ 1XWQG_\ !9I7_P 8K[$HH ^._P#AVW\8?^CQOC/_ ."S2O\
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MS_\ @LTK_P",5]B44 ?'?_#MOXP_]'C?&?\ \%FE?_&*/^';?QA_Z/&^,_\
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M6O\ V.^@_P#I4*SJR<:<I+L=> IQJ8JG3FKIR2?HV?$__#?G[7O_ $</;?\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
MPWY^U[_T</;?^&_TC_XBC_AOS]KW_HX>V_\ #?Z1_P#$5Q5%'^M&:?\ /W\(
M_P"0?\0/X)_Z O\ RI5_^6':_P##?G[7O_1P]M_X;_2/_B*/^&_/VO?^CA[;
M_P -_I'_ ,17%44?ZT9I_P _?PC_ )!_Q _@G_H"_P#*E7_Y8=K_ ,-^?M>_
M]'#VW_AO](_^(H_X;\_:]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$
M#^"?^@+_ ,J5?_EAVO\ PWY^U[_T</;?^&_TC_XBC_AOS]KW_HX>V_\ #?Z1
M_P#$5Q5%'^M&:?\ /W\(_P"0?\0/X)_Z O\ RI5_^6':_P##?G[7O_1P]M_X
M;_2/_B*/^&_/VO?^CA[;_P -_I'_ ,17%44?ZT9I_P _?PC_ )!_Q _@G_H"
M_P#*E7_Y8=K_ ,-^?M>_]'#VW_AO](_^(H_X;\_:]_Z.'MO_  W^D?\ Q%<5
M11_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\ PWY^U[_T</;?^&_TC_XB
MC_AOS]KW_HX>V_\ #?Z1_P#$5Q5%'^M&:?\ /W\(_P"0?\0/X)_Z O\ RI5_
M^6':_P##?G[7O_1P]M_X;_2/_B*/^&_/VO?^CA[;_P -_I'_ ,17%44?ZT9I
M_P _?PC_ )!_Q _@G_H"_P#*E7_Y8=K_ ,-^?M>_]'#VW_AO](_^(H_X;\_:
M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M]_Z.'MO_  W^D?\ Q%<511_K1FG_ #]_"/\ D'_$#^"?^@+_ ,J5?_EAVO\
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M>.?"%U<_;-(L)[^XMM0OC)+-.B9;RUG51EFZ  #/2LWX:_L__LJ_M@+>^'_
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MP7B+EU>EBW5I5*57"P=2=*<5&IR)-WBN9QDG;1J5KVO:Z/"Z*_1#]IC]GO\
M9>_9#UA)_$^@:WJ-SK*+)8Z#8ZA<NT,:X1I=QF0@%B3F23DJ0H^5JXG]IW]A
MWX<>+/V7?^%L_!UKV#3[2'[5<6$D[S))"'V2_P"M8NDD1R6&X@A&P,X)Z*W#
MV(I\Z4XRE!7<4];=[6_X)X^6^+V58OZM4EAZ]*EB)*$*LX)4W-_9YE)O?2]N
M6Z>MDV?*GP%^"NJ_M$?%C2O!VBSZ?:ZGK'G>3+?.Z0+Y4+S-N**S#Y8V PIY
M(^M'QZ^"NJ_L[_%C5?!VM3Z?=:GH_D^=+8N[P-YL*3+M+JK'Y9%!RHY!^M?4
M_P#P2T\9_"0?$;P7I#>$=:/Q5+7Y37?M+_8U'DW#_P"K\_;_ ,>^4_U74Y_V
MJZ3]O7XC_L_Z1\=?&FG>*?A]XEU7QZ+:%7U2WO9$MFE:RB,#;!<J,*AB!_=\
M[3P>IUAD]&67+$^TBI<UKW=K<M^7;XOP\SCQ'B%F-+C&63K!U9451<N51AS.
M7M>7VJ;J+]TUHKVE?[)\"T445\V?L04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!]Z?\&X7_)I_P 5_P#LK>N?^B+&OT(K\]_^#<+_ )-/^*__ &5O7/\
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MX<+OJM6[O<^4\)>#LTRW#XC'\1+_ &NNXQ=VI-4X148J\6UKK>SVM?4^OO\
MA]3\4_\ H > /_ &[_\ DFN&^#'[3ES\2O\ @H;X8^(GBJ/3K"?5-4MH+H6:
MO%;09@6T1@'9V  "L<L>_0=/GJBN"6<XRI*+K3<E%J23[H^KH>'/#^%HUZ>7
MX:-&5:G*G*4=^6:U6_H_D?8__!9[X>:II?Q_T?Q*]M(=&U728K2*Y"_(L\3R
M%HB>S;65AZ@G'0T?\$8?AWJNJ?'[5_$R6LHT72M)EM);HK^[:>5XBL0/=MJL
MQQT &?O#.;\(O^"LNO\ A?X<)X8\<^%-*^(MA#&($DO9Q#++&. LVZ.1)<#
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M** "BBB@ HHHH **** "BBB@#[T_X-PO^33_ (K_ /96]<_]$6-?H17Y[_\
M!N%_R:?\5_\ LK>N?^B+&OT(K]XP?\"'HOR/\L^(?^1KB?\ KY/_ -*85\(?
M\'%/_*/:U_['?0?_ $J%?=]?"'_!Q3_RCVM?^QWT'_TJ%77_ (4O1G-E7^^T
M?\4?S1^>5%%%?@A_JJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'M'C+]NGQ
M;XX_9IL?A7=Z=X<C\/Z?#;P1W$-O,+QE@8,F6,I3)(&?D'X5XO116]?$5:S3
MJN]E9>B/,RS)\%ET)T\#34%.3F[=92W?J[!1116!Z84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"+H_XAV_%'_1S?B/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\ $RO#7_0/7_\
M :?_ ,L/D"BOK_\ XAV_%'_1S?B/_P (RP_^+H_XAV_%'_1S?B/_ ,(RP_\
MBZ/]2<;_ #Q^]_\ R(?\3*\-?] ]?_P&G_\ +#Y HKZ__P"(=OQ1_P!'-^(_
M_",L/_BZ/^(=OQ1_T<WXC_\ ",L/_BZ/]2<;_/'[W_\ (A_Q,KPU_P! ]?\
M\!I__+#Y HKZ_P#^(=OQ1_T<WXC_ /",L/\ XNC_ (AV_%'_ $<WXC_\(RP_
M^+H_U)QO\\?O?_R(?\3*\-?] ]?_ ,!I_P#RP^0**^O_ /B';\4?]'-^(_\
MPC+#_P"+H_XAV_%'_1S?B/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\ $RO#7_0/
M7_\  :?_ ,L/D"BOK_\ XAV_%'_1S?B/_P (RP_^+H_XAV_%'_1S?B/_ ,(R
MP_\ BZ/]2<;_ #Q^]_\ R(?\3*\-?] ]?_P&G_\ +#Y HKZ__P"(=OQ1_P!'
M-^(__",L/_BZ/^(=OQ1_T<WXC_\ ",L/_BZ/]2<;_/'[W_\ (A_Q,KPU_P!
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M]'-^(_\ PC+#_P"+H_XAV_%'_1S?B/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\
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M_P"(=OQ1_P!'-^(__",L/_BZ/^(=OQ1_T<WXC_\ ",L/_BZ/]2<;_/'[W_\
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M ]?_ ,!I_P#RP^0**^O_ /B';\4?]'-^(_\ PC+#_P"+H_XAV_%'_1S?B/\
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MB/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\ $RO#7_0/7_\  :?_ ,L/D"BOK_\
MXAV_%'_1S?B/_P (RP_^+H_XAV_%'_1S?B/_ ,(RP_\ BZ/]2<;_ #Q^]_\
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M_P"+H_XAV_%'_1S?B/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\ $RO#7_0/7_\
M :?_ ,L/D"BOK_\ XAV_%'_1S?B/_P (RP_^+H_XAV_%'_1S?B/_ ,(RP_\
MBZ/]2<;_ #Q^]_\ R(?\3*\-?] ]?_P&G_\ +#Y HKZ__P"(=OQ1_P!'-^(_
M_",L/_BZ/^(=OQ1_T<WXC_\ ",L/_BZ/]2<;_/'[W_\ (A_Q,KPU_P! ]?\
M\!I__+#Y HKZ_P#^(=OQ1_T<WXC_ /",L/\ XNC_ (AV_%'_ $<WXC_\(RP_
M^+H_U)QO\\?O?_R(?\3*\-?] ]?_ ,!I_P#RP^0**^O_ /B';\4?]'-^(_\
MPC+#_P"+H_XAV_%'_1S?B/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\ $RO#7_0/
M7_\  :?_ ,L/D"BOK_\ XAV_%'_1S?B/_P (RP_^+H_XAV_%'_1S?B/_ ,(R
MP_\ BZ/]2<;_ #Q^]_\ R(?\3*\-?] ]?_P&G_\ +#Y HKZ__P"(=OQ1_P!'
M-^(__",L/_BZ/^(=OQ1_T<WXC_\ ",L/_BZ/]2<;_/'[W_\ (A_Q,KPU_P!
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M]'-^(_\ PC+#_P"+H_XAV_%'_1S?B/\ \(RP_P#BZ/\ 4G&_SQ^]_P#R(?\
M$RO#7_0/7_\  :?_ ,L/D"BOK_\ XAV_%'_1S?B/_P (RP_^+H_XAV_%'_1S
M?B/_ ,(RP_\ BZ/]2<;_ #Q^]_\ R(?\3*\-?] ]?_P&G_\ +#Y HKZ__P"(
M=OQ1_P!'-^(__",L/_BZ/^(=OQ1_T<WXC_\ ",L/_BZ/]2<;_/'[W_\ (A_Q
M,KPU_P! ]?\ \!I__+#M?^#<+_DT_P"*_P#V5O7/_1%C7Z$5\'?\$!?AE/\
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M'^/O 5C\9-(CTZ;2O#U_J%K-J,J37]M'(XL6<2NOV=YFR%P I;HIKNOV"O\
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MO\ _^R?:'_Z0PU[Q7@__  2W_P"4:_P#_P"R?:'_ .D,->\4 %%%% !1110
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M_%;PO\:?^"6WQY\0>#O$F@>+-!N?ASXECAU+1M0BO[25DTVY5PLL3,A*L""
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MX_\ @'JD?B.RNX!^^6R#QM.1@9_=/'#/DG"K#)ZUQO\ P;H_!O7OC'<?%/\
M:U^($"-XP^,^KW%OIC!"$M[".;,OD[LD1&95B4;CA;-1GU /#?\ @L-^U#X
M^)'_  4N\,_LX_%#QS>_##]G#X6:9:7.O6>DVMW(=8NFM8[B"UV6T4C;!%);
MHN5VQCS6!#%<<7^VOK/_  3.\8_L[ZFWP9\8?\(!\4?#5H]]X5U'2-'\1PR7
M%[$-\4$SRVY!$C*%\UB&0D-NP"#]0_\ !2/X#>/?V(_^"EUA^USX*^'T_P 5
MO!/B'1TT#Q]X?L;47%_ J)'$MPB;6)7;#;,&"G:UNP<JKAA2^(W_  7S^%WQ
M,\#W.B_ +X&^,O'?Q7U%/LVG:1=^#HEATVX;(#77E,[$(>2J<'&"Z#+  P?%
M7Q^^,/\ P4:_X-J;S6_#\FKZI\0;4?V5XB-AN-[KMG9W06X90@W,TEOL>11]
M_$JX.[:?,OV.OA5_P3I_;?\ @O\ #[P+;W%]\*/BWIOV#S[B:_FTO6;O4$VF
M9$NY=UM-YLBN% Q(-R[$C;"U^A'QT^/O[07[.7_!.G0_''AWX*>%-9^*MO\
M9[GQ/X/T>YEDM[&%MWGO;)$"\\H CS&K-MW.0THC^?\ -7_@J%^W/\!_^"IG
MP7@\+_#;X&>-;G]IC5;ZU6V*>&T@U/2'65#<+<31$O.AC#HH88&\.=FW% 'U
MU_P<3_L8?#%/^"<_Q+^*4GA&PNOB-HEIHEC9^([EY)M0CB&J65O@R,Q+$Q2.
MI+9)WDDY.:];_P""37_!/[X,_#;]F#X&?%'0OA[H&F?$'4/ .D7USKD*.+J:
M>ZTR$W#D[L9D\Q\\?Q&J'_!0[]E7XC?%[_@A9JWPO$<_B?XG6?@S0EODA/GS
M:K?:?+97%T(\<R22&VEV@9+,P !) KBO^".'_!63P+\6/AS\)/V?6\.^.]'^
M)GA/PO;:!JEM>Z1Y5I9-IUCL,DDI<%1(MN=H*[MS8(&": .'_P""-7_*8K]N
MK_L8D_\ 2V]KRC_@GU^SUI?_  7W_:G^*?QS^-]WJ7B/X>^$=9.A>#O"*WLM
MO9V\6/,7?Y;*P"Q&$L%(\V25RQPNT^K_ /!&K_E,5^W5_P!C$G_I;>UY9\+?
M'OB__@W&_:K^)>D>*_ GBCQ9^S=\1]3.LZ-KN@VXF_L1\MM5P2L8=8V$;H[(
M6$*.F1D$ N_\%W/^",OPY_9^_8R\5?%+X+V%U\/Y=(%I%XGT33[^?^S?$%@]
MW"J[X7<@/%.890!A?W9.TL%(Z[]N;]L#Q;^S1_P0C_9F\,_#Z\N=+\;?%SPK
MX7\+V5_ _E264#Z3 TS))_!(W[N($<@2LP(*@UX]_P %?O\ @KYJ?_!1#]A#
MQ=I/P9^'?CJT^%VEM8WGC3QAKMFME;^4;V&."SMPLCAV>Y> M\V[;&_R;<N/
MHK]IK]@;7_V\/^"$?[/4'@?:/B-X \&>&/$GAT&41-=21Z3 LENKGA6=&W+G
M \R*,$J"30!Z%\"?^#<G]FCX=_ Z#PYXL\&_\)QXDN[9?[6\0WNH74=U/<%?
MG>#RY%$*AL[0HSC&XL<FOE'_ ()G_LH7W[%/_!Q+XQ^'MQKVJ>)=+TGP).^A
M7NI7!GN1IK_8VMX78]XES%P ,1C  ( ]L^%'_!R3X:\.^";?P[\6?A1\7- ^
M,^FPBUOO#=CX>\QM3NE 5F@#NCH&;DJZC;NP"^,GP[_@F-\5_B+\<O\ @XE\
M:>+/B?X7N_!'B'7/ LUU;>'[I@9M(T]ELOLD3]"'\G8S!@K;G;*J3M !'_P4
M,_X)Y_!7X6_\%BOV5_ ?A_X<^'M*\'^,_-_MO2H(W$&I8E8#S 6ST Z&OJ'_
M (*G>,?"W_!%'_@FSXEO/@5X9TOP%K'CG7(-&LI-/C.VVO)X9&>ZPY(\Q;>V
MDVGH&"'!Q7!?\%T=)\1_ /\ ;K_9G_:,3PIK_BCP'\.+N6W\0G1[8W$^GJ95
M<.PZ ,COM+$*6CVEE++GNOVE[OP;_P '$O\ P3D\:Z3\+!K=C>^&M8@NM"O-
M?L?L,%SJ4,'F!5^9CY;Q7$D)<@;6<G! Y ,S]B;_ (-X/@;:?L_Z/J_QBT&]
M^)_Q(\664>J:_JNIZU> 17$Z"1XH?)E3(4MCS&+.S MN (4>0_"#PGJ/_!$;
M_@LGX*^$'A;7M6U'X$?'V$&ST6_N3<-HMZS21)L)YRLZQC?QOBGP^]HPU;G[
M/?\ P<-0?LB_"S2OAO\ M-_"_P"*/A?XF>#[2/2I9K/3(IXM>$*A$F7S)8L2
M. ,[2\;'+*X#!0[]DCX=?$O_ (*Z?\%._#?[3WC?P5JOP[^#_P +[3R?!.E:
MNI2[U>8>;LFVD#.)7,K2#Y08X8U+[68 'COQD_8DM_V_/^#FGXQ^!=9U/4K'
MP7%H6EZOXIMK&Y-O)J]A!IFC%;0L#G8]TUJ6QR A(PP##]>/V5OV.OAO^Q+X
M OO"_P +_#,7A70=2U%M6N;2.\N+E9+IH88&DS/([#,<$0(! RN<99B?@;]E
M7_E:L_:6_P"R;V?_ *3^&Z_4:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O,_P!M/_DSCXL_]B9K'_I#-7IE>9_MI_\
M)G'Q9_[$S6/_ $AFH Y/_@EO_P HU_@'_P!D^T/_ -(8:]XKP?\ X);_ /*-
M?X!_]D^T/_TAAKWB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[+G_ $73X=_^#-:/^'QO[+G_ $73X=_^#-: /I6BOFK_ (?&_LN?]%T^'?\
MX,UH_P"'QO[+G_1=/AW_ .#-: /I6BOFK_A\;^RY_P!%T^'?_@S6C_A\;^RY
M_P!%T^'?_@S6@#Z5HKYJ_P"'QO[+G_1=/AW_ .#-:/\ A\;^RY_T73X=_P#@
MS6@#Z5HKYJ_X?&_LN?\ 1=/AW_X,UH_X?&_LN?\ 1=/AW_X,UH ^E:*^:O\
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MGP[_ /!FM 'TK17S5_P^-_9<_P"BZ?#O_P &:T?\/C?V7/\ HNGP[_\ !FM
M'TK17S5_P^-_9<_Z+I\._P#P9K1_P^-_9<_Z+I\._P#P9K0!]*T5\U?\/C?V
M7/\ HNGP[_\ !FM'_#XW]ES_ *+I\.__  9K0!]*T5\U?\/C?V7/^BZ?#O\
M\&:T?\/C?V7/^BZ?#O\ \&:T ?2M>9_MI_\ )G'Q9_[$S6/_ $AFKS;_ (?&
M_LN?]%T^'?\ X,UK@/VK_P#@K5^S5XP_9;^)6DZ7\:O -]J>J>%=4L[2VBU)
M6DN)I+25$11W+,0!]: /7/\ @EO_ ,HU_@'_ -D^T/\ ](8:]XKX&_X)W_\
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M+G_1=/AW_P"#-: /I6BOFK_A\;^RY_T73X=_^#-:/^'QO[+G_1=/AW_X,UH
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M]%T^'?\ X,UH ^E:*^:O^'QO[+G_ $73X=_^#-:/^'QO[+G_ $73X=_^#-:
M/I6BOFK_ (?&_LN?]%T^'?\ X,UH_P"'QO[+G_1=/AW_ .#-: /I6BOFK_A\
M;^RY_P!%T^'?_@S6C_A\;^RY_P!%T^'?_@S6@#Z5HKYJ_P"'QO[+G_1=/AW_
M .#-:/\ A\;^RY_T73X=_P#@S6@#Z5HKYJ_X?&_LN?\ 1=/AW_X,UH_X?&_L
MN?\ 1=/AW_X,UH ^E:*^:O\ A\;^RY_T73X=_P#@S6C_ (?&_LN?]%T^'?\
MX,UH ^E:*^:O^'QO[+G_ $73X=_^#-:/^'QO[+G_ $73X=_^#-: /I6BOFK_
M (?&_LN?]%T^'?\ X,UH_P"'QO[+G_1=/AW_ .#-: /I6BOFK_A\;^RY_P!%
MT^'?_@S6C_A\;^RY_P!%T^'?_@S6@#Z5HKYJ_P"'QO[+G_1=/AW_ .#-:/\
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M_P#!-;__ !%=?10!R'_#/O@+_H2/"'_@FM__ (BC_AGWP%_T)'A#_P $UO\
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M_P#B*Z^B@#D/^&?? 7_0D>$/_!-;_P#Q%'_#/O@+_H2/"'_@FM__ (BNOHH
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M#_P36_\ \11_PS[X"_Z$CPA_X)K?_P"(KKZ* .0_X9]\!?\ 0D>$/_!-;_\
MQ%'_  S[X"_Z$CPA_P"":W_^(KKZ* .0_P"&?? 7_0D>$/\ P36__P 11_PS
M[X"_Z$CPA_X)K?\ ^(KKZ* .0_X9]\!?]"1X0_\ !-;_ /Q%?+G_  6K^"_@
M[P[_ ,$L?C1>Z?X3\-6-Y;Z&&BGM]+@BEB/VB$95E4$'Z5]I5\I?\%P_^43W
MQN_[ (_]*(: /:/ /P \"2^!=%9O!/A)F:P@))T>W))\M?\ 8K6_X9]\!?\
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M?-NA?\'1'[/-SK%O;Z]X8^,O@VUN'""_UKPW +=/4D07,LAQWVH3[4 ?>/\
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M /B*/^&?? 7_ $)'A#_P36__ ,177T4 <A_PS[X"_P"A(\(?^":W_P#B*/\
MAGWP%_T)'A#_ ,$UO_\ $5\B?MP?\'!7P9_8%_:+U;X8^,?#/Q.U+7M&@MKB
M>XT;3K&:T99X4F3:TMY$Y(5P#E!SG&>M>1_\1:_[.7_0E?&S_P $^F?_ "PH
M _1?_AGWP%_T)'A#_P $UO\ _$4?\,^^ O\ H2/"'_@FM_\ XBO"_P#@FQ_P
M5K^''_!4G_A-/^%?Z+XVT?\ X07[#]O_ .$AL[6W\[[7]H\ORO(N)LX^S2;M
MVW&5QG)Q]1T <A_PS[X"_P"A(\(?^":W_P#B*/\ AGWP%_T)'A#_ ,$UO_\
M$5U]% '(?\,^^ O^A(\(?^":W_\ B*/^&?? 7_0D>$/_  36_P#\177T4 <A
M_P ,^^ O^A(\(?\ @FM__B*/^&?? 7_0D>$/_!-;_P#Q%=?63X3\>:'X\MYY
M=#UG2M9BMI/)F>PNX[A8GZ[6*$X/L>: ,;_AGWP%_P!"1X0_\$UO_P#$4?\
M#/O@+_H2/"'_ ()K?_XBNOHH Y#_ (9]\!?]"1X0_P#!-;__ !%'_#/O@+_H
M2/"'_@FM_P#XBNOHH Y#_AGWP%_T)'A#_P $UO\ _$4?\,^^ O\ H2/"'_@F
MM_\ XBNOHH Y#_AGWP%_T)'A#_P36_\ \11_PS[X"_Z$CPA_X)K?_P"(KKZ*
M .0_X9]\!?\ 0D>$/_!-;_\ Q%'_  S[X"_Z$CPA_P"":W_^(KJ;^_@TJQFN
MKJ:*VMK:-I9II7")$BC+,S'@  $DGIBJOACQ;I7C;2$U#1M3T_5["1BJ7-E<
M)<0L0<$!T)!(/7F@# _X9]\!?]"1X0_\$UO_ /$4?\,^^ O^A(\(?^":W_\
MB*Z^B@#D/^&?? 7_ $)'A#_P36__ ,11_P ,^^ O^A(\(?\ @FM__B*Z^B@#
MD/\ AGWP%_T)'A#_ ,$UO_\ $4?\,^^ O^A(\(?^":W_ /B*Z^B@#D/^&??
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M_P $UO\ _$5U]% '(?\ #/O@+_H2/"'_ ()K?_XBC_AGWP%_T)'A#_P36_\
M\16/^US^T_H'[&/[.GB?XG>*+36+_0?"<$=Q=V^E11RW<BO-'"/+622-"=TB
MDY<< _2OA>P_X.H/@'=VT=U-X!^.UEIKC<;^;P]8FVC7^\62]8XSQP#UH _0
M#_AGWP%_T)'A#_P36_\ \11_PS[X"_Z$CPA_X)K?_P"(KE?V/OVWOAG^W?\
M#1O%7PR\2V^OZ?!((+R$HT%WITI&?+GA<!T.,X.-K8)4D<UYG_P3I_X*5_\
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MB@#D/^&?? 7_ $)'A#_P36__ ,11_P ,^^ O^A(\(?\ @FM__B*Z^B@#D/\
MAGWP%_T)'A#_ ,$UO_\ $4?\,^^ O^A(\(?^":W_ /B*Z^B@#D/^&?? 7_0D
M>$/_  36_P#\11_PS[X"_P"A(\(?^":W_P#B*Z^B@#D/^&?? 7_0D>$/_!-;
M_P#Q%'_#/O@+_H2/"'_@FM__ (BNOHH ^-/^"-FF6VC:7^TU:V=O!:VMO\?_
M !7%%##&$CB13:A551P    !T K[+KX[_P""/W^J_:@_[."\6_\ H5K7V)0
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M?A9\6O#:M)?^$/$D7EW+(N-[0OA=^W<I9&5' .X*5!8?&7_!)FS_ &U? /[
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M_@AI^V_\:OV=/A)\2K+X??LR>(OC!9:OXPFOKZ]L?$2V"Z5<&&-3:LIMI=S
M -NR/O=*_33_ (()?\HB_@M_V#;O_P!.%U7SG_P:Q?\ )O?QM_[*-<?^DT-
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MFEY9B!)0!DIOFN$&3@K)*.0#@ _6RBBB@ HHHH **** "BBB@ HHHH ^._\
M@C]_JOVH/^S@O%O_ *%:U]B5\=_\$?O]5^U!_P!G!>+?_0K6OL2@ KX[_P""
MV?\ R;+X#_[*GX4_].4=?8E?'?\ P6S_ .39? ?_ &5/PI_Z<HZ /L2BBB@
MHHHH **** "BBB@#+\;:++XD\&:OIT#1K-?V4UM&TA(4,Z,H)P"<9/I7R/\
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M/\"ZC\8?AQXB^ _A*YF*VJ:9(FN75JPF*VXWP%8U\UT?_7,0 5#;0 ?T&HH
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MO:7\2=<T?4O[3\:7VKM+9SRLN5B@T^WCA>-8D0XPTD:_W54#%?JG10!\D?\
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M?""^ ?"O[4'P_NO!%K$;*SU35;%WUVUMN0%5GLYFW!< $W!9,X5AM4U]._\
M!,'_ ():>&_^"<7@[7+DZS>^-OB/XVF%YXH\57ZGS]0EW,Y1 68I'O=V.6+.
MS;F8X4+]444 %%%% !1110 4444 %%%% !7F?[:?_)G'Q9_[$S6/_2&:O3*\
MS_;3_P"3./BS_P!B9K'_ *0S4 <G_P $M_\ E&O\ _\ LGVA_P#I##7O%>#_
M /!+?_E&O\ _^R?:'_Z0PU[Q0 4444 %%%% !1110 5\1?L=?\$U_'7[/?\
MP5:^.OQTUK5?"=SX2^)UI)!I=I975P^HV[-/;R#ST>!8U&(6^[(_)'X?;M%
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M4 ?'?_"8?MY_]"5^R[_X4.L__&*/^$P_;S_Z$K]EW_PH=9_^,5]B44 ?'?\
MPF'[>?\ T)7[+O\ X4.L_P#QBC_A,/V\_P#H2OV7?_"AUG_XQ7V)10!\=_\
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M0ZS_ /&*^Q** /CO_A,/V\_^A*_9=_\ "AUG_P",4?\ "8?MY_\ 0E?LN_\
MA0ZS_P#&*^Q** /CO_A,/V\_^A*_9=_\*'6?_C%'_"8?MY_]"5^R[_X4.L__
M !BOL2B@#X[_ .$P_;S_ .A*_9=_\*'6?_C%'_"8?MY_]"5^R[_X4.L__&*^
MQ** /CO_ (3#]O/_ *$K]EW_ ,*'6?\ XQ1_PF'[>?\ T)7[+O\ X4.L_P#Q
MBOL2B@#X[_X3#]O/_H2OV7?_  H=9_\ C%'_  F'[>?_ $)7[+O_ (4.L_\
MQBOL2B@#X[_X3#]O/_H2OV7?_"AUG_XQ1_PF'[>?_0E?LN_^%#K/_P 8K[$H
MH ^._P#A,/V\_P#H2OV7?_"AUG_XQ1_PF'[>?_0E?LN_^%#K/_QBOL2B@#X[
M_P"$P_;S_P"A*_9=_P#"AUG_ .,4?\)A^WG_ -"5^R[_ .%#K/\ \8K[$HH
M^._^$P_;S_Z$K]EW_P *'6?_ (Q1_P )A^WG_P!"5^R[_P"%#K/_ ,8K[$HH
M ^._^$P_;S_Z$K]EW_PH=9_^,4?\)A^WG_T)7[+O_A0ZS_\ &*^Q** /CO\
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M.#BO7?\ A,/V\_\ H2OV7?\ PH=9_P#C%>F?\$M_^4:_P#_[)]H?_I##7O%
M'QW_ ,)A^WG_ -"5^R[_ .%#K/\ \8H_X3#]O/\ Z$K]EW_PH=9_^,5]B44
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M?MY_]"5^R[_X4.L__&*/^$P_;S_Z$K]EW_PH=9_^,5]B44 ?'?\ PF'[>?\
MT)7[+O\ X4.L_P#QBC_A,/V\_P#H2OV7?_"AUG_XQ7V)10!\=_\ "8?MY_\
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M+]CWX17OQ?\ $/CGX5>/M%\.VYU77?!UKI4/F6-HGS2D/':PNZH@9I"MP64
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MRT444 %%%% !1110 4444 %%%% !7RE_P7#_ .43WQN_[ (_]*(:^K:^4O\
M@N'_ ,HGOC=_V 1_Z40T ?2OP^_Y$+1/^P?!_P"BUK8K'^'W_(A:)_V#X/\
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M % 'Z)45YW^S%^U?\/?VR?A?!XQ^&WBC3_%&@S/Y3RVY*RVLH 8Q31,!)%(
MP.QU!P0>A!KT2@ HHHH **** "BBB@ HHHH **** "O,_P!M/_DSCXL_]B9K
M'_I#-7IE>9_MI_\ )G'Q9_[$S6/_ $AFH Y/_@EO_P HU_@'_P!D^T/_ -(8
M:]XKP?\ X);_ /*-?X!_]D^T/_TAAKWB@ HHHH **** "BBB@ HHHH ****
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MLP?LIZW;:7XQL+HS^-O%CZ=;ZC::#$H'F0%9HY(SY0;,AVY\PQQ*0^\#I?\
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MEQXRT37/!O@Q%.I7>@WL.IE)7=$C@'E,1YKO+&JJ2.9%R0.:\%_XAT_V-_\
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MR: -SQ9XJT[P+X6U+6]8O;?3=(T>UEOKZ[G?9%:P1(7DD<]E55))]!7Y5_\
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M7_9_;3;KP[IG@N\C^)E_H 7^RKJX9)PGSQ_NY)/.-AN(R"\9ZLCFOO[]JO\
MX)[_  8_;<BM/^%H_#[1/%=Q8H8K>\D,EM>P(>2BW$#I,%SSMWXSSC-;?[,_
M['GPQ_8Y\)SZ)\,O!6B>#["[<2W(LHB9KM@, RS.6DD('3>QQVH ]*HHHH *
M*** "BBB@ HHHH **** "BBB@#X[_P""!W_**7X:_P#7[X@_]/\ J-?8E?'?
M_! [_E%+\-?^OWQ!_P"G_4:^Q* "BBB@ HHHH **** "BBB@ HHHH *_._\
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M35__ )+H ^Q**^._^' _[)'_ $2.+_PI-7_^2Z/^' _[)'_1(XO_  I-7_\
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M(XO_  I-7_\ DN@#[$HKX[_X<#_LD?\ 1(XO_"DU?_Y+H_X<#_LD?]$CB_\
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M_P#"DU?_ .2Z/^' _P"R1_T2.+_PI-7_ /DN@#[$HKX[_P"' _[)'_1(XO\
MPI-7_P#DNC_AP/\ LD?]$CB_\*35_P#Y+H ^Q**^._\ AP/^R1_T2.+_ ,*3
M5_\ Y+H_X<#_ +)'_1(XO_"DU?\ ^2Z /L2BOCO_ (<#_LD?]$CB_P#"DU?_
M .2Z/^' _P"R1_T2.+_PI-7_ /DN@#[$HKX[_P"' _[)'_1(XO\ PI-7_P#D
MNC_AP/\ LD?]$CB_\*35_P#Y+H ^Q**^._\ AP/^R1_T2.+_ ,*35_\ Y+H_
MX<#_ +)'_1(XO_"DU?\ ^2Z /L2BOCO_ (<#_LD?]$CB_P#"DU?_ .2Z/^'
M_P"R1_T2.+_PI-7_ /DN@#[$HKX[_P"' _[)'_1(XO\ PI-7_P#DNC_AP/\
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M+H ^Q**^._\ AP/^R1_T2.+_ ,*35_\ Y+H_X<#_ +)'_1(XO_"DU?\ ^2Z
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M_P *35__ )+H_P"' _[)'_1(XO\ PI-7_P#DN@#[$HKX[_X<#_LD?]$CB_\
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M4FK_ /R71_PX'_9(_P"B1Q?^%)J__P ET ?8E%?'?_#@?]DC_HD<7_A2:O\
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>products.jpg
<TEXT>
begin 644 products.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,P
M-@  DI(  @    ,P-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>BT5YU_PO7P1_P _5[_X!2?X4?\ "]?!'_/U>_\ @%)_A1=!RR['HM%>=?\
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M  O7P1_S]7O_ (!2?X470<LNQZ+17G7_  O7P1_S]7O_ (!2?X4?\+U\$?\
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MO3NSS]C?C^OY4_\ X7KX(_Y^KW_P"D_PHN@Y7V/1:*\Z_P"%Z^"/^?J]_P#
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M"/\ GZO?_ *3_"BZ#EEV/1:*\Z_X7KX(_P"?J]_\ I/\*/\ A>O@C_GZO?\
MP"D_PHN@Y9=CT6BO.O\ A>O@C_GZO?\ P"D_PH_X7KX(_P"?J]_\ I/\*+H.
M678]%HKSK_A>O@C_ )^KW_P"D_PH_P"%Z^"/^?J]_P# *3_"BZ#EEV/1:*\Z
M_P"%Z^"/^?J]_P# *3_"C_A>O@C_ )^KW_P"D_PHN@Y9=CT6BO.O^%Z^"/\
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M_P"?J]_\ I/\*+H.678]%HKSK_A>O@C_ )^KW_P"D_PH_P"%Z^"/^?J]_P#
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M/1:*\Z_X7KX(_P"?J]_\ I/\*/\ A>O@C_GZO?\ P"D_PHN@Y9=CT6BO.O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>,?\JZFN6^&/_)+O#O\ UXQ_RKJ:^C/QX**** "BBB@#Y?T[_C^UK_L*W/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR#_6/!>?W?\ !.?HKH/^%1>-_P#H-Z+_ -^I/\*/^%1>-_\ H-Z+_P!^I/\
M"CZG5\@_UCP7G]W_  3GZ*Z#_A47C?\ Z#>B_P#?J3_"C_A47C?_ *#>B_\
M?J3_  H^IU?(/]8\%Y_=_P $Y^BN@_X5%XW_ .@WHO\ WZD_PH_X5%XW_P"@
MWHO_ 'ZD_P */J=7R#_6/!>?W?\ !.?HKH/^%1>-_P#H-Z+_ -^I/\*/^%1>
M-_\ H-Z+_P!^I/\ "CZG5\@_UCP7G]W_  3GZ*Z#_A47C?\ Z#>B_P#?J3_"
MC_A47C?_ *#>B_\ ?J3_  H^IU?(/]8\%Y_=_P $Y^BN@_X5%XW_ .@WHO\
MWZD_PH_X5%XW_P"@WHO_ 'ZD_P */J=7R#_6/!>?W?\ !.?HKH/^%1>-_P#H
M-Z+_ -^I/\*/^%1>-_\ H-Z+_P!^I/\ "CZG5\@_UCP7G]W_  3GZ*Z#_A47
MC?\ Z#>B_P#?J3_"C_A47C?_ *#>B_\ ?J3_  H^IU?(/]8\%Y_=_P $Y^BN
M@_X5%XW_ .@WHO\ WZD_PH_X5%XW_P"@WHO_ 'ZD_P */J=7R#_6/!>?W?\
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M_P#T&]%_[]2?X4?\*B\;_P#0;T7_ +]2?X4?4ZOD'^L>"\_N_P""<_170?\
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M $&]%_[]2?X4?\*B\;_]!O1?^_4G^%'U.KY!_K'@O/[O^"<_170?\*B\;_\
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M*ST*_N;G6-(>&&VDDD5(Y-S*%)(''7 IK!U4[D5.(<%*#BKZKM_P3U3X8_\
M)+O#O_7C'_*NIKE?AAG_ (5;X>W$$_84Z#'&*ZJO7/S\**** "BBB@#SWX/_
M /( US_L/7G_ *$*] KS_P"#_P#R -<_[#UY_P"A"O0* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?:?RKT"O/]"_Y+OXJ_[!]I_*O0* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_ ,9_
M\E?^'G^_J'_HA:] KS_QG_R5_P"'G^_J'_HA:] H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<[54YSM7^]TQVKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN47AIB/J 2>@)YSAJ^C]#UNQ\1Z);:KI,PFM;E-R-W'J".Q!R"/44 :%%%%
M!1110 4444 %%%% !61XL_Y$O6_^P?/_ .BVK7K(\6?\B7K?_8/G_P#1;4 9
M_P ,?^27>'?^O&/^5=37+?#'_DEWAW_KQC_E74T %%%% !1110!Y[\'_ /D
M:Y_V'KS_ -"%>@5Y_P#!_P#Y &N?]AZ\_P#0A7H% !1110 4444 %%%% !7
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M]1[@4?#CXNZ5KFE0:;XDO(]-URV7R9ENV\L3,O&X,W&X]U.#G/&* /3J\/\
MCW&NF^*/"&N6?RWZ3L@*]7".C+^18_\ ?5>L:IXL\/Z)9M=:IK%G;Q*N[+3
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSRVXA6=4)_ZYAMOZ5L:1X2T/0=4O=1TC3TM;F^"B=D=MK!>@"D[5 ]@*V:*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZA_Z(6O0*\_\9_\ )7_AY_OZA_Z(6O0* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K(\6?\B7K?_8/G_\ 1;5KUD>+/^1+UO\ [!\_
M_HMJ ,_X8_\ )+O#O_7C'_*NIKEOAC_R2[P[_P!>,?\ *NIH **** "BBB@#
MSWX/_P#( US_ +#UY_Z$*] KS_X/_P#( US_ +#UY_Z$*] H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** //]"_Y+OXJ_P"P?:?RKT"O/]"_Y+OXJ_[!]I_*O0* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#S_ ,9_\E?^'G^_J'_HA:] KS_QG_R5_P"'G^_J
M'_HA:] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?(B_YY)_WR*/(B_YY)_WR* .&_X7;\/O^A@'_@'/_P#$4?\ "[?A]_T, _\
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M_P!# /\ P#G_ /B*[GR(O^>2?]\BCR(O^>2?]\B@#AO^%V_#[_H8!_X!S_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M '#?\+M^'W_0P#_P#G_^(H_X7;\/O^A@'_@'/_\ $5W/D1?\\D_[Y%'D1?\
M/)/^^10!PW_"[?A]_P!# /\ P#G_ /B*/^%V_#[_ *& ?^ <_P#\17<^1%_S
MR3_OD4>1%_SR3_OD4 <-_P +M^'W_0P#_P  Y_\ XBC_ (7;\/O^A@'_ (!S
M_P#Q%=SY$7_/)/\ OD4>1%_SR3_OD4 <-_PNWX??]# /_ .?_P"(H_X7;\/O
M^A@'_@'/_P#$5W/D1?\ /)/^^11Y$7_/)/\ OD4 <-_PNWX??]# /_ .?_XB
MC_A=OP^_Z& ?^ <__P 17<^1%_SR3_OD4>1%_P \D_[Y% '#?\+M^'W_ $,
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MOP^_Z& ?^ <__P 17<^1%_SR3_OD4>1%_P \D_[Y% '#?\+M^'W_ $, _P#
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MZ& ?^ <__P 17<^1%_SR3_OD4>1%_P \D_[Y% '#?\+M^'W_ $, _P# .?\
M^(H_X7;\/O\ H8!_X!S_ /Q%=SY$7_/)/^^11Y$7_/)/^^10!PW_  NWX??]
M# /_  #G_P#B*/\ A=OP^_Z& ?\ @'/_ /$5W/D1?\\D_P"^11Y$7_/)/^^1
M0!PW_"[?A]_T, _\ Y__ (BC_A=OP^_Z& ?^ <__ ,17<^1%_P \D_[Y%'D1
M?\\D_P"^10!PW_"[?A]_T, _\ Y__B*/^%V_#[_H8!_X!S__ !%=SY$7_/)/
M^^11Y$7_ #R3_OD4 <-_PNWX??\ 0P#_ , Y_P#XBC_A=OP^_P"A@'_@'/\
M_$5W/D1?\\D_[Y%'D1?\\D_[Y% '#?\ "[?A]_T, _\  .?_ .(H_P"%V_#[
M_H8!_P" <_\ \17<^1%_SR3_ +Y%'D1?\\D_[Y% '#?\+M^'W_0P#_P#G_\
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M@5Y_H7_)=_%7_8/M/Y5Z!0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?\ C/\ Y*_\
M//\ ?U#_ -$+7H%>?^,_^2O_  \_W]0_]$+7H% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5D>+/\ D2];_P"P?/\ ^BVK7K(\6?\
M(EZW_P!@^?\ ]%M0!G_#'_DEWAW_ *\8_P"5=37+?#'_ ))=X=_Z\8_Y5U-
M!1110 4444 >>_!__D :Y_V'KS_T(5Z!7G_P?_Y &N?]AZ\_]"%>@4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'G^A?\EW\5?]@^T_E7H%>?Z%_P EW\5?]@^T_E7H
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y_XS_P"2O_#S_?U#_P!$+7H%>?\ C/\
MY*_\//\ ?U#_ -$+7H% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5D>+/^1+UO_L'S_P#HMJUZR/%G_(EZW_V#Y_\ T6U &?\ #'_D
MEWAW_KQC_E74URWPQ_Y)=X=_Z\8_Y5U- !1110 4444 >>_!_P#Y &N?]AZ\
M_P#0A7H%>?\ P?\ ^0!KG_8>O/\ T(5Z!0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSV^GPP3Q;@VUA&%89!P>_0UYQX>T#XB?#K[=H?AO2K'6M)FG:6SNI[I8S!N
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MN?M3"-7).1A6W?=3&>1@^XXKT",N8E,H"O@;@#D ]Z '4444 %%%% !1110
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M94\O:, ;#C [8[>E ''ZU\:-&M8;&/PW8W?B*_OX1/%:6:G*J21AL D-D$8
M)X^E/\&?%VS\3>(&T#5])NM!U@ E;6Z.=Y R5R0I#8YP0.*Y_P#9PTFVA\'Z
MAJP0&[N+PP%\<A$52!^;$_E4/Q:C6T^,?@.]M@([B6ZCC>11RRB9!@_@[#\:
M /:J*** "BBB@#S_ ,9_\E?^'G^_J'_HA:] KS_QG_R5_P"'G^_J'_HA:] H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_AY_OZA_Z(6O0*\_\9_\E?\ AY_OZA_Z(6O0* "BBB@ HHHH **** "BBB@
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M!!ZJ<#CV[5UE% 'E%E\#O,GB;Q5XLU+7X+<Y@M9]PB0XXR"[9 ]!C-=/\-O
M?_"O?#]SIG]I?VCY]T;CS?(\K;E%7&-S?W<YSWKL** .+\#_  ]_X0S7-?U'
M^T_MO]LSB;R_L_E^3AG;&=QW??\ ;I4WQ(\"_P#"P?#D&E?VC_9_DW:W/F^1
MYN<(Z[<;E_OYSGM7744 16L'V:SA@W;O*C5-V,9P,9KD?#/P^_X1SQWKWB/^
MT_M/]L,S?9_L^SR<ON^]N.[TZ"NSHH **** "BBB@ HHHH \O^)VGW&J_$;P
M'9V>HS:;-*U_MNH "\>(D/&?4#'XUH?\*[\1?]%&UO\ [X2CQG_R5_X>?[^H
M?^B%KT"@#S__ (5WXB_Z*-K?_?"4?\*[\1?]%&UO_OA*] HH \__ .%=^(O^
MBC:W_P!\)1_PKOQ%_P!%&UO_ +X2O0** //_ /A7?B+_ **-K?\ WPE'_"N_
M$7_11M;_ .^$KT"B@#S_ /X5WXB_Z*-K?_?"4?\ "N_$7_11M;_[X2O0** /
M/_\ A7?B+_HHVM_]\)1_PKOQ%_T4;6_^^$KT"B@#S_\ X5WXB_Z*-K?_ 'PE
M'_"N_$7_ $4;6_\ OA*] HH \_\ ^%=^(O\ HHVM_P#?"4?\*[\1?]%&UO\
M[X2O0** //\ _A7?B+_HHVM_]\)1_P *[\1?]%&UO_OA*] HH \__P"%=^(O
M^BC:W_WPE'_"N_$7_11M;_[X2O0** //_P#A7?B+_HHVM_\ ?"4?\*[\1?\
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M;6_^^$KT"B@#S_\ X5WXB_Z*-K?_ 'PE'_"N_$7_ $4;6_\ OA*] HH \_\
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M1?\ 11M;_P"^$KT"B@#S_P#X5WXB_P"BC:W_ -\)1_PKOQ%_T4;6_P#OA*]
MHH \_P#^%=^(O^BC:W_WPE'_  KOQ%_T4;6_^^$KT"B@#S__ (5WXB_Z*-K?
M_?"4?\*[\1?]%&UO_OA*] HH \__ .%=^(O^BC:W_P!\)1_PKOQ%_P!%&UO_
M +X2O0** //_ /A7?B+_ **-K?\ WPE'_"N_$7_11M;_ .^$KT"B@#S_ /X5
MWXB_Z*-K?_?"4?\ "N_$7_11M;_[X2O0** //_\ A7?B+_HHVM_]\)1_PKOQ
M%_T4;6_^^$KT"B@#S_\ X5WXB_Z*-K?_ 'PE'_"N_$7_ $4;6_\ OA*] HH
M\_\ ^%=^(O\ HHVM_P#?"4?\*[\1?]%&UO\ [X2O0** //\ _A7?B+_HHVM_
M]\)6=XA\ Z_;>&-4GE^(&LW$<5G*[0NB;9 $)*GV/2O4:R/%G_(EZW_V#Y__
M $6U &=\,!CX6^'LDG_04Y/TKJJY;X8_\DN\._\ 7C'_ "KJ: "BBB@ HHHH
M \]^#_\ R -<_P"P]>?^A"O0*\_^#_\ R -<_P"P]>?^A"O0* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#S_0O^2[^*O\ L'VG\J] KS_0O^2[^*O^P?:?RKT"@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \_P#&?_)7_AY_OZA_Z(6O0*\_\9_\E?\ AY_O
MZA_Z(6O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK(\6?\B7K?\ V#Y__1;5KUD>+/\ D2];_P"P?/\ ^BVH S_AC_R2[P[_ ->,
M?\JZFN6^&/\ R2[P[_UXQ_RKJ: "BBB@ HHHH \]^#__ " -<_[#UY_Z$*]
MKS_X/_\ ( US_L/7G_H0KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_T+_DN_BK
M_L'VG\J] KS_ $+_ )+OXJ_[!]I_*O0* "BBB@ HHHH **** "BBB@ HHHH
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M*S].U_1]7)&DZM8WQ R1;7*28_[Y)K0H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#S_0O^2[^*O\ L'VG\J] KS_0O^2[
M^*O^P?:?RKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_P#&?_)7_AY_OZA_Z(6O
M0*\_\9_\E?\ AY_OZA_Z(6O0* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K(\6?\B7K?\ V#Y__1;5KUD>+/\ D2];_P"P?/\ ^BVH
M S_AC_R2[P[_ ->,?\JZFN6^&/\ R2[P[_UXQ_RKJ: "BBB@ HHHH \]^#__
M " -<_[#UY_Z$*] KS_X/_\ ( US_L/7G_H0KT"@ HHHH **** "BBB@ KYN
M^%O@70?&WB;Q8OB&VDG%I<J8=DS)MW/+GH>?NBOI&O$/@#_R-/C;_KYB_P#0
MYJ -36?V?= DA\_PQ>WFD7\?S0OYID0,.F?XA]0>/0TOPN\=:T/$EWX%\<MN
MU>S!^SW#'+3A1D@G^([<,&[C.>>OK5>(>/@MO^TGX1EL<"YDCA$VWNID=23_
M ,!R/H!0![!9:YI.IW4]MINJ65W<6YQ-%!<)(\1SCY@#D<\<U?KP_P 6#_A6
M?QRL/$T?[K2->S%>\_*K$@.3]#MD_P"^J]+^(7BE/!_@?4-5W 3JGEVRG^*5
MN%^N.I]@: ->SUS2=1O)[33]4L[JYMR1-#!<([Q$'!W*#D<\<U#>>)M!TZ[%
MKJ&MZ=:W!.!#/=QHY_ G->8_#;POJ>@_!O5]7LE8^(-8M9+F)\Y?[A\H#WY+
M#W:N0^&6F?#+7-!DM_&$ZCQ!-*XF:]N7A.2QVE&R%)]<Y.?PH ^CT=9(U>-@
MZ,,JRG((]15*SUW2-06Y:PU2RNA:G%P8;A'\D\_>P?EZ'KZ&LGP+X/M_!6@M
MIUCJ-U?6[RF6,W#@A >@7'0?S.3WKPSX=^!IO&_B;Q#;7U[<6^A07IDN8(6V
M_:9-[;5)] -WY\>H /H2R\3:#J5T;;3M;TZ[N!UB@NXW8?@#FM2O*?$7P$\,
MW&DN?#,4VEZG"N^"5;AW5W'0-N)QD]QC'7VJ3X9?$2XO_AQJMWXD9GOO#P<7
M+,?FE15+*3_M<,ON1ZF@#TF]U&RTR#S]2O+>TBZ>9/*L:_F34.FZYI.L!CI&
MJ65^%Y;[+<)+C_ODFO%? _@B3XLM<>,/'MU<7%O-*T=G9Q2%$50<'!'(4'@
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M%\K;QQG=G//I70UXAX3\16_BC]HN74;6"XMO^)4T4MO=1[)(I%(#*P]J]OH
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M 4444 %%%% 'G_C/_DK_ ,//]_4/_1"UZ!7G_C/_ )*_\//]_4/_ $0M>@4
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M7OY!)<'S7?>PSS\S''WCTQUK:HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#S_0O^2[^*O^P?:?RKT"O/]"_Y+OXJ_P"P?:?RKT"@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH \_\9_\E?\ AY_OZA_Z(6O0*\_\9_\ )7_AY_OZA_Z(
M6O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *=_
MI&FZJ83JFGVMZ8&WPFX@63RV]5W X/'45<HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *R/%G_ ")>M_\ 8/G_ /1;5KUD>+/^
M1+UO_L'S_P#HMJ ,_P"&/_)+O#O_ %XQ_P JZFN6^&/_ "2[P[_UXQ_RKJ:
M"BBB@ HHHH \]^#_ /R -<_[#UY_Z$*] KS_ .#_ /R -<_[#UY_Z$*] H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** //\ 0O\ DN_BK_L'VG\J] KS_0O^2[^*O^P?
M:?RKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \_\9_\ )7_AY_OZA_Z(6O0*\_\
M&?\ R5_X>?[^H?\ HA:] H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "LCQ9_R)>M_]@^?_ -%M6O61XL_Y$O6_^P?/_P"BVH S_AC_
M ,DN\._]>,?\JZFN6^&/_)+O#O\ UXQ_RKJ: "BBB@ HHHH \]^#_P#R -<_
M[#UY_P"A"O0*\_\ @_\ \@#7/^P]>?\ H0KT"@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \_T+_DN_BK_L'VG\J] KS_0O^2[^*O\ L'VG\J] H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** //_&?_)7_ (>?[^H?^B%KT"O/_&?_ "5_X>?[^H?^B%KT"@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_\ PM2?_H0/&/\ X*__ +*C_A:D_P#T('C'_P %?_V5 'H%%>?_ /"U)_\
MH0/&/_@K_P#LJ/\ A:D__0@>,?\ P5__ &5 'H%%>?\ _"U)_P#H0/&/_@K_
M /LJ/^%J3_\ 0@>,?_!7_P#94 >@45Y__P +4G_Z$#QC_P""O_[*C_A:D_\
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M'_HA:] KR_XG:HVB_$;P'?K87FH&%K\BVLHO,EDS$@^5>^,Y^@-:'_"U)_\
MH0/&/_@K_P#LJ /0**\__P"%J3_]"!XQ_P#!7_\ 94?\+4G_ .A \8_^"O\
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MH ] HKS_ /X6I/\ ]"!XQ_\ !7_]E1_PM2?_ *$#QC_X*_\ [*@#T"BO/_\
MA:D__0@>,?\ P5__ &5'_"U)_P#H0/&/_@K_ /LJ /0**\__ .%J3_\ 0@>,
M?_!7_P#94?\ "U)_^A \8_\ @K_^RH ] HKS_P#X6I/_ -"!XQ_\%?\ ]E1_
MPM2?_H0/&/\ X*__ +*@#T"BO/\ _A:D_P#T('C'_P %?_V5'_"U)_\ H0/&
M/_@K_P#LJ /0**\__P"%J3_]"!XQ_P#!7_\ 94?\+4G_ .A \8_^"O\ ^RH
M] HKS_\ X6I/_P!"!XQ_\%?_ -E1_P +4G_Z$#QC_P""O_[*@#T"BO/_ /A:
MD_\ T('C'_P5_P#V5'_"U)_^A \8_P#@K_\ LJ /0**\_P#^%J3_ /0@>,?_
M  5__94?\+4G_P"A \8_^"O_ .RH ] HKS__ (6I/_T('C'_ ,%?_P!E1_PM
M2?\ Z$#QC_X*_P#[*@#T"BO/_P#A:D__ $('C'_P5_\ V5'_  M2?_H0/&/_
M (*__LJ /0**\_\ ^%J3_P#0@>,?_!7_ /94?\+4G_Z$#QC_ ."O_P"RH ]
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MS_\ X6I/_P!"!XQ_\%?_ -E1_P +4G_Z$#QC_P""O_[*@#T"BO/_ /A:D_\
MT('C'_P5_P#V5'_"U)_^A \8_P#@K_\ LJ /0**\_P#^%J3_ /0@>,?_  5_
M_94?\+4G_P"A \8_^"O_ .RH ] HKS__ (6I/_T('C'_ ,%?_P!E1_PM2?\
MZ$#QC_X*_P#[*@#T"BO/_P#A:D__ $('C'_P5_\ V5'_  M2?_H0/&/_ (*_
M_LJ /0**\_\ ^%J3_P#0@>,?_!7_ /94?\+4G_Z$#QC_ ."O_P"RH ] HKS_
M /X6I/\ ]"!XQ_\ !7_]E1_PM2?_ *$#QC_X*_\ [*@#T"BO/_\ A:D__0@>
M,?\ P5__ &5'_"U)_P#H0/&/_@K_ /LJ /0**\__ .%J3_\ 0@>,?_!7_P#9
M4?\ "U)_^A \8_\ @K_^RH ] HKS_P#X6I/_ -"!XQ_\%?\ ]E1_PM2?_H0/
M&/\ X*__ +*@#T"BO/\ _A:D_P#T('C'_P %?_V5'_"U)_\ H0/&/_@K_P#L
MJ /0**\__P"%J3_]"!XQ_P#!7_\ 94?\+4G_ .A \8_^"O\ ^RH ] HKS_\
MX6I/_P!"!XQ_\%?_ -E1_P +4G_Z$#QC_P""O_[*@#T"BO/_ /A:D_\ T('C
M'_P5_P#V5'_"U)_^A \8_P#@K_\ LJ /0**\_P#^%J3_ /0@>,?_  5__94?
M\+4G_P"A \8_^"O_ .RH ] HKS__ (6I/_T('C'_ ,%?_P!E1_PM2?\ Z$#Q
MC_X*_P#[*@#T"BO/_P#A:D__ $('C'_P5_\ V5'_  M2?_H0/&/_ (*__LJ
M/0**\_\ ^%J3_P#0@>,?_!7_ /94?\+4G_Z$#QC_ ."O_P"RH ] K(\6?\B7
MK?\ V#Y__1;5RW_"U)_^A \8_P#@K_\ LJSO$/Q,FN_#&J6Y\#>+8!-9RQ^;
M-INU$RA&YCNX ZDT =5\,?\ DEWAW_KQC_E74URGPO;?\+?#QVLO^A(,,/3B
MNKH **** "BBB@#SWX/_ /( US_L/7G_ *$*] KS_P"#_P#R -<_[#UY_P"A
M"O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#S_0O^2[^*O^P?:?RKT"O/]"_Y+OXJ
M_P"P?:?RKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_\9_\E?\ AY_OZA_Z(6O0
M*\_\9_\ )7_AY_OZA_Z(6O0* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_V#[3^5>@5Y_H7_ "7?Q5_V#[3^5>@4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G
M_C/_ )*_\//]_4/_ $0M>@5Y_P",_P#DK_P\_P!_4/\ T0M>@4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC4M$8_\ 572@9RO)YP,]2#@],8K<^&7_ "2_P]_UXQ_RKA_C$%M_B)X!N['
MU,WVP;>K1^9'P?;+-^;4 >PT5Y+XKEU#Q[\6#X'@OY]/T?3;47.HFV;:\[$
MA<^F'3CIU/I63\1_A9:>%O &HWOA"]O;2%$7[;9/<%XKF/<.2#_$#@Y]C0![
MA17._#__ ))MX<_[!=O_ .BUKHJ "BO&?CK!>W7BOP);Z5.;>\FNIT@F7K&Q
M: !OPZU!X[^&-EX+\'S>)_#6J:E;ZUIVR22[>Y+-<98*V[WYSZ=CUH ]MHKR
MKQOX[U<?#SPP-%86VL>*1!&DJ\>2752Q7T.6 ![ YZBI3\"]&&GF2/5M577
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** //_&?_ "5_X>?[^H?^B%KT"O/_ !G_ ,E?
M^'G^_J'_ *(6O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K(\6?\B7K?_8/G_P#1;5KUD>+/^1+UO_L'S_\ HMJ ,_X8_P#)+O#O
M_7C'_*NIKEOAC_R2[P[_ ->,?\JZF@ HHHH **** //?@_\ \@#7/^P]>?\
MH0KT"O/_ (/_ /( US_L/7G_ *$*] H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //]
M"_Y+OXJ_[!]I_*O0*\_T+_DN_BK_ +!]I_*O0* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#S_QG_R5_P"'G^_J'_HA:] KS_QG_P E?^'G^_J'_HA:] H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?^#"3_&C_A2OA+TU+_P82?XT =_17 ?\*5\)>FI?^#"3_&C_ (4KX2]-2_\
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M@#OZ*X#_ (4KX2]-2_\ !A)_C1_PI7PEZ:E_X,)/\: ._HK@/^%*^$O34O\
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M_P *5\)>FI?^#"3_ !H [^BN _X4KX2]-2_\&$G^-'_"E?"7IJ7_ (,)/\:
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M1_PI7PEZ:E_X,)/\: ._HK@/^%*^$O34O_!A)_C1_P *5\)>FI?^#"3_ !H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>secondendpointlasttablesa02.jpg
<TEXT>
begin 644 secondendpointlasttablesa02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M,   DI(  @    ,R,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<_P#
MN7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K7/\
MP+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"AZUS_
M ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<
M_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K
M7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"A
MZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\
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M3LF95<GQM&'/.%EIU75V[]SZWHKY;\GQ3_T/6N?^!<O_ ,71Y/BG_H>M<_\
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M1Y/BG_H>M<_\"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\
M%T>3XI_Z'K7/_ N7_P"+H^MT>X?V%F'\GXK_ #/J2BODC2-0\5:G->H?&>MQ
M?9IC'D7LIW=>?O\ M6GY/BG_ *'K7/\ P+E_^+JI8FE%V;,J63XVM!3A"Z?F
MO\SZDHKY;\GQ3_T/6N?^!<O_ ,71Y/BG_H>M<_\  N7_ .+J?K='N:_V%F'\
MGXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K='N']A9A
M_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NCZW1[A_86
M8?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+H^MT>X?V
M%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K='N'
M]A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NCZW1[
MA_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+H^MT
M>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K
M='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NC
MZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+
MH^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\
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MZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\
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M% '-^$_^/S6/^OL_S-=)7-^$_P#C\UC_ *^S_,UTE;U_XC_KH>;E?^Z1^?\
MZ4PHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO W_($G_Z^F_]!6NE
MKFO W_($G_Z^F_\ 05K>'\*7R_4\VO\ [[1])_\ MITM%%%8'I!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ,F_X]Y/]T_RK!\$_P#(NC_KJW]*WIO^/>3_ '3_
M "K!\$_\BZ/^NK?TK>/\*7JOU/-J_P"_4O\ #+_VTZ&BBBL#T@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7'WJA-0N%4!5$K  #@#-:.#4%+N<E/$J>(G02UC;\2"BBBLSK"BBB@ HHHH
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M]>2>*X^L*[BY:=M?4];*Z=2G1:FFE=\J>ZCT04445SGJ!1110 4444 %%%%
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MH84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAYN5_P"Z1^?_ *4PHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH ****
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M2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M _Z^#_-*WH?Q/O\ R/-S3_=7ZQ_]*1TE%%%8'I!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '-^$_^/S6/^OL_S-=)7-^$_P#C\UC_ *^S
M_,UTE;U_XC_KH>;E?^Z1^?\ Z4PHHHK ](**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KFO W_($G_Z^F_]!6NEKFO W_($G_Z^F_\ 05K>'\*7R_4\VO\ [[1]
M)_\ MITM%%%8'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_X]Y/]T_RK!\$
M_P#(NC_KJW]*WIO^/>3_ '3_ "K!\$_\BZ/^NK?TK>/\*7JOU/-J_P"_4O\
M#+_VTZ&BBBL#T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/QC_P BQ<?[R?\
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M^!_Y^HWZ*P/^$K3_ *!.I?\ ?C_Z]'_"5I_T"=2_[\?_ %Z/J]7^4/[7P/\
MS]1OT5@?\)6G_0)U+_OQ_P#7H_X2M/\ H$ZE_P!^/_KT?5ZO\H?VO@?^?J-^
MBL#_ (2M/^@3J7_?C_Z]'_"5I_T"=2_[\?\ UZ/J]7^4/[7P/_/U&_16!_PE
M:?\ 0)U+_OQ_]>C_ (2M/^@3J7_?C_Z]'U>K_*']KX'_ )^HWZ*P/^$K3_H$
MZE_WX_\ KT?\)6G_ $"=2_[\?_7H^KU?Y0_M? _\_4;]%8'_  E:?] G4O\
MOQ_]>C_A*T_Z!.I?]^/_ *]'U>K_ "A_:^!_Y^HWZ*P/^$K3_H$ZE_WX_P#K
MT?\ "5I_T"=2_P"_'_UZ/J]7^4/[7P/_ #]1OT5@?\)6G_0)U+_OQ_\ 7H_X
M2M/^@3J7_?C_ .O1]7J_RA_:^!_Y^HWZ*P/^$K3_ *!.I?\ ?C_Z]'_"5I_T
M"=2_[\?_ %Z/J]7^4/[7P/\ S]1OT5@?\)6G_0)U+_OQ_P#7H_X2M/\ H$ZE
M_P!^/_KT?5ZO\H?VO@?^?J-^BL#_ (2M/^@3J7_?C_Z]'_"5I_T"=2_[\?\
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MO^_'_P!>CZO5_E#^U\#_ ,_4;]%8'_"5I_T"=2_[\?\ UZ/^$K3_ *!.I?\
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MU+_OQ_\ 7H_X2M/^@3J7_?C_ .O1]7J_RA_:^!_Y^HWZ*P/^$K3_ *!.I?\
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M_OQ_]>C_ (2M/^@3J7_?C_Z]'U>K_*']KX'_ )^HWZ*P/^$K3_H$ZE_WX_\
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M +\?_7H_X2M/^@3J7_?C_P"O1]7J_P H?VO@?^?J-^BL#_A*T_Z!.I?]^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y/\6?\ DI?PU_[";_\ H<%>L5Y/\6?^2E_#7_L)O_Z'!0!ZQ1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y/\%?^0YXZ_P"PR_\
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M* "BBB@ HHHH **** "BBB@#SOX[?\DAU/\ ZZP?^C5KL?#7_(IZ1_UXP_\
MH KCOCM_R2'4_P#KK!_Z-6NQ\-?\BGI'_7C#_P"@"@#3HHHH J:K_P @>]_Z
M]W_]!->>_L__ /)*8/\ K[F_F*]"U7_D#WO_ %[O_P"@FO/?V?\ _DE,'_7W
M-_,4 >FT444 %%9?B+Q#9^&-).I:DEPUJCJLC01&0Q@_Q$#G:.YJ71]=TOQ!
M9"[T2_@OH#U>%PVT^A'4'V- %^BL/Q7<^)+;2U_X0ZPL[N_9P#]MD*QQKW)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >=_';_DD.I_\ 76#_ -&K78^&O^13TC_KQA_] %<=\=O^20ZG
M_P!=8/\ T:M=CX:_Y%/2/^O&'_T 4 :=%%% %35?^0/>_P#7N_\ Z":\]_9_
M_P"24P?]?<W\Q7H6J_\ ('O?^O=__037GO[/_P#R2F#_ *^YOYB@#TVBBB@
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M &?/^26)_P!?LW]*](O_ /D&W/\ UQ?^1KS?]GS_ ))8G_7[-_2@#U"BBB@
MHHHH **** "BBB@ HHHH **** "BN=\3>/?#7@Z:WA\1ZD+.2X4M$OD22;@#
M@GY%..O>JWA_XF^$?%&K+IFA:O\ :KQU9UC^S3)D 9)RR ?K0!U=%%8L'C#0
M;GQ5-X;M]0275H4,DENB,=@&,Y;&W/(XSF@#:HHK$\0^,?#_ (41&\0ZK!9&
M091&)9V'J%4$D>^* -NBL3P[XR\/^+(W?P]JD-[Y8!=%RKJ/4HP# >^*K^)/
M'_A?PE.D'B#5XK2:0;EB"/(^/4J@) ]S0!T=%4M(UG3M?TV/4-&O(KRUD^[+
M$<C/<'N#['FJL/BK1KCQ1-X=@O/,U6",2RP)$Y$:X!^9\;0>1P3GF@#7HHK-
MTOQ!IFLWFH6NFW/G3:;-Y%TOELOEOZ9( /3J,B@#2HHHH **** "BBB@ HHH
MH **** "BBB@#SOX[?\ )(=3_P"NL'_HU:['PU_R*>D?]>,/_H KCOCM_P D
MAU/_ *ZP?^C5KL?#7_(IZ1_UXP_^@"@#3HHHH J:K_R![W_KW?\ ]!->>_L_
M_P#)*8/^ON;^8KT+5?\ D#WO_7N__H)KSW]G_P#Y)3!_U]S?S% 'IM%%% !1
M110 4444 %%5+;5M.O+ZXLK2_M9[JU($\$4RL\6?[R@Y7\:MT %%<I)\1M#@
M^(7_  AUS]H@U$JI2615$,C,H8(&W9W$'N!R,>F>KH HZY8R:GX>U&P@95EN
MK66%"Y(4,R$#..W-8OPX\,WG@_P%8:)J<L$MS;&4N]NQ9#ND9A@D ]&':F)\
M1M#E^(2^#;?[1-J.UB\D:J88RJEBI;=G=@=@>OUKJZ "BBB@ HHKEM:\87>D
M^-](T&'0+R\@U$9DU"+/EV_)'/!SC )R1@$=>E '4T444 %%%% !1110 444
M4 %%%<QXV\>Z;X$M;.?5;6]N1>2F*)+.-7;<!GHS+^E '3T5YC_PO31_^A9\
M4?\ @ G_ ,<KTN"47%O',H95D0, PP1D9YH ?1110 4444 %%%% !1110 44
M44 %>3_%G_DI?PU_[";_ /H<%>L5Y/\ %G_DI?PU_P"PF_\ Z'!0!ZQ1110
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MV\BAF*;-OS A5(;(^]TXK/\ @7K6DVG@8Z'<30V6K6%S,MW;S,$D)WDAL'J
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MV@Z7;^)=<\,:?%X?E=-\$<S&ZA1C\I8D[?3MU(SBI?VAP#X$TH$9!UF'(/\
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M!B>(O!OA[Q8B+XATJ"],8VI(V5=1Z!U(8#VS2^'O!_A_PI&Z>']+@LO,&'=
M6=AZ%F))_.MJB@!DL2SPO$^[;(I5MK%3@C'!'(/N*SO#WAK2/"NF?V?H%FMI
M;;S(4#LY9CU)9B2?Q-:E% ',^(?AUX3\57RWNO:-%<W*@#S@[QLP'3<4(W?C
MFMS3=,LM'T^*QTNUCM;6$82*)<*M6J* "BBB@ HHHH **** "BBB@ HHHH *
M*** "O)_V=O^2?ZC_P!A>7_T7%7K%>3_ +.W_)/]1_["\O\ Z+BH ]8HHHH
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MHNG3W8.1<26B-(#Z[B,U8MM)TZRO9[RST^UM[JYQY\\4*J\N.FY@,M^-6Z*
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MKYH7^[OQG'/3-6Z*  C(P>165#X7T"VOC>V^AZ;%=DY,\=I&LF?7<!FM6B@
MJI8Z5I^E^=_9EA:V?GN9)?L\*Q^8W]YL 9/N:MT4 5+?2M.M+^>^M;"UAN[G
M'GW$<*K)+CIN8#+?C1<Z5IUY>V]Y>6%K<75J2;>>6%6>$_[+$97\*MT4 5=0
MTRPU:T-KJME;WUN2&,-S$LB$CH<,"*LHBQHJ(H55& H& !Z4M% !1110 5Y/
M\6?^2E_#7_L)O_Z'!7K%>3_%G_DI?PU_[";_ /H<% 'K%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'D_P5_Y#GCK_L,O_P"A/7K%
M>3_!7_D.>.O^PR__ *$]>L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH \[^.W_ "2'4_\ KK!_Z-6NQ\-?\BGI'_7C#_Z *X[X[?\
M)(=3_P"NL'_HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_Z]W_ /037GO[
M/_\ R2F#_K[F_F*] UF01:%?R/\ =2VD8_0*:\#^%GQ@\.>#/ \>D:O#?O<K
M/)(3!"K+ACQR6% 'T317E'_#1?@S_GWU;_P'3_XNC_AHOP9_S[ZM_P" Z?\
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M7X,_Y]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >KUY/\6?^2E_#7_L)O\
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MH_X:+\&?\^^K?^ Z?_%T?\-%^#/^??5O_ =/_BZ /5Z*\H_X:+\&?\^^K?\
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M^??5O_ =/_BZ /5Z*\H_X:+\&?\ /OJW_@.G_P 71_PT7X,_Y]]6_P# =/\
MXN@#U>BO*/\ AHOP9_S[ZM_X#I_\71_PT7X,_P"??5O_  '3_P"+H ]7HKRC
M_AHOP9_S[ZM_X#I_\71_PT7X,_Y]]6_\!T_^+H ]7HKRC_AHOP9_S[ZM_P"
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MOJW_ (#I_P#%T >KT5Y1_P -%^#/^??5O_ =/_BZ/^&B_!G_ #[ZM_X#I_\
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M ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@
MP/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2
MBB@ P/2C ]*** *]^!_9MSQ_RQ?^1KS?]GP?\6L3_K]F_I7I%_\ \@VY_P"N
M+_R->;_L^?\ )+$_Z_9OZ4 >H8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I
M1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110
M 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'
MI110 8'I1@>E%% !@>E&!Z444 &!Z48'I110!YU\=@/^%0ZGQ_RU@_\ 1JUV
M7AK_ )%/2/\ KQA_] %<=\=O^20ZG_UU@_\ 1JUV/AK_ )%/2/\ KQA_] %
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MIKM)I-H[L69H$)8G))VCF@"S17G?Q=\4ZMH-CH^FZ#<+976M7HM?MS@$6ZY
M)YX!^8<^@-43\.O'.D207N@_$*^O+L2+YT&J%I('7/S84DX[\ 9]"* /4J*:
MF\1KYA4O@;BHP"?:G4 %>3_%G_DI?PU_[";_ /H<%>L5Y/\ %G_DI?PU_P"P
MF_\ Z'!0!ZQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y/\ !7_D.>.O^PR__H3UZQ7D_P %?^0YXZ_[#+_^A/7K% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#\A4] !7D_Q9_P"2E_#7_L)O_P"AP5ZQ7D_Q9_Y*7\-?^PF__H<% 'K%%%%
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M-'QY";0QC]B3SC_=[$UH^*/#?@+X:Z7<>*8?#]J+^,@6D;.[!YS]T*A8@>O
MX )KB]1T?5_#?AO1HM1OY+'5O&FJ+_;&I X>",D8B#?P_>R?H1TH ]ZT^PMM
M+TZWL;")8;:WC$<4:CA5 P*L5XGXF\-VGPFUCP[J?@V\NXI+[4$M+JPEG,BW
MB-]YB#W' SV++C%>V4 %%%% !1110 4444 %%%% !1110 4444 %>3_L[?\
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M5Z1?_P#(-N?^N+_R->;_ +/G_)+$_P"OV;^E 'J%%%% !1110 4444 %%%%
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MOC /S#C/<>M1^+-%\0>%_B4/'7A;3&U>&[MA:ZG81-B5@, .OK]U.@)^7T/
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M2\16.F:IX;:,:WH=T+JT60X63D$ID\<E5//!Q@]<UD7?Q$\9:AIDFG:7\/\
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M#+')<ZO+8(VY=.DOB;=3G/ QG]:]#M+2"QLXK6SA2"WA0)''&,*BC@ "I:*
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M[?\ )/\ 4?\ L+R_^BXJ /6**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !5'_"D[W_HH'B#_ +^M_P#%4 >L45Y/_P *3O?^B@>(/^_K?_%4?\*3O?\
MHH'B#_OZW_Q5 'K%%>3_ /"D[W_HH'B#_OZW_P 51_PI.]_Z*!X@_P"_K?\
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M_HH'B#_OZW_Q5'_"D[W_ **!X@_[^M_\50!ZQ17D_P#PI.]_Z*!X@_[^M_\
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M)WO_ $4#Q!_W];_XJ@#UBBO)_P#A2=[_ -% \0?]_6_^*H_X4G>_]% \0?\
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M!X@_[^M_\50!ZQ17D_\ PI.]_P"B@>(/^_K?_%4?\*3O?^B@>(/^_K?_ !5
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M#_OZW_Q5'_"D[W_HH'B#_OZW_P 50!ZQ17D__"D[W_HH'B#_ +^M_P#%4?\
M"D[W_HH'B#_OZW_Q5 'J%_\ \@VY_P"N+_R->;_L^?\ )+$_Z_9OZ52NO@M>
MQ6<TA\?:^VV-FVF4X.!T^]7(_"KX;7/BGP2NHP^*]6TI3<21_9[20A.,<]1R
M: /HNBO)_P#A2=[_ -% \0?]_6_^*H_X4G>_]% \0?\ ?UO_ (J@#UBBO)_^
M%)WO_10/$'_?UO\ XJC_ (4G>_\ 10/$'_?UO_BJ /6**\G_ .%)WO\ T4#Q
M!_W];_XJC_A2=[_T4#Q!_P!_6_\ BJ /6**\G_X4G>_]% \0?]_6_P#BJ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G^+/\ R4OX:_\
M83?_ -#@KUBO)_BS_P E+^&O_83?_P!#@H ]8HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \G^"O_ "'/'7_89?\ ]">O6*\G^"O_
M "'/'7_89?\ ]">O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_V
M=O\ DG^H_P#87E_]%Q5ZQ7D_[.W_ "3_ %'_ +"\O_HN*@#UBBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *]__ ,@VY_ZXO_(UYO\ L^?\DL3_ *_9OZ5Z
M1?\ _(-N?^N+_P C7F_[/G_)+$_Z_9OZ4 >H4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!YW\=O^20ZG_UU@_]&K78^&O^13TC_KQA_P#0!7'?';_DD.I_
M]=8/_1JUV/AK_D4](_Z\8?\ T 4 :=%%% %35?\ D#WO_7N__H)KSW]G_P#Y
M)3!_U]S?S%>A:K_R![W_ *]W_P#037GO[/\ _P DI@_Z^YOYB@#TVBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KR?XL_\E+^&O\ V$W_ /0X*]8K
MR?XL_P#)2_AK_P!A-_\ T."@#UBBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R?X*_P#(<\=?]AE__0GKUBO)_@K_ ,ASQU_V&7_]
M">O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_V=O^2?ZC_V%Y?_
M $7%7K%>3_L[?\D_U'_L+R_^BXJ /6**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH KW_P#R#;G_ *XO_(UYO^SY_P DL3_K]F_I7I%__P @VY_ZXO\ R->;
M_L^?\DL3_K]F_I0!ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G?QV_Y
M)#J?_76#_P!&K78^&O\ D4](_P"O&'_T 5QWQV_Y)#J?_76#_P!&K78^&O\
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MU#3M1D\WS%Q\P6)B"GID9]<T =%\4_%VK^'8-%TWPX88M2UJ]%K%<3+N6$9
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MNM\#:Q?W/Q>\<VM]J-S+9VC)Y,,T[-'",G.U2<+^% 'IU%>.Z WB7XNW%]K
M\1WWA_P_%.T%E;Z:_ERR[?XV?KW'X\#'>]HVK^(? WQ(L?"7B35I-:TO5XV-
MA>W _?1NO\#'JW3'/=E/'(H ]4HKP['BSQ-\;_$F@:;XFO\ 3=,B"/,8Y2QB
M0*F%B!.$)8]1CO\ 0ZFEW6O^ ?BUIOAG4->O-=TC6H6:)[]R\T#@-_$>>J@>
MF&Z<4 >NT444 %>3_%G_ )*7\-?^PF__ *'!7K%>3_%G_DI?PU_[";_^AP4
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M7K%>3_!7_D.>.O\ L,O_ .A/7K% !1110 4444 %%%% !1110 4444 %%%%
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M30[2'6[XW^H+&/M%QY:H&?O@*  !T%:% !1110 4444 %%%% !1110 4444
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M!@[F!Z/GBH]1M_BSXSM6TN[L].\*V$PV7,R7 EE=#U"E6/;Z?6@#G?AMK_\
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M;:8;&,87&W?L^4_Q#CL1W%)'?_&"TTW^RSH>E7=TB>6NK_:U"GMO,9();OT
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M HHHH **** "BBB@ HHHH \[^.W_ "2'4_\ KK!_Z-6NQ\-?\BGI'_7C#_Z
M*X[X[?\ )(=3_P"NL'_HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_Z]W_
M /037GO[/_\ R2F#_K[F_F*]"U7_ ) ][_U[O_Z":\]_9_\ ^24P?]?<W\Q0
M!Z;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y/\6?\ DI?PU_["
M;_\ H<%>L5Y/\6?^2E_#7_L)O_Z'!0!ZQ1110 4444 %%%% !1110 5R&H^
MSJ_Q*L/%.HZEYMOIL6VTT_R,!'_OE]W)R<_=[+Z5U]% !1110 4444 %%%%
M!1110 4444 >3_!7_D.>.O\ L,O_ .A/7K%>3_!7_D.>.O\ L,O_ .A/7K%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D_[.W_ "3_ %'_ +"\O_HN
M*O6*\G_9V_Y)_J/_ &%Y?_1<5 'K%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5[__ )!MS_UQ?^1KS?\ 9\_Y)8G_ %^S?TKTB_\ ^0;<_P#7%_Y&O-_V
M?/\ DEB?]?LW]* /4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA]_T'6_\ I__ (B@#T"BO/\ _A>/P^_Z#K?^ 4__ ,11_P +Q^'W_0=;_P
MI_\ XB@#T"BO/_\ A>/P^_Z#K?\ @%/_ /$4?\+Q^'W_ $'6_P# *?\ ^(H
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MA]_T'6_\ I__ (B@#T"BO/\ _A>/P^_Z#K?^ 4__ ,11_P +Q^'W_0=;_P
MI_\ XB@#T"BO/_\ A>/P^_Z#K?\ @%/_ /$4?\+Q^'W_ $'6_P# *?\ ^(H
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MO^@ZW_@%/_\ $4?\+Q^'W_0=;_P"G_\ B* /0**\_P#^%X_#[_H.M_X!3_\
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M%>?_ /"\?A]_T'6_\ I__B*/^%X_#[_H.M_X!3__ !% '<7_ /R#;G_KB_\
M(UYO^SY_R2Q/^OV;^E6KOXW> );*>--<8L\;*H^QS\DC_<KBO@]\3?"?A3P"
MNFZ]JAMKL7,DAC%M*_RG&#E5([4 >]T5Y_\ \+Q^'W_0=;_P"G_^(H_X7C\/
MO^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\ B*/^%X_#[_H.M_X!3_\
MQ% 'H%%>?_\ "\?A]_T'6_\  *?_ .(H_P"%X_#[_H.M_P" 4_\ \10!Z!17
MG_\ PO'X??\ 0=;_ , I_P#XBC_A>/P^_P"@ZW_@%/\ _$4 >@45Y_\ \+Q^
M'W_0=;_P"G_^(H_X7C\/O^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\
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MO^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\ B*/^%X_#[_H.M_X!3_\
MQ% 'H%%>?_\ "\?A]_T'6_\  *?_ .(H_P"%X_#[_H.M_P" 4_\ \10!Z!17
MG_\ PO'X??\ 0=;_ , I_P#XBC_A>/P^_P"@ZW_@%/\ _$4 >@45Y_\ \+Q^
M'W_0=;_P"G_^(H_X7C\/O^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\
MB*/^%X_#[_H.M_X!3_\ Q% $?QV_Y)#J?_76#_T:M=CX:_Y%/2/^O&'_ - %
M>/\ Q8^*7A#Q/\.;[2]$U4W-Y*\12,VTJ9"R*3RR@= :]>\+.LO@_1G0Y5K"
M @^H,:T :M%%% ",H92K $$8((ZUCIX.\,1KMC\.:2J^BV,0_P#9:V:* ,?_
M (1'PW_T+^E?^ 4?_P 31_PB/AO_ *%_2O\ P"C_ /B:V** ,?\ X1'PW_T+
M^E?^ 4?_ ,31_P (CX;_ .A?TK_P"C_^)K8HH Q_^$1\-_\ 0OZ5_P" 4?\
M\31_PB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]
M*_\  */_ .)K8HH Q_\ A$?#?_0OZ5_X!1__ !-'_"(^&_\ H7]*_P# */\
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MPB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]*_\
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M'_\ $T?\(CX;_P"A?TK_ , H_P#XFMBB@#'_ .$1\-_]"_I7_@%'_P#$T?\
M"(^&_P#H7]*_\ H__B:V** ,?_A$?#?_ $+^E?\ @%'_ /$T?\(CX;_Z%_2O
M_ */_P")K8HH Q_^$1\-_P#0OZ5_X!1__$T?\(CX;_Z%_2O_  "C_P#B:V**
M ,?_ (1'PW_T+^E?^ 4?_P 31_PB/AO_ *%_2O\ P"C_ /B:V** ,?\ X1'P
MW_T+^E?^ 4?_ ,31_P (CX;_ .A?TK_P"C_^)K8HH Q_^$1\-_\ 0OZ5_P"
M4?\ \31_PB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO
M_H7]*_\  */_ .)K8HH Q_\ A$?#?_0OZ5_X!1__ !-'_"(^&_\ H7]*_P#
M*/\ ^)K8HH Q_P#A$?#?_0OZ5_X!1_\ Q-'_  B/AO\ Z%_2O_ */_XFMBB@
M#'_X1'PW_P!"_I7_ (!1_P#Q-'_"(^&_^A?TK_P"C_\ B:V** ,?_A$?#?\
MT+^E?^ 4?_Q-'_"(^&_^A?TK_P  H_\ XFMBB@#'_P"$1\-_]"_I7_@%'_\
M$TU/!OAB-<1^'-)09SA;&(?^RUM44 8__"(^&_\ H7]*_P# */\ ^)H_X1'P
MW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P"
M4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8
M_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\
MH7]*_P# */\ ^)H_X1'PW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H_
M_B:/^$1\-_\ 0OZ5_P" 4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-
M_P#0OZ5_X!1__$UL44 8_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%
M'_\ $UL44 8__"(^&_\ H7]*_P# */\ ^)H_X1'PW_T+^E?^ 4?_ ,36Q10!
MC_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P" 4?\ \36Q10!C_P#"(^&_
M^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8_P#PB/AO_H7]*_\  */_
M .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\ H7]*_P# */\ ^)H_X1'P
MW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P"
M4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8
M_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\
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M H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]*_\  */_ .)K8HH
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1(,!0.  .PIU% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>slide13.jpg
<TEXT>
begin 644 slide13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M'DB"/YL,6 ^;/7BMWG&(OT^XB.08.VS^\_0J'_@K/\.)A_R!O&J>FZSMN?\
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MG_\ )5?E]+<JELW\*XQ7-ZRWV7:QV[6..:U7$&*MNON(7#>#;M9_>?JK<?\
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MM>&\]KIVLOQ_S/HH\.X9J[E+\/\ (_H*M?\ @K=^SK>1AHOB=ICJ>F+"\_\
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M84XWBSRK_@X>DCM_VV_#4G_+3_A![,#Z?VAJ%?$GA:*2*3+?=FDW >E?9_\
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M.,;65ES:^6FGFTCYL$JSH\BRQ<XP >AKI?#TK6UH&W+[FOT;_8S^$6@_MA?
M+QDWCKX,^$_!EU#,]OIMWI^D"SDEB:/>LB,0&!0G;D=<5Y;_ ,$C?V;?!?Q<
MU3Q=J?B:ST_7=4T-Q!I^E7A#P["#^^:/^+G"Y.0,>M<]'*9\\(Q>DTVGJMO(
MZ*V>4U"I*47>FTFM'OMJ?)NF74<L[JI#;>E3!?M$FY0493EL]#7UE^T+XM?X
M6_#/QGX>^(_P3\.>'-;U"-XO#VN:+IJ+:J^<A5EQSM&,'@G.*] ^$/[)%O\
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MM8\(^&;K5/#L-[;P7[:?&;B0)"75V;&2X)Z^PKC_ /@E9#X>^*OB_7/"^O\
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MC],_V"/@Y8_\$^CXF\8_$OQMX3T];^S6Q@M+'4ENE<!@Y?C!+$KM  []:?\
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ME:%^DC?O%VL$P3GU'3^9KD=5O7LV59.-K$_*?X37)B+[G13BI(OWNMQJ-O\
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MG/7.:[#3-3CUQ(Y-OEN&&Y?2FMC"M&43@?$=JME'RO\ $5K(L#YC_+78>/\
M3$>T=MVUD8D5R>E(JR3 <>6F2:U@]#*.JU*$EIYUX[$_*IVGFN2^*GA076G2
M #G[P(KM+)-_F)_"_)-5M?LO-TIE9=SCI]*J-1Q=S2I33B?&_P 5--DB=I5^
M7!VL/6OWW_X-)51/^"7FM"/I_P +!U;/U\BSK\0?V@/!8CTIKJW'"M\RYK]O
M_P#@TI79_P $O]<[?\7"U;_T19U]YE-3G5S\]SBGR*QY9_P<*?\ )[OA?/W1
MX)M,D_\ 7_J%?#L:'S=V17W)_P '"TBI^VKX9\S[O_"$VOX'[=?U\*V)\P?>
MKQ\Q7^T2]3Z/*6_JL/0N-<,Z"&&15E!R2XW53N;RYGM9%D*RE& )5/D ]A4.
MM-=1INBC4?[8[T>&[YG9E;S(=_4./UKS^0]WVAT.F3>:#NC$.Y0,*<Y_#M70
MZ;IL4EDO&V1>=V,&L_3(X(MDA(9FK=CN85AW$8V]J.0GVS3T+&F?Z)A5;Y%.
MXYZDUT>GZJ]PQC9E6/'RX[5RJZDLOW8V'<&FQ:P+23R_,7<_3FJBK(SES3=S
MLY+K(5(Y5=E^]S4L5^UN[,T@5NPKAHM=\RX=FW2*IP=G&*2?56B;<WG;?X1U
MQ579*IV^(])T76_,DVEEW*N26X_*K,^O1[=^UFW' XZ5YW8>(FC0-(=BYP"W
M&:T+?QC;NZJRR+N^[D=?I5*;1A.FF=I<ZI') J+M5NK$U@ZY?0Q-(K*K12_>
M8+TK'N]?AM;ABLF]6Z<]*AO_ !=#$BAN%/KU-*4KZBC3:V(=32&>Q^SO_J&.
M0X;[HJBULUSI[1K*)!V;/:H8O&EA=W4D/ES2#J8W7:&'M6=J.O0/$J(WDJ,E
M40UFXQ9V1]HMBOJ%S'9G:VYE (Y'>N+UV0VMV]Q:AHTD7_2(E/$B ]O?O6YJ
M>IR2H5+P[^?D8\XKE-7U..RDC:&1VN#N^0]^/Y4_9W1LJG<-,UZUU2W^S73*
M.I0CY<+_  J1ZBL/Q!+AYK7<WG6PW12.<DCTSW-.#68>\;8NU@&=L_<;VKGM
M2U*(RRJ\K,,#;G[PQ4^P-(U$M4;?A?6[BP<DS,;?EF(X6-\=Q751^(WBMD:6
MX62288 !^5_]KWXKRN/Q#(+I61XT^U#;(G\+ =ZL3ZE-91K]G96B/S,KM_J_
M]H'^E9RPMSLIXK34]$EUG_A&=]Y9F59'XFA!X<=R!Z5I/\1[G7]-6:2XBE$>
M(DW#A4[#\Z\TT?Q*]W*I69C+TCF(RNWN&]*ED\1P>&_,A:99K>ZR8QC&UQU
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MWBS0W,C37DFQ2%PN.YKXCM_B;K5I_J[S;[^4F?SQ6O8_M#^,=.C58=:E55&
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MYM0$<=K"R+,W+NE:^G>%YE!:1FN)) %8L:K:4C6C-)*/WDA&".M=18-(+I>
MRXZ5A*G;4V]HTK(U/"WAE--"S3 M)C&3_#75:,I:Y69N.< >HK-M)PMNI9D
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M6AX]/9+(1PRCJ<]Z\C^*<7D^-[M?9/\ T$5]$:CX;D!VKY5TO0-%)^O-?/\
M\:;1K+XBWT;KM91'QG/\ KV<').>G8^<S6FE13\_\SE:***],^>"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ IT9Q(OUIM.@&9D_WA0!]Z?#'Q ;C0%:
M?<!(%&[/.W KN='NXI)M^YE&,*2>&^M<.OPU_LY;>:TNI6A\M6\MFXZ#I7:^
M#?!-QK<8_=LBXQDMQ7P>(Y):GZCA8\J434GU9KJ]CAMU>0]-R]JZRST<:#I+
M+-,)+B;YOE[>U26OAA?#5C'';JC.1\SGJ#5.X@:\W*K[G+;G(;I]*\J7*MCW
M:,7='[^?\$:CN_X)G?"G_KQNO_2VXKXB_P""^VGK>?MF>&&8?=\&VO/_ &_7
MU?;_ /P1N79_P31^%0]+&Y_]+;BOB?\ X+TN1^V7X:&./^$-M>?^WZ^KZW,/
M^19#TC^1^?Y;_P CJKZS_,^'[F 0QG=G9T(JL;<1A<XV,<A?3WK0NL7$4BGL
M!4%K,LD?EOMSV-?*0:N?75HM;E^SN%NM,C(^;8Q!XK&\1ZY):7L!5MO8UHZ1
M$;"\\O[RR<@5@>*XE#32-NDD5LJ@[?C3J;DTTSJ-$A,C1G<?7CK72V\<*-$R
MKN93DYKS3_A,9-'\'ZMJ-KM:ZTVPGN51^5+)&S#/MD<U\,I_P6'^*$9)&F^#
M^?\ IPD_^.UWX'+ZE=-T^AQYAFE+#-*K?7R/U"3Q$D$_]T*?G]JEN/&GER;%
M?Y>_O]*_+*;_ (*\_$Z?=NT_PC\W7%C)S_Y$J,_\%</B<QC_ -!\)YCX4_8I
M/_CE=W]BXOLOO.'_ %@P/=_<?I=JGCAH+U@RN(7^7=Z&HH/B,MBJ+OSDG:3F
MOS8_X>Y_$IEDW:7X/?S!@EK"3CZ?O*JM_P %7?B-)%L;2_"++VS8R?+]/WE5
M_8V)\OO*7$6!ZM_<?J%'\3864;I,-V(/7VK4C^(%O):@^:NYNWI]:_)]?^"H
M_P 0DDW?V=X5_P# .3_XY3HO^"IOQ&A\S;8^%_WG7_0Y/_CE']CXGLOO"7$&
M7/J_N/U?3QM'*S0M(N[;GCH*J7<\6K\?=AQSZDU^5J?\%4OB0BX%IX9ZYS]D
MDS_Z,J[;_P#!7#XH6V,6GA=L>ME)_P#'*3R7%/HOO)?$& 7PM_<?I/KNG1Q6
MV4V[0.&/:N1U&UCN(%63 9S\Q/45\%W/_!7CXF7D/ER:;X092<_\>,G_ ,<J
MA-_P57^(T[-G3O"?/864G'_D2E_8F*\OO-(\38-=7]Q]O>)/#=O<WT;LVU@N
M$9>#7/M ([E1*%5@Q"L/X?\ :_&OC>X_X*?_ ! NG#/IOA7CI_H4G_QRJMU_
MP4H\=W97=I_A@;3VLWY_\B4O[#Q/5+[RO]9\'T;^X^W[74OL4:Q7;>:K9,<H
MX)^M7KJXFU?2FMV;=(Q_<X/>O@V;_@H[XYG@\MM/\-;<Y ^R/Q_X_4EE_P %
M)O'EA(K1V/AO* @9M)/_ (Y6<L@Q+?3[S6'%6"6[?W'W1I^JRO$,RR1R?<4[
ML8QP>*UK'Q3<6%OF:;:%.TX;M7Y^W?\ P4?\=7C[FL?#8^;=Q:..?^^Z5O\
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M%+-1N 7..!7RD?V_O!MW.SS1Z]TZ+;)_\75N7_@H3X),4,<:^(E6/KFU0_\
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M<W%O&)+A_.4>9ST.:F7PLUQ.1)(VZ3ABC<C%6]0UG^QF5E7EN"156Q\7"_\
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M%4]#[UT1SO&/>7X+_(Y)\-X%?8_%_P"9^<*?\$7/$EU.T=MXVT6XD4X;;8S
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MN&%5\K VM$3QR/3WK7@D6*.<)E6D7A"/O+US46A7K:5/)"LZR+(3Y1(Y)QD
M^U1>VQV1^&S&Z/J<4*R21LR*IX20_+^%;5MK(UC"Q[44 APW!/TK-AMI(4EM
MS%&S%OWBLO,?TK3BTF&.S26U=G:,=2*UIR=]3CJ129HK;I+#\\BKM)9=J9!'
M]UA_6L?4]"L26,<,<6[YBB-U/UI\FI74.XJH;S?DD8C[E20VW]IV;?NPNWA.
M<;C6K>EB53:]XYR72)HV8QMM4'_5LW6J5_J2B$;E,6TXY'6MR_A$IVR1?ZOC
M(;O6?+;"7]W,-OH<<8I&T8IF!?6W]H*6MSM;V.15=;4VPC1OWCGKN-;4^D+!
M;.+=M@]16=J44D:1EHV8CJP[5CRFYFWEP&5UPR$\ BLY6^SLO.]NY)SBMRWA
MB$;9=)&?]*R;VP:";E55?[PK,Z*>Q%<RL55MJ':?X3520K(^X!>>OS<CZ5<N
M8\Q;1-\Q[8JDJ&U;!5?F_B]*DZH[$5RK+]WS-OUJ"\*QD+^]*A<<FK7G2,<8
MW#Z50U-O,)Y<4TKC/W:_X(_'/_!-WX6XZ?8KG_TMN*_/7_@XJ3/[;'A=O^I(
MM./^W_4*_0?_ (([C;_P39^%O?\ T*Z_]+;BOSS_ .#B]\?MP>%OFQ_Q0]I_
MZ7ZA7V^/_P"17#TC^1^9Y0[9[5]9_FSX:ASY:KN^]5BWVM\VWIQUK/MW:/:S
M'=5B*<!/QS7Q<['Z3"1K1MMCXS^=7+>XW_=_+TK+M3N'7]*T+?;CY1CWK,LU
MK6$LG/+5(?,=?N[3[5!92D#AMU3EFDFRJJH]*?,SEJ45>Y8LW$47*[OKZU&]
MJTDZLL>).O'\-.AA5WVJ/^ X[U>M+";S&/W"W7_9K55#G<4]R%=+U6\=0MQ'
M",XV@?,1ZUTV@_#>&[FW7B33,J^G!J/2Y$T\(QS+SDMCOZ5UVD:[O.]ERNWC
M<^*J+CNS&HVM(E&Y\"V-I:*BV^V-1D QC^=9S^%M)L L_EQLQ(W<#BMG5/%1
MOMD5M#YDIX(W9Q[FJL/PZGUF=6O9O*5N=J' K3GC>T3*,)M7DRA<>(+,7#6]
MG;^=*>BI@*#]:+?0+BYQ+-.RD\-!&_7ZFNIL/AUI]G&T<:LIQSAN3^--OO#]
MC8P^6-T]QV3=V_"MHR:6K,)PNRG;:):Q6G-NNY>F&^]^-20W,-JNQ56XF?KY
M8^Y[$U&GAV2Z"23LR1@X6W5L*OUJUYP4>1:1C=GYF X HY^PN5E74;>39Y\S
M#;.,K K?SJ":.XM]/5@B+$I_A[5JW=U;R2B"&/=,WY >M9.LN_GK;0LQ5C\W
MIGO43NT5&-GJ9=YJPN-9EW*R[8258CJ:HRS2>5"ZO]YLL!VK6UNQELX6N'4;
M6&Q5 YK#91]BFE5_,AX4<=3[?C67*TCKIN*5T.LW?2O$EU-M+1S@*<G@$T[6
MI6NKS:JC=&OS9YROI5;39;F:\N(YMJ^4J]1C;GMGUKH[+PTU[ K'E0,LR_RJ
M#HG)63.0TZ.X@@^S,&_<2B5,+]U&.#4MSIL5CJ(DC5_)D)*L3R6':NTD\.BR
MG,VU\; F3_$.PK$DTR2\U.,>3NC@!.T=FHI_%8*U9.&I-X)622_,DVY78]37
M6^*-)CN[!G;#*T> ?0US^A+]GU!>^#@@UV%U;IJ#"W4D+& SG''7&*ZN5.-V
M>9/XTT>?60:VG2-D&5 P3W%=#I+1&[#*QC;H0.E4=7ME^U9\M@%/'^T*C>22
MWD\Z)E,8YP1S61UJ*>QZ1H^HM:F/<3,I/..U;3:PMR&B5C'GD =Q7 ^$O$!E
ME3=E5;@UVD(5K?SF95S]W YHDVD$86E9E@:IM<EE5MO&35JWOFAD5OO0MU]J
MPXF;SF+[E7/IG-7%N-LJ^06\OOE<USTZG<WJ4UT-IY8(;:1L0[G^Z2.36')<
M6XR[LS-V-)J6IL(69EDD<=., 5S5Q/)J:_O6:-.P!QBIK5MM#*G1W#Q'KC0-
M*-NYLG:*XF3SM=G\F0,T<CY9_P"Z/05VGV!?*8-R>@+<Y%5H[*.Q15C3&3DY
M[UCS!%Q4K):G0:%H*Z7IL:P_+'P0!]*S/%VG1SHWRX;(YK8M=4+:="0NU>F*
MS-=D^UQLR_+SU-=3C!PO%$2E*]WN<EX?M%M_$=Q;[F1;I?N^K5<\7^$C%8MY
M:XF0@H.Q;N:AN(]NH+<#Y9(VR,&NNU:V&N>'%FCRLNT''?/>JH133N14DTTS
MR75+5SJEOYS;9>,;N]0W++:W\BO$6:,;EQ_%7>:_X334-/AFD_A4Y;'*FN7E
MT?S+A9-W[Z'C!]/6L9Z'=2J1>Y3T:_668[6"QR< 'M6QHQ56D=@LL2G;C/(/
MJ*R;[PO(87FM^J_ZQ%Z@>M7-"C6#3UF^_'G;D?UI>TDMF*I3O\)TEC90S >9
M&V&/(]/>K0@O-+F!A8SVY.!NZJ*H:7K:KAV&Z-?E9>];UC,# <-D,<J<=/:M
MJ=1RT.&5'E>H^#5,I^_62)SPC"G2:P%.WSE;V:M1!')"RKM:3 !1AR?I69=:
M-'>>9M7=M'(QRIK?5:$<D7K8CN)24  D&[G '%4Y-1NM/5MP69,=#U%3M8WE
ME;XAD69.ZM]X5ER-+),5:-E/0YK&I)FD8I:%A=>6X/S ?0&L^YOY)I\[C)M[
M9^[1-:QP[I(SF3N"<5FWLLA?Y?W>?O8/6N5S;W.A4TQNJZMMF\M5^8\D5C:@
M\4P!95;V]*EU1IDDW+M4^IJCMQ%DC=GWJ>9LWC32U*-SI\<I)7Y>?2HDM!%G
MU]?6K;,ZM\NY?:FAVW#<I-2=*V&BVS#QU%8]^=C,O4X]:V+N;:&_AP/SK!OI
M&R6]JSE%,Z*<4]#G]:&4YXYKD];G,,G7\JZK5WWP?,OXYZ5QNN/Y4O'3WK2G
M%&D]K%%RS]/NMTQ_6OW$_P"#=2R:Q_8$U!6ZMXOU!OSBMJ_$3P_!YU\J[<K(
M^TU^Z'_! 6S^P?L-WT7]WQ7??^BK>OJN'[K%6\G^A\#Q;*^$^:/F+_@OH=O[
M:'AMF&5_X0NT_P#2Z_KXXTYR&^5<JW7_ &:_5/\ X*=?\$P?'W[:'[0>C^+O
M"FL>#]/L-/\ #T.DR1ZM=7,4S2)<W,I($<$B[=LR@$D'(/'0GY_@_P"""_QB
MB_YF3X;?AJ-[_P#(E:9AE^(J8B<XQ=FR<IS;!T\'3A4J)-+5'R*DBBV8'[V*
MN6LX:TVKM7:O [DU]=I_P0I^+VWYO$?PX_#4+W_Y$JW;?\$-/BU ZG_A(?AT
M=HQ_Q_WG_P BUQ_V7B_Y&=W]LX'_ )^H^.WCWVBO& LF<2 GI4.F^(8WU"2
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M'_X(??%UI5;_ (23X=_+_P!/UYD?^2M:%K_P1$^)EO N[7O 4DV223?7>/\
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M[0D_X(9_%PM\OB+X<C@C_C_O/_D6LR]_X(-_&2[D8_\ "3?#;:QR =1ON/\
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M@?\ GXCX/UJVQ#C.<\UCVT+6;LR?Q$*W.-HSUK[SNO\ @A!\8+M-K^)/AO\
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M[(Q?_/MG7_;67_\ /U'R@FBPVDN]UVX8;EQ]ZMF"P40R2P'Y<;MOI7U9;_\
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MVV_X.)/@K=2K&GA7XJ%B,_\ (-L./_)RKUI_P<#?!F]9@OAOXFC:.=VG6/\
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M?^#=5DM=2TN^T^X4[?(N[=HY$/?J/Y58M[AIT">6W[MQN9N^:_5GX&:II_\
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M( Z_2J,<4C#=_P \\L3]T-Z?6HE)IFD8I[FD;M8/]8LC>< WTI!#);W/WB)
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M_P#PNS6M+_X*J7*3:I>R60U$Z-]D64^7Y!C^4;<XX9MV<9KC?^"HW@R/P?\
MM(RS:?'!:P^(=/CGG6-<9E4D,Y]SQ^556P]*-)U:=_=ERN_YCP^,JSKJC52]
MZ*DK?D_\SYLU.[FE$\ZX5Y"3^?\ ^JLW0O,;:+@[BA.2*N72D/M63*&%0,_W
MQTJW'IL.GW05?F9U&\GD;^]>+*[=SZ".BL+;7<J:G&EOPK'//I6TACF19)3\
MS*>E9".4\EN/.16#$<"ET]C);[FR5CSCFNB,E;4Q<'<T) EG:21[5"W'+;>W
MI0MZ$C4^6TG/S!NW%5;V^6.1T\L*I(;/O3;J^BFO6D>9A^Y+[5Z9'%4^6URH
MQ:9&)1+;.\<?EGS0,@^]17BJM])N\S"X)J&RE(#2?-Y:L&X;&3FG&>XFENF\
MK<'P.O2N7VRD[1-G!I7+>QHI V8VW#<GJ![T10MY_G-Q(R$?K5/^T_L'E)Y*
M[IEVY/48]Z'NY+."-9&W-DX]A6G,B>5E^TGD22.U_C9<D^E.>1FBGN"RB6)L
M$>HK.CUUM/OG9!&QD3:=PS@>U6+34(]59\QK&[=<# -2ZB0^5EB[F6^N%;;P
MS$#'O3;<XO\ YOEAWY;W%56.V9GW?NX&&X+Q\PJ198YD&5DSG/7J*/:)Z!RL
MN/<M!/,T#?N@A(SZU#;3_P"EEI&4^6F]?<T&\\B;RU12K#H1UJ.$()QOC5=O
M(_\ KU,I);C]FRY%,L+0S1R8,V=P]*5M4:WB*G$B^9D^U95K,D;EL?=)VXZ#
M-27+_:+4;6559^<=:I35A<K)B5AN+ABVQ9),_I5>.19]/9^%6/.:;++_ &C;
M-#T96R#ZUFN/LX^SQ>9ME^]N.:4I7V+BNY>L]2C$D*PQ^8&SEJ=$?**E3_%D
MBJMO"]EM:-2JK\HSTS2V\@A.V0EGY(YJ;A*UC7M;E;<3,R_ZP<5/&'2UBED;
MY9/W87]:K"ZP^PJNT)NZ412+=RV\GV@;5?<BXX!]ZNYCRLOK<M,_R1J9-^Y6
M/\.!5OR(WCN(UNI%N) ID&/E('-8J2M#?R$,S*2$)7CWXK0@1-*FAD9I)8\$
M,"V2<^IHC*^B)EIN"WRMY>XF0J&&:PUO!-*(67Y)E/Z&MJ:YBLD6*15"R!W0
MXY&36'?2QJMNL7R-",9;G.>34U-AQUU(=2MHX[J1TZ%57]*P7:2UF:/^&%#&
M1]:W+Z)FM?W:_P ?4]\5S^L++%J5S(P.)"';'J*XY;FT96+>E2PQRQJT?S0H
M03^%8S&2';C[JBKGVB0V]Q<*OR2 *OK5>V;REF9HV:-.,$\UG+49/IC_ &CR
MQM4B3.[=_2DN4627R<.D8;)(HM+9FMUX"S1G*CMSZU/J$$D,2!@S&3J4.,4U
M%J)G?WC%NYHWADW22#RVVK[BLJ]N887D;S'95 P*N:_=L+A8?+Z=<"LR2Q#S
M3\MM8 [<^U9\KN;1DD4K>]S%M$C%78D!A5JW0K(%\N-O?TINDZ;]I@W2E048
M[ 5Z5I6WDM/]W=)T.#Q2Y6:<Z$F@^9-R"1O[]0&#$)9FW-SS5B_D";F#$;?N
MC-5Q<38V!%V]2<=:<I6W".YGS76YBK?*/6JJ7,8D^]^8JU=#[0S"';N49((Z
MBLU_W&XR1J6?[N#]VL^:^J.A,6_B#_</RU%;1M#MQTW9-2VJXMV9?7G-(TZ@
M?+][J<TPEJB+4'$MP[,>%&*_5_\ X(#QB+]CWQ-COXSNC_Y(V%?D;J4S#S"K
M=3\V:_6__@@!(9/V./$V?^ASNA_Y(V%?2<,_[XO1GRO%47]1;\T?F#_P76U*
M/P__ ,%2/BQ=L-TC#244_P#/,?V199(KY0TR1I@J^6S1IM8,1]_/-?2G_!>9
M&N/^"M/Q4#*'@C_LC.>@/]CV/'T/I7SKILY,4:M&JKP-J]CZ#VKTL=_%EZO\
MSDRM_NH>B_)'KG[*JR2_'OP>VQ4V:U:KM]1O%?IE_P ' TXA\3_#?YU5FM[@
M ;N3SV%?FG^S1\8]2_9_^+.E^,-,TS1]0U3227MX-5MC<6JOC"R; R_,O4'/
M!K[#N_\ @M'\4OB#+'_;'ASX9:A-;?ZF2YT%IVA_W=\AQ7#3K45AIT:C:<FN
ME]OF=];"XB6+IXFE%-036KMO\F?7/_!-+0YOV0_^">OBCQIXPAETVVU,S:NE
MK,/*F\M8_+08;^*0J"HZG<*^=OV*?V,X?B+^S)XQ^)'B_P 9>+M%^'</VJZN
M-&\/SE)]2$()D>13\C="H4J2<=17B7QQ_:^^(G[3D C\9>()KS389/.@T^!1
M#:P-[1KUQQC<3CM75?LT_MY>/_V7O!VH^'_#[Z+?:'?.9C9ZM:FXBC8C#;0&
M7 ;N#D&CZ]AI5(0DGR0BTN]WU:OMY7,(Y?C%"=6$E[2<DWVY5?1-K?SL?;O[
M .I^#?$G[ /CJY\&>$]8\,Z+-'>J#JEW]JDU'$3#S=VU5QCC &!7S5_P1O\
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M 3VH^)W_  4=^)?Q5TBZTG6HO"-[8W%N8I6ET1#)$&&"4<L2K>A'2L7]GO\
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M1_+L /-8N3A\)K[1$NH7&V6 Q?-AB&I+.874LSYPV[!I+6V:1?F;;M)/UJ)
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ML5VMGDGC'OBL8RTNS1I7L7KJ95N7V_>]*IVUZ(0R$MC.1_LU*CXO&F9M^T$
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M\%E/C N?D4Z+V_Z@FGUX5IZ;[>,AD=2/<5[=_P %Z$W_ /!9WXQ+-N>/.BE
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M_)ME^N6/84V*>1+7'5>C _TJE)=JMJT>_<,]#ZUC4J:&E.GJ3Q7T8;.PL5&
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MFC^7@,1_":PXWDLW5MS$+R3C!Q2W.JR-;-Y+;L'+%>C5T<Q/*=!A!%#M4,S
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M5SFA+I^H32I"9.7*8'L:6[N/LT\8F7YAU8]JKO>1Q/ .K$]!UJ:\B-Q=G<<
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M0N_LR+A D/\ $>N:X/Q8(WU+Y$^5CD 'K7;:Y&OV"1?M321X^4L.<UYY>/\
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M,^9XJ_W)^J/SA_X+?N(O^"F?Q,D^;>ATH#CM_9-G7Q\<VK-+U;/RX]Z^Q?\
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MF/5=5;<O[MLEQGK[4XT)=0=;4ZS18V@MX2'/;> X&% ^]5O5=1*W+K'EX[P
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M.TEXTTN1+_"OOBNATRT1Y(S)-YB]#L7G%;>R*NC95D,2W!NO]+V[58MYF/\
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M=D**9ATXQ7RQ_P -+>-3C_B=/\K;A^XBZ_\ ?-3C]J?QV)0_]N-N'?[-%_\
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M_%]GPCD=ANK\Y+;]I[QU:8V>(KKY3D;D1OYBK3_M<?$*08/B.XVYS@0Q8_\
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M(VE>&V8G/-J__P 74-S^W9XJNKOSFTSPZLF"N5MG7@_\#KQ.BG_9V&_D1/\
M;&-?_+QGL47[;'B>$-_Q+?#[;QM.ZV9N/Q>HG_;-\3,)@+#05^T##_Z,W/\
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M5-5_:E9*SFSG_L?#M^["-O0^:M/_ ."0_P )9 OVB/Q5",99WU(+^GEU+/\
M\$@_A#C,!\33+GAEU1=N/^_=?2XL)IF\^ZF,\;#&5.%_+K5Y(8[6..3$:0YZ
M#C=4?VEB/YW]YI_9&%M=TU]Q\J+_ ,$DO@^)U$T?BJ&/NYU,%3]/W?2ENO\
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M84444 %%%% !1110 4444 %%%% !1110 4444 %=E\ =W_"U--VKN.). /\
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M'6K>ZO;?RR5E2,Q ^F!SC\Z\3_X*%PW$7P%NH_+N/*ANK8.TS[C]\XYP*]#
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M."N?!B7K2&^G:1E&42)LKGWQ45MHJV,!W1QQD'@*.,5VWBD2/?&18U'D@+L
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M,9%^RG<OG$2'_9)YQ7USXB_X)G?'+4]+DA'@4R9V;%_MK3P1@DD9\^N1O?\
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M?\O-7&_X(D?M(+:R-'X!RSJH\N37M,.#SG!^TXKT;XA;0E]S//K2P3?\2/\
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M66US3<M_Y,?SJ2U_X)"_M#6)CEC\!R^<2&D UW3,'U'_ !\UE*CBGO"7W/\
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M_P#(TEF&"ZU8_P#@2_S/F+<T$+?:I/F;!V,.1^';/I4EC'<7=R@:)HU)Y"9
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MQ4ZD8OJT>7W'_!9K]FNU=5D^)!5FZ#_A'M5_^1J7_A\Q^S9C_DI'_EOZI_\
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M+_P5<^ ,)^;Q[C_N":C_ /(]?CVY8V+/A7VGK67>QQW#M,)%R1C92_UHQ?\
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M)^2>E_S/1/AQ^P#\2OB3\(=;\<+I\.A^']%LI;\3ZF6A:^2-2S") "Q.!P6
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MCQ-FK']6E%%%?J1^*A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KRG]NTX_8@^,G_8C:W_Z03UZM7E/
M[=HS^P_\9/\ L1M;_P#2">LZW\.7HS;#_P 6/JOS/YM=-C\OYNOS9KJM'O#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;(V?F '05O:;<7#2Y^4AN@!^:M*9G)\IT,$*B-_EYZ9J.ST_]Q,ZLWF YY'
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M-VMQ!(,L&7N?6DTVX\^'!;;G&<FLJ:5R[WC8Z:WE6'C=C:!G!ZU=@G%VN58
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M8^)$\J-)N6WA7Y7).7?Z"J^D>(+[5[IFC9K>S X;;\Q/M6?<68N!')Y*.R]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ(S_ -JWWV6V#[HQSG[M4]'U:\\5W:PVJ[DZ/)VKKM'\.3:8IC$:H&8;YAU
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M'PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8MRJ%V]SBFNJ!2V-V.WK7EGM>S/ZA****_4#\7"BBB@ HHHH **** "BBB@
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MRUHK]4?#_P"SMX UNSA\SP'X3,G(81V*#CL<^M4=<_9=\"Z=<--;^#O#;(V
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M<*M-_"-O]:U)=(CG&R2%5Y()QR#]:/[<Q?\ -^"_R#^P\N>B@_O?^9^;Z_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830242656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 20, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EOLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EVOLUS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001570562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828334672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 93,162<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Related party receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,639<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">94,339<span></span>
</td>
<td class="nump">72,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset</a></td>
<td class="nump">56,076<span></span>
</td>
<td class="nump">56,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">171,844<span></span>
</td>
<td class="nump">152,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,718<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">138,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,276<span></span>
</td>
<td class="nump">212,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders, a related party</a></td>
<td class="nump">50,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders, a related party</a></td>
<td class="nump">16,904<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">14,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">87,460<span></span>
</td>
<td class="nump">227,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 27,274,991 and 16,527,000 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">207,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(123,025)<span></span>
</td>
<td class="num">(75,543)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">84,384<span></span>
</td>
<td class="num">(75,543)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">171,844<span></span>
</td>
<td class="nump">152,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830983344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 12, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818391632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,487<span></span>
</td>
<td class="nump">$ 6,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,146<span></span>
</td>
<td class="nump">4,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty', window );">Revaluation of contingent royalty obligation to Evolus Founders, a related party</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">46,142<span></span>
</td>
<td class="nump">11,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(46,142)<span></span>
</td>
<td class="num">(11,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(863)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(46,802)<span></span>
</td>
<td class="num">(11,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(7,251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,867)<span></span>
</td>
<td class="num">(4,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (46,867)<span></span>
</td>
<td class="num">$ (4,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">24,402,368<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of Contingent Royalty Obligation Payable to Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RevaluationofContingentRoyaltyObligationPayabletoRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6831047136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>IPO</div></th>
<th class="th">
<div>IPO </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>IPO </div>
<div>Additional Paid In Capital</div>
</th>
<th class="th"><div>Follow-on Offering</div></th>
<th class="th">
<div>Follow-on Offering </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Follow-on Offering </div>
<div>Additional Paid In Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="num">$ (7,106)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 59,700<span></span>
</td>
<td class="num">$ (66,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Capital contribution from Parent - therapeutic option right, net of tax</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to Parent - note obligation</a></td>
<td class="num">(66,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,791)<span></span>
</td>
<td class="num">(4,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="num">(75,543)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable', window );">Deemed contribution from Parent, increase of related-party receivable</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to Parent - note obligation</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,385)<span></span>
</td>
<td class="num">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Capital contribution from Parent, convertible note write-off</a></td>
<td class="nump">66,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="nump">13,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock conversion upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="nump">2,065,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,446<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 53,445<span></span>
</td>
<td class="nump">$ 67,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="num">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">$ 84,384<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 207,408<span></span>
</td>
<td class="num">$ (123,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Contribution From Parent, Increase Of Related-Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830856592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (46,867)<span></span>
</td>
<td class="num">$ (4,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,971<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_InterestExpenseOperatingActivities', window );">Interest expense</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(6,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_TaxBenefitFromTherapeuticOptionRight', window );">Tax benefit from therapeutic option right</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent royalty obligation to Evolus Founders, a related party</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(992)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="num">(2,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,667)<span></span>
</td>
<td class="num">(13,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting fees</a></td>
<td class="nump">56,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees</a></td>
<td class="nump">67,680<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party borrowings</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">14,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding paid on behalf of employees for stock-based awards</a></td>
<td class="num">(239)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">118,838<span></span>
</td>
<td class="nump">13,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and restricted cash</a></td>
<td class="nump">93,162<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">93,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Related party receivable</a></td>
<td class="nump">73,690<span></span>
</td>
<td class="num">(72,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="num">(68,767)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashNoteObligation', window );">Note obligation</a></td>
<td class="num">(140,688)<span></span>
</td>
<td class="nump">138,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentRoyaltyObligation', window );">Contingent royalty obligation payable to Evolus Founders, a related party</a></td>
<td class="nump">39,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentPromissoryNote', window );">Contingent promissory note payable to Evolus Founders, a related party</a></td>
<td class="nump">16,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionConvertibleNoteWriteOff', window );">Capital contribution from Parent, convertible note write-off</a></td>
<td class="nump">66,998<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashCapitalDistributionFromParent', window );">Capital distribution to Parent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="nump">13,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionTherapeuticOptionRightNetOfTax', window );">Capital contribution from Parent - therapeutic option right, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeferredOfferingCostsAccruedUnpaid', window );">Deferred offering costs accrued, unpaid</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(2,885)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountsPayablePaidbyParent', window );">Accounts payable, paid by Parent</a></td>
<td class="num">$ (163)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountsPayablePaidbyParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Paid by Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountsPayablePaidbyParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionConvertibleNoteWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Convertible Note Write-Off</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionConvertibleNoteWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Forgiveness of Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionForgivenessofRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionTherapeuticOptionRightNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Therapeutic Option Right, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionTherapeuticOptionRightNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredOfferingCostsAccruedUnpaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Accrued, Unpaid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredOfferingCostsAccruedUnpaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_InterestExpenseOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_InterestExpenseOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashCapitalDistributionFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Capital Distribution From Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashCapitalDistributionFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Deferred Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashNoteObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Note Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashNoteObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Related Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_TaxBenefitFromTherapeuticOptionRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit From Therapeutic Option Right</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_TaxBenefitFromTherapeuticOptionRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821306080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Organization</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. On February 1, 2019, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved the Company&#8217;s first product Jeuveau&#8482; (the &#8220;Product&#8221;). The Product is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company is headquartered in Newport Beach, California.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company&#8217;s board of directors and its then-sole stockholder approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a split of shares of the Company&#8217;s common stock on a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.6527</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-for-1 basis (the &#8220;Stock Split&#8221;). The Company&#8217;s then-outstanding shares of convertible Series A preferred stock (&#8220;Series A preferred stock&#8221;), the par value of the common stock, and the authorized shares of the common stock were not adjusted as a result of the Stock Split. All issued and outstanding shares of common stock, stock options, restricted stock units and related per share amounts contained in the financial statements have been retroactively adjusted to reflect this Stock Split for all periods presented. The Stock Split was effected on January 26, 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock, which included the exercise by the underwriters of their option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> additional shares of common stock, at an offering price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> after deducting underwriting discounts and commissions, excluding other offering costs. In connection with the IPO, the Company&#8217;s then-outstanding shares of Series A preferred stock were automatically converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock. In connection with the completion of its IPO, the Company&#8217;s amended and restated certificate of incorporation was further amended and restated to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share.   </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Company completed a follow-on public offering (the &#8220;Follow-On Offering&#8221;) in which the Company sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock in August 2018, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from the Follow-On Offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the completion of its IPO, the Company also entered into a services agreement (the &#8220;Services Agreement&#8221;) with ALPHAEON Corporation (&#8220;ALPHAEON&#8221; or &#8220;Parent&#8221;), its controlling stockholder. The Services Agreement sets forth certain agreements between ALPHAEON and the Company that govern the respective responsibilities and obligations between ALPHAEON and the Company as it relates to the services to be performed between the parties. Pursuant to the Services Agreement, ALPHAEON provides the Company, and the Company provides ALPHAEON, certain administrative and development support services. Prior to the IPO, the Company was dependent upon ALPHAEON for its working capital and financing requirements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON, which is majority-owned by SCH-AEON, LLC (&#8220;SCH&#8221;), owns&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of the Company&#8217;s outstanding shares of common stock.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Financial Condition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he Company incurred operating losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Additionally, the Company used </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in cash for operations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in cash and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">has an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. On March 15, 2019, the Company entered into a term loan facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (see Note 11, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain market acceptance of its product and achieve a level of revenues adequate to support its cost structure, and operate its business and sell products without infringing third party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes that its current capital resources will be sufficient to fund operations through at least the next twelve months based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of its equity securities, incurring debt, entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs and other operational goals.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809512736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The financial statements for the periods prior to the Company&#8217;s IPO have been prepared on a standalone basis and are derived from ALPHAEON&#8217;s consolidated financial statements and accounting records and included an allocation of certain assets and liabilities that have historically been held at the ALPHAEON corporate level but which were specifically identifiable or allocable to the Company. . These results reflect amounts attributable to the Company&#8217;s business, including the costs ALPHAEON incurred for the development and commercialization of the Product and costs and expenses under the License and Supply Agreement (the &#8220;Daewoong Agreement&#8221;) entered into with Daewoong Pharmaceuticals Co., Ltd. (&#8220;Daewoong&#8221;), a South Korean pharmaceutical manufacturer, in September 2013, as further described below in Note 5, C</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">ommitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO, ALPHAEON charged the Company external and internal administrative and research and development expenses that ALPHAEON incurred on the Company&#8217;s behalf. External research and development expenses charged to the Company included costs for contract research organizations (&#8220;CROs&#8221;), costs to conduct nonclinical and clinical studies on the Product, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON charged these costs to the Company at the same amount that ALPHAEON incurred such cost. Internal development expenses included costs for the work that ALPHAEON development employees perform for the Company. ALPHAEON charged the Company a full-time equivalent (&#8220;FTE&#8221;) rate that covers personnel-related expenses, including salaries and benefits, plus an allocation of facility-related expenses, including rent, utilities, depreciation, insurance and property taxes, for those research and development employees who work either directly or indirectly on the development of the Company&#8217;s drugs and certain administrative employees. ALPHAEON calculated the facility-related expenses to the Company based on a percentage of aggregate expenses incurred at ALPHAEON. ALPHAEON calculated depreciation expense of property and equipment using the straight-line method over the estimated useful lives of its assets of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, the Company historically incurred related party borrowings from ALPHAEON for its share of the internal and external expenses for each of these functions based on the Company&#8217;s relative use of each function, plus an allocation of facility-related expenses. The Company&#8217;s management believes that the allocation and results were reasonable. As of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">, the Company did not have any accounts receivable or payable with ALPHAEON pursuant to the Services Agreement or otherwise.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has calculated its income tax amounts using a separate return methodology and has presented these amounts as if it were a separate taxpayer from ALPHAEON in each jurisdiction for each period the Company presented. Subsequent to the IPO, the Company will prepare a stand-alone tax return. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not have a tax sharing agreement with ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus was formed in November 2012 for the purposes of developing the Product for distribution and sale. In October 2013,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in a Stock Purchase Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH acquired all of the Company&#8217;s outstanding equity in exchange for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Class AA units of SCH and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Class D units of SCH, which resulted in SCH obtaining a controlling financial interest in Evolus.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the transaction with SCH, Evolus had executed a License and Supply Agreement with Daewoong and thereby secured exclusive rights to license and distribute the Product for aesthetic indications in the United States and certain other international markets, as well as non-exclusive rights to distribute in Japan (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 4, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The acquisition of the Company, which represented a business combination by SCH, was to provide SCH and ALPHAEON access to the license held by Evolus to develop, produce and market clinical neurotoxins. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In a series of related transactions in 2013, SCH acquired all of the Company&#8217;s outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed equity that it had acquired in 2013 to ALPHAEON. As a result of these transactions, the Company became a wholly-owned subsidiary of ALPHAEON.  The Company remained a wholly-owned subsidiary of ALPHAEON until the completion of the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH elected to apply push-down accounting pursuant to the guidance in ASC 805, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Business Combinations</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Accordingly, the financial statements reflect the new basis of accounting established by SCH when SCH obtained control of the Company in October 2013. The assets acquired and liabilities assumed in connection with the acquisition were recognized based on their estimated fair values at the acquisition date. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates.&#160;The estimated fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition, SCH and ALPHAEON entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) pursuant to which they were obligated to make certain contingent payments to the Evolus Founders. However, since Evolus did not have an obligation associated with the contingent consideration arrangement prior to the Company&#8217;s IPO, no amounts were recognized in the Company&#8217;s financial statements for the contingent royalty obligation arrangement between SCH and ALPHAEON, and the Evolus Founders. As described in Note 4, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, on December 14, 2017, SCH and ALPHAEON entered into an amendment to the Stock Purchase Agreement (the &#8220;Amended Purchase Agreement&#8221;), and the Company joined as a contractual party. Upon the closing of the IPO on February 12, 2018, ALPHAEON immediately and automatically assigned to the Company its payment obligations under the Amended Purchase Agreement. These payment obligations are referred to as the &#8220;contingent royalty obligation payable to Evolus Founders, a related party&#8221; and the &#8220;contingent promissory note payable to Evolus Founders, a related party&#8221; in the accompanying balance sheets. Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&#8217;s former Chief Operating Officer. Mr. Marmo was retained as a consultant to the Company until December 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">royalty obligations, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although it has received the regulatory approval from the FDA and Health Canada, the Company has not commenced principal operations in the form of commercialized Product sales. The Product also requires regulatory approval from the European Medicines Agency and other similar regulatory authorities prior to commercial sales in the related jurisdictions. The Product and any future product candidates of the Company may not receive necessary approvals in the jurisdictions where approval is sought. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of the Product and any future product candidates, ability to obtain regulatory approval of the Product and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company relies on Daewoong, our exclusive and sole supplier, to manufacture the Product. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of the Product. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reporting unit. There has been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The intangible asset in the accompanying balance sheets represents IPR&amp;D projects acquired that have not yet been completed. IPR&amp;D assets with indefinite useful lives are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the IPR&amp;D assets are either amortized over their estimated useful lives or written-off immediately. There has been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Offering Costs</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Deferred offering costs, which primarily consisted of direct incremental legal and accounting fees relating to the IPO or Follow-On Offering, are capitalized until such time as the offering closes. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of deferred offering costs were offset against proceeds from the sale of registered equity securities in the Company&#8217;s IPO and Follow-On Offering. As of December&#160;31, 2018, the Company did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t capitalize any deferred offering costs. As of December&#160;31, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of deferred offering costs were capitalized and included in &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; in the accompanying balance sheet.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Joint and Several Liability Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has (i) agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amounts that the Company expects to pay on behalf of its co-obligors. The determination of the &#8220;best estimate&#8221; from within the range of amounts that might be paid involves substantial judgment by the Company&#8217;s management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no reimbursements of research and development expenses during the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At each financial reporting date, the Company accrues and expenses the estimated costs of clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates based upon a review of the agreements, data collected by internal and external personnel regarding the progress or stage of completion of trials or services. This progress or stage of completion of trials or services is monitored pursuant to contracts with clinical research organizations and other service providers. The agreed-upon fee to be paid for such services is based upon facts and circumstances known to the Company at each financial reporting date. If the actual performance of activities varies from the assumptions used in the estimates, the accruals are adjusted accordingly. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Payment Obligation Payable to the Evolus Founders, a Related Party</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in the non-current liabilities in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders, a Related Party</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company assumed the liability concurrent with the IPO and determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees and members of the Board of Directors based on the fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of actual forfeitures, when they occur.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units are based on the fair value of the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Compensation cost related to the grant of awards to the Company&#8217;s employees is recognized as an increase to additional paid-in capital in the balance sheets and in the general and administrative or research and development expenses in the statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the IPO, the ALPHAEON common stock awards were valued at fair value on the date of grant and that fair value was recognized over the requisite service period. Estimates were used to determine the fair value of these awards, as shares of ALPHAEON&#8217;s common stock are not publicly traded. ALPHAEON common stock awards are subject to specified vesting schedules and requirements. The Company estimated the fair value of each ALPHAEON option on the date of grant using the Black-Scholes model. Stock-based compensation expense is allocated to the Company over the required service period over which these ALPHAEON common stock awards and options would vest and is based upon the relative percentage of time utilized by ALPHAEON employees on Company matters. These ALPHAEON awards were recognized as a capital contribution which was recorded in the statement of stockholder&#8217;s equity (deficit) and a corresponding entry was recorded in the accompanying statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the effects of common stock equivalents such as convertible preferred stock and stock options outstanding. Diluted net loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issued common stock were exercised or converted to common stock. Dilutive common share equivalents are comprised of convertible preferred stock and stock options outstanding during the period, but are excluded if their impact is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-18,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires transactions in collaborative arrangements to be accounted for under ASC 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company will adopt the guidance on January 1, 2019, and does not expect such adoption will have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2021. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU 2018-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;ASU 2018-13&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the FASB issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">, Compensation - Stock Compensation - Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this ASU clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2019. The Company is in the process of determining the effects the adoption will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the FASB issued ASU No. 2018-07,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2018-07&#8221;) which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2017-09&#8221;) which amends the scope of modification accounting for stock-based payment arrangements.&#160;The amendment&#160;provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company adopted this guidance effective January 1, 2018 and this guidance did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2017-04,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles&#8212;Goodwill and Other (Topic 350</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">):&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This standard simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for us beginning January&#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU 2017-01,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Business Combinations (Topic 805)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Definition of a Business</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies when transactions should be accounted for as acquisitions (or disposals) of assets or business. ASU 2017-01 is effective for us beginning January&#160;1, 2019. Early adoption is permitted for transactions not previously reported in issued financial statements. The Company is evaluating the effect of this standard on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that supersedes the current lease guidance under </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases, (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard requires lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The new accounting standard will be effective for the Company starting in the first quarter of fiscal 2019. The Company will elect the transition package of three practical expedients permitted under the transition guidance and will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods. Further, the Company will elect a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company will record right-of-use assets and liabilities and the corresponding deferred tax assets and liabilities on its balance sheet as of January 1, 2019, primarily associated with its operating leases. The Company is also finalizing the impact of the standard to its accounting policies, processes, disclosures, and internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2016-13&#8221;), which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. We are in the process of reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821279104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Asset</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Goodwill and Intangible Asset</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill and an intangible asset were established as a result of the application of push-down accounting in connection with the acquisition of the Company by SCH in October 2013, as described in Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">, Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The purchase price was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the excess of which over the fair value of net assets acquired was recognized as goodwill of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;Goodwill recognized in connection with the acquisition is not deductible for tax purposes. The net assets acquired as of the acquisition date comprised solely of IPR&amp;D valued at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and a deferred tax liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which represented the difference between the book and tax basis related to the IPR&amp;D asset. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The IPR&amp;D asset related to the development of the Product in clinical trials in the United States as of the acquisition date. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the carrying value of the IPR&amp;D, included in intangible asset in the balance sheets, was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the carrying value of goodwill in the accompanying balance sheets was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The estimated fair value of the IPR&amp;D asset on the acquisition date was determined </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">using a discounted cash flow model using an income approach (the multiple-period excess earnings method). Significant assumptions used in the valuation included projected future cash flows, projected costs, a weighted average cost of capital and appropriate discount rates.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The IPR&amp;D recognized represents the license and associated distribution rights to develop the Product and the ability to pursue new indications and is subject to the success of clinical studies. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of the transaction, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in additional cash consideration is due to Daewoong based upon Evolus&#8217; successful completion of certain technical and sales milestones. The fair value of the milestones was recorded by the Company as an element of the acquired IPR&amp;D at the acquisition date.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Through 2018 the IPR&amp;D asset is classified as an indefinite-lived intangible asset. With the recent FDA approval of Jeuveau, the IPR&amp;D is no longer considered an indefinite-lived asset and amortization of the asset will commence in 2019.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809505104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Services with ALPHAEON</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO and since the Company&#8217;s acquisition in 2014 by ALPHAEON, the Company had funded its operations primarily through contributions and related party borrowings from ALPHAEON. ALPHAEON has historically provided Evolus certain services, including, without limitation, research and development, general and administrative support services and support services. ALPHAEON had historically allocated a certain percentage of personnel to perform the services that it provides to the Company based on its good faith estimate of the required services. These allocated costs reflect the ALPHAEON FTE rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing Evolus these services. Evolus historically had not paid a mark-up on the external or internal expenses ALPHAEON allocated to it. Prior to February 12, 2018, all research and development, general and administrative, and other support services expenses shown in the Company&#8217;s financial statements for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> excluding stock-based compensation which is treated as a capital contribution, were treated as related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company entered into the Services Agreement with ALPHAEON, which became effective upon the Company&#8217;s IPO. The Services Agreement sets forth certain agreements between ALPHAEON and the Company that governs the respective responsibilities and obligations between ALPHAEON and the Company </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as it relates to the services to be performed between them</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> The Services Agreement has a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> year term and thereafter will renew for successive </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> year terms unless sooner terminated by either party. The Company or ALPHAEON may terminate the Services Agreement upon sixty days&#8217; notice to the other party. In accordance with the Services Agreement, the Company paid ALPHAEON </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> during the first quarter of 2018, subsequent to the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Evolus had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related party accounts receivable or payable with ALPHAEON. As of December&#160;31, 2017, Evolus had related party accounts receivable and related party borrowings of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$72.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> with ALPHAEON, respectively.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the amounts that were allocated from ALPHAEON prior to the IPO, and included in Evolus&#8217; general and administrative expenses as disclosed in the accompanying </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">statements of operations and comprehensive loss for the following periods (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Compensation &amp; Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Third party service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Facility related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,906</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">After completion of the Company&#8217;s IPO on February 12, 2018, ALPHAEON did not incur any administrative or research and development expenses on the Company&#8217;s behalf.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Note Obligation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2016, ALPHAEON entered into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> separate debt transactions: (i) a convertible note with one of its stockholders, also a related party (the &#8220;Bridge Note&#8221;) with a principal amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and (ii) a Secured Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which ALPHAEON could issue up to an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;Note Facility&#8221; and together with the Bridge Note, the &#8220;Notes&#8221;). The Notes have substantially similar terms and accrue simple interest at a rate of ten percent (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) per annum, subject to adjustment pursuant to terms of the Notes. The Notes may be paid at a redemption price equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> times the face amount of the Note less any prepayment of principal and any principal amount of the Notes that may convert into shares of ALPHAEON on (i) maturity in December 2018, (ii) a required prepayment event, or (iii) prepayment at any time at ALPHAEON&#8217;s election. Upon the occurrence of certain corporate events at ALPHAEON, at the election of the holder, the Notes will convert into a variable number of shares of ALPHAEON with an aggregate fair value equaling the principal value of the Notes or such Notes will continue to maturity as unsecured promissory notes with a reduced interest rate.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ALPHAEON&#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&#8217;s assets, including all of the shares of the Company&#8217;s capital stock held by ALPHAEON, which as of December 31, 2017 represented all of the Company&#8217;s outstanding capital stock, as collateral for the holders of the Notes.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2017, ALPHAEON amended and restated the Purchase Agreement (the &#8220;Amended and Restated Secured Note Purchase Agreement&#8221;) with the Note holders to amend and restate the terms of the Purchase Agreement and the outstanding Notes and form of Notes to be issued. In addition, the Purchase Agreement was amended and restated to, among other things, set forth the terms for the issuance of up to an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in principal amount of Notes. Concurrent with the Amended and Restated Secured Note Purchase Agreement, the Company also executed two substantially similar guaranty and security agreements (the &#8220;Guaranty Agreements&#8221;), with the holders of the Notes. Pursuant to the Guaranty Agreements, the Company absolutely, unconditionally and irrevocably guaranteed, as primary obligor and not merely as surety, the full and punctual payment when due, whether at stated maturity or earlier, by reason of acceleration all the obligations of the Notes. In addition, pursuant to the Guaranty Agreements, the Company agreed to a first priority lien and security interest in and to all its right, title and interest in the assets of the Company. As a result of executing the Guaranty Agreements, there was no requirement that the holders of the Notes first seek payment from ALPHAEON. Instead, they may demand payment from the Company, from ALPHAEON or from both simultaneously. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements stipulate that any payment by the Company under their terms shall result in a dollar-for-dollar offset and reduction in the amount of related party loans owed by the Company to ALPHAEON. The Guaranty Agreements will terminate upon the earlier of (i) the date on which all secured obligations under the Guaranty Agreements have been paid and performed in full and (ii) the date on which the entire outstanding principal amount of the Notes has been either converted into equity or unsecured notes pursuant to the terms of the Notes.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Concurrent with the execution of the Guaranty Agreements with the holders of the Notes in April 2017, the Company jointly and severally agreed to pay the redemption amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> times the principal amount of the Notes upon maturity if not paid by ALPHAEON. As a co-obligor to these Notes, the Company applied the accounting guidance provided in ASC 405-40, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Obligations Resulting from Joint and Several Liability Arrangements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This guidance requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount that the entity has (i) agreed to pay on the basis of its arrangement with its co-obligors and (ii) any additional amount that the entity expects to pay on behalf of its co-obligors. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company initially recorded a liability and corresponding deemed distribution to ALPHAEON as a reduction to additional paid-in-capital in equity in April 2017 to reflect the joint and several liability. These amounts were subsequently adjusted to reflect changes in the balance of the Note obligation.  As the Company and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, the Company developed a range of amounts that it expected to pay under the Guaranty Agreements and selected the amount from within that range that it determined to be the best estimate, which equaled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$138.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, the Company and ALPHAEON entered into amendments with the holder of the convertible bridge note, and with the collateral agent for the holders of the convertible promissory notes. Under the terms of the amendment it was agreed that the Company&#8217;s guaranty of the Notes and the security interest in the Company&#8217;s assets would terminate effective upon the closing of the IPO. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subsequent to December 31, 2017, ALPHAEON issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> additional convertible promissory notes, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> convertible promissory notes to Murthy Simhambhatla, Ph.D., the Company&#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the Notes increased </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> times the total outstanding principal amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) immediately prior to the IPO. Approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in excess of the then balance of additional paid-in capital was recorded in accumulated deficit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As provided for within the Amended and Restated Secured Note Purchase Agreement and Guaranty Agreements, in conjunction with its recognition of the joint and several liability, the Company also recorded a receivable from ALPHAEON, which equals the current balance of the amounts it owed to ALPHAEON under its related party borrowing arrangements. No amounts were paid under this joint and several liability by the Company in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The difference between the amount of the joint and several liability and the related party receivable of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$66.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was recorded as a deemed distribution to ALPHAEON, in stockholders&#8217; equity (deficit) to additional paid-in capital in the period the transaction with the related party was made. Approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in excess of the then additional paid-in capital balance was recorded in accumulated deficit as of December 31, 2017. In January 2018 immediately prior to its IPO, the Company recorded </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an increase of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the receivable from ALPHAEON with a corresponding increase in additional paid-in capital. The related party receivable balance increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> immediately prior to the IPO</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the Company was released of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> note obligation for all guaranty and security obligations under the Guaranty Agreements, and the related party receivable from ALPHAEON of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was settled, resulting in a capital contribution of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ALPHAEON&#8217;s security interest in Evolus&#8217; assets was also terminated. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 9</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">-Equity Related Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information regarding equity transactions that occurred in connection with the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evolus Founders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals who were previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&#8217;s former Chief Operating Officer and consultant to the Company through December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Payment Obligations Related to the Acquisition by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition by SCH and ALPHAEON, as described in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Evolus Founders were issued Class D units of SCH which contained certain rights and privileges that provide the Evolus Founders with a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> economic interest in Evolus. The original payment obligations included (i) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">perpetual quarterly royalties of a mid-teen percentage of net sales of the Product within the United States and (iii) a high-single digit percentages of net sales of the Product outside of the United States. As these future royalty streams are perpetual, ALPHAEON had the right under the Stock Purchase Agreement to terminate any future payments for a one-time lump sum payment to SCH of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$145.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 14, 2017, SCH and ALPHAEON entered into the Amended Purchase Agreement, whereby Evolus also joined as a contractual party. Pursuant to the Amended Purchase Agreement, ALPHAEON&#8217;s existing payment obligations were replaced with revised payment obligations, payable directly to the Evolus Founders, to be distributed to them ratably in accordance with their previous respective percentage ownership in Series A preferred stock, and in exchange for the cancellation of the Class D units of SCH. Pursuant to the Amended Purchase Agreement, effective upon the closing of the IPO, ALPHAEON immediately and automatically assigned to Evolus and Evolus immediately and automatically accepted and assumed all of ALPHAEON&#8217;s payment obligations under the Stock Purchase Agreement, as amended by the Amended Purchase Agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, the revised payment obligations consist of (i) an approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> up-front payment upon obtaining FDA approval for the Product for the treatment of glabellar lines, (ii) quarterly royalty payments of a low single digit percentage of net sales of the Product within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of the Product outside of the United States, and (iv) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> promissory note that will mature on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years anniversary of the first commercial sale of the Product in the United States. The revised payment obligations set forth in (ii) and (iii) above will terminate in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> year anniversary of the first commercial sale of the Product in the United States. As these revised payment obligations are not perpetual, neither Evolus nor ALPHAEON will have the right to terminate any future payments for a one-time lump sum payment. Under the Amended Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders was </font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent promissory note) as of February 12, 2018. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for more information about the Company&#8217;s accounting thereof. In addition, the outstanding related party borrowings from ALPHAEON were set-off and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations Evolus assumed from ALPHAEON, the fair value of which, as of February 12, 2018, was </font><font style="font-family:Times New Roman;font-size:10pt;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, Evolus agreed to make one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to certain of its former and current employees upon FDA approval of the Product, including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> payable to Rui Avelar, M.D., Evolus&#8217; Chief Medical Officer and Head of Research &amp; Development.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus will have the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal will become immediately due and payable at the option of the holder. An event of default will occur under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> days. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of Evolus, all unpaid principal will become immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&#8217; assets, (ii) the exclusive license of the Product or the business related to the Product to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company determined the fair value of the contingent royalty obligation payable to the Evolus Founders, a related party, was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and recorded a revaluation charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the accompanying statements of operations and comprehensive loss. The charges were driven by changes in assumptions relating to the timing of cash flows and the discount rate. The Company will revalue the contingent royalty obligation payable to the Evolus Founders, a related party, at each reporting period. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Amended Purchase Agreement, Evolus entered into a tax indemnity agreement with the Evolus Founders (&#8220;Tax Indemnity Agreement&#8221;) pursuant to which, effective upon Evolus&#8217; assumption of the revised payment obligations under the Amended Purchase Agreement, which occurred upon the completion of the IPO, Evolus was obligated to indemnify the Evolus Founders for any tax liability resulting from such assignment of the revised payment obligations from ALPHAEON to Evolus. Under the Stock Purchase Agreement, the payment obligations are contingent and are thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. The entry into the Amended Purchase Agreement would cause the Evolus Founders to be treated for U.S. federal income tax purposes as receiving a distribution from SCH of the right to receive the contingent payments in a transaction in which no gain or loss is recognized such that the Evolus Founders may continue installment sale reporting with respect to the revised payment obligations to the same extent that installment sale reporting was available to SCH with respect to the original payment obligations prior to the execution of the Amended Purchase Agreement. Under the Tax Indemnity Agreement, Evolus was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Evolus&#8217; assumption of the revised payment obligations under the Amended Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (the &#8221;Distribution Agreement&#8221;), with Clarion Medical Technologies Inc. (&#8220;Clarion&#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply the Product to Clarion in Canada.&#160; Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind ALPHAEON&#8217;s acquisition of Clarion. As a result, ALPHAEON owes the equity holders of Clarion an unwinding fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;Unwinding Fee&#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of the Product purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee ALPHAEON owes. In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Distribution Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">if the Company did not receive approval from Health Canada to promote and</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sell the Product in Canada prior to October 31, 2018, the Company was obligated to pay liquidated damages to</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clarion in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> days of December 31, 2018, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">which damages would not reduce the Unwinding Fee. In August 2018, the Company received approval from Health Canada to promote and sell the Product. Accordingly, the Company has concluded that no obligation exists and no liability has been recorded as of December 31, 2018. No amounts have been paid towards the Unwinding Fee as of December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Therapeutic Optio</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">n Letter Agreement</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 18, 2017, the Company entered into a therapeutic option letter agreement with ALPHAEON whereby certain rights to the therapeutic indications of the Product under the Daewoong Agreement were transferred by the Company to ALPHAEON. The Company recorded this transaction as a reduction of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the related party borrowings and a non-cash capital contribution from ALPHAEON, in additional paid-in capital on the balance sheets as of December 31, 2017. Once exercised, the rights to the therapeutic indications shall be solely in the control of ALPHAEON. As of December 31, 2018, the right to exercise the therapeutic option was exercised by ALPHAEON, which remitted the exercise price directly to Daewoong.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821270944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Operating Lease</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total&#160;rental&#160;expense for the years ended&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong. Certain purchase obligations or milestone payments have been excluded because they are contingent upon the occurrence of future events, including receipt of governmental approvals and our future sales in various jurisdictions, and we do not know the timing of such potential obligations with certainty. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">FDA Milestone Payments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Daewoong Agreement, as described in detail below, the Company is obligated to make future milestone payments for certain confidential development and commercial milestones associated with the Product. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In October 2013, Evolus entered into the Daewoong Agreement with Daewoong. Pursuant to the Daewoong Agreement, the Company has an exclusive distribution license to the Product from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Product will be manufactured by Daewoong in a recently constructed facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than the Product) in a territory covered by the Daewoong Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company held an option to obtain the therapeutic rights to the Product in its licensed territories which was held in trust for ALPHAEON during the fourth quarter of 2017 for a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reduction in related party borrowings. In September&#160;2018, ALPHAEON exercised the right to obtain the therapeutic option to the Product and remitted the option exercise price directly to Daewoong.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions, which have not yet been obtained as of December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. The Company is not subject to any currently pending legal matters or claims that would have a material adverse effect on its accompanying financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> amounts were accrued as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, ALPHAEON, SCH and Daewoong are defendants to a lawsuit brought by Medytox, Inc. (&#8220;Medytox&#8221;) alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain and that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture the Product (the &#8220;Medytox Litigation&#8221;). The Company believes it has meritorious defenses and intends to vigorously defend Medytox&#8217;s claims. Given the early stage in the Medytox Litigation, the Company is unable to determine the likelihood of success of Medytox&#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Citizen Petition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2017, Medytox filed a Citizen Petition (the &#8220;Citizen Petition&#8221;) with the FDA. The Citizen Petition seeks to delay approval of the Biologics License Application submitted by the Company to the FDA in May 2017 for the Product until the FDA determines the identity and source of the botulinum strain for the Product and validates the integrity of the data and information in the Biologics License Application. Medytox further requests that the FDA require the source and identity information in the Biologics License Application to include a single nucleotide polymorphism analysis of the whole genome sequence of the botulinum strain for the Product. In connection with the FDA approval of the Product, on February 1, 2019 the Citizen Petition was dismissed.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">ITC Case</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &#8220;Allergan&#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &#8220;ITC&#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that the Product is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of the Product is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;ITC Complaint&#8221;).  The ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930. The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin bacterial strain</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> into the United States and a cease and desist order which would bar sales and marketing of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Product </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">within the United Sates either of which would adversely affect our ability to carry our out our business and which would have an adverse effect on our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821275728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The carrying amounts of cash, accounts payable, and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments Not Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> contingent promissory note payable under the Amended Purchase Agreement to the Evolus Founders, that will mature </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years after the anniversary date of the first commercial sale of the Product in the United States. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with a corresponding increase to the non-current liabilities in the balance sheets. The Company measures the fair value of this contingent promissory note at present value based on Level 2 inputs, using a discount rate for similar rated debt securities and is based on an estimated date that the Company believes the contingent promissory note will mature. The fair value of the contingent promissory note could be impacted by changes such as: (i) changes in the discount rate assumed, or (ii) a delay in the first commercial sale of the Product in the United States.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company assumed the liability concurrent with its IPO in February 2018 and therefore, did not carry a contingent promissory note payable balance at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The following table (in thousands) presents the difference between the carrying balance and the fair value of the contingent promissory note payable to the Evolus founders, a related party:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.15079365079364%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Carrying Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent promissory note payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">17,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) presents the major security types the Company held at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, that are measured at fair value on a recurring basis. The Company did not hold any major security types that required a fair value measurement on a recurring basis at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Hierarchy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in non-current liabilities in the balance sheets. The significant unobservable input assumptions that can significantly change the fair value includes (i) timing of the FDA approval of the Product, (ii) projected and timing of net revenues during the payment period, which will terminate for the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> year anniversary of the first commercial sale of the Product in the United States, (iii) the discount rate, and (iv) the timing of payments. During the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company utilized discount rates ranging from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">18%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, reflecting changes in the Company&#8217;s risk profile. Net revenue projections were also updated to reflect changes in the timing of expected regulatory approval and commercialization.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable to a related party for year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.71428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Assumption of the royalty obligation payable to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">39,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821278016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accrued Expenses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:6px;text-indent:26px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.17460317460318%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payroll and related benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Professional services and related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821301120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(775</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred (benefit) provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total provision (benefit) for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">72.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which will begin to expire in year 2034. NOL carryforwards generated by the Company have been included in the consolidated and unitary income tax returns of ALPHAEON. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which has an indefinite carryforward period. Deferred tax assets in the accompanying financial statements are presented as if the Company filed separate income tax returns. Accordingly, the NOL and the R&amp;D credit carryforwards allocable to the Company based on ALPHAEON&#8217;s consolidated and unitary income tax returns may ultimately differ from those presented in the financial statements on a separate return methodology.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period (a &#8220;Section 382 ownership change&#8221;), utilization of its pre-change NOL carryforwards and the R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards and R&amp;D credit carryforwards before utilization and may be material. As of December&#160;31, 2018, the Company has not determined to what extent a potential ownership change will impact the annual limitation that may be placed on the Company&#8217;s utilization of its NOL carryovers and R&amp;D credit carryforwards. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The components of deferred tax assets and liabilities were as follows </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">29,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">648</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(34,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(24,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recorded deferred tax assets of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which have been fully offset by a valuation allowance. The valuation allowance </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increased</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> primarily driven by the current year operating loss. </font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in Federal tax rate due to tax reform</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revaluation of contingent royalty obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax provision (benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.  The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company&#8217;s tax returns for all years since inception are open for audit. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2017, the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) was enacted. The TCJA includes a number of changes to existing U.S. tax laws that impact the company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The TCJA also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017 as well as prospective changes beginning in 2018, including additional limitations on executive compensation, limitations on the deductibility of interest and capitalization of research and development expenditures.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While there were no changes in the net deferred tax assets, the Company has recorded a decrease in the valuation allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and a reduction in the net deferred tax liability and a benefit to income tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The TCJA no longer allows deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance based compensation. It also subjects the principal executive officer, principal financial officer and three other highest paid officers to the limitation and once the individual becomes a covered person, the individual will remain a covered person for all future years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The company recognized the income tax effects of the TCJA in its 2017 financial statements in accordance with Staff Accounting Bulletin No. 118, which provides SEC staff guidance for the application of ASC Topic 740, Income Taxes, in the reporting period in which the TCJA was signed into law. As such, the Company's 2017 financial results reflected the provisional income tax effects of the TCJA for which the accounting was incomplete but a reasonable estimate was made. The Company&#8217;s accounting for the elements of the TCJA was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809504528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company completed its IPO of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock, which included the exercise by the underwriters of their option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> additional shares of common stock, for net proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering costs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Company completed the Follow-On Offering in which the Company sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock in August 2018, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from the Follow-On Offering, after deducting underwriting discounts and commissions, and excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,500,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized, of which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,250,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were issued or outstanding. ALPHAEON, as the previous sole holder of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock prior to the IPO,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> had certain dividends, conversion, redemption, voting, protective, and liquidation preferences. The number of shares of common stock to which a preferred stockholder was entitled was the product obtained by multiplying the Series A preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the amended and restated certificate of incorporation. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the IPO, all shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock. In addition, the Company also amended and restated its certificate of incorporation. As a result, shares of Series A convertible preferred stock were canceled, with none authorized, issued or outstanding as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the completion of its IPO, the Company also amended and restated its certificate of incorporation to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of preferred stock authorized, of which none were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the completion of its IPO, the Company also amended and restated its certificate of incorporation to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock authorized, of which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27,274,991</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Equity Related Transactions</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the Company assumed from ALPHAEON the revised payment obligations under the Amended Purchase Agreement of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent promissory note at that date). See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information. Pursuant to the Amended Purchase Agreement, ALPHAEON agreed to offset and reduce the amount of related party borrowings by the estimated value of the revised payment obligations on a dollar-for-dollar basis and pursuant to the Services Agreement. Additionally, the Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to ALPHAEON in satisfaction of a portion of the outstanding related party borrowings (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The remaining balance of related party borrowings of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was recharacterized as a capital contribution from ALPHAEON pursuant to the Services Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 21, 2017, t</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he board of directors and the then-sole stockholder of the Company approved the Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,361,291</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares, plus an annual increase on each anniversary of November 21, 2017 equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2018, an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,091,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were reserved under the evergreen provision of the Plan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company reserved an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,888,484</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock for future issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Award Activity and Balances</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of restricted stock units (&#8220;RSUs&#8221;) is estimated at the Company&#8217;s grant date common share price. Options are granted at exercise prices based on the Company&#8217;s grant date common share price. The RSUs and options generally vest over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">- to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period. There have been no awards with performance conditions and no awards with market conditions. The options generally have a contractual term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ten</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. The Black&#8209;Scholes option pricing model has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The Company records share&#8209;based compensation expense net of actual forfeitures. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The significant assumptions used in the Black-Scholes option-pricing are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determining Fair Value of the underlying common stock.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;For options awards granted after the completion of the Company&#8217;s IPO, the fair value for its underlying common stock was determined using the fair value of the grant date price as reported on the Nasdaq Global Select Market. Since the Company&#8217;s common stock was not traded in a public stock market exchange prior to the Company&#8217;s IPO, prior to such date the Board of Directors considered numerous factors including new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company&#8217;s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company&#8217;s initial public offering, the Board of Directors determined the Company&#8217;s common stock fair market value on as needed basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Volatility.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company has limited data regarding company&#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Term.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience for exercise and post-vesting employment or contractual termination behavior after its common stock has been publicly traded. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Risk&#8209;Free Rate.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Dividends.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not grant stock options, restricted stock units, or restricted stock awards during the year ended December 31, 2017. The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.04761904761905%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.76%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.65%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,840,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">8,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(582,923)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the Company&#8217;s common stock for those awards that have an exercise price below the estimated fair value at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the year ended December 31, 2018, the Company recorded expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to stock options. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of total unrecognized compensation cost, net of actual forfeitures, related to stock option based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of the status of the Company&#8217;s nonvested options as of and changes during the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted-Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,840,724</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(582,923)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of restricted stock unit activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">321,516</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(34,602)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(15,510)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the year ended December 31, 2018, the Company recorded expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to restricted stock units. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of total unrecognized compensation cost, net of actual forfeitures, related to stock option based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.9</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense (in thousands) amounts recorded in the accompanying statements of operations and comprehensive loss pursuant to the Plan in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and allocated to Evolus by ALPHAEON in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">586</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Separation of Service with the Former President and Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2018, the Company entered into a separation agreement (the &#8220;Separation Agreement&#8221;) with its then President and Chief Executive Officer</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Murthy Simhambhatla, Ph.D</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Pursuant to the Separation Agreement, the Company modified previously </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">granted stock options resulting in an incremental vesting of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,424</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> stock options and related stock-based compensation expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As part of the Separation Agreement, the Company issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34,602</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock net of tax withholding for vested restricted stock units. An additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50,112</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock were immediately vested and will be issued in February 2020. Stock-based compensation expense relating to the issuance of common stock and accelerated vesting was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The aforementioned non-cash charges are reflected in general and administrative on the statements of operations and comprehensive loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821306752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average shares outstanding used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24,402,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company incurred a net loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and, accordingly, the Company did not include the following dilutive common equivalent shares:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">221,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,479,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809533104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 1, 2019, the FDA granted approval of the Company&#8217;s BLA for the Product. In February 2019, pursuant to the Amended Purchase Agreement, the Company paid a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment to the Evolus Founders and one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to certain former and current employees, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> payable to Rui Avelar, M.D., Evolus&#8217; Chief Medical Officer and Head of Research &amp; Development. In addition, pursuant to the Daewoong Agreement, the Company paid Daewoong a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment in February 2019.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, the Company entered into a credit facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> with Oxford Finance, LLC (&#8220;Oxford&#8221;). Pursuant to the credit facility the lender will make term loans available in two advances. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was funded on the closing date. The second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing six month basis and no event of default is occurring. The credit facility bears an annual interest rate equal to the greater of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the 30-day U.S. Dollar LIBOR rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company has agreed to pay interest only on each tranche funded for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> months until May 2022, which will be followed by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&#8217;s request, the interest only period may be extended by an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> months to a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> months followed by an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company will be required to pay to Oxford a final payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the full principal amount of the term loans funded, or the final payment. The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs thereafter (the &#8220;Prepayment Fee&#8221;). If the term loans are accelerated following the occurrence of an event of default, the Company will be required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the final payment, the Prepayment Fee, and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including its cash.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830340720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The financial statements for the periods prior to the Company&#8217;s IPO have been prepared on a standalone basis and are derived from ALPHAEON&#8217;s consolidated financial statements and accounting records and included an allocation of certain assets and liabilities that have historically been held at the ALPHAEON corporate level but which were specifically identifiable or allocable to the Company. . These results reflect amounts attributable to the Company&#8217;s business, including the costs ALPHAEON incurred for the development and commercialization of the Product and costs and expenses under the License and Supply Agreement (the &#8220;Daewoong Agreement&#8221;) entered into with Daewoong Pharmaceuticals Co., Ltd. (&#8220;Daewoong&#8221;), a South Korean pharmaceutical manufacturer, in September 2013, as further described below in Note 5, C</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">ommitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation activities with ALPHAEON</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO, ALPHAEON charged the Company external and internal administrative and research and development expenses that ALPHAEON incurred on the Company&#8217;s behalf. External research and development expenses charged to the Company included costs for contract research organizations (&#8220;CROs&#8221;), costs to conduct nonclinical and clinical studies on the Product, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON charged these costs to the Company at the same amount that ALPHAEON incurred such cost. Internal development expenses included costs for the work that ALPHAEON development employees perform for the Company. ALPHAEON charged the Company a full-time equivalent (&#8220;FTE&#8221;) rate that covers personnel-related expenses, including salaries and benefits, plus an allocation of facility-related expenses, including rent, utilities, depreciation, insurance and property taxes, for those research and development employees who work either directly or indirectly on the development of the Company&#8217;s drugs and certain administrative employees. ALPHAEON calculated the facility-related expenses to the Company based on a percentage of aggregate expenses incurred at ALPHAEON. ALPHAEON calculated depreciation expense of property and equipment using the straight-line method over the estimated useful lives of its assets of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, the Company historically incurred related party borrowings from ALPHAEON for its share of the internal and external expenses for each of these functions based on the Company&#8217;s relative use of each function, plus an allocation of facility-related expenses. The Company&#8217;s management believes that the allocation and results were reasonable. As of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">, the Company did not have any accounts receivable or payable with ALPHAEON pursuant to the Services Agreement or otherwise.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has calculated its income tax amounts using a separate return methodology and has presented these amounts as if it were a separate taxpayer from ALPHAEON in each jurisdiction for each period the Company presented. Subsequent to the IPO, the Company will prepare a stand-alone tax return. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not have a tax sharing agreement with ALPHAEON. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus was formed in November 2012 for the purposes of developing the Product for distribution and sale. In October 2013,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in a Stock Purchase Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH acquired all of the Company&#8217;s outstanding equity in exchange for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Class AA units of SCH and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Class D units of SCH, which resulted in SCH obtaining a controlling financial interest in Evolus.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the transaction with SCH, Evolus had executed a License and Supply Agreement with Daewoong and thereby secured exclusive rights to license and distribute the Product for aesthetic indications in the United States and certain other international markets, as well as non-exclusive rights to distribute in Japan (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 4, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The acquisition of the Company, which represented a business combination by SCH, was to provide SCH and ALPHAEON access to the license held by Evolus to develop, produce and market clinical neurotoxins. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In a series of related transactions in 2013, SCH acquired all of the Company&#8217;s outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed equity that it had acquired in 2013 to ALPHAEON. As a result of these transactions, the Company became a wholly-owned subsidiary of ALPHAEON.  The Company remained a wholly-owned subsidiary of ALPHAEON until the completion of the IPO.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH elected to apply push-down accounting pursuant to the guidance in ASC 805, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Business Combinations</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Accordingly, the financial statements reflect the new basis of accounting established by SCH when SCH obtained control of the Company in October 2013. The assets acquired and liabilities assumed in connection with the acquisition were recognized based on their estimated fair values at the acquisition date. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates.&#160;The estimated fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition, SCH and ALPHAEON entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) pursuant to which they were obligated to make certain contingent payments to the Evolus Founders. However, since Evolus did not have an obligation associated with the contingent consideration arrangement prior to the Company&#8217;s IPO, no amounts were recognized in the Company&#8217;s financial statements for the contingent royalty obligation arrangement between SCH and ALPHAEON, and the Evolus Founders. As described in Note 4, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, on December 14, 2017, SCH and ALPHAEON entered into an amendment to the Stock Purchase Agreement (the &#8220;Amended Purchase Agreement&#8221;), and the Company joined as a contractual party. Upon the closing of the IPO on February 12, 2018, ALPHAEON immediately and automatically assigned to the Company its payment obligations under the Amended Purchase Agreement. These payment obligations are referred to as the &#8220;contingent royalty obligation payable to Evolus Founders, a related party&#8221; and the &#8220;contingent promissory note payable to Evolus Founders, a related party&#8221; in the accompanying balance sheets. Certain of the Evolus Founders from whom SCH purchased its equity interests include individuals previously employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&#8217;s former Chief Operating Officer. Mr. Marmo was retained as a consultant to the Company until December 2018.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">royalty obligations, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although it has received the regulatory approval from the FDA and Health Canada, the Company has not commenced principal operations in the form of commercialized Product sales. The Product also requires regulatory approval from the European Medicines Agency and other similar regulatory authorities prior to commercial sales in the related jurisdictions. The Product and any future product candidates of the Company may not receive necessary approvals in the jurisdictions where approval is sought. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of the Product and any future product candidates, ability to obtain regulatory approval of the Product and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company relies on Daewoong, our exclusive and sole supplier, to manufacture the Product. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of the Product. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reporting unit. There has been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of goodwill for any of the periods presented.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Asset</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The intangible asset in the accompanying balance sheets represents IPR&amp;D projects acquired that have not yet been completed. IPR&amp;D assets with indefinite useful lives are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the IPR&amp;D assets are either amortized over their estimated useful lives or written-off immediately. There has been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of long-lived assets for any periods presented</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Offering Costs</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Deferred offering costs, which primarily consisted of direct incremental legal and accounting fees relating to the IPO or Follow-On Offering, are capitalized until such time as the offering closes. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of deferred offering costs were offset against proceeds from the sale of registered equity securities in the Company&#8217;s IPO and Follow-On Offering. As of December&#160;31, 2018, the Company did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t capitalize any deferred offering costs. As of December&#160;31, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of deferred offering costs were capitalized and included in &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; in the accompanying balance sheet</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Joint and Several Liability Assessment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Joint and Several Liability Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has (i) agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amounts that the Company expects to pay on behalf of its co-obligors. The determination of the &#8220;best estimate&#8221; from within the range of amounts that might be paid involves substantial judgment by the Company&#8217;s management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no reimbursements of research and development expenses during the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At each financial reporting date, the Company accrues and expenses the estimated costs of clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates based upon a review of the agreements, data collected by internal and external personnel regarding the progress or stage of completion of trials or services. This progress or stage of completion of trials or services is monitored pursuant to contracts with clinical research organizations and other service providers. The agreed-upon fee to be paid for such services is based upon facts and circumstances known to the Company at each financial reporting date. If the actual performance of activities varies from the assumptions used in the estimates, the accruals are adjusted accordingly. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Payment Obligation Payable and Contingent Promissory Note Payable to the Evolus Founders, a Related Party</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Payment Obligation Payable to the Evolus Founders, a Related Party</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable to a related party based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in the operating expenses in the statements of operations and comprehensive loss and in the non-current liabilities in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders, a Related Party</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company assumed the liability concurrent with the IPO and determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Accretion related to the contingent promissory note is recorded in interest expense in the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees and members of the Board of Directors based on the fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of actual forfeitures, when they occur.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units are based on the fair value of the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Compensation cost related to the grant of awards to the Company&#8217;s employees is recognized as an increase to additional paid-in capital in the balance sheets and in the general and administrative or research and development expenses in the statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the IPO, the ALPHAEON common stock awards were valued at fair value on the date of grant and that fair value was recognized over the requisite service period. Estimates were used to determine the fair value of these awards, as shares of ALPHAEON&#8217;s common stock are not publicly traded. ALPHAEON common stock awards are subject to specified vesting schedules and requirements. The Company estimated the fair value of each ALPHAEON option on the date of grant using the Black-Scholes model. Stock-based compensation expense is allocated to the Company over the required service period over which these ALPHAEON common stock awards and options would vest and is based upon the relative percentage of time utilized by ALPHAEON employees on Company matters. These ALPHAEON awards were recognized as a capital contribution which was recorded in the statement of stockholder&#8217;s equity (deficit) and a corresponding entry was recorded in the accompanying statements of operations and comprehensive loss.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the effects of common stock equivalents such as convertible preferred stock and stock options outstanding. Diluted net loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issued common stock were exercised or converted to common stock. Dilutive common share equivalents are comprised of convertible preferred stock and stock options outstanding during the period, but are excluded if their impact is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-18,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires transactions in collaborative arrangements to be accounted for under ASC 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company will adopt the guidance on January 1, 2019, and does not expect such adoption will have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2021. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU 2018-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;ASU 2018-13&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the FASB issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">, Compensation - Stock Compensation - Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this ASU clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2019. The Company is in the process of determining the effects the adoption will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the FASB issued ASU No. 2018-07,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2018-07&#8221;) which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2017-09&#8221;) which amends the scope of modification accounting for stock-based payment arrangements.&#160;The amendment&#160;provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company adopted this guidance effective January 1, 2018 and this guidance did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2017-04,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles&#8212;Goodwill and Other (Topic 350</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">):&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This standard simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for us beginning January&#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU 2017-01,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Business Combinations (Topic 805)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Definition of a Business</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies when transactions should be accounted for as acquisitions (or disposals) of assets or business. ASU 2017-01 is effective for us beginning January&#160;1, 2019. Early adoption is permitted for transactions not previously reported in issued financial statements. The Company is evaluating the effect of this standard on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that supersedes the current lease guidance under </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases, (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard requires lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The new accounting standard will be effective for the Company starting in the first quarter of fiscal 2019. The Company will elect the transition package of three practical expedients permitted under the transition guidance and will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods. Further, the Company will elect a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company will record right-of-use assets and liabilities and the corresponding deferred tax assets and liabilities on its balance sheet as of January 1, 2019, primarily associated with its operating leases. The Company is also finalizing the impact of the standard to its accounting policies, processes, disclosures, and internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#8220;ASU 2016-13&#8221;), which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. We are in the process of reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821336656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the amounts that were allocated from ALPHAEON prior to the IPO, and included in Evolus&#8217; general and administrative expenses as disclosed in the accompanying </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">statements of operations and comprehensive loss for the following periods (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Compensation &amp; Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Third party service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Facility related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,906</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809415504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments for operating leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">uture minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6606384144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of difference between carrying balance and fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) presents the difference between the carrying balance and the fair value of the contingent promissory note payable to the Evolus founders, a related party:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.15079365079364%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Carrying Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent promissory note payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">17,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial instruments recorded at fair value on a recurring basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) presents the major security types the Company held at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, that are measured at fair value on a recurring basis. The Company did not hold any major security types that required a fair value measurement on a recurring basis at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Hierarchy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders, a related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of fair value measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table (in thousands) shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable to a related party for year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.71428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Assumption of the royalty obligation payable to Evolus Founders, a related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">39,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">50,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809516960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:center;padding-left:6px;text-indent:26px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.17460317460318%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payroll and related benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Professional services and related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6658722192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The current and deferred expense is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(775</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred (benefit) provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total provision (benefit) for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The components of deferred tax assets and liabilities were as follows </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">29,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">648</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(34,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(24,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in Federal tax rate due to tax reform</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revaluation of contingent royalty obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax provision (benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6598713520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.04761904761905%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.76%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.65%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of the status of the Company&#8217;s nonvested options as of and changes during the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted-Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,840,724</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(582,923)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,840,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">8,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(582,923)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of restricted stock unit activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">321,516</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(34,602)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(15,510)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense allocation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense (in thousands) amounts recorded in the accompanying statements of operations and comprehensive loss pursuant to the Plan in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and allocated to Evolus by ALPHAEON in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">586</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809455568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(4,480</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average shares outstanding used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24,402,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of securities excluded from computation of diluted net loss per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company incurred a net loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and, accordingly, the Company did not include the following dilutive common equivalent shares:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.301587301587304%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">221,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,479,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6832212640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 15, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriters fees | $</a></td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,330,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees | $</a></td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,680,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,867,000)<span></span>
</td>
<td class="num">(4,480,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,667,000)<span></span>
</td>
<td class="num">(13,222,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,162,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (123,025,000)<span></span>
</td>
<td class="num">$ (75,543,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">47,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares of convertible preferred stock converted (in shares)</a></td>
<td class="nump">2,065,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Majority Shareholder | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_OxfordFinanceLLCMember', window );">Oxford Finance, LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_OxfordFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_OxfordFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6832201456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred costs offset against IPO proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance', window );">Provisional decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit', window );">Reduction in net deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc. | Class AA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued as part of business acquisition (in shares) | shares</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc. | Class D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued as part of business acquisition (in shares) | shares</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Adjustment, Increase (Decrease) In Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Provisional Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eols_CommonClassAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eols_CommonClassAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eols_CommonClassDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eols_CommonClassDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6829950608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="nump">$ 21,208<span></span>
</td>
<td class="nump">$ 21,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,100<span></span>
</td>
<td class="nump">$ 56,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">56,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Assets acquired, indefinite-lived intangible assets (IPR&amp;D)</a></td>
<td class="nump">56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Liabilities assumed in acquisition, deferred tax liabilities</a></td>
<td class="nump">$ 20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration upon successful completion of certain technical and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6836177296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 12, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 14, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>transaction</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">138,687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,025,000<span></span>
</td>
<td class="nump">75,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="num">(66,048,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Non-cash related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,690,000<span></span>
</td>
<td class="num">(72,639,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationLiquidatedDamages', window );">Liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded', window );">Period in which liquidated damages will be awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionTermOfAgreement', window );">Term of service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionRenewalPeriodOption', window );">Period of successive renewal of services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach', window );">Period available to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessAcquisitionUnwindingFee', window );">Unwinding fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Note | Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfDebtTransactions', window );">Debt instrument, number of debt transactions | transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Note | Bridge Note | Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Note | Purchase Agreement | Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance', window );">Additional amount authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eols_ALPHAEONMember', window );">ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eols_ALPHAEONMember', window );">ALPHAEON | Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Notes receivable from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionTotalAmountsofTransaction', window );">Total amounts of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,700,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Non-cash related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyBorrowingsandNonCashCapitalContribution', window );">Related party borrowings and non-cash capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired (at least)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation', window );">Amounts of transaction related to contingent royalty obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote', window );">Amounts of transaction related to contingent promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote', window );">Period of anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale', window );">Period of termination of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eols_CommonClassDMember', window );">Class D | Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval', window );">Up-front payment upon obtaining FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">One-time lump sum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders, a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recorded in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Evolus, Inc. | Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval', window );">Up-front payment upon obtaining FDA approval</a></td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessAcquisitionUnwindingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Unwinding Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessAcquisitionUnwindingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Liquidated Damages</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Period in Which Liquidated Damages will be Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Up-front Payment Upon Obtaining FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Amount Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalAmountAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfDebtTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Debt Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfDebtTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Related Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyBorrowingsandNonCashCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Borrowings and Non-Cash Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyBorrowingsandNonCashCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Amounts Of Transaction Related To Contingent Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Amounts Of Transaction Related To Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionAmountsOfTransactionRelatedToContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period Of Termination Of First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period of Maturity of Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodofMaturityofPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionRenewalPeriodOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Renewal Period Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionRenewalPeriodOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionTotalAmountsofTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Total Amounts of Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionTotalAmountsofTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Period Available to Cure Breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockPurchaseAgreementPeriodAvailabletoCureBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_BridgeNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_BridgeNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eols_CommonClassDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eols_CommonClassDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6834751296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Related Party Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 29,146<span></span>
</td>
<td class="nump">$ 4,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Compensation &amp; Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Third party service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Facility related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eols_CompensationAndBenefitTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eols_CompensationAndBenefitTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eols_ThirdPartyServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eols_ThirdPartyServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eols_StockBasedCompensationTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eols_StockBasedCompensationTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eols_FacilityRelatedTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eols_FacilityRelatedTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eols_OtherTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eols_OtherTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6834750144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,767,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating leases, future minimum payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=eols_DaewoongMember', window );">Daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=eols_DaewoongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=eols_DaewoongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818120944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>year</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent royalty obligation payable to Evolus Founders, a related party</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable | $</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term of debt</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input | year</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Minimum | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Maximum | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813711936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Promissory Note (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Balance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable to Evolus Founders, a related party</a></td>
<td class="nump">$ 16,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable to Evolus Founders, a related party</a></td>
<td class="nump">$ 17,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6832031264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring Basis (Details) - Contingent royalty obligation payable to Evolus Founders, a related party<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Assumption of the royalty obligation payable to Evolus Founders, a related party</a></td>
<td class="nump">39,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 50,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6810154256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">$ 2,577<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services and related expenses</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 3,718<span></span>
</td>
<td class="nump">$ 977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818442240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred (benefit) provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">44<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision (benefit)</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(6,255)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="num">$ (7,251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6829944960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 99,800<span></span>
</td>
<td class="nump">$ 72,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="num">(34,500)<span></span>
</td>
<td class="num">(24,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, decrease in valuation allowance</a></td>
<td class="num">(10,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in Federal tax rate due to tax reform</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance', window );">Provisional decrease to valuation allowance</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit', window );">Reduction in net deferred tax liability</a></td>
<td class="num">(6,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | R&amp;D Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | R&amp;D Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Adjustment, Increase (Decrease) In Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Provisional Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819071728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 29,782<span></span>
</td>
<td class="nump">$ 21,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount', window );">Promissory note - debt discount</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">2,436<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34,536)<span></span>
</td>
<td class="num">(24,072)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible amortization</a></td>
<td class="num">(15,055)<span></span>
</td>
<td class="num">(14,990)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(15,055)<span></span>
</td>
<td class="num">(14,990)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income taxes</a></td>
<td class="num">$ (15,055)<span></span>
</td>
<td class="num">$ (14,990)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Promissory Note, Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssetsPromissoryNoteDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6824505392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at statutory rate</a></td>
<td class="num">$ (9,828)<span></span>
</td>
<td class="num">$ (3,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of Federal benefit</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in Federal tax rate due to tax reform</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Meals and entertainment</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount', window );">Promissory note - debt discount</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation', window );">Revaluation of contingent royalty obligation</a></td>
<td class="nump">2,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">7,309<span></span>
</td>
<td class="num">(6,548)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="num">$ (7,251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818991712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,109<span></span>
</td>
<td class="nump">$ 1,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases to current year tax positions</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,435<span></span>
</td>
<td class="nump">$ 2,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819559152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2018</div></th>
<th class="th"><div>Dec. 14, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 21, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees</a></td>
<td class="nump">$ 56,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,680<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, offering price (in dollars per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders, a related party</a></td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders, a related party</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,904<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Additional shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,971<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 27 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock option costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for unrecognized costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized costs other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for unrecognized costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares of convertible preferred stock converted (in shares)</a></td>
<td class="nump">2,065,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,570<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Compensation Award, Tranche One | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Compensation Award, Tranche Two | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="nump">$ 55,700<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">47,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Forgiveness of Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionForgivenessofRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809431312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">57.76%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 2 months 27 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819485792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,840,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,840,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(582,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,257,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">11.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">9.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">11.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm', window );">Exercised</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm', window );">Cancelled/forfeited</a></td>
<td class="text">9 years 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">9 years 3 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue', window );">Granted | $</a></td>
<td class="nump">8,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue', window );">Cancelled/forfeited | $</a></td>
<td class="num">(1,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance | $</a></td>
<td class="nump">7,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6655221200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Nonvested Award Options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,840,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Cancelled/forfeited (in shares) | shares</a></td>
<td class="num">(582,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">3,257,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">11.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">9.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818223840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">321,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(34,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(15,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">271,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">14.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">9.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">9.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6834754368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Stock-based Compensation Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">$ 6,971<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">5,570<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6820261152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (46,867)<span></span>
</td>
<td class="num">$ (4,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">24,402,368<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares)</a></td>
<td class="nump">3,479,093<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">3,257,801<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares)</a></td>
<td class="nump">3,257,801<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares)</a></td>
<td class="nump">221,292<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830758720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Dec. 14, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval', window );">Up-front payment upon obtaining FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval', window );">One-time bonus payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_DaewoongMember', window );">Daewoong | Evolus, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement', window );">Up-front payment upon purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=eols_ApplicableRateMember', window );">Applicable Rate | Term Loan Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentDefaultInterestRate', window );">Default interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember', window );">Chief Medical Officer | Evolus, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period of agreement of interest payments</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment', window );">Additional period of agreement of interest payment</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentTermAggregatePeriod', window );">Total term of debt</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalAmortizationPeriod', window );">Additional amortization period</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment', window );">Percentage of final payment of full principal amount</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths', window );">Percentage of final payment of full principal amount, next twelve months</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo', window );">Percentage of final payment of full principal amount, year two</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter', window );">Percentage of final payment of full principal amount, thereafter</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility | Term Loan Facility, Tranche One | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility | Term Loan Facility, Tranche Two | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility | LIBOR | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, One-Time Bonus Payment Upon Obtaining FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationOneTimeBonusPaymentUponObtainingFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Up-front Payment Upon Obtaining FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Up-front Payment Upon Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationUpfrontPaymentUponPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Period Of Agreement Of Interest Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage Of Principal Amount, Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentTermAggregatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Aggregate Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentTermAggregatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_DaewoongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_DaewoongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eols_ApplicableRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eols_ApplicableRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=eols_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=eols_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MP^\F[(*Q!_N/C:^"70N_[J+[ E!+ P04    " #E@'1.F5R<(Q &  "<)P
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M23+M],UE?@$4WMY";?\'4$L#!!0    ( .6 =$Y1WDBKEP(  -\*   8
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M    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5-A;YLP$/TKEG] G3BDJR)
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M971S+W-H965T.2YX;6Q]4]MNG# 0_17+'Q"S["7I"I"RJ:I62J15JJ;/7AC
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M7C;UOT;T$*1L[L((M>&#S8:"VL?C?3C;<<Q&PV,W_2 V?^/B%U!+ P04
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M_6^,\8!2DAL<H0X_V&)(:'PXWN'93F,V&=[T\P]BRS<N_P!02P,$%     @
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MV&Q(J%TX[OW9C&,V&@Z[Z0>Q^1L7OP%02P,$%     @ Y8!T3D**<F&S 0
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M4]MNW" 0_17$!X0UWB;1RK:4316E4BNM4K5]9NWQ1>'B %ZG?]\!.ZZ;N"_
M#.><N3!DH['/K@7PY%5)[7+:>M\?&'-E"TJX*].#QIO:6"4\FK9AKK<@JDA2
MDO'=[IHIT6E:9-%WLD5F!B\[#2=+W*"4L+^/(,V8TX2^.9ZZIO7!P8JL%PU\
M!_^C/UFTV*)2=0JTZXPF%NJ<WB6'XS[@(^!G!Z-;G4FHY&S,<S"^5#G=A81
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MSD@4!$?":=?C(G.^JRPR,6K6]7"52(V<4_G[ DQ,.0[QN^.Y:UIM':3(!MK
M=] _AJLT%EE9JHY#KSK1(PEUCA_#\R6U> =XZ6!2FSVRE=R$>+7&ERK'@4T(
M&)3:,E"SW.$)&+-$)HU?"R=>)6W@=O_._LG5;FJY405/@OWL*MWF^(11!34=
MF7X6TV=8ZDDP6HK_"G=@!FXS,1JE8,I]43DJ+?C"8E+A]&U>N]ZMTWR2)$N8
M/R!: J(UX.1TR"SD,O](-2TR*28DY[L?J/W%X3DR=U-:I[L*=V:25\9[+Z)#
MG)&[)5HPEQD3;3#ABB"&?96(?!*7Z+_PR!]^\&9X<.&'K7J:^ EB+T'L".)_
M2DQV)?HP1[](XA5)/ 3I3L2'.?E%CEZ1HX?@PT[$@XD#OTCJ%4D]!.%.Q(?9
M_U2R>8(<9..:3Z%2C+UK_(UW[>_'R#WAO_!Y.'RCLNEZA6Y"FT9PS[460H-)
M)7@PM]J:>;0:#&IMMZG9R[DK9T.+81DX9)UZQ1]02P,$%     @ Y8!T3O2@
M\DGA 0   04  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL;51MCYP@
M$/XKAA]PN*POVXV:W%[3M$F;;*YI^YG5\24'8@'7Z[\OH&>MQQ=AAF>>9P:9
MR28A7U0+H(-7SGJ5HU;KX8RQ*EO@5#V( 7IS4@O)J3:F;+ :)-#*!7&&21@F
MF-.N1T7F?%=99&+4K.OA*@,U<D[EGPLP,>7H@-X<SUW3:NO 13;0!KZ#_C%<
MI;'PRE)U''K5B3Z04.?H\7"^I!;O #\[F-1F']A*;D*\6.-+E:/0)@0,2FT9
MJ%GN\ 2,62*3QN^%$ZV2-G"[?V/_Y&HWM=RH@B?!?G65;G-T0D$%-1V9?A;3
M9UCJB5&P%/\5[L ,W&9B-$K!E/L&Y:BTX N+2873UWGM>K=.\TF:+&'^ +($
MD#7@Y'3P+.0R_T@U+3(IID#.=S]0^XL/9V+NIK1.=Q7NS"2OC/=>D.B8X;LE
M6C"7&4,VF,.*P(9]E2 ^B0MY%T[\X4=OAD<7?MRJIR<_0>0EB!Q!]%^)T:Y$
M'R;VB\1>D=A#D.Q$?)C4+Y)X11(/P6DGXL-\\(ND7I'T/4$<[D1\F/V;P)LG
MR$$VKOE44(JQ=XV_\:[]_4C<$_X'GX?#-RJ;KE?!36C3".ZYUD)H,*F$#^96
M6S./5H-!K>TV-7LY=^5L:#$L P>O4Z_X"U!+ P04    " #E@'1.\B=LN\8!
M   W!   &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QU5-N.VR 0_17$
M!RP)B7?3R+:TV:IJI5:*MFK[3.RQC9:+"SC>_GT!>UTWI2^&&<Z<,\,PSD=M
M7FP'X-"K%,H6N'.N/Q)BJPXDLW>Z!^5/&FTD<]XT+;&] 5;'("D(W6SNB61<
MX3*/OK,I<STXP16<#;*#E,S\.H'08X&W^,WQS-O.!0<I\YZU\!7<M_YLO$46
MEII+4)9KA0PT!7[<'D]9P$? =PZC7>U1J.2B]4LP/M4%WH2$0$#E @/SRQ6>
M0(A Y-/X.7/B13($KO=O[!]B[;Z6"[/PI,4/7KNNP >,:FC8(-RS'C_"7$^&
MT5S\9[B"\/"0B=>HM+#QBZK!.BUG%I^*9*_3RE5<Q^GDX=T<E@Z@<P!= @Y1
MATQ",?/WS+$R-WI$9KK[GH46;X_4WTT5G/$JXIE/WGKOM:09S<DU$,V8TX2A
M*\QV01#/ODC0E,2)_A-.T^&[9(:[&+Y;JQ_^H[]/$NPCP?ZO$G<W):8P^[1(
MEA3)$@39C4@*<W\C0E:-DV#:^&0MJO2@XKBLO,M4/-+8^#_P::2^,--R9=%%
M._]\8I,;K1WX5#9W/I?.3_%B"&A<V#[XO9G>\F0XW<]C2I9_1?D;4$L#!!0
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MMFPY5TQKC&_TV=OK6;E?E&RKS&VF[T4[,+8+Q9MN&([ZB7SQ#U!+ P04
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M&1$ZHT!,G02&;4"4=J.8,;A3/#CCZ3(D HI$P8JZ!GRJ!D )[1SP5EGVMF#
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MCQ!8DPBT?W"5Q V"T$H0:H)P3@#]Q2D,F$1C6HU9( H3L4J2R*XCLNJ(+#K
M0L> B>[H,!$K"&]<66S5$5MT+"YM%_]7AXE8I6ELUY%8=23FQ<+ 3K"V$JP_
M<+%K0V88+C(Q(:L8)C=22:U*T@]<;6J$64**NY K&<"W/WC?(B1<OGC?"!-'
M"R46C#R4Z,;_#FZ4'V!1$RW5 .-AF6I,S"J!T?)LO%E=;# [Z1;"G9*>6Z$J
MT,PZM:E'J.KJPKY3[4O7VW>:H?=]1^Q4M]S94R&KMJZM1TH%EBK]!WE:E6RW
MTX+@HU!3V1T<-O2<82%H-_93;VKJ^3]02P,$%     @ Y8!T3C);)5&9 @
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M0<6.RKRF^EUT3;L;*-[V%Y)@N!6M_P)02P,$%     @ Y8!T3@ZRB!.? @
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M(MJDJQW$'X8;/B0F<G44:G$,U7,YY5U.J<NQ,^G1=1M"])QHZ@M; Q+J1LR
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M2VED$B&0NX!$AI((M:P6<,B>P"$+.&3'M+V6<L@8%VLJBP):: '/+,<SM"R
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M_L,J/%;-VT87BMU/X78?JGS;_<QOMO^MX>5_4$L#!!0    ( .6 =$[G6\F
M,0(  .D&   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;(U5[6Z;,!1]
M%<0#U'PF)")(#=.T29L4=5KWVR$W =5@9CNA>_O9AE(*MUO_Q/;U.>>>:^+K
MM./B298 RGFN62-W;JE4NR5$%B745-[Q%AJ]<^:BIDHOQ87(5@ ]65+-2.!Y
M*U+3JG&SU,8.(DOY5;&J@8-PY+6NJ?BS!\:[G>N[+X&'ZE(J$R!9VM(+_ #U
MLST(O2*CRJFJH9$5;QP!YYU[[V]SWS,$BWBLH).3N6-*.7+^9!9?3SO7,XZ
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M%,1-+S:[(@C2/2/@$I@N-''Y$":4$K=X8>88!UZAZ<6GLT=AG/B6]P/#>#+
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M#T$8^1CFQ" G!CCQC!,O.8@0].#<$I"3 !P\XR0+#HY1Z(<P)P4Y*7"' E@
M^7"E^,M043(OE=XH_O<U0@_J$0&4^5T=C!":8%"X>E15"*S++<+ V2\2PDM4
MNDH?D> "1@% 6B05_!<)KG0$E#J>WZ?!*)V>'EE-3KDG>9,WM&'B;+N'= I^
M:6WKFNR.'6J+[1O\U[QO;]^H.%>M= Y<Z9?<OK<GSA73T?@K?;%+W5''1<U.
MRDQC/1=]6^D7BG=#R_3&OIW_ 5!+ P04    " #E@'1.)JA,VBL"  !]!@
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M8M\;J__&#[Q2<CT2E6,IJJ[_[RWWG13UZ**&4A?OP[%L^N-Q>)*R,0P'T#&
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M&[R,<1Z>V$3'L[E[D2S)'RE/Z/#4>MGT6Y'V /]8PXIA?+B<3.?HL]_@,E^
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MRE[7)E1L1B@6I",Q-7-V?QF^_I0!6P+.ML45]YIM!&8.3)^5%$RE&$@' >H
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MO*MK+@(4JAG?8O;&A@=R+ ?R@1?<=H;&S=UD^YXMD=%B@ZOE_BJ%<KP4^/S
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M!<'&SD7<=JKD6:(DZ0Z 41WP?V;:189XGDN ;(QQ;8$BV-*H6^PEW3Z.PTE
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M2^8M0!(:GU"ZZY6)GO%U^ T[-Z-$+DK\JZ/D[WONHRPY4.S!::UE31DDVNK
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M! '3VN:.^Z:C'K34^0D^BE4P*]L'^<5A\$V],ZX[3$Z%["C+&/^/6VQPD8R
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MH,C0S;G+1]([99%?GL]J4R(]$/)D_]JOY5-2BU\:97RL+@13=^PP*E';!WK
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M=:J/-]/?UX#,<U%$[5[FZJ?3DFU3F.2:$"'D']ENVN_/JWOF5GK5@TLEM%L
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M?N)E:4LULJ(UR.#QW&KJQX5X.**8HH<UZ%K.[8E7%=U>AD!*(N'/6(^F>QG
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M-^(6:LAIV]C3HLE&,(I?=_-[TC#=5#%),<O,. <PL#]\J1+2\()"*HUH*O/
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MIA3:8WHX95>47FK:6DE>4N!F8D3;4\M)4Q%C@G*\I5UKE".I)?VB%!M8'WJ
MDY.Y^.2SW@4)[JY1J!$(LL3 _.7P2:6\YZ\OY\/@W3[ *01R//*+X%5W)P7
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M,BHNSBY8%QF/AKIVH(N<NX^_*"[/SSL9?_I<F==!_5/_NLQJ<<1Z6-+*9^/
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M  IR@L>1M.XN>>_W69B[!^<WUV.3=VE2 ;N?6D0AI<QT\5Z60L%W6,^%RTU
MB<0UB[/,P,FOC8$?KBSA#D"F?$4*MU16A14*PR"HJ'3SR?ZZ_D=T/N!@0TY
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M<+!O<$(J=M$4'/Y91#\!4$L#!!0    ( .6 =$X5^U+</00  $4@   /
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MEHU2IU!VI;\:WAXTAS9V)_B?_P502P,$%     @ Y8!T3FO7?"O/ 0  =1T
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MY!M02P$"% ,4    " #E@'1.'R// \     3 @  "P              @ $
M    7W)E;',O+G)E;'-02P$"% ,4    " #E@'1.)^B'#H(   "Q    $
M            @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .6
M=$[LK^86[@   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .6 =$Z97)PC$ 8  )PG   3              "
M ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Y8!T3GSG\9S.
M @  E L  !@              ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .6 =$ZEA?OSW0,  )$2   8              "
M ?L+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #E@'1.
M4=Y(JY<"  #?"@  &               @ $.$   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ Y8!T3I^$Q(4* P  U L  !@
M     ( !VQ(  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M .6 =$X$315-/00  "T4   8              "  1L6  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #E@'1.!8"E9?($  ""&0  &
M            @ &.&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ Y8!T3M91!B&P 0  T@,  !@              ( !MA\  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .6 =$YXFQLGM0$  -(#
M   8              "  9PA  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #E@'1.2KMY_K0!  #2 P  &               @ &'(P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ Y8!T3M^()K^T
M 0  T@,  !D              ( !<24  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #E@'1.II8J5K0!  #2 P  &0
M@ %<)P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .6
M=$[:;WXIM@$  -(#   9              "  4<I  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ Y8!T3CYF+*"S 0  T@,  !D
M         ( !-"L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #E@'1.5XY(V+0!  #2 P  &0              @ $>+0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .6 =$[/7JLSM0$  -(#
M   9              "  0DO  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ Y8!T3D**<F&S 0  T@,  !D              ( !]3
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #E@'1.D61F
M1+0!  #2 P  &0              @ '?,@  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( .6 =$Y4*0,<DP(  $,*   9
M  "  <HT  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MY8!T3@ _,7RV 0  T@,  !D              ( !E#<  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #E@'1./*^I6;<!  #2 P  &0
M            @ &!.0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( .6 =$ZDAL'#U0$  )P$   9              "  6\[  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ Y8!T3KT#=IVX 0
MT@,  !D              ( !>ST  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #E@'1.*S3AE> !   !!0  &0              @ %J
M/P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .6 =$[T
MH/))X0$   $%   9              "  8%!  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ Y8!T3O(G;+O& 0  -P0  !D
M     ( !F4,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6 =$Z1\ YOM@(  ,H*   9              "
M :95  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ Y8!T
M3KJ3;WZW @   @H  !D              ( !DU@  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #E@'1.WUUXQD "  !&!P  &0
M        @ &!6P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( .6 =$X<PQNBR0$  (0$   9              "  ?A=  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ Y8!T3K$Z'9;Q 0  !P4
M !D              ( !^%\  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #E@'1.W:0(9OD!  !J!0  &0              @ $@8@
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .6 =$Y%?1+1
M90(  . '   9              "  5!D  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ Y8!T3C);)5&9 @  (0D  !D
M ( ![&8  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #E
M@'1.#K*($Y\"   9"@  &0              @ &\:0  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .6 =$ZVSB1XIP(  $<)   9
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M970T,RYX;6Q02P$"% ,4    " #E@'1.E5'L!4D"  #Q!@  &0
M    @ %U?@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M .6 =$[W900)8P(  ,,'   9              "  ?6   !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ Y8!T3B:H3-HK @  ?08  !D
M             ( !CX,  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #E@'1.JK!(S9T"   '"0  &0              @ 'QA0  >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .6 =$[_/?@25 ,
M $40   9              "  <6(  !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ Y8!T3I$+1UR:K0  9Z<" !0              ( !
M4(P  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ Y8!T3G1LO<9=
M @  9@P   T              ( !'#H! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " #E@'1.%?M2W#T$  !%(   #P              @ &D/ $ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ Y8!T3FO7?"O/ 0  =1T  !H
M     ( !#D$! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ Y8!T3AE[T@[! 0  =AT  !,              ( !%4,! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #D .0"!#P  !T4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Goodwill and Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAsset</Role>
      <ShortName>Goodwill and Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/RelatedPartyTransactions</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/Organization</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Goodwill and Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetDetails</Role>
      <ShortName>Goodwill and Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/GoodwillAndIntangibleAsset</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Related Party Transactions - Related Party Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails</Role>
      <ShortName>Related Party Transactions - Related Party Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Fair Value Measurements - Contingent Promissory Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsContingentPromissoryNoteDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Promissory Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Fair Value Measurements - Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Income Taxes - Components of Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesComponentsOfIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfValuationAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Nonvested Award Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfNonvestedAwardOptionsDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Nonvested Award Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2409407 - Disclosure - Stockholders' Equity (Deficit) - Stock-based Compensation Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Stock-based Compensation Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/NetLossPerShareAttributableToCommonStockholdersTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="eols-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>eols-20181231.xml</File>
    <File>eols-20181231.xsd</File>
    <File>eols-20181231_cal.xml</File>
    <File>eols-20181231_def.xml</File>
    <File>eols-20181231_lab.xml</File>
    <File>eols-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001570562-19-000038-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001570562-19-000038-xbrl.zip
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MQ.<D"&"_.W3:A!<@7!4AQG@@%0U>>\FR %(QWD"J;;=_+"X[=]>3.?4^K*?
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M:8Z6$C&H6&$LI8A8TAG;P/1 !#;9'-'X0"/5.7IOG"88DT,$!#A.7C?:'/M
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MTXJ+4;??N?ZC4Z/E8>/'HDO%T<F\5*;&.I(8E]:[H+P,B4;.094$96U4F )
MR3_:R;@MNMN1;7CYKC.Y0]$^O-P@"1Z?7-93#RZWHR'IF#R8.E:Q+,'1BM1:
MCB>&[!_JW>*Z[YZ8;J+4AV)0?%VD]=TV;=DEB_$XFO;>-U7H"1E"@6_ Y6>9
M.J +ITESSATGR$8;N*@&ITUD0(9;2FI\6A(H)J,@&6P)<,M=5A14+I+ 4Q4Y
MJ(<M2+"&ST;TAY-YEM)XN"S#&BV*TS+.5I1J=&"CB* PX9 E:I)!E\M$0L#3
MMA4!S[;1J8T$.B!E3]+L7::LS%DS'HG0:/TFD9EA8*Y@T(*27#U3!3-Y&]VY
M#6T7!P+#M@.!66F4R7#Y2SN[<2Y3XDFT2B3B0:5QA:6PM" L.AU8)0Y]C]X#
MH#P6KAO</RFU32!G Y9?D<H1Y6V)*P'EI$DEJC,]UR.'1;GDP$^5!N:C$3:^
M1O'UZ?O]([/4P+*,Q52VC],WM Q@[.\%7A@K>NY+,>I\+CX4-]/+_J5G >C>
M=:Y1,&[,%-FU==^2=1EH4BF%I$"Q6P)R1WMKE!&&$PL>$XCNA0WTV&@?C-YY
M.+HL^I-3H'<V5"K/?/2:.RO!B"(@E"BXJCE;0SG0V_Z#O-/Q0#3?%?7#T[P_
M,_G>H+,\&/>[?X,=N#GY:6<2-UXER^"L.J-H5B1FD!-> ,%#I"HXERLG1K 4
M2T>,1Z;"P:C]%RR3=PK\[9S6F@EKG/99"RN\<4!N(;,20@E2\C=_Q^RA&'PW
MS ]-\"=F[LP%N&6&,B,XP1J4X)<!M2-F8%$2*Z:C49P=CKE;:7!/:<2F+-[7
MBW=XB#E]>GJ3>'Z1#=,F%K>.WV"5CT%1FE1_[T^NP!N%+V.CWC(/\OUUI]D8
MW2UW<NFCF_*+ TCG[)E28&EE*W2TX-K8H,&<Y%S*95+/KU5SH18)QD>APB8:
MEPMQ:!(W'R0SKH#QL,ZCRBP()!)0R."%"DIH]9"6+9\E' .%)Z'/HZ3O!D)8
M\$9AY2G&@\XNJBFM@?#</SFM*W=YIU]P7SK]ZZEA'>Y&A1\5G>Y5<VSKR&$+
MQPD5B1NOG72$>RJ"8%D:<)P(D3&O5*_;&:T%03YVOOEB4%SV)Y@=4U\S8G>?
MSR?,;(S9@R63\)(Q,2QAT5_#0 %4LCEM69-RALLV$#T0_$V91S)+IF)@)&K*
ME!-)< "?428U-=7B._M"'NY@NPUZ_S[\-';=R<4E$K9,Y+N%Q2IF%4K13+A"
MG?=F,$OO6T_G?3\:?NF/I[>Q>__O;CRY64IT!UXM__MF\+>Y;^FNKX=?*[?A
MMZE*%+)V@8.+ZZ2DF5#0ZH%EC@T%8+JK)H6LUAH] 92;R3_< Y:W_<ZG\O[+
M$CR+3,Q9XM^,(W:F=7)"Z^ \A?\2$:3A3.-]?1(<L4E4]M!KQ5MI?63\D+#S
MEC5KM75G)=]WR]IGP4H;;)99$]AX("$X%L5VDFMM8&0=?2&F"6KM,.P#95M:
M?HZ22*:39IZ0#.(9;_T@E&CVREQ3B$B:W<'$VQ+SI>@7X[WH&<'VD5ACAWGG
MC(LT2&S^ ?PE.26L6@U2ZW5 Z\'8$]8VJOHD+?=$XLT28Z,E-)6PNJR54K02
M1N,@E?<&%EC[LAA/>3L7>U(796%2W*BLDK.&V R^3!8*2]!*4<UG-ZH6X 98
M'@)U&YV-]9I+L#"DQ[X-8*#Q/(4ZRR1=)31K.=T7ZGH[<C<B*VJ5IY;FJ,%U
M<1D<><>2H)Z'@"T%:M3RAN_O!6(;18,!I]>1I$D*"4P?D-R\!)$9I8VO<"XC
M6I U5M@&U+G*&W\<-CR_9M:7F?_+919V-HJ<CR(#CQ#%@LQ4$.^Q1)^D7BBA
MI&RNEGE(L!^+#(_B)V$P&UQU8U)0T0"S<&*F)%5"LU@Y 3H-DI9.BU\/S"R%
MA<8?BNG9??%',?K2[\ZNX>*ME,^#_EYIX)XH'I+1X%.JQ'**$;N9^"1D #N!
M5LN8S0O^/3)B)T3+1^%@YZPCQFH.TB Y;[%WQ6Q=+&&\N1#C<UB72O!QXV<:
MXJN;+D=9YF'G4S!TM&,N@>E#@(B14L6\)I5# &G4?C3<$Z%3(-[CR./(=8@I
M@I"),>; L4)EN1"&4"8J&<<O:R$VU3NP)I&L#9CI/B69F U$8XU/:;/+IGJC
MP6KZ=-2[OAYV,397+UMFKFU-WA);L-C4#UZPXUM\WSQ9;?[,7\ W'G6NP0EW
MO9O^H&P8508FI^]_>-9)N.H7E^E;T;W#UUY<7@+VH_5Z8\6XO'>X4H"C%NWI
MP<]:P_?&  71!(P5KZDCD3AP>+B.!G.M3,:N8Q4/?9[JL-L:/'#5MI&_V4@6
MC1;1",Z92-I+!X@$XZ2GOGHUHK+M'QF1P[-@2T*+ &)@\1]*HQ)"&J%*TD@"
M=FJU=H*4]/F0!@L%=T;=*Z!-++X4U\/;4J]L19BL@=L#:&T)QHX2F3#I2\+
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M53[R^@#'@1";_VZFM5<J[ YZ,R4^GI<56Q[>44,SK*T)(H)9[V!I%7%:)_#
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M5G_/4R&Q [**H._ ["A3C@%8,,UDK-9J7JM.NPNDJP>#H>SJ_6:P<XF#;58
MQ*Z-QBE)5<K6"2SV VX?\=I;0ZMM%95<NP+Z<*"/38)-VR[1& 1C-('VR2*"
M.<=G),CPR\J=,LW7$D\?E0)IT,'$,AP'SVSW?EP$_!E-,W.4&Z<=51X/(JD2
M8- +4['6^'H_KIW .R!>&Q81:^FF"#(C@^"48%'D)*=XP<JVUX(]-$8-&]W-
M>][AQ<B[R1"$[6+^7BL)3FH"'2M=-I0GJ3'Q/B/7@C&;JHD*K[DU6^W<_>!_
M1,)L.CH@21,+]-"$@I>HO%9L2AC0+[R:F?3:&O:TA &%VRMZ=]VR=<?LY>\*
MP,P->@G5+]Z1O:DDI6_!)-10$50B4BD\ =+&T7);1 DRCY-*')IO0X>MP3TN
MZILD@HDI1) +3ELIJ,D2Z[$@ZHP+)ZIMC?4IX+YMJ;%MJCM8XI-E5OG$,.!F
M1,9]0)W&WGFB$K?A?*M=L!O4CT"&36:;Q)0NYVG.@4619= S,H20M:F005#U
M)&2HK\M<E^&Y8=UMH)PY;.$.G"] $:I0*H:D8_"T1OY17N=$; W@07';U'@V
MZ1 -U88)!WZU ;M;37%++( U4WOS[YB8+>IX-E06W:81L*!2&JN48@2=(<M,
M0@:E4:MH5;50@VAP+#9!=B!T-LE=D1SC46<+5HAVR7K%I^BHE+BMD;N'06=4
MP,:+Q?2_;P:NV\4:#?,4T#UJXRAPOR5X!-9CH0*;/ 5O#VQ,Y7B@U?;,3%2W
M43M,#T1@4\=:1<"B!^%OL%\J!RL /#M$0(L4<JSVG&#5A7@@_*.[E9MLNR>F
M&A.$#2J+C%7MF.(2 R(9ZT3(7-T9G%3LEXU /1R)#>N@04P))JPFB>@<380-
M42)!.2?95@\(-#\T%G,/]"%K8;((1I(<L6\,T9&"D"K1$. UQU Y'7M=D;R;
M@3H %IM\?2!M3%Q$R[%)"!4JQA(+;DF*M$XW'AJ-,I]B4:R[KM;>-F72L/BT
M=-;QC-W+F4\*S+KD8K#.DNKF;D6A#J)#X+!A+;)AREC/(K=9PI(0 @[*%(>4
M75VIMTHDXL&(O!\5MYU^;ZUP*I@"Y:OV7!RL20>F%\F*2AV24KIL8P7_@.\E
M7#796Y$-B&T#YC$0W50^*TE#979@AX%!9K$]4ZDCP='.6E?KQUF[24/NCF@/
M7'#X2/&V_Z6HE(C<<)2S*2- ",8-2.,((B-Z HJT/&T6F*\@X"_5H\WUVBV[
MPG=8W-I.T@4XACE$XHC'UGW,@UV J7\J\B#!\#DV;JL/_UY,]EBKE>H!.H&-
M9BA5R4:I.8%M5V8IZ&B2\35K1?2ZBMH,T\-Q:,NTB%1ISC25+$J?4A9&DQ('
M&;(*L6(Z'P2'\G!GWZM#W"7GK<T B'%1,##1:'DF@J5'K:Y8!>L6YLK7=P)L
M@VCR7D:N;>D+<Y:D#T*6@'$A= X516_4NJ)O 0VOZTX;5Z.KLO<IJ949!"=(
M3\VBXM98,-*=]5R#EXLABU8E7@_#?G!N4M3<\^ -#=I'<.TL"Y)-X0Q8X:):
M +=BAF\&]BW*?Y#S6)B\<[T+.ZXDXZ@@@\EH4"B;HG/<"+"_0W)""I^K93C6
M1%HM%'N 64/0E8IOD8;L05J!#<<B"67]?P SAB2EE=6[LSN#N6_]<)H,6,$A
M8#OW#+P)_)G*1H6*PL]5R!C3>DT$-1C">Y<*ARUKN/<,#5N;00.3&*9='T$H
M>E81,4:+-7MJ,T1 RS(O=YK(.)Y6K-RQ50H) OLD!@-RQS *]A"6T*7>8KN'
MFBIO$OLM-<%9"]##@&^CL4&/.FOL  K;Q%E!@. (O%'"TJHDHIJ:M=:W>P*_
M5Z4@R;25QFL)-HSBS$:F$ '01$FBQJ_)N=-KI];M!78>6@XHBB@\J!Z>(JH>
MYA7Q)8 &>WG+JB)?;XB\";Q!<7$Y#8?-+SZ\ZWSKW]S=^.%H-/R*'2T[MS#2
MP @GW;J[*:D**T*!?DPF)7"L(A/2*NSDK94"%:HKJ6^S8KWDYQ6Z;D^Y@U!\
M5@*N.3GSXMOE<-2;$JVHIF@^N$S;*@TS#Y$GG[ETD6)0UEJ0JUBM'':2X=7X
M^8R&IT#".<JK#=J7$O^+T<W;86<P?SEFLG>OBHM!L4;3M\/!9[! ;O!%"X+6
MON*XBT$C-@1.X%V:0)G,.F@"BC=0DLM2#Y7$$WE"#+WG:GS\.CS1U? 6 YE*
M2&G0JS&&BHBKX<L.D]7FX^P45^-4B.D4R<*!H(Y,:@R8"*N F* $DU&J>MEC
M(6<.0DT@ J*[K&EV[$O%B1>"B11# /L7[^^9:;]N\"6Y;BM56_?QW8%K+?:J
M7) D6L7 IV$L.&IX"1PEVM-<K7> E8971?A#85RNA][HY1!PA12>87H9" <F
M@)UD:!*DK&J=:N"LJ)J-<(['TQS7S\6@^WW6Y,I->RK"+YNK]31S+JA"$<#%
M9<8E%GU0,@66P7ZT@2<P-5J7?@MP#@!_:U-T@BV(+)J?#IQ*;2ENO,R4]-89
M4HW(/ 3^=_U!>0EL[M!??!V O7_5OWU?C+KHFWX&N_)]I[8N[OW5FB-?7*DV
M) C7G?'XXK+T45;N:-\,!^58K(JWY4JKT47'L NWH5I[(8,%]9V%Y#SXG%<Z
M*PSNRA?]1GZF2X3>@6Z'(C<J"6Q<L)AST)K#\RF-MP(/IV=6SA^ J0DS.EO#
MF,L^!*% 52MK!".9Z]J%D.KA*_%[ 9MB?/5^-,1V$CW__<\Q!L!GKL_@LP-*
M?=GOG#5@%%5ZSC1PE S"&TD8F"/.:29=JL@?BH5:5J3F]L ="J4-\4."F4B2
M@G*BBGN?&>.J1*D\A*T>NE)JS%HNVD%QFL8C'[9,6BKO"/;XQH)#8"EP"TK8
MJ2P2B:QZ07,S+C50'0J731D[>"RGL:@B(UCR+#B8A;C@S<I<O?CZVFZS-OOA
M<W]ZN__:.,44=A9A@03E$UY8]>4AOU*>QFJ@ !/@&-L&IQKHCHC32G%8"G++
M"YV4@ UO//$.](VU>&Z0M*B(A5E2W]/BM"E#R4FIC4]@'T:\$FY+*QO62?*<
MLZSBQ*12^O1P6BF$KVF(&,/'1A&>@(W (JZ3B$$I2BM&[^MIAZN#X'1_^6OW
M;#=,;DM!1ZD=)5EE'VU9/!YT#JNI3_=:"%.!^O[[.P-VW*Y1CF+!6"F%!5]$
M22- ++#DHP'O5!!V1.PVY2:G""Z1I,GP:+4*%&142782LQ;5GJ%XXZ^Z QX
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M]1W+A7\0,&[@&$#&+@!&^0; E-G\-LRCCR"];GJ"\H^E61F!*6J&KQFZ&@3
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M FL+(B=R#.98QR!:H($9A@3_8;DC&N4!'8,I*J;F]E6KR(:DBNKEG\4SV=O
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M--'7-%<%9#: 29JF:($I+NI#,<F7;WY(V&_58U09#,\<+F#:BBG)JNDIEAF
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MP\>LC!8_Q>$U#AN(HQQNHY$TK:^\.)^OTKS,(DX;7V#?S@J4_"<4^P"C\MS
M$'4C"%S?UVSDSH&JB 9@LF;IW_WE?ZZ*'Q?QG9 7#ZOHS]\MX9'OE^$Z7CW\
M\"4&G4OX.;H7?DG78?(C_98#&?\@B9OBQ^_^YTWQX];M*[#DWM\2G'X V?G'
M'S?A F'R_CHMBG3]@Z1LOM;?%>GF!Q$^XQ[>AZOX)OEA%2V+O>_![U^P3OIX
MS]9T#=82>R"'O8"M!1+@0OB"/^&EH[Q-V'G\GP!J0P#0Z@%@]3M^:" <)PO
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MY(*8/X#E&K95BS@2J )L$L&2P/_8CF=PU3Q$$.-+HZ^T30ZX30E;#>$GT'%
M_4(G20^(FV<U*YK#\M*$% .AJ>M'$7"3IHO[>+4BU:Y9W+QA4U>7K@W[=^FJ
MS(7[D)3)-5-5?P;H5L)2;I3,$K2GG.FM'-TJ%:72+/#2!>ABI.^@YH$XEH>K
MZ$KXD @?YT5:B^!CB=9^OK<K\X8#*2$3];02/E5(6^M&LS'?_-G]6X/V0+T5
M[?1IFVE3_B]$K#4:+!QHCIH\T$F.N%))F\'?1WR!0 T+!=NF-@F$LP0=P,<+
MV);7V=6,&S', &$DC)M-KPLV+1/P$?4L+,?H&KPQ*>? T^$.Q@FNA#'A\ZEM
MGQ;-F$5F&-!6.$.Z#=$RP=F*B,J'+9*N58&7H%2*KA] PH"M1"F5(#])?I/W
MDN3TJO7(FF=%.^PL!/" F(OG *-%S&S3O-^>)[N*FZPI"4:"+Y,D9)5DOY.4
M V9['V%I3"XD:?*^;W6M%<'3_AX"_0KO\B@:\W3([%''XE![K!X^7E.@^9I"
M>_3FB#OE/I66LK?%*AN2VC#7&&%AGX8@ )HQ&@SIX$ [NP.MI^8VM=V.OJ \
MKY"_PC[R4\ C.-KCR3/1.L,G 18R!&6H(\R!?LG 3:(R2XOT:YSDC]AOS]!1
MS--443Z0<RK*8J9Z5&G2+?9!],@,^X%%X)KTH/PVWM2\,N?LE50:>*G*7DH,
ME@AV43V,_%-Q0;RL7A-?*9YTA1J@<0/SX.R;+SCO\,>\JX:CEKQ&??K^%ECZ
MP_OT/H$GY_4X"/(LU@\G5*]NS6B",F'S$VX6T#):<2_4>K.*VJ3RX=/'8=7C
M\S :\; C=/ QNR8D8;0I\]OW"P!EQR5<9GD9PGLYS=^4,?,= P[8GUW!%+4C
M,]O*$2.T/3&C^I9L\I@#-"I3LM<[7+E,\8($GG]=!29:T 32 Z,YSF^C!>>Y
M:'^V-1W>9 O4G"VJ1X"WC0_._;?LQ#WV,-X,CTVBEJ92; D/<A^W;$N:F8Q>
M=;@0S-/*6[!H6:MYY9UN/P<=Z&QQE9%=.W#[GU%[*'*@$O)=P]%UG1.TC4W%
M)KD?84:^[R0M8,?KF*'RK'YI9=;!8V*N436O9YYC0&G.$9C*U/)+P/]_ V#E
ML^IOS.%_4P+?3H&_ ,6 C Q7< %_*BFE)7IKP5C/;P7,?LC;;@U:!=X&QC^Z
M[T$[(KP0T)F?7S59#0BZ/=#.$42,9HMGG#X=;7V>V/\/=#GNI*G@>O%>@@^/
MDL!L5^'I>/XQO(06<>W&"?<&%/:9SIVP0INW,E4-GO+ 3BL%-G$3<OZ\#G^/
M:JU\7OG4"V'#)IK7"AE7P(*4PB"@5?TMO0?DRV9 6LBS^>^+>$%D0V$G="RQ
M=Y&O(\_3>4SOK2'4>F'E#N,7-W/6GQ2UF\%;ZXC2-KOAUDC?K0?#AJW59>E#
MN *=I;V?UA*OH^(^XLRV?<BSRMS:A1_H-$UHI0JJO GK8H:<HN[6@PHB-I=X
ME$( X@#K!<&;(\,^4MBA&1OOQ'T>I)KFM"K!^%O*E,&\<A%@T R098/PNA)^
MW3 9)F &!S+A1O7#/0;1=5:BRBC)M$=SU@I3KH%[(C5@&!S%4 D,+BQX='6;
M&]>"&K"34V8+%=NQR?T[K>*P??>'1#"LG2EI;;FP!<'#M+!A"2]XZQ:BSTAS
M9UA&4&L!O 9W_WM GJUC8!H P 2)XX4OX=3?R6FX#E>D:8*V!%+N2G KM\2R
MCUA99!_L@37A:,6C%W0<M674F#\4KR=_")BZ)89NP4J^B],RAZ.-V)A14M*V
M=+!TP]D?8!AH:5$GU/UW6.5MAH'\#;I._A%F:U!)/MU>>5>S_>P-?=89W!A'
M2^$C>SP\Z^,25*$HNQ+^@?_AD\@\S_C@AAK?T>!J*>C54IG54U,P8O9A$=\3
M)-T;\FP'1MTFYFLGBT[$MTF;>D[VDZ,'IJQ(@:4'@>[[OFUB]U0I<&7;<U7M
M[60_[7C\W6.$UY\:;!C*2CZA7+*&^'["'MF7KA%_20$8C=V!>8WMSSRIIM:T
M'J(0V"Q)K@,IV,,MK^)=S<L4B8GH,8,3(T=7>EMT#??X!E8@*XYR2G\0KQ0!
M[EWUI5^<S[G -N0C;&.&'M(-VJ!WH%3VN+V'>Y5-SJ=+HT]4_Q/4[KFO!3T]
MZW+=F,*-EIW6W'P5=:SUG-FV&+::HX:Y8AIKE*US :X!#14?0!D7C.N1ZDW9
M!2ORZARK=?9S1./9M<7F;8E%<;@NU^H@7:[-5^YR?=P^TV=2/'M0?9)'4Y?
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M?@)L=$\.^&[[%ZIO[*3^+C#O;L7ZJW39+E9Y[&1KU^'I'5)#-MO*Y5ZR;@J
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M+@MN\W79Y PM2_)(W,=5WW)LM3ARAO"13@TQNS_'ZAT=VW6*.BZ@-?S22NI
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M_#;#,9VK.+R.5VR>)QNKF>3Q@D:7@U5T'8$5Q(.5(;4L2*M9F/#E)IK3=TU
M,H<[V"1,'IG,;].L> ^V\UI(PJ+,^ \ISL5,\B(KZ< .#S(\!]2DVP[/\ WB
M!/@%SE?]T.Q<^#DMA%\B;".!K3\*H872:0)&Z"\X;C5C_J8\'@RU^^!R IAL
M%Q<W8[3;&.0VQ 8O([[N#[)X)1YC+/T3<@[(E4+;M]>LQ<RG,IO?AD#\]DT6
M$;/>2DQH_"]L]C#L0U@SQC'B9N0K;4Q0L1&ZX;+@T B3!-AFEH< L 7.Y>7,
M<AEG>4%-87!0,C"*/%S5/W[*TD6)PX=9=LBO28R^J<_ EJ/\2K"!G4<T'K/R
M6G&X'CBF.(>+.>>!I\;HXHQ@ ='73900@V8L'%_!F!4L)=U$6<C&**,8H2G,
MT2U<CX*@=U[,((#L9ZECX@2-SPYA@QE*NI0U:(R3.0[3KM-I0 =]3VV;X*UM
M2<I!5V7NY*@CPBFU^SVMF<*2]Z;TT)#SO0<7%E4"$;_G.J0YV(GP4W07K009
MWK\I"R"B,B>50%B YHE*@) ANF%;J3P&N(09?;$0%M%UT9[LC4<;Y\USPT0
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MYW IP>H@&<'F*Z>5'C<C>,HVNHC0\4E&A_<DPHW?R^>$G*[C.PR#6M3/6KH
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M:PTS1/NT=[YD+T\[;)@]A;XOQ'BKC*+_UFFWP#EKKTI<>U6$>V#/W-;O,^+
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M$>_3VP?>L"YT:3^1G"\T*3I&*9RGJVA%1/+ATR^T7/S/8P<W=CMDQ%3I".?
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MXC6-A8+WE7"*F<#7FM-B\?&*J=238+&7( Y:_ 6G&Y4(^ 6-@I$L4Y_1;"=
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MX$O!=RFD?$94>[Z2[^T1Z3M]IJG#!<BF^<T7;.UU5S!6C_M6_X*>]FKC8.I
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MX(I'0(H[:Y83-F#"1=&]&X 6D&A9D'0) 6^I+A>HASD@\<)UN(CV&[>MIU:
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M(4#5M<!'KM,,%<+?([#LP=)/* )#)G^.&$JR'94!ILCAF?>\E&F!/(I5Q?%
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MCWM[M<AFZEHH]1*?^MI1CBD994MV6*D84(KQ(KL:,_@Y'R3B M9"35T!4E"
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M4CV$>R1J[B&O760IPX#N6-^NVK@4\HWKSS 5R]WK;NA8<J XR [JQL=^=^R
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M]"GX,DIE$"Y]K!))2TGRX0]4,+*)T-#C*0R?DO94;N9.$OY[IK>4#@&HYS!
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M==#^FM\W5M_*X7O"CM('H-#F>&#@G6Q?!$F$(X:/24V>3#!^ R+L6\0M?;F
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M+9F1"L!^O\Z%Q-6%A5@,<!LEBX4=PE41/ .H?3;!G<I4-EOB._XL<EB\EKW
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M=M3J=!IM>RCYNY-UM&7)G W,])Z.=CUWZ9!+/VI$T<8BJ$<FK,[6P(OLVH!
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MC#UIKE*&@AD9DU8$9AKLMRQ6Y<R$ O?EQ'<*@\1E.8@TCQ>!*);@>U/$57;
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M"8AF2M%EGIR,# 4>DR<>U>QC R!8"#63@,N'-19"""82YI'//ON:XBTZO7*
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M$7?!?&_CR_[.2>ZNMO_EWW][G26=&\^;OR%&1KF@XN3R/YF?WO\1I>K"3T9
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MXC G&%#D22&OE,YWR81#NY(?:5!':<_UWR@X79%A%\+U:;E:C,:K$[I_^F
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MCL!16*/BVZ"]EZ79TYKW\C+<K\5[6:!QOTGU5]YW^6.[ !3V3@@0IW'LB%;
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M0 JE&)342 OB@K);2PRJD?ZF[:2E?2ZHC>'9#TM*'8@=:Q*09"#:O!$C%J=
M8;2/W]Q)")4?> W9.BH[J?W:"+U$+@QJ(1\2!1I:WS]FB[LW^6CN1^--TI/3
MZ_OAIP,A&F  L:0*$8.M]V[?5T7L *OKU8<];QJ6SHYYXE*6_6L=Q7;?XO^4
M"/HZTB)HS+6GE #KD,;"8@3WBQZ31%56^^6)[ZYOY6\&U!Y)<SX@YEB;0(56
M$DHO;81-<LREWLN80D2&;0#4UMQY)M3"Z65R8I"&P'"H, @*G+]=?^CY(*G
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M$JX16]&:&5I'47D[L%14_7*Q>J3V^*_G*H^_"C??Y]EB^67Z]8A)\<,SP2N
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MZCZ%UN(JNN)*58RZXLKC?#F/0DN6^O[Q7\Y8@^5?$K!EA&BAD!78 N2 ]:Y
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MY2;)_HB2)UVD&Z_GRPM]]?'HRW.M_D$2 HEBW"-/-&)."*;+M0M+1AC%UX:
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MX0PX'(=S2N!R;HBV*#S4N5K2#7%:+7^HRX5>+Z=9NERJR9_KZ7):(_9F3X\
M,?!26Z$H<LA'X8Y5I1UCB9N?CJ>7K3V?Q:@;<,Y)_.+717K<GG"T;["24^VU
M@XQ*3;QUDLG**(K-R+U 6E.R!F=T@==?@U=&I5J-ET4Z$N]NXYY[D4T.R_<7
MS8(4C!N (8YGIH>20JE9Z4I)M!W4GEC/[M AXGEGP RUHPOWF(MLN5JL-^D6
M#DO]GQL'H9! @!'OK*>8 .<\+E<%G6MNG#B]Z-WY!'YK7,Y#[5HI,_=U"=)C
M8RE#R!%CE#28$UNN$%DS\@>C-B0[2/W6"/V*O#!*R3T&%NA(5K]T4"Q<5R9?
MTJOLR,O!L7[!F@( J NW24XDH514@1'QU^;7]=ZD>7M2'/+\; E0UP2^_I8W
M(G#5+S GF(?"&$.]%1X#$G6<W?P=A<T39?3V3#0(@9L"=%XO;48 $APH+9S$
M0'OKBU>R[5P5 R,J=38,,1O!,I3\?:F!'@^OVM,C6*"8EL8PPG7\R3'ELEP?
MYJ:Y,][IM7K/IX-W \X9B7\\>?V^/@%3"T2\ET8.MYA2*BD'5?BBTB-WOFY-
MN>.<T JG7Y,G1JF2CX<51L$"1[VZ7FT?M*(8>08!=-19!Q&1E4[*'!AA7H@.
MZ'28\HV0::S,E19%DS_<3+--2HG/\[CJ;+5+:_IYGF=7-ZNXP&EV'Q>GYO-%
M_C69O4+J=@,&J+0'6D>M!UEN (6^C'>+^.D6*<F'XH7+QD'Z@R+7):_$V^5U
M/#)UGJV7W3',":,&K*V FT2!C&K$8+S=5G80A\$(;X6]<TU_\ UF\%NGU_FS
M,)AINC3KQ:*P?66W[_-LLOWCD/VOW@@!>@>@1-QY(!DG$A5%6$K,C6Q>W::_
ME/!=9P;I!ZI^)=*']6+R)5FFZGZ1I@^OLT*+T0)U@B& %8;04"&D!IY46IRB
M0SJRCN54Z1ZVP0(2XE*N[LPBO9VN*GM+\GWZL'[0^6*1?XMGHDGF\9/5XX$C
MY91A L,$"&:X4SK>"#03'*D2"6Y@<\7V=.^B<YTK/>)UGH>GYQ5;-BD$BTQO
MD_A!<G\H#U7]08+ST"L@B6!:04"PQ*IZ>#>.-8]B//V)^FS2J"^TSL,S.EE.
MEY_FBS2YO<J>AXT<*H%3=XC +83*.TX]A !#ZIDUU7D+Z^5JZ\B<.@Y^Z0RK
MYJ[&/\QGFPKRZJ[DXZML]KB3H*^9ST\<(3C M-EPOF&*1.3B JLG/0Z;^["*
MT=._7Z@Z(K]ZR*,^_;^-_K2=73VB_]PO;%X8I%926VPA$L3)ZG$/.=O\Y42^
M15*W!J@K M_>;O!,9B7S5<KP$Q_N>+ FZ4\8,6 CF.52 NP9<41:"W6Y9D!,
MB]H1X$UR17_8=<0OQ;.ONH^3NH\RZ903X96.00FL%$72Z @8YP)H6)G],!$M
M,IV]$8MIUQ!U?B@T/O\/C! XD90R":((4X@52<KC08< PI0Z*5R+3?]&3)Z]
M8=6=TK>[HES=?5A,L\ETOIG<NM!/9[,\SNX4B5![N."$9,A:@SSPA0 $ #RA
MB7&+4MWCMV8."%Q7;+)(Y]OO]VGZ--?WZ??5];=T]C5]EV>K+W6O"?4&"\HA
M(0B+U^.H_CJMM+*5U$-2M'AK?R.6S2%@ZY=!_ILFB^MO>2N^V(T1""EJ8TJ/
M/42<%R>DJ7S7'/>^.3N,WT[9-UK]<L'UEZC-)G>K ^',IPT3HFYD)4",.L>T
MX]P(^!3U@W&+1'GCMSX. %A'[&"W?E]'"LG7ZQAP/+T()T! SJ(VA!2'3T$$
M4K6X08S?@-@+1$]$[J>PROKA(5D\7MU]FMYGT[OI)(GZ[V12:#33[/Y#/IM.
MIKW65ZGS]><NAO)AD<_3Q>KQPRS9/&$7%6@V!9DJ7CE@>C_>.1 I/0$(4>D1
M@IY*7-PIM:6<8&KJN:[WY)-7E>3<NXSZ97@/#Q$ 15@91BQ44@$3X;!LBP+V
M#(KF#OP=%U+IDJ![B^5VBE4RYC(K0Z=L%Y[%2YE4$B+*M1!0(EQ"IXT;,GMO
MP^JX7?%&\S3NIV$XU#MIVZ3=F"#L*(RW<\D5)XY24:T*Q-O:N",)^B#?\>S=
MS3#[53CB/)S071KW 1GA/ SP+OD]7TQ7CYM2A]OZ@4?C"O;V"4@)#)T'&GCL
MXGT=8.YW8AT4$=-#LD/CQ.^U"97W TL]T@^47M0[!QG"'",FC''>2%=-'0J!
M&U.T[_HM?2D#[4'JB;[NU%253F!FO7"$%&[&;E/$>S=IA8D?IS!O!?_>G)6-
MH'@C=!R5"#X+^3HR"C9..4JBJJ UEMIJ383!7GE>S@]P.NJ4HW6A/9AR]#0
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M:F3)V,VN^.<F;NI__NW_4$L#!!0    ( .6 =$Z:!\96$\@   [B"@ 5
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M>93;+YN$0D6YT&+/RN[6.78N;$J-)M2-O:3Q9E2&.]IX_>FWBJ(DRR(_">(
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MB3>;ZMN2<[OP8T(CE .?9BC)<P!\KIV=63SU \EB6WP6Y;$_21YV_A%LDE*
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M#)BU3[@12N:EH')HC*J>9;[GNEJV2_K\ZTW1;@IOU_A.W-G]CVY+(R*4B2H
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M>2GU0[79L*K^MJS7"^:#R$\CWF04I<B/:) .-T%8',5*N9#IMBUKSP#7^V4
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MS0<KW)_;D9C7T0YL4\Q,0.7,H!N?J;0IDC9.$"8H2V ,8DI]%*0P&<H%HX#
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MX:%+R=&L/<*-.#,S!\]3- <\HO P3G57'-[AZ9'@[V6S\.,$0#_B'QZA,,X
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M8*FQ(KT_M5ONVH.%U[>LW/)>4RXWPT#=;XV%,/)IEO.Q&@<YA0Q1<8TG2@(
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M/EV-7@33)E13F"QP.5Z4KF99_#K#C8H:*;+IJ!*I6O&:"FFQHJU QW/2P$<
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M/3\0MWC$>\I*F95&*TJ2M >D'/U'I4XZY"EE399YTTN8YE<C'2$:SZ@;&F3
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MSP0J\L3^B^JAQY0KJJ&)_H5:C&%!(27Y_JE>;IM2W'/MSIHMTA02&H<L\',
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M#50)K>4(-V#Q'LMBLYY[FJ?GSQD70JVYTKU@M^\I/_@L[Y3KIEX"U>HV#L5
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M,I"#V,] 1@*8Y_Q_L7BC&R"DM)H_HAG+\>2W8G>\_,[A=0LS SZUT#&&3KD
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M&X"QO="/I>IYJ[=B.)C_4;'>\FU7\E]U>F!R\7P"?V(Q?1[JY.(ZQ_3[ =3
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M5)<L3JE4<7"Y3YYK]"N]*"1)DI0"&.!'40,6>2OH"0MOZX D6U8I@2SVU[5
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MOW0+;*N I,#+ &:-!3B)X\0GV=A6'&2RM9,56C"=G#%09?6%/R>^JW_D6S9
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MKF'='-%(J( L,0)2:9 3.9$<@:BHHRPO$KIHD!\U113G24P*GQIX3@05:;!
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M6=2MLR3/!CRZ2.9\-121^*F2YAZRN8Q9TKEVA)F9;=:;*RLQ+AI.^/Y?5C.
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M&ATT4"H1%N:E5BT>3*18+ Z\2<2Y *"/00N47Z,QM9%>)J'U_0F]5YJ"?IP
MF!$"7$K2)*:9/S85!B015GC5!@SK>@=+0G"4>1)0[CDHDM/K_I[,5)%6YDQ"
MFN?@3DV053@44^$S-I_3WJD46:"XDTVH-789+:=$WI=5\:XM'IH5@9D78A!
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MDALPM!R0-/!E-$9'>Z:7H7N(3M%C[.< -8?);^,HBY$6IL6D:6Z2Y81JY'>
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M,C.]%?,BPX$=3OK,/EQ>I^7RB)E(I36#9JH=+\>-%F8D'K+\7#]]V&YLD&0
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M:F%=WK?$WQWI?^C/^7_L<A6+I_R;&MYCD%#R3,A$.>"Z+(HSRMGPSR#A-/!
MF8(&[)O.&VSKZ+SO?'8.G0:F#YH07H^@E]8<AM+.V_?7)W)?.3N/^]V2WF>G
M<]H:P)XA]5PJHL&.LP.Y1ELX35,TKJ8NA,?;YZ;,EU&2Q8+(D$51&J229M'N
M)E\B24I2T)509QLQOK$\W+4(7=>?+YL>)U=1# ;#O5CV3")?DVD&9(N5M8-6
MRYM1(H\X&'?23;55\\WZ6UYU,#S95.$D:RWXL9I[TI![+!VM,D9 *8%+;1FF
MT)>\<3Z7M9HYY)73.0ACT6(I]9"TIHHP,@V>[06TAU!OJ#8#*BR][> 56FM*
M,Z,21J\O^=^#NDM5N54O?^4'*=53-Q)%SDQ$;B28YV8I9<R5HQN!!XHAHALW
MOJ72SF8/"I<YQT[#:(<OO1[^+JHZC(?*U=?5M@>-4$5G6&FL<^R I[GFE2L-
M<F!DL+C9%G^*7YMM,REO5^3UWGCJDDR2Q/<HET3RD&:B+^H9TR#@*2@8B&/2
M=/SO\?Y^4SVW1[T.'#YZV'N7@1%!),$U@X#K:PV,^\UK>\%:R'K2S<7Q<+6W
M@X_8C9I&ZTQHMF?AX0CZK%Y]>#?\1'UK@\\?WOT#4$L#!!0    ( .6 =$Z/
ML3-Z78H  -3[!@ 5    96]L<RTR,#$X,3(S,5]P<F4N>&UL[+W9=B,YDB9\
M/T^1?\YU5F)?^G3-'*S5,1,9THF([)K_RH\'Z9)\BJ*KN$2$ZND'3M*IE:23
M\$U43T]W*"4 #OOL V P& S__C]_WDY^^9[-YGDQ_>NO\"_@UU^RZ:@8Y]/K
MO_[ZYY??U!?SX<.O__-__+=___]^^^W_Z,\??['%:'F;31>_F%F6+K+Q+S_R
MQ<TO?Q]G\W_\<C4K;G_Y>S'[1_X]_>VW=:5?5C],\ND__JW\/]_2>?;+SWG^
M;_/137:;?BQ&Z6+U[9O%XN[??O_]QX\??_GY;3;Y2S&[_AT!@'_?UMI9HORO
MWZIBOY6_^@VBWS#\R\_Y^-=?@H33^>K;-3Y2%?_YHOP/O"H-I92_K_ZZ+3K/
M7RL8FH6__Y\_/GY9R?E;/ITOTNDH^_5__+=??EG#,2LFV>?LZI?RWS\_?WC2
M2/:]F"SG?QD5M[^7?_Y=C4:S939V/^^RZ3R;AV^OFKB995=__34K)O,@-A00
MK87^[SN*+^[OLK_^.L]O[R9!TM\;Z8K-%FD^.;9'SVJUT;&OZ;?)T4@]K=1(
MMW0Z*17_Y2;+%@>[\VKAYKMQF<["$+[)%ODHG1S5IU=K-M)!4]S>YHMR:IFK
MZ=@4TT68A,)DE!]68HVJ;7>QYC"HWT+;':XW/&HWT$AWJ[4E?,J%+RWN/TRO
MBMGM:H4XU-,Z=1OII$_SV7^FDV7V1Y;.E[-L!<ZAWNVMU%ZWM@I;7(:E.9_/
MB]G]IV*1U61K3)OM"?4IG<V"6K]'2;&KD?:Z_3D;+6>S@)Q.YWG=^>+XEMH3
MH-Z,4:-J(UW\6U&,?^2321CO'Z;!M+K.PR?4?)XM#O7P<,V6.UA3][4;:*2[
M'X+9?YM]37\>5O$K19ON0EAW[HII29V+J^VO:^)V9#--=]UF5]ELEHW#?ZR4
M52Z<'_/T6S[)%_4-A9,;;%J<8V?;&E6;[F*8#XM@DDSRU6)_<>6NKK)1^=V3
M.'-$:TT+4F^&W5FAZ>[\.9T%+*ZG^;]6Y-/9-+O*%R<PN%Y#C73_4[;X6,SG
ME]GLRTW8JJC%8I9_6RY*G+X6I35;3+\LBM$_;HK).)L=%.+$YOH0I:9:XEKM
M0[!ZHR*JT4;$NIA=IX'BM78KKY5MO!,U&;&G2B-=^IQ-2D?A93I;W'^=I=-Y
M.BH_=;!?A^JUVKECE[UCVVFU\X]_?Z2?+J+)5D6J-PG4J]U(1[\LPI=NUZ:E
M2><W?E+\.-B_O94:[];%739;C>JU[^;V;I;=!,4%,I8SY3%]K==2XP(\GK#=
M/Y?YXC[8PODH/[C%.ZJ1AKI]<E=[[=ZQ\]S1#;7;_?)T9;R<9!=7GXKI]VP>
M!K_ZD<[&%W<KML8*=5SS78GZ.71DEH]"9U:%_YSF"U7N4%9EFQ*X_D>Z$GM5
M9(U\\^(>;KPK,4OGV6JN#9O]Y6W3/*[1>LN"EG_0Z3Q;K2-A$5GU9F-2J,ED
M<R <+?%)GVE7]'HV3,WJS71U^6V>_7,9%DKWO<XQQJ[RK72F+@7V5VNH:[>W
MZ>P^3!/Y]30/VDBG838<%<O54<AE,<GK'%,>UTJ'':^-] F-=2A&LWIH1!^/
MHTSD6I9I=EWN43ZFW[)G1^^OU9O,9D^JE>$ML@QO@6PERVNM-=S3TK/2:&>?
M-]AP?R^S65Z,W;1AB%]OMI6^A^W+K&',=S7<</^_AD4K:[;G+YMLNL_%(ITT
MW.<733;7YQ.(L7C9S9HL"!O]>5A45[;2Q_"+3?FRW5/BU=;?R7XNLNDX&Z]B
MX:HO!8OL-9%6XERE\V\KF9;SWZ[3].[W<CK_/9LLYM5O5A/\;P!NHO[^^^;7
MR65ZO[*:U'2\ZE(ZF:MO86.3CK;[ZTD)Q%]_#=]/:M1*D!;6(<&TU4HB8KS!
M5"!BH=&,44:>BKJR,XO9!M-V9=TL8?--[S<J>'12&,2Y6-QDL\>'A_E\-"G*
M<WJSG)6175^#<G3HWS_VP-/LAQ+FN/%* BXTII9P[OD64>V0K8/H8YZJV>B7
M8A;,Y[_^"G_])?QE?7SZ<2W(SA#0%6\7+R:;=#9ZP?:G%3<E?K];A<;]-KK)
M)^.J=AD1VP*WB@$I)(A?31F_OSIG-#Z;O&IAONE)Q2".%0AJEQHY'4B%G9"0
M,.@EPX$'_4TJ+BP)Q7V6;3SKCPBTH<T>B0_633@24 %H # (* 48X:"2FSM1
M2^[S&/JU&5"TB_'#:&Y]L2J'].6LN,KFY>V#=.*S.J3:7S&A6$,!I.*:86,-
MD4!8"2TAT@OO*(A@%'H?C&H4X*[HM%K=7JY[A^FTOV+"!%)>&"^4EA!! I11
M&Q"YMD!&T F_#SHU"G#'L]-13-HM(Z;<<14,J8!AD!$2[U$E(T T9I4C1Y/H
MQ<[T+9"H*6R[MU5?<]J_:5-5*&!H4" D**P$+D ,5;4Y\)+4FA';D?7AD.LE
M759JJ+.WK=](8L/:I\-*:%S8L%$-&5)LNTWBF+T?X[4V)XJ.P.Y@G.^YJ=?A
M^-X&NEQ<^7P:.I2GD\MBGJ_X='B@UZF>:&:-L-A(SIW'@@?H5U,L"G8@8MST
M..*K[J_(4D?.5<$$>^PT4Q0!2D#)* ]I)9%4&I_7R&U6R<^'< RR79ESVTZ:
M23JO0L+4SWQ>AS+/ZR0L2"*UIP(8*ZSQWNL**H@-.K-Y_U0%[^))))Q=4>9Q
M-VUQF^;3/5QY63@! AE!&5"0$L$U"O\M*JD<4?1,27*Z=HN&(>V,*&5@X&Q1
MWLV[K+2RZO4?V>VW;+:/-?MK)D((QIVUF#C,"084>5+)*Z4[,^=HC,*?<Z=1
M8#M?I((5FGT(/]9:G;:%$P(<]% JS[3TD",EF-Q(A91UZ+P\GTTO2Z?BV)E'
M:GWS\[!)_[1@ KAE#B H-5>2$<8PTY4T DM^7I-(C#J?NYQB<.R6%1M?6&UR
M/"N?..H YIYH#)D(FVQ*'R *.X(SVPZ=JMA7^1$'96<V2CJ_*2_NA'_*B.+O
MZ625T&5ATMGL/I]>K_(U[+-4ZM1/C)?*2$F=<1!JI!UP8HLD1[7\!&^-1B?K
M_[G)T@+"7;$KV%AW:5YYO*M0DR?X[/,U'ZZ=8$>HX9!8!XARS'-$*H,-.XG/
MS+1IEEG-X]L5K^PR\P&<1W<Z:YW#[:N6>"$,H2@,(!YL FD@H*Z2%$A>*WKO
M[9SG-LND!H'MQ3ZJ:Q<E@'IE#'8& T MXV$#49D$F(7A<5[GM<V2) ;)KECQ
M+)O2_%.V<#]'DV69];1*NK2'+'6J)]8&BY*" *,FREIC)=U*3J!5Y[AD1=O4
M+2#;%:=J\&8K01@#2%C-L W#2V.O #>5!#K =HZ+4#0W3D2OVP"T-6N+Z:AF
MW-FS\@G" )/2]J)(82!(X+.M9 N&F>YTY7DKS&@"RFX-DH.62.( 10$)18D$
MT ,9T*A('DQU$+.7ID,U01IRR1R)75>:?WH;X^4E[QK>N[I-))XP#S#&Q'$#
M$-="*EXA$' ]LR#H!IV^+2'< \?J^X1W5TJ\"]*XL,A:Q,,_B#C@*RE-$/J\
M/'K-*W\WN^*0[C ,^O&]LEHQT*]42()<Q#-EE:%A%V@H,!I6TI7_<[8\.EG-
M^R_XG8;KVPR>YT@(K;TAC%,G*=<&5X.-0J%C FD&N):UPYU&H.W0[?NU.,'I
MNZ-2X@RQVA'BI.&*><49K&P!*AR,"=<;X&Z[!0(UAFU7#"I?(ZB_9KU2.L'(
M<JU,6-TAP=188[<K/"7(Q%Q)'^ ^O 7.Q(/:G\U\E*V<2%CZ'STG6%!FK(?,
M5&>RE'$48]L,<*?> E6B,>UL8=JHXG,9YQK^S1>U/'W[JB4,*^$U* ]@J5->
M6Z*W8R+L*\[L9+OU'5:#6'<8/[R2>9E.+KY-\NLG*<%?CQI^63X!FG.)PR*,
MH$:(!;BH>9#MW,ZU6^=1$R!WMH 5T^NOV>SV\9*[;PE[I7@BO$- >^"M)IHR
M3_QV:#"#7(R-/&Q[IR5'3SS&72]JV]<Z'H'S*:NSKNVHF5B/I6"::V"@P0 K
M2+?R4L-CG-#'&T9OGU/-PMV#=5W/K$ZP$<A")K#1 #+*E*#5N1TC.NKDBPW:
MGF[=YWPDM-T90 <?[WS5#-I9*Q'<"5RF46-(ATVG"+N1RBO!(+$QNW?^#F>>
MYJ#N[BK5":>K>Y##1BH:=J1:6L0@(TH]S*U&XQCK6KQ#0C6&=(<1[H]N$1ZZ
M+?%*Z;#WM$9Z0Z3@6#)-C%7;J==CV.EUX._9[%O1^IE\O(I?!K)'PMKEBK9Y
M;>S@S9IG11/'L9 (6QJ ,4(3HF05BL\!!C'W]0;H$&J!)I&(=G9(.AZO$G"D
MD\LT#T:]2>_R1;HO?'1'C41 ZX-9%XQ_S !&%#M;^5VY92S&8!Z@ZZ<%QC0#
M;%?$^5PFOYUF8Y?.IL$.FZO1:'F[7!W./7LXZA4.':Z<4&^)]81[13TFQ"&O
MJRF5.\AC8GX&Z IJ@4Z-8]R?U7R4M9QPBRD0@-/RG ]Z+)2L]@(\6(,QP<L#
M/ EK@3G1F XEEC4BAC7AW&II*'$TV'3(!P0QJ"3F ,5<OI+#8U&7_I\F\'Y@
M6#>)]2Y7*-YDBWST8!R=998]S EPVFK.PEAWW M'U%H//(Q[76OV;%GZ([/L
M"0D0%@8I)WAYC"\@]95$B%%W7E&?S2IY?Y:]XY#M/(%1(UGV)/:<4JL) .7U
M#:P\VLQ+'#D/SRPIR:D*KIUE[S@X._.41&;9LPI2)K7#2!H-$<94PJU4("KG
MU9!)<KIV#V?9.P[2#J-D6LJR)X%&A#-)M$20&5(.MDI>(_&9K5(Q"C\RR]YQ
MP':^2'T\+<L>PQA@:)5UCG--H'>255))9&/N;@_2/]OLLG0JCOT<](3-Q\5L
MU??QRI5\F<V^W 3<:I_][&H@P0AZ#H@UEB+$%?!!YHWTV#-__EGY:JM_[R%0
M0_CVPZY53^=JN;@I9OF_LG%M5CVOF& *2)AG%4.&:(X ";9 ):W&4>^+#'E.
M:II-D;CVR:(/\_GR: :M*R4.*VE-Z4ZD7#LDI!"FDA)9'!,M,\CSHU;9<Q*F
M?3+G8KF8+])IF6'G2/H\JIE80  60!+*N2,.*:4J6P]+S,\L?KAE#IT.; \!
M#B?82#5J)X"$38-$ACI(D"0<4R@JN:D0W9XEO25"-0]N#Z0ZPC3:4RM!P$DB
M+: *,0<8(@9M!X_ M-M0XC=*HDA0>R//08MH1XU$$^:X,-Q*RK!0%C*^.6CC
M97[+F,1] PP>;I,T)P':&V'J&4+[JH6A(:!0$#/B-">68 LJJX\@B&)<B0,,
M$VZ3.J>CVL$!=8T+"YV?4._IT\-#[S6.JH]J)]&2(T4X#)L=S,-.AUDMD6.:
M.Q5,55&+\#WB4><]R.,:2L).CTKKH;5:,VU4F.]PA8C"[LPR9K7$EOKW3^)5
MT.]\8<M8P<E[FS8\4I9#JI452&)!UOD=';9:::1M+7]E2X%MQ7S^I/>'0EY>
MKY (2U"P>Y"F0$,+ ;9"5A(:C&.,R#<_#=36_HM+U0U W95YN<I)^QB7_6$P
MKQ5/POREF#=6>4J#E+[<>6TD,Z[FNZMOAT2QZGTM*7 <HGUQY6 @S.L5$D+*
MM^RDTDYP+I3W%/%*.JNC<H ,D"]Q"C[ EI,0/<R7K)C,5RR :,.!\C>)3;,?
M13&]WAG+\DJIQ&"B!>6,8LRLHC+LJF'5-Z/-F;U"&ZN@HBD@ZTT*\VI6F&>C
MOUP7WW\?9_EZ0@@_/)\'PJ^2C]EU.G%A]EO<[U@J7BF5 *HMT,P3#:2UU$JC
MP*;K%EET;KDQFUDAXH%LB0/K_NR<_9\7212R%!"KI):.6BZ(WQI25DIQ)A&R
M4>HJ&H'NY(E=?;S\#^4N/NV?V)^62A"0'DKAO:7>:>;*;%-5W\+>^4QB@TY7
M2=$4=-TEZ'HV;WVL$7JXNU+"I778E9$$V@ L*0,<55("P6."G@<8L-'POJ Q
M7#L+VEC.1C?I/*N5'/!EX01I#(-MA#6Q6"NOO;:NDHIX&W.2/J#II$GU/@_1
MB,7TY.7C4S$M'P1]E'KY7A>S6?&CO%:\:S796RFAH:.AY\(BS*DF*P_IIN<.
M0-N-Q2C7;)B&53UT\>M;(D7C$'>V"&7IZO7/,C-JL*76KX'N6W]>*Y]0KQP#
MB#E(;?DV*!>FFG4=]^;,<DVT,)DT 6L_=LO]ZAV!=%+_U>A:]1.++1'!?"?8
M ZFM+2\Z;V5G^MQ2K;= J19@[LSU>9?-TK+GJW$Q]\O%<I;]D4_SV^7M97J_
M=O4L:R3Q/ZZA\G$XAZ6B0#$GE8+(/0PX OR9A1>V0+I6\1X8^SY,O_XH_O\L
MG>T]P3FVK<1@**6GGFN&L4:44D8K3*R/>F-B@-&)_7'P9,B'1\/PU:PY(FY;
M2R310@.FD'>E#C0UKL+%"TAB4C4/,.:Q5RJ>"OK R!A/P 0@Y0FQGG,@H0)E
M%MEJ3?#>15V\/CY:LOU$/[V1[DB@^PV(6CGWWEL\E)#&E_J@C@DL,2(2B4W$
M&M%>]1@/]65TDXV7D^SBZ@F[UKO7BF.^F#VCXDJ+=:(K&VD_T5HX7$Z?R!B!
ME(%*Z H_*-F[#KJLS:WG5_9[T$P'4X\M1LNRZP&Y]>G3A^E5,;M]XE<_8M;9
M%="QYRM[9H_:=1.(H9, ,X @4MQ"KCPC5B/C 548U3KZ;>3,NNKMU_"A'6?6
MCXLDVDEJ#?<"6$>%PL8"5W6<(W@F0[4%11:- -I2Y((*W1F77?*3]+7;,R_*
M).7N"SF 82F^P  (9ZMN,V[E>42NM,N#&$1;(D(EZV4VRXL@[MBFBT/SPI.R
M":-464*Q\! !1@'SY3L2:S$P%S$3Q(!.&+J9(&*0;9D@/E@JZ:3<"/OPFUWQ
M;CM*)Q810P4RV%&./0B?,6HKB@9G<F;0#4GBL.V$)FL>UR?*H_*)%-(9( W%
M$&FJPPZ;\(TXC'L;<V(Y($]_EU0Y'=V6R/)UEI871;_<WWXK7GM X469)&Q\
M( 34&X\M!!!!"TC5;8-L3.ST@%SO[9(B!M%6 V@_9]=Y*==T\2F]W65\O%8T
M0<( 7!Y1$8P1L $$6DU]#$H1$QPS(#=XN[1H -A6V6&R\F77R8>PM?_YO[/7
M,M7O+)MPRZV P!+AM!)444MD)8;C_$SN]W?!CSAD6R+(YK#ZP2#:OW_953QA
M$C)LA%2"&$&TE6$COET4$8TY33O^!8,W2I.&P&UU*O'Y))N9T*GK8K9_(GE2
M,K',0LD!-)I83I1V5E1K)?=(Q*20+=^!>!\$B0>VW67FN/0R]2HF5&C/O",P
MK)Z(*J,<K,QM7EYXBV'.NW&?-HYSJT2Z7'Z;Y",_*=+73@Q>+9>47AZL.< 0
MA':9QP&@JOMA<$1=#7TWWM586%MEA;O-9M>!J7^;%3\6-X'+=^ET_Q+T:HV$
MEPG>N=4PB*%@Z?)QY$$D')5BX-VX6YL#N%7.?+E-)Q.]G.?3;+[+C_9*R00S
MXAV$3'..+#7>4:^V(F 6=<WTW7A;XX%M=S[Y^35LUM>/%:W]>_LGDQ?%$RFY
M<13[L+V'T%#)'*J.GSAA/,8E#]^-H[4A=-N=1FZRR:3.BO.X8&*(]@ A%K
MF!!,M:$; 82#<6^!O1N7:S2NK1+C/XO),FAGMMZ4[5]AGI5-(!=A:91<E)?
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MU8G'N26*K/NS<PUY7B2AQL'POZ'73@EHE(;!TMIT&F%Q)IFWH]15- +=R:N
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ME8=[W-+WK-><0KJF7I4^K?B:_BR?T2LS4Y>/FQ6SH^][G=ID H6#3D)H/(
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MDP5[_&E_YQ>WVL=++D5[1TFC=MVO/!U85--<F%3"2%N %8P$JM:E,<NI=S;
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M/Q$N_<AJ\I_$Q=>1<!+]>KT7]*(VG4K7$](I1)2/J_EA;73$6P+'V@%!@5,
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M-N[0/Q.;#H=?^I],@$H!PAT$TF/&*30652:%$,9E71KX'6@X%Y_&)SV#D)J
M#1)((Q6M<$LI5JG>0^2"AQY)YT!.\Y;QAR<Z /O9Y/)()%QF!"-;*/N;2> F
MTM\J8Q@T''/%(*TA@YC)NL\^/#UV:3(Y6"!<G*)\[JD.0G$>/:G@F70""(&
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M*G]/IQ" ( IHJ:UG'/G45H?7GJU^?,E]=/<X?F4QS +!Y8MAG8EQ5DE\,8M
M!(@@\48 0S3@6"A6._[1,,G)J6V></!;&'L6QEP<7+X\#M$_Y%!!QY#1V$HB
MC-(,J8H'CKB<(Z"CRX#WF/SS*PMB'@1&)(8'4Z(&$RT]9J9!4.FU%P0JA2CD
M#F*(*GXBUJR&SR_@:UY$.+5#QO]*@CQPZ0W"<\HXC7]X*Q05T4.I$2@)RRFY
M^"M':;N1G@'N D<"Z/)%?P#7UMJ>8Q @ E "ZZPE2FOG)*ZCA BPK)8\(]+;
MOXSX=XN?R]\#GD;WAKD''#G'0 U2R "N.4].(V,0  F]\9BH:)_FI$(,]9;<
M[SW@;/BY_#U@&U1\B) ?Y@9PS 2#L59 F_H0::A8JOE-:OQ9YW-*LQQ]$^^W
M])]?^CL$S^6+_GB\?X]@ZF'AO '08H"$]W4R-U(PYSSLUXW!7[CH=P:?8=S;
M?=1?[-+OZPHAF!,&:^&%], 0!KD4C#%'8=R2&]TS_7U?MPA$.JJECMHKFJR>
M"RFYV=(140S&70"_,8@ZNZ]['/F'?5_78 ZXAQQ[1[ E2 -;KT5! \<%I3-@
M8.]]W>.H/QA#] +NZSJI",6,( R<UPXC#ZI= C-(1K9%GHBJ/N[K'L>(OB!>
M=^#[:5P=O*N[<TQPT,JHCKS10&&NK%.,5FO$1O1Z3W< P8A.8;*KE6(F4P:S
MMY[YAJY$VE%N!/;61"+1^#.KJ*8@MR,[63N[/= [RP8/]*U7?_6P6JXF\YOI
M_*[CW+*]'PR:"^*XT!0:!;".>I7!+76)!ZC76X$#V-M;A&/+M5!;X=\%2D=W
M&=*[OA4X1D:)Z'DK+*T 2@BDMS2EXD67^U\\!ZLE>'8G+2<Q]5($Y?QMQ[PA
M !O%.>:0*8FDPFI+5R8HZK6)Q""*^%R6H.2SM#=122[0F^7RH;BQ#XM(OLV4
MUZM;/O*/ENY[L;B>QN7NDX2C7Q8YY #!CEDK2=P^K&7,5U2)U,IJACXB2ZDC
MF'?-KTO9\!\E G1YEW/WUX)R48]Z!7BDI4DWEVAT"3=TY=K@?E)3+N;.YC!W
M_7R^7HJ\G->3L%%W(H\HXDP3;:'7LC(ZX^Y$<V1E;/D<PQ247)9>BIALU6:*
M]74N)B^^%11+&:H.2(Z=%%)XB"KN<JA43H'N(49E+S<(E<NZ2Q&'1V+_+.NJ
MLB_?+Z;7Z\2QVSXCMPTG$XS@R*5>2%Q&'<Y)9 RIN"(,,;]]E8$(5.>\'9G$
MG5_,@L)1Z2.$F(2>8Z.]0W)+?R$@_!T=[AGFYY'((V$P&#'<><[;Y*IA:Z+8
MWBR"5] 338254BLM"?'4UGSP647DQQY_/KLHG@T&%R..U2+/+I%'321$C]P!
M@0PU"!FMG(6PBB5%1P'G%,(?D_UY@2+9)0XN1BI?"9^>2RZ/G$KP3#"GB%$0
M6R0U@(97P)$(R9QKY6.Z6'J!DMDM$@8CFZ/Q(P5@J5FU@$P@:Z,K$7%2T9_H
M9MT=?]FS@;-+XUE <"E"^"A,?"8A;#B#X(0CV@@J(2+.&L@ $A7]M<U*?QV3
M.CQ_H+0;AEZ*0*F;FVGZ83*ST^7UK%PF+=_@@G*GWPW4,"<1M4ZD,U%.O">F
MIK7)NEQYM ;[+3P]L?&PR!3E;+D6!(BV8I#^Y7#_\D\_?CZR*QCTH@K"AR+=
MKXIJUI3S]7(>)K./Q>+^%:$XPRR"EP9CYZ7SD:PFNK]$UK0EE.54X!W3]8IV
M<5I>"K_/)DMUEN29I>G8>03+HPW/A?+"*2J%TL!5J<D* /T[4V3H\M0QQ\\F
M475/BS-+U+'S" 0:Y$4TDQ6,MHB!Q-K*8%80H1R)&F&H?H 2U3''>W61]I%!
M[R?#[HC++D*@0XY3O[,)W&.$D/(> XZD@Y3@JD: DM[^CD5T*(F7P_=+D<?=
M 9M=E( =RN,)LPD"4N2!)<YSG@XR+:)5[%@IF54K@HU('EL*;PR:N6<S*]_$
M:4_GR^GUNL#CGHA?AU\+2G/ED6?"6@X=%HQS69O@5N2TS.2_!6%0S+N4@/@C
M/?MTW?T<[#[]9O!>:N>MIII(0+'00KHMC=,=H5ZC?%VG! \"J]V=UF9Q]MRQ
M\>DV[^.@2'3_T2 0-QA1YB%-9^Y,IEK$%>64SVDG.:!(W9"D87!,O11E\B*G
M\6.YFLQZTRM-/A^BVTJU(= PQ"CPW'A:F10:4I93&7Y 8;HAB=. V7O^*'>_
MFN; 9X-(_7.%$88B8-(U "6K2Z@ZLCLGACV\DA1#DI$!<O=2E,ZP/!B).12
M2.48HXAQA7!5359K ',N; PL&75(XC,TOEY@;/GI>GL*(3_[:- <28:E3;==
M@(.>B+HZK@$*Y23"B>$89^.*%.?Q<!B]<]+4-Q18+A_N-TN\U.8YCL+H3@IM
M*$! .Z"@6U\5XR3YG*Z1@]/1;G51S7.B(8H<]U'Y*.I,W/DMJ^D8C:61=3PY
M%42=-<\YCOS#;IZ#)!=<V]1J0TI@")645FO16HVM[T/_&-C;/.<XZ@_&[;F
MYCD,1>L\&B"$2TP<$HI"M*6L<(J/#-<GHJJ/YCG',>(RF^=0&]=F .!6,B^3
M.H*R6B/3/B>+9(!@.R],&C?/.8XI@]E;S]P\!YEH3Q'M!7=46$L!UC4?N- C
M.=(;CCW0.\L&#_2ZU>TCA]=]_U)<KXJ;?Y:S^)I9= <^3%:=1%&;?ST@;9G6
M%D F+)8"2^!@17<4]YM?;-=O$:AMR4AGS+Q((?HP7?[M%T6*BA41=JL^1>BU
M;P>#D;<0$, ID9YAZ+#>TEP2DU4=8XBZ9B0"U (K!W\&L6_CZ"R-_>!'@Y8
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MF=AG#+.DR:]^5'<?EF^6RX?BYFJ1_DR"^.XA[<UQPT_Y)-O?'A>+.>$#02&
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MX=<*R7M/T_@\6=QM ]&-C+;] P,%T!LN%)7&:,.\%*ARAA5P-"?O;(A-WCI
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M;',M,C Q.#$R,S$N>&UL4$L! A0#%     @ Y8!T3OW[I#$ $   R;   !$
M             ( !CVH! &5O;',M,C Q.#$R,S$N>'-D4$L! A0#%     @
MY8!T3M[@[Q]A&0  >0D! !4              ( !OGH! &5O;',M,C Q.#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( .6 =$Z^4EWB)V,  !SH!  5
M      "  5*4 0!E;VQS+3(P,3@Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #E
M@'1.F@?&5A/(   .X@H %0              @ &L]P$ 96]L<RTR,#$X,3(S
M,5]L86(N>&UL4$L! A0#%     @ Y8!T3H^Q,WI=B@  U/L& !4
M     ( !\K\" &5O;',M,C Q.#$R,S%?<')E+GAM;%!+!08     !@ & (H!
(  ""2@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
